

1

2

3

Melanoma:

4

assessment and management of melanoma

5

6

7

8

9

Evidence Review

10

11

12

13

14

15

Developed for NICE by the National Collaborating Centre for Cancer

16

17

18

©2015 National Collaborating Centre for Cancer

19

Contents

1. Communication and Support	5
Review question: What are the specific information needs of people with melanoma and their carers at different milestones/points in the patient pathway?	5
Review question: What are the specific support needs of people with melanoma and their carers at different milestones/points in the patient pathway?	5
Review question: What are the most effective ways of meeting the patients information needs?	5
Review question: What are the most effective ways of meeting the patients support needs?	5
2. Diagnosing Melanoma	85
2.1 Dermoscopy and other visualisation techniques	85
Review question: To what extent can the diagnostic accuracy of, history-taking and visual examination for the clinical identification of melanoma be improved by dermoscopy or/and new visualisation techniques?	85
2.2 Photography	125
Review question: Is photography an effective method of detecting progression of pigmented lesions, including dermoscopy pictures?	125
2.3 Borderline and Spitzoid melanocytic lesions?	141
Review question: What is the best approach to resolving clinico-pathological diagnostic uncertainty for borderline or spitzoid melanocytic lesions?	141
2.4 Tumour samples for genetic testing	224
Review question: What is the most appropriate tumour sample (primary or secondary) on which to carry out genetic testing to identify people who might benefit from targeted therapies?	224
2.5 Genetic testing in stage I-III melanoma	259
Review question: What is the role of genetic testing of the tumour at diagnosis for a person with early stage [I-III] melanoma?	259
3. Staging of Melanoma	262
Review question: What is the most effective method of accurately staging melanoma in patients with clinicopathological stage IA melanoma?	262
Review question: What is the most effective method of accurately staging melanoma in patients with clinicopathological stage IB-IIC melanoma?	262
Review question: What is the most effective method of accurately staging melanoma in patients with clinicopathological stage III melanoma?	262
Review question: What is the most effective method of accurately staging melanoma in patients with clinicopathological stage IV melanoma?	262
Economic Evidence Summary	384

1	4. Stage 0-II melanoma	397
2	4.1 Surgical Management	397
3	Review question: What is the most effective surgical treatment for stage 0-II melanoma to	
4	achieve clear margins and improved patient outcomes?	397
5	4.2 The use of imiquimod in stage 0 melanoma and skin metastases	434
6	Review question: How effective is imiquimod in the treatment of stage 0 melanoma and skin	
7	metastases?	434
8	5. Stage III Melanoma.....	458
9	5.1 Surgical Management	458
10	Review question: What is the most effective surgical treatment for stage III melanoma?	458
11	5.2 Adjuvant radiotherapy.....	539
12	Review question: What is the effectiveness of adjuvant radiotherapy to the resected lymph	
13	node basin for stage III melanoma in people who have undergone curative resection?	539
14	5.3 In transit metastases	568
15	Review question: What is the most effective treatment for in transit melanoma metastases (for	
16	example, surgery, isolated limb infusion, isolated limb perfusion, palliative radiotherapy,	
17	cryotherapy, electro-chemotherapy or the laser)?	568
18	6. Stage IV Melanoma.....	612
19	6.1 Localised treatments for metastatic stage IV melanoma	612
20	Review question: How effective is surgery, ablative treatments or stereotactic radiotherapy for	
21	people with stage IV melanoma with oligometastatic disease?	612
22	6.2 Localised treatment for brain metastases	654
23	Review question: What is the effectiveness of local treatment using surgery or radiotherapy	
24	compared with systemic drug therapy or supportive care in the management of brain	
25	metastases in people with stage IV melanoma?	654
26	6.3 The role of systemic anticancer therapy	687
27	Review question: What is the effectiveness of systemic anticancer therapy compared with	
28	supportive care in the treatment (first and second line) of patients with stage IV metastatic	
29	melanoma?	687
30	Economic Evidence Summary	712
31	7. Follow-up.....	718
32	7.1 Frequency and duration of follow-up?.....	718
33	Review question: In asymptomatic patients who have undergone treatment with curative intent	
34	for melanoma, what is the optimal method, frequency and duration of follow-up?	718
35	Economic Evidence Summary	785
36	7.2 Brain Imaging	795

1	Review question: In patients with melanoma who are undergoing body imaging as part of	
2	follow-up and who have no neurological signs or symptoms, should brain imaging be included?	
3	795
4	Review question: Where imaging is indicated, is CT or MRI the most appropriate method of	
5	imaging for brain metastasis as part of follow-up for asymptomatic patients?.....	803
6	8. Other management issues during follow-up	808
7	8.1 Managing suboptimal vitamin D levels	808
8	Review question: How should sub-optimal vitamin D levels be managed in people with	
9	melanoma (including supplements and monitoring)?.....	808
10	8.2 Concurrent Drug Therapies	848
11	Review question: What is the most effective approach to the management of risks to patients	
12	associated with concurrent drug therapies used to treat other conditions, which may affect the	
13	prognosis from melanoma (for example, immunosuppressants, levadopa, metformin, HRT,	
14	COCP)?	848
15	Appendix	881
16	Health Economic Search Strategies	881
17	Excluded Health Economic Studies	882
18		
19		
20		
21		

1. Communication and Support

Review question: What are the specific information needs of people with melanoma and their carers at different milestones/points in the patient pathway?

Review question: What are the specific support needs of people with melanoma and their carers at different milestones/points in the patient pathway?

Review question: What are the most effective ways of meeting the patients information needs?

Review question: What are the most effective ways of meeting the patients support needs?

Background

High quality, appropriate and clear **individualised** information, at different points in the patients pathway, may empower patients/carers to participate in the clinical decision making with regards to treatment, including risks/ benefits and may positively impact on physical and psycho- social wellbeing. Needs may differ in various age groups. Some patients / carers may want to know all information available, while others may wish to know little or nothing, this highlights the need for individualised information assessment/ prescription, needs may change during the pathway.

The emotional impact of cancer diagnosis can be significant, however psycho-social support needs vary from patient to patient, and may be associated with treatment morbidity. Holistic needs assessment (HNA) is a tool which is currently used to measure patient needs and opens up communication between patient/carer and healthcare professionals. It can help HCP to recognise and effectively treat depression and other symptoms of stress, or refer patients to available resources.

Question in PICO Format

Population	Intervention	Outcomes
<ul style="list-style-type: none"> People with Melanoma Carers of people with melanoma Stage: <ul style="list-style-type: none"> 0-Ia Ib – IIIa IIIb – IIIC IV 	Specific information needs of people with melanoma and their carers at different milestones/points in the patient pathway? Different age groups? Cultural groups?	Health Related Quality of Life Patient satisfaction Treatment decision making Patient reported outcomes

How will the information be searched?

Searches:

Can we apply date limits to the search (<i>Please provide information on any date limits we can apply to the searches for this topic. This can be done for each individual intervention as appropriate</i>)	Date limit of 1980 to be applied
Are there any study design filters to be used (<i>RCT, systematic review, diagnostic test</i>).	Any study type including RCT, Systemic reviews, Case reports
List useful search terms. (<i>This can include such information as any alternative names for the interventions etc</i>)	<ul style="list-style-type: none"> • Information cancer patients • Unmet needs cancer patients • psychosocial distress, • health literacy • psycho-social support.

1

2 The Review Strategy

3 Evidence was be identified, assessed and synthesised according to the methods outlined in the
 4 Guidelines Manual (2012). Relevant studies were identified through sifting the abstracts and
 5 excluding studies clearly not relevant to the PICO. In the case of relevant or potentially relevant
 6 studies, the full paper was ordered and reviewed, whereupon studies considered to be not relevant
 7 to the topic were excluded. Studies which were identified as relevant were critically appraised and
 8 quality assessed using GRADE methodology and NICE checklists. Data relating to the identified
 9 outcomes were extracted from the relevant studies. The data were not meta-analysed due to the
 10 difference in interventions and populations (in terms of melanoma thicknesses) of the included
 11 studies, but were instead summarised per study in tabular form, and further in GRADE tables and
 12 evidence statements.

13

14 Search Results

Database name	Dates Covered	No of references found	Finish date of search
<i>Medline</i>	1946-2014	4681	24/03/2014
<i>Premedline</i>	Mar 24 2014	303	25/03/2014
<i>Embase</i>	1947-2014	8894	25/03/2014
<i>Cochrane Library</i>	Issue 3, Mar 2014	152	25/03/2014
<i>Web of Science (SCI & SSCI)</i>	1900-2014	6494	25/03/2014
<i>PsycInfo</i>	1806-2014	143	25/03/2014
<i>CINAHL</i>	1979-2014	392	31/03/2014
Total References retrieved (after databases combined, de-duplicated and sifted): 352 & 1 reference added 30/04/2014			

15 Medline search strategy (*This search strategy is adapted to each database*)

- 16 1. exp Melanoma/
- 17 2. melanoma\$.tw.

- 1 3. (maligna\$ adj1 lentigo\$).tw.
- 2 4. (hutchinson\$ adj1 (freckle\$ or melano\$)).tw.
- 3 5. dubreuilh.tw.
- 4 6. LMM.tw.
- 5 7. or/1-6
- 6 8. Health Services Accessibility/
- 7 9. Office Visits/
- 8 10. Remote Consultation/
- 9 11. Physician-Patient Relations/
- 10 12. Nurse-Patient Relations/
- 11 13. Professional-Patient Relations/
- 12 14. Professional-Family Relations/
- 13 15. ((patient* or consumer* or carer* or caregiver* or spouse* or famil* or relati*) adj2 (decision*
- 14 or choice* or preference* or support* or participat* or educat*)).tw.
- 15 16. ((personal or interpersonal or individual*) adj2 (decision* or choice* or preference* or support*
- 16 or participat* or educat*)).tw.
- 17 17. (information adj2 (aid* or support* or need* or provision or deliver* or material* or
- 18 resource*)).tw.
- 19 18. ((patient* or carer* or caregiver* or spouse* or famil* or relati*) adj2 (information or
- 20 literature)).tw.
- 21 19. ((web* or print* or electronic*) adj2 (information or resource*)).tw.
- 22 20. Patient Education as Topic/
- 23 21. Pamphlets/
- 24 22. (pamphlet* or leaflet* or booklet* or guide* or sheet* or flyer* or flier*).tw.
- 25 23. ((electronic or email) adj (report* or support)).tw.
- 26 24. exp Audiovisual Aids/
- 27 25. (video* or dvd* or tape* or cd*1 or film*1 or telephone* or phone* or computer* or internet or
- 28 online or web or electronic).tw.
- 29 26. exp Internet/
- 30 27. exp telephone/
- 31 28. exp hotlines/
- 32 29. ((hot or help* or tele* or phone) adj (line* or support)).tw.
- 33 30. Communication/
- 34 31. (communicat* or talking).tw.
- 35 32. exp social support/
- 36 33. exp Self-Help Groups/
- 37 34. ((inform* or support*) adj2 (tool* or method* or group*)).tw.
- 38 35. (face* adj face*).tw.
- 39 36. Psychoeducation/
- 40 37. Psychotherapy/
- 41 38. ((psychosocial or psycho*) adj2 (support* or educat* or need*)).tw.
- 42 39. Stress, Psychological/
- 43 40. Counseling/
- 44 41. exp Patient Education/mt [Methods]
- 45 42. or/8-41

- 1 43. 7 and 42
- 2 44. limit 43 to yr="1980 -Current"

Screening Results

The literature search identified 351 potentially relevant papers of which 19 were ordered. Four systematic reviews (Cornish et al, 2009; Kasparian et al, 2009; Barker et al, 2011 and Rychetnick et al 2013) were included and one primary study (Olivera et al, 2013). Additional evidence about patient information and support needs came from the 2012-2013 NHS England Cancer Patient Experience Survey which was sent to all adult patients with a primary diagnosis of cancer who were treated in a hospital as an inpatient or day-case patient between September and November 2012.

Evidence statements

Information needs

Timing of Information

In one UK based survey (Stamataki et al, 2014) participants reported feeling there was no standard procedure for when patients were provided with information. Some participants reported getting too much information up front and some participants felt that information was provided too late, particularly in the case of sun protection advice.

Information needs at diagnosis

In the Cancer Patient Experience Survey (2012-2013), despite scoring highly in comparison to other cancers, around 15% of patients with melanoma felt they were not given clear information about their cancer or test results.

A UK based study (Stamataki et al, 2014) found that patients felt they could not comprehend the information provided about their prognosis or stage and this contributed to feelings of anxiety and uncertainty for the future.

Information needs during treatment

In the Cancer Patient Experience Survey (2012-2013) the experience of patients with melanoma ranked the lowest amongst cancer types for being given written information about side effects (68%) and being told they could get free prescriptions (56%).

Information needs during follow up

Follow up was an important source of information about sun-related behaviours (Rychetnik et al, 2013) – the clinic doctor, books & magazines and the clinic nurse being the main sources. Some patients reported a lack of confidence in skin self examination in Olivera (2013).

In the Cancer Patient Experience Survey (2012-2013) 13% of patients with melanoma felt they were not given clear information about what to do post discharge.

In a UK based study (Stamataki et al, 2014) patients reported a strong desire for more detailed information on sun protection. They reported feeling that the information provided was not detailed enough and did not cover issues such as travelling to hot countries, type of sunscreen and frequency of sunscreen application.

Source of Information

In a survey of melanoma survivors (Hamilton et al, 2014) 90% of patients (n=28) had used the internet as a source of melanoma information. 69% of patients chose melanoma websites based on

top hits returned by searches; 42% chose websites from a known reputable source and 15% chose websites based on recommendations from doctors or health care providers.

52% of internet users reported that internet use affected their specialist consultation by helping their decision making while 37% felt it did not influence their decision making and 7% considered it to make their decision more difficult (Hamilton et al, 2014).

Ease of access was considered the main strength of the internet (74%) followed by the volume and detail of information (52%) , discussion of different perspectives/options (37%) and anonymity (7%) though 54% of users reported that available information was difficult to understand (Hamilton et al, 2014)

Support needs

General support needs

There was consistent evidence that around 20% to 30% of patients with melanoma experience clinically significant levels of distress (Cornish, Kasparian 2009; Rychetnik, 2013). Rychetnik (2013) reported that around half of patients surveyed would be interested in professional emotional support, preferably from their doctor rather than a psychiatrist or psychologist.

In the Cancer Patient Experience Survey (2012-2013) around 25% of patients with melanoma felt that emotional support was insufficient from hospital and G.P. practice staff. In the survey 85% of melanoma patients said that hospital staff gave them information about support groups but only 57% said hospital staff gave them information about financial support.

One cross-sectional study carried out in two UK centres (Molassiotis et al, 2014) reported that young patients had higher unmet needs relating to the psychological domain ($p<0.001$). Participants with lymph node involvement expressed significantly higher levels of unmet needs for physical and daily living ($p<0.001$), psychological needs ($p=0.045$), sexual needs ($p=0.015$) and overall score for needs ($p=0.006$).

Psychological needs were the most common unmet needs particularly fears about cancer spreading (29%) and uncertainty about the future (25.2%).

Support needs at diagnosis

In a systematic review of qualitative studies, Barker (2011) reported that on receiving a diagnosis of skin cancer individuals experience strong emotional responses including anxiety, shock and panic. In a systematic review of quality of life studies in melanoma, Cornish et al (2009) noted that the immediate period following diagnosis was often associated with impairment in health related quality of life, with patients reporting increased pain, less energy and physical or emotional distress which impaired social functioning.

In the Cancer Patient Experience survey 64% of melanoma patients said they were told they could bring a friend with them when they were first told they had cancer; this was the lowest proportion of all the cancer types.

During treatment

Barker et al (2011) noted that once the initial emotional response to a skin cancer diagnosis had subsided individuals typically expressed satisfaction with their experience of care. Cornish et al. (2009) reported that during this phase patients were more likely to be anxious about disease recurrence than the physical limitations related to melanoma or its treatment.

During follow up

There was evidence that follow-up was a source of both anxiety and reassurance for patients with melanoma. Psychological distress was reported during follow-up, potentially interfering with adherence to screening and preventative behaviours (Cornish, 2009; Olivera, 2013; Rychetnik, 2013) and some people delayed seeking medical advice for their skin cancer symptoms (Barker, 2011). In the Rychetnik (2013) systematic review around half of surveyed patients said that follow up appointments made them anxious (with clinically significant levels in approximately 20% of patients). This was sometimes accompanied by physical symptoms and sometimes started weeks before the appointment. Overall satisfaction with follow-up, however, was high and receiving good news from physician screenings was reassuring (Olivera, 2013; Rychetnik, 2013).

1 **Table 1.1. Results of the NHS England 2012-2013 Cancer Patient Experience Survey**

No.	Survey question	Overall (N=68,737)	Melanoma† (N=1854)	Rank*
Seeing your GP				
1	Saw GP once or twice before being told had to go to hospital	74%	90%	2
2	Patient thought they were seen as soon as necessary	84%	87%	2
3	How long was it from the time you first thought something might be wrong with you until you first saw a hospital doctor? (% answering less than 12 months)	94%	N.S.	N.S.
4	Patient's health got better or remained about the same while waiting	80%	94%	1
Diagnostic tests				
5	% answering they've had diagnostic tests for cancer in last 12 months	90%	N.R.	N.R.
6	Staff gave complete explanation of purpose of test(s)	84%	N.S.	N.S.
7	Staff explained completely what would be done during test	87%	N.S.	N.S.
8	Given easy to understand written information about test	88%	N.S.	N.S.
9	Given complete explanation of test results in understandable way	78%	85%	1
Finding out what was wrong				
10	% answering that they were first told by a doctor (incl GP) or nurse	95%	N.R.	N.R.
11	Patient told they could bring a friend when first told they had cancer	74%	63%	13
12	Patient felt they were told sensitively that they had cancer	84%	88%	1
13	Patient completely understood the explanation of what was wrong	73%	81%	1
14	Patient given written information about the type of cancer they had	71%	81%	1
Deciding best treatment				
15	Patient given a choice of different types of treatment (if more than one treatment was suitable)	85%	88%	3
16	Patient's views definitely taken into account by doctors and nurses discussing treatment	71%	77%	1
17	Possible side effects explained in an understandable way	75%	74%	6
18	Patient given written information about side effects	82%	68%	13
19	Patient definitely told about treatment side effects that could affect them in the future	55%	57%	5
20	Patient definitely involved in decisions about care and treatment	72%	79%	1

No.	Survey question	Overall (N=68,737)	Melanoma† (N=1854)	Rank*
Clinical nurse specialist				
21	Patient given the name of the CNS in charge of their care	88%	84%	10
22	Patient finds it easy to contact their CNS	75%	N.S.	N.S.
23	CNS definitely listened carefully the last time spoken to	91%	N.S.	N.S.
24	Get understandable answers to important questions all/most of the time	91%	N.S.	N.S.
Support for patients				
25	Hospital staff gave information about support groups	82%	85%	2
26	Hospital staff gave information about impact cancer could have on work/education	74%	76%	3
27	Hospital staff gave information on getting financial help	54%	52%	9
28	Hospital staff told patient they could get free prescriptions	76%	56%	13
Research				
29	Patient has seen information about cancer research in the hospital	85%	80%	12
30	Taking part in cancer research discussed with patient	32%	18%	12
31	Patient has taken part in cancer research (% of those who were asked)	64%	60%	11
Operations				
32	% ans. they've had an operation in last 12 months	56%	N.R.	N.R.
33	Staff gave complete explanation of what would be done	87%	N.S.	N.S.
34	Patient given written information about the operation	74%	68%	7
35	Staff explained how operation had gone in understandable way	77%	N.S.	N.S.
Hospital doctors				
36	% ans. they've stayed overnight for cancer care in last 12 months	67%	N.R.	N.R.
37	Got understandable answers to important questions all/most of the time	83%	N.S.	N.S.
38	Patient had confidence and trust in all doctors treating them	85%	N.S.	N.S.
39	Doctors did not talk in front of patient as if they were not there	83%	88%	2
40	Patient's family definitely had opportunity to talk to doctor	66%	74%	1
Ward nurses				
41	Got understandable answers to important questions all/most of the time	75%	N.S.	N.S.

No.	Survey question	Overall (N=68,737)	Melanoma† (N=1854)	Rank*
42	Patient had confidence and trust in all ward nurses	69%	77%	1
43	Nurses did not talk in front of patient as if they were not there	85%	89%	1
44	Always / nearly always enough nurses on duty	61%	74%	1
Hospital care and treatment				
45	Patient did not think hospital staff deliberately misinformed them	89%	N.S.	N.S.
46	Patient never thought they were given conflicting information	79%	87%	1
47	All staff asked patient what name they preferred to be called by	56%	53%	12
48	Always given enough privacy when discussing condition/treatment	84%	N.S.	N.S.
49	Always given enough privacy when being examined or treated	94%	N.S.	N.S.
50	Patient was able to discuss worries or fears with staff during visit (of those with worries or fears)	64%	N.S.	N.S.
51	Hospital staff did everything to help control pain all of the time (of those with pain)	85%	N.S.	N.S.
52	Always treated with respect and dignity by staff	83%	N.S.	N.S.
Information before leaving and home support				
53	Given clear written information about what should / should not do post discharge	84%	87%	2
54	Staff told patient who to contact if worried post discharge	94%	N.S.	N.S.
55	Family definitely given all information needed to help care at home	61%	N.S.	N.S.
56	Patient definitely given enough care from health or social services (of those who needed it)	60%	61%	3
Day / outpatient care				
57	Staff definitely did everything to control side effects of radiotherapy (of those receiving it)	79%	N.S.	N.S.
58	Staff definitely did everything to control side effects of chemotherapy (of those receiving it)	81%	N.S.	N.S.
59	Staff definitely did everything they could to help control pain	82%	N.S.	N.S.
60	Hospital staff definitely gave patient enough emotional support	70%	74%	1
Outpatient appointments				
61	% ans. they've had an OP appt with a cancer doctor in last 12 months	94%	N.R.	N.R.

No.	Survey question	Overall (N=68,737)	Melanoma† (N=1854)	Rank*
62	Doctor had the right notes and other documentation with them	96%	N.S.	N.S.
Care from general practices				
63	GP given enough information about patient's condition and treatment	95%	N.S.	N.S.
64	Practice staff definitely did everything they could to support patient	68%	76%	1
Overall NHS care				
65	Hospital and community staff always worked well together	64%	70%	1
66	Have you had treatment from any of the following range of therapists for your cancer?	-	-	-
67	Given the right amount of information about condition and treatment	88%	N.S.	N.S.
68	Patient offered written assessment and care plan	22%	20%	10
69	Patient did not feel that they were treated as a 'set of cancer symptoms'	81%	88%	1
70	Patient's rating of care 'excellent' / 'very good'	88%	N.S.	N.S.

†The survey used a "skin cancer" classification, but ICD10 C44 tumours were excluded, so it is assumed that these were patients with melanoma.

*Rank of skin cancer patients in comparison to the 12 other cancer types: breast, colorectal/lower gastro, lung, prostate, brain/CNS, gynaecological, haematological, head & neck, sarcoma, upper gastro, urological and other.

Abbreviations: N.R., not reported – results were not analyzed or reported by cancer type; N.S. – although there was some variation between cancer types this was not statistically significant and the figures were not reported by cancer type.

References

Included studies

- Barker, J. (2011). The needs and experiences of people with a skin cancer: a systematic review. Joanna Briggs Institute Library of Systematic Reviews, 9, 104-121.
- Cornish, D., Holterhues, C., van de Poll-Franse, L., Coebergh, J. W., & Nijsten, T. (2009). A systematic review of health-related quality of life in cutaneous melanoma. *Annals of Oncology*, 20, 51-58.
- Hamilton, S. N., Scali, E. P., Yu, I., Gusnowski, E., and Ingledew, P. A. Sifting Through It All: Characterizing Melanoma Patients' Utilization of the Internet as an Information Source. *Journal of Cancer Education* . 1-8-2014.
- Kasparian, N. A., McLoone, J. K., Butow, P. N., Kasparian, N. A., McLoone, J. K., & Butow, P. N. (2009). Psychological responses and coping strategies among patients with malignant melanoma: a systematic review of the literature. [Review] [67 refs]. *Archives of Dermatology*, 145, 1415-1427.
- McLoone, J., Menzies, S., Meiser, B., Mann, G. J., & Kasparian, N. A. (2013). Psycho-educational interventions for melanoma survivors: a systematic review. *Psycho-Oncology* 27[7], 1444-1456.
- Molassiotis, A., Brunton, L., Hodgetts, J., Green, A. C., Beesley, V., Mulatero, C., Newton-Bishop, J. A., and Lorigan, P. Prevalence and correlates of unmet supportive care needs in patients with resected invasive cutaneous melanoma. *Annals of Oncology* . 31-7-2014. National Cancer Patient Experience Survey 2012-13 National Report. Quality Health (2013).
- Oliveria, S. A., Shuk, E., Hay, J. L., Heneghan, M., Goulart, J. M., Panageas, K. et al. (2013). Melanoma survivors: health behaviors, surveillance, psychosocial factors, and family concerns. *Psycho-Oncology*, 22, 106-116.
- Palesh, O., Aldridge-Gerry, A., Bugos, K., Pickham, D., Chen, J. J., Greco, R., and Swetter, S. M. Health behaviors and needs of melanoma survivors. *Supportive Care in Cancer* . 31-5-2014.
- Stamataki, Z., Brunton, L., Lorigan, P., Green, A. C., Newton-Bishop, J., and Molassiotis, A. Assessing the impact of diagnosis and the related supportive care needs in patients with cutaneous melanoma. *Supportive Care in Cancer* . 5-9-2014

Evidence tables

Table 1.2 Study Quality

	Barker et al (2011)	Cornish et al (2009)	Kasparian, N. A et al (2009)	Molassiotis et al (2014)	Nicole Hamilton et al (2014)	Palesh et al (2014)	Rychetnik, L et al (2013)	Stamataki et al (2014)
The review addresses an appropriate and clearly focused question that is relevant to the review question	Yes	Yes	Yes				Yes	
The review collects the type of studies you consider relevant to the guidance review question	Yes	Yes	Yes				Yes	
The literature search is sufficiently rigorous to identify all the relevant studies	Yes	Yes	Yes				Yes	
Study quality is assessed and reported	Yes	Yes	Yes				Yes	
An adequate description of the methodology used is included, and the methods used are appropriate to the question	Yes	Yes	Yes				Yes	
Additional Comments	Overall assessment of internal validity. Are	Overall assessment of internal validity. Are	Overall assessment of internal validity. Are				Overall assessment of internal validity. Are	

	Barker et al (2011)	Cornish et al (2009)	Kasparian, N. A et al (2009)	Molassiotis et al (2014)	Nicole Hamilton et al (2014)	Palesh et al (2014)	Rychetnik, L et al (2013)	Stamataki et al (2014)
	the results internally valid? Yes Overall assessment of external validity – Are the results externally valid (i.e. generalisable to the whole source population)? Partially – one of the studies included a minority (5/18) of patients with melanoma.	the results internally valid? Yes Overall assessment of external validity – Are the results externally valid (i.e. generalisable to the whole source population)? Partially – the included studies cover a range of treatments so it is difficult to draw specific conclusions about HRQOL impairments.	the results internally valid? Yes Overall assessment of external validity – Are the results externally valid (i.e. generalisable to the whole source population)? Yes				the results internally valid? Yes Overall assessment of external validity – Are the results externally valid (i.e. generalisable to the whole source population)? Yes	

	Oliveria, S. A et al (2013
Is a qualitative approach appropriate?	Appropriate
Is the study clear in what it seeks to do?	Clear
How defensible/rigorous is the research design/methodology?	Defensible
How well was the data collection carried out?	Appropriate
Is the context clearly described?	Clear
Were the methods reliable?	Reliable
Are the data 'rich'?	Rich
Is the analysis reliable?	Reliable
Are the findings convincing?	Convincing
Are the conclusions adequate?	Adequate
Was the study approved by an ethics committee?	Not reported
Is the role of the researcher clearly described?	Clear

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
Barker et al (2011)	To assess the needs and experiences of adults following a diagnosis of skin cancer	Systematic review of qualitative studies	2 qualitative studies met the inclusion criteria: one 2009 study of 10 men with melanoma and another 2004 study of skin cancer (5/18 had melanoma). Both were UK studies and used semi-structured interviews to needs and experiences of the participants.	Used the Joanna Briggs Institute Qualitative Assessment and Review approach for meta-synthesis. The findings of each study were extracted – these were then organised into categories which were finally summarised into “synthesised findings”.		N/A	<p>Four categories were distilled from the 12 study findings:</p> <ol style="list-style-type: none"> 1. On receiving a diagnosis of skin cancer individuals experience a strong emotional response such as anxiety, shock and panic. 2. Individuals develop a range of mechanisms to help them cope with a diagnosis of skin cancer 3. Once the initial emotional response to a diagnosis subsides, individuals express satisfaction with their experience of care 4. Individuals delay seeking medical advice in relation to symptoms associated with skin cancer often trivialising their significance <p>Two findings were synthesised from the above four categories</p> <ol style="list-style-type: none"> 1. There should be a strategy to help clinicians assess and

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>address the psychosocial needs of skin cancer patients: Patients given a diagnosis of skin cancer experience extreme emotional responses and develop specific coping responses to help them deal with their emotions</p> <p>2. There is a need to address the lack of awareness regarding symptoms of skin cancer and promote early detection through public education: Individuals delay seeking medical help but once a diagnosis is given and the initial emotional response subsides patients express satisfaction with their care</p>
Cornish et al (2009)	To summarise the available literature on HRQOL in melanoma	Systematic review of quantitative studies	Patients with cutaneous melanoma	Three studies investigated the effects of a specific therapy on HRQOL the others were studies of HRQOL in melanoma patients in			<p>20 different measures of HRQOL were reported in the 13 studies. Both generic measures (EORTCQLQ-30, EQ-5D, SF-36, BSI etc) and specific melanoma measures were reported (e.g. FACT-M)</p> <p>Approximately one third of patients reported clinically significant levels of distress. The results indicated that there were three distinct periods of</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
				general.			<p>HRQOL impairment in melanoma: diagnosis, treatment and follow-up.</p> <p>Diagnosis</p> <p>The immediate period following diagnosis was often associated with HRQOL impairment. Patients reported increased pain, less energy and physical or emotional distress which impaired social functioning.</p> <p>Treatment</p> <p>During this phase patients were anxious about disease recurrence: even more so than the physical limitations related to melanoma or its treatment.</p> <p>Follow-up</p> <p>Psychological distress was reported during follow-up, potentially interfering with adherence to screening and preventative behaviours.</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							Predictors of HRQOL impairment Factors associated with impaired HRQOL were: poor physical health, non-cancer life stresses, low levels of social support and maladaptive coping styles.
Kasparian, N. A et al (2009)	What is the prevalence of psychological distress among people with melanoma or with a high risk of developing melanoma? What are the risk factors for psychological distress in this population?	Systematic Review of quantitative studies. Included studies came from Australia, Israel, Sweden, USA, Finland, Germany, Croatia, Austria and The Netherlands.	Melanoma or with a high risk of developing melanoma.	Three studies investigated the effects of a specific therapy on HRQOL the others were studies of HRQOL in melanoma patients in general.			20 different measures of HRQOL were reported in the 13 studies. Both generic measures (EORTCQLQ-30, EQ-5D, SF-36, BSI etc) and specific melanoma measures were reported (e.g. FACT-M) Prevalence of psychological distress (anxiety and depression) When measured using a validated scale approximately 30% of patients reported levels of psychological distress indicative of the need for clinical intervention. Demographic, clinical and psychosocial predictors of distress Demographic risk factors: female sex, younger age group, absence of spouse

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>or partner, fewer children, lower education and economic adversity were all factors associated with increased reporting of psychological distress.</p> <p>Clinical factors: The association between clinical factors (for example stage of disease and tumour thickness) and psychological distress is unclear. There is some evidence that patients with greater physical deterioration or tumours on visible parts of the body experience greater distress.</p> <p>Psychological and social factors: Patients with melanoma who form positive or meaningful appraisals of their cancer experience, have an active-cognitive coping style and/or greater social support are more likely to demonstrate healthy psychological adjustment.</p>
Molassiotis et al (2014)	To examine unmet supportive	Cross-sectional survey	N=455 Patients with resected stage	Questionnaire Assessment	N/A		82% of the sample were from hospital A and 18% from hospital B

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
	care needs of patients with invasive melanoma, with and without lymph node involvement	2 centres in the UK	<p>I-III melanoma diagnosed at least months-5 years previously.</p> <p><i>Exclusions</i> Other Cancers <3 months post-treatment</p>	<p>Patient needs were assessed using the Supportive Care Needs Survey Short Form and the supplementary melanoma module.</p> <p>Anxiety and depression were assessed using the Hospital Anxiety and Depression scale</p> <p>Quality of life was assessed using the 51 item Functional Assessment of cancer Therapy-Melanoma</p>			<p>Response Rates were 79% in hospital A (face to face recruitment) 50% in hospital B (recruitment by mail)</p> <p><i>Supportive Care Needs (Univariate Analysis)</i></p> <p>Moderate and high response needs were merged with low to give a dichotomous score (need versus no need).</p> <p>Significantly more patients who were divorced/separated/widowed, left school at 14-15, had no qualifications, performed manual work or had lymph node involvement or lymphoedema had at least one unmet need.</p> <p>Young patients had higher unmet needs relating to the psychological domain ($p<0.001$).</p> <p>Participants with lymph node involvement expressed significantly higher levels of unmet needs for physical and daily living ($p<0.001$), psychological needs ($p=0.045$), sexual needs ($p=0.015$) and overall score for needs ($p=0.006$).</p> <p>Breslow thickness and time since diagnosis were not associated with</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>unmet needs.</p> <p>Psychological needs were the most common unmet needs: Fears about cancer spreading = 29% Uncertainty about the future = 25.2%</p> <p>There was a low level reported for melanoma specific needs.</p> <p><i>Anxiety, depression and quality of life</i> Mean HADS scores for anxiety was 5.66 (SD=3.9) and depression was 3.2 (SD=3.2)</p> <p>29% of patients reported signs of anxiety: Borderline=15.6% Definitive=13.4%</p> <p>11% reported signs of depression Borderline = 7.5% Definitive = 3.4%</p> <p>Anxiety and depression were significantly associated with unmet supportive care needs. Patients reporting no unmet needs or needs met had a mean anxiety score of 4.89 (SD=3.6) compared with a</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>mean score of 8.98 (SD=4.04) for patients with unmet needs ($p<0.001$). Patients reporting no unmet needs or needs met had a mean depression score of 2.59 (SD=2.8) compared with a mean score of 5.36 (SD=3.45) for patients with unmet needs ($p<0.001$).</p> <p>Quality of life scores were relatively high overall though patients with lymph node involvement had significantly worse quality of life in relation to physical and emotional wellbeing ($p<0.05$) but not for overall quality of life.</p> <p><i>Associations with unmet supportive care needs (multivariate analysis)</i> Leaving school aged ≥ 18 years versus 14-15 years (OR=4.85, 95% CI 2.23-20.54, $p<0.001$)</p> <p>High emotional (OR=0.65, 95% CI 0.58-0.74) and social (OR=0.91, 95% CI 0.86-0.96) quality of life was associated with lower odds of unmet needs</p> <p>Patients aged >70 had fewer psychological needs compared to patients aged <50 ($p<0.05$).</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>Patients recording a higher emotional quality of life were less likely to have specific psychological ($p<0.001$), health systems and information ($p<0.001$) and patient care and support needs ($p<0.001$).</p> <p>The predictive power for all logistic regression models was good classification rates 0.76-0.85 AUC 0.75-0.82</p> <p>Regression models showed 2-3fold greater sensitivity (0.41-0.69) than the random prediction of having unmet needs (0.27)</p>
National Cancer Patient Experience Survey 2012-13 National Report. Quality Health (2013).		Questionnaire/ Patient Survey	The sample included 1854 patients with skin cancer. Patients with an ICD code of C44 (other malignant neoplasms of the skin) were excluded from the survey – this means almost all the included skin	2012-2013 English NHS Cancer Patient Experience Survey. returned.			<p>The survey was sent to all adult patients with a primary diagnosis of cancer who were treated in a hospital as an inpatient or day-case patient between 1st September 2012 and 31st November 2012. 116,490 surveys were send out and 68,737 (64%) were</p> <p>For full results see Table 1.1 in evidence review</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
			cancer patients had melanomas (a few may have had Merkel cell carcinoma).				
Nicole Hamilton et al (2014)	To provide updated assessment of how melanoma patients use the internet as a source of information and to assess how the internet impacted patients interactions with their oncologists and treatment decisions	Retrospective Case Series Single Centre (Canada) 2010-2013	N=62 patients agreed to take part	Internet as a source of melanoma information	N/A		<p>31 questionnaires were completed and returned giving a response rate of 50%.</p> <p>29 patients (93%) reported internet use and 68% of these patients reported using the internet 1-4 times a day.</p> <p>97% accessed the internet at home 55% accessed the internet at work 100% accessed the internet themselves and 21% also asked family/friends to access the internet for them.</p> <p>90% of patients (n=28) had used the internet as a source of melanoma information.</p> <p>Patients who did not use the internet as a source of melanoma information reported being satisfied with the information provided by health</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>professionals (n=3), being confused or overwhelmed by the available information (n=2) or were not internet users (n=1).</p> <p>90% of patients used Google, 11% used Yahoo, 7% used Bing and 4% used Microsoft Network.</p> <p>69% of patients chose melanoma websites based on top hits returned by searches 42% chose websites from a known reputable source 15% chose websites based on recommendations from doctors or health care providers</p> <p>54% viewed 1-5 melanoma sites 39% viewed 6-10 sites 8% viewed more than 10 websites</p> <p>46% of internet users visited specific hospital/cancer institute specific websites 15% visited commercial health or general knowledge websites for melanoma information. 38% could not recall the sites they used</p> <p>96% sought information on</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>melanoma treatment</p> <p>64% sought information on prevention</p> <p>64% sought information on screening</p> <p>54% sought information on symptom management and treatment toxicity</p> <p>18% sought information on clinical trials</p> <p>14% sought information on alternative/complementary therapy</p> <p>‘melanoma’(75%) and ‘skin cancer’ (36%) were the most common search terms</p> <p>25% also used terms specific to melanoma treatments, 11% searched for terms relating to symptoms and 11% for melanoma staging.</p> <p>In evaluating the quality of available information, 64% compared data from several websites and 64% discussed the information with their family doctor or oncologist.</p> <p>32% selected information from academic or government sites.</p> <p>Only 14% referred to the author credentials</p> <p>11% examined the references cited on the website.</p> <p>85% of internet users reported the</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>internet to be a useful source of melanoma information. 78% of users reported that the internet improved their understanding of their diagnosis and 71% felt that it had been influential on their treatment decisions.</p> <p>52% of internet users reported that internet use affected their specialist consultation by helping their decision making while 37% felt it did not influence their decision making and 7% considered it to make their decision more difficult.</p> <p>Ease of access was considered the main strength of the internet (74%) followed by the volume and detail of information (52%) , discussion of different perspectives/options (37%) and anonymity (7%).</p> <p>54% of users reported that available information was difficult to understand.</p>
Oliveria, S. A et al (2013)	What are the experiences of melanoma survivors regarding	Focus Groups Qualitative Study	48 patients diagnosed with invasive primary melanoma,	Thematic text analysis of the focus group transcripts.			Impact of melanoma on life outlook and broader health (themes with representative quotes)

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
	surveillance, psychosocial and family concerns?		stages I-III and 1-10 years since diagnosis who were treated at Memorial Sloan Kettering Cancer Centre between 1996 and 2005. Random sample, stratified by age.				<ul style="list-style-type: none"> Receiving good news from physician screenings was psychologically reassuring for survivors. <p>‘Coming back to the dermatologist, sort of getting that stamp of approval for me is always a positive thing. And then afterwards you sort of get—you know, it actually clears your head a little bit. So I don’t mind coming. Not just clears your head that, okay, there’s something on the plus side, but it clears you of any potential negative thoughts and worries.’ (Patient <50 years of age; 1 to <5 years since diagnosis)</p> <ul style="list-style-type: none"> Melanoma diagnosis prompted many survivors to assess and

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>reprioritize life values and develop a more positive life outlook.</p> <p>‘In terms of my life, I think it just made me focus down on the day-to-day and not be so overwhelmed with irritations at work. . . It’s just—it’s like it’s not that important. The fact that I’m alive another day is more important than this.’ (Patient <50 years of age; 1 to <5 years since diagnosis)</p> <ul style="list-style-type: none"> • Receiving melanoma diagnosis elevated the importance of being more vigilant and proactive regarding monitoring one’s health and interacting with physicians to obtain good care. <p>‘So what I should have done</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>right from the beginning was, as soon as I saw something like that, if they're not real sure, why not just get it taken off? And why don't you biopsy it or do something? So that taught me to be real proactive. If somebody says, "Well, don't worry about it," I'll tell you what, if it bothers me, I'm not going to take that for an answer anymore. I'm going to say, "Do something. I demand it.'" (Patient ≥50 years of age; 1 to <5 years since diagnosis)</p> <ul style="list-style-type: none"> • Receiving a melanoma diagnosis served to either strengthen or place stress on survivors' relationships with romantic partners.

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>‘Well I’ve been married to the same person for 42 years, and I love him dearly, but he didn’t do well with my diagnosis, which was two years ago. And it was a stage II, and it was a big—it was a fairly big deal. But for some reason he became sick when I got the diagnosis. It was almost as though I was getting more attention than he was, and this became a problem just because I sort of—I guess I’m sort of an insular person, and when this happened I sort of turned inward, and you’re trying to steel yourself and get through this, and you just don’t want to deal with—I don’t want to</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>deal with other people and their problems. I need to focus on this. And it's a selfish thing for me, I know that, but I couldn't deal with him. I never took him with me to the doctor because the first time I did I came out to the waiting room and there he is and he says, "Oh, I feel awful." Wait a minute, you know? I'm the guy with cancer, and you feel awful? So this was a problem for probably the first year.'</p> <p>(Patient ≥50 years of age; 1 to <5 years since diagnosis)</p> <p>Modifications to melanoma risk</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>reduction behaviours</p> <ul style="list-style-type: none"> Survivors became more conscious of sun exposure and expanded use of sun protection measures following diagnosis. <p>‘The need for sun protection is just a part of life.’ (Patient <50 years of age; 5–10 years since diagnosis)</p> <ul style="list-style-type: none"> Melanoma survivors sought to continue outdoor pursuits but used sun protection. <p>‘Because I still do the outdoor stuff. . . my whole thought process is I’m going to protect myself to the best I can, but I’m not going to stop doing what I want to do because I just want to do it.’</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>(Patient <50 years of age; 1 to <5 years since diagnosis)</p> <p>‘I obviously try to stay out of the sun. I wear sunscreen every day on my face. I garden but I try to stay in the shade. I wear long sleeve shirts. I wear hats in the summer if I know I’m going to be out, but to be honest with you, one way that I do manage this illness is I don’t cover up completely, because I don’t want it to overtake my life.’ (Patient <50 years of age; 5–10 years since diagnosis)</p> <ul style="list-style-type: none"> • A majority of survivors were more likely to engage in regular, consistent sun protection during the summer

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>months.</p> <p>‘But since all my doctors told me what to do to reduce any kind of risk—I wear the super strength sunscreen, put it on every hour. I’m actually never in the direct sun at all ever, but if I am even in the shade I put the sunscreen on every hour, wear a hat. I wear long sleeves, long pants.’ (Patient ≥50 years of age; 1 to <5 years since diagnosis)</p> <ul style="list-style-type: none"> • The perception that melanoma is not a serious cancer and confidence that dermatologists will identify new melanomas at an early stage both minimized the necessity of establishing consistent sun protection

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>habits for some survivors.</p> <p>‘I take precautions I don’t drastically change my life. If I go to . . . have my skin examined twice a year, which I do now, with someone who’s very competent. . . They would spot it very early. So the risk of it being a serious matter is minimal, in a way. . . I don’t see the need to really radically change things, except to take precautions.’ (Patient ≥50 years of age; 1 to <5 years since diagnosis)</p> <p>Physician screening and skin-self examination practices</p> <ul style="list-style-type: none"> • Survivors regularly visited

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>dermatologists for screening and that seeing a dermatologist is an effective strategy to ensure new melanomas would be identified early.</p> <p>‘It’s a way of life’ and</p> <p>‘it’s a lifetime commitment.’</p> <p>(Patient <50 years of age; 1 to <5 years since diagnosis)</p> <ul style="list-style-type: none"> • Skin-self examination varied significantly across the sample but most did not conduct skin self-examinations on a regular basis. <p>‘I guess what I mean between formal and informal is I don’t formally have a set schedule.’ (Patient <50 years of age; 1 to <5 years since diagnosis)</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<ul style="list-style-type: none"> Survivors believed it is important to find a dermatologist whom they perceive to be competent—some survivors had dermatologists who had missed their melanoma. <p>‘And there’s a lot of ignorance around. Doctor says something, you think that’s it. I was very ignorant with that first melanoma. . .’ (Patient ≥50 years of age; 1 to <5 years since diagnosis)</p> <ul style="list-style-type: none"> Negative associations with seeing dermatologists were discomfort and embarrassment being naked and anxiety prior to appointments that the dermatologist may identify a suspicious area. <p>‘When I’d first come for the</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>quarterly check-ups or whatever, I'd feel a little tense, realizing that I could walk out of here with a different answer, or my life could change.' (Patient <50 years of age; 5–10 years since diagnosis)</p> <ul style="list-style-type: none"> • Lack of confidence in ability to identify a suspicious mole was cited as a barrier to conducting skin self-examination, and some survivors preferred to off-load the responsibility to the doctor. <p>'I don't check myself. . . But my skin I don't check, because the time I said, "Look at this, this, and this," and they'll say, "It's nothing."' (Patient ≥50 years of age; 1 to <5 years</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>since diagnosis)</p> <p>‘But over time I’ve really come to rely on—same thing—I really believe that in some ways I’ve sort of put some of the responsibility on my doctors and the photography—and I have dysplastic nevus as well—but I don’t feel like I could ever do a body check.’ (Patient <50 years of age; 5–10 years since diagnosis)</p> <p>Economic issues arising from diagnosis and treatment</p> <ul style="list-style-type: none"> • Melanoma diagnosis elevated the importance of retaining health care insurance and purchasing life

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>insurance for younger survivors.</p> <p>‘I mean and then what do you do if you can’t get health insurance? I’ll have to take a lousy job that I don’t want to work at so that I’ll have health insurance. Yeah, that’s actually a huge fear for me.’ (Patient <50 years of age; 1 to <5 years since diagnosis)</p> <p>‘Economically I just think I’ll find the money somewhere. That’s not going to be the issue that I’m going to stress over.’ (Patient <50 years of age; 5– 10 years since diagnosis)</p> <ul style="list-style-type: none"> • Economic concerns were far more prominent for younger melanoma

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>survivors; financial concerns were not a major worry for older survivors, with insurance/Medicare coverage.</p> <p>‘It (my melanoma diagnosis) really didn’t hit me until I went to apply for life insurance. . .it was the life insurance that made it hit home and there was a difference—I have a history that affected my life.’ (Patient <50 years of age; 5–10 years since diagnosis)</p> <p>Concerns for family members</p> <ul style="list-style-type: none"> Survivors were aware their diagnosis increased melanoma risk (genetic susceptibility) and the need for family members to be screened,

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>yet many did not discuss risk reduction with family members.</p> <p>‘I wanted to make sure that they (children) understood that this wasn’t something that you worry about for this summer, that you have to be concerned about it. I try to teach them that their whole life they need to be aware of the effect the sun can have on them and take appropriate measures for it. . .I didn’t want to scare them or anything like that, or make them feel like, “Oh my God, I can never go outside again.” I was just kind of like, “Hey, this is something that can happen. There’s a hereditary</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>component, and you're at risk because of that," but I didn't make it—I didn't play the whole thing up like. . .'</p> <p>(Patient <50 years of age; 1 to <5 years since diagnosis)</p> <p>Anxiety post-treatment, concerns about recurrence, and thoughts about cancer status</p> <ul style="list-style-type: none"> • Some survivors experienced anxiety if outdoors without sun protection. <p>'When I don't think I'm going to be out and I end up having to be out, you get stressed. Like I'm outside for a half hour and I'm like, "I've got to get out of the sun. I don't have anything on."' (Patient</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p><50 years of age; 1 to <5 years since diagnosis)</p> <ul style="list-style-type: none"> Some survivors minimized their melanoma diagnosis, regarding melanoma to be a disease that develops on the surface of the skin. <p>‘You said the word cured, and that’s the last word I would think about, because I never thought of me as having cancer, because skin cancer is almost outside of you. . .It’s not like something inside you, systemic or something. This is sort of like, okay, it was on my skin that had to be removed. That’s not—that was on top of my skin’ (Patient <50 years of age; 5–10 years since</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>diagnosis)</p> <ul style="list-style-type: none"> • Perceptions of cancer status and likelihood of future recurrences varied. <p>‘Well, I was surprised when I got the call, because they said it was for “survivors,” and I don’t even consider myself a survivor. I mean I don’t even think about it. It happened, they fixed it and it might happen again and it might not.’ (Patient ≥50 years of age; 1 to <5 years since diagnosis)</p> <ul style="list-style-type: none"> • Diagnosis prompted younger female survivors to shift their attitudes toward child-bearing (decision not to have children because of fear of

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>recurrence and passing down risk to children; decision to expand family size to 'live more fully').</p> <p>'It's (hearing about increase likelihood of getting a new melanoma if you get pregnant) a disappointment. He (doctor) said there are studies showing that you can—so you're actually taking a personal risk by getting pregnant, not to mention that then that's a period of not being as vigilant, because I can't do some of the screens I was doing. So it's sort of just hard to put at odds having a family versus taking care of your own body.'</p> <p>'I'm thirty-nine and between</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>my age and the impact of getting pregnant with hormonal levels on melanoma—I think one of the things that’s impacted me most significantly is that I’ve decided not to get pregnant.’(Patient <50 years of age; 1 to <5 years since diagnosis)</p> <p>‘I always have little skin stuff. I have lumps over here and, you know—I don’t know which of these things are things to worry about or not, so going to him regularly gives a way to check. . .’ (Patient <50 years of age; 1 to <5 years since diagnosis)</p>
Palesh et al	To investigate	Prospective	N=160		N/A		<i>Sun Protective Practices</i>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
(2014)	psychosocial and physical function, long-term effects, support needs and health behaviours such as physician follow-up and self skin screening of melanoma survivors	Case Series Single Centre (USA) July 20, 2012-September 10, 2012	patients providing evaluable data Mean age was 61.9 years (SD=13.5) Median time since diagnosis was 77 months (2-400 months) Median time since treatment was 59 months (0-336 months)				<p>Following melanoma diagnosis there was an increase in sun protection practices</p> <ul style="list-style-type: none"> 71% used sunscreen 73.8% wore protective clothing when outdoors 73% reduced time in the sun 63% reduced time seeking a tan 27.5% decreased sun bed use <p><i>Long Term Effects</i></p> <p>Anxiety was the most prevalent long term effect (34%) followed by numbness and tingling (32%), forgetfulness (26%), depression and sleep problems (23-24%) and fatigue and pain (17-18%)</p> <p>The majority of patients reported no changes in physical and psychosocial domains of vitality, bodily pain, physical functioning, mental health, social functioning, emotional health, body image and sexual functioning (range 72.5%-88.8%) compared with symptoms experienced prior to diagnosis.</p> <p>A subset of participants experienced diminished self-perception of body image (23%) and physical functioning</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>(15%) and a small group of patients experienced improvement in psychosocial function.</p> <p><i>Survivor Needs</i></p> <p>42.5% of patients requested additional education about the long-term effects of melanoma</p> <p>27.5% wanted information on their family's risk of melanoma</p> <p>32.5% did not require additional help following melanoma diagnosis</p> <p>53% of patients requested additional information specific to melanoma</p> <p>8% of patients responded that they would like help beyond the survey options, specifically help with treatment advances, screening, education, symptom relief, financial support and addressing cosmetic concern.</p> <p>42.5% of patients reported negative changes in at least one domain of physical and psychosocial function. It was reported that health providers did not address these adverse signs or symptoms 55.9% of the time. Of the 30% of health providers who did address the changes, 31% initiated the conversation with the patient.</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p><i>Differences in behaviours and Symptoms by Sex</i> Sun protection practices, long-term effects and changes in life quality measures were comparable between males and females.</p> <p>73% of females reported a reduction in time seeking a tan compared with 54% of males ($p=0.01$)</p> <p>Females had an increased perception of post-operative swelling of the arm or leg compared with males ($p=0.014$).</p> <p>63.5% of males did not want additional help following diagnosis compared with 36.5% of females (0.032).</p> <p>There was no difference in perceptions of anxiety or depression ($p=0.05$)</p> <p><i>Differences by Education</i> There were no statistically significant differences by level of education.</p> <p><i>Differences by time since diagnosis</i> Long term survivors were less likely to</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>receive routine skin screening every 3-6 months compared with short term survivors (37% vs. 83%, $p<0.001$).</p> <p>Long term survivors were less likely to receive routine follow up for their melanoma in the 6 months prior to survey completion compared with short term survivors (54% vs. 76%, $p<0.04$).</p> <p>Long term survivors decreased sunbed use compared with short term survivors (35% vs. 18%, $p<0.02$) and time seeking a tan (74% vs. 48%, $p=0.001$).</p> <p>Short term survivors reported more numbness/tingling at the surgical site ($p=0.027$).</p> <p><i>Differences by extent of treatment</i> Patients who received more extensive treatment (WLE+) reported greater fatigue ($p=0.001$), arm or leg swelling ($p<0.001$) and weakness ($p=0.001$) compared with patients undergoing WLE alone.</p> <p>Patients undergoing WLE+ were more apt to follow-up recently with their health care provider when compared</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>with patients undergoing WLE only (67% vs. 53% at 3-6 months, $p=0.025$).</p> <p>More patients undergoing WLE reduced their tanning bed usage compared with patients undergoing WLE+ (40% vs. 23%, $p=0.047$).</p> <p>More patients undergoing WLE wanted information on sun protection compared with patients undergoing WLE+ (40% vs. 11%, $p<0.001$).</p>
Rychetnik, L et al (2013)	<p>What are patient preferences, experiences and other psychosocial outcomes associated with follow-up after surgical treatment of stage I or II melanoma?</p> <p>What are clinician preferences and</p>	<p>Systematic Review of quantitative and qualitative studies</p> <p>The review included studies from USA, UK, Austria, Germany and Sweden</p>	Patients with stage I or II melanoma	Post treatment follow-up			<p>15 studies included (published before April 2010): nine from the patient's perspective, 3 from the clinician's perspective and 3 from both. 12 were quantitative and 3 qualitative. Overall the studies were at low risk of bias (as assessed using the Effective Public Health Practice Project Quality Assessment Tool).</p> <p>Information needs</p> <p>Follow up was an important source of patient information about sun-related behaviours. The main sources of information were the clinic doctor, books & magazines and the clinic nurse. Overall satisfaction with follow up was high (both G.P. based and</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
	experiences of providing follow-up after surgical treatment of stage I or II melanoma?						<p>hospital based) on the whole patients felt reassured and were able to ask questions at their follow up appointments.</p> <p>Support needs</p> <p>More than half the patients surveyed were interested in professional emotional support, and most preferred to get this from their doctor rather than a psychiatrist or psychologist. Requests for support were also associated with greater interest in complementary therapies.</p> <p>Around half of surveyed patients reported anxiety associated with follow up appointments (clinically significant levels in approximately 20% of patients). This was sometimes accompanied by physical symptoms and sometimes started weeks before the appointment. Patients expressed interest in trialing GP-led follow up.</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>Patients wanted rapid access to a specialist if a suspicious lesion was found.</p> <p>Approximately half the patients surveyed managed to adhere to follow-up schedules. Non adherence was typically attributed to logistical problems.</p> <p>Authors concluded that – patients experience substantial anxiety associated with follow-up visits but overall find it reassuring to have regular checkups with the chance to ask questions. Patients also report a degree of unmet need for emotional support which they would rather receive from their doctor than from a psychologist or psychiatrist.</p>
Stamataki et al (2014)	To investigate the impact of melanoma diagnosis on the supportive care needs of patients with cutaneous melanoma	<p>Qualitative Cross sectional survey</p> <p>2 specialist cancer referral centres (UK)</p>	<p>N=15 patients included in analysis</p> <p>Mean age 52 years (27-78 years)</p>	Questionnaire	N/A		<p>Four major themes were identified:</p> <ul style="list-style-type: none"> Emotional effects Effect on relationships Functional effects Health system and information needs <p><i>Emotional Effects</i></p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p><i>Uncertainty</i> Uncertainty for the future contributed to the feelings of anxiety, fear and low moods of melanoma patients. Participants expressed feelings of helplessness and frustration due to their inability to be proactive (receiving treatment to reduce risk of recurrence) and only being reactive (looking for new moles etc).</p> <p>Patients reported being over vigilant and over anxious that any new change might be indicative of recurrence.</p> <p>A lack of emotional support from the health care system resulted in increased concerns, anxiety and feelings of helplessness.</p> <p><i>Altered Body Image</i> Some participants reported an altered body image as a result of melanoma surgery. Issues reported included appearance of WLE scar and lymphoedema Patients reported a disparity between pre-surgery expectation and perceived post surgery appearance of scar and felt that they had not properly been prepared for the appearance of the scar despite</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>speaking to health professionals prior to surgery.</p> <p>There appeared to be disparity between doctors perceptions of a healing scar and the language used to describe a well healing scar compared with a patient's perception of their healing scar which has implications for how doctors might discuss post-surgery expectations.</p> <p>Some participants denied being overly concerned by their altered body image while others downplayed their concern and some patients described wearing clothes/make-up to hide their scar.</p> <p>Some participants described concerns about how altered body image affected their confidence and appearance.</p> <p><i>Fear of the Sun</i></p> <p>Fear of the sun emerged as a strong theme with patients reporting feelings of panic or anxiety that they were going to burn and fear of the sun meant that participants had concerns about living their everyday life.</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>There was a strong desire from some participants to receive more detailed information on sun protection and that the information they received was too general and did not cover issues such as travelling to hot countries, type of sunscreen and frequency of sunscreen application.</p> <p><i>Effects on Relationships</i> Concerns around changes to working lives included changes to working relationships or an inability to perform their job as previously. Some changes resulted in feelings of embarrassment or awkwardness about how their illness impacted their working lives or a loss of confidence and higher work related stress. Some participants reported feeling a lack of support and understanding from work colleagues and managers and felt that this may be due to a lack of public awareness about melanoma suggesting a need to increase campaigns to improve understanding.</p> <p><i>Family Relationships</i> Participants generally felt they had good support from family members and friends. Participants reported being mindful of</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>not discussing their diagnosis with family and friends for fear of pushing their partner away or to protect family members.</p> <p><i>Functional Effects</i> Patients experienced side effects including lymphoedema, pain and fatigue following surgery. These side effects impacted on participants daily lives including their ability to carry out normal daily tasks, take part in sports or hobbies and caused mood changes.</p> <p>Patients affected by fatigue felt that it was an inevitable consequence of surgery and as a result did not seek health care support and tried to adapt their lives to manage their symptoms.</p> <p>Patients seem to want some reassurance and emotional support to help cope with their symptoms regardless of whether they were already under the care of a specialist.</p> <p><i>Health Care System and Information Needs</i></p> <p><i>Clarity of Information</i> Participants reported that they could not comprehend the information</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>provided about their prognosis or stage of melanoma and this contributed to feelings of anxiety and uncertainty for the future.</p> <p><i>Quality of Information</i> One participant reported that enough information was provided by the Nurse specialist but that access to a Nurse specialist should have been available from diagnosis.</p> <p><i>Information at the right time</i> There were differing experiences regarding access to information at the right time, Patients reported feeling there was no standard procedure for when patients were provided with information.</p> <p>Some participants reported getting too much information up front and some participants felt that information was provided too late, particularly in the case of sun protection advice.</p> <p>Some participants expressed anxiety around the amount of time they had to wait for their test results.</p> <p><i>Time spent with health professionals</i></p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							<p>Participants expressed disappointment for not getting the opportunity to ask questions at clinics and feeling that doctors were so busy that they did not want to prolong their visit by asking questions.</p> <p>Lack of time with health professionals to discuss their emotional needs regarding their melanoma diagnosis was a strong theme. It was a particularly important to patients who avoided speaking to their family members/partners.</p> <p>Some participants did not feel they could access health professionals between clinic visits or access help or advice over the phone resulting in a feeling of abandonment.</p>

1 **Question in PICO Format**

Population	Intervention	Comparator	Outcomes
<ul style="list-style-type: none"> • People with Melanoma • Carers of people with melanoma Stage: <ul style="list-style-type: none"> • 0-Ia • Ib – IIIa • IIIb – IIIc • IV 	Information delivery in different formats (digital/written) provided at different milestones/points in the pathway <ul style="list-style-type: none"> • Clinician • CNS • Helplines/charity organisations • Support groups (inc online support groups) 	Each other Different age groups? Cultural groups?	Health Related Quality of Life Patient satisfaction/experience Treatment decision making Patient reported QoL

2

3 **Search Results**

Database name	Dates Covered	No of references found	Finish date of search
<i>Medline</i>	1946-2014	4681	24/03/2014
<i>Premedline</i>	Mar 24 2014	303	25/03/2014
<i>Embase</i>	1947-2014	8894	25/03/2014
<i>Cochrane Library</i>	Issue 3, Mar 2014	152	25/03/2014
<i>Web of Science (SCI & SSCI)</i>	1900-2014	6494	25/03/2014
<i>PsycInfo</i>	1806-2014	143	25/03/2014
<i>CINAHL</i>	1979-2014	392	31/03/2014
Total References retrieved (after databases combined, de-duplicated and sifted): 352 & 1 reference added 30/04/2014			

4 **Medline search strategy** (This search strategy is adapted to each database)

- 5 1. exp Melanoma/
- 6 2. melanoma\$.tw.
- 7 3. (maligna\$ adj1 lentigo\$).tw.
- 8 4. (hutchinson\$ adj1 (freckle\$ or melano\$)).tw.

- 1 5. dubreuilh.tw.
- 2 6. LMM.tw.
- 3 7. or/1-6
- 4 8. Health Services Accessibility/
- 5 9. Office Visits/
- 6 10. Remote Consultation/
- 7 11. Physician-Patient Relations/
- 8 12. Nurse-Patient Relations/
- 9 13. Professional-Patient Relations/
- 10 14. Professional-Family Relations/
- 11 15. ((patient* or consumer* or carer* or caregiver* or spouse* or famil* or relati*) adj2 (decision*
- 12 or choice* or preference* or support* or participat* or educat*)).tw.
- 13 16. ((personal or interpersonal or individual*) adj2 (decision* or choice* or preference* or support*
- 14 or participat* or educat*)).tw.
- 15 17. (information adj2 (aid* or support* or need* or provision or deliver* or material* or
- 16 resource*)).tw.
- 17 18. ((patient* or carer* or caregiver* or spouse* or famil* or relati*) adj2 (information or
- 18 literature)).tw.
- 19 19. ((web* or print* or electronic*) adj2 (information or resource*)).tw.
- 20 20. Patient Education as Topic/
- 21 21. Pamphlets/
- 22 22. (pamphlet* or leaflet* or booklet* or guide* or sheet* or flyer* or flier*).tw.
- 23 23. ((electronic or email) adj (report* or support)).tw.
- 24 24. exp Audiovisual Aids/
- 25 25. (video* or dvd* or tape* or cd*1 or film*1 or telephone* or phone* or computer* or internet or
- 26 online or web or electronic).tw.
- 27 26. exp Internet/
- 28 27. exp telephone/
- 29 28. exp hotlines/
- 30 29. ((hot or help* or tele* or phone) adj (line* or support)).tw.
- 31 30. Communication/
- 32 31. (communicat* or talking).tw.
- 33 32. exp social support/
- 34 33. exp Self-Help Groups/
- 35 34. ((inform* or support*) adj2 (tool* or method* or group*)).tw.
- 36 35. (face* adj face*).tw.
- 37 36. Psychoeducation/
- 38 37. Psychotherapy/
- 39 38. ((psychosocial or psycho*) adj2 (support* or educat* or need*)).tw.
- 40 39. Stress, Psychological/
- 41 40. Counseling/
- 42 41. exp Patient Education/mt [Methods]
- 43 42. or/8-41
- 44 43. 7 and 42
- 45 44. limit 43 to yr="1980 -Current"

1 **Screening Results**

2 The literature search identified 351 potentially relevant papers of which 19 were ordered. One
3 systematic review was included (McLoone et al, 2013).

4

Evidence statements

Interventions for information

Evidence about educational interventions for patients with melanoma came from a systematic review by McLoone et al (2013) which included five randomized controlled trials (RCTs) and five other studies. Most interventions involved a personal or group instruction session from a nurse, GP or dermatologist which was also reinforced by printed information (see Table 1). One study examined whole body photography as an aid to skin self examination (SSE).

Educational interventions were typically associated with increased melanoma knowledge, better adherence to SSE and better satisfaction with care, but not in all cases. Purely educational interventions did not appear to affect anxiety, depression or psychosomatic symptoms, in the studies that measured these outcomes.

Differences between the interventions used in the studies and the way outcomes were measured makes it difficult to identify the effective components of a successful educational intervention.

Interventions for support

Evidence from a systematic review of three randomized trials (McLoone et al, 2013; see Table 2) suggests uncertainty about the effectiveness of clinical psychologist or psychiatrist led cognitive behavioural therapy (CBT) for improving psychological well-being among people with melanoma. One qualitative study described a telephone peer-support intervention for people with melanoma, which both the patients and their supporting peers viewed as effective.

Combined information and support interventions

Three randomized controlled trials evaluated variations on the same combined educational and psychological intervention (McLoone et al, 2013; see Table 3). Each of these studies reported decreases in distress (anxiety, depression, hostility, and mood disturbance). The largest of these trials, however, reported only short-term emotional and physiological benefits, and there were no long term group differences in survival or time to recurrence. In a fourth randomized trial, participants who attended an average of 19 sessions with an oncology counsellor over a period of 6 months reported a greater decline in anxiety, hostility and depression than a control group

Table 1.3. Educational Interventions (McLoone et al 2013)

Study	Intervention(s)	Population	Design	Follow up	Outcomes
Brandberg <i>et al.</i> (1994; 1996);	A nurse-led, group information session (1.5 h) held prior to the patient's first medical visit, plus an information booklet versus control group (standard care). The control group received active intervention after their first medical visit.	171 stage I melanoma patients.	RCT	3 months, 6 months	Intervention group reported an increase in melanoma-related knowledge and satisfaction with the provision of information, compared with controls. No psychological or psychosomatic differences were reported between groups. After receiving the intervention, control group knowledge increased to equal intervention group levels. No differences in attitude toward the program were reported between those who participated before or after the first medical visit. No psychological or psychosomatic differences were reported between groups.
Murchie <i>et al.</i> (2010)	CSE by a GP (followed-up every 3–6 months), instruction in SSE and a patient information booklet (detailing SSE) versus control (standard care).	142 melanoma patients from 17 medical practices.	RCT	12 months	Intervention participants reported increased satisfaction with care and greater adherence to patient guidelines. No group differences in anxiety or depression were reported at baseline or post-intervention.
Murchie <i>et al.</i> (2009)	GPs received 4 h training and a detailed manual on how to conduct CSE and implement the	17 GPs providing follow-up care for melanoma patients	N.R.	N.R.	GPs qualitatively reported high satisfaction with the intervention program and perceived patients to

Study	Intervention(s)	Population	Design	Follow up	Outcomes
	aforementioned intervention for patients, versus control (no additional training).				be highly satisfied also.
Berwick <i>et al.</i> (2000)	Nurse-led educational intervention, consisting of SSE training, educational reading materials, and an SSE diary.	75 individuals at high and average melanoma risk	Prospective	N.R.	Knowledge improved post-intervention and was associated with a personal history of melanoma and increased SSE. Post intervention, the proportion of participants performing optimal-frequency SSE almost doubled. However, of participants who performed SSE at follow-up, only 29% conducted a full SSE including difficult to see areas of the body.
Robinson and Turrise (2006)	One, dermatologist-led group session, teaching SSE (by the ABCDE rules of discrimination; placing transparencies of a lesion on the participant's arm to personalize learning; a slide show; a brochure; and a bookmark).	100 individuals with a personal or family history of melanoma.	Prospective	20 minutes after intervention	Identification of border irregularity, colour variation and diameter improved with education; asymmetry and identification of change did not. 87% thought the brochure was too long (20 min to review) and preferred the bookmark. Border, colour, and the decision to see a physician improved after skills training.
Robinson <i>et al.</i> (2007; 2009)	Participants were randomly assigned to receive intervention as a solo learner or dyadic-partnership. The ABCDE recognition system and	130 patients with a personal/family history of melanoma, or dysplastic nevi and their cohabitating	RCT	4 months	Dyadic learners placed more importance on conducting SSE monthly, partner assistance and reported greater self-efficacy for conducting SSE than solo learners

Study	Intervention(s)	Population	Design	Follow up	Outcomes
	SSE training were taught.	partners versus control group. (Robinson 2007) 174 melanoma patients and their partners. (Robinson, 2009)			at both post-intervention 4-month follow-up. Dyadic learners also reviewed SSE guidelines, examined the skin with and without their partner, more frequently, than solo learners. The ABCDE illustrated card was used more by dyadic learners. Cards stored in bedrooms and bathrooms were used most frequently. Dyadic learners referred to the card mainly for checking colour variation, single learners referred to the card to show their partner what to check.
Robinson <i>et al.</i> (2010)	Participants were randomly assigned to receive an in-person intervention (as previously mentioned above in Robinson 2007;2009) or a workbook intervention (39 pages).	40 stage I–II melanoma patients and control group	RCT	N.R.	Both groups increased partner assisted SSE, SSE self-efficacy, attitude toward SSE and SSE knowledge. There were no group differences. Workbooks were referred to more often than ABCDE cards.
Phelan <i>et al.</i> (2003); Oliveria <i>et al.</i> (2004); Hay <i>et al.</i> (2006)	Nurse-led intervention using a personalized photo-book containing whole body digital photography to aid SSE versus control (pamphlet on how to conduct and diarize SSE).	100 high-risk melanoma patients (based on a past history of melanoma, dysplastic nevus, or skin biopsy) plus control group	RCT	4 months	Intervention had no effect on skin cancer knowledge, awareness or SSE self-efficacy. Both groups reported an increase in the above variables at 4-month follow-up. SSE adherence was significantly increased in the intervention group, compared with controls

Study	Intervention(s)	Population	Design	Follow up	Outcomes
					Participation in the intervention group was significantly associated with increased SSE self-efficacy and adherence to SSE. Adherence to SSE was more likely if high self-efficacy and skin cancer knowledge was reported, irrespective of intervention condition.
Uliasz and Lebwohl (2007)	Patient education in conjunction with routine follow-up surveillance by a clinician.	111 stage I–II melanoma patients who developed a second primary melanoma. Identified using the American Joint Committee on Cancer database	Retrospective study.	N.R.	Melanoma diagnoses after patient education were more likely to be <i>in situ</i> than the initial diagnosis, be less invasive and less thick.
DiFonzo <i>et al.</i> (2001)	Patient education in conjunction with routine follow-up surveillance by a clinician.	82 stage I–II melanoma patients who developed a second primary melanoma. Identified using the American Joint Committee on Cancer database	Retrospective study.	N.R.	A second melanoma after patient education and routine follow-up care was more likely to be less invasive, diagnosed at a lower stage and less thick.

Abbreviations: ABCDE, Asymmetry, Border, Colour, Diameter, Evolving; CSE, clinical skin examination; RCT, randomized controlled trial; SSE, skin self-examination;

Table 1.4. Psychological Interventions (McLoone et al 2013)

Study	Intervention(s)	Population	Design	Follow up	Outcomes
Trask <i>et al.</i> (2003)	Three weekly 50-min sessions of CBT, versus standard care. CBT focused on relaxation training, cognitive challenging, and problem solving.	48 stage I–III melanoma patients with medium-to-high distress 2 months after initial consultation	RCT	6 months	Overall, CBT had no effect on distress levels. Anxiety scores were significantly lower for the CBT group at both 2-month and 6-month follow-up. General health, vitality, social functioning, and mental health scores all improved immediately after the CBT, However, only general health scores remained higher with CBT than the standard care group at 6-month follow-up.
MacCormack <i>et al.</i> (2001)	6–8, individual sessions with a psychologist using a manualized, CBT program. Sessions were 90 min on average, conducted at home or at hospital, held over a 3-month period. The control condition consisted of relaxation therapy with unstructured ‘chat’ time. Therapists did not address issues or problems, but provided empathic listening and reflection of content.	26 metastatic melanoma patients, breast and gynaecological cancer patients.	RCT & qualitative	N.R.	Talking to an objective person outside the family was beneficial; fewer feelings of isolation and stigmatism and a greater sense of being heard and feeling ones situation was normal; Therapist warmth was supportive; Individual therapy was preferred (excluding family members), although specific sessions purposely for the family could have been useful;

Study	Intervention(s)	Population	Design	Follow up	Outcomes
					Preference for being seen at home; more structured follow-up would have been helpful.
Rudy <i>et al.</i> (2001)	Peer-led, telephone-based social support. Two telephone contacts initiated by the helper, prior to the helpee's 1st and 2nd immunotherapy treatment.	88 stage III–IV melanoma patients receiving treatment and 'helpers'	Qualitative	N.R.	<p>Helpees became more sensitive and open to available social support</p> <p>Helpers and helpees viewed intervention as effective;</p> <p>Telephone contact was a satisfactory substitute for face-to-face support.</p>
Bares <i>et al.</i> (2002)	Four weekly 50-min sessions of CBT versus standard care. CBT focused on relaxation training, cognitive challenging, and problem solving.	30 stage I–III melanoma patients with medium-to-high distress 2 months after initial consultation.	RCT	9 months	<p>Distress levels decreased to within 'normal' range 5 months post-intervention.</p> <p>No change in distress for patients receiving standard care only.</p> <p>Cost analysis demonstrated an expense of \$402 (standard care) versus \$7.66 (CBI) per unit decrease in distress.</p>

Abbreviations: CBT: Cognitive behavioural therapy; RCT, randomized controlled trial; N.R. not reported.

Table 1.5. Combined educational and psychological interventions (McLoone et al 2013)

Authors (year)	Intervention(s)	Population	Design	Follow up	Outcomes
Boesen et al. (2005; 2007)	Six, 2.5 h, weekly educational sessions, delivered by physician (1–4 months post surgery), based on manual by Fawzy <i>et al.</i> 1995 and included health education, coping and problem-solving techniques, stress management, and psychological support.	262 melanoma patients versus control.	RCT	1 year	Intervention reduced fatigue and mood disturbance and increased vigour and active-behavioural/active-cognitive coping. Improvements were only significant at 6-month follow-up; there were no differences between groups at 12 months.
Gordon et al. (1980)	Oncology counsellor-led (i.e. psychologists, social workers and psychiatric nurses), versus control (standard care). Intervention consisted of Education; medical information relating to ones diagnosis, how to live with cancer and dealing with the medical system. Counselling; reactions and feelings towards ones disease. Environment; consults and service referrals. Daily contact was made by the same oncology counsellor while an in-patient and on an as-needs basis post discharge (11 hospital contacts of 20 min each on average, eight out-patient contacts of 20 min each on average, for melanoma patients). Intervention duration was 6 months.	308 breast, lung, and melanoma patients ($n = 107$), versus control.	RCT & qualitative	6 months	Intervention group reported a greater decline in anxiety, hostility and depression; Intervention group reported a more realistic outlook on life; were more likely to have returned to their previous work status; Intervention group displayed a more active pattern of time usage.
Fawzy et al. (1990; 1993;	Six, weekly, 1.5 h, psychiatrist-led, group psychotherapy intervention versus control (standard care), involving health education; illness-related	68 stage I–II malignant melanoma	RCT	10 years	Immediate post therapy Increased vigour and active-behavioural

Authors (year)	Intervention(s)	Population	Design	Follow up	Outcomes
2003)	problem-solving skills; stress management; psychological support.	patients, versus control group.			<p>coping methods were reported by intervention versus control group. At 6 months</p> <p>6 months post-intervention, increased vigour and decreased depression, fatigue, confusion and total mood disturbance were reported by the intervention group versus controls. In addition, more active coping styles and less passive-resignation were reported by the intervention versus control group. At 5 years</p> <p>The intervention group only showed an increase in natural killer cell percentages post intervention, compared with baseline.</p> <p>Intervention participants had a significantly better survival rate, and there was a trend toward a lower recurrence rate, 5 years post-intervention.</p> <p>When controlling for other risk factors, intervention participation lowered the risk of recurrence by more than 2.5-fold and decreased the risk of death approximately sevenfold.</p>

Authors (year)	Intervention(s)	Population	Design	Follow up	Outcomes
					<p>At 10 years</p> <p>Survival benefit of intervention was no longer independently significant, although significant differences were present after controlling for other prognostic factors.</p> <p>Those with smaller Breslow depths who were female and who attended the intervention survived longer.</p> <p>When controlling for other risk factors, intervention participation reduced the risk of death threefold.</p>
Fawzy (1995)	6-week program including an educational manual and 3 h total of individual nurse-led psycho-education focusing on; health education, stress management and coping skills.	61 stage I–II malignant melanoma patients, post surgery, versus control group.	RCT	3 months	<p>At 3 months, the intervention group reported significant reductions in total mood disturbance, fatigue, and somatisation compared with the control group.</p> <p>Less passive resignation coping strategies were used by the intervention group compared with controls.</p> <p>Use of positive coping strategies did not increase.</p> <p>Within-group analysis of change scores found significant decreases for somatisation, general distress, anxiety, fatigue, confusion, vigour, and total mood disturbance in the intervention group only.</p>

Abbreviations: RCT, randomized controlled trial; SSE, skin self-examination;

References

Included Studies

McLoone, J., Menzies, S., Meiser, B., Mann, G. J., & Kasparian, N. A. (2013). Psycho-educational interventions for melanoma survivors: a systematic review. *Psycho-Oncology* 27[7], 1444-1456.

Studies included in the McLoone et al (2013) systematic review

Berwick M, Oliveria S, Luo ST, Headley A, Bologna JL, Berwick M, et al. A pilot study using nurse education as an intervention to increase skin self-examination for melanoma. *J Cancer Educ* 2000;15(1):38–40.

Phelan D, Oliveria S, Christos P, Dusza S, Halpern A. Skin self-examination in patients at high risk for melanoma: a pilot study. *Oncol Nurs Forum* 2003;30(6):1029–1036.

Brandberg Y, Bergenmar M, Bolund C, Michelson H, Mansson-Brahme E, Ringborg U, et al. Information to patients with malignant melanoma: a randomized group study. *Patient Educ Couns* 1994;23(2):97–105.

Brandberg Y, Bergenmar M, Michelson H, Mansson-Brahme E, Sjoden PO. Six-month follow-up of effects of an information programme for patients with malignant melanoma. *Patient Educ Couns* 1996;28(2):201–208.

Robinson JK, Turrisi R, Stapleton J. Efficacy of a partner assistance intervention designed to increase skin self-examination performance. *Arch Dermatol* 2007;143:37–41.

Oliveria SA, Dusza SW, Phelan DL, Ostroff JS, Berwick M, Halpern AC. Patient adherence to skin self-examination: effect of nurse intervention with photographs. *Am J Prev Med* 2004;26(2):152–155.

Hay JL, Oliveria SA, Dusza SW, Phelan DL, Ostroff JS, Halpern AC, et al. Psychosocial mediators of a nurse intervention to increase skin self-examination in patients at high risk for melanoma. *Cancer Epidemiol Biomarkers Prev* 2006;15(6):1212–1216.

Robinson JK, Turrisi R. Skills training to learn discrimination of ABCDE criteria by those at risk of developing melanoma. *Arch Dermatol* 2006;142:447–452.

Robinson JK. Use of photographs illustrating ABCDE criteria in skin self-examination. *Arch Dermatol* 2009;145:332–333.

Robinson JK, Turrisi R, Mallett K, Stapleton J, Pion M. Comparing the efficacy of an in-person intervention with a skin self-examination workbook. *Arch Dermatol* 2010;146:91–94.

Uliasz A, Lebwohl M. Patient education and regular surveillance results in earlier diagnosis of second primary melanoma. *Int J Dermatol* 2007;46:575–577.

Bares CB, Trask PC, Schwartz SM. An exercise in cost-effectiveness analysis: treating emotional distress in melanoma patients. *J Clin Psychol Med Settings* 2002;9(3):193–200.

- 1 DiFonzo LA, Wanek LA, Morton DL. Earlier diagnosis of second primary melanoma confirms the
2 benefits of patient education and routine postoperative follow-up. *Cancer* 2001;91:1520–1524.
- 3 Murchie P, Delaney EK, Campbell NC, Hannaford PC. GP-led melanoma follow-up: the practical
4 experience of GPs. *Fam Pract* 2009;26:317–324.
- 5 Murchie P, Nicolson MC, Hannaford PC, Raja EA, Lee AJ, Campbell NC. Patient satisfaction with GP-
6 led melanoma follow-up: a randomised controlled trial. *Br J Cancer* 2010;102:1447–1455.
- 7 Fawzy F, Kemeny M, Fawzy N, Elashoff R, Morton D, Cousins N, et al. A structured psychiatric
8 intervention for cancer patients. II. Changes over time in immunological measures. *Arch Gen*
9 *Psychiatry* 1990;47(8):729–735.
- 10 Fawzy F, Fawzy N, Hyun C, Elashoff R, Guthrie D, Fahey J, et al. Malignant melanoma: effects of an
11 early structured psychiatric intervention, coping, and affective state on recurrence and survival 6
12 years later. *Arch Gen Psychiatry* 1993;50:681–689.
- 13 Fawzy FI, Canada AL, Fawzy NW. Malignant melanoma: effects of a brief, structured psychiatric
14 intervention on survival and recurrence at 10-year follow-up. *Arch Gen Psychiatry* 2003;60(1):100–
15 103.
- 16 Boesen E, Boesen S, Frederiksen K, Ross L, Dahlstrom K, Schmidt G, et al. Survival after a
17 psychoeducational intervention for patients with cutaneous malignant melanoma: a replication
18 study. *J Clin Oncol* 2007;25(36):5698–5703.
- 19 Trask PC, Paterson AG, Griffith KA, Riba MB, Schwartz JL, Trask PC, et al. Cognitive-behavioral
20 intervention for distress in patients with melanoma: comparison with standard medical care and
21 impact on quality of life. *Cancer* 2003;98(4):854–864.
- 22 Boesen E, Ross L, Frederiksen K, Thomsen B, Dahlstrom K, Schmidt G, et al. Psychoeducational
23 intervention for patients with cutaneous malignant melanoma: a replication study. *J Clin Oncol*
24 2005;23(6):1270–1277.
- 25 Fawzy F, Kemeny M, Fawzy N, Elashoff R, Morton D, Cousins N, et al. A structured psychiatric
26 intervention for cancer patients: I. Changes over time and methods of coping in affect of
27 disturbance. *Arch Gen Psychiatry* 1990;47:720–725.
- 28 Fawzy FI, Fawzy FI. A short-term psychoeducational intervention for patients newly diagnosed with
29 cancer. *Support Care Cancer* 1995;3(4):235–238.
- 30 MacCormack T, Simonian J, Lim J, Remond L, Roets D, Dunn S, et al. Someone who cares: a
31 qualitative investigation of cancer patients' experiences of psychotherapy. *Psycho-Oncology*
32 2001;10:52–65.
- 33 Rudy RR, Rosenfeld LB, Galassi JP, Parker J, Schanberg R. Participants' perceptions of a peer-helper,
34 telephone-based social support intervention for melanoma patients. *Health Commun* 2001;13:285–
35 305.

- 1 Gordon WA, Frieidenbergs I, Diller L, Hibbard M, Wolf C, Levine L, et al. Efficacy of psychosocial
- 2 intervention with cancer patients. *J Consult Clin Psychol* 1980;48:743–759.
- 3 Fawzy N. A psychoeducational nursing intervention to enhance coping and affective state in newly
- 4 diagnosed malignant melanoma patients. *Cancer Nurs* 1995;18:427–438.

Evidence Tables**Study Quality**

	McCloone et al (2013)
The review addresses an appropriate and clearly focused question that is relevant to the review question	Yes
The review collects the type of studies you consider relevant to the guidance review question	Yes
The literature search is sufficiently rigorous to identify all the relevant studies	Yes
Study quality is assessed and reported	Yes
An adequate description of the methodology used is included, and the methods used are appropriate to the question	Yes
Additional Comments	<p>Overall assessment of internal validity. Are the results internally valid? Yes</p> <p>Overall assessment of external validity – Are the results externally valid (i.e. generalisable to the whole source population)? Differences in the interventions included in the review mean that it is difficult to generalize.</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
McCloone et al (2013)	To compare the effectiveness and quality of psychological and educational interventions designed for people with melanoma	<p>Systematic review of qualitative and quantitative studies</p> <p>Australia</p> <p>16 intervention studies were included (12 quantitative, 2 qualitative and 2 mixed; 11 were RCTs). The quality of each included study was evaluated according to whether the intervention was adequately reported, whether it measured clinically meaningful outcomes and whether implementation of the intervention (practicality) had been assessed.</p>	People with melanoma	<ul style="list-style-type: none"> Psychological interventions (for example cognitive behavioural therapy, psychotherapy) Educational interventions (increasing understanding of the disease and possible psychological responses) <p>Psycho-educational interventions (a combination of the above)</p>			<p>Interventions for education see Table 1.2.</p> <p>Interventions for support see Table 1.3.</p> <p>Combined education see Table 1.4.</p> <p>Authors conclude that interventions in this field vary widely, limiting the identification of 'active ingredients' for psychological or behavioural change. Future intervention studies should ensure sufficient information is provided to support program replication and comprehensive assessment of program outcomes.</p>

2. Diagnosing Melanoma

2.1 Dermoscopy and other visualisation techniques

Review question: To what extent can the diagnostic accuracy of, history-taking and visual examination for the clinical identification of melanoma be improved by dermoscopy or/and new visualisation techniques?

Background

We know that the earlier a melanoma is diagnosed and removed, the more likely the patient is to be cured. Until 20 years or so ago, melanoma was diagnosed based on history and clinical examination alone. In an attempt to improve the accuracy of diagnosing melanoma, various new techniques have been developed which seek to optimise the visualisation of suspicious skin lesions. Dermoscopy (dermatoscopy) is now widely used by specialist dermatologists and some primary care doctors with a particular interest in dermatology. The evidence suggests that this technique can be used in two ways, firstly to aid in the diagnosis of specific lesions, something that requires a lot of experience, and secondly to enable less experienced doctors to use simple algorithms to separate the suspicious from the benign. In the hands of dermatologists there seems to be evidence that dermoscopy can improve diagnostic accuracy, but this may not be the case in less experienced doctors. More recently new technologies seek to replace the clinician by the use of dermoscopic images and artificial intelligence systems (using computer generated algorithms). Such new technologies might be helpful but are associated with the problem of either missing melanomas or unduly raising a patient's anxiety by being over suspicious of malignancy. What we need to know is whether dermoscopy should be considered an essential tool for those involved in diagnosing melanoma and whether any of the other new techniques, such as artificial intelligence systems and confocal microscopy, might help. Some people are suggesting that the use of teledermatology with 'store and forward' images (including dermoscopic images) can be used effectively to diagnose melanoma but there is debate about this.

Question in PICO format

Population	Intervention (Index Test)	Comparator (Reference Standard)	Outcomes
Patients with lesions suspicious of melanoma (e.g. suspicious skin lesions) Subgroup Analysis: <ul style="list-style-type: none"> • Superficial spreading melanoma • Nodular melanoma • Lentigo maligna melanoma • Acral lentiginous 	<ul style="list-style-type: none"> • Dermoscopy • Teledermatology with dermoscopy • New visualisation techniques: (Digital dermoscopy , Confocal microscopy; Artificial intelligence based systems) 	<ul style="list-style-type: none"> • Visual Exam • History Taking 	<ul style="list-style-type: none"> • Histological confirmation • Clinical opinion

melanoma <ul style="list-style-type: none"> • Desmoplastic melanoma • Severely dysplastic naevi 			
---	--	--	--

1

2 **How will the information be searched?**

Searches:	
Can we apply date limits to the search (<i>Please provide information on any date limits we can apply to the searches for this topic. This can be done for each individual intervention as appropriate</i>)	Most of the studies will be since 1990
Are there any study design filters to be used (<i>RCT, systematic review, diagnostic test</i>).	<p>An initial search was conducted with the SIGN Systematic reviews and RCTs filters added</p> <p>At the request of the GDG and second search of prospective studies was conducted with no filter to be added</p>
List useful search terms. (<i>This can include such information as any alternative names for the interventions etc</i>)	<p>Dermoscopy, dermatoscopy, artificial intelligence, teledermatology, confocal microscopy, dermoscopic algorithms. Some use dermatoscopy others dermoscopy</p> <p>Also should specify dermoscopy of naevi (sometimes spelt nevi)</p> <p>Epiluminescence microscopy</p>

3 **The Review Strategy**

4 Evidence was be identified, assessed and synthesised according to the methods outlined in the
 5 Guidelines Manual (2012). Relevant studies were identified through sifting the abstracts and
 6 excluding studies clearly not relevant to the PICO. In the case of relevant or potentially relevant
 7 studies, the full paper was ordered and reviewed, whereupon studies considered to be not relevant
 8 to the topic were excluded. Studies which were identified as relevant were critically appraised and
 9 quality assessed using GRADE methodology and NICE checklists. Data relating to the identified
 10 outcomes were extracted from the relevant studies. The data were not meta-analysed due to the
 11 difference in interventions and populations (in terms of melanoma thicknesses) of the included
 12 studies, but were instead summarised per study in tabular form, and further in GRADE tables and
 13 evidence statements.

1 **Search Results**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	1946-2013	465	92	24/06/2013
<i>Premedline</i>	24 Jun 2013	3	0	25/06/2013
<i>Embase</i>	1947-2013	294	77	25/06/2013
<i>Cochrane Library</i>	Issue 6 of 12 June 2013	80	31	25/06/2013
<i>Web of Science (SCI & SSCI)</i>	1900-2013	466	41	25/06/2013
1 new reference added 09/07/2013				
Total References retrieved (after de-duplication): 174				

- 2 At the request of the GDG, a second search below was performed to find prospective studies only
3 (see below for Medline filter). The results were downloaded into a reference manager database,
4 deduplicated and sifted.

5 **Prospective Studies Search**

Database name	Dates Covered	No of references found	Finish date of search
<i>Medline & Premedline</i>	1946-2013	204	24/07/2013
<i>Embase</i>	1947-2013	266	24/07/2013
<i>Web of Science (SCI & SSCI)</i>	1900-2013	306	24/07/2013
Total References retrieved (after de-duplication and sifting in Reference Manager): 251			

6 **Update Searches**

- 7 For the update search, the same search criteria/filters were applied as initial search

Database name	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	59	15	23/09/2014
<i>Premedline</i>	7	4	23/09/2014
<i>Embase</i>	57	9	23/09/2014
<i>Cochrane Library</i>	3	0	23/09/2014
<i>Web of Science (SCI & SSCI)</i>	92	3	23/09/2014

5 records found in Pubmed 23/09/2014

Total References retrieved (after de-duplication): 27

1 Prospective Studies search


Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline & Premedline</i>	1946-2013	45	10	23/09/2014
<i>Embase</i>	1947-2013	63	15	23/09/2014
<i>Web of Science (SCI & SSCI)</i>	1900-2013	66	6	23/09/2014
Total References retrieved (after de-duplication): 27				

2 Medline search strategy (This search strategy is adapted to each database)

1. exp Melanoma/
2. melanoma\$.tw.
3. (maligna\$ adj1 lentigo\$).tw.
4. (hutchinson\$ adj1 (freckle\$ or melano\$)).tw.
5. dubreuilh.tw.
6. LMM.tw.
7. or/1-6
8. Dermoscopy/
9. Microscopy, Confocal/
10. (dermoscop* or dermatoscop* or epiluminescence or ELM or videodermatoscop* or (incident adj2 microscop*) or (skin adj2 microscop*) or (surface adj microscop*) or (confocal adj microscop*)).tw.
11. or/8-10
12. ((visual or naked eye) adj (exam* or assess*)).tw.
13. (skin adj exam*).tw.
14. Physical Examination/
15. Photography/
16. exp Telemedicine/
17. telederm*.tw.
18. Algorithms/
19. exp Diagnosis, Computer-Assisted/
20. exp Image Processing, Computer-Assisted/
21. exp Artificial Intelligence/
22. artificial intelligence.tw.
23. (artificial adj2 network*).tw.
24. (neural adj analy*).tw.
25. (computer* adj (analy* or diagnos*)).tw.
26. or/12-25
27. 11 or 26

1 28. 7 and 27

2 Screening Results






3
4

Study quality

Risk of bias and applicability were assessed using QUADAS-2 (see figure 2.1). Figure 2.2 illustrates the setting of the included studies.

Figure 2.1. Risk of bias and applicability of the included studies – using QUADAS 2

	Risk of Bias				Applicability Concerns		
	Patient Selection	Index Test	Reference Standard	Flow and Timing	Patient Selection	Index Test	Reference Standard
Argenziano 2006	?	?	?	?	?	+	+
Ascierto 2010	+	+	+	+	+	+	+
Barzegari 2005	+	+	+	+	+	+	+
Benelli 1999	+	?	?	?	+	+	+
Bono 2002	+	?	?	?	+	+	+
Bono 2006	+	?	?	?	+	+	+
Borve 2013	+	+	+	+	+	+	+
Carli 2003	+	?	?	?	+	+	+
Carli 2004	+	?	?	?	+	+	+
Cristofolini 1994	+	?	?	?	+	+	+
Curchin 2011	+	+	+	+	+	+	+
Dreiseitl 2009	+	+	+	+	+	+	+
Dummer 1993	+	?	?	?	+	+	+
Fueyo-Casado 2009	+	+	?	?	+	+	+
Glud 2009	+	+	+	+	+	+	+
Guitera 2009	+	+	+	+	+	+	+
Guitera 2010	?	+	+	+	+	+	+
Langley 2007	+	+	+	+	+	+	+
Monheit 2011	+	+	+	+	+	+	+
Moreno-Ramirez (2007)	+	+	?	+	?	?	+
Pellicani 2007	?	+	+	+	+	+	+
Perrinaud 2007	+	+	+	?	+	+	+
Piccolo 2004	?	+	+	?	+	+	+
Rosendahl 2010	+	+	?	+	?	+	+
Stanganelli 2000	+	?	?	?	+	+	+
Tan 2010	+	+	?	?	+	+	+
Tomatis 2005	+	+	+	+	+	+	+
Walter 2012	+	+	+	+	?	+	?
Warshaw 2009	+	+	+	?	+	+	+

 High	 Unclear	 Low
--	---	---

Evidence statements

High quality evidence (Vestergaard 2008; Rosendahl, 2011) suggests that dermoscopy is both more sensitive and more specific in classifying lesions as melanoma versus not melanoma than clinical examination with the naked eye alone (see Table 4 and Figure 5).

Evidence suggests that reflectance confocal microscopy (Stevenson, 2013) is more sensitive than dermoscopy ((Vestergaard 2008) but less specific in classifying lesions as melanoma versus not melanomas (see Table 4 and Figure 5).

There is uncertainty over whether computer aided diagnosis can improve upon the diagnostic accuracy of dermoscopy in classifying lesions as melanoma versus not melanoma. The results from studies of computer aided diagnosis using spectrophotometry (Monheit et al 2011; Glud et al 2009) suggest their algorithms were optimised for high sensitivity at the expense of specificity.

Studies excluded lesions in sites that were inaccessible to the imaging technique used. In such lesions cases clinical examination with the naked eye would be the only option. There is also a test failure rate associated with computer aided diagnostic algorithms: Perrinaud et al (2007) reported failure rates ranging from 5% to 32% of lesions depending on which system was used.


The trade off between sending benign lesions for biopsy/histopathology and the risk of missing melanomas is illustrated in Table 1. This uses a hypothetical cohort of 1000 pigmented skin lesions with a melanoma prevalence of 12%, combined with the diagnostic accuracy data from Table 4.

Table 2.1. Illustration of trade off when using tests to select pigmented lesions for biopsy in a cohort of 1000 lesions (assumed 12% melanoma prevalence)

Test	Benign lesions selected for biopsy	Melanomas not selected for biopsy (missed)
Naked eye	158/880 (18%)	36/120 (30%)
Dermoscopy	106/880 (12%)	14/120 (12%)
Reflectance confocal microscopy	211/880 (24%)	8/120 (7%)
Computer aided dermoscopy	132/880 (15%)	26/120 (22%)
Computer aided spectrophotometry	625/880 (71%)	4/120 (3%)

There was inconsistent evidence about the accuracy of teledermatoscopy. Some studies report relatively high diagnostic accuracy for classification of melanoma versus not melanoma (Piccolo, 2004; Tan, 2010). Warshaw et al (2009), however, reported a significant proportion of melanomas would be mismanaged with potentially serious consequences on the basis of teledermatology (19% for macro images alone, 6% if polarised light dermatoscopy was added, 16% if contact immersion dermatoscopy was added).

1 Figure 2.2. Setting of the included studies in the diagnostic pathway



1. Studies in primary care

Naked eye: Argenziano (2006), Walter (2012), Rosendahl (2011)

Dermoscopy: Argenziano (2006), Rosendahl (2011)

Computer aided diagnosis (CAD) Spectrophotometry: Walter (2012)

Teledermatology: Moreno-Ramirez (2007)

Teledermatoscopy

2. Studies about initial tests in secondary care

Naked eye: Vestergaard Benelli (1999), Bono (2002), Bono (2006), Carli (2003), Carli (2004), Cristofolini (1994), Dummer (1993), Stanganelli (2000)

Dermoscopy: Benelli (1999), Bono (2002), Bono (2006), Carli (2003), Carli (2004), Cristofolini (1994), Dummer (1993), Stanganelli (2000)

CAD Dermoscopy: Driesetl (2009), Barzegari (2005), Fueyo-Casado (2009)

Teledermatology/Teledermatoscopy: Warshaw (2009), Piccolo (2004), Tan (2010), Borve (2013)

3. Studies about further tests for equivocal lesions in secondary care

Dermoscopy: Ascierto (2010)

CAD-dermoscopy: Perrinaud (2007)

CAD-spectrophotometry: Ascierto (2010), Glud (2009), Monheit (2011)

Reflectance confocal microscopy: Stevenson (2013)

Table 2.2. Summary diagnostic accuracy statistics

Test	N studies	N lesions	Sensitivity*[95% C.I.]	Specificity*[95% C.I.]	PPV [†]	NPV [†]
Naked eye clinical examination	8	5628	70% [58-80%]	82% [57-94%]	35%	95%
Dermoscopy	12	6535	88% [83-91%]	88% [74-95%]	50%	98%
Reflectance confocal microscopy	5	910	93% [89-96%]	76% [68-83%]	35%	99%
Artificial intelligence using dermoscopy images	5	1317	78% [67-86%]	85% [78-90%]	41%	97%
Artificial intelligence using spectrophotometry images	2	1715	97% [91-99%]	29% [4-82%]	16%	99%

*Using bivariate meta-analysis (Reitsma et al 2005); [†] Assuming melanoma prevalence of 12% (the average prevalence across the dermoscopy studies).

Abbreviations: CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value;

Sensitivity and specificity

Sensitivity and specificity are measures defined conditional on the disease status. They are calculated as proportions of the number diseased and the number non-diseased respectively. Sensitivity and specificity values are reported either as proportions (0 to 1) or percentages (0% to 100%).

The sensitivity of a test is the probability that the index test result will be positive in a person with the disease. The closer the test gets to 100% sensitivity the better it is at identifying people with the disease.

The specificity of a test is the probability that the index test result will be negative in a non-diseased person. The closer the test gets to 100% specificity the better it is at identifying people without the disease.

Predictive values


Predictive values are measures defined conditional on the index test results. They are calculated as proportions of the total with positive and negative index test results. Predictive values are reported either as proportions (0 to 1) or percentages (0% to 100%)

The positive predictive value (PPV) of a test is the proportion of those with a positive test result who have the disease.


The negative predictive value (NPV) of a test is the proportion of those with a negative test result who do not have the disease.

1 **Figure 2.3. Illustration in 1000 patients with lesions if tests are used to select patients for biopsy**
2 **(using accuracy from table 3 and assuming melanoma prevalence of 12%).**


3 **TP** = true positive (melanomas selected for biopsy), **FP** = false positive (benign lesions selected for
4 biopsy), **TN**= true negative (benign lesions not selected for biopsy), **FN** = false negative (melanomas
5 not selected for biopsy).



1 **Figure 2.4. Summary sensitivity and specificity estimates (with 95% confidence regions) and ROC**
 2 **curves for the classification of melanoma versus not melanoma using naked-eye, dermoscopy,**
 3 **reflectance confocal microscopy (RCM) and computer aided diagnosis (CAD) using dermoscopy or**
 4 **spectrophotometry.**




5



6

1 **Figure 2.5 Summary sensitivity and specificity estimates (with 95% confidence regions) and SROC**
 2 **curves (bivariate model) for individual melanoma tests**



Tables 2.3 to 2.7. Test accuracy data from individual studies**2.3: Naked eye clinical exam (including studies from Vestergaard 2008 systematic review)**

Study	Test	Setting	Classification	TP	FP	FN	TN	SN (%)	SP (%)
Argenziano 2006 *	Naked eye clinical examination, by primary care physician	Primary care, patients with skin tumours or requesting screening	Melanoma versus not melanoma	46	362	39	898	54	71
Benelli 1999	Naked eye clinical examination by expert dermatologist	Secondary/tertiary care, patients referred with suspicious pigmented skin lesions	Melanoma versus not melanoma	40	71	20	270	67	79
Bono 2002	Naked eye clinical examination by expert dermatologist	Secondary/tertiary care, patients referred with suspicious pigmented skin lesions	Melanoma versus not melanoma	57	56	9	191	86	77
Bono 2006	Naked eye clinical examination by expert dermatologist	Secondary/tertiary care, patients referred with suspicious pigmented skin lesions	Melanoma versus not melanoma	10	16	13	167	43	91
Carli 2003	Naked eye clinical examination by expert dermatologist	Secondary/tertiary care, patients referred with suspicious pigmented skin lesions	Melanoma versus not melanoma	3	40	0	0	100	0
Carli 2004	Naked eye clinical examination by expert dermatologist	Secondary/tertiary care, patients referred with suspicious pigmented skin lesions	Melanoma versus not melanoma	3	44	0	255	100	85
Cristofolini 1994	Naked eye clinical examination by expert dermatologist	Secondary/tertiary care, patients with suspicious pigmented skin lesions scheduled for excision	Melanoma versus not melanoma	28	46	5	141	85	75
Dummer 1993	Naked eye clinical examination by expert dermatologist	Secondary/tertiary care, patients referred with suspicious pigmented skin lesions scheduled for excision	Melanoma versus not melanoma	15	49	8	699	65	93
Stanganelli 2000	Naked eye clinical examination by expert dermatologist	Secondary/tertiary care, patients referred with suspicious pigmented skin lesions	Melanoma versus not melanoma	37	33	18	3284	67	99

Study	Test	Setting	Classification	TP	FP	FN	TN	SN (%)	SP (%)
Barzegari 2005	Naked eye clinical examination (expert dermatologist)	Clinically suspicious melanocytic skin lesions, following naked eye examination.	Melanoma versus not melanoma	5	5	1	111	83	96
Walter 2012	Naked eye clinical examination by GP	Suspicious pigmented lesion in primary care	Fast track cancer referral versus manage in primary care.	111	61	5	588	96	91

Abbreviations: TP, true positive; FP, false positive; FN, false negative; TN, true negative; SN, sensitivity; SP, specificity.

*Excluded from meta-analysis – due to primary care setting.

2.4: Dermoscopy (including studies from Vestergaard 2008 systematic review)

Study	Test	Setting	Classification	TP	FP	FN	TN	SN (%)	SP (%)
Perrinaud 2007	Dermoscopy (expert dermatologist)	Secondary/tertiary care, clinically suspicious pigmented lesions, excluding obvious melanomas.	Melanoma or dysplastic nevus versus benign	59	19	1	11	98	37
Ascierto 2010	Dermoscopy	Secondary/tertiary care, Clinically suspicious melanocytic lesions selected for excision following dermoscopy	Melanoma versus not melanoma	12	24	0	18	100	43
Ascierto 2010	Dermoscopy	Secondary/tertiary care, Clinically suspicious melanocytic lesions selected for excision following dermoscopy	Melanoma or dysplastic nevus versus benign	34	4	0	18	100	82
Glud 2009	Dermoscopy	Secondary/tertiary care, Clinically suspicious melanocytic lesions selected for excision following clinical examination.	Melanoma versus not melanoma	11	13	1	58	92	82
Driesetl 2009	Dermoscopy (expert dermatologist)	Clinically suspicious pigmented lesions in secondary/tertiary care,	Melanoma versus not melanoma	26	120	1	311	96	72
Fueyo-Casado 2009	Dermoscopy (general dermatologist)	Secondary care, melanocytic skin lesions at first general dermatology consultation.	Melanoma versus not melanoma	6	10	0	287	100	97
Argenziano 2006*	Dermoscopy, by primary care physician	Primary care, patients with skin tumours or requesting screening	Melanoma versus not melanoma	61	318	16	808	79	72

Study	Test	Setting	Classification	TP	FP	FN	TN	SN (%)	SP (%)
Benelli 1999	Dermoscopy by expert dermatologist	Secondary/tertiary care, patients referred with suspicious pigmented skin lesions	Melanoma versus not melanoma	48	37	12	304	80	89
Bono 2002	Dermoscopy by expert dermatologist	Secondary/tertiary care, patients referred with suspicious pigmented skin lesions	Melanoma versus not melanoma	60	65	6	182	91	74
Bono 2006	Dermoscopy by expert dermatologist	Secondary/tertiary care, patients referred with suspicious pigmented skin lesions	Melanoma versus not melanoma	19	57	4	126	83	69
Carli 2003	Dermoscopy by expert dermatologist	Secondary/tertiary care, patients referred with suspicious pigmented skin lesions	Melanoma versus not melanoma	3	10	0	30	100	75
Carli 2004	Dermoscopy by expert dermatologist	Secondary/tertiary care, patients referred with suspicious pigmented skin lesions	Melanoma versus not melanoma	2	26	0	283	100	92
Cristofolini 1994	Dermoscopy by expert dermatologist	Secondary/tertiary care, patients with suspicious pigmented skin lesions scheduled for excision	Melanoma versus not melanoma	29	39	4	148	88	79
Dummer 1993	Dermoscopy by expert dermatologist	Secondary/tertiary care, patients referred with suspicious pigmented skin lesions scheduled for excision	Melanoma versus not melanoma	22	10	1	738	96	99
Rosendahl 2011*	Dermoscopy in primary care skin cancer practice	Primary care, patients with pigmented skin lesions scheduled for excision	Melanoma versus not melanoma	23	56	6	161	79	74
Stanganelli 2000	Dermoscopy by expert dermatologist	Secondary/tertiary care, patients referred with suspicious pigmented skin lesions	Melanoma versus not melanoma	51	12	4	3305	93	100

Abbreviations: TP, true positive; FP, false positive; FN, false negative; TN, true negative; SN, sensitivity; SP, specificity.

*Excluded from meta-analysis – due to primary care setting.

2.5: Computer assisted diagnostic systems

Study	Test	Setting	Classification	TP	FP	FN	TN	Sn (%)	Sp (%)
Perrinaud 2007	CAD dermoscopy (operated by expert dermatologist) – system I	Secondary/tertiary care, clinically suspicious pigmented lesions (post dermoscopy and excluding obvious melanomas).	Melanoma versus not melanoma	3	12	1	71	75	86
Perrinaud 2007	CAD dermoscopy (operated by expert dermatologist) – system III	Secondary/tertiary care, clinically suspicious pigmented lesions (post dermoscopy and excluding obvious melanomas).	Melanoma versus not melanoma	1	3	3	77	25	96
Perrinaud 2007	CAD dermoscopy (operated by expert dermatologist – system I	Secondary/tertiary care, clinically suspicious pigmented lesions (post dermoscopy and excluding obvious melanomas).	Melanoma or dysplastic nevus versus benign	24	9	35	19	41	68
Perrinaud 2007	CAD dermoscopy (operated by expert dermatologist – system II	Secondary/tertiary care, clinically suspicious pigmented lesions (post dermoscopy and excluding obvious melanomas).	Melanoma or dysplastic nevus versus benign	8	0	51	27	14	100
Perrinaud 2007	CAD dermoscopy (operated by expert dermatologist – system III	Secondary/tertiary care, clinically suspicious pigmented lesions (post dermoscopy and excluding obvious melanomas).	Melanoma or dysplastic nevus versus benign	23	10	33	18	41	64
Ascierto 2010	CAD spectrophotometry (Spectroshade)	Secondary/tertiary care, clinically suspicious melanocytic lesions selected for excision following dermatoscopy	Melanoma or dysplastic nevus versus benign	8	10	4	32	67	76
Glud 2009	CAD spectrophotometry (SIAscope II – operator unclear)	Secondary/tertiary care, clinically suspicious melanocytic lesions selected for excision following clinical examination.	Melanoma versus not melanoma	12	29	0	42	100	59
Driesetl 2009	CAD dermoscopy (non-expert physicians)	Secondary/tertiary care, clinically suspicious pigmented lesions	Melanoma versus not melanoma.	19	82	8	349	70	81

Barzegari 2005	CAD dermoscopy (expert dermatologist)	Secondary/tertiary care, clinically suspicious melanocytic skin lesions, following naked eye examination.	Melanoma versus not melanoma.	5	5	1	111	83	96
Fueyo-Casado 2009	CAD dermoscopy (Fotofinder, with TeachScreen software operated by a general dermatologist)	Secondary care, melanocytic skin lesions at first general dermatology consultation.	Melanoma versus not melanoma	5	46	1	251	83	85
Monheit 2011	CAD spectrophotometry (MelaFind operated by expert dermatologist)	Secondary/tertiary care, pigmented lesions scheduled for selected for excision.	Melanoma (>1% likelihood) versus not melanoma	172	1300	3	157	98	11
Walter 2012*	CAD spectrophotometry (MoleMate operated by GP)	Suspicious pigmented lesion in primary care	Fast track cancer referral versus manage in primary care.	130	99	2	535	98	84

Abbreviations: TP, true positive; FP, false positive; FN, false negative; TN, true negative; SN, sensitivity; SP, specificity.

*Excluded from meta-analysis – due to primary care setting.

2.6: Reflectance confocal microscopy (studies from Stevenson 2013 systematic review)

Study	Test	Setting	Classification	TP	FP	FN	TN	Sn (%)	Sp (%)
Curchin 2011	RCM	Equivocal lesions – probably post dermoscopy	Melanoma versus not melanoma	12	3	1	19	92	86
Guitera 2009	RCM	Equivocal lesions – probably post dermoscopy	Melanoma versus not melanoma	112	65	11	138	91	68
Guitera 2010	RCM	Equivocal lesions – probably post dermoscopy	Melanoma versus not melanoma	27	8	2	36	93	82
Langley 2007	RCM	Equivocal lesions – probably post dermoscopy	Melanoma versus not melanoma	36	15	1	73	97	83
Pellicani 2007	RCM	Equivocal lesions – probably post dermoscopy	Melanoma versus not melanoma	125	66	11	149	92	69

Abbreviations: TP, true positive; FP, false positive; FN, false negative; TN, true negative; SN, sensitivity; SP, specificity.

2.7: Teledermatology or teledermatoscopy

Study	Test	Setting	Classification	TP	FP	FN	TN	Sn(%)	Sp(%)
Moreno-Ramirez (2007)	Teledermatology (digital images)	Clinically suspicious lesions in primary care	Refer for a face to face consultation or not	168	88	1	146	99%	62%
Piccolo (2004)	Teledermatoscopy (not reported who acquired images)	Acral lesions in secondary care	Melanoma or not melanoma	5-6	0-6	0-1	65-71	91%	95%
Tan (2010)	Teledermatoscopy (operated by trained melanographer – interpreted by dermatologist)	Clinically suspicious lesions in secondary care.	Melanoma or not melanoma	18	5	0	486	100%	99%
Warshaw (2009)	Teledermatology (macro digital images)	Lesions selected for biopsy after clinical and dermoscopic exam in secondary care	Appropriate management plan	Accuracy 70%, 7/36 (19%) melanomas mismanaged with potentially life threatening consequences					
Warshaw (2009)	Teledermatoscopy (macro digital images plus polarized light dermatoscopy)	Lesions selected for biopsy after clinical and dermoscopic exam in secondary care	Appropriate management plan	Accuracy 70%, 3/36 (8%) melanomas mismanaged					
Warshaw (2009)	Teledermatoscopy (macro digital images plus contact immersion dermatoscopy)	Lesions selected for biopsy after clinical and dermoscopic exam in secondary care	Appropriate management plan	Accuracy 74%, 6/36 (17%) melanomas mismanaged					
Borve (2013)	Teledermatoscopy (operated by expert dermatologist – interpreted by expert dermatologists)	Lesions selected for biopsy after clinical and dermoscopic exam in secondary care	Benign versus malignant	Accuracy 75% to 80%					

References

- Ascierto, P. A., Palla, M., Ayala, F., De, M., I, Caraco, C., Daponte, A. et al. (2010). The role of spectrophotometry in the diagnosis of melanoma. *BMC Dermatology*, 10, 5.
- Barzegari, M., Ghaninezhad, H., Mansoori, P., Taheri, A., Naraghi, Z. S., Asgari, M. et al. (2005). Computer-aided dermoscopy for diagnosis of melanoma. *BMC Dermatology*, 5, 8.
- Borve, A., Terstappen, K., Sandberg, C., & Paoli, J. (2013). Mobile teledermoscopy--there's an app for that! *Dermatol.Pract Concept.*, 3, 41-48.
- Dreiseitl, S., Binder, M., Hable, K., Kittler, H., Dreiseitl, S., Binder, M. et al. (2009). Computer versus human diagnosis of melanoma: evaluation of the feasibility of an automated diagnostic system in a prospective clinical trial. *Melanoma Research*, 19, 180-184.
- Fueyo-Casado, A., Vazquez-Lopez, F., Sanchez-Martin, J., Garcia-Garcia, B., Perez-Oliva, N., Fueyo-Casado, A. et al. (2009). Evaluation of a program for the automatic dermoscopic diagnosis of melanoma in a general dermatology setting. *Dermatologic Surgery*, 35, 257-259.
- Glud, M., Gniadecki, R., Drzewiecki, K. T., Glud, M., Gniadecki, R., & Drzewiecki, K. T. (2009). Spectrophotometric intracutaneous analysis versus dermoscopy for the diagnosis of pigmented skin lesions: prospective, double-blind study in a secondary reference centre. *Melanoma Research*, 19, 176-179.
- Monheit, G., Cognetta, A. B., Ferris, L., Rabinovitz, H., Gross, K., Martini, M. et al. (2011). The performance of MelaFind: a prospective multicenter study. *Archives of Dermatology*, 147, 188-194.
- Moreno-Ramirez, D. (2007). Store-and-forward teledermatology in skin cancer triage: Experience and evaluation of 2009 teleconsultations. *Archives of Dermatology*, 143, 479-484.
- Perrinaud, A., Gaide, O., French, L. E., Saurat, J. H., Marghoob, A. A., Braun, R. P. et al. (2007). Can automated dermoscopy image analysis instruments provide added benefit for the dermatologist? A study comparing the results of three systems. *British Journal of Dermatology*, 157, 926-933.
- Piccolo, D., Soyer, H. P., Chimenti, S., Argenziano, G., Bartenjev, I., Hofmann-Wellenhof, R. et al. (2004). Diagnosis and categorization of acral melanocytic lesions using teledermoscopy. *Journal of Telemedicine and Telecare*, 10, 346-350.
- Rosendahl, C., Tschandl, P., Cameron, A., Kittler, H., Rosendahl, C., Tschandl, P. et al. (2011). Diagnostic accuracy of dermatoscopy for melanocytic and nonmelanocytic pigmented lesions. *Journal of the American Academy of Dermatology*, 64, 1068-1073.
- Stevenson, A. D., Mickan, S., Mallett, S., & Ayya, M. (2013). Systematic review of diagnostic accuracy of reflectance confocal microscopy for melanoma diagnosis in patients with clinically equivocal skin lesions. *Dermatol.Pract Concept.*, 3, 19-27. **The Stevenson systematic review contains the following five studies:**
1. Curchin, C. E., Wurm, E. M., Lambie, D. L., Longo, C., Pellacani, G., & Soyer, H. P. (2011). First experiences using reflectance confocal microscopy on equivocal skin lesions in Queensland. *Australas.J Dermatol.*, 52, 89-97.
 2. Guitera, P., Pellacani, G., Longo, C., Seidenari, S., Avramidis, M., & Menzies, S. W. (2009). In vivo reflectance confocal microscopy enhances secondary evaluation of melanocytic lesions. *J Invest Dermatol.*, 129, 131-138.

3. Guitera, P., Pellacani, G., Crotty, K. A., Scolyer, R. A., Li, L. X., Bassoli, S. et al. (2010). The impact of in vivo reflectance confocal microscopy on the diagnostic accuracy of lentigo maligna and equivocal pigmented and nonpigmented macules of the face. *J Invest Dermatol.*, 130, 2080-2091
 4. Pellacani, G., Guitera, P., Longo, C., Avramidis, M., Seidenari, S., & Menzies, S. (2007). The impact of in vivo reflectance confocal microscopy for the diagnostic accuracy of melanoma and equivocal melanocytic lesions. *J Invest Dermatol.*, 127, 2759-2765.
 5. Langley, R. G., Walsh, N., Sutherland, A. E., Propperova, I., Delaney, L., Morris, S. F. et al. (2007). The diagnostic accuracy of in vivo confocal scanning laser microscopy compared to dermoscopy of benign and malignant melanocytic lesions: a prospective study. *Dermatology*, 215, 365-372.
- Tan, E., Yung, A., Jameson, M., Oakley, A., Rademaker, M., Tan, E. et al. (2010). Successful triage of patients referred to a skin lesion clinic using teledermoscopy (IMAGE IT trial). *British Journal of Dermatology*, 162, 803-811.
- Tomatis S. (2005). Automated melanoma detection with a novel multispectral imaging system: results of a prospective study. *Physics in Medicine and Biology*, 50, 1675-1687.
- Vestergaard, M. E. M. (2008). Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: A meta-analysis of studies performed in a clinical setting. *British Journal of Dermatology*, 159, 669-676. **The Vestergaard systematic review includes the following nine studies:**
1. Argenziano, G., Puig, S., Zalaudek, I., Sera, F., Corona, R., Alsina, M. et al. (2006). Dermoscopy improves accuracy of primary care physicians to triage lesions suggestive of skin cancer. *J Clin Oncol*, 24, 1877-1882.
 2. Benelli, C., Roscetti, E., Pozzo, V. D., Gasparini, G., & Cavicchini, S. (1999). The dermoscopic versus the clinical diagnosis of melanoma. *Eur J Dermatol.*, 9, 470-476.
 3. Bono, A., Bartoli, C., Cascinelli, N., Lualdi, M., Maurichi, A., Moglia, D. et al. (2002). Melanoma detection. A prospective study comparing diagnosis with the naked eye, dermatoscopy and telespectrophotometry. *Dermatology*, 205, 362-366.
 4. Bono, A., Tolomio, E., Trinccone, S., Bartoli, C., Tomatis, S., Carbone, A. et al. (2006). Micro-melanoma detection: a clinical study on 206 consecutive cases of pigmented skin lesions with a diameter ≤ 3 mm. *Br J Dermatol.*, 155, 570-573.
 5. Carli, P., Mannone, F., De, G., V, Nardini, P., Chiarugi, A., & Giannotti, B. (2003). The problem of false-positive diagnosis in melanoma screening: the impact of dermoscopy. *Melanoma Res*, 13, 179-182.
 6. Carli, P., De, G., V, Chiarugi, A., Nardini, P., Weinstock, M. A., Crocetti, E. et al. (2004). Addition of dermoscopy to conventional naked-eye examination in melanoma screening: a randomized study. *J Am Acad.Dermatol.*, 50, 683-689.
 7. Cristofolini, M., Zumiani, G., Bauer, P., Cristofolini, P., Boi, S., & Micciolo, R. (1994). Dermatoscopy: usefulness in the differential diagnosis of cutaneous pigmentary lesions. *Melanoma Res*, 4, 391-394.
 8. Dummer, W., Doehnel, K. A., & Remy, W. (1993). [Videomicroscopy in differential diagnosis of skin tumors and secondary prevention of malignant melanoma]. *Hautarzt*, 44, 772-776.

9. Stanganelli, I., Serafini, M., & Bucch, L. (2000). A cancer-registry-assisted evaluation of the accuracy of digital epiluminescence microscopy associated with clinical examination of pigmented skin lesions. *Dermatology*, 200, 11-16.

Walter, F. M., Morris, H. C., Humphrys, E., Hall, P. N., Prevost, A. T., Burrows, N. et al. (2012). Effect of adding a diagnostic aid to best practice to manage suspicious pigmented lesions in primary care: randomised controlled trial. *BMJ*, 345, e4110.

Warshaw, E. M., Lederle, F. A., Grill, J. P., Gravely, A. A., Bangerter, A. K., Fortier, L. A. et al. (2009). Accuracy of teledermatology for pigmented neoplasms.[Erratum appears in *J Am Acad Dermatol*. 2010 Feb;62(2):319]. *Journal of the American Academy of Dermatology*, 61, 753-765.

Excluded Studies

M. L. Bafounta, A. Beauchet, P. Aegerter, and P. Saiag. Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanoma? Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests.[comment]. *Arch.Dermatol*. 137 (10):1343-1350, 2001.

Reason: Outdated systematic review

R. Bowns. Telemedicine in dermatology: A randomised controlled trial. *Health Technology Assessment* 10 (43):iii-39, 2006.

Reason: not specifically concerned with melanoma

A. Blum, H. Luedtke, U. Ellwanger, R. Schwabe, G. Rassner, C. Garbe, A. Blum, H. Luedtke, U. Ellwanger, R. Schwabe, G. Rassner, and C. Garbe. Digital image analysis for diagnosis of cutaneous melanoma. Development of a highly effective computer algorithm based on analysis of 837 melanocytic lesions. [Review] [40 refs]. *Br.J.Dermatol*. 151 (5):1029-1038, 2004.

Reason: same group of lesions used to develop the algorithm are also used to validate it

Friedman RJ, Gutkowitz-Krusin D, Farber MJ, Warycha M, Schneider-Kels L, Papastathis N, Mihm MC Jr, Googe P, King R, Prieto VG, Kopf AW, Polsky D, Rabinovitz H, Oliviero M, Cagnetta A, Rigel DS, Marghoob A, Rivers J, Johr R, Grant-Kels JM, Tsao H. *Arch Dermatol*. 2008 Apr;144(4):476-82.

Reason: Case control diagnostic study comparing digital dermatoscopy with A.I. MelaFind system

M. J. Jamora, B. D. Wainwright, S. A. Meehan, J. C. Bystry, Maria Jasmin Jamora, Brent D. Wainwright, Shane A. Meehan, and Jean Claude Bystry. Improved identification of potentially dangerous pigmented skin lesions by computerized image analysis. *Arch.Dermatol*. 139 (2):195-198, 2003.

Reason: Looks at A.I. (DermaGenius system) as an add-on test in the follow up of patients with clinically unusual lesions which were not sufficiently unusual to trigger biopsy

K. Korotkov, R. Garcia, Computerized analysis of pigmented skin lesions: a review. [Review]. *Artif.Intell.Med*. 56 (2):69-90, 2012.

Reason: Expert Review

Z. Liu, J. Sun, L. Smith, M. Smith, R. Warr, Zhao Liu, Jiui Sun, Lyndon Smith, Melvyn Smith, and Robert Warr. Distribution quantification on dermoscopy images for computer-assisted diagnosis of cutaneous melanomas. [Review]. *Med.Biol.Eng Comput*. 50 (5):503-513, 2012.

Reason: not validated with an independent sample

May, C. G. (2008). Prospective observational comparative study assessing the role of store and forward teledermatology triage in skin cancer. *Clinical and Experimental Dermatology*, 33, 736-739.

- 1 Reason: does not report diagnostic accuracy
- 2 J. Mayer. Systematic review of the diagnostic accuracy of dermatoscopy in detecting malignant melanoma.
- 3 [Review] [25 refs]. *Med.J.Aust.* 167 (4):206-210, 1997.
- 4 Reason: Outdated systematic review
- 5 A. M. M. Oakley. Excised skin lesions diagnosed by teledermoscopy. *Australas.J.Dermatol.* Conference
- 6 (var.pagings):May, 2010.
- 7 Reason: Conference Abstract
- 8 S. M. Rajpara, A. P. Botello, J. Townend, and A. D. Ormerod. Systematic review of dermoscopy and digital
- 9 dermoscopy/ artificial intelligence for the diagnosis of melanoma. [Review] [95 refs]. *Br.J.Dermatol.* 161 (3):591-
- 10 604, 2009.
- 11 Reason: includes retrospective studies and double counts studies in the meta-analysis
- 12 B. Rosado, S. Menzies, A. Harbauer, H. Pehamberger, K. Wolff, M. Binder, and H. Kittler. Accuracy of computer
- 13 diagnosis of melanoma: a quantitative meta-analysis. *Arch.Dermatol.* 139 (3):361-367, 2003.
- 14 Reason: Outdated systematic review

Evidence tables

Study Quality

	Was a consecutive or random sample of patients enrolled?	Was a case-control design avoided?	Did the study avoid inappropriate exclusions?	Were the index test results interpreted without knowledge of the results of the reference standard?	If a threshold was used, was it pre-specified?	Is the reference standard likely to correctly classify the target condition?	Were the reference standard results interpreted without knowledge of the results of the index test?	Was there an appropriate interval between index test(s) and reference standard?	Did all patients receive a reference standard?	Did patients receive the same reference standard?	Were all patients included in the analysis?	Quality
Ascierto et al (2010)	Consecutive	Yes	only those selected for excision on the basis of dermoscopy were included	Yes	Not reported	Yes	Not Reported	Not Reported	Yes	Yes	Yes	High Low risk of bias overall
Barzegari et al (2005)	Consecutive	Yes	Yes	Unclear	Not Reported	Yes	Not Reported	Not reported	Yes	Yes	Yes	High Low risk of bias overall
Borve et al (2013)	Consecutive	Yes	Yes	Yes	Not reported	Yes	Yes	Not reported	Yes	Yes	Yes	High Low risk of bias overall
Dreiseitl et al (2009)	Consecutive	Yes	Yes	Yes	Not Reported	Yes	Yes	Not Reported	Yes	Yes	No 458/511 patients (806/3827 lesions) were missing follow up information and not included in the analysis.	High Low risk of bias overall
Fueyo-Casado et al (2009)	Random	Yes	Yes	Yes	Not Reported	Unclear (no details given about dermoscopy follow up)	Not Reported	Not Reported	Yes	No	Yes	Moderate Unclear risk of bias relating to the reference

	Was a consecutive or random sample of patients enrolled?	Was a case-control design avoided?	Did the study avoid inappropriate exclusions?	Were the index test results interpreted without knowledge of the results of the reference standard?	If a threshold was used, was it pre-specified?	Is the reference standard likely to correctly classify the target condition?	Were the reference standard results interpreted without knowledge of the results of the index test?	Was there an appropriate interval between index test(s) and reference standard?	Did all patients receive a reference standard?	Did patients receive the same reference standard?	Were all patients included in the analysis?	Quality
												standard
Glud et al (2009)	Consecutive	Yes	Lesions selected for excision based on clinical examination – unclear whether this involved dermoscopy	Yes	Not Reported	Yes	Not reported	Not reported	Yes	Yes	Yes	High Low concerns overall regarding the potential risk of bias
Monheit et al (2011)	Consecutive	Yes	Yes (although there were some exclusions when digital imaging was unfeasible)	Yes	Not Reported	Yes	Yes	Not Reported	Yes	Yes	Yes	High Low risk of bias overall
Moreno-Ramirez, D. (2007)	Random	Yes	Yes	Yes	Not Reported	Unclear – patients not biopsied were not followed up beyond face to face consultation	Yes	Not Reported	Yes	No	Yes	Moderate Unclear risk of bias relating to the reference standard
Perrinaud et al (2007)	Consecutive	Yes	Yes	Yes	Not Reported	Yes	Not reported	Not Reported	Yes	Yes	If the computer diagnosis system was unable to analyse a lesion – it was excluded from the analysis	High Low risk of bias overall
Piccolo et al (2004)	Unclear	Unclear	Unclear	Yes	Not Reported	Yes	Yes	Not Reported	Yes	Yes	Yes	Moderate Unclear risk of

	Was a consecutive or random sample of patients enrolled?	Was a case-control design avoided?	Did the study avoid inappropriate exclusions?	Were the index test results interpreted without knowledge of the results of the reference standard?	If a threshold was used, was it pre-specified?	Is the reference standard likely to correctly classify the target condition?	Were the reference standard results interpreted without knowledge of the results of the index test?	Was there an appropriate interval between index test(s) and reference standard?	Did all patients receive a reference standard?	Did patients receive the same reference standard?	Were all patients included in the analysis?	Quality
												bias relating to patient selection
Rosendahl et al (2011)	Yes	Yes	Yes	Yes	Not reported	Yes	Unclear	Not reported	Yes	Yes	Yes	High
Stevenson et al. (2013).	Not reported	Yes	Yes Low risk of bias in 3/5 studies, unclear in 2/5 studies	Not reported Low risk of bias in 5/5 studies	Not Reported	Yes	Not reported Low risk of bias in 5/5 studies	Not reported	Not reported	Not reported	Not Reported Low risk of bias in 5/5 studies	High
Tan et al (2010)	Consecutive	Yes	Yes	Yes	Not Reported	Yes	No	Not Reported	Yes	No	Yes	Moderate
Tomatis S. (2005)	Consecutive	Yes	Yes	The index test is objective and should not be influenced by histopathology	Not Reported	Yes	Not Reported	Not Reported	Yes	Yes	94 images were inadequate (technical failure) – 1391 lesions were included in the analysis.	Moderate
Vestergaard et al (2008)	Consecutive	Yes	Yes	Yes	Not Reported	Yes	Not reported	Not reported	No	Not reported	Yes	Moderate
Walter et al (2012)	Random	Yes	Yes	Yes	Not Reported	Yes	No	Not Reported	Yes	Yes	No	High Low risk of bias overall
Warshaw et al (2009)	Consecutive	Yes	Yes	Yes	Not Reported	Yes	Yes	Yes	Yes	Yes	Yes	High Low risk of bias overall

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
-------	-----	---------	------------	--------------	------------	-----------	----------------------

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
Ascierto et al (2010)		Secondary/tertiary care, National Cancer Institute of Naples, Italy	54 melanocytic lesions in 54 patients, 65% female, median age 41 years (range 19 to 73 years). <u>Inclusion criteria:</u> Patients selected for surgical excision of melanocytic lesions, following a screening full body clinical skin examination with dermoscopy of clinically relevant lesions. Excision was recommended for all high or very high risk lesions and for lower risk lesions if there was cosmetic or functional justification. <u>Exclusion criteria:</u> Not reported	Dermatoscopy (Molemax II) classifying lesions as: very low risk, low risk, medium risk, high risk and very high risk Spectrophotometry with computer assisted diagnosis (SpectroShade) classified lesions as not melanoma, doubtful melanoma, suspected melanoma or probable melanoma	Histopathology of excised lesion		See tables 2.3-2.7
Barzegari et al (2005)		Secondary care Dermatology Department, Razi Hospital, Tehran, Iran.	122 pigmented skin lesions from 91 Iranian patients, 68% female, mean age 32 years (range 6 to 94 years). <u>Inclusion criteria:</u>	CAD dermoscopy (microDERM dermoscope) using neural network classifier to give a score of 0-10 where 10 was	Histopathology		First each lesion was examined clinically with naked eyes, and then CAD dermoscopy was used. Finally

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
			pigmented skin lesions <15mm in diameter, with a clinical naked eye diagnosis of a melanocytic lesion, referred for diagnostic or cosmetic reasons. <u>Exclusion criteria:</u> Not reported (but only excised lesions are included in the analysis).	highest likelihood of melanoma. For the analysis 7.88 was used as the threshold for melanoma versus not melanoma. Naked eye clinical diagnosis by expert dermatologist – for the analysis the most likely diagnosis was used as the diagnostic category where there were several possibilities.			lesions were excised and examined histologically.
Borve et al (2013)		Newly referred patients following their first dermoscopic and clinical examination in secondary/tertiary care (Department of Dermatology, Sahlgrenska University Hospital, Sweden).	62 patients, 39% female, median age not reported, race not reported. <u>Inclusion criteria:</u> Patients with suspicious skin lesions requiring biopsy or excision, following dermoscopic and clinical examination by an expert dermatologist. <u>Exclusion criteria:</u> Age < 18 years, lesions on sites not	Teledermatoscopy – an overview image of each lesion plus a dermoscopic image of each lesion, taken using a smart phone dermoscopy system (Fotofinder Handyscope). Images were transferred using a web-based teledermoscopy application (TeleDermis iDoc24). Images and relevant	Histopathological diagnosis		Patients were referred from GP to dermatologist, following expert dermatologist face-to-face clinical & dermoscopy examination those with lesions needing biopsy were included. The dermoscopy images and clinical information were forwarded to other expert dermatologists for the

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
			accessible to the smart phone dermascope, no knowledge of Swedish language	clinical information were sent to two expert dermatologists who classified each lesion as malignant versus not malignant, and melanocytic versus not melanocytic and also to allocate one of 12 primary diagnostic categories to the lesion. Face-to-face – a single expert dermatologist examined the lesion clinically and dermatoscopically and recorded the same diagnostic classifications as in the teledermatology above.			teledermatology evaluation. Lesions were excised and results of both tests were compared with histopathology Study reports overall diagnostic accuracy (cannot extract sensitivity and specificity) and concordance between the face-to-face and teledermatologists.
Dreiseitl et al (2009)		Secondary/tertiary care – pigmented skin lesion clinic at the Dermatology Department, University of Vienna, Austria.	511 patients with 3827 pigmented lesions entered the study. 458 patients with 3021 lesions were included in the analysis. Prevalence of	CAD dermatology (using Molemax II images) – used by one of 6 physicians (depending on availability) with 0-4 years training in dermatology and	Histopathology in those with excised lesions 6 months clinical follow up for lesions that were not excised		All patients had clinical exam and dermoscopy by an expert dermatologist – the decision to excise lesion was based on this. The CAD

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
		2004	<p>melanoma was 27/458 (6%).</p> <p><u>Inclusion criteria:</u> Patients referred for evaluation of pigmented lesions</p> <p><u>Exclusion criteria:</u> Not reported</p>	<p>with no specific training in dermatoscopy. A neural network classifier scored each lesion as benign, suspicious or melanoma. Physicians were free to choose which lesions to examine – so not all lesions were analysed by the computer system. Dermatoscopy (used by an expert dermatologist) diagnosed each patient as melanoma or not.</p>			dermoscopy was also done
Fueyo-Casado et al (2009)		Secondary/tertiary care, general dermatology consultancy of a tertiary teaching hospital, Oviedo, Spain. 2007	<p>303 lesions in 39 patients, 56% female, mean age 35 (range 19-71 years)</p> <p><u>Inclusion criteria:</u> adult patients with melanocytic skin lesions</p> <p><u>Exclusion criteria:</u> non melanocytic skin lesions</p>	<p>Dermoscopy (Dermlite Pro) – done by a panel of 3 general dermatologists – classified lesions as requiring excision at the time of first examination or not requiring immediate excision. Automated dermoscopy</p>	<p>Histopathology (decision to biopsy was based on clinical consensus) Short term digital dermoscopy follow up was the reference standard for lesions that were not biopsied but</p>		<p>Patients initially had both dermoscopy and the automated analysis Moleanalyzer tests. Some lesions were excised on the basis of clinical consensus, discordant index tests were followed up with dermoscopy. Some</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
				diagnosis (Fotofinder Moleanalyzer) – classified lesions as typical melanocytic lesions, somewhat atypical (and should be re-examined) or high probability of being melanoma. The first two categories were considered as not requiring excision at the time of examination.	had discordant classification between dermoscopy and the automated system. No reference standard for those negative on both index tests.		patients had no reference standard test.
Glud et al (2009)		Secondary care – Departments of Plastic Surgery and Dermatology, Denmark	65 patients (83 lesions), 55% female, median age 47 years (range <u>Inclusion criteria:</u> Patients referred by G.P.s for excision biopsy of pigmented lesions where melanoma could not be ruled out on clinical examination. <u>Exclusion criteria:</u> Not reported	Dermoscopy by expert dermatologist–classification melanoma versus not melanoma CAD spectrophotometry – SIAscope II using Australian algorithm to classify as “strong chance of melanoma” or “not melanoma”	Histopathology		See tables 2.3-2.7
Monheit et al (2011)		3 academic and 4 community	1383 patients with 1831 lesions. 1632	Artificial Intelligence	Dermatopathology – melanoma		Patients received dermoscopy and

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
		dermatology departments in the USA.	<p>lesions were included in analysis. 162 lesions were not evaluable due to unsuccessful imaging attempts, 19 lesions were missing histopathology information. Median age 47 years (range 7-97 years). 46% male 54% female. 98% white race.</p> <p><u>Inclusion criteria:</u> Patients with at least one pigmented lesion scheduled for complete biopsy</p> <p><u>Exclusion criteria:</u> Allergy to isopropyl alcohol, lesion less than 2mm or greater than 22mm in diameter, lesion not accessible to imaging device, lesion not previously biopsied, skin not intact, lesion within 1mm of the eye,</p>	<p>algorithm (MelaFind) using digital multispectral images to classify atypical lesions as either positive (requiring biopsy to rule out melanoma) or negative (lesion to be considered for later evaluation). Clinical diagnosis (with or without dermoscopy)</p> <p>dermoscopy was used for 645/1632 lesions.</p>	and borderline lesions such as high grade dysplastic nevi and atypical melanocytic hyperplasias or proliferations were defined as histologically positive lesions.		CAD-spectrophotometry before histopathologic reference standard

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
			lesions on palmar, plantar or mucosal surface or under nails, lesion in an area of scarring or containing foreign matter (e.g. tattoo).				
Moreno-Ramirez, D. (2007)		Referral from primary care (12 primary care centres) to secondary care (pigmented lesion and skin cancer clinic, University Hospital Virgen Macarena, Seville, Spain), 2004-2005.	<p>1589 patients received two teledermatology consultations – a random sample of 403 were included in the comparison with face-to-face consultation. Of these 403 patients, 59% were female, median age 46 years.</p> <p><u>Inclusion criteria:</u> Patients presenting to primary care with a lesion fulfilling at least one of the following: changes in ABCD criteria, symptoms, patient request for surgical treatment and concern.</p>	<p>Teledermatology – 2 digital images (a panoramic view and a close up) were taken of each lesion (presumably by the primary care doctor/nurse?). Images together with clinical information were sent electronically to two dermatologists for independent consultation. The dermatologists classified each lesion with a possible primary diagnosis and gave a refer or do-not refer decision.</p>	Histopathology or face-to-face clinical examination and dermoscopy where there was no surgery		<p>Patients had teleconsultation, most had a second teleconsultation from these a random sample were selected for face-to-face consultation – these form the analysis group. Some of these patients then had excision/biopsy as appropriate – in others</p> <p>See tables 2.3-2.7</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
			<u>Exclusion criteria:</u> Not reported				
Perrinaud et al (2007)		Secondary/tertiary care – pigmented lesion and melanoma clinic, Dermatology Department of the University Hospital Geneva, Switzerland	102 lesions: 91 clinically suspicious melanocytic lesions, 11 non-melanocytic pigmented lesions. <u>Inclusion criteria:</u> Melanocytic lesions judged suspicious by a dermatologist (based on clinical and dermoscopy examination). Pigmented non-melanocytic lesions and clinically obvious melanomas were also included. <u>Exclusion criteria:</u> clinically obvious melanomas.	3 computer assisted diagnosis digital dermoscopy systems (artificial intelligence): Dermogenius Ultra, Fotofinder and Microderm. Results of the tests were anonymised and reported as System I, II and III. One of the systems automatically classified lesions into malignant/suspicious/benign whereas the other two gave a probability score for malignancy (requiring the authors to choose threshold values for classification)	Histopathology		Patients were examined clinically & dermoscopically, those with suspicious lesions (not obviously malignant) were entered into the study. Their lesions were analysed using the computer assisted systems – those whose lesion could be analysed were included in the second phase of the study (comparing dermoscopy and computer tests). Lesions were then excised and analysed histopathologically If the computer diagnosis system was unable to analyse a lesion – it was excluded from

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
							the analysis
Piccolo et al (2004)		Secondary/tertiary care (Departments of Dermatology, Universities of Graz, Austria and L'Aquila, Italy.	77 lesions (71 melanocytic naevi and 6 melanomas) <u>Inclusion criteria:</u> acral lesions included in the databases of 2 dermatology departments <u>Exclusion criteria:</u> Not reported	Teledermatoscopy – dermoscopy images plus clinical information (age, sex of patients and site of lesion) were sent electronically to 11 dermatologists of varying levels of experience. Clinical images were not sent.	Histopathology		Dermoscopy images were selected from databases of 2 dermatology departments, histopathology information was probably already on file.
Rosendahl et al (2011)		Primary care skin cancer practice in Queensland Australia.	3/466 lesions were excluded due to poor quality dermoscopic images. 463 lesions (389 patients) included in the analysis. 33% female, mean age 57 years. 246 lesions were melanocytic and 217 were non-melanocytic. <u>Inclusion criteria:</u> pigmented lesions scheduled for biopsy <u>Exclusion criteria:</u>	Dermoscopy – the expertise of the observer is not reported Naked eye clinical examination – the expertise of the observer is not reported	Histology		See tables 2.3-2.7

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
			Not reported				
Stevenson et al. (2013).		Systematic review of diagnostic accuracy of reflectance confocal Post dermoscopy and clinical examination in secondary/tertiary care	909 lesions – average prevalence of melanoma was 36.2% (range 29% to 39%) <u>Inclusion criteria:</u> Patients presenting with lesions suspicious for melanoma <u>Exclusion criteria:</u> Cohort studies, diagnostic threshold setting studies	Reflectance confocal microscopy – no restriction on algorithm or diagnostic process. 3/5 studies used the Pellacani (2005) algorithm 2/5 used the Guitera (2010) algorithm 1 did not use a named algorithm	Histopathology of the excised skin lesion or long term clinical follow up.		See Tables 2.3-2.7
Tan et al (2010)		Secondary/tertiary care, Waikato Hospital Dermatology department, New Zealand. 2008	200 patients (491 lesions), 63% female, 94% European race, age range 11 to 94 years. <u>Inclusion criteria:</u> Patients referred from primary care for evaluation of skin lesions, Able to give informed consent <u>Exclusion criteria:</u>	Face-to-face clinical examination with dermoscopy (done by two dermatologists independently). Each lesion was assigned one of 11 diagnostic categories. Teledermatology – digital images and all electronic history were	Histopathology – in cases where the lesion was excised. Face-to-face diagnosis in cases where the lesion was not excised.		Patients were first seen by a melanographer who took digital images of the skin lesions (panoramic and macroscopic) then dermoscopic images. The patient was then seen face-to-face independently by two dermatologists who examined

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
			none reported	reviewed at least 4 weeks after the clinical examination by the same dermatologists involved in the clinical examination. Each lesion was assigned one of 11 diagnostic categories.			their lesions clinically and with a hand held dermoscope.
Tomatis S. (2005)		Secondary / tertiary care – melanoma unit of the National Cancer Institute of Milan, Italy	1359 patients (1485 cutaneous lesions), 56% female. 94 images were inadequate – 1391 lesions were included in the analysis. Lesions were randomly assigned to train, verify or validation samples which were used to develop, constrain and validate the index test algorithm respectively. <u>Inclusion criteria:</u> pigmented lesions clinically and/or dermoscopically	Artificial intelligence analysis of spectrophotometer images – the image data then fed into a neural network which classified lesions as malignant or benign.	Histopathology		See tables 2.3-2.7 Spectrophotometric images of the lesions were acquired in vivo before surgery 94 images were inadequate (technical failure) – 1391 lesions were included in the analysis.

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
			suspicious for cutaneous melanoma. <u>Exclusion criteria:</u> clearly thick or large melanomas, lesions inaccessible to the imaging device (for example interdigital, on ears, on the nose in the navel)				
Vestergaard et al (2008)		Systematic Review and Meta-analysis Mostly secondary care (referral centres with experts) 1/9 studies was done in primary care with non-experts Studies were done in the period 1990-2004, in Italy (7/9 studies), Germany (1 study) or Spain & Italy (1 study).	<u>Inclusion criteria:</u> Studies comparing clinical examination with and without dermoscopy that reported sensitivity and specificity for both, used a valid reference standard, did tests prospectively (without knowledge of the index test result), included <u>Exclusion criteria:</u> Retrospective studies, studies using only images of melanoma, non-	Naked eye examination (ABCD(E) rule 6/9 studies, no specified rule 3/9) Dermoscopy (pattern analysis 5/9, ABCD criteria 2/9, 7 point checklist 2/9, 3 point checklist 1/9)	Histopathology in 8/9 studies, follow up for presumed benign lesions in 3/9 studies Expert diagnosis in 1/9 studies (the primary care study)		See Tables 2.3-2.7

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
			English language				
Walter et al (2012)		<u>Clinical setting:</u> primary care (15 general practices), England, 2008-2010	1297 patients with 1580 lesions, mean age 45 years, 64% female, 94% white race. <u>Inclusion criteria:</u> age > 18 years, suspicious pigmented lesion <u>Exclusion criteria:</u> unable to give consent or considered inappropriate to refer by the G.P.	Patients were randomised to receive either of 2 index tests: Naked eye clinical assessment by GP or nurse practitioner using Cambridge University NHS Trust guidelines. Lesions were classified as requiring fast track referral for suspected skin cancer or not. Naked eye clinical assessment supported by CAD spectrophotometry (MoleMate system) by GP or nurse practitioner using a primary care scoring system. Lesions were classified as requiring fast track referral for suspected skin cancer or not.	For referred lesions reference standard was expert opinion on appropriateness of referral by a histologist or dermatologist For non-referred lesions reference standard was review by two dermatology experts on appropriateness of referral, using all available clinical and imaging data as well as the MoleMate image where available. All non-referred patients were offered a consultation with the lead clinician for the trial, including a		

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
					second photograph, at 3-6 months after the initial consultation.		
Warshaw et al (2009)		Secondary/tertiary care, Minneapolis Department Veterans' Affairs dermatology clinic, USA	<p>542 patients (542 index lesions), 96% male 97% Caucasian race. 36 melanomas</p> <p><u>Inclusion criteria:</u> patients referred from primary care for evaluation of pigmented skin lesions, who also underwent excision of the lesion</p> <p><u>Exclusion criteria:</u> not reported</p>	<p>Clinical examination with one of 11 staff clinic dermatologists including tests normally available in the clinical setting (e.g. palpation, diascopy, dermatoscopy). The lesion was assigned one of 17 common primary diagnoses, and up to 2 differential diagnoses.</p> <p>Teledermatology – one of 3 expert dermatologists reviewed the transmitted digital photographs (including dermatoscopy images) of the pigmented lesions. The lesion was</p>	Histopathology. An independent panel of 3 expert dermatologist (not involved in the index tests) agreed the most appropriate management plan for each patient		Patients all had clinical examination. The teledermatology took place after this. Then all index lesions were excised.

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and Results
				assigned one of 17 common primary diagnoses, and up to 2 differential diagnoses			

2.2 Photography

Review question: Is photography an effective method of detecting progression of pigmented lesions, including dermoscopy pictures?

Background

Melanoma typically presents as a new enlarging mole or a change in size shape or colour of an existing mole.

Early diagnosis and treatment is associated with better survival.

In the absence of screening programmes for melanoma, emphasis might better be directed towards developing tools that enable patients to self monitor their moles, particularly for those patients that have a lot of large unusual looking moles.

Assessing change in moles can be difficult both for patients and health care professionals. Monitoring moles by sequential photography could well be helpful particularly if dermoscopic pictures are used in combination with ordinary close up pictures that show clearly the measurements of the mole. Additionally, general photographs of the skin to 'map' where moles are on the body might help patients and clinicians to notice when new moles are appearing and growing. The latter is called mole mapping, and mole mapping services are provided on the High Street by a range of private providers, but there is limited access to this service for NHS patients.

What we don't know is whether this type of sequential photography (with or without dermoscopic images) can help us to diagnose melanoma and, in particular, the time intervals that would be used to repeat the photographs (e.g. 6 weeks, 3 months), in order to detect an early melanoma.


Question in PICO format

Patients/population	Intervention	Comparison	Outcomes
Patients with lesions suspicious of melanoma (e.g. suspicious skin lesions)	Photography +/- dermoscopy photographs	no photography	Stage at diagnosis of melanoma Time to diagnosis
People with atypical moles			

Screening Results

465 potentially relevant papers were identified through database searching and an additional 6 were identified through other sources (references in identified papers). Abstracts for these 471 papers were screened for their relevance for the review question and 417 papers were excluded leaving 54 papers to be ordered and the full text screened (figure 1). From these 54 papers 4 were relevant and included in the evidence review and 50 papers were excluded (table 4).

1 **Figure 2.6. Screening results**



2

3 Photographic surveillance of single lesions or the entire body has been proposed to limit the number of
4 unnecessary skin surgeries and to enhance the early detection of melanoma.

5 A number of the assessed papers demonstrated the usefulness of photography as a screening tool (Banky et al
6 2005; Bowns et al 2006; Feit et al 2004; Goodson et al 2010; Kelly et al 1997; Rivers et al 1990; Salerni et al 2012;
7 Wang et al 2004). However these studies did not compare photography with other screening methods and so are
8 not included in the evidence review.

9 There were 4 studies that compared the use of photography as a screening tool in patients with lesions
10 suspicious of melanoma against similar patients that did not have photography; 2 retrospective studies, 1
11 randomized trial and 1 cohort study. The studies looked at the outcomes of thickness of melanoma (which is a
12 marker for stage of disease) or clinical stage of melanoma. None of the studies looked at time to diagnosis. Two
13 studies only had baseline photography, 1 study took photographs yearly and 1 study took photographs at follow
14 up every 6 or 12 months.

1 **Evidence statements**

2 **Thickness of melanoma**

3 One randomized controlled trial, one cohort study and two retrospective studies examined the thickness of
4 melanoma in patients that had photography compared to patients that had not had photography. All of the
5 studies found that the melanomas excised were thinner in the photography patients.

6 In the randomized trial (Del Mar et al 1995) over 50 medical practitioners, mostly in general practices, in two
7 cities in Queensland, Australia were recruited into the trial. Practitioners in one city randomized to receive the
8 intervention were provided with an algorithm for clinical management of patients with suspicious moles and a
9 Polaroid instant camera. Pathology reports of all lesions excised during the 2 year intervention period were
10 obtained and analyzed. The median thickness of melanomas excised in the intervention group (photography) was
11 0.50 mm compared with 0.60mm in the control group (no photography).

12 In the cohort study (Drugge et al 2009) an assessment of melanoma thickness was compiled from 6 melanoma
13 biopsy cohorts which had undergone different clinical screening methods. The test cohort included patients who
14 were screened using photography yearly, two cohorts represented melanoma biopsies obtained from separate
15 pathology laboratories and the other 3 cohorts were from outside non-dermatologist physician referrals, patients
16 who were self-refereed and a cohort of patients followed by a dermatologist but without photographic
17 screening. The photography cohort had significantly thinner melanomas (0.13-1.4 mm thinner) compared to the
18 3 other clinical screening groups as well as the 2 pathology laboratory cohorts.

19 In the retrospective study (Salerni et al 2011) clinical and dermoscopic characteristics of 215 melanomas
20 consecutively excised and diagnosed over a 2 year period were analyzed. Melanomas diagnosed in patients in a
21 follow up program (total body photography and digital dermoscopy) were compared with melanomas diagnosed
22 in patients not in the follow up program over a 2 year period and were found to be 1.17mm thinner (mean
23 thickness 0.55mm compared to 1.72mm).

24 In another retrospective study (Rademaker et al 2010) 52 invasive melanomas identified from the Molemap NZ
25 database (which involved whole body photography and sequential digital dermoscopy) were compared to 15839
26 invasive melanomas detected by traditional methods as reported to the new Zealand cancer registry and were
27 found to be 0.20mm thinner (mean thickness 0.67mm compared to 0.87 mm). The study also examined
28 proportions of melanomas at different thicknesses. 69% of melanomas from patients who had photography and
29 52% of melanomas from patients who did not have photography were less than 0.75mm. 2% of melanomas from
30 patients who had photography and 11% of melanomas from patients who did not have photography were thicker
31 than 3mm.

32 **Clinical stage of melanoma**

33 One randomized controlled trial and one retrospective study examined the stage of melanoma in patients that
34 had photography compared to patients that had not had photography.

35 In the randomized trial (Del Mar et al 1995) it was found that there was no difference in the percentage of
36 invasive melanomas excised (72%) in the intervention group (photography) compared with the control group (no
37 photography).

38 In the retrospective study (Salerni et al 2011) 30% of melanomas were invasive melanomas in the patients that
39 had photography compared with 72% in patients without photography. The study also looked at the melanomas
40 in greater detail and classified them according to the American joint committee on cancer staging system. In
41 patients with photography 70% presented at as stage 0 at diagnosis and 30% at stage IA. No melanomas were

- 1 diagnosed above this stage. However in patients without photography 27.9% presented at stage 0 at diagnosis,
- 2 37.6% at stage IA, 12.7% at stage IB, 10.9% as stage II, 8.5% at stage III and 2.4% at stage IV.

1 **Grade Table 2.1: Should Photography be used**

Quality assessment							Summary of findings				Importance
							No of melanomas excised		Effect	Quality	
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	photography	no photography	Relative (95% CI)	Absolute	
stage of melanoma											
1	observational studies ¹	serious ²	no serious inconsistency	no serious indirectness	no serious imprecision	strong association	50	165	-	42% more in situ melanomas in patients that had photography compared to those who did not have photography.	LOW
stage of melanoma											
1	randomised trials	serious ²	no serious inconsistency	no serious indirectness	no serious imprecision	none	114	113	-	No difference in the numbers of in situ and invasive melanomas between patients that had photography compared to those who did not have photography.	MODERATE
thickness of melanoma											

Quality assessment							Summary of findings				Importance	
							No of melanomas excised		Effect			Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	photography	no photography	Relative (95% CI)	Absolute		
3	observational studies ¹	serious ²	no serious inconsistency	no serious indirectness	no serious imprecision	strong association	118	17846	-	Breslow depth of melanoma was 0.1 – 1.4 mm thinner in patients that had photography compared to those who did not have photography.	LOW	
thickness of melanoma												
1	randomised trials	serious ²	no serious inconsistency	no serious indirectness	no serious imprecision	none	114	113	-	Median Breslow depth of melanoma was 0.1mm thinner in patients that had photography compared to those who did not have photography.	MODERATE	

¹retrospective cohort study²bias

For the two retrospective studies and one cohort study there is selection bias in that it is high risk patients that are included in screening programs with photography. If these patients are at high risk the practitioner may be more likely to excise the lesion anyway and so we would expect to observe melanomas diagnosed at an earlier stage in this group of patients. The randomised trial is not subject to this bias. However it is not without its own limitations in that there is one city in each arm of the trial - ideally several cities would have been randomised to each arm. Also as the study cannot be blinded and practitioners know they are in the intervention city this could also introduce bias. Furthermore it is possible that the study underestimated the full potential of photography because of the duration of the follow up and review (4-8 weeks) may not have been long enough for the photography to detect morphologic change of atypical moles, given that many melanomas are slow growing.

References

Included Studies

- Del Mar CB, Green AC. (1995) Aid to diagnosis of melanoma in primary medical care. *BMJ* 310(6978):492-5.
- Drugge RJ, Nguyen C, Drugge ED, Gliga L, Broderick PA, McClain SA, Brown CC. (2009) Melanoma screening with serial whole body photographic change detection using Melanoscan technology. *Dermatol Online J.* 15(6):1.
- Rademaker M, Oakley A. (2010) Digital monitoring by whole body photography and sequential digital dermoscopy detects thinner melanomas. *J Prim Health Care* 2(4):268-72.
- Salerni G, Lovatto L, Carrera C, Puig S, Malvehy J. (2011) Melanomas detected in a follow-up program compared with melanomas referred to a melanoma unit. *Arch Dermatol.* 147(5):549-55.

Excluded Studies

- Argenziano,G.. Slow-growing melanoma: A dermoscopy follow-up study. *British Journal of Dermatology*
Reason: Not a study looking at photography.
- Banky JP, Kelly JW, English DR, Yeatman JM, Dowling JP. (2005) Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma. *Arch Dermatol.* 141(8):998-1006.
Reason: No comparison with no photography.
- Bowns,I.R.C.. Telemedicine in dermatology: A randomised controlled trial. *Health Technology Assessment*
Reason: Not relevant to PICO
- Brown,N. and Brown,N.. Exploration of diagnostic techniques for malignant melanoma: an integrative review. [Review] [36 refs]. *Clinical Excellence for Nurse Practitioners*
Reason: Systematic review of diagnostic techniques (1952-1999):
- Buhl,T.. Integrating static and dynamic features of melanoma: The DynaMel algorithm. *Journal of the American Academy of Dermatology*
Reason: Not a study looking at photography
- Carli,P. and de Giorgi,V. and Chiarugi,A. and Nardini,P. and Weinstock,M.A. and Crocetti,E. and Stante,M. and Giannotti,B.. Addition of dermoscopy to conventional naked-eye examination in melanoma screening: a randomized study. *Journal of the American Academy of Dermatology*
Reason: Not a study looking at photography.
- Carli,P. and De,Giorgi,V and Giannotti,B.. Why digital follow-up of dermoscopically equivocal pigmented lesions should be discouraged. *British Journal of Dermatology*
Reason: Expert opinion.
- Coates E.Menzies. Total body photography self-examination in patients at high risk of melanoma. *Australasian Journal of Dermatology*
Reason: Conference report on a case series.
- Coates E.Moloney. Melanoma detection in high risk patients: A case series. *Australasian Journal of Dermatology*
Reason: Conference abstract.

1 De Giorgi,V. Total body photography versus digital dermoscopic follow-up in the diagnosis of pigmented lesions.
2 Dermatologic Surgery
3 Reason: Expert opinion.

4 Drugge,R.J. and Nguyen,C. and Gliga,L. and Drugge,E.D. and Drugge,Rhett J. and Nguyen,Chi and Gliga,Luciana
5 and Drugge,Elizabeth D.. Clinical pathway for melanoma detection using comprehensive cutaneous analysis with
6 Melanoscan. Dermatology Online Journal
7 Reason: Not relevant to PICO

8 English DR, Burton RC, et al. (2003) Evaluation of aid to diagnosis of pigmented skin lesions in general practice:
9 controlled trial randomised by practice. BMJ 327 (7411): 375.
10 Reason: Study does not outcomes in PICO.

11 Feit NE, Dusza SW, Marghoob AA. (2004) Melanomas detected with the aid of total cutaneous photography. Br J
12 Dermatol. 150(4), 706-714.
13 Reason: Not relevant to PICO

14 Fikrle,T. and Pizinger,K. and Szakos,H. and Panznerova,P. and Divisova,B. and Pavel,S. and Fikrle,T. and Pizinger,K.
15 and Szakos,H. and Panznerova,P. and Divisova,B. and Pavel,S.. Digital dermatoscopic follow-up of 1027
16 melanocytic lesions in 121 patients at risk of malignant melanoma. Journal of the European Academy of
17 Dermatology & Venereology
18 Reason: Not a study looking at photography.

19 Goodson,A.G.F.. Comparative analysis of total body and dermatoscopic photographic monitoring of nevi in similar
20 patient populations at risk for cutaneous melanoma. Dermatologic Surgery
21 Reason: No comparison to no photography.

22 Gray,M.. The MoleMap experience 15 years on. Australasian Journal of Dermatology
23 Reason: Conference abstract

24 Guitera,P. and Menzies,S.W. and Guitera,Pascale and Menzies,Scott W.. State of the art of diagnostic technology
25 for early-stage melanoma. [Review]. Expert Review of Anticancer Therapy
26 Reason: Expert Review

27 Guitera-Rovel,P. and Vestergaard,M.E. and Guitera-Rovel,P. and Vestergaard,M.E.. [Diagnosis tools for cutaneous
28 melanoma]. [Review] [58 refs] [French]. Annales de Dermatologie et de Venereologie
29 Reason: Foreign Language

30 Haenssle,H.A.K.. Results from an observational trial: Digital epiluminescence microscopy follow-up of atypical nevi
31 increases the sensitivity and the chance of success of conventional dermoscopy in detecting melanoma. Journal of
32 Investigative Dermatology
33 Reason: Not a study looking at photography,

34 Haenssle,H.A.K.. Selection of patients for long-term surveillance with digital dermoscopy by assessment of
35 melanoma risk factors. Archives of Dermatology
36 Reason: Not a study looking at photography.

37 Haenssle,H.A.K.. Seven-point checklist for dermoscopy: Performance during 10 years of prospective surveillance of
38 patients at increased melanoma risk. Journal of the American Academy of Dermatology
39 Reason: Not a study looking at photography.

- 1 Hanrahan PF, D'Este CA, Menzies SW, Plummer T, Hersey P. (2002) A randomised trial of skin photography as an aid
2 to screening skin lesions in older males. J Med Screen 9(3):128-32.
3 Reason: No data
- 4 Hanrahan,P.F. and Hersey,P. and Menzies,S.W. and Watson,A.B. and D'Este,C.A. and Hanrahan,P.F. and Hersey,P.
5 and Menzies,S.W. and Watson,A.B. and D'Este,C.A.. Examination of the ability of people to identify early changes of
6 melanoma in computer-altered pigmented skin lesions. Archives of Dermatology
7 Reason: Not relevant to PICO
- 8 Kacenjar S.Zook. An automated multi-imaging registration method for the detection and quantification of
9 morphological changes across pigmented skin lesions. Pigment Cell and Melanoma Research
10 Reason: Conference abstract.
- 11 Kelly JW, Yeatman JM, Regalia C, Mason G, Henham AP. (1997) A high incidence of melanoma found in patients with
12 multiple dysplastic naevi by photographic surveillance. Med J Aust. 167(4), 191-194.
13 Reason: No comparisons with no photography.
- 14 Kittler,H. and Binder,M.. Follow-up of melanocytic skin lesions with digital dermoscopy: risks and benefits. Archives
15 of Dermatology
16 Reason: Brief Comment
- 17 Kittler,H. and Pehamberger,H. and Wolff,K. and Binder,M.. Diagnostic accuracy of dermoscopy. Lancet Oncology
18 Reason: Not a study looking at photography.
- 19 Korotkov,K. and Garcia,R. and Korotkov,Konstantin and Garcia,Rafael. Computerized analysis of pigmented skin
20 lesions: a review. [Review]. Artificial Intelligence in Medicine
21 Reason: Methodological review
- 22 Lucas,C.R. and Sanders,L.L. and Murray,J.C. and Myers,S.A. and Hall,R.P. and Grichnik,J.M.. Early melanoma
23 detection: nonuniform dermoscopic features and growth. Journal of the American Academy of Dermatology
24 Reason: Not relevant to PICO
- 25 Macbeth,A.E. and Grindlay,D.J. and Williams,H.C. and Macbeth,A.E. and Grindlay,D.J.C. and Williams,H.C.. What's
26 new in skin cancer? An analysis of guidelines and systematic reviews published in 2008-2009. [Review]. Clinical &
27 Experimental Dermatology
28 Reason: Expert review
- 29 Mayer,J.. Systematic review of the diagnostic accuracy of dermoscopy in detecting malignant melanoma. [Review]
30 [25 refs]. Medical Journal of Australia
31 Reason: Not a study looking at photography.
- 32 Menzies,S.W.S.. Variables predicting change in benign melanocytic nevi undergoing short-term dermoscopic
33 imaging. Archives of Dermatology
34 Reason: Not relevant to PICO
- 35 Milano,A.Bonifazi. Congenital melanocytic nevus. Clinical and dermoscopic signs of malignancy. European Journal of
36 Pediatric Dermatology
37 Reason: Not relevant to PICO
- 38 Moloney,F.J.G.. Observation of a five year high risk clinic for primary melanoma. Australasian Journal of Dermatology

1 Reason: Abstract

2 NHS Centre for Reviews and Dissemination. Systematic review of the diagnostic accuracy of dermoscopy in
3 detecting malignant melanoma (Structured abstract). Database of Abstracts of Reviews of Effectiveness
4 Reason: Abstract

5 Oakley,A.M.M.. Excised skin lesions diagnosed by teledermoscopy. Australasian Journal of Dermatology
6 Reason: Abstract

7 Rajpara S.Woo. The role of conventional naked eye examination, dermoscopy and digital dermoscopy follow-up in
8 the management of melanocytic skin lesions: A prospective study. British Journal of Dermatology
9 Reason: Abstract

10 Rajpara,S.M. and Botello,A.P. and Townend,J. and Ormerod,A.D. and Rajpara,S.M. and Botello,A.P. and
11 Townend,J. and Ormerod,A.D.. Systematic review of dermoscopy and digital dermoscopy/ artificial intelligence for
12 the diagnosis of melanoma. [Review] [95 refs]. British Journal of Dermatology
13 Reason: No Photography

14 Rivers JK, Kopf AW, Vinokur AF, Rigel DS, Friedman RJ, Heilman ER, Levenstein M. (1990) Clinical characteristics of
15 malignant melanomas developing in persons with dysplastic nevi. Cancer 65(5), 1232-1236.
16 Reason:No comparisons with no photography.

17 Rubegni,P.Burroni. Objective melanoma progression. Skin Research and Technology
18 Reason: No photography

19 Salerni,G. and Carrera,C. and Lovatto,L. and Marti-Laborda,R.M. et al. Characterization of 1152 lesions excised over
20 10 years using total-body photography and digital dermatoscopy in the surveillance of patients at high risk for
21 melanoma. Journal of the American Academy of Dermatology
22 Reason: Not relevant to PICO

23 Salerni,G. and Carrera,C. and Lovatto,L. Et al. Benefits of total body photography and digital dermatoscopy ('two-
24 step method of digital follow-up') in the early diagnosis of melanoma in patients at high risk for melanoma. Journal
25 of the American Academy of Dermatology
26 Reason: No comparison

27 Scope,A. and Dusza,S.W. and Marghoob,A.A. and Satagopan,J.M. and Braga Casagrande,Tavoloni J. and Psaty,E.L.
28 and Weinstock,M.A. and Oliveria,S.A. and Bishop,M. and Geller,A.C. and Halpern,A.C. and Scope,Alon and
29 Dusza,Stephen W. et al. Clinical and dermoscopic stability and volatility of melanocytic nevi in a population-based
30 cohort of children in Framingham school system. Journal of Investigative Dermatology
31 Reason: Not Melanoma

32 Seybold,K.Mertz. An automated change detection image analysis system as an aid in the early identification of skin
33 cancer. Journal of Investigative Dermatology
34 Reason: Abstract

35 Slue,Jr. Total body photography for melanoma surveillance. New York State Journal of Medicine
36 Reason: Review

37 Terushkin,V. and Dusza,S.W. and Scope,A. Et al. Changes observed in slow-growing melanomas during long-term
38 dermoscopic monitoring. British Journal of Dermatology

1 Reason: No photography

2 Vestergaard,M.E. and Menzies,S.W. and Vestergaard,Malene E. and Menzies,Scott W.. Automated diagnostic
3 instruments for cutaneous melanoma. [Review] [20 refs]. Seminars in Cutaneous Medicine & Surgery

4 Reason: No Photography

5 Vyas,R.Oakley. Dermoscopy of fading naevi. British Journal of Dermatology

6 Reason: Abstract

7 ¹ Wang SQ, Kopf AW, Koenig K, Polsky D, Nudel K, Bart RS. (2004) Detection of melanomas in patients followed up
8 with total cutaneous examinations, total cutaneous photography, and dermoscopy. J Am Acad Dermatol. 50(1), 15-
9 20.

10 Reason: No relevant comparison

11 Xu,L.Kittler. Assessment of growth rate of melanomas based on sequential dermatoscopic images. Melanoma
12 Research

13 Reason: Abstract

14

Evidence Tables

Study Quality

Study	Appropriate Randomisation	Appropriate Concealment	Comparable groups at baseline	Comparable Care apart from intervention	Patient Blinding	Treatment Administrator Blinding	Equal Follow-up	Equal Treatment Completion/Loss to follow up	Appropriate follow-up length	Precise definition of outcome	Valid method of measuring outcome	Investigator or blinding	Quality
Del Mar et al (2011)	Yes	No	No	Yes	No	No	Yes	Yes	No	Yes	Yes	Yes	Moderate

Study Quality (Cohort Studies)

	method of allocation to treatment groups was unrelated to potential confounding factors	Attempts were made within the design or analysis to balance the comparison groups for potential confounders	groups were comparable at baseline	comparison groups received the same care apart from the intervention	Blinding	followed up for an equal length of time	comparable for treatment completion	comparable with respect to the availability of outcome data	appropriate length of follow-up	precise definition of outcome	Investigators were kept 'blind' to participants' exposure	Investigators were kept 'blind' to other important confounding and prognostic factors
Drugge et al (2009)	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Rademaker et al 2010	Yes	Unclear	No	Yes	No	No	Yes	Unclear	No	Yes	Yes	Yes

Salemi et al (2011)	No	Unclear	No	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes
---------------------	----	---------	----	-----	----	-----	-----	-----	----	-----	-----	-----

Study	Study Type	Population	Intervention	Comparison	Outcomes	Results
Del Mar et al 1995	randomised trial	Over 50 medical practitioners, Mostly in general practice, in each of two cities in tropical Queensland, Australia. Control: 1997 excisions (113 melanomas) Intervention:2468 excisions (114 melanomas)	an algorithm and use of an instant developing camera (photographs only taken at baseline – follow up and review in 4-8 weeks) Intervention for 2 years.	no algorithm and no instant developing camera	- stage of the melanoma - mean Breslow depths	
Drugge et al 2009	Cohort study	Total number of melanoma biosies analysed was 1854. 9 years. Control: 1842 melanoma	Serial scanning cohort (SSC): Serial whole body photography (Melanoscan®) for the detection of melanoma (photographs: yearly)	- Patient self-referral (PSR) - MD referred (MDR) - Followed by dermatologist (FBD) - Community pathology laboratory	mean Breslow depths	

Study	Study Type	Population	Intervention	Comparison	Outcomes	Results									
		excisions Intervention:16 melanoma excisions		(CPL) - Dermatopathology laboratory (DPL)		<table><tr><td>Followed by dermatologist (FBD)</td><td>49</td><td>0.2257</td></tr><tr><td>Community pathology laboratory (CPL)</td><td>24</td><td>1.4460</td></tr><tr><td>Dermatopathology laboratory (DPL)</td><td>1728</td><td>0.1824</td></tr></table> <	Followed by dermatologist (FBD)	49	0.2257	Community pathology laboratory (CPL)	24	1.4460	Dermatopathology laboratory (DPL)	1728	0.1824
Followed by dermatologist (FBD)	49	0.2257													
Community pathology laboratory (CPL)	24	1.4460													
Dermatopathology laboratory (DPL)	1728	0.1824													

Study	Study Type	Population	Intervention	Comparison	Outcomes	Results																														
						patients with melanoma identified by traditional methods. Average with photography = 0.67mm v 0.87mm without photography.																														
Salerni et al 2011	Retrospective analysis	201 patients , 40 of whom were included in a follow-up program and 161 of whom were referred for evaluation. Melanoma Unit, Barcelona 2 years Control: 165 melanoma excisions Intervention: 50 melanoma excisions	follow-up programs with total-body photographs and digital dermoscopy Follow up: 8 patients yearly, 32 patients evey 6 months	patients referred to a melanoma unit	- clinical stage of the melanoma - mean Breslow depths	<table><tr><td></td><td>follow-up program</td><td>Referred patients</td></tr><tr><td>Stage 0</td><td>35 (70%)</td><td>46 (27.9%)</td></tr><tr><td>Stage IA</td><td>15 (30%)</td><td>62 (37.6%)</td></tr><tr><td>Stage IB</td><td>-</td><td>21 (12.7%)</td></tr><tr><td>Stage II</td><td>-</td><td>18 (10.9%)</td></tr><tr><td>Stage III</td><td>-</td><td>14 (8.5%)</td></tr><tr><td>Stage IV</td><td>-</td><td>4 (2.4%)</td></tr></table> <table><tr><td></td><td>follow-up program</td><td>Referred patients</td></tr><tr><td>Thickness mm</td><td>0.55</td><td>1.72</td></tr><tr><td>Mean</td><td>(0.25-0.90)</td><td>(0.25-13.00)</td></tr></table>		follow-up program	Referred patients	Stage 0	35 (70%)	46 (27.9%)	Stage IA	15 (30%)	62 (37.6%)	Stage IB	-	21 (12.7%)	Stage II	-	18 (10.9%)	Stage III	-	14 (8.5%)	Stage IV	-	4 (2.4%)		follow-up program	Referred patients	Thickness mm	0.55	1.72	Mean	(0.25-0.90)	(0.25-13.00)
	follow-up program	Referred patients																																		
Stage 0	35 (70%)	46 (27.9%)																																		
Stage IA	15 (30%)	62 (37.6%)																																		
Stage IB	-	21 (12.7%)																																		
Stage II	-	18 (10.9%)																																		
Stage III	-	14 (8.5%)																																		
Stage IV	-	4 (2.4%)																																		
	follow-up program	Referred patients																																		
Thickness mm	0.55	1.72																																		
Mean	(0.25-0.90)	(0.25-13.00)																																		

Study	Study Type	Population	Intervention	Comparison	Outcomes	Results		
						(range)		
						p=0.001		

2.3 Borderline and Spitzoid melanocytic lesions?

Review question: What is the best approach to resolving clinico-pathological diagnostic uncertainty for borderline or spitzoid melanocytic lesions?

Background

Melanocytic lesions are difficult in clinical and histopathology practice. Early and reliable diagnosis is very important in the management of such lesions, but it is difficult to achieve, due to various factors. One of the reasons is that there is a number of borderline lesions, which require thorough investigations, and may necessitate extensive workup. These lesions comprise atypical melanocytic proliferations, unusual variations of well-known entities and melanocytic lesion is presenting in unusual age groups. Spitzoid lesions are one of the most important differential diagnostic subgroup for melanoma, especially in the younger age group.

Clinico-pathological correlation of the lesions is very important and while currently histopathological diagnosis is the gold standard, significant advancement was made in clinical assessment with the more extensive use of dermoscopy. Current development in the histopathology practice (immunohistochemistry and molecular genetics tests) resulted in more accurate diagnostic methods, which will enable us to achieve more accurate and earlier diagnosis.

Distinction between the benign and malignant lesions is important, which is this enables us to direct patient pathway better, avoid unnecessary tests and anxiety of the patients. The borderline melanocytic lesion group causes significant diagnostic difficulty at clinical and histopathology level and while no single test is able to differentiate between these and melanoma, we need to assess new techniques and tool, which are now available. As the clinico-pathological correlation is very important, we should look at the clinical and histopathologic diagnostic methods in combination as well.

Question in PICO format:

Patients/population	Intervention	Comparison	Outcomes
Patients presenting with borderline or spitzoid melanocytic lesions	Clinical assessment & Dermoscopy	Clinical assessment	1. Positive Predictive Value 2. Negative Predictive Value 3. Sensitivity 4. Specificity 5. Accuracy 6. Reader variability/interobserver variability
	Histopathological examination	Immunohistochemistry FISH/molecular genetics testing ?each other	
	SLNB	No SLNB	

How will the information be searched?

Searches:	
Can we apply date limits to the search (<i>Please provide information on any date limits we can apply to the searches for this topic. This can be done for each individual intervention as appropriate</i>)	No Epidemiology data is available from early 80's onwards
Are there any study design filters to be used (<i>RCT, systematic review, diagnostic test</i>).	Diagnostic Accuracy studies including RCTs if available If we use study filters, this might limit the scope - the ones to be considered would be review and diagnostic test.

List useful search terms. (<i>This can include such information as any alternative names for the interventions etc</i>)	Atypical melanocytic, spitzoid, borderline melanocytic, nevoid, naevoid, melanoma, lentigo maligna, meltump, stump, uncertain malignant potential, dysplastic naevus, naevus of special sites,
---	--

1 The Review Strategy

Evidence was identified, assessed and synthesised according to the methods outlined in the Guidelines Manual (2012). Relevant studies were identified through sifting the abstracts and excluding studies clearly not relevant to the PICO. In the case of relevant or potentially relevant studies, the full paper was ordered and reviewed, whereupon studies considered to be not relevant to the topic were excluded. Studies which were identified as relevant were critically appraised and quality assessed using GRADE methodology and NICE checklists. Data relating to the identified outcomes were extracted from the relevant studies. The data were not meta-analysed due to the difference in interventions and populations (in terms of melanoma thicknesses) of the included studies, but were instead summarised per study in tabular form, and further in GRADE tables and evidence statements.

10 Search Results


Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
Medline	1946-2013	340	111	16/10/2013
Premedline	15 Oct 2013	40	7	16/10/2013
Embase	1947-2013	532	187	16/10/2013
Cochrane Library	Issue 6 of 12 June 2013	37	2	23/10/2013
Web of Science (SCI & SSCI)	1900-2013	691	163	23/10/2013
Total References retrieved (after de-duplication): 334				

11 Medline search strategy (*This search strategy is adapted to each database*)

1. exp Melanoma/
2. melanoma\$.tw.
3. (maligna\$ adj1 lentigo\$).tw.
4. (hutchinson\$ adj1 (freckle\$ or melano\$)).tw.
5. dubreuilh.tw.
6. LMM.tw.
7. or/1-6
8. "Nevus, Epithelioid and Spindle Cell"/
9. (spitz* adj2 (melano* or nevi* or naevi* or nevo* or naevo* or nevu* or naevu* or mole* or lesion* or tumor?r*)).tw.
10. (borderline* adj2 (melano* or nevi* or naevi* or nevo* or naevo* or nevu* or naevu* or mole* or lesion* or tumor?r*)).tw.
11. (atypical* adj2 (melano* or nevi* or naevi* or nevo* or naevo* or nevu* or naevu* or mole* or lesion* or tumor?r*)).tw.

12. (uncertain* adj2 (melano* or nevi* or naevi* or nevo* or naevo* or nevu* or naevu* or mole* or lesion* or tumo?r*)).tw.
13. (ambiguous adj2 (melano* or nevi* or naevi* or nevo* or naevo* or nevu* or naevu* or mole* or lesion* or tumo?r*)).tw.
14. (dysplastic adj2 (melano* or nevi* or naevi* or nevo* or naevo* or nevu* or naevu* or mole* or lesion* or tumo?r*)).tw.
15. (stump or meltump).tw.
16. (pigmented adj2 melanocytoma*).tw.
17. cutaneous melanocytoma*.tw.
18. or/8-17
19. 7 and 18
20. exp Histological Techniques/
21. exp Immunohistochemistry/
22. histopathology*.tw.
23. immunohistochem*.tw.
24. ((fluorescen* or immunofluorescen*) adj2 (test* or techni*)).tw.
25. In Situ Hybridization,Fluorescence/
26. FISH.tw.
27. Molecular Diagnostic Techniques/
28. Genetic Testing/
29. ((molecular or genetic) adj2 (test* or techni*)).tw.
30. Physical examination/
31. ((physical or clinical or skin) adj (exam* or assessment*)).tw.
32. exp Dermoscopy/
33. (dermoscop* or dermatoscop*).tw.
34. exp Sentinel Lymph Node Biopsy/
35. (sentinel and node* and biops*).tw.
36. (SNB or SNLB).tw.
37. or/20-36
38. 19 and 37
39. exp "Sensitivity and Specificity"/
40. sensitivity.tw.
41. specificity.tw.
42. ((pre-test or pretest) adj probability).tw.
43. post-test probability.tw.
44. predictive value\$.tw.
45. likelihood ratio\$.tw.
46. (diagnos* adj accura*).tw.
47. *"Predictive Value of Tests"/
48. Diagnosis, Differential/
49. exp Diagnostic Errors/
50. or/39-49
51. 38 and 50

1 Screening Results



Note. The database contained 334 articles but one article was recorded twice (and ordered twice) with the wrong author information so numbers presented are minus this duplication.

Study Quality

Figure 2.7. QUADAS summary for clinical assessment and dermoscopy papers (n=2).




Figure 2.8. QUADAS summary for Immunohistochemistry papers (n=14).





Figure 2.9. QUADAS summary for sentinel lymph node biopsy papers (n=7).



1 **Evidence Statements**

2 *What is the best approach to resolving clinico-pathological diagnostic uncertainty for borderline or Spitzoid*
3 *melanocytic lesions?*

4 Twenty three low quality studies provided information on diagnostic tests. All studies were retrospective case
5 reviews with very limited information on patient selection.

6 *Melanoma versus Melanocytic Nevi/naevus*

7 Low quality evidence from two studies suggests that clinical assessment is more sensitive when using dermoscopy
8 for detecting melanoma in populations with melanocytic naevi lesions.

9 Low quality evidence from one study showed that in patients with melanocytic lesions (*atypical cellular blue nevi,*
10 *atypical congenital nevi, atypical desmoplastic nevi, and combined nevi*) 44% had a positive sentinel node biopsy.

11 *Melanoma versus Spitzoid melanoma*

12 Low quality evidence from one study did not identify a genetic test (BRAF Exon 11, 15; NRAS Exon 2, 3; HRAS Exon 2,
13 3) that reliably discriminates between melanoma and Spitzoid melanoma.

14 Low quality evidence from two studies suggests that between 35% and 56% of patients with Spitzoid melanoma will
15 have positive sentinel lymph node biopsies.

16 *Melanoma versus Spitz nevi.*

17 Low quality evidence from five studies suggests that some genetic tests (FISH, BRAF Exon 15, CGH and NRAS Exon 2)
18 are potentially useful in discriminating between melanoma and Spitz nevi.

19 *Melanoma versus Atypical Spitz nevi.*

20 Low quality evidence from one study suggests that genetic tests involving BRAF Exon 15 may have a role in
21 discriminating between melanoma and atypical Spitz nevi.

22 Low quality evidence from three studies suggests that between 0% and 47% of patients with atypical Spitz nevi will
23 have positive sentinel lymph node biopsies.

24 *Melanoma versus Atypical Spitz tumour*

25 Low quality evidence from two studies suggests that genetic tests (FISH and BRAF Exon 15) are potentially useful in
26 discriminating between melanoma and Atypical Spitz tumour.

27 *Spitzoid melanoma versus Spitz nevi*

28 Low quality evidence from one study suggests that FISH is a potentially useful test in discriminating between Spitzoid
29 melanoma and Spitz nevi.

30 *Spitzoid melanoma versus Atypical Spitz nevi*

31 Low quality evidence from one study suggests genetic tests involving BRAF Exon 15 may have a role in discriminating
32 Spitzoid melanoma from Atypical Spitz nevi.

33 Low quality evidence from one study suggests that rates of positive sentinel lymph node biopsy of 26% and 35% in
34 patients with Atypical Spitz nevi and Spitzoid melanoma respectively.

35 *Spitzoid melanoma versus Atypical spitz tumour*

36 Low quality evidence from two studies did not identify a genetic test (FISH; BRAF V600E) that reliably discriminates
37 Spitzoid melanoma from Atypical Spitz tumour.

- 1 *Atypical spitzoid nevomelanocytic versus Typical spitz nevi*
- 2 Low quality evidence from one study did not identify a genetic test (BRAF V600E; NRAS Exon 2) that reliably
- 3 discriminates Atypical Spitzoid nevomelanocytic from typical spitz nevi.

- 4 *Primary cutaneous melanoma and Spitz nevi*
- 5 Low quality evidence from one study did not identify a genetic test (BRAF V600E; NRAS; HRAS) that reliably
- 6 discriminates Primary cutaneous melanoma from Spitz nevi.

- 7 *Atypical Spitzoid tumour:*
- 8 Low quality evidence from one study suggests that 28.6% patients with Atypical Spitzoid tumours will have positive
- 9 sentinel node biopsy.

1 Evidence Summary

2 Table 2.8. Overview of evidence for clinical assessment and dermoscopy (n=2).

Article	Lesion/Intervention	N	Sensitivity	Specificity	PPV	NPV	Accuracy
Carli et al. (2004)		3053					
	Non-users*		50.7	97.3			
Melanoma (n)	319	Dermoscopy Users ⁺	63.9	95.7			
Spitz/naevus (n)	77						
Krähn et al. (1998)	Correct diagnosis total	80					
	Clinical		78.8				
	Dermatoscopic		91.3				
	Melanoma	39					
	Clinical		79.4	78	77	80	65
	Dermatoscopic		89.8	93	92	90	83
	Dysplastic nevi	3					
	Clinical		0				
	Dermatoscopic		100				
	Common nevi	38					
	Clinical		84.2				
	Dermatoscopic		92.1				

3 Note. Non-users refer to 4 dermatologists from general dermatology clinics where their main activity was clinical assessment without dermoscopy. ⁺Dermoscopy
4 users refer to two dermatologists from pigmented lesion clinics where their main activity was clinical assessment with dermoscopy.

5 Table 2.9. Overview of evidence for sentinel lymph node biopsy (n=7).

Article	Lesion type	N	N SLNB		SLNB+		SLNB-	
			n	%	n	%	n	%
Caraco et al. (2012)	Atypical Spitz nevi	40	40	100	0	0	40	100
Cochran et al. (2010)	Melanocytic	33	18	54.5	8	44	10	66
	Combined nevi		5		3	60	2	40
	Atypical cellular blue nevi		4		2	50	2	50
	Atypical congenital nevi		4		2	50	2	50
	Atypical desmoplastic nevi		2		1	50	1	50
Hung et al. (2013)	Spitzoid melanocytic tumour	40	40	100	12	30	28	70
	Atypical spitz tumour		23		6	26.1	17	73.9
	Spitzoid melanoma		17		6	35.3	11	64.7
Ludgate et al. (2009)	Atypical spitz	57	57	100	27	47.4	30	52.6
Murali et al. (2008)	Atypical spitzoid tumour	21	21	100	6	28.6	15	71.4
Urso et al. (2006)	Atypical spitz	12	12	100	4	33.3	8	66.7
Paradela et al. (2009)	Spitzoid melanoma	38	25	65.8	14	56	8	44

6

Table 2.10. Overview of evidence for Immunohistochemistry (n=14) according to test (FISH, CGH, individual genetic markers) and outcome (e.g. melanoma, spitz nevi):

Author	Test: FISH	Outcome: Disease		Sensitivity	Specificity	PPV	NPV	Accuracy
		DM	SMN					
Gerami et al. 2011	Positive FISH	7	0	46.7	100	100	65.2	73.3
	Negative	8	15					
		SCMM	PSCN					
Diaz et al. 2011	Positive FISH	11	1	73.3	93.3	91.7	77.8	83.3
	Negative	4	14					
		M	N					
Hossain et al. 2011	Positive FISH	112	20	71.8	90.2	84.8	80.8	82.3
	Negative	44	185					
Martin et al. 2012	Positive FISH	12	0	85.7	100	100	84.6	92
	Negative	2	11					
		M	SN					
Hossain et al. 2011	Positive FISH	112	3	71.8	94.5	97.4	54.2	77.7
	Negative	44	52					
Martin et al. 2012	Positive FISH	12	19	85.7	62.7	38.7	94.1	67.7
	Negative	2	32					
	Positive FISH	9	2	90	80	81.8	88.9	85
	Negative	1	8					
		SM	SN					
Kerl et al. 2012	Positive FISH (Abbott criteria)	21	18	61.8	73.9	53.8	79.7	69.9
	Negative	13	51					
	Positive FISH (Gerami et al. criteria)	22	16	64.7	76.8	57.9	81.5	72.8
	Negative	12	53					
	Positive FISH Combined	24	22	70.6	68.1	52.2	82.5	68.9
	Negative	10	47					
Requena et al. 2012	Positive FISH (Abbott criteria)	7	0	87.5	100	100	83.3	92.3
	Negative	1	5					
	Positive FISH (Gerami et al. criteria)	8	0	100	100	100	100	100
	Negative	0	5					
		M	AST					
Massi et al. 2011	Positive FISH	9	6	90	76	60	95	80
	Negative	1	19					
		SM	AST					
Kerl et al. 2012	Positive FISH (Abbott criteria)	24	47	61.8	47.8	30.9	76.8	51.6
	Negative	10	43					
	Positive FISH (Gerami et al. criteria)	24	54	64.7	40	28.9	75	46.8

	Negative	10	36					
	Positive FISH Combined	24	56	70.6	37.8	30	77.3	46.8
	Negative	10	34					

Note. DM: Desmoplastic melanoma. SMN: Sclerosing melanocytic nevi. MM/M: Malignant melanoma. SM: Spitzoid melanoma. ASN: Atypical spitz nevi. AST: Atypical spitz tumour. SN: Spitz nevi.

Author	Test: CGH	Outcome: Disease		Sensitivity	specificity	PPV	NPV	Accuracy
Bastian et al. 2003		MM	SN	96.2	74.1	94.8	80	92.5
	At least one chromosomal aberration	127	7					
	No aberrations	5	20					

Note. MM/M: Malignant melanoma. SN: Spitz nevi.

Author	Test: BRAF V600E	Outcome: Disease		Sensitivity	specificity	PPV	NPV	Accuracy
Fullen et al. 2006		SM	AST	15.4	100	100	38.9	45
	Positive mutation	2	0					
	Negative	11	7	15.4	79.2	16.7	77.6	65.6
		SM	SN					
	Positive mutation	2	10					
Takata et al. 2007	Negative	11	38	45.8	100	100	48	63.9
		PCM	SN					
	Positive mutation	11	0	0	83.3	0	27.8	26.3
Emley et al. 2010	Negative	13	12					
		ASN	TSN					

Note. PCM: Primary Cutaneous Melanoma. SM: Spitzoid melanoma. ASN: Atypical spitz nevi. AST: Atypical spitz tumour. SN: Spitz nevi. TSN: Typical Spitz nevi.

Author	Test: NRAS 1	Outcome: Disease		Sensitivity	specificity	PPV	NPV	Accuracy
Emley et al. 2010		ASN	TSN	33.3	100	100	57.9	65.2
	Positive mutation	4	0					
	Negative	8	11					

Note. ASN: Atypical spitz nevi. TSN: Typical Spitz nevi.

Author	Test: NRAS 2	Outcome: Disease		Sensitivity	specificity	PPV	NPV	Accuracy
Emley et al. 2010		ASN	TSN	0	100	-	31.6	31.6
	Positive mutation	0	0					
	Negative	13	6					

Note. ASN: Atypical spitz nevi. TSN: Typical Spitz nevi.

Author	Test: NRAS	Outcome: Disease		Sensitivity	specificity	PPV	NPV	Accuracy
Takata et al. 2007		PCM	SN	33.3	100	100	57.9	65.2
	Positive mutation	4	0					
	Negative	8	11					

Note. PCM: Primary Cutaneous Melanoma. SN: Spitz nevi.

Author	Test: HRAS	Outcome: Disease		Sensitivity	specificity	PPV	NPV	Accuracy
Takata et al. 2007		PCM	SN	0	100	0	33.3	33.3
	Positive mutation	0	0					
	Negative	22	11					

Note. PCM: Primary Cutaneous Melanoma. SN: Spitz nevi.

Author	Test: BRAF Exon 15	Outcome: Disease		Sensitivity	specificity	PPV	NPV	Accuracy
Van Dijk et al. 2005		MM	SM	70	36.1	23.3	81.3	35.3
	Positive mutation	7	23					
	Negative	3	13					
		MM	ASN	70	100	100	84.2	68.5
	Positive mutation	7	0					
	Negative	3	16					
		MM	SN	70	100	100	82.4	65.3
	Positive mutation	7	0					
	Negative	3	14					
		SM	ASN	63.9	100	100	55.2	75
	Positive mutation	23	0					
	Negative	13	16					
Gill et al. 2004		SM	SN	0	100	0	52.6	52.6
	Positive mutation	0	0					
	Negative	9	10					
Raskin et al. 2011		M	AST	66.7	87.5	50	93.3	84.2
	Positive mutation	2	2					
	Negative	1	14					
		M	SN	66.7	100	100	88.9	90.1
	Positive mutation	2	0					
	Negative	1	8					

Note. MM/M: Malignant melanoma. SM: Spitzoid melanoma. ASN: Atypical spitz nevi. AST: Atypical spitz tumour. SN: Spitz nevi.

Author	Test: BRAF Exon 11	Outcome: Disease		Sensitivity	specificity	PPV	NPV	Accuracy
Van Dijk et al. 2005		MM	SM	0	100	0	89.7	89.7
	Positive mutation	0	0					
	Negative	3	26					

		MM	ASN	0	100	0	81.3	81.3
	Positive mutation	0	0	0	100	0	81.3	81.3
	Negative	3	13					
		MM	SN	0	100	0	75	75
	Positive mutation	0	0	0	100	0	75	75
	Negative	3	9					
		SM	ASN	0	100	0	33.3	33.3
Gill et al. 2004	Positive mutation	0	0	0	100	0	33.3	33.3
	Negative	26	13					
		SM	SN					
	Positive mutation	0	0					
	Negative	9	10	0	100	0	52.6	52.6

Note. MM/M: Malignant melanoma. SM: Spitzoid melanoma. ASN: Atypical spitz nevi. AST: Atypical spitz tumour. SN: Spitz nevi.

Author	Test: NRAS Exon 2	Outcome: Disease		Sensitivity	specificity	PPV	NPV	Accuracy
Van Dijk et al. 2005		MM	SM	0	100	0	83.3	83.3
	Positive mutation	0	0	0	100	0	83.3	83.3
	Negative	7	35					
		MM	ASN	0	100	0	68.2	68.2
	Positive mutation	0	0	0	100	0	68.2	68.2
	Negative	7	15					
		MM	SN	0	100	0	65	65
	Positive mutation	0	0	0	100	0	65	65
	Negative	7	13					
		SM	ASN	0	100	0	30	30
Gill et al. 2004	Positive mutation	0	0	0	100	0	30	30
	Negative	35	15					
		SM	SN					
	Positive mutation	0	0					
Raskin et al. 2011	Negative	9	10	0	87.5	0	70	63.6
		M	AST					
	Positive mutation	0	2					
	Negative	3	14					
		M	SN					
	Positive mutation	2	1					
	Negative	1	7					

Note. MM/M: Malignant melanoma. SM: Spitzoid melanoma. ASN: Atypical spitz nevi. AST: Atypical spitz tumour. SN: Spitz nevi.

Author	Test: NRAS Exon 3	Outcome: Disease		Sensitivity	specificity	PPV	NPV	Accuracy
Van Dijk et al. 2005		MM	SM	28.6	80	22.2	84.8	68.7
	Positive mutation	2	7	28.6	80	22.2	84.8	68.7

	Negative	5	28	28.6	100	100	73.7	68.7
		MM	ASN					
	Positive mutation	2	0					
	Negative	5	14	28.6	100	100	73.7	68.7
		MM	SN					
	Positive mutation	2	0					
	Negative	5	14	20	100	100	33.3	42.9
		SM	ASN					
	Positive mutation	7	0					
Gill et al. 2004	Negative	28	14	11.1	100	100	55.6	57.9
		SM	SN					
	Positive mutation	1	0					
	Negative	8	10					

Note. MM/M: Malignant melanoma. SM: Spitzoid melanoma. ASN: Atypical spitz nevi. AST: Atypical spitz tumour. SN: Spitz nevi.

Author	Test: HRAS Exon 2	Outcome: Disease		Sensitivity	specificity	PPV	NPV	Accuracy
Van Dijk et al. 2005		MM	SM	0	100	0	85.4	85.4
	Positive mutation	0	0					
	Negative	6	35					
		MM	ASN	0	100	0	72.7	72.7
	Positive mutation	0	0					
	Negative	6	16					
		MM	SN	0	100	0	68.4	68.4
	Positive mutation	0	0					
	Negative	6	13					
		SM	ASN	0	100	0	31.4	31.4
	Positive mutation	0	0					
	Negative	35	16					
Gill et al. 2004		SM	SN	44.4	40	40	44.4	42.1
	Positive mutation	4	6					
	Negative	5	4					
Raskin et al. 2011		M	AST	0	100	0	88.9	88.9
	Positive mutation	0	0					
	Negative	2	16					
		M	SN	0	87.5	0	77.8	70
	Positive mutation	0	1					
	Negative	2	7					

Note. MM/M: Malignant melanoma. SM: Spitzoid melanoma. ASN: Atypical spitz nevi. AST: Atypical spitz tumour. SN: Spitz nevi.

Author	Test: HRAS Exon 3	Outcome: Disease		Sensitivity	specificity	PPV	NPV	Accuracy
Van Dijk et al. 2005		MM	SM	0	100	0	85	85

DRAFT FOR CONSULTATION

	Positive mutation	0	0					
	Negative	6	34					
		MM	ASN	0	88.2	0	71.4	65.2
	Positive mutation	0	2					
	Negative	6	15	0	76.5	0	68.4	56.5
		MM	SN					
	Positive mutation	0	4					
	Negative	6	13					
		SM	ASN	0	88.2	0	30.6	29.4
	Positive mutation	0	2					
	Negative	34	15					
Gill et al. 2004		SM	SN	11.1	90	50	52.9	52.6
	Positive mutation	1	1					
	Negative	8	9					

Note. MM: Malignant melanoma. SM: Spitzoid melanoma. ASN: Atypical spitz nevi. SN: Spitz nevi.

Figure 2.10. SROC for genetic tests comparing Melanoma (MM) and Spitzoid melanoma (SM).




Figure 2.11 . SROC for genetic tests comparing Melanoma (MM) and Spitz nevi (SN).






Figure 2.12. SROC for genetic tests comparing Melanoma (MM) and Atypical spitz nevi (ASN).**Figure 2.13. SROC for genetic tests comparing Melanoma (M) and Atypical spitz tumour (AST).**

Figure 2.14. SROC for genetic tests comparing Spitzoid melanoma (SM) and Spitz nevi (SN).




Figure 2.15. SROC for genetic tests comparing Spitzoid melanoma (SM) and Atypical spitz nevi (ASN).




Figure 2.16. SROC for genetic tests comparing Spitzoid melanoma (SM) and Atypical spitz tumour (AST).




Figure 2.17. SROC for genetic tests comparing Atypical spitzoid nevomelanocytic (ASN) and Typical spitz nevi (TSN).





Figure 2.18. SROC for genetic tests comparing Primary cutaneous melanoma (PCM) and Spitz nevi (SN).

References

Included Studies

- Bastian, BC et al. Classifying melanocytic tumors based on DNA copy number changes. *American Journal of Pathology* 2003; 163(5): 1765-1770.
- Caraco, C et al. Sentinel lymph node biopsy in atypical Spitz nevi: Is it useful? *Ejso* 2012; 38(10): 932-935.
- Carli, P et al. Improvement of malignant/benign ratio in excised melanocytic lesions in the 'dermoscopy era': a retrospective study 1997-2001. *British Journal of Dermatology* 2004; 150(4): 687-692.
- Cochran, AJ et al. The role of lymphatic mapping and sentinel node biopsy in the management of atypical and anomalous melanocytic lesions. *Journal of Cutaneous Pathology* 2010; 37 Suppl 1: 54-59.
- Diaz, A., Valera, A., Carrera, C., Hakim, S., Aguilera, P., Garcia, A., Palou, J., Puig, S., Malvehy, J., and Alos, L. (2011). Pigmented Spindle Cell Nevus: Clues for Differentiating It From Spindle Cell Malignant Melanoma. A Comprehensive Survey Including Clinicopathologic, Immunohistochemical, and FISH Studies. Note: Mentions key search terms but not spitzoid/spitz.
- Emley, A et al. Oncogenic BRAF and the tumor suppressor IGFBP7 in the genesis of atypical spitzoid nevi/melanocytic proliferations. *Journal of Cutaneous Pathology* 2010; 37(3): 344-349.
- Fullen, DR et al. BRAF and NRAS mutations in spitzoid melanocytic lesions. *Modern Pathology* 2006; 19(10): 1324-1332.
- Gerami, P et al. Fluorescence in situ hybridization as an ancillary method for the distinction of desmoplastic melanomas from sclerosing melanocytic nevi. *Journal of Cutaneous Pathology* 2011; 38(4): 329-334.
- Gill, M et al. Genetic similarities between Spitz nevus and Spitzoid melanoma in children. *Cancer* 2004; 101(11): 2636-2640.
- Hossain, D. Differential diagnosis of melanomas using fluorescence in situ hybridization (FISH)-melano fish. *Laboratory Investigation* 2011; Conference(var.pagings): February
- Hung, T et al. Sentinel lymph node metastasis is not predictive of poor outcome in patients with problematic spitzoid melanocytic tumors. *Human Pathology* 2013; 44(1): 87-94.
- Kerl, K., Palmedo, G., Wiesner, T., Mentzel, T., Rutten, A., Scharer, L., Paredes, B., Hantschke, M., Kutzner, H., Kerl, Katrin, Palmedo, Gabriele, Wiesner, Thomas, Mentzel, Thomas, Rutten, Arno, Scharer, Leo, Paredes, Bruno, Hantschke, Markus, and Kutzner, Heinz (2012). A proposal for improving multicolor FISH sensitivity in the diagnosis of malignant melanoma using new combined criteria. Note: Mentions key search terms but not spitzoid/spitz.
- Krahn, G. Dermatoscopy and high frequency sonography: two useful non-invasive methods to increase preoperative diagnostic accuracy in pigmented skin lesions. *Pigment cell research / sponsored by the European Society for Pigment Cell Research and the International Pigment Cell Society* 1998; 11(3): 151-154.
- Ludgate, MW et al. The Atypical Spitz Tumor of Uncertain Biologic Potential A Series of 67 Patients From a Single Institution. *Cancer* 2009; 115(3): 631-641.
- Martin, V et al. Presence of cytogenetic abnormalities in Spitz naevi: a diagnostic challenge for fluorescence in-situ hybridization analysis. *Histopathology* 2012; 60(2): 336-346.
- Massi, D et al. Atypical Spitzoid melanocytic tumors: A morphological, mutational, and FISH analysis. *Journal of the American Academy of Dermatology* 2011; 64(5): 919-935.

- 1 Murali, R et al. Sentinel lymph node biopsy in histologically ambiguous melanocytic tumors with spitzoid features
2 (so-called atypical spitzoid tumors). *Annals of Surgical Oncology* 2008; 15(1): 302-309.
- 3 Paradela, S et al. Spitzoid melanoma in children: clinicopathological study and application of immunohistochemistry
4 as an adjunct diagnostic tool. *Journal of Cutaneous Pathology* 2009; 36(7): 740-752.
- 5 Raskin, L et al. Copy number variations and clinical outcome in atypical spitz tumors. *American Journal of Surgical*
6 *Pathology* 2011; 35(2): 243-252.
- 7 Requena, C et al. Fluorescence in situ hybridization for the differential diagnosis between Spitz naevus and spitzoid
8 melanoma. *Histopathology* 2012; 61(5): 899-909.
- 9 Takata, M. Genetic and epigenetic alterations in the differential diagnosis of malignant melanoma and spitzoid
10 lesion. *British Journal of Dermatology* 2007; 156(6): 1287-1294.
- 11 Urso, C et al. Sentinel lymph node biopsy in patients with "atypical Spitz tumors." A report on 12 cases. *Human*
12 *Pathology* 2006; 37(7): 816-823.
- 13 Van Dijk, MCRF, Bernsen, MR, and Ruiter, DJ. Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the
14 differential diagnosis of Spitz nevus and spitzoid melanoma. *American Journal of Surgical Pathology* 2005; 29(9):
15 1145-1151.
- 16 *Excluded Studies*
- 17 Alomari, AA. Immunohistochemistry versus mass spectrometry in the detection of the differential expression of
18 vimentin and actin in spitz nevi and spitzoid malignant melanomas. *American Journal of Dermatopathology* 2013;
19 Conference(var.pagings): e85
20 Reason: Not in PICO.
- 21 Amin, K et al. Ex vivo dermoscopy of cutaneous biopsies for melanocytic neoplasms: a retrospective review of 517
22 cases with histopathologic correlation. *American Journal of Dermatopathology* 2012; 34(7): 710-715.
23 Reason: Not in PICO.
- 24 Andreassi, L., Perotti, R., Rubegni, P., Burroni, M., Cevenini, G., Biagioli, M., Taddeucci, P., Dell'Eva, G., and Barbini, P.
25 (1999). Digital dermoscopy analysis for the differentiation of atypical nevi and early melanoma - A new quantitative
26 semiology. Note: Mentions key search terms but not spitzoid/spitz.
27 Reason: No intervention comparator.
- 28 Antonio, J. R., Soubhia, R. M., D'Avila, S. C., Caldas, A. C., Tridico, L. A., Alves, F. T., Antonio, Joao Roberto, Soubhia,
29 Rosa Maria Cordeiro, D'Avila, Solange Correa Garcia Pires, Caldas, Adriana Cristina, Tridico, Livia Arroyo, and Alves,
30 Fernanda Tome (2013). Correlation between dermoscopic and histopathological diagnoses of atypical nevi in a
31 dermatology outpatient clinic of the Medical School of Sao Jose do Rio Preto, SP, Brazil. Note: Mentions key search
32 terms but not spitzoid/spitz.
33 Reason: No intervention comparator (e.g. clinical assessment).
- 34 Baran, JL and Duncan, LM. Combined Melanocytic Nevi: Histologic Variants and Melanoma Mimics. *American Journal*
35 *of Surgical Pathology* 2011; 35(10): 1540-1548.
36 Reason: No comparator.
- 37 Barnhill, RL. Atypical Spitz nevi/tumors: Lack of consensus for diagnosis, discrimination from melanoma, and
38 prediction of outcome. *Human Pathology* 1999; 30(5): 513-520.
39 Reason: No comparator, clinical assessment.

- 1 Berlingeri-Ramos, AC et al. Spitz Nevus in a Hispanic Population: A Clinicopathological Study of 130 Cases. American
2 Journal of Dermatopathology 2010; 32(3): 267-275.
3 Reason: No comparator of interventions.
- 4 Binder, SW et al. The Histology and Differential-Diagnosis of Spitz Nevus. Seminars in Diagnostic Pathology 1993;
5 10(1): 36-46.
6 Reason: No comparator of interventions.
- 7 Braun, R. P., Gutkowitz-Krusin, D., Rabinovitz, H., Cognetta, A., Hofmann-Wellenhof, R., Ahlgrim-Siess, V., Polsky,
8 D., Oliviero, M., Kolm, I., Googe, P., King, R., Prieto, V. G., French, L., Marghoob, A., Mihm, M., Braun, R. P.,
9 Gutkowitz-Krusin, D., Rabinovitz, H., Cognetta, A., Hofmann-Wellenhof, R., Ahlgrim-Siess, V., Polsky, D., Oliviero,
10 M., Kolm, I., Googe, P., King, R., Prieto, V. G., French, L., Marghoob, A., and Mihm, M. (2012). Agreement of
11 dermatopathologists in the evaluation of clinically difficult melanocytic lesions: how golden is the 'gold standard'?.
12 Note: Mentions key search terms but not spitzoid/spitz.
13 Reason: Assessment of clinical judgements, no comparison to dermoscopy.
- 14 Broganelli, P. Spitz nevus in adults or spitzoid melanoma? Histologicdermatological correlations. Giornale Italiano di
15 Dermatologia e Venereologia 2003; 138(2): 147-149.
16 Reason: N<10 (n=3) case studies. Italian.
- 17 Buonaccorsi, JNS. Potential misdiagnosis of atypical benign melanocytic lesion of the thigh: A clinicopathologic study
18 of 41 cases. American Journal of Dermatopathology 2011; Conference(var.pagings): 422-423.
19 Reason: Abstract only.
- 20 Carli, P., de Giorgi, V., Massi, D. & Giannotti, B. (2000) The role of pattern analysis and the ABCD rule of dermoscopy
21 in the detection of histological atypia in melanocytic naevi. British Journal of Dermatology, 143: 290-297.
22 Reason: No comparison to melanoma.
- 23 Carrera, C et al. Early Stages of Melanoma on the Limbs of High-risk Patients: Clinical, Dermoscopic, Reflectance
24 Confocal Microscopy and Histopathological Characterization for Improved Recognition. Acta Dermato-Venereologica
25 2011; 91(2): 137-146.
26 Reason: No comparator. Descriptive, no comparison of interventions.
- 27 Cavalcanti, PG, Scharcanski, J, and Baranoski, GVG. A two-stage approach for discriminating melanocytic skin lesions
28 using standard cameras. Expert Systems with Applications 2013; 40(10): 4054-4064.
29 Reason: Not in PICO.
- 30 Cerroni, L et al. Melanocytic Tumors of Uncertain Malignant Potential Results of a Tutorial Held at the XXIX
31 Symposium of the International Society of Dermatopathology in Graz, October 2008. American Journal of Surgical
32 Pathology 2010; 34(3): 314-326.
33 Reason: Description of characteristics. No comparison of interventions.
- 34 Cesinaro, AM et al. Spitz nevus is relatively frequent in adults - A clinico-pathologic study of 247 cases related to
35 patient's age. American Journal of Dermatopathology 2005; 27(6): 469-475.
36 Reason: Description of characteristics of SN. No comparison of interventions.
- 37 Chung, LS, Man, YG, and Lupton, GP. WT-1 expression in a spectrum of melanocytic lesions: Implication for
38 differential diagnosis. Journal of Cancer 2010; 1: 120-125.
39 Reason: Results are presented in such a way that outcomes cannot be obtained
- 40 Clemente, C., Bettio, D., Venci, A., Scopsi, L., Rao, S., Ferrari, A., Piris, A., Mihm, M. C., Jr., Clemente, C., Bettio, D.,
41 Venci, A., Scopsi, L., Rao, S., Ferrari, A., Piris, A., and Mihm, M. C. J. (2009). A fluorescence in situ hybridization (FISH)

- 1 procedure to assist in differentiating benign from malignant melanocytic lesions. Note: Mentions key search terms
- 2 but not spitzoid/spitz.
- 3 Reason: Not in PICO
- 4 Coates, E. Use of a novel dermoscopic technique in combination with in vivo reflectance confocal microscopy to
- 5 diagnose amelanotic and hypomelanotic melanoma in a 22 case series. *Australasian Journal of Dermatology* 2013;
- 6 Conference(var.pagings): May
- 7 Reason: Abstract only..
- 8 Crotty, KA et al. Malignant-Melanoma in Childhood - A Clinicopathological Study of 13 Cases and Comparison with
- 9 Spitz Nevi. *World Journal of Surgery* 1992; 16(2): 179-185.
- 10 Reason: No intervention comparison.
- 11 De Wit, PE et al. DNA in situ hybridization as a diagnostic tool in the discrimination of melanoma and Spitz naevus.
- 12 *Journal of Pathology* 1994; 173(3): 227-233.
- 13 Reason: Not in PICO..
- 14 Diaconeasa, A et al. Histopathologic features of Spitzoid lesions in different age groups. *Romanian Journal of*
- 15 *Morphology & Embryology* 2013; 54(1): 51-62.
- 16 Reason: No comparison, intervention.
- 17 Diaz, A. Clinicopathologic, immunohistochemical and molecular analysis in the differential diagnosis of reed nevus
- 18 and spindle cell melanoma. *Laboratory Investigation* 2011; Conference(var.pagings): February
- 19 Reason: Abstract only.
- 20 Erdem, O, I. Use of immunohistochemistry (HMB-45,P16 and KI-67) in the diagnosis of spitzoid lesions. *Laboratory*
- 21 *Investigation* 2012; Conference(var.pagings): February
- 22 Reason: Abstract only.
- 23 Ferrara, G et al. The spectrum of Spitz Nevi - A clinicopathologic study of 83 cases. *Archives of Dermatology* 2005;
- 24 141(11): 1381-1387.
- 25 Reason: No intervention comparator.
- 26 Gammon, B et al. Enhanced detection of spitzoid melanomas using fluorescence in situ hybridization with 9p21 as an
- 27 adjunctive probe. *American Journal of Surgical Pathology* 2012; 36(1): 81-88.
- 28 Reason: Not in PICO.
- 29 Gerami, P et al. A highly specific and discriminatory FISH assay for distinguishing between benign and malignant
- 30 melanocytic neoplasms. *American Journal of Surgical Pathology* 2012; 36(6): 808-817.
- 31 Reason: Not in PICO.
- 32 Gerami, P., Jewell, S. S., Morrison, L. E., Blondin, B., Schulz, J., Ruffalo, T., Matushek, P., Legator, M., Jacobson, K.,
- 33 Dalton, S. R., Charzan, S., Kolaitis, N. A., Guitart, J., Lertsbarapa, T., Boone, S., Leboit, P. E., Bastian, B. C., Gerami,
- 34 Pedram, Jewell, Susan S., Morrison, Larry E., Blondin, Beth, Schulz, John, Ruffalo, Teresa, Matushek, Paul, Legator,
- 35 Mona, Jacobson, Kristine, Dalton, Scott R., Charzan, Susan, Kolaitis, Nicholas A., Guitart, Joan, Lertsbarapa, Terakeith,
- 36 Boone, Susan, Leboit, Philip E., and Bastian, Boris C. (2009). Fluorescence in situ hybridization (FISH) as an ancillary
- 37 diagnostic tool in the diagnosis of melanoma.[Erratum appears in *Am J Surg Pathol.* 2010 May;34(5):688].
- 38 Reason: Not in PICO.
- 39 Gerami et al. (2013). Risk assessment for atypical Spitzoid melanocytic neoplasms using FISH to identify
- 40 chromosomal copy number aberrations. *AM J Surg Pathol* 2013;37:676-684.
- 41 Reason: no comparator to melanoma.

- 1 Gerami et al. (2010). Superficial melanocytic neoplasms with pageoid melanocytosis. A study of interobserver
2 concordance and correlation with FISH. Am J Surg Pathol 2010;34:816-821.
3 Reason: Not in PICO.
- 4 Gonzalez, A. Cutaneous melanoma in children and adolescents. JDDG - Journal of the German Society of
5 Dermatology 2013; Conference(var.pagings): July
6 Reason: Abstract only.
- 7 Gonzalez-Campora, R et al. Nucleolar organizer regions in pigmented skin lesions. Value in the differential diagnosis
8 of Spitz nevi. Analytical & Quantitative Cytology & Histology 1991; 13(1): 16-22.
9 Reason: Not in PICO.
- 10 Haenssle, H. A., Krueger, U., Vente, C., Thoms, K. M., Bertsch, H. P., Zutt, M., Rosenberger, A., Neumann, C., Emmert,
11 S., Haenssle, Holger A., Krueger, Ullrich, Vente, Claudia, Thoms, Kai Martin, Bertsch, Hans P., Zutt, Markus,
12 Rosenberger, Albert, Neumann, Christine, and Emmert, Steffen (2006). Results from an observational trial: digital
13 epiluminescence microscopy follow-up of atypical nevi increases the sensitivity and the chance of success of
14 conventional dermoscopy in detecting melanoma. Note: Mentions key search terms but not spitzoid/spitz.
15 Reason: Not in PICO.
- 16 Hafiji, J et al. The spectrum of spitzoid tumours: A clinical study. Australasian Journal of Dermatology 2012; 53(3):
17 211-215.
18 Reason: No comparative data on interventions.
- 19 Hantschke, M. Consumption of the epidermis: A diagnostic criterion for the differential diagnosis of melanoma and
20 spitz nevus. American Journal of Surgical Pathology 2004; 28(12): 1621-1625.
21 Reason: Description of characteristics of melanoma and spitz nevus. No intervention comparator.
- 22 Harvell, JD et al. High-resolution array-based comparative genomic hybridization for distinguishing paraffin-
23 embedded Spitz nevi and melanomas. Diagnostic Molecular Pathology 2004; 13(1): 22-25.
24 Reason: N<10 (n=5) case studies.
- 25 Harvell, JDM. Spitz's nevi with halo reaction: A histopathologic study of 17 cases. Journal of Cutaneous Pathology
26 1997; 24(10): 611-619.
27 Reason: No comparator.
- 28 Kashani-Sabet, M et al. A multi-marker assay to distinguish malignant melanomas from benign nevi. Proceedings of
29 the National Academy of Sciences of the United States of America 2009; 106(15): 6268-6272.
30 Reason: Not in PICO
- 31 Kauffman, CLS. Development and validation of a chromogenic RNA in situ hybridization assay for diagnosis of
32 atypical melanocytic nevi and malignant melanoma. Laboratory Investigation 2013; Conference(var.pagings):
33 February
34 Reason: Not in PICO.
- 35 Kollipara, R and Singh, V. Atypical spitz nevus and melanoma in children: A clinicopathologic study. Pediatric and
36 Developmental Pathology 2013; Conference(var.pagings): 56-February.
37 Reason: Abstract only.
- 38 Kuzbicki, L. The value of cyclooxygenase-2 expression in differentiating between early melanomas and
39 histopathologically difficult types of benign human skin lesions. Melanoma Research 2012; 22(1): 70-76.
40 Reason: Intervention not currently used in the UK.
- 41 Langley, RGB. The diagnostic accuracy of in vivo confocal scanning laser microscopy compared to dermoscopy of
42 benign and malignant melanocytic lesions: A prospective study. Dermatology 2007; 215(4): 365-372.

1 Reason: Not in PICO.

2 Lazova, R et al. Imaging mass spectrometry--a new and promising method to differentiate Spitz nevi from Spitzoid
3 malignant melanomas. American Journal of Dermatopathology 2012; 34(1): 82-90.

4 Reason: Not in PICO

5 Mazzarello, V et al. Melanoma versus dysplastic naevi: microtopographic skin study with noninvasive method.
6 Journal of Plastic Reconstructive and Aesthetic Surgery 2006; 59(7): 700-705.

7 Reason: No intervention comparator.

8 Medeiros, AC, I. Epiluminescence microscopy of pigmented skin lesions in southern Brazil: The region with the
9 highest incidence of melanoma. Journal of the American Academy of Dermatology 2011; Conference(var.pagings):
10 AB122

11 Reason: Abstract only

12 Mihic-Probst, D. Absence of BRAF gene mutations differentiates Spitz nevi from malignant melanoma. Anticancer
13 Research 2004; 24(4): 2415-2418.

14 Reason: No comparator.

15 Murali, R. Fluorescence in situ hybridisation in the evaluation of melanocytic tumours. Pigment Cell and Melanoma
16 Research 2010; Conference(var.pagings): 965

17 Reason: Abstract only.

18 Niemann, TH and Argenyi, ZB. Immunohistochemical Study of Spitz Nevi and Malignant-Melanoma with Use of
19 Antibody to Proliferating Cell Nuclear Antigen. American Journal of Dermatopathology 1993; 15(5): 441-445.

20 Reason: Not in PICO

21 Nojavan, H, Cribier, B, and Mehregan, DR. Desmoplastic Spitz nevus: A histopathological review and comparison with
22 desmoplastic melanoma. Annales de Dermatologie et de Venereologie 2009; 136(10): 689-695.

23 Reason: Foreign Language

24 North, J. Fishing for melanoma at UCSF: A review of 804 clinical cases. American Journal of Dermatopathology 2011;
25 Conference(var.pagings): 421

26 Reason: Abstract only.

27 Okun, MR and Okun, MR. Silhouette symmetry: an unsupportable histologic criterion for distinguishing Spitz nevi
28 and compound nevi from malignant melanoma. Archives of Pathology & Laboratory Medicine 1997; 121(1): 48-53.

29 Reason: Not in PICO

30 Paredes, B and Hardmeier, T. Spitz nevus and Reed nevus: Simulation of melanoma in adults. Pathologie 1998; 19(6):
31 403-411.

32 Reason: Foreign Language

33 Pellacani, G et al. In Vivo Confocal Microscopic and Histopathologic Correlations of Dermoscopic Features in 202
34 Melanocytic Lesions. Archives of Dermatology 2008; 144(12): 1597-1608.

35 Reason: Not in PICO

36 Pellacani, G et al. Spitz nevi: In vivo confocal microscopic features, dermoscopic aspects, histopathologic
37 correlates, and diagnostic significance. Journal of the American Academy of Dermatology 2009; 60(2): 236-247.

38 Reason: Not in PICO

39 Pizzichetta, MA et al. Negative pigment network: an additional dermoscopic feature for the diagnosis of melanoma.
40 Journal of the American Academy of Dermatology 2013; 68(4): 552-559.

- 1 Reason: no comparison of interventions.
- 2 Requena, C et al. Characteristics of spitzoid melanoma and clues for differential diagnosis with spitz nevus. American
3 Journal of Dermatopathology 2012; 34(5): 478-486.
- 4 Reason: No comparator.
- 5 Requena, C. Spitz nevus: a clinicopathological study of 349 cases. The American Journal of dermatopathology 2009;
6 31(2): 107-116.
- 7 Reason: No comparator.
- 8 Ribe, A et al. S100A6 protein expression is different in Spitz nevi and melanomas. Modern Pathology 2003; 16(5):
9 505-511.
- 10 Reason: Not in PICO
- 11 Rubegni, P et al. Differentiation between pigmented Spitz naevus and melanoma by digital dermoscopy and stepwise
12 logistic discriminant analysis. Melanoma Research 2001; 11(1): 37-44.
- 13 Reason: no intervention comparison.
- 14 Shanks, JH et al. VS38 immunostaining in melanocytic lesions. Journal of Clinical Pathology 1996; 49(3): 205-207.
- 15 Reason: Not in PICO
- 16 Soura E. Clinical features of spitz nevi in greek population: A retrospective study of 64 cases. JDDG - Journal of the
17 German Society of Dermatology 2013; Conference(var.pagings): July
- 18 Reason: Abstract only
- 19 Stanelle, EJB. Clinical experience with atypical spitzoid tumors in patients younger than age 18: Does fluorescence in
20 situ hybridization predict lymph node metastasis? Journal of Clinical Oncology 2012; Conference(var.pagings)
- 21 Reason: Abstract only.
- 22 Steiner, A et al. Pigmented Spitz Nevi - Improvement of the Diagnostic-Accuracy by Epiluminescence Microscopy.
23 Journal of the American Academy of Dermatology 1992; 27(5): 697-701.
- 24 Reason: No comparator to melanoma.
- 25 Stephens, P. Next-generation sequencing of genomic and cDNA to identify a high frequency of kinase fusions
26 involving ROS1, ALK, RET, NTRK1, and BRAF in Spitz tumors. Journal of Clinical Oncology 2013;
27 Conference(var.pagings)
- 28 Reason: Abstract only.
- 29 Takata, M. Genome profiling of melanocytic tumors using multiplex ligation-dependent probe amplification (MLPA):
30 Its usefulness as an adjunctive diagnostic tool for melanocytic tumors. Journal of Dermatological Science 2005; 40(1):
31 51-57.
- 32 Reason: Intervention not currently available in the UK.
- 33 Takeuchi, M. Pigmented spindle cell nevus and pigmented Spitz nevus--clinical and histopathological study on
34 pigmented Spitz nevus, and its differentiation from early melanoma by fluorescence method and measurement of 5-
35 S-CD level in the lesion. Nippon Hifuka Gakkai zasshi 1990; The Japanese journal of dermatology. 100(11): 1153-
36 1165.
- 37 Reason: Foreign Language
- 38 van Dijk, MC et al. Allelic imbalance in the diagnosis of benign, atypical and malignant Spitz tumours. Journal of
39 Pathology 2002; 197(2): 170-178.
- 40 Reason: Not in PICO

- 1 Walsh, N et al. Spitz nevus versus spitzoid malignant melanoma: an evaluation of the current distinguishing
2 histopathologic criteria. Human Pathology 1998; 29(10): 1105-1112.
3 Reason: No intervention comparator.
- 4 Wang, L. Clinical and histopathological analysis of 16 cases of Spitz nevus. Journal of Clinical Dermatology 2006;
5 35(10): 640-642.
6 Reason: Foreign Language
- 7 Wiesner, T et al. A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1
8 expression. American Journal of Surgical Pathology 2012; 36(6): 818-830.
9 Reason: No breakdown per melanoma and spitz in the results.
- 10 Wititsuwannakul, J et al. Neuropilin-2 as a useful marker in the differentiation between Spitzoid malignant
11 melanoma and Spitz nevus. Journal of the American Academy of Dermatology 2013; 68(1): 129-137.
12 Reason: Not in PICO
- 13 Wititsuwannakul, J. Neuropilin-2 (NRP2) as a useful marker in the differential diagnosis of Spitzoid malignant
14 melanoma and Spitz nevus. American Journal of Dermatopathology 2012; Conference(var.pagings): e62
15 Reason: Abstract only.
- 16 Zalaudek, I et al. "White" network in Spitz nevi and early melanomas lacking significant pigmentation. Journal of the
17 American Academy of Dermatology 2013; 69(1): 56-60.
18 Reason: No comparison of interventions.
- 19 Argenziano, G et al. Dermatoscopic pitfalls in differentiating pigmented Spitz naevi from cutaneous melanomas.
20 British Journal of Dermatology 1999; 141(5): 788-793.
21 Reason Not enough data to extract for the relevant outcomes in PICO.
- 22 Wettengel, GV et al. Differentiation between Spitz nevi and malignant melanomas by interphase fluorescence in situ
23 hybridization. International Journal of Oncology 1999; 14(6): 1177-1183.
24 Reason: Not in PICO.
- 25 Bayer-Garner, IB et al. Vascular endothelial growth factor expression in malignant melanoma: prognostic versus
26 diagnostic usefulness. Modern Pathology 1999; 12(8): 770-774.
27 Reason: Not in PICO
- 28 Bergman, R et al. A comparative immunohistochemical study of MART-1 expression in Spitz nevi, ordinary
29 melanocytic nevi, and malignant melanomas. Journal of the American Academy of Dermatology 2000; 42(3): 496-
30 500.
31 Reason: Not in PICO
- 32 Bergman, R et al. Immunohistochemical study of p53 protein expression in Spitz nevus as compared with other
33 melanocytic lesions. American Journal of Dermatopathology 1995; 17(6): 547-550.
34 Reason: Not in PICO
- 35 Bergman, R. MIB-1 monoclonal antibody to determine proliferative activity of Ki-67 antigen as an adjunct to the
36 histopathologic differential diagnosis of Spitz nevi. Journal of the American Academy of Dermatology 2001; 44(3):
37 500-504.
38 Reason: Not in PICO
- 39 Berk, DR et al. Melanoma and Melanocytic Tumors of Uncertain Malignant Potential in Children, Adolescents and
40 Young Adults-The Stanford Experience 1995-2008. Pediatric Dermatology 2010; 27(3): 244-254.
41 Reason: Not in PICO

- 1 Blokhin, E et al. Immunohistochemical expression of p16 in desmoplastic melanoma. Journal of Cutaneous Pathology
2 2013; 40(9): 796-800.
3 Reason: Not in PICO
- 4 Ferrara, G et al. The impact of molecular morphology techniques on the expert diagnosis in melanocytic skin
5 neoplasms. International Journal of Surgical Pathology 2013; 21(5): 483-492.
6 Reason: Not in PICO
- 7 Garcia-Martin, R. Different protein expressions between Spitz nevus and melanoma. Virchows Archiv 2009;
8 Conference(var.pagings): August
9 Reason: Not in PICO
- 10 Garrido-Ruiz, MC et al. The immunohistochemical profile of Spitz nevi and conventional (non-Spitzoid) melanomas: a
11 baseline study. Modern Pathology 2010; 23(9): 1215-1224.
12 Reason: Not in PICO
- 13 Garrido-Ruiz, MC. Immunohistochemical profile distinguishes Spitz nevi from melanomas. Laboratory Investigation
14 2010; Conference(var.pagings): February
15 Reason: Not in PICO
- 16 George E. Immunohistochemical evaluation of p16INK4A, E-cadherin, and cyclin D1 expression in melanoma and
17 Spitz tumors. American Journal of Clinical Pathology 2010; 133(3): 370-379.
18 Reason: Not in PICO
- 19 Hilliard, NJ et al. p16 expression differentiates between desmoplastic Spitz nevus and desmoplastic melanoma.
20 Journal of Cutaneous Pathology 2009; 36(7): 753-759.
21 Reason: Not in PICO
- 22 Kapur, P et al. Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical analysis. Modern
23 Pathology 2005; 18(2): 197-204.
24 Reason: Not in PICO
- 25 King, MS et al. Differentiating spitzoid melanomas from Spitz nevi through CD99 expression. Journal of Cutaneous
26 Pathology 2007; 34(7): 576-580.
27 Reason: Not in PICO
- 28 Le Sache-de Peufelhous, L et al. Clinical features of Spitz naevus in children: A retrospective study of 196 cases.
29 Annales de Dermatologie et de Venereologie 2012; 139(6-7): 444-451.
30 Reason: Not in PICO
- 31 Mason, A et al. Expression of p16 alone does not differentiate between Spitz nevi andSpitzoid melanoma. Journal of
32 Cutaneous Pathology 2012; 39(12): 1062-1074.
33 Reason: Not in PICO
- 34 Moore, J. Adoption of FISH for diagnosis of melanoma. Laboratory Investigation 2012; Conference(var.pagings):
35 February
36 Reason: Not in PICO
- 37 Nagasaka, T et al. Cyclin D1 overexpression in Spitz nevi: an immunohistochemical study. American Journal of
38 Dermatopathology 1999; 21(2): 115-120.
39 Reason: Not in PICO

- 1 Pilloni, L et al. The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions. European
2 Journal of Histochemistry 2011; 55(2): e20
3 Reason: Not in PICO
- 4 Puri, PK et al. Statistical analysis of the concordance of immunohistochemical stains with the final diagnosis in
5 spitzoid neoplasms. American Journal of Dermatopathology 2011; 33(1): 72-77.
6 Reason: Not in PICO
- 7 Rosner, K et al. WT1 marker is not sufficient for distinguishing between melanoma and melanocytic nevi. Journal of
8 Cutaneous Pathology 2009; 36(10): 1077-1082.
9 Reason: Not in PICO
- 10 Shanks, JH and Banerjee SS. (1996). VS38 immunostaining in melanocytic lesions. J Clin Pathol 1996;49:205-207.
11 Reason: Not in PICO
- 12 Stefanaki, C. Cell cycle and apoptosis regulators in Spitz nevi: Comparison with melanomas and common nevi.
13 Journal of the American Academy of Dermatology 2007; 56(5): 815-824.
14 Reason: Not in PICO
- 15 Wang, L. Clinical and histopathologic characteristics of desmoplastic Spitz nevus and pigmented spindle cell nevus.
16 Journal of Clinical Dermatology 2008; 37(8): 500-502.
17 Reason: Not in PICO
- 18 Zhang, G., Li, G., Zhang, Guohong, and Li, Gang (2012). Novel multiple markers to distinguish melanoma from
19 dysplastic nevi. Note: Mentions key search terms but not spiztoid/spitz.
20 Reason: Not in PICO
- 21 Zhu, YI and Fitzpatrick, JE. Expression of c-kit (CD117) in Spitz nevus and malignant melanoma. Journal of Cutaneous
22 Pathology 2006; 33(1): 33-37.
23 Reason: Not in PICO

Evidence Tables

Evidence tables for the included studies comparing clinical assessment to dermoscopy (N=2):

Carli, P et al. "Improvement of malignant/benign ratio in excised melanocytic lesions in the 'dermoscopy era': a retrospective study". British Journal of Dermatology (2004) 150: 687-692.									
Pub year: 2004		Patient selection		Index test		Reference standard		Flow and timing	
Country	Italy	<i>Inclusion criteria:</i> All histologically confirmed melanocytic lesions consecutively excised at the Dermosurgery room of the Department of Dermatology of the University of Florence in the period 1997-2001 were retrieved. <i>Exclusion criteria:</i> patients diagnosed in private practice.		Non-users: Clinical assessment (4 dermatologists from general dermatology clinics) Users: Dermatoscopy (2 dermatologists from pigmented lesions clinics)		Histological examination routinely made by the same staff of pathologists.		All skin lesions were excised and all patients received all index tests. No information provided regarding the time between index test(s) and reference standard.	
Design, period	Retrospective case review 1997-2001	Was a consecutive or random sample of patients enrolled?	Yes	Were the index test results interpreted without knowledge of the results of the reference standard?	Yes	Is the reference standard likely to correctly classify the target condition?	Yes	Was there an appropriate interval between index test(s) and reference standard?	Unclear
N	3053 melanocytic lesions	Was a case-control design avoided?	Yes	If a threshold was used, was it pre-specified?	Unclear	Were the reference results interpreted without knowledge of the results of	Yes	Did all patients receive a reference standard?	Yes
Follow-up	Not provided	Did the study avoid inappropriate exclusions?	Yes					Did all patients	Yes

						the index test?		receive the same reference standard ?							
		Could the selection of patients have introduced bias?	Low	Could the conduct or interpretation of the index test have introduced bias?	Low	Could the reference standard, its conduct, or its interpretation have introduced bias?	Low	Were all patients included in the analysis?	Yes						
Funding source	Not mentioned	Are there concerns that the included patients do not match the review question?	Low	Are there concerns that the index test, its conduct, or interpretation differ from the review question?	High. Not just comparing different index tests but also the impact of different diagnostic settings (general dermatology clinics versus pigmented lesion clinics)	Are there concerns that the target condition as defined by the reference standard does not match the review question?	Low	Could the patient flow have introduced bias?	Low						
Results	N = 3053 histological diagnosed melanocytic lesions. N = 319 melanomas (10.4%) N = 77 spitz or reed naevus (2.5%) Patients attending the PLC were older (38.2 years) compared to those attending the dermatology clinic (36.3 years). Dermoscopy more likely to refer problem naevi among benign lesions. Overall, 54.1% Table 1. Outcomes according to total sample for the period 1998-2001. <table><tr><td></td><td>Sensitivity %</td><td>Specificity %</td></tr><tr><td>Non-users</td><td>50.7</td><td>97.3</td></tr></table>										Sensitivity %	Specificity %	Non-users	50.7	97.3
	Sensitivity %	Specificity %													
Non-users	50.7	97.3													

	Users		63.9	95.7	Note. Differences in sensitivity and specificity between users and non-users did not reach statistical significance in either the study period as a whole or for each study year.				
Comments	No information provided on what a clinical assessment entailed. No sample characteristics provided. Comparing two different settings not just types of index test. Authors state that according to the pattern of referral to their PLC it is presumed that the two diagnostic settings differed in terms of the percentage of patients with atypical moles and melanoma risk factors examined. Not enough raw data provided by authors to create all outcomes for both melanoma and problem naevi.								
Krähn, G et al. "Dermatoscopy and high frequency sonography: two useful non-invasive methods to increase preoperative diagnostic accuracy in pigmented skin lesions". Pigment Cell Research (1998) 11: 151-154.									
Pub year: 1998		Patient selection		Index test		Reference standard		Flow and timing	
Country	Germany	80 patients with pigmented skin lesions. All skin lesions excised. Inclusion criteria: None provided, unclear how patients were selected. Exclusion criteria: None provided		Clinical assessment Dermatoscopy		Histopathology: Malignant melanoma Dysplastic nevi Common nevi		All skin lesions were excised and all patients received all index tests. No information provided regarding the time between index test(s) and reference standard.	
Design, period	Monocentric, no time period	Was a consecutive or random sample of patients enrolled?	Unclear	Were the index test results interpreted without knowledge of the results of the reference standard?	Yes	Is the reference standard likely to correctly classify the target condition?	Yes	Was there an appropriate interval between index test(s) and reference standard?	Unclear
N	80	Was a case-control design avoided?	Yes	If a threshold was used, was it pre-specified?	Unclear	Were the reference results interpreted without knowledge of the	Yes Histological diagnosis performed by at least two	Did all patients receive a reference standard?	Yes
Follow-up	Not provided	Did the study avoid inappropriate exclusions?	Unclear					Did all	Yes

						results of the index test?	independent dermatopathologists	patients receive the same reference standard ?	
		Could the selection of patients have introduced bias?	Unclear. No information on patient selection.	Could the conduct or interpretation of the index test have introduced bias?	Unclear. Dermatoscopy conducted by a single dermatologist	Could the reference standard, its conduct, or its interpretation have introduced bias?	Low	Were all patients included in the analysis?	Yes
Funding source	Not mentioned	Are there concerns that the included patients do not match the review question?	Low	Are there concerns that the index test, its conduct, or interpretation differ from the review question?	Low	Are there concerns that the target condition as defined by the reference standard does not match the review question?	Low	Could the patient flow have introduced bias?	Low
Results	In all 80 cases the clinical diagnosis of melanocytic lesions could be confirmed histologically. Table 1. Histopathological accuracy of the clinical and dermatoscopic diagnosis of the total sample and according to diagnosis.								
		Total sample N=80		Malignant melanoma n=39		Dysplastic nevi n=3		Common nevi n=	
		Present	Sensitivity %	Present	Sensitivity %	Present	Sensitivity %	Present	Sensi
Clinical diagnosis	Positive	63	78.8	31	79.4	0	0	32	8
	Negative	17		8		3		6	
Dermatoscopic	Positive	73	91.3	35	89.8	3	100	35	9

	diagnosis	Negative	7	4	0	3
	<i>Table 2. Outcomes according to the malignant melanoma lesions.</i>					
	Malignant melanoma n=39					
		Sensitivity %	Specificity %	PPV %	NPV %	Accuracy %
	Clinical diagnosis	79	78	77	80	65
	Dermatoscopic diagnosis	90	93	92	90	83
Comments	No information on what the clinical diagnosis entailed. No sample characteristics provided. Authors provide limited data in order to create all outcomes for each diagnosis. Authors acknowledge that the diagnostic accuracy was higher than published data and could be explained by the fact that a monocentric study was conducted and Dermatoscopy was performed by a single dermatologist.					

Evidence tables for the included studies assessing immunohistochemistry FISH/molecular genetics (N=14):

FISH studies (n=7) CGH (n=1):

Gerami, P et al. "Fluorescence in situ hybridization as an ancillary method for the distinction of desmoplastic melanomas from sclerosing melanocytic nevi". J Cutan Pathol (2011) 38: 329-334.

Pub year: 2011		Patient selection		Index test		Reference standard		Flow and timing	
Country	USA	Retrieval of archival data of desmoplastic melanomas and sclerosing melanocytic nevi from two dermatology departments. <i>Inclusion criteria:</i> Diagnostically unequivocal lesions. <i>Exclusion criteria:</i> Diagnostically controversial or ambiguous cases.		FISH Four probes targeting Ras-responsive element-binding protein-1, myeloblastosis, cyclin D1 or chromosome 11q, and centromeric enumeration probe control for chromosome 6.		Histopathologically confirmed unequivocal lesions.		No information provided regarding the time between index test(s) and reference standard. No follow-up data.	
Design, period	Retrospective case review	Was a consecutive or random sample of patients enrolled?	No	Were the index test results interpreted without knowledge of the results of the reference standard?	Unclear	Is the reference standard likely to correctly classify the target condition?	Yes	Was there an appropriate interval between index test(s) and reference standard?	Unclear
N	30	Was a case-control design avoided?	Yes	If a threshold was used, was it pre-specified?	Yes	Were the reference results interpreted without knowledge of the results of the index test?	Yes	Did all patients receive a reference standard?	Yes
Follow-up	Not provided	Did the study avoid inappropriate exclusions?	Yes					Did all patients receive the same reference standard?	Yes
		Could the selection of patients have introduced bias?	Low	Could the conduct or interpretation of the index test have introduced bias?	Low	Could the reference standard, its conduct, or its interpretation	Low	Were all patients included in the analysis?	Yes

						<i>n have introduced bias?</i>			
Funding source	Honoraria for consultant work at Abbott Molecular Labs and Neogenomics. IDP Foundation, the Dermatology Foundation and the American Cancer Society. Abbott Molecular.	<i>Are there concerns that the included patients do not match the review question?</i>	Low	<i>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</i>	Low	<i>Are there concerns that the target condition as defined by the reference standard does not match the review question?</i>	Low	<i>Could the patient flow have introduced bias?</i>	Low
Results	Demographic data:								
			N	Female/male		Mean age		Median age	Age range
	Total		30	10/20		-		-	
	Desmoplastic melanoma (DM)		15	2/13		67.6		71	20-90
	Sclerotic melanocytic nevi (SMN)		15	8/7		41		40	10-70
	FISH		Disease		Sensitivity	specificity	PPV	NPV	Accuracy
		DM	SMN	46.7	100	100	65.2	57	
	Positive FISH	7	0						
	Negative	8	15						
Comments									

Diaz, A et al. "Pigmented spindle cell nevus: Clues for differentiating it from spindle cell malignant melanoma. A comprehensive survey including clinicopathologic, immunohistochemical, and FISH studies". Am J Surg Pathol (2011) 35: 1733-1742.

Pub year: 2011		Patient selection		Index test		Reference standard		Flow and timing	
Country	Spain	Retrieval of archival data of formalin-fixed, paraffin-embedded samples of pigmented spindle cell nevus (PSCN) and spindle cell malignant melanoma (SCMM) from one hospital clinic. <i>Inclusion criteria:</i> Only cases with complete uniformity of opinion of 3 blinded dermatopathologists. <i>Exclusion criteria:</i> Atypical forms of PSCN.		FISH 4-colour probe set targeting the ras responsive element binding protein 1 (RREB1) on 6p25, V-myb myeloblastosis viral oncogene homolog (MYB) on 6q23, cyclin D1 (CCND1) on 11q13, and the chromosome 6 centromeric region (Abbott Molecular, Des Plaines, IL)		Histopathologically examination by 3 blinded dermatopathologists.		No information provided regarding the time between index test(s) and reference standard.	
Design, period	Retrospective case review 2005-2009	Was a consecutive or random sample of patients enrolled?	No	Were the index test results interpreted without knowledge of the results of the reference standard?	Unclear	Is the reference standard likely to correctly classify the target condition?	Yes	Was there an appropriate interval between index test(s) and reference standard?	Unclear
N	46	Was a case-control design avoided?	Yes	If a threshold was used, was it pre-specified?	Yes	Were the reference results interpreted without knowledge of the results of the index test?	Yes	Did all patients receive a reference standard?	Yes
Follow-up	Mean: 26 months	Did the study avoid inappropriate exclusions?	Yes					Did all patients receive the same reference standard?	Yes
		Could the selection of patients have introduced bias?	Low	Could the conduct or interpretation of the index test	Low	Could the reference standard, its conduct, or	Low	Were all patients included in the analysis?	Yes

				have introduced bias?		its interpretation have introduced bias?			
Funding source	Authors disclosed that they have no significant relationship with, or financial interest in, any commercial companies pertaining to this article	Are there concerns that the included patients do not match the review question?	Low	Are there concerns that the index test, its conduct, or interpretation differ from the review question?	Low	Are there concerns that the target condition as defined by the reference standard does not match the review question?	Low	Could the patient flow have introduced bias?	Low
Results	Demographic data:								
				N	Female/male	Median age	Age range		
	Total			46	30/16	-	-		
	Pigmented spindle cell nevus (PSCN)			22	18/4	22	3-54		
	Spindle cell malignant melanoma (SCMM)			24	12/12	62	26-90		
	FISH could be assessed in 30 of 44 cases (15 PSCN and 15 SCMM). The remaining cases were excluded because only <30 nuclei could be assessed properly or because nuclei did not show signals for all probes.								
	FISH			Disease		Sensitivity	specificity	PPV	NPV
			SCMM	PSCN	73.3	93.3	91.7	77.8	57.7
Positive FISH			11	1					
Negative			4	14					
Comments									

Hossain, D et al. "Differential diagnosis of melanomas using fluorescence in situ hybridization (FISH) - MelanoFISH". Conference(var.pagings): February 2011									
Pub year: 2011		Patient selection		Index test		Reference standard		Flow and timing	
Country	USA	Skin biopsy specimens were retrospectively collected from patients with benign diagnosis, dysplastic nevi spitz nevus and melanoma. <i>Exclusion criteria:</i> Not provided.		FISH Probes for chromosomes 6, 7, 11 and 20.		Diagnosis independently confirmed by two dermatopathologists.		No information provided regarding the time between index test(s) and reference standard. No follow-up data.	
Design, period	Retrospective case review	Was a consecutive or random sample of patients enrolled?	Unclear	Were the index test results interpreted without knowledge of the results of the reference standard?	Unclear	Is the reference standard likely to correctly classify the target condition?	Yes	Was there an appropriate interval between index test(s) and reference standard?	Unclear
N	465	Was a case-control design avoided?	Yes	If a threshold was used, was it pre-specified?	Yes	Were the reference results interpreted without knowledge of the results of the index test?	Yes	Did all patients receive a reference standard?	Unclear
Follow-up	Not provided	Did the study avoid inappropriate exclusions?	Unclear					Did all patients receive the same reference standard?	Unclear
		Could the selection of patients have introduced bias?	Unclear	Could the conduct or interpretation of the index test have introduced bias?	Low	Could the reference standard, its conduct, or its interpretation have introduced bias?	Low	Were all patients included in the analysis?	Unclear

Funding source	Not provided	Are there concerns that the included patients do not match the review question?	Unclear	Are there concerns that the index test, its conduct, or interpretation differ from the review question?	Low	Are there concerns that the target condition as defined by the reference standard does not match the review question?	Low	Could the patient flow have introduced bias?	Unclear																			
Results	Sample:																											
																N												
	Total															465												
	Benign nevi (compound nevus, blue nevus, melanocytic nevus) (N)															205												
	Dysplastic nevi (clark’s, compound, junctional and residual) (DN)															55												
	Spitz nevi (SN)															49												
	Melanoma (M)															156												
		MelanoFISH				M and DN					M and SN					M and N					DN and							
		Disease																										
	M	D N	SN	N	Sen	Spe	PPV	NP V	Acc	Sen	Spe	PPV	NPV	Acc	Sen	Spe	PP V	NP V	Acc	Sen	Spe	PPV						
Positive	112	19	3	20	71.8	61.2	85.5	40.5	69.3	71.8	94.5	97.4	54.2	77.7	71.8	90.2	84.8	80.8	82.3	38.8	94.5	86.4						
Negative	44	30	52	185																								
					DN and N					SN and N																		
					38.8	90.2	48.7	86	91.8	5.5	90.2	13	78.1	74.2														
The overall percent agreement between histologic diagnosis (melanoma vs. all others) and MelanoFISH results was 82%.																												
Comments	Abstract of conference presentation so limited information. No demographic information provided. Unclear whether the 465 cases were all the participants included in the analysis.																											

Martin, V et al. "Presence of cytogenetic abnormalities in Spitz naevi: a diagnostic challenge for fluorescence in-situ hybridization analysis". Histopathology (2012) 60: 336-346.									
Pub year: 2012		Patient selection		Index test		Reference standard		Flow and timing	
Country	Switzerland	Consecutive series of 82 patients with spitz naevi diagnosed between 1990-2008. Control group included 11 patients with benign nevi and 14 patients with malignant melanomas. <i>Exclusion criteria:</i> Spitzoid melanoma, spitz tumours of uncertain malignant potential and controversial diagnosis.		FISH Four-colour probe set LSI RREB1/LSI MYB/LSI CCND1/CEP6.		Histological review by two senior pathologists with extensive experience in neoplastic dermatopathology. Unequivocal confirmation of original diagnosis.		No information provided regarding the time between index test(s) and reference standard. Clinical follow-up available for 49 patients (of the 51 spitz naevi patients).	
Design, period	Retrospective case review Spitz naevi only: 1990-2008	Was a consecutive or random sample of patients enrolled?	Yes	Were the index test results interpreted without knowledge of the results of the reference standard?	Unclear	Is the reference standard likely to correctly classify the target condition?	Yes	Was there an appropriate interval between index test(s) and reference standard?	Unclear
N	76/107	Was a case-control design avoided?	No. Authors included controls. Unclear if age-matched.	If a threshold was used, was it pre-specified?	Yes	Were the reference results interpreted without knowledge of the results of the index test?	Unclear	Did all patients receive a reference standard?	Yes
Follow-up	Spitz naevi only (49/51): Median: 8.18 years Range: 2-20 years)	Did the study avoid inappropriate exclusions?	Yes					Did all patients receive the same reference standard?	Yes
		Could the selection of patients have introduced bias?	Unclear	Could the conduct or interpretation of the index test have introduced bias?	Low	Could the reference standard, its conduct, or its interpretation have	Low	Were all patients included in the analysis?	No 51/82 spitz naevi gave analysable results by FISH

						<i>introduced bias?</i>													
Funding source	Abbott Molecular provided	<i>Are there concerns that the included patients do not match the review question?</i>	Low	<i>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</i>	Low	<i>Are there concerns that the target condition as defined by the reference standard does not match the review question?</i>	Low	<i>Could the patient flow have introduced bias?</i>	Unclear										
Results	Sample:																		
					N		Female/male			Mean age			Age						
	Total				76		-			-									
	Benign nevi (N)				11		-			-									
	Spitz naevi (SN)				51		36/15			24			1						
	Malignant melanoma (MM)				14		-			-									
			FISH			MM and SN					MM and N					SN and N			
			Disease																
			MM	SN	N	Sensitivity	Specificity	PPV	NPV	Accuracy	Sensitivity	Specificity	PPV	NPV	Accuracy	Sensitivity	Specificity	PPV	
	Positive		12	19	0	85.7	62.7	38.7	94.1	67.7	85.7	100	100	84.6	92	37.3	100	100	
	Negative		2	32	11														
Comments	Demographic data only available for the spitz naevi group. No information on how the controls were selected. Authors state that the majority (14/19: 74%) of the FISH+ spitz naevi cases were characterised by positivity for two or three of the four diagnostic criteria, thus reducing the risk of misinterpretation.																		

Kerl, K et al. "A proposal for improving multicolour FISH sensitivity in the diagnosis of malignant melanoma using new combined criteria". Am J Dermatopathol (2012) 34: 580-585.									
Pub year: 2012		Patient selection		Index test		Reference standard		Flow and timing	
Country	Germany	Formalin-fixed paraffin-embedded specimens were selected from the archives and consultation files of Dermatopathologie Friedrichshafen. <i>Inclusion criteria:</i> Not provided. <i>Exclusion criteria:</i> Not provided. The authors present data on all 575 lesions according to diagnosis. I selected the spitz nevus, atypical spitz tumour and Spitzoid melanoma data only 193/575.		FISH Multicolour FISH probe mix (Abbott) consisting of 4 probes used for the detection of amplifications or deletions of RREB1, MYB and CCND1 genes and of centromere 6: RREB1 (RAS responsive element-binding protein 1 encoding gene) on 6p25, MYB (myeloblastosis gene) on 6q23, CCND1 (cyclin D1 gene) on 11q13, and CEP6 (centromeric probe of chromosome 6).		Diagnosis independently confirmed by dermatopathologists using standard criteria in conjunction with hematoxylin and eosin (H&E) – stained sections and immunohistochemical stains for MelanA, HMB45, p16, p21, phosphohistone H3 serin10, MPM2 and Ki67.		No information provided regarding the time between index test(s) and reference standard. No follow-up data provided.	
Design, period	Retrospective case review	Was a consecutive or random sample of patients enrolled?	No	Were the index test results interpreted without knowledge of the results of the reference standard?	Unclear	Is the reference standard likely to correctly classify the target condition?	Yes	Was there an appropriate interval between index test(s) and reference standard?	Unclear
N	193/575	Was a case-control design avoided?	Yes	If a threshold was used, was it pre-specified?	Yes	Were the reference results interpreted without knowledge of the results of the index test?	Yes	Did all patients receive a reference standard?	Yes
Follow-up	Not provided	Did the study avoid inappropriate exclusions?	Yes					Did all patients receive the same reference	Yes

								<i>standard?</i>									
		<i>Could the selection of patients have introduced bias?</i>	Low	<i>Could the conduct or interpretation of the index test have introduced bias?</i>	Low	<i>Could the reference standard, its conduct, or its interpretation have introduced bias?</i>	Low	<i>Were all patients included in the analysis?</i>	Yes but not all reported in this table								
Funding source	No funding information. Authors declared no conflicts of interest.	<i>Are there concerns that the included patients do not match the review question?</i>	Low	<i>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</i>	Low	<i>Are there concerns that the target condition as defined by the reference standard does not match the review question?</i>	Low	<i>Could the patient flow have introduced bias?</i>	Low								
Results	Sample:			N													
	Total			193													
	Spitz nevus (SN)			69													
	Atypical spitz tumour (AST)			90													
	Spitzoid melanoma (SM)			34													
	Disease			SM and AST					SM and SN					AST and SN			
	SM	AST	SN	Sensitivity	Specificity	PPV	NPV	Accuracy	Sensitivity	Specificity	PPV	NPV	Accuracy	Sensitivity	Specificity	PPV	
Positive Abbott	21	47	18	61.8	47.8	30.9	76.8	51.6	61.8	73.9	53.8	79.7	69.9	52.2	73.9	72.3	
Negative	13	43	51														
Positive Gerami	22	54	16	64.7	40	28.9	75	46.8	64.7	76.8	57.9	81.5	72.8	60	76.8	77.1	
Negative	12	36	53														
Positive	24	56	22	70.6	37.8	30	77.	46.8	70.6	68.1	52.	82.	68.9	62.2	68.1	71.	

	Combined							3				2	5				8		
	Negative	10	34	47															
Comments	No demographic data provided on sample.																		

Massi, D et al. "Atypical Spitzoid melanocytic tumors: a morphological, mutational, and FISH analysis". <i>Dermatopathology</i> (2011) 64: 919-935.									
Pub year: 2011		Patient selection		Index test		Reference standard		Flow and timing	
Country	Italy	Atypical spizoid lesions: Archival data from pathology files of three hospitals (n=38). Comparator: independent cohort of unambiguously classified as Spitz nevi and unequivocal melanomas (n=20). <i>Inclusion criteria:</i> Patients whose tumors measured at least 1mm in thickness. <i>Exclusion criteria:</i> Not provided.		FISH Multicolor FISH DNA kit composed from LSI RRED1 (6p25) SpectrumRed/LSI MYB (6q23) SpectrumGold/LSI CCND1 (11q13) SpectrumGreen/CEp6 (6p11.1-q11 Alpha Satellite DNA) SpectrumAgua.		For the atypical Spitzoid lesions: <i>Histopathological slides independently reviewed and then re-evaluated on the multiheaded microscope by 4 pathologists with specific background in dermatopathology.</i> For the unambiguously classified spitz nevi and unequivocal melanomas: <i>reviewed by at least two dermatopathologists who agreed the diagnosis.</i>		No information provided regarding the time between index test(s) and reference standard. Clinical follow-up available for 49 patients (of the 51 spitz naevi patients).	
Design, period	Retrospective case review	Was a consecutive or random sample of patients enrolled?	No	Were the index test results interpreted without knowledge of the results of the reference standard?	Unclear	Is the reference standard likely to correctly classify the target condition?	Yes	Was there an appropriate interval between index test(s) and reference	Unclear

								<i>standard?</i>	
N	45/58	<i>Was a case-control design avoided?</i>	No	<i>If a threshold was used, was it pre-specified?</i>	Yes	<i>Were the reference results interpreted without knowledge of the results of the index test?</i>	Yes	<i>Did all patients receive a reference standard?</i>	Yes
Follow-up	8 months – 13 years Mean: 4 years 10 months	<i>Did the study avoid inappropriate exclusions?</i>	Unclear					<i>Did all patients receive the same reference standard?</i>	No. The control group only assessed by 2 dermatopathologists
		<i>Could the selection of patients have introduced bias?</i>	Unclear		Low		Low	<i>Were all patients included in the analysis?</i>	No. 13 of the AST did not perform in the FISH analysis
Funding source	Supported in part by Abbott Molecular Inc. ACC/R8.5 research project, and Fondazione Ente Cassa di Risparmio di Firenze.	<i>Are there concerns that the included patients do not match the review question?</i>	Low	<i>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</i>	Low	<i>Are there concerns that the target condition as defined by the reference standard does not match the review question?</i>	Low	<i>Could the patient flow have introduced bias?</i>	Low
Results	Sample:								
			N	Female/male	Mean age	Age range			
	Total		45/58	-	-	-			

	Spitz naevi (SN)			10	-				-				-						
	Atypical Spitzoid tumours (AST)			25/38	21/17				24				1-65						
	Melanoma (M)			10	-				-				-						
	Only 25/38 atypical Spitzoid tumours performed in the FISH analysis.																		
		FISH			M and AST					M and SN					AST and SN				
		Disease																	
	M	AST	SN	Sensitivity	Specificity	PPV	NPV	Accuracy	Sensitivity	Specificity	PPV	NPV	Accuracy	Sensitivity	Specificity	PPV	NPV	Accuracy	
Positive	9	6	2	90	76	60	95	80	90	80	81.8	88.9	85	24	80	75	29.6		
Negative	1	19	8																
Comments	Demographic data only available for the atypical Spitzoid tumour group. No information on how the controls were selected.																		
Requena, C et al. "Fluorescence in situ hybridization for the differential diagnosis between spitz naevus and Spitzoid melanoma". Histopathology (2012) 61: 899-909.																			
Pub year: 2012		Patient selection					Index test			Reference standard				Flow and timing					
Country	Spain	All cases of Spitzoid melanomas treated at one hospital assessed. N= 17. Comparator: Cases of spitz naevi from hospital files included. N = 6. <i>Inclusion criteria:</i> Not provided. <i>Exclusion criteria:</i> Two cases of Spitzoid melanoma excluded as the original biopsies could not be obtained, two because of doubts in the differential diagnosis and one because the Spitzoid area accounted for <25% of the biopsy specimen. N=5.					FISH Vysis Melanoma FISH Probe Kit (Abbott Molecular Inc., Des Plaines, IL). Designed to detect the copy number of RREB1, MYB and CCND1 genes and of centromere 6 labelled with SpectrumRed, SpectrumGold, SpectrumGreen and SpectrumAqua.			Histopathological diagnosis based on histopathological features (Requena et al., 2012)				No information provided regarding the time between index test(s) and reference standard.					
Design, period	Retrospective case review 2008-2011	Was a consecutive or random sample of patients enrolled?		No		Were the index test results interpreted without		Unclear		Is the reference standard likely to correctly		Yes		Was there an appropriate interval between index test(s) and		Unclear			

				<i>knowledge of the results of the reference standard?</i>		<i>classify the target condition?</i>		<i>reference standard?</i>	
N	18	<i>Was a case-control design avoided?</i>	No	<i>If a threshold was used, was it pre-specified?</i>	Yes	<i>Were the reference results interpreted without knowledge of the results of the index test?</i>	Yes	<i>Did all patients receive a reference standard?</i>	Yes
Follow-up	Range: 2-82 months	<i>Did the study avoid inappropriate exclusions?</i>	Yes					<i>Did all patients receive the same reference standard?</i>	Yes
		<i>Could the selection of patients have introduced bias?</i>	Unclear					<i>Were all patients included in the analysis?</i>	No
Funding source	Conselleria de sanitat of the generalitat valenciana	<i>Are there concerns that the included patients do not match the review question?</i>	Low	<i>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</i>	Low	<i>Are there concerns that the target condition as defined by the reference standard does not match the review question?</i>	Low	<i>Could the patient flow have introduced bias?</i>	Low

Results	Sample:							
		N		Female/male	Mean age	Age range		
	Total	18		12/6	-	-		
	Spitz naevi (SN)	6		4/2	-	7-38		
	Spitzoid Melanoma (SM)	12		8/4	-	19-56		
	Only 8/12 Spitzoid melanomas performed in the FISH analysis. 5/6 spitz naevi performed in the FISH analysis.							
	FISH	Disease		Sensitivity	specificity	PPV	NPV	Accuracy
		SM	SN	87.5	100	100	83.33333	92.3
	Positive FISH (Abbott criteria)	7	0					
	Negative	1	5					
	Positive FISH (Gerami et al. criteria)	8	0	100	100	100	100	100
	Negative	0	5					
Comments	Demographic data only available for the atypical Spitzoid tumour group. No information on how the controls were selected.							

Bastian, BC et al. "Classifying melanocytic tumors based on DNA copy number changes". American Journal of Pathology (2003) 163: 1765-1770.									
Pub year: 2003		Patient selection		Index test		Reference standard		Flow and timing	
Country	USA and Germany	Paraffin-embedded primary invasive melanomas retrieved from archives at two hospitals. <i>Inclusion criteria:</i> Cases were required to have at least one area from which a rather pure population of tumor cells could be isolated to yield sufficient amounts of DNA for CGH analysis. <i>Exclusion criteria:</i> Not provided. Of the 54 benign nevi (27 spitz nevi; 19 blue nevi; 7 congenital nevi) only the 27 spitz nevi will be reported.		DNA extraction and Comparative Genomic Hybridization (CGH). Results interpreted blinded to the histopathological information.		Histopathological diagnosis		No information provided regarding the time between index test(s) and reference standard.	
Design, period	Retrospective case review	Was a consecutive or random sample of patients enrolled?	No	Were the index test results interpreted without knowledge of the results of the reference standard?	Yes	Is the reference standard likely to correctly classify the target condition?	Yes	Was there an appropriate interval between index test(s) and reference standard?	Unclear
N	159/186	Was a case-control design avoided?	Yes	If a threshold was used, was it pre-specified?	Yes	Were the reference results interpreted without knowledge of the results of the index test?	Yes	Did all patients receive a reference standard?	Yes
Follow-up	Not provided	Did the study avoid inappropriate exclusions?	Yes					Did all patients receive the same reference standard?	Yes
		Could the selection of patients have introduced bias?	Low					Were all patients included in the analysis?	Yes. But not presented in this table

				<i>test have introduced bias?</i>		<i>its interpretation have introduced bias?</i>			
Funding source	Roma and Marvin Auerback Melanoma Fund	<i>Are there concerns that the included patients do not match the review question?</i>	Low	<i>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</i>	Low	<i>Are there concerns that the target condition as defined by the reference standard does not match the review question?</i>	Low	<i>Could the patient flow have introduced bias?</i>	Low
Results	Sample:								
				N	Female/male		Mean age		
	Total			186	89/97		53.7		
	Benign nevi (blue nevi, congenital nevi)			27	-		-		
	Spitz nevi (SN)			27	-		-		
	Malignant Melanoma (MM)			132	65/67		68		
	Of the 54 benign nevi (27 spitz nevi; 19 blue nevi; 7 congenital nevi) only the 27 spitz nevi will be reported.								
	CGH		Disease		Sensitivity	specificity	PPV	NPV	Accuracy
			MM	SN	96.2	74.1	94.8	80	92.5
	At least one chromosomal aberration		127	7					
No aberrations		5	20						
Comments	CGH findings of 79 cases has been published previously.								

BRAF, NRAS and HRAS genes studies (n=6):

Emley, A et al. "Oncogenic BRAF and the tumopr suppressor IGFBP7 in the genesis of atypical spitzoid nevomelanocytic proliferations". J Cutan Pathol (2010) 37: 344-349.									
Pub year: 2010		Patient selection		Index test		Reference standard		Flow and timing	
Country	USA	Archival materials between 2006-2008 with a diagnosis of spitz nevus (n=6) and atypical spitzoid nevomelanocytic proliferations were retrieved from the pathology files of Skin Pathology Laboratory, Boston University. <i>Inclusion criteria:</i> Not provided. <i>Exclusion criteria:</i> Not provided.		Immunohistochemistry – <i>BRAFV600E gene; NRAS1 gene; NRAS2 gene.</i> DNA was extracted by proteinase K digestion of laser capture microdissected samples per protocol.		Histopathology. Histological evaluation. Diagnosis re-reviewed and confirmed by a dermatopathologist.		No information provided regarding the time between index test(s) and reference standard.	
Design, period	Retrospective case review 2006-2008	<i>Was a consecutive or random sample of patients enrolled?</i>	No	<i>Were the index test results interpreted without knowledge of the results of the reference standard?</i>	Unclear	<i>Is the reference standard likely to correctly classify the target condition?</i>	Yes	<i>Was there an appropriate interval between index test(s) and reference standard?</i>	Unclear
N	20	<i>Was a case-control design avoided?</i>	Yes	<i>If a threshold was used, was it pre-specified?</i>	Yes	<i>Were the reference results interpreted without knowledge of the results of the index test?</i>	Yes	<i>Did all patients receive a reference standard?</i>	Yes
Follow-up	Not provided.	<i>Did the study avoid inappropriate exclusions?</i>	Yes					<i>Did all patients receive the same reference standard?</i>	Yes
		<i>Could the selection of patients have introduced bias?</i>	Low	<i>Could the conduct or interpretation of the index test have introduced bias?</i>	Low	<i>Could the reference standard, its conduct, or its interpretation have introduced</i>	Low	<i>Were all patients included in the analysis?</i>	Yes

						<i>bias?</i>			
Funding source	Not provided.	<i>Are there concerns that the included patients do not match the review question?</i>	Low	<i>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</i>	Low	<i>Are there concerns that the target condition as defined by the reference standard does not match the review question?</i>	Low	<i>Could the patient flow have introduced bias?</i>	Low
Results	Demographic data:								
			N	Female/male		Mean age	Median age	Age range	
	Total		20	15/5		29.6	25.5	3-76	
	Atypical spitzoid nevomelanocytic proliferations*		14	10/4		Note. *ASN group contains 1 spitzoid melanoma.			
	Typical spitz		6	5/1					
	Gene/antibody		BRAF V600E		NRAS1		NRAS2		
			Disease		Disease		Disease		
			ASN	TSN	ASN	TSN	ASN	TSN	
	Positive mutation		0	1	0	0	0	0	
	Negative		13	5	13	6	13	6	
Sensitivity/specificity		0	83.3	0	100	0	100		
PPV/NPV		0	27.8	-	31.6	-	31.6		
Accuracy		26.3		31.6		31.6			
Note. ASN: Atypical spitzoid nevomelanocytic proliferation. TSN: Typical spitz nevus. *No lesional tissue for three cases. ^No lesional tissue for four cases.									
1 spitzoid melanoma recorded – No mutations in any of the genes reported.									
Comments	Paper also looked at KRAS, IGFBP7 and pERK but these have not been extracted.								
Fullen, DR et al. “BRAF and NRAS mutations in spitzoid melanocytic lesions”. Modern Pathology (2006) 19: 1324-1332.									
Pub year: 2006		Patient selection		Index test		Reference standard		Flow and timing	

Country	USA	Archival materials with a diagnosis of spitz nevi, atypical spitz tumor and spitzoid melanomas from the pathology department at the University of Michigan. <i>Inclusion criteria:</i> Not provided. <i>Exclusion criteria:</i> Not provided.		Immunohistochemistry – <i>BRAFV600E</i> gene. DNA extraction information presented.		Histopathology. Histological evaluation. Reviewed by three board certified dermatopathologists. 12/68 patients did not have a full set of diagnostic slides available for review.		No information provided regarding the time between index test(s) and reference standard.	
Design, period	Retrospective case review	<i>Was a consecutive or random sample of patients enrolled?</i>	No	<i>Were the index test results interpreted without knowledge of the results of the reference standard?</i>	Unclear	<i>Is the reference standard likely to correctly classify the target condition?</i>	Yes	<i>Was there an appropriate interval between index test(s) and reference standard?</i>	Unclear
N	68	<i>Was a case-control design avoided?</i>	Yes	<i>If a threshold was used, was it pre-specified?</i>	Yes	<i>Were the reference results interpreted without knowledge of the results of the index test?</i>	Yes	<i>Did all patients receive a reference standard?</i>	Yes
Follow-up	Not provided.	<i>Did the study avoid inappropriate exclusions?</i>	Yes					<i>Did all patients receive the same reference standard?</i>	Yes
		<i>Could the selection of patients have introduced bias?</i>	Low	<i>Could the conduct or interpretation of the index test have introduced bias?</i>	Low	<i>Could the reference standard, its conduct, or its interpretation have introduced bias?</i>	Low	<i>Were all patients included in the analysis?</i>	Yes

Funding source	NCI U01 CA83180 (SBG) and NIH T32 HG00040 (JNP), generous gift from Lewis and Lillian Becker. Babcock Memorial Trust. Ann Arbor Veterans Affairs Hosptial.	Are there concerns that the included patients do not match the review question?	Low	Are there concerns that the index test, its conduct, or interpretation differ from the review question?	Low	Are there concerns that the target condition as defined by the reference standard does not match the review question?	Low	Could the patient flow have introduced bias?	Low																																																																																																											
Results	<div>Demographic data:</div> <table><tr><td></td><td>N</td><td>Female/male</td><td>Median age</td><td>Age range</td></tr><tr><td>Total</td><td>68</td><td>39/29</td><td>-</td><td>2-60</td></tr><tr><td>Spitz nevi</td><td>48</td><td>24/24</td><td>20</td><td>2-49</td></tr><tr><td>Atypical spitz tumours</td><td>7</td><td>5/2</td><td>24</td><td>12-52</td></tr><tr><td>Spitzoid melanoma</td><td>13</td><td>10/3</td><td>24</td><td>10-60</td></tr></table> <div></div> <table><tr><td></td><td colspan="3">BRAF V600E</td><td colspan="5">AST and SN</td><td colspan="5">SN and SM</td><td colspan="5">SM and AST</td><td></td></tr><tr><td></td><td colspan="3">Disease</td><td colspan="5"></td><td colspan="5"></td><td colspan="5"></td><td></td></tr><tr><td></td><td>SM</td><td>AST</td><td>SN</td><td>Sensiti vity</td><td>Specifi city</td><td>PPV</td><td>NPV</td><td>Accura cy</td><td>Sensitivit y</td><td>Specificit y</td><td>PPV</td><td>NPV</td><td>Accura cy</td><td>Sensitivit y</td><td>Specifi city</td><td>PPV</td><td>NPV</td><td>Ac cu ra cy</td></tr><tr><td>Positive mutation</td><td>2</td><td>0</td><td>10*</td><td rowspan="2">0</td><td rowspan="2">79.2</td><td rowspan="2">0</td><td rowspan="2">84.4</td><td rowspan="2">69.1</td><td rowspan="2">15.4</td><td rowspan="2">79.2</td><td rowspan="2">16.7</td><td rowspan="2">77.6</td><td rowspan="2">65.6</td><td rowspan="2">15.4</td><td rowspan="2">100</td><td rowspan="2">100</td><td rowspan="2">38.9</td><td rowspan="2">45</td></tr><tr><td>Negative</td><td>11</td><td>7</td><td>38</td></tr></table> <div>Note. SN: Spitz nevi. APT: Atypical spitz tumour. SM: Spitzoid melanoma. * Five out of 10 were classic typical spitz nevi and 5/10 were atypical spitz nevi.</div>										N	Female/male	Median age	Age range	Total	68	39/29	-	2-60	Spitz nevi	48	24/24	20	2-49	Atypical spitz tumours	7	5/2	24	12-52	Spitzoid melanoma	13	10/3	24	10-60		BRAF V600E			AST and SN					SN and SM					SM and AST							Disease																				SM	AST	SN	Sensiti vity	Specifi city	PPV	NPV	Accura cy	Sensitivit y	Specificit y	PPV	NPV	Accura cy	Sensitivit y	Specifi city	PPV	NPV	Ac cu ra cy	Positive mutation	2	0	10*	0	79.2	0	84.4	69.1	15.4	79.2	16.7	77.6	65.6	15.4	100	100	38.9	45	Negative	11	7	38
	N	Female/male	Median age	Age range																																																																																																																
Total	68	39/29	-	2-60																																																																																																																
Spitz nevi	48	24/24	20	2-49																																																																																																																
Atypical spitz tumours	7	5/2	24	12-52																																																																																																																
Spitzoid melanoma	13	10/3	24	10-60																																																																																																																
	BRAF V600E			AST and SN					SN and SM					SM and AST																																																																																																						
	Disease																																																																																																																			
	SM	AST	SN	Sensiti vity	Specifi city	PPV	NPV	Accura cy	Sensitivit y	Specificit y	PPV	NPV	Accura cy	Sensitivit y	Specifi city	PPV	NPV	Ac cu ra cy																																																																																																		
Positive mutation	2	0	10*	0	79.2	0	84.4	69.1	15.4	79.2	16.7	77.6	65.6	15.4	100	100	38.9	45																																																																																																		
Negative	11	7	38																																																																																																																	

Comments	Authors conclude that BRAF mutation status does not reliably distinguish all Spitz nevi from non-spitz nevi and melanomas.
----------	--

Van Dijk, MCRF et al. "Analysis of Mutations in BRAF, NRAS and HRAS genes in the differential diagnosis of spitz nevus and spitzoid melanoma". Am J Surg Pathol (2005) 29: 1145-1151.									
Pub year: 2005		Patient selection		Index test		Reference standard		Flow and timing	
Country	Netherlands	Paraffin blocks of 101 spitzoid lesions sent for consultation to an expert dermatopathologist obtained from hospitals in the Netherlands. <i>Inclusion criteria:</i> paraffin blocks containing spitzoid lesions (n=96). <i>Exclusion criteria:</i> paraffin blocks that did not contain a spitzoid lesion (n=5).		Immunohistochemistry – BRAF exon 15 and exon 11; NRAS exon 2 and exon 3; HRAS exon 2 and exon 3. DNA extraction information presented.		Histological evaluation at 2 month intervals with one expert pathologist unaware of the results of the genetic analysis/index test.		Some of the lesions received with incomplete clinical information (n=unknown) or with unknown follow-up for reasons of privacy (n=44) however all included in the index test.	
Design, period	Retrospective case review	Was a consecutive or random sample of patients enrolled?	No	Were the index test results interpreted without knowledge of the results of the reference standard?	Unclear	Is the reference standard likely to correctly classify the target condition?	Yes	Was there an appropriate interval between index test(s) and reference standard?	Unclear
N	96	Was a case-control design avoided?	Yes	If a threshold was used, was it pre-specified?	Yes	Were the reference results interpreted without knowledge of the results of the index test?	Yes	Did all patients receive a reference standard?	No
Follow-up	1-88 years	Did the study avoid inappropriate exclusions?	Unclear					Did all patients receive the same reference standard?	No
		Could the selection of patients have introduced bias?	Unclear	Could the conduct or interpretation of the index test have introduced bias?	Low	Could the reference standard, its conduct, or its interpretation have introduced	Low	Were all patients included in the analysis?	No

						<i>bias?</i>			
Funding source	Dutch Cancer Society	<i>Are there concerns that the included patients do not match the review question?</i>	Unclear	<i>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</i>	Low	<i>Are there concerns that the target condition as defined by the reference standard does not match the review question?</i>	Low	<i>Could the patient flow have introduced bias?</i>	High
Results	Demographic data:								
		N	Female/male*	Mean age	Age range	Mean follow-up (years)* ⁺	Recurrence*	Metastasis*	No further events*
	Total	96	37/28	34.76 ⁺	1-88	7.4	-	-	-
	Spitz nevus (SN)	14	9/1	27.8	10-43	7.8 (6-16)	0	0	3
	Atypical spitz nevus (ASN)	16	8/8	19	1-49	6 (2-9)	0	0	3
	Suspected for melanoma (SusM)	23	7/4	35	13-59	7.6 (4-10)	0	2	14
	Spitzoid melanoma (SM)	36	11/13	52	10-88	8.2 (4-12)	0	8	24
	Melanoma metastasis (MM)	7	2/2	40	26-66	-	-	-	-
Note. *Missing data in each group. ⁺ Mean age and follow-up not provided by authors and taken from a mean of the provided sub-groups.									

		Disease					MM and SM					MM and SUSM					MM and ASN					MM and SN				
		MM	SM	Sus M	ASN	SN	Se n	Sp e	PP V	NP V	Ac c	Se n	Sp e	PP V	NPV	Ac c	Se n	Sp e	PP V	NP V	Ac c	Se n	Sp e	PP V	NP V	Ac c
BRAF Exon 15	Positive	7	23	6	0	0	70.0	36.1	23.3	81.3	35.3	70.0	79.3	53.8	88.5	76.9	70.0	10.0	10.0	84.2	68.5	70.0	10.0	10.0	82.4	65.3
	Negative	3	13	23	16	14																				
BRAF Exon 11	Positive	0	0	0	0	0	0	10.0	0	89.7	89.7	0	10.0	0	87.0	87.0	0	10.0	0	81.3	81.3	0	10.0	0	75.0	75.0
	Negative	3	26	20	13	9																				
NRAS Exon 2	Positive	0	0	1	0	0	0	10.0	0	83.3	83.3	0	95.7	0	75.9	73.3	0	10.0	0	68.2	68.2	0	10.0	0	65.0	65.0
	Negative	7	35	22	15	13																				
NRAS Exon 3	Positive	2	7	1	0	0	28.6	80.0	22.2	84.8	68.7	28.6	95.7	66.7	81.5	80.0	28.6	10.0	10.0	73.7	68.7	28.6	10.0	10.0	73.7	68.7
	Negative	5	28	22	14	14																				
HRAS Exon 2	Positive	0	0	0	0	0	0	10.0	0	85.4	85.4	0	10.0	0	78.6	78.6	0	10.0	0	72.7	72.7	0	10.0	0	68.4	68.4
	Negative	6	35	22	16	13																				
HRAS Exon 3	Positive	0	0	1	2	4	0	10.0	0	85.0	85.0	0	95.5	0	77.8	75.0	0	88.2	0	71.4	65.2	0	76.5	0	68.4	56.5
	Negative	6	34	21	15	13																				

Note. Any positive mutation has been recorded but paper does breakdown mutation according to type within the gene (e.g. BRAF V600E, V600K, Q61R, Q61K etc.)

		SM and ASN				
		Se n	Sp e	PP V	NP V	Ac c
BRA F Exon 15	Positiv e	63.9	10.0	10.0	55.2	75
	Negati ve					
BRA F Exon 11	Positiv e	0	10.0	0	33.3	33.3
	Negati ve					
NRA S Exon	Positiv e	0	10.0	0	30	30
	Negati ve					

	2	ve					
	NRA	Positive	20	100	100	33.3	42.9
	S	Negative					
	Exon						
	3						
	HRA	Positive	0	100	0	31.4	31.4
	S	Negative					
	Exon						
	2						
	HRA	Positive	0	88.2	0	30.6	29.4
	S	Negative					
	Exon						
	3						
Comments							

Gill, M et al. "Genetic similarities between spitz nevus and spitzoid melanoma in Children". Cancer (2004) 101: 2636-40.									
Pub year: 2004		Patient selection		Index test		Reference standard		Flow and timing	
Country	USA	Formalin-fixed paraffin-embedded tumor specimens selected from Spitzoid melanoma specimens from children age ≤10 years (disease confirmed by the presence of metastases) and from typical spitz nevus specimens obtained from children age ≤10 years. <i>Exclusion criteria:</i> Not provided.		Immunohistochemistry – BRAF exon 15 and exon 11; NRAS exon 2 and exon 3; HRAS exon 1 and exon 2. DNA extraction information presented.		Histopathological re-evaluation by two dermatopathologists. Presence of metastases for the melanoma specimens and diagnostic criteria previously published in Paniago-Pereira et al. (1978) and Mines et al. (2003) for the spitz nevus.		No information provided regarding the time between index test(s) and reference standard. No follow-up data provided.	
Design, period	Retrospective case review	Was a consecutive or random sample of patients enrolled?	No	Were the index test results interpreted without knowledge of the results of the reference standard?	Unclear	Is the reference standard likely to correctly classify the target condition?	Yes	Was there an appropriate interval between index test(s) and reference standard?	Unclear
N	19	Was a case-control design avoided?	No. Age-matched specimens	If a threshold was used, was it pre-specified?	Yes	Were the reference results interpreted without knowledge of the results of the index test?	Unclear	Did all patients receive a reference standard?	Yes
Follow-up	Not provided.	Did the study avoid inappropriate exclusions?	Unclear					Did all patients receive the same reference standard?	Yes
		Could the selection of patients have introduced bias?	Unclear					Were all patients included in the analysis?	Yes
				Could the conduct or interpretation of the index test have introduced	Low	Could the reference standard, its conduct, or its interpretation	Low		

				<i>bias?</i>		<i>have introduced bias?</i>								
Funding source	Dermatology foundation and the Waterbor Burn and Cancer Foundation	<i>Are there concerns that the included patients do not match the review question?</i>	High	<i>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</i>	Low	<i>Are there concerns that the target condition as defined by the reference standard does not match the review question?</i>	Low	<i>Could the patient flow have introduced bias?</i>	Low					
Results	Demographic data:													
				N		Female/male		Median age		Age range				
	Total			19		3/6		6		2-10				
	Spitz nevi (SN)			10		24/24		20		2-49				
	Spitzoid melanoma (SM)			9		10/3		24		10-60				
	Gene/antibody		BRAF E11		BRAF E15		NRAS E2		NRAS E3		HRAS E2		HRAS E3	
			Disease		Disease		Disease		Disease		Disease		Disease	
			SM	SN	SM	SN	SM	SN	SM	SN	SM	SN	SM	SN
	Positive mutation		0	0	0	0	0	0	1	0	4	6	1	1
	Negative		9	10	9	10	9	10	8	10	5	4	8	9
	Sensitivity/specificity		0	100	0	100	0	100	11.1	100	44.4	40	11.1	90
PPV/NPV		0	52.6	0	52.6	0	52.6	100.0	55.6	40.0	44.4	50.0	52.9	
Accuracy		52.6		52.6		52.6		57.9		42.1		52.6		
Comments	Authors conclude that mutation analysis of BRAF, NRAS and HRAS is not useful in differentiating between spitzoid melanoma and spitz nevus in children. The authors changed the diagnosis of some of the SM patients from the original histopathological diagnosis at biopsy by the referring pathologist.													

Raskin, L et al. "Copy number variations and clinical outcomes in atypical spitz tumors". Am J Surg Pathol (2011) 35: 243-252.									
Pub year: 2011		Patient selection		Index test		Reference standard		Flow and timing	
Country	USA	FFPE blocks of AST (collected between 1999 and 2009), benign spitz nevi, spitzoid melanoma and a classic superficial spreading melanoma were collected. <i>Exclusion criteria:</i> Not provided.		Immunohistochemistry – BRAF exon 5; NRAS exon1 and exon 2; HRAS exon 1 and exon 2. DNA extraction information presented.		Histopathological diagnosis based on previously published criteria by a board-certified dermatopathologist(s) in the Michigan melanoma program with concordance by multiple dermatopathologists for equivocal cases.		Large range of follow-up for patients. Information on clinical and histopathological characteristics was missing for the spitz nevi group.	
Design, period	Retrospective case review 1999-2009	Was a consecutive or random sample of patients enrolled?	No	Were the index test results interpreted without knowledge of the results of the reference standard?	Unclear	Is the reference standard likely to correctly classify the target condition?	Yes	Was there an appropriate interval between index test(s) and reference standard?	Unclear
N	27	Was a case-control design avoided?	Yes	If a threshold was used, was it pre-specified?	Yes	Were the reference results interpreted without knowledge of the results of the index test?	Yes	Did all patients receive a reference standard?	Yes
Follow-up	July 1999 – January 2010	Did the study avoid inappropriate exclusions?	Unclear					Did all patients receive the same reference standard?	Yes
		Could the selection of patients have introduced bias?	Unclear					Were all patients included in the analysis?	Yes

				<i>bias?</i>		<i>have introduced bias?</i>														
Funding source	Gifts from the Becker, Cooper and Fischer Funds	<i>Are there concerns that the included patients do not match the review question?</i>	Low	<i>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</i>	Low	<i>Are there concerns that the target condition as defined by the reference standard does not match the review question?</i>	Low	<i>Could the patient flow have introduced bias?</i>	Low											
Results	Demographic data:																			
				N	Female/male		Mean age		Age range											
	Total			27	-		-		-											
	Spitz nevi (SN)			8	Data not presented		Data not presented		Data not presented											
	Atypical spitz tumour (AST)			16	10/6		23.25		5-65											
	Melanoma (M) (2 spitzoid, 1 superficial spreading)			3	0/3		32		8-59											
	See next page for table of results.																			
			Disease			AST and SN					SN and M					M and AST				
			M	AST	SN	Sensitivity	Specificity	PPV	NPV	Accuracy	Sensitivity	Specificity	PPV	NPV	Accuracy	Sensitivity	Specificity	PPV	NPV	Accuracy
	BRAF Exon 15	Positive	2	2	0	12.5	100	100	36.4	35.3	66.7	100	100	88.9	90.1	66.7	87.5	50	93.3	84.2
		Negative	1	14	8															
	NRAS Exon 1	Positive	0	3	0	18.8	100	100	38.1	36.3	0	100	0	72.7	72.7	0	81.3	0	81.3	68.4
		Negative	3	13	8															
	NRAS Exon 2	Positive	0	2	1	12.5	87.5	0	33.3	31.2	0	87.5	0	70	63.6	0	87.5	0	82.4	73.7
		Negative	3	14	7															
	HRAS Exon 1	Positive	0	1	0	6.7	100	100	33.3	32.8	0	100	0	77.8	77.8	0	93.3	0	87.5	82.4
		Negative	2	14	7															

	HRAS Exon 2	Positive	0	0	1	0	87.5	0	30.4	29.2	0	87.5	0	77.8	70	0	100	0	88.9	88.9
		Negative	2	16	7															
	Note. SN: Spitz nevi. APT: Atypical spitz tumour. SM: Spitzoid melanoma. *Authors state some data for the genetic mutations was not available and therefore totals do not add up to n for all lesions.																			
Comments	Authors conclude that BRAF mutation status does not reliably distinguish all Spitz nevi from non-spitz nevi and mealnomas.																			

Takata, M et al. "Genetic and epigenetic alterations in the differential diagnosis of malignant melanoma and spitzoid lesions". <i>British Journal of Dermatology</i> (2007) 156: 1287-1294.									
Pub year: 2007		Patient selection		Index test		Reference standard		Flow and timing	
Country	Japan	Paraffin-embedded tissues of primary Cutaneous melanoma, spitz naevus and cases in which the histopathological diagnosis was ambiguous retrieved from the archives of three hospitals in Japan. <i>Exclusion criteria:</i> none provided.		Immunohistochemistry – <i>BRAF codon 600; NRAS codon 61; HRAS condon 61.</i> DNA extraction information presented.		Histological evaluation. All slides reviewed by two pathologists.		No information provided regarding the time between index test(s) and reference standard.	
Design, period	Retrospective case review	Was a consecutive or random sample of patients enrolled?	No	Were the index test results interpreted without knowledge of the results of the reference standard?	Unclear	Is the reference standard likely to correctly classify the target condition?	Yes	Was there an appropriate interval between index test(s) and reference standard?	Unclear
N	52	Was a case-control design avoided?	Yes	If a threshold was used, was it pre-specified?	Yes	Were the reference results interpreted without knowledge of the results of the index test?	Yes	Did all patients receive a reference standard?	Yes
Follow-up	None provided.	Did the study avoid inappropriate exclusions?	Unclear					Did all patients receive the same reference standard?	Yes
		Could the selection of patients have introduced bias?	Unclear	Could the conduct or interpretation of the index test have introduced bias?	Low	Could the reference standard, its conduct, or its interpretation have introduced bias?	Low	Were all patients included in the analysis?	Yes

Funding source	Cancer Research from the Ministry of Health, Labor and Welfare of Japan, Science Research from Japan society for the Promotion of Science.	Are there concerns that the included patients do not match the review question?	Low	Are there concerns that the index test, its conduct, or interpretation differ from the review question?	Low	Are there concerns that the target condition as defined by the reference standard does not match the review question?	Low	Could the patient flow have introduced bias?	Low											
Results	Demographic data:																			
						N		Female/male			Mean age			Age range						
	Total					52		35/17			43.3			2-86						
	Spitz naevus (SN)					12		8/4			64.2			2-50						
	Ambiguous lesions (AL)					16		12/4			18.6			2-79						
	Primary cutaneous melanoma (PCM)					24		15/9			30.6			25-86						
	Note. *Missing data in each group. †Mean age and follow-up not provided by authors and taken from a mean of the provided sub-groups.																			
			Disease			AL and SN					SN and PCM					PCM and AL				
			PCM*	AL*	SN*	Sensitivity	Specificity	PPV	NPV	Accuracy	Sensitivity	Specificity	PPV	NPV	Accuracy	Sensitivity	Specificity	PPV	NPV	
	BRAF	Positive	11	1	0	6.3	100	100	44.4	43.9	45.8	100	100	48	63.9	45.8	93.8	91.7	53.6	
		Negative	13	15	12															
	NRAS	Positive	4	1	0	7.7	100	100	47.8	46.8	33.3	100	100	57.9	65.2	33.3	92.3	80	60	
		Negative	8	12	11															
	HRAS	Positive	0	0	0	0	100	0	47.8	47.8	0	100	0	33.3	33.3	0	100	0	35.3	
		Negative	22	12	11															
Note. SN: Spitz naevus. AL: Ambiguous lesions. PCM: Primary cutaneous melanoma. * Some lesions were either not examined or no data obtained so the totals for each gene may not add up to total number of lesions in each subtype.																				

Evidence tables for the included studies assessing sentinel lymph node biopsy (N=7):

Caraco, C et al. "Sentinel lymph node biopsy in atypical spitz nevi: is it useful?". EJSO (2012) 38: 932-935.									
Pub year: 2012		Patient selection		Index test		Reference standard		Flow and timing	
Country	Italy	Records from the National Institute of Naples were retrospectively reviewed. <i>Inclusion criteria:</i> 40 patients with ASN who underwent SLNB. <i>Exclusion criteria:</i> All cases with uncertain diagnosis or histological features indicative of melanoma [no information on how many this was]		Review of medical records and pathology slides by four experienced dermatopathologists. Each member of the review panel assessed slides separately without recourse to medical notes and blinded to each others' diagnosis. 4/10 lesions initial disagreement but consensus achieved after lengthy discussion.		Sentinel lymph node biopsy		No information provided regarding the time between index test(s) and reference standard.	
Design, period	Retrospective case review 2003-2011	Was a consecutive or random sample of patients enrolled?	No	Were the index test results interpreted without knowledge of the results of the reference standard?	Unclear	Is the reference standard likely to correctly classify the target condition?	Yes	Was there an appropriate interval between index test(s) and reference standard?	Unclear
N	40	Was a case-control design avoided?	Yes	If a threshold was used, was it pre-specified?	Yes Diagnostic histomorphological criteria	Were the reference results interpreted without knowledge of	Yes	Did all patients receive a reference standard?	Yes
Follow-up	Mean: 52 months Median: 46	Did the study avoid inappropriate exclusions?	Unclear						

	months (range: 16-103)				for ASN (Barnhill & Hoang, 1995)	<i>the results of the index test?</i>		<i>Did all patients receive the same reference standard?</i>	Yes
		<i>Could the selection of patients have introduced bias?</i>	Unclear	<i>Could the conduct or interpretation of the index test have introduced bias?</i>	Low. Used consensus opinion	<i>Could the reference standard, its conduct, or its interpretation have introduced bias?</i>	Low	<i>Were all patients included in the analysis?</i>	Yes
Funding source	Disclosed no financial and personal relationships.	<i>Are there concerns that the included patients do not match the review question?</i>	Low	<i>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</i>	Low	<i>Are there concerns that the target condition as defined by the reference standard does not match the review question?</i>	Low	<i>Could the patient flow have introduced bias?</i>	Low
Results	<p>N = 40 Mean age at diagnosis: 33 years (median 32 years, range 11-65 years) 24 women (60%) 16 men (40%)</p> <p>0/40 sentinel node positivity was recorded. No patients developed nodal involvement during the follow-up. All patients were alive and without evidence of loco-regional or distant relapse at time of review.</p>								
Comments	Numbers presented in Table 1 do not match the description in the text regarding follow-up.								

Cochran, AJ et al. "The role of lymphatic mapping and sentinel node biopsy in the management of atypical and anomalous melanocytic lesions". J Cutan Pathol (2010) 37 (1): 54-59.									
Pub year: 2010		Patient selection		Index test		Reference standard		Flow and timing	
Country	USA	Database of 651 UCLA patients who underwent SNB for melanocytic lesions. <i>Inclusion criteria:</i> Patients who underwent SNB for atypical and anomalous melanocytic lesions. <i>Exclusion criteria:</i> Patients who underwent SNB for all other melanocytic lesions (n=618)		Unclear. Database included diagnosed lesions so assume diagnosis made by either/or clinical assessment, dermoscopy and/or histopathology. No information provided		Sentinel lymph node biopsy		No information provided. No follow-up data provided.	
Design, period	Retrospective case review 2000-2006	Was a consecutive or random sample of patients enrolled?	No	Were the index test results interpreted without knowledge of the results of the reference standard?	Unclear	Is the reference standard likely to correctly classify the target condition?	Yes	Was there an appropriate interval between index test(s) and reference standard?	Unclear
N	33	Was a case-control design avoided?	Yes	If a threshold was used, was it pre-specified?	Unclear	Were the reference results interpreted without knowledge of the results of the index test?	Unclear	Did all patients receive a reference standard?	Yes
Follow-up	Not provided.	Did the study avoid inappropriate exclusions?	Unclear					Did all patients receive the same reference standard?	Yes

		<i>Could the selection of patients have introduced bias?</i>	High. Majority of patients were referred to UCLA with the request that they be considered for SNB.	<i>Could the conduct or interpretation of the index test have introduced bias?</i>	Unclear	<i>Could the reference standard, its conduct, or its interpretation have introduced bias?</i>	Low	<i>Were all patients included in the analysis?</i>	Yes
Funding source	National Cancer Institute.	<i>Are there concerns that the included patients do not match the review question?</i>	Unclear	<i>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</i>	Unclear	<i>Are there concerns that the target condition as defined by the reference standard does not match the review question?</i>	Low	<i>Could the patient flow have introduced bias?</i>	Low
Results	No demographic information provided.								
		Total sample	Combined nevi	Atypical cellular blue nevi	Atypical congenital nevi	Atypical desmoplastic nevi			
	N (%)	18	5 (27.8)	4 (22.2)	4 (22.2)	2 (11.1)			
	SLN+	8 (44)	3 (60)	2 (50)	2 (50)	1 (50)			
	SLN-	10 (66)	2 (40)	2 (50)	2 (50)	1 (50)			
	<i>Note. SLN: sentinel lymph node; +: positive; -: negative.</i>								
	Authors state they were unaware that any of the patients in the group developed additional ‘metastases’ or died of their disease.								
Comments	No demographic information of sample. No follow-up data. Potential sampling bias as majority of patients were referred to UCLA with the request that they be considered for SNB.								

Hung, T et al. "Sentinel lymph node metastasis is not predictive of poor outcome in patients with problematic spitzoid melanocytic tumors". Human Pathology (2013) 44: 87-94.									
Pub year: 2013		Patient selection		Index test		Reference standard		Flow and timing	
Country	USA	Records from the Massachusetts general hospital melanoma center <i>Inclusion criteria:</i> 40 patients who underwent SLNB. 23/40 AST and 17/40 SM. <i>Exclusion criteria:</i> No information provided		Case review by 2 or more dermatopathologists.		Sentinel lymph node biopsy		No information provided regarding the time between index test(s) and reference standard.	
Design, period	Retrospective case review 1998-2008	Was a consecutive or random sample of patients enrolled?	No	Were the index test results interpreted without knowledge of the results of the reference standard?	Unclear	Is the reference standard likely to correctly classify the target condition?	Yes	Was there an appropriate interval between index test(s) and reference standard?	Unclear
N	40	Was a case-control design avoided?	Yes	If a threshold was used, was it pre-specified?	Yes	Were the reference results interpreted without knowledge of the results of the index test?	Yes	Did all patients receive a reference standard?	Yes
Follow-up	Mean: 57 months (range: 2-144)	Did the study avoid inappropriate exclusions?	Unclear					Did all patients receive the same reference standard?	Yes

		<i>Could the selection of patients have introduced bias?</i>	Unclear	<i>Could the conduct or interpretation of the index test have introduced bias?</i>	Unclear	<i>Could the reference standard, its conduct, or its interpretation have introduced bias?</i>	Low	<i>Were all patients included in the analysis?</i>	Yes																																			
Funding source	Not mentioned	<i>Are there concerns that the included patients do not match the review question?</i>	Low	<i>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</i>	Low	<i>Are there concerns that the target condition as defined by the reference standard does not match the review question?</i>	Low	<i>Could the patient flow have introduced bias?</i>	Low																																			
Results	N = 40																																											
	<table><tr><td></td><td>Total sample</td><td>AST</td><td>SM</td></tr><tr><td>N (%)</td><td>40</td><td>23 (57.5)</td><td>17 (42.5)</td></tr><tr><td>Mean age</td><td>33</td><td>27</td><td>30</td></tr><tr><td>Age range</td><td>11-65</td><td>5-60</td><td>9-63</td></tr><tr><td>Female (%)</td><td>26 (65)</td><td>16 (70)</td><td>10 (59)</td></tr><tr><td>Male (%)</td><td>14 (35)</td><td>7 (30)</td><td>7 (41)</td></tr></table>					Total sample	AST	SM	N (%)	40	23 (57.5)	17 (42.5)	Mean age	33	27	30	Age range	11-65	5-60	9-63	Female (%)	26 (65)	16 (70)	10 (59)	Male (%)	14 (35)	7 (30)	7 (41)	<table><tr><td></td><td></td><td>AST</td><td>SM</td></tr><tr><td rowspan="2">SNLB</td><td>Positive</td><td>6 (26.1)</td><td>6 (35.3)</td></tr><tr><td>Negative</td><td>17 (73.9)</td><td>11 (64.7)</td></tr></table>							AST	SM	SNLB	Positive	6 (26.1)	6 (35.3)	Negative	17 (73.9)	11 (64.7)
		Total sample	AST	SM																																								
	N (%)	40	23 (57.5)	17 (42.5)																																								
	Mean age	33	27	30																																								
	Age range	11-65	5-60	9-63																																								
	Female (%)	26 (65)	16 (70)	10 (59)																																								
	Male (%)	14 (35)	7 (30)	7 (41)																																								
		AST	SM																																									
SNLB	Positive	6 (26.1)	6 (35.3)																																									
	Negative	17 (73.9)	11 (64.7)																																									
At follow-up (57 months, range 2-144 months) metastases beyond the SLN basin were not observed in any of the 40 patients. One patient developed an in-transit metastasis 3 years after SLN mapping and remained free of additional metastatic tumour 1 year later.																																												
Comments	Some variability in terminology existed over the course of the decade of reported lesions. Tumours considered to be AST were also reported as “atypical spit tumour”, “spitz nevus with atypia”, “borderline Spitz nevus”, “borderline spitz tumour”. Tumours considered to be SM were reported as “spitzoid melanoma” and melanoma with features of spitz tumour”.																																											

Ludgate, MW et al. "The atypical spitz tumour of uncertain biologic potential". Cancer (2009) 115(3): 631-641.									
Pub year: 2009		Patient selection		Index test		Reference standard		Flow and timing	
Country	USA	Searched prospectively collected melanoma database for all cases of spitzoid melanocytic proliferations between 1994 and 2007. <i>Inclusion criteria:</i> Patients with a diagnosis of an atypical spitz tumour or spitzoid melanocytic proliferation of uncertain biologic potential. <i>Exclusion criteria:</i> None provided.		Diagnosis of database lesions rendered by at least ¼ board-certified dermatopathologists (or by a dermatopathologist outside the institution).		Sentinel lymph node biopsy Follow-up		N = 57 Wide local excision and SLNB N = 10 Wide local excision only (14.9%): – 6 patients had primary lesions with a depth <1mm with no other adverse features – 4 patients suitable for SLNB but received wide local excision only. ¼ due to age (18 months), ¾ treated at different institutions and 2 lost to follow-up. Follow-up data available for 65 patients (range: 7.1-57.3 months)	
Design, period	Retrospective case review 1994-2007	Was a consecutive or random sample of patients enrolled?	No	Were the index test results interpreted without knowledge of the results of the reference standard?	Yes	Is the reference standard likely to correctly classify the target condition?	Yes	Was there an appropriate interval between index test(s) and reference standard?	Yes
N	67	Was a case-control design avoided?	Yes	If a threshold was used, was it pre-specified?	Unclear	Were the reference results interpreted without knowledge of the results of the index test?	Unclear	Did all patients receive a reference standard?	No
Follow-up	SLNB-positive group: 43.8 months SLNB-negative	Did the study avoid inappropriate exclusions?	Unclear					Did all patients receive the same	No

	group: 28.6 months							reference standard ?	
	WLE-only group: 32.5 months	<i>Could the selection of patients have introduced bias?</i>	Unclear	<i>Could the conduct or interpretation of the index test have introduced bias?</i>	Unclear	<i>Could the reference standard, its conduct, or its interpretation have introduced bias?</i>	Low	<i>Were all patients included in the analysis?</i>	No 2 patients treated at an outside institution did not receive SNLB and were lost to follow-up
Funding source	Authors made no disclosures	<i>Are there concerns that the included patients do not match the review question?</i>	Low	<i>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</i>	Low	<i>Are there concerns that the target condition as defined by the reference standard does not match the review question?</i>	Low	<i>Could the patient flow have introduced bias?</i>	Unclear
Results	<p>N=67, median age 23.7 years (range: 1.7-65 years). 41 female (61.2%) and 26 male (38.8%)</p> <p>Original lesion was congenital in 4 patients (6.0%). A positive family history of melanoma was present in 8 patients (12%); none was immunosuppressed. 59/67 cases reviewed by 2 or more UM dermatopathologists. Concordant diagnosis was reached in 38 (64%). Of the 21 (36%) cases with discordance, the alternative diagnoses included atypical spitz nevus in 35% and spitzoid melanoma in 65%.</p> <p>57 wide local excision and SLNB:</p> <ul style="list-style-type: none"> – 30 SLNB negative – 27 SLNB positive <ul style="list-style-type: none"> ○ 27 complete lymph node dissection <ul style="list-style-type: none"> ▪ 26 negative non-sentinel nodes ▪ 1 positive non-sentinel node 								
Comments									

Murali, R et al. "Sentinel lymph node biopsy in histologically ambiguous melanocytic tumours with spitzoid features (so-called atypical spitzoid tumors)". <i>Annals of Surgical Oncology</i> (2008) 15(1): 302-309.									
Pub year: 2008		Patient selection		Index test		Reference standard		Flow and timing	
Country	Australia	Databases of the SMU and the Department of Anatomical Pathology at the Royal Prince Alfred Hospital. <i>Inclusion criteria:</i> Patients whose primary Cutaneous melanocytic lesion was reported as "atypical spitz nevus", "atypical spitzoid tumor", or "spitzoid tumor of uncertain malignant potential" and who had undergone SLN biopsy. <i>Exclusion criteria:</i> None provided.		All available histopathologic slides of the primary tumours and their corresponding SLNs reviewed by four pathologists.		Sentinel lymph node biopsy		No information provided regarding the time between index test(s) and reference standard. Range of follow-up with some less than 6 months.	
Design, period	Retrospective case review 1999-2006	Was a consecutive or random sample of patients enrolled?	Unclear	Were the index test results interpreted without knowledge of the results of the reference standard?	Unclear	Is the reference standard likely to correctly classify the target condition?	Yes	Was there an appropriate interval between index test(s) and reference standard?	Unclear. No reported
N	21	Was a case-control design avoided?	Yes	If a threshold was used, was it pre-specified?	Yes	Were the reference results interpreted without knowledge of the results of the index test?	No	Did all patients receive a reference standard?	Yes
Follow-up	Mean: 21.5 months; Median: 10.7 months (range: 1.0-62.1)	Did the study avoid inappropriate exclusions?	Unclear					Did all patients receive the same reference	Yes

								standard ?	
		Could the selection of patients have introduced bias?	Unclear	Could the conduct or interpretation of the index test have introduced bias?	Low	Could the reference standard, its conduct, or its interpretation have introduced bias?	Low	Were all patients included in the analysis?	Yes
Funding source	Cancer institute NSW Clinical Research Fellowship program, university of Sydney Cancer Research fund, Australian National Health and Medical Research Council, Melanoma Foundation	Are there concerns that the included patients do not match the review question?	Low	Are there concerns that the index test, its conduct, or interpretation differ from the review question?	Low	Are there concerns that the target condition as defined by the reference standard does not match the review question?	Low	Could the patient flow have introduced bias?	Low
Results	N=21, median age 31 years (range: 6-50 years).								
		Total sample	SLN+	SLN-	Complete lymph node dissection completed in 5/6 patients. No further metastasis was identified in the CLND specimens. All patients remained alive and disease-free				
	N (%)	21	6 (28.6)	15 (11.4)					
	Mean age	Median: 31	15.2	29.9					

		Age range	6-50	6-38	12-50	over a media follow-up period of 10.7 months (mean: 21.5 months; range: 1.0-62.1 months)				
		Female (%)	12 (57.1)	4 (66.7)	7 (46.7)					
		Male (%)	9 (42.9)	2 (33.3)	8 (53.3)					
Note. SLN: sentinel lymph node; +: positive; -: negative.										
Comments	Authors note that the high SLN-positive rates for atypical spitzoid tumours are likely (at least partly) to be a result of selection bias; the tumours in their study were thick lesions, most being Clark level IV or greater. Large variation in follow-up.									
Urso, C et al. "Sentinel lymph node biopsy in patients with "atypical spitz tumours." A report on 12 cases". Human Pathology (2006) 37: 816-823.										
Pub year: 2006		Patient selection			Index test		Reference standard		Flow and timing	
Country	Italy	Cases retrieved from the files of S.M Annunziata Hospital of Florence, G. Rummo General Hospital of Benevento, and Misericordia e Dolce Hospital of Prato, Italy, over a period of 7 years. Inclusion criteria: All cases diagnosed as "atypical spitz nevi", "atypical spitz tumors", "potentially malignant spitz tumors", "possible malignant spitz tumors" and "possible spitzoid melanomas". Tumor had to show histological features characteristic of spitz nevus mixed to histological features generally referred to malignant melanoma, appearing as spindle and/or epithelioid cell lesion "deviating more or less from the stereotypical morphology of classic spitz nevi. The tumor had not a clear-cut diagnosis of benign spitz nevus or malignant melanoma and the patient underwent sentinel lymph node biopsy. Exclusion criteria: None provided.			Unclear. Database included diagnosed lesions so assume diagnosis made by either/or clinical assessment, dermoscopy and/or histopathology. No information provided		Sentinel lymph node biopsy		No information provided regarding the time between index test(s) and reference standard. Range of follow-up with some less than 6 months.	
Design, period	Retrospective case review	Was a consecutive or random sample of patients enrolled?	No		Were the index test results interpreted without knowledge of the results of the reference standard?	Unclear	Is the reference standard likely to correctly classify the target condition?	Yes	Was there an appropriate interval between index test(s) and reference standard?	Unclear

N	12	<i>Was a case-control design avoided?</i>	Yes	<i>If a threshold was used, was it pre-specified?</i>	Unclear	<i>Were the reference results interpreted without knowledge of the results of the index test?</i>	Unclear	<i>Did all patients receive a reference standard?</i>	Yes
Follow-up	Mean 26.3 months Range: 2-90	<i>Did the study avoid inappropriate exclusions?</i>	No					<i>Did all patients receive the same reference standard?</i>	Yes
		<i>Could the selection of patients have introduced bias?</i>	Low	<i>Could the conduct or interpretation of the index test have introduced bias?</i>	Unclear	<i>Could the reference standard, its conduct, or its interpretation have introduced bias?</i>	Low	<i>Were all patients included in the analysis?</i>	Yes
Funding source	Not provided.	<i>Are there concerns that the included patients do not match the review question?</i>	Low	<i>Are there concerns that the index test, its conduct, or interpretation differ from the review question?</i>	Unclear	<i>Are there concerns that the target condition as defined by the reference standard does not match the review question?</i>	Low	<i>Could the patient flow have introduced bias?</i>	Low
Results									
			Total sample	SLN+	SLN-				
	N (%)		12	4	8				

	Mean age	23.2	15.3	27.1
	Age range	2-48	2-30	11-48
	Female (%)	9 (57.1)	2(66.7)	7(46.7)
	Male (%)	3 (42.9)	2 (33.3)	1 (53.3)
	<p><i>Note. SLN: sentinel lymph node; +: positive; -: negative.</i></p> <p>2/12 patients had a local recurrence after excision of the primary lesion.</p>			
Comments	<p>Authors note that the presence of melanocytes in a lymph node is not always an evidence of metastatic spread because nevus cell aggregates can be found in lymph nodes.... also lymph node metastases do not necessarily imply capacity of distant metastatic disease, especially if they are minimal. Patients with atypical spitz tumors should be treated as other melanoma patients, with wide local excision of the primary lesion, sentinel node biopsy and adequate long-term follow-up.</p>			

Paradela, S et al. "Spitzoid melanoma in children: clinicopathological study and application of immunohistochemistry as an adjunct diagnostic tool". J Cutan Pathol (2009) 36: 740-752.									
Pub year: 2009		Patient selection		Index test		Reference standard		Flow and timing	
Country	USA	UT-MD Anderson Cancer Center <i>Inclusion criteria:</i> All cases of SM in children and teenagers younger than 18 years old. <i>Exclusion criteria:</i> None provided.		Clinical parameters, pathological parameters, prognostic indicators, Immunohistochemical parameters, follow-up features		Sentinel lymph node biopsy		Average number of days between initial surgery and SLND: 45, SD: 39.2 Average number of days between initial surgery and WLE: 35.1, SD: 19.3 Days between SLND and ELND: 12.3, SD: 9.0	
Design, period	Retrospective observational study 1992-2007	Was a consecutive or random sample of patients enrolled?	No	Were the index test results interpreted without knowledge of the results of the reference standard?	No	Is the reference standard likely to correctly classify the target condition?	Yes	Was there an appropriate interval between index test(s) and reference standard?	Yes
N	38	Was a case-control design avoided?	Yes	If a threshold was used, was it pre-specified?	Yes	Were the reference results interpreted without knowledge of the results of the index test?	No	Did all patients receive a reference standard?	No
Follow-up	Mean 37.9 (SD: 42.1)	Did the study avoid inappropriate exclusions?	No					Did all patients receive the same reference standard	No

								?																															
		Could the selection of patients have introduced bias?	Low	Could the conduct or interpretation of the index test have introduced bias?	Low	Could the reference standard, its conduct, or its interpretation have introduced bias?	Low	Were all patients included in the analysis?	Yes																														
Funding source	Not provided.	Are there concerns that the included patients do not match the review question?	Low	Are there concerns that the index test, its conduct, or interpretation differ from the review question?	Low	Are there concerns that the target condition as defined by the reference standard does not match the review question?	Low	Could the patient flow have introduced bias?	Low																														
Results	<p>All patients had spitzoid melanoma. 15 patients were not entirely treated at the centre, so the authors cannot be certain whether they received treatment consistent with their protocol.</p> <table><tr><td></td><td>Total sample</td><td>SLND sample</td><td>SLN+</td><td>SLN-</td></tr><tr><td>N (%)</td><td>38</td><td>25 (65.8)</td><td>14 (56)</td><td>8 (44)</td></tr><tr><td>Mean age</td><td>9.9</td><td></td><td></td><td></td></tr><tr><td>SD</td><td>12</td><td></td><td></td><td></td></tr><tr><td>Female (%)</td><td>17 (44.7)</td><td></td><td></td><td></td></tr><tr><td>Male (%)</td><td>21 (55.3)</td><td></td><td></td><td></td></tr></table> <p>Note. SLN: sentinel lymph node; +: positive; -: negative.</p> <p>In the 14 patients with positive SLN no cases of death detected so far.</p>										Total sample	SLND sample	SLN+	SLN-	N (%)	38	25 (65.8)	14 (56)	8 (44)	Mean age	9.9				SD	12				Female (%)	17 (44.7)				Male (%)	21 (55.3)			
	Total sample	SLND sample	SLN+	SLN-																																			
N (%)	38	25 (65.8)	14 (56)	8 (44)																																			
Mean age	9.9																																						
SD	12																																						
Female (%)	17 (44.7)																																						
Male (%)	21 (55.3)																																						

Comments	
----------	--

2.4 Tumour samples for genetic testing

Review question: What is the most appropriate tumour sample (primary or secondary) on which to carry out genetic testing to identify people who might benefit from targeted therapies?

Background

Genetic testing for malignant melanoma became important with the recent advances in therapy. Different molecular pathways, which are involved in the development of melanoma, can be targeted with specific medicines, and the susceptibility/suitability for these therapies can be assessed by molecular testing.

It is important to assess, when it is best to do these tests (at the time of primary diagnosis or when secondaries present) so primary or metastatic tumour blocks are best used for testing. The tumours – including melanoma – change their molecular profile and signalling pathways in response to treatment, therefore accurate and timely information on their genetic features is important.

The main genetic tests included now are: BRAF, NRAS and c-kit mutation analysis, however this list is likely to grow in the future. Issues regarding safety included in background.

Question in PICO format


Patients/population	Intervention	Comparisons	Outcomes
Patients with metastatic melanoma who are being considered for systemic therapy.	Genetic testing on primary tumour sample for: <ul style="list-style-type: none"> BRAF NRAS, CKIT 	Genetic testing on secondary tumour sample Genetic testing on multiple tumour samples	<ul style="list-style-type: none"> Diagnostic accuracy (true positives, true negatives, false positives, false negatives) Sample adequacy (diagnostic rate - Size of tumour/ age/ volume/ pigmentation) Morbidity due to biopsies

Search Results

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	2002-2013	951	234	11/11/2013
<i>Premedline</i>	2002-2013	254	60	11/11/2013
<i>Embase</i>	2002-2013	1019	237	14/11/2013
<i>Cochrane Library</i>	2002-2013	174	10	14/11/2013

Web of Science (SCI & SSCI)	2002-2013	1230	70	21/11/2013
Total References retrieved (after de-duplication): 494				

1 Screening Results




2
3

4 Risk of bias in the included studies

5 Only one study (Boursault et al, 2013) fully reported the patient sampling strategy: studies typically
6 relied on institutional tumour banks. It was also unclear whether the patients included in the studies
7 had been candidates for chemotherapy. One of the studies (Capper et al, 2012) included only
8 samples from brain metastases. The flow and timing of tests was not well reported in the studies –
9 for example the delay between obtaining the tumour samples and the mutation tests was unclear.
10 Some of the studies used more than one test for genetic mutation – in these cases one of the tests
11 was considered the reference standard (gold standard) test.

1 **Figure 2.18. Risk of bias and applicability (QUADAS-2)**



Evidence statements

Concordance between primary and metastatic samples for BRAF mutations

Low quality evidence suggests that paired primary and metastatic melanoma tumour samples are discordant for BRAF mutation status in between 5% and 40% of patients.

In one study (Yancovitz et al 2012) all patients whose primary tumour sample was BRAF wild type had a BRAF mutant metastatic tumour sample. In the remaining studies between 0% and 45% of patients whose primary tumour sample was BRAF wild type had a BRAF mutant metastatic tumour sample.

In one study (Yancovitz et al 2012) all patients whose metastatic tumour sample was BRAF wild type had a BRAF mutant primary tumour sample. In the remaining studies between 0% and 50% of patients whose metastatic tumour sample was BRAF wild type had a BRAF mutant primary tumour sample.

Concordance between primary and metastatic samples for NRAS mutations

Low quality evidence suggests that paired primary and metastatic melanoma tumour samples are discordant for NRAS mutation status in between 2% and 13% of patients.

Between 0% and 11% of patients whose primary tumour sample was NRAS wild type had an NRAS mutant metastatic tumour sample.

Between 2% and 6% of patients whose metastatic tumour sample was NRAS wild type had an NRAS mutant primary tumour sample.

Concordance between primary and metastatic samples for CKIT mutations

Our literature searches identified no studies comparing CKIT mutations in paired primary and metastatic tumour samples.

Sample adequacy

In two studies comparing paired primary and metastatic tumours samples there was no primary tumour sample available to test in between 11% and 39% of eligible patients (Boursault et al 2013; Heinzerling et al 2013). It was unclear why this was: the delay between obtaining the primary and metastatic tumour samples was not reported in any of the included studies. Colombino et al (2012) reported that DNA sequencing was not possible in 8% of samples due to DNA degradation.

Morbidity

The morbidity associated with obtaining tumour samples for mutation tests was not reported in any of the included studies

Table 2.11. Concordance between primary and secondary tumour samples for BRAF mutations

Study	Technique	Gene / mutation	Sample adequacy (primary)	Sample adequacy (metastasis)	BRAF mutation rate (primary)	BRAF mutation rate (metastasis)	Concordance between primary and metastatic tumour samples (per patient)			Morbidity
Boursault (2013)	High resolution melting analysis followed by Sanger sequencing	BRAF exon 15	Primary tumour samples not available for 11/99 (11%) patients	N.R.	54.5%	55.6%		Primary tumour BRAF mutant	Primary tumour BRAF wt	N.R.
							Metastatic tumour BRAF mutant	45 (51.1%)	3 (3.4%)	
							Metastatic tumour BRAF wt	1 (1.1%)	39 (44.3%)	
							Number of paired samples = 88 Discordant samples = 4/88 (4.5%)			
Capper (2012)	Immunohistochemistry	BRAF V600E-mutant protein expression	15/85 (18%)- genetic analysis was unsuccessful		N.R.	42/76 (55%)		Primary tumour BRAF mutant	Primary tumour BRAF wt	N.R.
							Metastatic tumour BRAF mutant	6	0	
							Metastatic tumour BRAF wt	0	N.R.	
							Number of paired samples=? Discordant samples =?			
Colombino (2012)	DNA sequencing	BRAF exon 11 exon 15	9/108 (8.3%) sample inadequacy due to DNA degradation.		43%	48%		Primary tumour BRAF mutant	Primary tumour BRAF wt	N.R.
							Metastatic tumour BRAF mutant	N.R.	6 (6%)	
							Metastatic tumour BRAF wt	6 (6%)	N.R.	
							Number of paired samples= 99 Discordant samples =18/99 (18%)			
Columbino (2013)	DNA sequencing	BRAF exon 15	N.R.		49%	51%		Primary tumour BRAF mutant	Primary tumour BRAF wt	N.R.
							Metastatic tumour BRAF mutant	N.R.	16 (6.8%)	
							Metastatic tumour BRAF	13 (5.5%)	N.R.	

Study	Technique	Gene / mutation	Sample adequacy (primary)	Sample adequacy (metastasis)	BRAF mutation rate (primary)	BRAF mutation rate (metastasis)	Concordance between primary and metastatic tumour samples (per patient)	Morbidity									
							<table><tr><td>wt</td><td></td><td></td></tr></table> <p>Number of paired samples = 236 Discordant samples = 29/236 (12.3%)</p>	wt									
wt																	
Edlundh-Rose (2006)	Pyrosequencing	BRAF exon 15 codon 600	The authors report the majority of samples were successfully analysed		N.R.	N.R.	<table><tr><td></td><td>Primary tumour BRAF mutant</td><td>Primary tumour BRAF wt</td></tr><tr><td>Metastatic tumour BRAF mutant</td><td>N.R.</td><td>0</td></tr><tr><td>Metastatic tumour BRAF wt</td><td>2</td><td>N.R.</td></tr></table> <p>Number of paired samples=39? Discordant samples =?</p>		Primary tumour BRAF mutant	Primary tumour BRAF wt	Metastatic tumour BRAF mutant	N.R.	0	Metastatic tumour BRAF wt	2	N.R.	N.R.
	Primary tumour BRAF mutant	Primary tumour BRAF wt															
Metastatic tumour BRAF mutant	N.R.	0															
Metastatic tumour BRAF wt	2	N.R.															
Heinzerling (2013)	Pyrosequencing	BRAF V600E	Primary tumour samples missing for 16/41 (39%) of eligible patients	N.R.	45.5%	51.6%	<table><tr><td></td><td>Primary tumour BRAF mutant</td><td>Primary tumour BRAF wt</td></tr><tr><td>Metastatic tumour BRAF mutant</td><td>6 (37.5%)</td><td>0</td></tr><tr><td>Metastatic tumour BRAF wt</td><td>5 (31.25%)</td><td>5 (31.25%)</td></tr></table> <p>Number of paired samples=16 Discordant samples =5/16 (31.3%)</p>		Primary tumour BRAF mutant	Primary tumour BRAF wt	Metastatic tumour BRAF mutant	6 (37.5%)	0	Metastatic tumour BRAF wt	5 (31.25%)	5 (31.25%)	N.R.
	Primary tumour BRAF mutant	Primary tumour BRAF wt															
Metastatic tumour BRAF mutant	6 (37.5%)	0															
Metastatic tumour BRAF wt	5 (31.25%)	5 (31.25%)															
Houben (2004)	Direct sequencing of PCR products	BRAF Exon 11 exon 15	N.R.	N.R.	34.2%	41.9%	<table><tr><td></td><td>Primary tumour BRAF mutant</td><td>Primary tumour BRAF wt</td></tr><tr><td>Metastatic tumour BRAF mutant</td><td>5 (20.8%)</td><td>3 (12.5%)</td></tr><tr><td>Metastatic tumour BRAF wt</td><td>1 (4.2%)</td><td>15 (62.5%)</td></tr></table> <p>Number of paired samples=24 Discordant samples =4/24 (16.7%)</p>		Primary tumour BRAF mutant	Primary tumour BRAF wt	Metastatic tumour BRAF mutant	5 (20.8%)	3 (12.5%)	Metastatic tumour BRAF wt	1 (4.2%)	15 (62.5%)	N.R.
	Primary tumour BRAF mutant	Primary tumour BRAF wt															
Metastatic tumour BRAF mutant	5 (20.8%)	3 (12.5%)															
Metastatic tumour BRAF wt	1 (4.2%)	15 (62.5%)															
Omholt (2003)	PCR-SSCP sequencing	BRAF exon 15 exon 11	N.R.	N.R.	N.R.	N.R.	<table><tr><td></td><td>Primary tumour BRAF mutant</td><td>Primary tumour BRAF wt</td></tr><tr><td>Metastatic tumour BRAF mutant</td><td>N.R.</td><td>2 (4%)</td></tr><tr><td>Metastatic tumour BRAF wt</td><td>0</td><td>N.R.</td></tr></table>		Primary tumour BRAF mutant	Primary tumour BRAF wt	Metastatic tumour BRAF mutant	N.R.	2 (4%)	Metastatic tumour BRAF wt	0	N.R.	N.R.
	Primary tumour BRAF mutant	Primary tumour BRAF wt															
Metastatic tumour BRAF mutant	N.R.	2 (4%)															
Metastatic tumour BRAF wt	0	N.R.															

Study	Technique	Gene / mutation	Sample adequacy (primary)	Sample adequacy (metastasis)	BRAF mutation rate (primary)	BRAF mutation rate (metastasis)	Concordance between primary and metastatic tumour samples (per patient)			Morbidity
							Number of paired samples=51 Discordant samples =2/51 (3.9%)			
Yancovitz (2012)	BRAF mutant-specific PCR	BRAF V600E	N.R.	N.R.	66.7%	77.7%		Primary tumour BRAF mutant	Primary tumour BRAF wt	N.R.
							Metastatic tumour BRAF mutant	10 (55.5%)	6 (33.3%)	
							Metastatic tumour BRAF wt	2 (11.1%)	0	
							Number of paired samples=18 Discordant samples =8/ 18 (44%)			
Yadzi (2010)	BRAF exon 15 DNA sequencing	BRAF V600E	N.R.	N.R.	45%	62%		Primary tumour BRAF mutant	Primary tumour BRAF wt	N.R.
							Metastatic tumour BRAF mutant	6 (30%)	5 (25%)	
							Metastatic tumour BRAF wt	3 (15%)	6 (30%)	
							Number of paired samples= 20 Discordant samples =8/20 (40%)			

Abbreviations: N.R., not reported; wt, wild type;

Table 2.12. Concordance between primary and secondary tumour samples for NRAS mutations

Study	Technique	Gene / mutation	Sample adequacy (primary)	Sample adequacy (metastasis)	NRAS mutation rate (primary)	NRAS mutation rate (metastasis)	Concordance between primary and metastatic tumour samples (per patient)				Morbidity
Colombino (2012)	DNA Sequencing	NRAS exon 2, exon 3	9/108 (8.3%) sample inadequacy due to DNA degradation.		15%	15%		Primary tumour NRAS mutant	Primary tumour NRAS wt	N.R.	
							Metastatic tumour NRAS mutant	N.R.	4 (4%)		
							Metastatic tumour NRAS wt	1 (1%)	N.R.		
							Number of paired samples=99 Discordant samples =5/99 (5%)				
Columbino (2013)	DNA sequencing	NRAS exon 2, exon 3	N.R.		15%	16%		Primary tumour NRAS mutant	Primary tumour NRAS wt	N.R.	

		3					<table><tr><td>Metastatic tumour NRAS mutant</td><td>N.R.</td><td>4 (1.7%)</td></tr><tr><td>Metastatic tumour NRAS wt</td><td>3 (1.3%)</td><td>N.R.</td></tr></table> <p>Number of paired samples = 236 Discordant samples =7/236 (3.0%)</p>	Metastatic tumour NRAS mutant	N.R.	4 (1.7%)	Metastatic tumour NRAS wt	3 (1.3%)	N.R.				
Metastatic tumour NRAS mutant	N.R.	4 (1.7%)															
Metastatic tumour NRAS wt	3 (1.3%)	N.R.															
Edlundh-Rose (2006)	Pyrosequencing	NRAS exon 2 codon 61	The authors report the majority of samples were successfully analysed		N.R.	N.R.	<table><tr><td></td><td>Primary tumour NRAS mutant</td><td>Primary tumour NRAS wt</td></tr><tr><td>Metastatic tumour NRAS mutant</td><td>N.R.</td><td>0</td></tr><tr><td>Metastatic tumour NRAS wt</td><td>2</td><td>N.R.</td></tr></table> <p>Number of paired samples=39? Discordant samples =?</p>		Primary tumour NRAS mutant	Primary tumour NRAS wt	Metastatic tumour NRAS mutant	N.R.	0	Metastatic tumour NRAS wt	2	N.R.	N.R.
	Primary tumour NRAS mutant	Primary tumour NRAS wt															
Metastatic tumour NRAS mutant	N.R.	0															
Metastatic tumour NRAS wt	2	N.R.															
Houben (2004)	Direct sequencing of PCR products	NRAS exon 1, exon 2	N.R.	N.R.	6/24 (25%)	7/24 (29%)	<table><tr><td></td><td>Primary tumour NRAS mutant</td><td>Primary tumour NRAS wt</td></tr><tr><td>Metastatic tumour NRAS mutant</td><td>5 (20.8%)</td><td>2 (8.3%)</td></tr><tr><td>Metastatic tumour NRAS wt</td><td>1 (4.2%)</td><td>16 (66.7%)</td></tr></table> <p>Number of paired samples=24 Discordant samples =3/24 (12.5%)</p>		Primary tumour NRAS mutant	Primary tumour NRAS wt	Metastatic tumour NRAS mutant	5 (20.8%)	2 (8.3%)	Metastatic tumour NRAS wt	1 (4.2%)	16 (66.7%)	N.R.
	Primary tumour NRAS mutant	Primary tumour NRAS wt															
Metastatic tumour NRAS mutant	5 (20.8%)	2 (8.3%)															
Metastatic tumour NRAS wt	1 (4.2%)	16 (66.7%)															
Omholt (2002)	PCR-SSCP sequencing	NRAS exon 2 codon 61	N.R.	N.R.	28%	38%	<table><tr><td></td><td>Primary tumour NRAS mutant</td><td>Primary tumour NRAS wt</td></tr><tr><td>Metastatic tumour NRAS mutant</td><td>19 (35.8%)</td><td>0</td></tr><tr><td>Metastatic tumour NRAS wt</td><td>1 (1.9%)</td><td>33 (62.3%)</td></tr></table> <p>Number of paired samples=53 Discordant samples =1/53 (1.9%)</p>		Primary tumour NRAS mutant	Primary tumour NRAS wt	Metastatic tumour NRAS mutant	19 (35.8%)	0	Metastatic tumour NRAS wt	1 (1.9%)	33 (62.3%)	N.R.
	Primary tumour NRAS mutant	Primary tumour NRAS wt															
Metastatic tumour NRAS mutant	19 (35.8%)	0															
Metastatic tumour NRAS wt	1 (1.9%)	33 (62.3%)															

Abbreviations: N.R., not reported; wt, wild type;

References

Included Studies

- Boursault, L., Haddad, V., Vergier, B., Cappellen, D., Verdon, S., Bellocq, J. P. et al. (2013). Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing. *PLoS ONE [Electronic Resource]*, 8, e70826.
- Capper, D., Berghoff, A. S., Magerle, M., Ilhan, A., Wohrer, A., Hackl, M. et al. (2012). Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. *Acta Neuropathologica*, 123, 223-233.
- Colombino, M., Capone, M., Lissia, A., Cossu, A., Rubino, C., De, G., V et al. (2012). BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. *Journal of Clinical Oncology*, 30, 2522-2529.
- Colombino, M., Lissia, A., Capone, M., De, G., V, Massi, D., Stanganelli, I. et al. (2013). Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. *Journal of Translational Medicine*, 11, 202.
- Edlundh-Rose, E., Egyhazi, S., Omholt, K., Mansson-Brahme, E., Platz, A., Hansson, J. et al. (2006). NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. *Melanoma Research*, 16, 471-478.
- Heinzerling, L., Baiter, M., Kuhnappel, S., Schuler, G., Keikavoussi, P., Agaimy, A. et al. (2013). Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations. *Br J Cancer*, 109, 2833-2841.
- Houben, R., Becker, J. C., Kappel, A., Terheyden, P., Brocker, E. B., Goetz, R. et al. (2004). Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. *J Carcinog.*, 3, 6.
- Omholt, K., Platz, A., Kanter, L., Ringborg, U., & Hansson, J. (2003). NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. *Clin Cancer Res*, 9, 6483-6488.
- Omholt, K., Karsberg, S., Platz, A., Kanter, L., Ringborg, U., & Hansson, J. (2002). Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. *Clin Cancer Res*, 8, 3468-3474.
- Yancovitz, M., Litterman, A., Yoon, J., Ng, E., Shapiro, R. L., Berman, R. S. et al. (2012). Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma. *PLoS ONE*, 7, e29336.
- Yazdi, A. S., Ghoreschi, K., Sander, C. A., & Rocken, M. (2010). Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independently of the BRAF T1799A mutation. *European Journal of Dermatology*, 20, 575-579.

Excluded studies

Busam, K. J., Hedvat, C., Pulitzer, M., Von, D. A., & Jungbluth, A. A. (2013). Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions. *American Journal of Surgical Pathology*, 37, 413-420. 1.

Reason: Does not compare primary versus secondary tumour samples

Capper, D., Berghoff, A. S., Von, D. A., & Preusser, M. (2012). Clinical neuropathology practice news 2-2012: BRAF V600E testing. *Clinical Neuropathology*, 31, 64-66.

Reason: Expert review

Colombino, M., Capone, M., Maio, M., De, G., V, Cossu, A., Lissia, A. et al. (2011). Mutation frequency in BRAF and NRAS genes among primary tumors and different types of metastasis from melanoma patients. *Journal of Clinical Oncology*, 29.

Reason: Abstract only

Culos, K. A. & Cuellar, S. (2013). Novel Targets in the Treatment of Advanced Melanoma: New First-Line Treatment Options. *Annals of Pharmacotherapy*, 47, 519-526.

Reason: Expert review

Czirbesz, K., Plotar, V., Serester, O., & Liskay, G. (2013). BRAF V600 mutation in malignant melanoma. *JDDG - Journal of the German Society of Dermatology*, 11, 44-45.

Reason: Abstract only

Hafner, C., Scheitler, S., Rummele, P., Gantner, S., Landthaler, M., & Klein, C. (2011). Divergent BRAF mutation status of matched primary tumours and metastases in melanoma patients. *JDDG - Journal of the German Society of Dermatology*, 9, 771.

Reason: Abstract only

Hocker, T. & Tsao, H. (2007). Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. [Review] [22 refs]. *Human Mutation*, 28, 578-588.

Reason: Does not compare primary versus secondary tumour samples

Lee, J. H., Choi, J. W., & Kim, Y. S. (2011). Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. *British Journal of Dermatology*, 164, 776-784.

Reason: Does not compare primary versus secondary tumour samples

Libra, M., Malaponte, G., Navolanic, P. M., Gangemi, P., Bevelacqua, V., Proietti, L. et al. (2005). Analysis of BRAF mutation in primary and metastatic melanoma. *Cell Cycle*, 4, 1382-1384.

Reason: Does not compare primary versus secondary tumour samples

Manca, A., Colombino, M., Capone, M., Lissia, A., Cossu, A., Rubino, C. et al. (2012). Pattern and distribution of BRAF/NRAS and P16CDKN2A mutations among primary an secondary lesions in melanoma patients. *Cancer Research*, 72.

Reason: Abstract only

- 1 McArthur, G. A., Ribas, A., Chapman, P. B., Flaherty, K. T., Kim, K. B., Puzanov, I. et al. (2011).
- 2 Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and
- 3 resistance in repeated biopsies from BRAF mutation-positive metastatic melanoma patients (pts).
- 4 Journal of Clinical Oncology, 29.
- 5 Reason: Does not compare primary versus secondary tumour samples
- 6 Meier, F., Niessner, H., Forschner, A., Garbe, C., Bauer, J., & Quintanilla-Martinez, L. (2012). The AKT
- 7 survival pathway is strongly activated in melanoma brain metastases. JDDG - Journal of the German
- 8 Society of Dermatology, 10, 676.
- 9 Reason: Abstract only
- 10 Palmieri, G., Lissia, A., Cossu, A., Ascierto, P. A., Botti, G., Caraco, C. et al. (2013). Different
- 11 prevalence of BRAF and NRAS somatic mutations in melanomas according to the patients' origin.
- 12 Journal of Clinical Oncology, 31.
- 13 Reason: Abstract only
- 14 Polsky, D., Tadepalli, J. S., Hafner, S., Chang, G., Fleming, N. H., Shao, Y. et al. (2013). Analysis of
- 15 plasma-based BRAF and NRAS mutation detection in patients with stage III and IV melanoma. Journal
- 16 of Clinical Oncology, 31.
- 17 Reason: Abstract only
- 18 Pracht, M., Mogha, A., Fautrel, A., Lespagnol, A., Mouchet, N., Le, G. F. et al. (2012). C-kit, B-raf, and
- 19 N-ras mutations in melanoma subtypes. Journal of Clinical Oncology, 30.
- 20 Reason: Abstract only
- 21 Romano, E., Pradervand, S., Paillusson, A., Weber, J., Harshman, K., Muehlethaler, K. et al. (2013).
- 22 Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAF(V600E)-
- 23 Mutated Cutaneous Melanoma Successfully Rechallenged after Progression. Clinical Cancer
- 24 Research, 19, 5749-5757.
- 25 Reason Does not compare primary versus secondary tumour samples
- 26 Safaee, A. G., Jafarnejad, S. M., Tan, L., Saeedi, A., & Li, G. (2012). The prognostic value of BRAF
- 27 mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. [Review]. PLoS
- 28 ONE [Electronic Resource], 7, e47054.
- 29 Reason Does not compare primary versus secondary tumour samples
- 30 Santos-Briz, A., Godoy, E., Arango, L., Antunez, P., Alcaraz, E., & Fernandez, E. (2013). Should
- 31 BRAFV600E be tested in primary or metastatic malignant melanoma? Laboratory Investigation, 93,
- 32 120A.
- 33 Reason Abstract only
- 34 Satzger, I., Marks, L., Klages, S., Kerick, M., Ruschoff, J., Middel, P. et al. (2013). BRAFV600 mutations
- 35 are highly consistent in primary melanomas and matched metastases-an analysis of 160 paired
- 36 tissue samples by real time PCR and next-generation sequencing. JDDG - Journal of the German
- 37 Society of Dermatology, 11, 4.
- 38 Reason: Abstract only

- 1 Vergier, B., Boursault, L., Haddad, V., Capellen, D., Verdon, S., Bellocq, J.-P. et al. (2013). Tumor
- 2 homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma
- 3 determined by immunohistochemical and molecular testing. JDDG - Journal of the German Society of
- 4 Dermatology, 11, 47.
- 5 Reason: Abstract only
- 6 Wang, H., Lee, S., Nigro, C. L., Lattanzio, L., Merlano, M., Monteverde, M. et al. (2012). NT5E (CD73)
- 7 is epigenetically regulated in malignant melanoma and associated with metastatic site specificity.
- 8 British Journal of Cancer, 106, 1446-1452.
- 9 Reason Does not compare primary versus secondary tumour samples

10

Evidence Tables

	Was a consecutive or random sample of patients enrolled?	Was a case-control design avoided?	Did the study avoid inappropriate exclusions?	Were the index test results interpreted without knowledge of the results of the reference standard?	If a threshold was used, was it pre-specified?	Is the reference standard likely to correctly classify the target condition?	Were the reference standard results interpreted without knowledge of the results of the index test?	Was there an appropriate interval between index test(s) and reference standard?	Did all patients receive a reference standard?	Did patients receive the same reference standard?	Were all patients included in the analysis?	Quality
Boursault et al (2013)	Consecutive	Yes	Yes	Yes	Not Reported	Yes	Yes	Unclear	Yes	Yes	No – primary tumour samples were not available for 11/99 patients	High Low risk of bias overall
<i>Capper (2012)</i>	Not reported	Unclear	Unclear	Not reported	Not reported	Yes	Not reported	Not reported	No	No	No	Moderate Unclear risk of bias
<i>Colombino (2012)</i>	Consecutive	Yes	Not reported	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Unclear	High Low risk of bias overall
<i>Colombino</i>	Consecutive	Yes	Unclear	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Unclear	High

	Was a consecutive or random sample of patients enrolled?	Was a case-control design avoided?	Did the study avoid inappropriate exclusions?	Were the index test results interpreted without knowledge of the results of the reference standard?	If a threshold was used, was it pre-specified?	Is the reference standard likely to correctly classify the target condition?	Were the reference standard results interpreted without knowledge of the results of the index test?	Was there an appropriate interval between index test(s) and reference standard?	Did all patients receive a reference standard?	Did patients receive the same reference standard?	Were all patients included in the analysis?	Quality
(2013)												Low risk of bias overall
<i>Edlundh-rose (2006)</i>	Not reported	Unclear	Unclear	Not reported	Not reported	Yes	Not reported	Not Reported	Not reported	Not reported	No	Moderate Unclear risk of bias
<i>Hienzerling (2013)</i>	Consecutive	Yes	Yes	Yes	Not reported	Yes	Yes	Not reported	No (only equivocal cases)	Yes	No	High Low risk of bias
<i>Houben (2004)</i>	Not reported	Unclear	Unclear	N/A	N/A	N/A	N/A	N/A	Unclear	Unclear	Paired samples only available for 24/86 patients – unclear why this	Moderate Unclear risk of bias

	Was a consecutive or random sample of patients enrolled?	Was a case-control design avoided?	Did the study avoid inappropriate exclusions?	Were the index test results interpreted without knowledge of the results of the reference standard?	If a threshold was used, was it pre-specified?	Is the reference standard likely to correctly classify the target condition?	Were the reference standard results interpreted without knowledge of the results of the index test?	Was there an appropriate interval between index test(s) and reference standard?	Did all patients receive a reference standard?	Did patients receive the same reference standard?	Were all patients included in the analysis?	Quality
											was.	
<i>Omholt (2002)</i>	Not reported	Unclear	Unclear	N/A	N/A	N/A	N/A	N/A	Unclear	Unclear	Results are presented for 72 patients – but it is unclear how many others might have been eligible	Moderate Unclear risk of bias
<i>Omholt (2003)</i>	Not reported	Unclear	Unclear	N/A	N/A	N/A	N/A	N/A	Unclear	Unclear	Results are presented for 72 patients – but it is unclear how many others might have been eligible	Moderate Unclear risk of bias
<i>Yancovitz</i>	Not reported	Not	Not reported	Not Reported	Not	Unclear – authors	Not Reported	Not reported	Yes	Yes	Yes	Moderate

	Was a consecutive or random sample of patients enrolled?	Was a case-control design avoided?	Did the study avoid inappropriate exclusions?	Were the index test results interpreted without knowledge of the results of the reference standard?	If a threshold was used, was it pre-specified?	Is the reference standard likely to correctly classify the target condition?	Were the reference standard results interpreted without knowledge of the results of the index test?	Was there an appropriate interval between index test(s) and reference standard?	Did all patients receive a reference standard?	Did patients receive the same reference standard?	Were all patients included in the analysis?	Quality
(2012)		reported			reported	report MS-PCR as more sensitive than conventional sequencing.						Unclear Risk of bias
Yadzi (2012)	Not reported	Not reported	Not reported	N/A	Not Reported	N/A	N/A	N/A	N/A	N/A	Yes	Moderate Unclear Risk of bias

Study	Study Type	Population	Intervention	Comparison	Outcomes Results	
Boursault et al (2013)	Diagnostic	N=117 <u>Inclusion criteria:</u> available of tumour tissue from both primary melanoma and metastasis, and pathologically confirmed	Immunohistochemistry with an anti-BRAF ^{V600E} antibody	High resolution melting analysis followed by Sanger sequencing	Origin of metastatic samples	
					Site	Proportion from that site
					Lymph nodes	81/142 (57%)

Study	Study Type	Population	Intervention	Comparison	Outcomes Results																						
		<p>stage IIIb, IIIc or IV on AJCC</p> <p><u>Exclusion criteria:</u> Patients without paired primary-metastasis tissue samples (N=13), inappropriate fixation of material (N=5)</p> <p><u>Clinical setting:</u> Secondary/tertiary care, France, Dermatology Unit</p>			<table><tr><td>Brain</td><td>1/142 (<1%)</td></tr><tr><td>Skin</td><td>45/142 (32%)</td></tr><tr><td>Liver</td><td>4/142 (3%)</td></tr><tr><td>Lung</td><td>6/142 (4%)</td></tr><tr><td>Other</td><td>5/142 (4%)</td></tr></table> <p>In primary tumour samples</p> <table><tr><td>Tests for BRAF mutation – in primary tumour samples</td><td>Mutation analysis positive for BRAF</td><td>Mutation analysis negative for BRAF (wild-type)</td></tr><tr><td>BRAF immunostaining positive</td><td>42</td><td>0</td></tr><tr><td>BRAF immunostaining negative</td><td>3</td><td>41</td></tr></table> <p>Sensitivity 93% , Specificity 100%</p> <p>In metastatic tumour samples (per tumour analysis – some patients contributed more than one sample)</p> <table><tr><td>Tests for BRAF mutation –</td><td>Mutation analysis</td><td>Mutation analysis</td></tr></table>	Brain	1/142 (<1%)	Skin	45/142 (32%)	Liver	4/142 (3%)	Lung	6/142 (4%)	Other	5/142 (4%)	Tests for BRAF mutation – in primary tumour samples	Mutation analysis positive for BRAF	Mutation analysis negative for BRAF (wild-type)	BRAF immunostaining positive	42	0	BRAF immunostaining negative	3	41	Tests for BRAF mutation –	Mutation analysis	Mutation analysis
Brain	1/142 (<1%)																										
Skin	45/142 (32%)																										
Liver	4/142 (3%)																										
Lung	6/142 (4%)																										
Other	5/142 (4%)																										
Tests for BRAF mutation – in primary tumour samples	Mutation analysis positive for BRAF	Mutation analysis negative for BRAF (wild-type)																									
BRAF immunostaining positive	42	0																									
BRAF immunostaining negative	3	41																									
Tests for BRAF mutation –	Mutation analysis	Mutation analysis																									

Study	Study Type	Population	Intervention	Comparison	Outcomes Results																		
					<table><tr><td>in metastatic tumour samples</td><td>positive for BRAF</td><td>negative for BRAF (wild-type)</td></tr><tr><td>BRAF immunostaining positive</td><td>67</td><td>0</td></tr><tr><td>BRAF immunostaining negative</td><td>9</td><td>63</td></tr></table> <p>Sensitivity 88%, Specificity 100%</p> <p>Concordance between primary and metastatic tumour samples for mutation analysis</p> <table><tr><td></td><td>Primary tumour mutation analysis positive for BRAF</td><td>Primary tumour mutation analysis negative for BRAF</td></tr><tr><td>Metastatic tumour mutation analysis positive for BRAF</td><td>45</td><td>3</td></tr><tr><td>Metastatic tumour mutation analysis negative for BRAF</td><td>1</td><td>39</td></tr></table> <p>The BRAF status was concordant between the primary and metastatic samples for 84 patients (95.5%).</p> <p>Discordant results for BRAF status were observed in 4 patients out of 88 (4.5%).</p>	in metastatic tumour samples	positive for BRAF	negative for BRAF (wild-type)	BRAF immunostaining positive	67	0	BRAF immunostaining negative	9	63		Primary tumour mutation analysis positive for BRAF	Primary tumour mutation analysis negative for BRAF	Metastatic tumour mutation analysis positive for BRAF	45	3	Metastatic tumour mutation analysis negative for BRAF	1	39
in metastatic tumour samples	positive for BRAF	negative for BRAF (wild-type)																					
BRAF immunostaining positive	67	0																					
BRAF immunostaining negative	9	63																					
	Primary tumour mutation analysis positive for BRAF	Primary tumour mutation analysis negative for BRAF																					
Metastatic tumour mutation analysis positive for BRAF	45	3																					
Metastatic tumour mutation analysis negative for BRAF	1	39																					

Study	Study Type	Population	Intervention	Comparison	Outcomes Results							
					<p>Non interpretable results</p> <table><tr><td></td><td>Primary tumour samples</td><td>Metastatic tumour samples</td></tr><tr><td>BRAF immunostaining</td><td>2/88 (2.3%)</td><td>3/142 (2.1%)</td></tr></table> <p>5/117 eligible patients had inappropriate fixation of samples – so they could not be analysed.</p>		Primary tumour samples	Metastatic tumour samples	BRAF immunostaining	2/88 (2.3%)	3/142 (2.1%)	
	Primary tumour samples	Metastatic tumour samples										
BRAF immunostaining	2/88 (2.3%)	3/142 (2.1%)										
<i>Capper (2012)</i>	Retrospective cohort study	<p><u>Inclusion criteria:</u> Age 16 or older with histologically diagnosed brain metastasis of solid cancer. FFPE samples of brain metastasis, (and primary tumour or other metastasis if available) were retrieved. Samples from 874 patients were included, 76 of which had melanoma.</p> <p><u>Exclusion criteria:</u></p> <p><u>Clinical setting:</u></p>	Immunohistochemistry using anti-BRAF V600E	Sequencing	<p>Origin of metastatic samples</p> <table><tr><th>Site</th><th>Proportion from that site</th></tr><tr><td>Brain</td><td>76/76 (100%)</td></tr></table> <p>Concordance between primary and metastatic tumour samples for BRAF V600E immuno-staining</p> <table><tr><td></td><td>Primary tumour mutation analysis positive for BRAF</td><td>Primary tumour mutation analysis negative for BRAF</td></tr></table>	Site	Proportion from that site	Brain	76/76 (100%)		Primary tumour mutation analysis positive for BRAF	Primary tumour mutation analysis negative for BRAF
Site	Proportion from that site											
Brain	76/76 (100%)											
	Primary tumour mutation analysis positive for BRAF	Primary tumour mutation analysis negative for BRAF										

Study	Study Type	Population	Intervention	Comparison	Outcomes Results														
		Secondary/tertiary care, Medical University of Vienna, Austria			<table><tr><td>Metastatic tumour mutation analysis positive for BRAF</td><td>6</td><td>0</td></tr><tr><td>Metastatic tumour mutation analysis negative for BRAF</td><td>0</td><td>N.R.</td></tr></table> <p>Non interpretable results</p> <table><tr><td></td><td>Primary tumour samples</td><td>Metastatic tumour samples</td><td>Overall</td></tr><tr><td>Sequencing</td><td>N.R.</td><td>N.R.</td><td>15/85 (18%)-genetic analysis was unsuccessful</td></tr></table>	Metastatic tumour mutation analysis positive for BRAF	6	0	Metastatic tumour mutation analysis negative for BRAF	0	N.R.		Primary tumour samples	Metastatic tumour samples	Overall	Sequencing	N.R.	N.R.	15/85 (18%)-genetic analysis was unsuccessful
Metastatic tumour mutation analysis positive for BRAF	6	0																	
Metastatic tumour mutation analysis negative for BRAF	0	N.R.																	
	Primary tumour samples	Metastatic tumour samples	Overall																
Sequencing	N.R.	N.R.	15/85 (18%)-genetic analysis was unsuccessful																
Colombino (2012)	Retrospective Study	Inclusion criteria: 108 patients with AJCC stage III or IV (tumour samples were formalin fixed and paraffin embedded). 29 Melanoma cell lines cultured from primary and metastatic tumours were	Mutation analysis using automated DNA sequencing.	N/A	<p>Origin of metastatic samples in paired analysis</p> <table><tr><th>Site</th><th>Proportion from that site</th></tr><tr><td>Lymph nodes</td><td>84/165 (51%)</td></tr></table>	Site	Proportion from that site	Lymph nodes	84/165 (51%)										
Site	Proportion from that site																		
Lymph nodes	84/165 (51%)																		

Study	Study Type	Population	Intervention	Comparison	Outcomes Results												
		<p>also included for controls.</p> <p><u>Exclusion criteria:</u> Not reported</p> <p><u>Clinical setting:</u> Not reported - (patients were recruited from a number of Italian institutions).</p>			<table><tr><td>Brain</td><td colspan="2">20/165 12%)</td></tr><tr><td>Skin</td><td colspan="2">36/165 (22%)</td></tr><tr><td>Liver</td><td colspan="2">20/165 (12%)</td></tr><tr><td>Lung</td><td colspan="2">5/165 (3%)</td></tr></table>	Brain	20/165 12%)		Skin	36/165 (22%)		Liver	20/165 (12%)		Lung	5/165 (3%)	
Brain	20/165 12%)																
Skin	36/165 (22%)																
Liver	20/165 (12%)																
Lung	5/165 (3%)																
<p>Concordance between primary and metastatic tumour samples for BRAF mutation analysis</p> <table><tr><td></td><td>Primary tumour mutation analysis positive for BRAF</td><td>Primary tumour mutation analysis negative for BRAF</td></tr><tr><td>Metastatic tumour mutation analysis positive for BRAF</td><td>N.R.</td><td>6</td></tr><tr><td>Metastatic tumour mutation analysis negative for BRAF</td><td>6</td><td>N.R.</td></tr></table> <p>99 patients had paired primary and metastatic samples</p>							Primary tumour mutation analysis positive for BRAF	Primary tumour mutation analysis negative for BRAF	Metastatic tumour mutation analysis positive for BRAF	N.R.	6	Metastatic tumour mutation analysis negative for BRAF	6	N.R.			
	Primary tumour mutation analysis positive for BRAF	Primary tumour mutation analysis negative for BRAF															
Metastatic tumour mutation analysis positive for BRAF	N.R.	6															
Metastatic tumour mutation analysis negative for BRAF	6	N.R.															
<p>Concordance between primary and metastatic tumour samples for NRAS mutation analysis</p> <table><tr><td></td><td>Primary tumour mutation analysis positive for NRAS</td><td>Primary tumour mutation analysis</td></tr></table>							Primary tumour mutation analysis positive for NRAS	Primary tumour mutation analysis									
	Primary tumour mutation analysis positive for NRAS	Primary tumour mutation analysis															

Study	Study Type	Population	Intervention	Comparison	Outcomes Results		
					Metastatic tumour mutation analysis positive for NRAS	N.R.	4
					Metastatic tumour mutation analysis negative for NRAS	1	N.R.
					99 patients had paired primary and metastatic samples		
					Non interpretable results		

Study	Study Type	Population	Intervention	Comparison	Outcomes Results																								
		<p>(stage III to IV). 236 paired primary – metastatic samples were available from 138 patients.</p> <p><u>Exclusion criteria:</u> Not reported</p> <p><u>Clinical setting:</u> Not reported - (patients were recruited from a number of Italian institutions) 2008-2013.</p>	BRAF (exon 15).		<table><tr><th>Site</th><th>Proportion from that site</th><th>Concordance with primary for BRAF/NRAS status</th></tr><tr><td>Lymph nodes</td><td>120/236 (51%)</td><td>90.8%</td></tr><tr><td>Brain</td><td>24/236 (10%)</td><td>79.2%</td></tr><tr><td>Skin</td><td>52/236 (22%)</td><td>71.2%</td></tr><tr><td>Visceral</td><td>40/236 (17%)</td><td>92.5%</td></tr></table> <p>Concordance between primary and metastatic tumour samples for BRAF mutation analysis</p> <table><tr><td></td><td>Primary tumour mutation analysis positive for BRAF</td><td>Primary tumour mutation analysis negative for BRAF</td></tr><tr><td>Metastatic tumour mutation analysis positive for BRAF</td><td>N.R.</td><td>16</td></tr><tr><td>Metastatic tumour mutation analysis negative for BRAF</td><td>13</td><td>N.R.</td></tr></table> <p>138 patients provided 236 paired primary and metastatic samples (some patients had samples from multiple metastatic sites)</p>	Site	Proportion from that site	Concordance with primary for BRAF/NRAS status	Lymph nodes	120/236 (51%)	90.8%	Brain	24/236 (10%)	79.2%	Skin	52/236 (22%)	71.2%	Visceral	40/236 (17%)	92.5%		Primary tumour mutation analysis positive for BRAF	Primary tumour mutation analysis negative for BRAF	Metastatic tumour mutation analysis positive for BRAF	N.R.	16	Metastatic tumour mutation analysis negative for BRAF	13	N.R.
Site	Proportion from that site	Concordance with primary for BRAF/NRAS status																											
Lymph nodes	120/236 (51%)	90.8%																											
Brain	24/236 (10%)	79.2%																											
Skin	52/236 (22%)	71.2%																											
Visceral	40/236 (17%)	92.5%																											
	Primary tumour mutation analysis positive for BRAF	Primary tumour mutation analysis negative for BRAF																											
Metastatic tumour mutation analysis positive for BRAF	N.R.	16																											
Metastatic tumour mutation analysis negative for BRAF	13	N.R.																											

Study	Study Type	Population	Intervention	Comparison	Outcomes Results									
					<p>Concordance between primary and metastatic tumour samples for NRAS mutation analysis</p> <table><tr><td></td><td>Primary tumour mutation analysis positive for NRAS</td><td>Primary tumour mutation analysis negative for NRAS</td></tr><tr><td>Metastatic tumour mutation analysis positive for NRAS</td><td>N.R.</td><td>4</td></tr><tr><td>Metastatic tumour mutation analysis negative for NRAS</td><td>3</td><td>N.R.</td></tr></table> <p>138 patients provided 236 paired primary and metastatic samples (some patients had samples from multiple metastatic sites)</p> <p>Non interpretable results: not reported</p>		Primary tumour mutation analysis positive for NRAS	Primary tumour mutation analysis negative for NRAS	Metastatic tumour mutation analysis positive for NRAS	N.R.	4	Metastatic tumour mutation analysis negative for NRAS	3	N.R.
	Primary tumour mutation analysis positive for NRAS	Primary tumour mutation analysis negative for NRAS												
Metastatic tumour mutation analysis positive for NRAS	N.R.	4												
Metastatic tumour mutation analysis negative for NRAS	3	N.R.												
<i>Edlundh-rose (2006)</i>	Diagnostic Study	<p><u>Inclusion criteria:</u> 219 patients with cutaneous melanoma treated at a single institution.</p> <p><u>Exclusion criteria:</u> Not reported</p>	Mutation analysis using pyrosequencing of fresh frozen or formalin-fixed paraffin embedded samples.	Single strand conformation polymorphism nucleotide sequencing	<p>Origin of metastatic samples</p> <table><tr><th>Site</th><th>Proportion from that site</th></tr><tr><td>Not reported</td><td>Not reported</td></tr></table>	Site	Proportion from that site	Not reported	Not reported					
Site	Proportion from that site													
Not reported	Not reported													

Study	Study Type	Population	Intervention	Comparison	Outcomes Results															
		<u>Clinical setting:</u> Secondary/tertiary care: Department of Oncology, Karolinska University Hospital, Sweden			<p>Concordance between primary and metastatic tumour samples for BRAF mutation analysis</p> <table><tr><td></td><td>Primary tumour mutation analysis positive for BRAF</td><td>Primary tumour mutation analysis negative for BRAF</td></tr><tr><td>Metastatic tumour mutation analysis positive for BRAF</td><td>N.R.</td><td>0</td></tr><tr><td>Metastatic tumour mutation analysis negative for BRAF</td><td>2</td><td>N.R.</td></tr></table> <p>In 2/57 cases the primary tumour sample had a BRAF mutation but the metastatic sample was wild type.</p> <p>Concordance between primary and metastatic tumour samples for NRAS mutation analysis</p> <table><tr><td></td><td>Primary tumour mutation analysis positive for NRAS</td><td>Primary tumour mutation analysis negative for NRAS</td></tr><tr><td>Metastatic tumour mutation analysis positive for NRAS</td><td>N.R.</td><td>0</td></tr></table>		Primary tumour mutation analysis positive for BRAF	Primary tumour mutation analysis negative for BRAF	Metastatic tumour mutation analysis positive for BRAF	N.R.	0	Metastatic tumour mutation analysis negative for BRAF	2	N.R.		Primary tumour mutation analysis positive for NRAS	Primary tumour mutation analysis negative for NRAS	Metastatic tumour mutation analysis positive for NRAS	N.R.	0
	Primary tumour mutation analysis positive for BRAF	Primary tumour mutation analysis negative for BRAF																		
Metastatic tumour mutation analysis positive for BRAF	N.R.	0																		
Metastatic tumour mutation analysis negative for BRAF	2	N.R.																		
	Primary tumour mutation analysis positive for NRAS	Primary tumour mutation analysis negative for NRAS																		
Metastatic tumour mutation analysis positive for NRAS	N.R.	0																		

Study	Study Type	Population	Intervention	Comparison	Outcomes Results											
					<table><tr><td>Metastatic tumour mutation analysis negative for NRAS</td><td>2</td><td>N.R.</td></tr></table> <p>In 2/57 cases the primary tumour sample had a NRAS mutation but the metastatic sample was wild type.</p> <p>Non interpretable results</p> <table><tr><td></td><td>Primary tumour samples</td><td>Metastatic tumour samples</td><td>Overall</td></tr><tr><td>Pyrosequencing</td><td>N.R.</td><td>N.R.</td><td>The majority of samples were successfully analysed</td></tr></table>	Metastatic tumour mutation analysis negative for NRAS	2	N.R.		Primary tumour samples	Metastatic tumour samples	Overall	Pyrosequencing	N.R.	N.R.	The majority of samples were successfully analysed
Metastatic tumour mutation analysis negative for NRAS	2	N.R.														
	Primary tumour samples	Metastatic tumour samples	Overall													
Pyrosequencing	N.R.	N.R.	The majority of samples were successfully analysed													
Hienzerling (2013)	Diagnostic Study	<u>Inclusion criteria:</u> Patients with stage IV melanoma (53 patients). 12 patients with rare BRAF mutations were excluded. Results only reported for the remaining 41 patients of these primary tumour samples were missing	Pyrosequencing	Sanger sequencing (used only in equivocal cases)	<p>Origin of metastatic samples</p> <table><tr><th>Site</th><th>Proportion from that site</th></tr><tr><td>Skin</td><td>137/256 (54%)</td></tr><tr><td>Lymph node</td><td>20/256 (8%)</td></tr><tr><td>Other (including liver, lung and brain)</td><td>37/256 (14%)</td></tr><tr><td>Unknown</td><td>62/256 (24%)</td></tr></table>	Site	Proportion from that site	Skin	137/256 (54%)	Lymph node	20/256 (8%)	Other (including liver, lung and brain)	37/256 (14%)	Unknown	62/256 (24%)	
Site	Proportion from that site															
Skin	137/256 (54%)															
Lymph node	20/256 (8%)															
Other (including liver, lung and brain)	37/256 (14%)															
Unknown	62/256 (24%)															

Study	Study Type	Population	Intervention	Comparison	Outcomes Results																	
		<p>for 25 patients: 9 were unknown primary and for 16 samples no longer available.</p> <p><u>Exclusion criteria:</u> uveal melanoma</p> <p><u>Clinical setting:</u> Secondary/tertiary care, University Hospital Erlangen, Germany</p>			<p>Concordance between primary and metastatic tumour samples for BRAF mutation analysis (only patients with BRAF V600E, V600K or wild-type were included)</p> <table><tr><td></td><td>Primary tumour mutation analysis positive for BRAF</td><td>Primary tumour mutation analysis negative for BRAF</td></tr><tr><td>Metastatic tumour mutation analysis positive for BRAF</td><td>6</td><td>0</td></tr><tr><td>Metastatic tumour mutation analysis negative for BRAF</td><td>5</td><td>5</td></tr></table> <p>Non interpretable results</p> <table><tr><td></td><td>Primary tumour samples</td><td>Metastatic tumour samples</td><td>Overall</td></tr><tr><td>Pyrosequencing</td><td>Primary tumour samples no longer available for 16/41 (39%) patients.</td><td></td><td></td></tr></table>		Primary tumour mutation analysis positive for BRAF	Primary tumour mutation analysis negative for BRAF	Metastatic tumour mutation analysis positive for BRAF	6	0	Metastatic tumour mutation analysis negative for BRAF	5	5		Primary tumour samples	Metastatic tumour samples	Overall	Pyrosequencing	Primary tumour samples no longer available for 16/41 (39%) patients.		
	Primary tumour mutation analysis positive for BRAF	Primary tumour mutation analysis negative for BRAF																				
Metastatic tumour mutation analysis positive for BRAF	6	0																				
Metastatic tumour mutation analysis negative for BRAF	5	5																				
	Primary tumour samples	Metastatic tumour samples	Overall																			
Pyrosequencing	Primary tumour samples no longer available for 16/41 (39%) patients.																					

Study	Study Type	Population	Intervention	Comparison	Outcomes Results													
<i>Houben (2004)</i>	Diagnostic Study	<p><u>Inclusion criteria:</u> Paraffin embedded tumour samples from 114 primary and 86 metastatic tumours. Paired primary and metastatic samples were available for 24 patients.</p> <p><u>Exclusion criteria:</u> None reported</p> <p><u>Clinical setting:</u> Not reported</p>	Sequencing	N/A	<p>Origin of metastatic samples</p> <table><tr><th>Site</th><th>Proportion from that site</th></tr><tr><td>N.R.</td><td>N.R.</td></tr></table> <p>Concordance between primary and metastatic tumour samples for BRAF V599 mutation</p> <table><tr><td></td><td>Primary tumour mutation analysis positive for BRAF</td><td>Primary tumour mutation analysis negative for BRAF</td></tr><tr><td>Metastatic tumour mutation analysis positive for BRAF</td><td>5</td><td>3</td></tr><tr><td>Metastatic tumour mutation analysis negative for BRAF</td><td>1</td><td>15</td></tr></table> <p>Concordance between primary and metastatic tumour samples</p>	Site	Proportion from that site	N.R.	N.R.		Primary tumour mutation analysis positive for BRAF	Primary tumour mutation analysis negative for BRAF	Metastatic tumour mutation analysis positive for BRAF	5	3	Metastatic tumour mutation analysis negative for BRAF	1	15
Site	Proportion from that site																	
N.R.	N.R.																	
	Primary tumour mutation analysis positive for BRAF	Primary tumour mutation analysis negative for BRAF																
Metastatic tumour mutation analysis positive for BRAF	5	3																
Metastatic tumour mutation analysis negative for BRAF	1	15																

Study	Study Type	Population	Intervention	Comparison	Outcomes Results																	
					<div>for NRAS 61 mutation</div> <table><tr><td></td><td>Primary tumour mutation analysis positive for NRAS</td><td>Primary tumour mutation analysis negative for NRAS</td></tr><tr><td>Metastatic tumour mutation analysis positive for NRAS</td><td>5</td><td>2</td></tr><tr><td>Metastatic tumour mutation analysis negative for NRAS</td><td>1</td><td>16</td></tr></table> <div>Non interpretable results</div> <table><tr><td></td><td>Primary tumour samples</td><td>Metastatic tumour samples</td><td>Overall</td></tr><tr><td>sequencing</td><td>N.R.</td><td>N.R.</td><td>N.R.</td></tr></table>		Primary tumour mutation analysis positive for NRAS	Primary tumour mutation analysis negative for NRAS	Metastatic tumour mutation analysis positive for NRAS	5	2	Metastatic tumour mutation analysis negative for NRAS	1	16		Primary tumour samples	Metastatic tumour samples	Overall	sequencing	N.R.	N.R.	N.R.
	Primary tumour mutation analysis positive for NRAS	Primary tumour mutation analysis negative for NRAS																				
Metastatic tumour mutation analysis positive for NRAS	5	2																				
Metastatic tumour mutation analysis negative for NRAS	1	16																				
	Primary tumour samples	Metastatic tumour samples	Overall																			
sequencing	N.R.	N.R.	N.R.																			
Omholt (2002)	Diagnostic Study	<u>Inclusion criteria:</u> Malignant melanoma primary tumour samples (N=74), metastatic tumour	PCR single strand conformation polymorphism (PCR-SSCP) sequencing –	N/A	<div>Origin of metastatic samples</div>																	

Study	Study Type	Population	Intervention	Comparison	Outcomes Results																	
		<p>samples (N=88). Of these 54 were paired allowing within patient comparison. Samples were formalin fixed and paraffin embedded.</p> <p><u>Exclusion criteria:</u></p> <p><u>Clinical setting:</u> Secondary/tertiary care, Department of Oncology, Karolinska Hospital, Sweden.</p>	screening for N-ras exon 2 mutations		<table><tr><th>Site</th><th>Proportion from that site</th></tr><tr><td>Lymph node</td><td>50/88 (57%)</td></tr><tr><td>Skin</td><td>37/88 (42%)</td></tr><tr><td>Unknown</td><td>1/88 (1%)</td></tr></table> <p>Concordance between primary and metastatic tumour samples for NRAS codon 61 mutation (per patient analysis)</p> <table><tr><td></td><td>Primary tumour mutation analysis positive for NRAS</td><td>Primary tumour mutation analysis negative for NRAS (wild type)</td></tr><tr><td>Metastatic tumour mutation analysis positive for NRAS</td><td>19</td><td>0</td></tr><tr><td>Metastatic tumour mutation analysis negative for NRAS (wild type)</td><td>1</td><td>33</td></tr></table> <p>Non interpretable results</p>	Site	Proportion from that site	Lymph node	50/88 (57%)	Skin	37/88 (42%)	Unknown	1/88 (1%)		Primary tumour mutation analysis positive for NRAS	Primary tumour mutation analysis negative for NRAS (wild type)	Metastatic tumour mutation analysis positive for NRAS	19	0	Metastatic tumour mutation analysis negative for NRAS (wild type)	1	33
Site	Proportion from that site																					
Lymph node	50/88 (57%)																					
Skin	37/88 (42%)																					
Unknown	1/88 (1%)																					
	Primary tumour mutation analysis positive for NRAS	Primary tumour mutation analysis negative for NRAS (wild type)																				
Metastatic tumour mutation analysis positive for NRAS	19	0																				
Metastatic tumour mutation analysis negative for NRAS (wild type)	1	33																				

Study	Study Type	Population	Intervention	Comparison	Outcomes Results														
					<table><tr><td></td><td>Primary tumour samples</td><td>Metastatic tumour samples</td><td>Overall</td></tr><tr><td>PCR-SSCP</td><td>N.R.</td><td>N.R.</td><td>N.R.</td></tr></table>		Primary tumour samples	Metastatic tumour samples	Overall	PCR-SSCP	N.R.	N.R.	N.R.						
	Primary tumour samples	Metastatic tumour samples	Overall																
PCR-SSCP	N.R.	N.R.	N.R.																
<i>Omholt (2003)</i>	Diagnostic Study	<p><u>Inclusion criteria:</u> Malignant melanoma primary tumour samples (N=52), metastatic tumour samples (N=82). Of these 51 were paired allowing within patient comparison. Samples were formalin fixed and paraffin embedded.</p> <p><u>Exclusion criteria:</u></p> <p><u>Clinical setting:</u> Secondary/tertiary care, Department of Oncology, Karolinska Hospital, Sweden.</p>	PCR single strand conformation polymorphism (PCR-SSCP) sequencing – screening for BRAF exon 11 and exon 15 mutations	N/A	<p>Origin of metastatic samples</p> <table><tr><th>Site</th><th>Proportion from that site</th></tr><tr><td>Lymph node</td><td>50/88 (57%)</td></tr><tr><td>Skin</td><td>37/88 (42%)</td></tr><tr><td>Unknown</td><td>1/88 (1%)</td></tr></table> <p>Concordance between primary and metastatic tumour samples for BRAF (per patient analysis, N=51)</p> <table><tr><td></td><td>Primary tumour mutation analysis positive for BRAF</td><td>Primary tumour mutation analysis negative for BRAF (wild type)</td></tr><tr><td>Metastatic tumour mutation analysis</td><td>N.R.</td><td>2</td></tr></table>	Site	Proportion from that site	Lymph node	50/88 (57%)	Skin	37/88 (42%)	Unknown	1/88 (1%)		Primary tumour mutation analysis positive for BRAF	Primary tumour mutation analysis negative for BRAF (wild type)	Metastatic tumour mutation analysis	N.R.	2
Site	Proportion from that site																		
Lymph node	50/88 (57%)																		
Skin	37/88 (42%)																		
Unknown	1/88 (1%)																		
	Primary tumour mutation analysis positive for BRAF	Primary tumour mutation analysis negative for BRAF (wild type)																	
Metastatic tumour mutation analysis	N.R.	2																	

Study	Study Type	Population	Intervention	Comparison	Outcomes Results								
					<table><tr><td>positive for BRAF</td><td></td><td></td></tr><tr><td>Metastatic tumour mutation analysis negative for BRAF (wild type)</td><td>0</td><td>N.R.</td></tr></table>	positive for BRAF			Metastatic tumour mutation analysis negative for BRAF (wild type)	0	N.R.		
					positive for BRAF								
					Metastatic tumour mutation analysis negative for BRAF (wild type)	0	N.R.						
					Non interpretable results								
<table><tr><td></td><td>Primary tumour samples</td><td>Metastatic tumour samples</td><td>Overall</td></tr><tr><td>PCR-SSCP</td><td>N.R.</td><td>N.R.</td><td>N.R.</td></tr></table>		Primary tumour samples	Metastatic tumour samples	Overall	PCR-SSCP	N.R.	N.R.	N.R.					
	Primary tumour samples	Metastatic tumour samples	Overall										
PCR-SSCP	N.R.	N.R.	N.R.										
Yancovitz (2012)	Diagnostic Study	<p><u>Inclusion criteria</u> Patients has stage III or IV melanoma. 112 tumour samples were analysed (94 metastatic, 18 primary)</p> <p><u>Exclusion criteria</u>: Not reported</p> <p><u>Clinical setting</u>: Not reported.</p>	Conventional sequencing	Mutation specific PCR	<p>Origin of metastatic samples</p> <table><tr><th>Site</th><th>Proportion from that site</th></tr><tr><td>Lymph node</td><td>43 (46%)</td></tr><tr><td>Skin</td><td>33 (35%)</td></tr><tr><td>Visceral</td><td>18 (19%)</td></tr></table> <p>Concordance between primary and metastatic tumour samples</p>	Site	Proportion from that site	Lymph node	43 (46%)	Skin	33 (35%)	Visceral	18 (19%)
Site	Proportion from that site												
Lymph node	43 (46%)												
Skin	33 (35%)												
Visceral	18 (19%)												

Study	Study Type	Population	Intervention	Comparison	Outcomes Results																					
					<div>for BRAF V600E mutation</div> <table><tr><td></td><td>Primary tumour mutation analysis positive for BRAF</td><td>Primary tumour mutation analysis negative for BRAF (wild type)</td></tr><tr><td>Metastatic tumour mutation analysis positive for BRAF</td><td>10</td><td>6</td></tr><tr><td>Metastatic tumour mutation analysis negative for BRAF (wild type)</td><td>2</td><td>0</td></tr></table> <div>Non interpretable results</div> <table><tr><td></td><td>Primary tumour samples</td><td>Metastatic tumour samples</td><td>Overall</td></tr><tr><td>MS-PCR</td><td>N.R.</td><td>N.R.</td><td>N.R.</td></tr><tr><td>Sequencing</td><td>N.R.</td><td>N.R.</td><td>N.R.</td></tr></table>		Primary tumour mutation analysis positive for BRAF	Primary tumour mutation analysis negative for BRAF (wild type)	Metastatic tumour mutation analysis positive for BRAF	10	6	Metastatic tumour mutation analysis negative for BRAF (wild type)	2	0		Primary tumour samples	Metastatic tumour samples	Overall	MS-PCR	N.R.	N.R.	N.R.	Sequencing	N.R.	N.R.	N.R.
	Primary tumour mutation analysis positive for BRAF	Primary tumour mutation analysis negative for BRAF (wild type)																								
Metastatic tumour mutation analysis positive for BRAF	10	6																								
Metastatic tumour mutation analysis negative for BRAF (wild type)	2	0																								
	Primary tumour samples	Metastatic tumour samples	Overall																							
MS-PCR	N.R.	N.R.	N.R.																							
Sequencing	N.R.	N.R.	N.R.																							

Study	Study Type	Population	Intervention	Comparison	Outcomes Results													
Yadzi (2012)	Diagnostic Study	<p><u>Inclusion criteria:</u> Malignant melanoma (N=20 patients), with both primary and metastatic tumour samples. Samples were formalin fixed paraffin embedded.</p> <p><u>Exclusion criteria:</u> Not reported</p> <p><u>Clinical setting:</u> Secondary/tertiary care, Germany</p>	Sequencing	N/A	<p>Origin of metastatic samples</p> <table><tr><th>Site</th><th>Proportion from that site</th></tr><tr><td>N.R.</td><td>N.R.</td></tr></table> <p>Concordance between primary and metastatic tumour samples for BRAF T1799A mutation</p> <table><tr><td></td><td>Primary tumour mutation analysis positive for BRAF</td><td>Primary tumour mutation analysis negative for BRAF (wild type)</td></tr><tr><td>Metastatic tumour mutation analysis positive for BRAF</td><td>6</td><td>5</td></tr><tr><td>Metastatic tumour mutation analysis negative for BRAF (wild type)</td><td>3</td><td>6</td></tr></table>	Site	Proportion from that site	N.R.	N.R.		Primary tumour mutation analysis positive for BRAF	Primary tumour mutation analysis negative for BRAF (wild type)	Metastatic tumour mutation analysis positive for BRAF	6	5	Metastatic tumour mutation analysis negative for BRAF (wild type)	3	6
Site	Proportion from that site																	
N.R.	N.R.																	
	Primary tumour mutation analysis positive for BRAF	Primary tumour mutation analysis negative for BRAF (wild type)																
Metastatic tumour mutation analysis positive for BRAF	6	5																
Metastatic tumour mutation analysis negative for BRAF (wild type)	3	6																

Study	Study Type	Population	Intervention	Comparison	Outcomes Results			
					Non interpretable results			
						Primary tumour samples	Metastatic tumour samples	Overall
					Sequencing	N.R.	N.R.	N.R.

2.5 Genetic testing in stage I-III melanoma

Review question: What is the role of genetic testing of the tumour at diagnosis for a person with early stage [I-III] melanoma?

Background

Early stage melanoma includes primary melanomas and melanomas with nodal/in-transit or satellite metastases, but no distant organ metastases present. Detecting genetic abnormalities early may be beneficial for the prevention or at least more effective treatment of distant secondary metastases. We would like to assess if genetic testing is beneficial in early stage disease, or later testing is more suited for the treatment of metastatic disease. It is important to see if the results of early tests can guide treatment.


There is no real alternative to genetic testing, but we need to assess its' usefulness in early disease. The timing of the testing is important, as well as the genetic mutation types, which may have different significance in relation to the melanoma subtypes.

Question in PICO format

Patients/population	Intervention	Comparison	Outcomes
Patients with melanoma at stage: Ia Ib& II IIla IIlb IIlc	Genetic testing of tumour at diagnosis	No genetic testing at diagnosis	<ul style="list-style-type: none"> • (Rate of stratification for treatment) • Prognosis estimation • Survival • Rate of recurrence • Failure to obtain a valid mutation test result • Treatment delays • Morbidity • HRQOL

1 **Search Results**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	2002-2013	864	71	18/11/2013
<i>Premedline</i>	2002-2013	38	4	18/11/2013
<i>Embase</i>	2002-2013	820	53	22/11/2013
<i>Cochrane Library</i>	2002-2013	1022	2	25/11/2013
<i>Web of Science (SCI & SSCI)</i>	2002-2013	514	11	20/11/2013
Total References retrieved (after de-duplication): 113				

2 **Screening Results**

3
4

Evidence statements

Our literature searches identified no studies comparing genetic testing at diagnosis with no genetic testing at diagnosis.

References

Excluded studies

G. J. Mann, G. M. Pupo, A. E. Campain, C. D. Carter, S. J. Schramm, S. Pianova, S. K. Gerega, Silva C. De, K. Lai, J. S. Wilmott, M. Synnott, P. Hersey, R. F. Kefford, J. F. Thompson, Y. H. Yang, and R. A. Scolyer. BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. *J.Invest.Dermatol.* 133 (2):509-517, 2013.

Reason: Does not compare testing at diagnosis with no testing at diagnosis

3. Staging of Melanoma

Review question: What is the most effective method of accurately staging melanoma in patients with clinicopathological stage IA melanoma?

Review question: What is the most effective method of accurately staging melanoma in patients with clinicopathological stage IB-IIC melanoma?

Review question: What is the most effective method of accurately staging melanoma in patients with clinicopathological stage III melanoma?

Review question: What is the most effective method of accurately staging melanoma in patients with clinicopathological stage IV melanoma?

Background

Skin melanoma is routinely treated with surgical excision. The removed skin melanoma is examined by the pathologist who will review the melanoma under a microscope. The pathologist will comment on the depth of skin penetration commonly called the Breslow thickness. The depth of penetration is an important marker of the aggressiveness of the tumour. Additional information including whether the melanoma is involving adjacent blood vessels or lymphatics plus whether the tumour has broken through the skin surface, ulceration, also inform patient and clinical team of the chances of cure from surgery and predicts the probability of whether the melanoma will spread to other parts of the body following the initial surgery. Spread of melanoma to local lymph nodes or other parts of the body can occur at any time. Thin melanomas are unlikely to spread and may be followed up clinically. Melanomas that are thicker or demonstrate ulceration or blood vessel or lymphatic infiltration have a high rate of spreading to other parts of the body. These pathological findings together with clinical examination and patient symptoms determine whether further imaging is required. There are many radiological techniques that can be used to image patients. These include SNB, US, CT, MRI, PET-CT and PET-MRI. We have to ask the following questions:

1. At what pathological and clinical stage do we image patients?
2. When imaging is required, what test do we choose and why?

Determining whether melanoma has spread or not informs both patient and clinical team of where the cancer is and allows informed decisions on treatment. Current treatment options available include chemotherapy, radiotherapy, immunotherapy, surgery or tumour ablative techniques. Treatment options for patients whose melanoma has spread to either the local lymph nodes or other parts of the body have rapidly changed within the last few years. Chemotherapy has recently proved to improve survival in selected patients. Additional questions to consider include:

3. What imaging technique is optimal in evaluating patient response assessment when receiving chemotherapy agents?
4. Can the more modern radiological techniques, including both functional and molecular techniques predict patients that may or may not benefit from chemotherapy?

The accuracy of a radiological technique is determined by the number of false negative and false positive results i.e. melanoma disease that we fail to detect on imaging and also findings we think

- 1 are melanoma that with biopsy, surgical removal or more commonly follow up imaging turn out to
- 2 be not that of melanoma.

3 Question in PICO Format

Population	Intervention (Index Test)	Comparator (Reference Standard)	Outcomes
Patients with clinicopathological stage IA melanoma	SLNB Ultrasound	<ul style="list-style-type: none"> Clinical examination Each Other 	<ol style="list-style-type: none"> True Positives/Negatives False Positives/Negatives Regional recurrence Melanoma specific Survival (5 & 10 yr) Overall survival (5 & 10 yr) HRQL Adverse events long term, inc: Lymphoedema Adverse Events short term surgical
Patients with clinicopathological stage IB-IIC melanoma	<ul style="list-style-type: none"> Ultrasound ±FNAC Targeted Ultrasound ±FNAC SLNB CT PET-CT Whole body MRI MR-PET 	<ul style="list-style-type: none"> Clinical Exam Each other 	<ol style="list-style-type: none"> True Positives/Negatives False Positives/Negatives Regional recurrence Melanoma specific Survival (5 & 10 yr) Overall survival (5 & 10 yr) Adverse events long term, inc: Lymphoedema HRQL Adverse Events short term surgical Change to treatment management
Patients with clinical stage III (palpable nodal disease) melanoma	<ul style="list-style-type: none"> FNAC±Ultrasound Core biopsy of the node CT (whole body, chest, abdo, pelvis) CT (brain and whole body) PET-CT Whole body MRI MR-PET 	Each other	<ol style="list-style-type: none"> Diagnostic accuracy of nodal disease Diagnostic accuracy for disease outside the nodal basin Melanoma specific Survival (5 & 10 yr) Metastasis free survival Overall survival (5 & 10 yr) HRQL Adverse events long term Adverse Events short term Change to treatment management
Patients with clinical changes suggestive of stage IV melanoma	<ul style="list-style-type: none"> CT (whole body, chest, abdo, pelvis) CT (brain and whole body) PET-CT Whole body MRI 	Each other	<ol style="list-style-type: none"> Diagnostic accuracy for sites of stage IV disease Melanoma specific Survival (5 & 10 yr) Metastasis free survival Overall survival (5 & 10 yr)

	<ul style="list-style-type: none"> MR-PET 		yr) 5. HRQL 6. Adverse events long term 7. Adverse Events short term 8. Change to treatment management
--	--	--	--

1 How will the information be searched?

Searches:	
Can we apply date limits to the search (Please provide information on any date limits we can apply to the searches for this topic? This can be done for each individual intervention as appropriate)	Searches were not carried out before 1994 as this was when the largest trial began recruiting and the GDG considered information before this time to be of little use to the review question.
Are there any study design filters to be used (RCT, systematic review, diagnostic test).	No filters were applied to the searches as the outcomes covered both clinical and diagnostic elements and therefore all available study types were considered necessary, particularly: Interventional studies which report the listed outcomes Prognostic studies may also be of relevance to this topic Diagnostic Accuracy studies including RCTs if available
List useful search terms. (This can include such information as any alternative names for the interventions etc)	Post surgical morbidity Stratification criteria for RCT SNB as eligibility criterion for RCT Prognosis MSLT1 MSLT2 Peg-INTRON EORTC trial melanoma 1. change in stage 2. change in management 3. clinical impact of diagnostic tests / imaging 4. impact on decision making / treatment plan

2 The Review Strategy

Relevant studies will be identified through sifting the abstracts and excluding studies clearly not relevant to the PICO. In the case of relevant or potentially relevant studies, the full paper will be ordered and reviewed, whereupon studies considered not to be relevant to the topic will be excluded.

Studies which are identified as relevant will be critically appraised and quality assessed using GRADE methodology and NICE checklists. Data relating to the identified outcomes will be extracted from relevant studies.

- 1 If possible a meta-analysis of available study data will be carried out to provide a more complete
- 2 picture of the evidence body as a whole.
- 3 An evidence summary outlining key issues such as volume, applicability and quality of evidence and
- 4 presenting the key findings from the evidence as it relates to the topic of interest will be produced.

5 Search Results

6 E1

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	1946-2014	1556	264	13/01/2014
<i>Premedline</i>	Jan 6 2014	79	10	07/01/2014
<i>Embase</i>	1947-2014	2089	355	28/01/2014
<i>Cochrane Library</i>	Issue 1, 12 Jan 2014	47	18	14/01/2014
<i>Web of Science (SCI & SSCI)</i>	1900-2014	1383	367	29/01/2014

7 Updates

Database name	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	75	13	07/10/2014
<i>Premedline</i>	7	1	07/10/2014
<i>Embase</i>	52	15	07/10/2014
<i>Cochrane Library</i>	0	0	07/10/2014
<i>Web of Science (SCI & SSCI)</i>	63	17	07/10/2014

8 E2

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	1946-2014	1888	367	05/02/2014
<i>Premedline</i>	Feb 4 2014	89	16	05/02/2014
<i>Embase</i>	1947-2014	3197	577	12/02/2014

<i>Cochrane Library</i>	Issue 2, Feb 2014	93	26	05/02/2014
<i>Web of Science (SCI & SSCI)</i>	1900-2014	1880	436	11/02/2014

1 Updates

Database name	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	87	26	07/10/2014
<i>Premedline</i>	14	3	07/10/2014
<i>Embase</i>	100	29	07/10/2014
<i>Cochrane Library</i>	1	0	07/10/2014
<i>Web of Science (SCI & SSCI)</i>	71	20	07/10/2014

2 E3

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	1946-2014	935	197	26/02/2014
<i>Premedline</i>	Feb 25 2014	60	12	26/02/2014
<i>Embase</i>	1947-2014	1970	214	06/03/2014
<i>Cochrane Library</i>	Issue 2, Feb 2014	71	13	26/02/2014
<i>Web of Science (SCI & SSCI)</i>	1900-2014	858	171	03/03/2014

3 Updates

Database name	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	48	15	07/10/2014
<i>Premedline</i>	11	1	07/10/2014
<i>Embase</i>	69	16	07/10/2014
<i>Cochrane Library</i>	1	0	07/10/2014

Web of Science (SCI & SSCI)	45	5	07/10/2014
--	----	---	------------

1 **E4**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
Medline	1946-2014	538	186	10/03/2014
Premedline	Mar 07 2014	44	10	10/03/2014
Embase	1947-2014	1428	169	12/03/2014
Cochrane Library	Issue 2, Feb 2014	55	9	11/03/2014
Web of Science (SCI & SSCI)	1900-2014	845	161	11/03/2014

2 **Updates**

Database name	No of references found	No of references retrieved	Finish date of search
Medline	38	7	07/10/2014
Premedline	5	0	07/10/2014
Embase	58	7	07/10/2014
Cochrane Library	1	0	07/10/2014
Web of Science (SCI & SSCI)	43	3	07/10/2014

3 **Total references in all databases combined (merged and de-duplicated): 1373**4 **Medline search strategy** (*This search strategy is adapted to each database*)5 **E1**

- 6 1. exp Melanoma/
- 7 2. melanoma\$.tw.
- 8 3. (maligna\$ adj1 lentigo\$).tw.
- 9 4. (hutchinson\$ adj1 (freckle\$ or melano\$)).tw.
- 10 5. dubreuilh.tw.
- 11 6. LMM.tw.
- 12 7. or/1-6
- 13 8. exp neoplasm staging/
- 14 9. *cancer staging/
- 15 10. (stag\$ or restag\$ or re-stag\$ or upstag* or classif* or TNM or stratif*).tw.

- 1 11. or/8-10
- 2 12. 7 and 11
- 3 13. exp Sentinel Lymph Node Biopsy/
- 4 14. ((sentinel and node) adj biops*).tw.
- 5 15. (sentinel adj1 lymphadenectom*).tw.
- 6 16. ((sentinel and node) adj dissect*).tw.
- 7 17. ((sentinel and node) adj procedure).tw.
- 8 18. ((sentinel and node) adj detection).tw.
- 9 19. (SNLB or SNB).tw.
- 10 20. or/13-19
- 11 21. exp Physical Examination/
- 12 22. ((clinical or physical) adj exam*).tw.
- 13 23. ((clinical or physical) adj assess*).tw.
- 14 24. *Palpation/
- 15 25. palpat*.tw.
- 16 26. or/21-25
- 17 27. exp Ultrasonography/
- 18 28. (ultraso* or sonogra* or echogra* or echotomogra*).tw.
- 19 29. 27 or 28
- 20 30. 20 or 26 or 29
- 21 31. 12 and 30
- 22 32. limit 31 to yr="1994 -Current"
- 23 **E2**
- 24 1. exp Melanoma/
- 25 2. melanoma\$.tw.
- 26 3. 1 or 2
- 27 4. exp Neoplasm Staging/
- 28 5. *Cancer Staging/
- 29 6. (stag\$ or restag\$ or re-stag\$ or upstag* or classif* or TNM or stratif*).tw.
- 30 7. or/4-6
- 31 8. 3 and 7
- 32 9. exp Physical Examination/
- 33 10. ((clinical or physical) adj exam*).tw.
- 34 11. ((clinical or physical) adj assess*).tw.
- 35 12. *Palpation/
- 36 13. palpat*.tw.
- 37 14. or/9-13
- 38 15. exp Ultrasonography/
- 39 16. (ultraso* or sonogra* or echogra* or echotomogra*).tw.
- 40 17. 15 or 16
- 41 18. *Diagnostic Imaging/
- 42 19. exp Radionuclide Imaging/
- 43 20. (radionuclide adj1 (scan* or imaging)).tw.
- 44 21. exp Magnetic Resonance Imaging/

- 1 22. magnet* resonance.tw.
- 2 23. (MRI or MRI*1 or NMR*1).tw.
- 3 24. (MR adj (imag* or scan*)).tw.
- 4 25. (magnet* adj (imag* or scan*)).tw.
- 5 26. (magneti?ation adj3 imaging).tw.
- 6 27. (wbmr* or whole body mr*).tw.
- 7 28. Whole Body Imaging/
- 8 29. exp Tomography/
- 9 30. exp Tomography, X-Ray Computed/
- 10 31. PET*1.tw.
- 11 32. PET-CT.tw.
- 12 33. (comput* adj1 tomogra*).tw.
- 13 34. ((diffusion or planar or echoplanar or functional or nuclear or radionuclide or radioisotope or
- 14 conventional) adj2 (scan* or imag* or tomogra*)).tw.
- 15 35. (FDG-PET or FES-PET or 18F-FDG-PET or FLT-PET).tw.
- 16 36. ((CT or CAT) adj (scan* or imaging or examination)).tw.
- 17 37. (PET adj (scan* or imaging or examination)).tw.
- 18 38. positron emission tomograph.tw.
- 19 39. scintigraph*.tw.
- 20 40. or/18-39
- 21 41. exp Biopsy, Fine-Needle/
- 22 42. (fine needle adj1 (biops* or cytolog*)).tw.
- 23 43. (FNAC or FNA).tw.
- 24 44. or/41-43
- 25 45. 14 or 17 or 40 or 44
- 26 46. 8 and 45
- 27 47. limit 46 to yr="1994 -Current"

28 **E3**

- 29 1. exp Melanoma/
- 30 2. melanoma\$.tw.
- 31 3. 1 or 2
- 32 4. exp Neoplasm Staging/
- 33 5. *Cancer Staging/
- 34 6. (stag\$ or restag\$ or re-stag\$ or upstag* or classif* or TNM or stratif*).tw.
- 35 7. or/4-6
- 36 8. 3 and 7
- 37 9. exp Physical Examination/
- 38 10. ((clinical or physical) adj exam*).tw.
- 39 11. ((clinical or physical) adj assess*).tw.
- 40 12. *Palpation/
- 41 13. palpat*.tw.
- 42 14. or/9-13
- 43 15. exp Ultrasonography/
- 44 16. (ultraso* or sonogra* or echogra* or echotomogra*).tw.

- 1 17. 15 or 16
- 2 18. *Diagnostic Imaging/
- 3 19. exp Radionuclide Imaging/
- 4 20. (radionuclide adj1 (scan* or imaging)).tw.
- 5 21. exp Magnetic Resonance Imaging/
- 6 22. magnet* resonance.tw.
- 7 23. (MRI or MRI*1 or NMR*1).tw.
- 8 24. (MR adj (imag* or scan*)).tw.
- 9 25. (magnet* adj (imag* or scan*)).tw.
- 10 26. (magneti?ation adj3 imaging).tw.
- 11 27. (wbmr* or whole body mr*).tw.
- 12 28. Whole Body Imaging/
- 13 29. exp Tomography/
- 14 30. exp Tomography, X-Ray Computed/
- 15 31. PET*1.tw.
- 16 32. PET-CT.tw.
- 17 33. (comput* adj1 tomogra*).tw.
- 18 34. ((diffusion or planar or echoplanar or functional or nuclear or radionuclide or radioisotope or
- 19 conventional) adj2 (scan* or imag* or tomogra*)).tw.
- 20 35. (FDG-PET or FES-PET or 18F-FDG-PET or FLT-PET).tw.
- 21 36. ((CT or CAT) adj (scan* or imaging or examination)).tw.
- 22 37. (PET adj (scan* or imaging or examination)).tw.
- 23 38. positron emission tomograph.tw.
- 24 39. scintigraph*.tw.
- 25 40. or/18-39
- 26 41. exp Biopsy, Fine-Needle/
- 27 42. (fine needle adj1 (biops* or cytolog*)).tw.
- 28 43. (FNAC or FNA).tw.
- 29 44. or/41-43
- 30 45. 14 or 17 or 40 or 44
- 31 46. 8 and 45
- 32 47. limit 46 to yr="1994 -Current"

33 **E4**

- 34 1. exp Melanoma/
- 35 2. melanoma\$.tw.
- 36 3. 1 or 2
- 37 4. exp Neoplasm Staging/
- 38 5. *Cancer Staging/
- 39 6. (stag\$ or restag\$ or re-stag\$ or upstag* or classif* or TNM or stratif*).tw.
- 40 7. or/4-6
- 41 8. 3 and 7
- 42 9. exp Magnetic Resonance Imaging/
- 43 10. magnet* resonance.tw.
- 44 11. (MRI or MRI*1 or NMR*1).tw.

- 1 12. (MR adj (imag* or scan*)).tw.
- 2 13. (magnet* adj (imag* or scan*)).tw.
- 3 14. (magneti?ation adj3 imaging).tw.
- 4 15. (wbmr* or whole body mr*).tw.
- 5 16. Whole Body Imaging/
- 6 17. exp Tomography/
- 7 18. exp Tomography, X-Ray Computed/
- 8 19. PET*1.tw.
- 9 20. (PET-CT or PETCT).tw.
- 10 21. (comput* adj1 tomogra*).tw.
- 11 22. ((diffusion or planar or echoplanar or functional or nuclear or radionuclide or radioisotope or
- 12 conventional) adj2 (scan* or imag* or tomogra*)).tw.
- 13 23. (FDG-PET or FES-PET or 18F-FDG-PET or FLT-PET).tw.
- 14 24. (MRPET or MR-PET).tw.
- 15 25. ((CT or CAT) adj (scan* or imaging or examination)).tw.
- 16 26. (PET adj (scan* or imaging or examination)).tw.
- 17 27. positron emission tomograph.tw.
- 18 28. scintigraph*.tw.
- 19 29. or/9-28
- 20 30. 8 and 29
- 21 31. limit 30 to yr="1994 -Current"
- 22

1 **Screening Results**

2 Due to the high degree of overlap between the studies found for each of the individual stages of
3 Melanoma, all four individual databases were combined and sifted as one single search with a total
4 of 1322 references. The database was sifted and studies selected firstly according to which stage
5 they were potentially relevant to and secondly according to whether they related to clinical or
6 diagnostic outcomes.




Table 3.1-3.3: Characteristics of included studies**3.1 Diagnostic Meta-Analysis**

Study	Study Design	Population included	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis
Acland et al (2000)	Retrospective		54	PET	Positive Histology/Disease Progression	Scans
Acland et al (2000)	Retrospective		54	PET	Histology and clinical follow-up mean 25 months (range 22-47 months)	Scans
Acland et al (2001)	Prospective	>1mm thick or lymphatic invasion	50	PET	Sentinel node biopsy and clinical follow-up of up to 13 months (range 5-26 months)	Patients
Agnese et al (2007)	Retrospective		755	SLNB	Histology	
Aukema et al (2010)	Retrospective		70	PET	Biopsy, clinical follow-up, further imaging	Scans
Bachter et al (2001)	Retrospective		256	SLNB	Histology	
Basler et al (1997)	Retrospective			FNAC	Histology/Follow-up	
Bastiaannet et al (2011)	Prospective		253	PET	Biopsy, clinical follow-up, further imaging	Scans

Study	Study Design	Population included	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis
Belhocine et al (2002)	Prospective	Early stage melanoma	21	PET	Sentinel node biopsy and clinical follow-up 12 months	Patients
Berk et al (2005)	Retrospective		274	SLNB	Histology	
Blessing et al (1995)	Retrospective		19	PET	Histopathology or follow-up	
Blessing et al (1995)	Retrospective		19	Ultrasound	Histopathology or follow-up	
Blumenthal et al (2002)	Retrospective	Stage IB-II	60	SLNB	Histology	
Borgogoni et al (2004)	Retrospective		385	SLNB	Histology	
Brady et al (2006)	Prospective		103	CT		Patients
Cangiarella et al (2000)	Retrospective	Clinically suspicious lymph nodes	115	FNAC	Histology/Follow-up	Lymph Nodes
Caraco et al (2004)	Retrospective		331	SLNB	Histology	

Study	Study Design	Population included	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis
Cascinelli et al (2006)	Retrospective		1108	SLNB	Histology	
Cascinelli et al (2000)	Retrospective	Stage IB-II	829	SLNB	Histology	
Cecchi et al (2006)	Retrospective		111	SLNB	Histology	
Chakera et al (2004)	Retrospective		243	SLNB	Histology	
Chao et al (2002)	Retrospective		1183	SLNB	Histology	
Clark et al (2006)	Retrospective	T2-T4 melanoma	64	PET		Patients
Corrigan et al (2006)	Retrospective		149	SLNB	Histology	
Crippa et al (2000)	Prospective	Clinical/Instrument detected lymph node metastases	38	PET	Lymph node dissection plus histology	Regional Lymph Nodes
Dalal et al (2007)	Retrospective		1046	SLNB	Histology	

Study	Study Design	Population included	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis
Dalle et al (2006)	Retrospective			FNAC	Histology/Follow-up	
Damian et al (1996)	Retrospective	Stage II-IV	100	PET	Clinical exam, scans and/or histopathology	metastases
De Giorgi et al (2007)	Retrospective		104	SLNB	Histology	
Doting et al (2002)	Retrospective	Stage I-II	200	SLNB	Histology	
Eigtved et al (2000)	Prospective		38	PET	Histopathology and clinical follow-up	Patients
Estourgie et al (2003)	Prospective		250	SLNB	Histology	
Fincher et al (2003)	Retrospective	All stages	198	SLNB	Histology	
Fink et al (2004)	Prospective	>1mm thick with no palpable lymph nodes	48	PET	Sentinel node biopsy and clinical follow up 12 months	Patients
Finkelstein et al (2004)	Prospective	Stage IV	18	PET	Histopathology and clinical follow-up (median 24 months)	

Study	Study Design	Population included	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis
Gad et al (2006)	Retrospective		278	SLNB	Histology	
Gershenwald et al (1998)	Retrospective	Primary cutaneous melanoma	317	SLNB	Histology	
Gipponi et al (2005)	Retrospective		175	SLNB	Histology	
Gomez-Rivera et al (2008)	Retrospective		113	SLNB	Histology	
Hafner et al (2004)	Prospective	All patients with melanoma	100	PET	Histopathology and clinical follow-up 6 and 12 months	
Hafner et al (2004)	Prospective	All patients with melanoma	100	Ultrasound	Sentinel node biopsy and clinical follow-up 6 months and 12 months	
Hafner et al (2004)	Prospective	All patients with melanoma	100	US/PET	Histopathology and clinical follow-up 6 and 12 months	
Hafstrom et al (1980)	Retrospective			FNAC	Histology/Follow-up	
Harlow et al (2001)	Retrospective	Clinically node negative	336	SLNB	Histology	

Study	Study Design	Population included	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis
		melanoma				
Havenga et al (2003)	Prospective	>1mm thick with no palpable lymph nodes	45	PET		Regional Lymph Nodes
Hershko et al (2006)	Retrospective		64	SLNB	Histology	
Hinz et al (2011)	Prospective	Any cutaneous melanoma	81	Ultrasound		
Hocevar et al (2004)	Retrospective	Unclear	57	Ultrasound	Histology	Patients
Horn et al (2006)	Retrospective	Cutaneous melanoma & subclinical lymph node metastases	33	PET	Biopsy, clinical follow-up, further imaging	Patients
Kettlewell et al (2006)	Prospective		482	SLNB		
Klein et al (2000)	Prospective	Patients with cutaneous melanoma	17	PET	Sentinel node biopsy and clinical follow-up of up to 22 months	Scans
Klein et al	Prospective	Patients with cutaneous	17	PET	Clinical follow-up 3-19 months	

Study	Study Design	Population included	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis
(2000)		melanoma				
Kokoska et al (2001)	Prospective	>1mm thick with clinically negative nodes	18	PET		
Koskivuo et al (2007)	Retrospective		305	SLNB	Histology	
Landi et al (2000)	Retrospective	Stage I-II	455	SLNB	Histology	
Longo et al (2003)	Prospective	≥1mm	25	PET	Sentinel node biopsy and clinical follow-up >10 months (range 10-29)	
MacFarlane et al (1998)	Prospective	Stage II-III	23	PET	Lymph node dissection plus histology	Patients
Macripo et al (2004)	Prospective		274	SLNB	Histology	
Manca et al (2003)	Retrospective		127	SLNB	Histology	
Mattsson et al (2008)	Retrospective		422	SLNB	Histology	

Study	Study Design	Population included	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis
Maubec et al (2007)	Prospective	>4mm thick	25	PET		Patients
Medina-Franco et al (2001)	Retrospective		54	SLNB	Histology	
Moehrle et al (2004)	Retrospective		283	SLNB	Histology	
Morton et al (2003)	Retrospective		1599	SLNB	Histology	
Morton et al (2006)	Retrospective		769	SLNB	Histology	
Murali et al (2007)	Retrospective			Image guided FNAC	Histology/Follow-up	
Murali et al (2007)	Retrospective			Palpation guided FNAC	Histology/Follow-up	
Nowecki et al (2006)	Retrospective		1207	SLNB	Histology	
Paquet et al (2000)	Retrospective		24	PET	Sentinel Node biopsy and clinical follow-up of 18 months	scans

Study	Study Design	Population included	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis
Perry et al (1986)	Retrospective			FNAC	Histology/Follow-up	
Pfannenberget al (2007)	Prospective	Stage III/IV melanoma	64	PET		Lesions
Pfannenberget al (2007)	Prospective	Stage III/IV melanoma	64	PET-CT		Lesions
Pfluger et al (2011)	Retrospective		50	PET	Biopsy, clinical follow-up	Scans
Reinhardt et al (2002)	Retrospective	>0.75mm & Clarks level III-IV	67	PET	Clinical, conventional images and/or biopsy. Clinical follow-up ≥6 months	Scans
Rex et al (2005)	Retrospective		240	SLNB	Histology	
Rodriguues et al (2000)	Retrospective			FNAC	Histology/Follow-up	
Roka et al (2005)	Retrospective		309	SLNB	Histology	
Rossi et al (2000)	Retrospective	All patients with melanoma	69	Ultrasound		

Study	Study Design	Population included	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis
Rossi et al (2003)	Prospective	>1mm thick cutaneous melanoma	125	Ultrasound		Regional Lymph Nodes
Roulin et al (2008)	Retrospective		327	SLNB	Histology	
Schmalbach et al (2003)	Retrospective		80	SLNB	Histology	
Schmid-Weber et al (2004)	Prospective	Lesions suspicious of metastases	22	Ultrasound		
Schoegen et al (1993)	Retrospective			FNAC	Histology/Follow-up	
Sibon et al (2007)	Prospective	≤1mm thick or ulcerated cutaneous melanoma	131	Ultrasound	Histology	Regional Lymph Nodes
Starrit et al (2005)	Prospective	All patients with melanoma	304	Ultrasound		Patients with histologically confirmed metastases

Study	Study Design	Population included	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis
Stas et al (2002)	Retrospective	patients with regional or distant recurrence or with suspected recurrence on conventional screening	84	PET	Clinical, conventional images and/or biopsy. Clinical follow-up ≥ 12 months	Lesions
Steinart et al (1995)	Prospective		33	PET	\geq conventional imaging or histopathology	
Stewart et al (2005)	Retrospective		178	SLNB	Histology	
Swetter et al (2002)	Retrospective		104	PET	Clinical, conventional images and/or biopsy	
Teltzrow et al (2007)	Retrospective		106	SLNB	Histology	
Testori et al (2005)	Prospective	Stage I	88	Ultrasound	Histology	Regional Lymph Nodes
Testori et al (2009)	Prospective		1313	SLNB		
Tyler et al	Prospective	Clinically evident stage III lymph	95	PET	Clinical, conventional images and/or biopsy. Clinical follow-up	Lesions

Study	Study Design	Population included	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis
(2000)		node and/or in transit metastases			≥6 months	
Van Akkooi et al (2006)	Retrospective		262	SLNB	Histology	
van Rijk et al (2006)	Prospective	Patients with cutaneous melanoma eligible for SLNB	107	Ultrasound		
Veit-Haibach et al (2009)	Prospective	Any cutaneous melanoma	74	PET-CT		
Veit-Haibach et al (2009)	Prospective	Any cutaneous melanoma	74	PET-CT		
Vereecken et al (2005)	Prospective	Intermediate/Poor prognosis melanoma	43	PET	Sentinel node biopsy and clinical follow-up 6 months	Patients
Vereecken et al (2005)	Prospective	Intermediate/Poor prognosis melanoma	43	PET	Sentinel node biopsy and clinical follow-up 6 months	Lesions
Vidal Sicart et al (2003)	Retrospective		435	SLNB		

Study	Study Design	Population included	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis
Voit et al (2000)	Retrospective			Image guided FNAC	Histology/Follow-up	
Voit et al (2000)	Retrospective			Palpation guided FNAC	Histology/Follow-up	
Voit et al (2006)	Prospective	>1mm thick	127	Ultrasound		Patients
Voit et al (2014)	Retrospective	≥1.00mm thick	1000	Ultrasound ± FNAC ± SLNB	Histology	Patients
Vucetic et al (2006)	Retrospective		201	SLNB	Histology	
Vuylsteke et al (2003)	Retrospective		209	SLNB	Histology	
Wagner et al (1997)	Prospective	Stage I-II	12	PET	Lymph node dissection plus histology	
Wagner et al (1999)	Prospective	Stage I-III	74	PET	Sentinel lymph node biopsy and follow-up	
Wagner et al (2003)	Retrospective		408	SLNB		
Wagner et al (2005)	Prospective	>1mm thick early stage melanoma	144	PET	Sentinel node biopsy and clinical follow-up ≥ 6 months	Regional Lymph

Study	Study Design	Population included	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis
						Nodes
Wagner et al (2005)	Prospective	Stage I-II	136	PET	Clinical , conventional images and/or biopsy	
Wagner et al (2005)	Prospective	Stage I-III	136	PET	Clinical follow-up median 41.4 months	
Wagner et al (2011)	Retrospective		46	PET	Biopsy, clinical follow-up, further imaging	Scans
Wagner et al (2011)	Retrospective	Histologically proven melanoma with metastatic involvement of the sentinel lymph node and clinically exempt of metastases	46	PET-CT	Biopsy, clinical follow-up, further imaging	Distant Metastases
Wasserberg et al (2004)	Retrospective		250	SLNB	Histology	
Yancovitz et al (2007)	Retrospective	Stage T1b-3b, clinically node negative and no distant metastasis	158	PET-CT		Scans

Study	Study Design	Population included	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis
Yee et al (2005)	Retrospective		1012	SLNB	Histology	
Zeelen et al (1990)	Retrospective			FNAC	Histology/Follow-up	

Table 3.2 Clinical Outcomes

Study	Study Type	Population	Aim	Intervention	Comparison	Outcomes
Faries et al (2010)	Randomised Controlled Trial	N=225 patients who underwent wide local excision with SLNB and early complete lymph node dissection	To investigate whether early lymph node dissection was associated with less morbidity than delayed dissection at the time of clinical recurrence	Wide local excision + SLNB + CLND	Wide local excision + delayed CLND	Acute Toxicity including: Wound separation, seroma/hematoma, haemorrhage, infection, thrombophlebitis, urinary tract infection, pneumonia and cardiac complications Chronic Toxicity including lymphoedema and nerve dysfunction
Freeman et al (2013)	Systematic review and Meta-analysis	Articles which evaluated the risk of overall survival and mortality according to SLN status in patients with melanoma.	To determine whether SLN status provides significant prognostic information in addition to Breslow thickness alone	Positive Sentinel Lymph Node Biopsy	Negative Sentinel Lymph Node Biopsy	Overall Survival
Harlow et al (2001)	Prospective Case Series	N=336 with biopsy proven invasive cutaneous melanoma (Clark level II or higher)	To determine the success rate of identifying and removing sentinel lymph nodes in melanoma patients and to determine the rate of disease recurrence, location of recurrence and overall	Sentinel Node Biopsy	N/A	Disease Recurrence Location of recurrence Overall Survival

Study	Study Type	Population	Aim	Intervention	Comparison	Outcomes
			survival rates for patients			
Kettlewell et al 2006	Observational Case Series	N=472 patients (482 SNB procedures)	To determine whether sentinel node status adds prognostic information to that gained from measuring tumour thickness	SLNB	N/A	Time to Recurrence Death from Melanoma
Kunte et al (2010)	Prospective Case Series	N=1049 patients with melanoma stage 1/11 scheduled to undergo SLNB	To evaluate the effect of tumour characteristics and SLN status on disease free survival	SLNB	N/A	Disease Free Survival Overall Survival
Moehrle et al (2004)	Prognostic Case Series Study	N=283 patients with sentinel lymph node biopsy in clinical stage I/II between 1996- 1999.	To determine the prognostic significance of histological status of sentinel lymph node biopsy in regard to overall survival, disease free survival and survival without distant metastases.	Sentinel Lymph Node Biopsy	N/A	Recurrence Disease Free Survival Survival without distant metastases Overall Survival
Morton et al (2014)	Randomised Controlled Trial	Intervention Arm N=1000 Control Arm N=661	To determine whether sentinel-node biopsy could be used to identify patients with clinically occult nodal metastases and whether immediate-completion	Wide excision of primary melanoma plus sentinel-node biopsy (60%) with immediate	Wide excision plus post- operative nodal observation (40%) with	Primary Outcomes Melanoma specific survival

Study	Study Type	Population	Aim	Intervention	Comparison	Outcomes
			lymphadenectomy yielded better outcomes than complete lymphadenectomy performed only when nodal recurrence was revealed during observation	lymphadenectomy if metastases were detected	lymphadenectomy if nodal metastases developed during observation	Secondary Outcomes Disease free survival Incidence Timing Anatomic distribution of distant metastases Morbidity of procedures Significance of TA90 levels Incidence of Sentinel Node Metastases (biopsy) vs. Clinical metastases (observation) Accuracy of LM
Voit et al (2014)	Retrospective Case Series	To evaluate the increased experience with sentinel lymph node biopsy as an addition to US-FNAC	N=1,000	Ultrasound ± FNAC ± SLNB	N/A	Disease Free Survival Melanoma Specific Survival
Wasserberg et al (2004)	Retrospective Case Series	To determine the incidence and severity of SLNB	N=250 patients with malignant melanoma who underwent SLNB between	SLNB	N/A	Wound Complications Sensory Complications

Study	Study Type	Population	Aim	Intervention	Comparison	Outcomes
		related complications over the long term and to identify possible risk factors	1994 and 2002. Median age was 56.5 years (range 17-84 years)			Other Complications

Table 3.3 Children and Adolescents

Study	Study Type	Population	Aim	Intervention	Comparison	Outcomes
Butter et al (2005)	Retrospective Case Series	N=12 patients aged <18 years with cutaneous melanoma	To review the experience with paediatric cutaneous melanoma and SLNB	SLNB		Disease free survival Overall Survival
Howman-Giles et al (2009)	Retrospective Case Series	N=55 patients aged <20 years with stage I-II cutaneous melanoma	To assess outcomes in young patients undergoing SLNB for intermediate thickness localised melanoma	SLNB	N/A	Overall Survival
Pacella et al (2003)	Retrospective Case Series	N=7 patients aged between 4-11 years with biopsy proven melanoma or a borderline melanocytic lesion of uncertain	To determine the clinical utility of intraoperative lymph node mapping and sentinel lymph node biopsy	SLNB		Unclear

		biologic potential.			
Raval et al (2010)	Retrospective Review	N=671 patients aged <18 years with invasive melanoma	To assess the utilisation of SLNB in children with melanoma, to determine the clinicopathological, socioeconomic or hospital level factors associated with SLNB use and to identify factors associated with lymph node metastases in children with melanoma	SLNB	Factors impacting SLNB Lymph node metastases
Roaten et al (2005)	Retrospective Case Series	N=20 patients aged <21 years undergoing SLNBX for melanoma or other melanocytic skin lesions	To determine outcomes and complications of children and adolescents undergoing SLNBX	SLNB	Adverse events (complications)
Toro et al (2003)	Retrospective Case Series	N=12 patients aged <18 years with clinically node negative melanoma	To investigate the use of SLNB in the paediatric population focusing on its diagnostic and therapeutic implications	SLNB	Recurrence Adverse Events (complications)

Study Quality


Diagnostic Outcomes

Evidence for the diagnostic outcomes was taken primarily from a number of systematic reviews and supplemented where necessary with data from any other relevant studies. Overall the quality of the evidence for diagnostic outcomes ranged from low to high quality for a number of reasons.

There were no randomised trials of any of the diagnostic interventions and as a result the studies included in the meta-analysis were at high risk of bias with the included populations highly selected for SLNB or imaging and in many cases it was unclear whether the intervention was being utilised as part of staging at diagnosis or as part of follow-up and surveillance.

Other reasons for downgrading the quality of the evidence were similar across the studies and included unmet quality criteria relating to insufficient reporting of patient withdrawals, intermediate results and selection and training of raters (Xing et al, 2010) Several potential sources of bias with many studies failing to report inclusion and exclusion criteria as well as not reporting sufficient population information. Other possible sources of bias identified included potential review bias resulting from a lack of blinding of test reviewers. In many cases, test results were not blinded for reference test results or index test results and only a small proportion of included studies reported how to deal with indeterminate results (Krug et al, 2008).

Figure 3.1 Diagnostic Study Quality



Clinical Outcomes

One systematic review and meta-analysis, 1 randomised trial and 1 cohort study were identified to inform the clinical outcomes of interest. Evidence was only available for sentinel lymph node biopsy and the quality of the evidence ranged from high to very low as assessed by GRADE.

1 **Children and Adolescents**

2 Evidence relating to children and adolescents specifically was limited and very low in quality as
3 assessed by GRADE. A total of 5 studies, all retrospective reviews with small sample sizes and looking
4 only at SLNB, provided the evidence for this topic.

5

Evidence Statements

Diagnostic Outcomes

Patients with clinically negative nodes

Breslow thickness

Evidence from a randomized trial (Morton et al, 2014), a systematic review (Lens et al, 2002) and an observational study (Han et al 2013) shows that in patients undergoing sentinel lymph node biopsy, Breslow thickness is associated with the likelihood of a positive result (see figure 4). In those with a Breslow thickness of 0.75mm or less (Lens et al 2002; Han et al, 2013) the positive sentinel lymph node rate was 1% to 3%. This compares with 6% for those with a Breslow thickness of 0.75mm to 1.0mm (Han et al 2013) and 8% for those with a Breslow thickness of 0.75mm to 1.5mm (Lens et al 2002).

Sentinel lymph node biopsy (SLNB)

Meta-analysis of 47 studies indicates a sensitivity and specificity of 86.6% and 100% respectively for SLNB. Clinical stage was I or II where mentioned and it was likely that these SLNB studies only included patients with clinically negative nodes given their relatively low prevalence of positive nodes (ranging from 9% to 41%; see Table 1), compared to the studies of other tests.

Imaging (Ultrasound or PET)

In patients with clinical stage I melanoma, US had a sensitivity of 49.5% and specificity of 91.9% (from meta-analysis of 3 studies; see Table 1). In patients with clinical stage I-II primary melanoma, PET had a sensitivity of 22.3% and specificity of 94.9% for the detection of regional lymph node metastases (from meta-analysis of 4 studies; see Table 1).

Voit et al (2014) used lymphoscintigraphy to target ultrasound at the sentinel node in patients scheduled for SLNB. Any suspicious nodes on US underwent FNAC, with the rationale that patients with positive FNAC could be spared the morbidity of surgical SLNB. The sensitivity of targeted ultrasound and FNAC for lymph node metastasis was 50% with 99% specificity. According to these figures about half of those with positive nodes could avoid surgical SLNB, but the absolute number of patients spared SLNB would depend on the prevalence of lymph node metastasis.

Patients with clinically positive nodes

FNAC for regional nodes

The evidence about FNAC came from studies with relatively a high prevalence of positive nodes (ranging from 48% to 87%; see Table 1), where the patients included were more likely than not to have a positive node. It is assumed that FNAC was used as a targeted test for clinically or radiologically suspicious nodes, rather than as a routine test in all patients. Meta-analysis indicated a sensitivity and specificity of FNAC for the identification of regional lymph node metastasis of 95.7% and 97.8% respectively (12 studies)

PET for regional nodes

In patients with clinical stage II-III primary melanoma, PET had a sensitivity of 64.7% and specificity of 93.9% for the detection of regional lymph node metastases (3 studies).

Imaging for any metastasis (including distant metastasis)

Meta-analysis of available data for each modality reported a sensitivity and specificity of PET for the identification of any metastases of 87.4% and 88.6% respectively (5 studies) compared with a sensitivity and specificity of 90.6% and 77.2% for PET-CT (1 study).

In patients with clinical stage III-IV primary melanoma, PET had a sensitivity of 70.4% and specificity of 83.7% for the detection of any metastases (1 study).

Table 3.4 Diagnostic accuracy of tests for identifying regional nodes

FNAC

Stage	N studies (N data points)	Prevalence	Sensitivity (95% CI)	Specificity (95%CI)	LR+ (95%CI)	LR-(95%CI)
Any	12 (3203)	48% to 87%	95.7% (93.2% to 97.4%)	97.8% (96.1% to 98.8%)	46.5 (24.0 to 81.9)	0.04 (0.03 to 0.07)
I	-	-	-	-	-	-
I,II	-	-	-	-	-	-
II	-	-	-	-	-	-
II,III	-	-	-	-	-	-
III	-	-	-	-	-	-
III,IV	-	-	-	-	-	-
IV	-	-	-	-	-	-

PET

Stage	N studies (N data points)	Prevalence	Sensitivity (95% CI)	Specificity (95%CI)	LR+ (95%CI)	LR-(95%CI)
Any	9 (753)	15% to 66%	51.3% (26.3% to 75.6%)	92.4% (86.3% to 95.9%)	6.6 (3.9 to 10.7)	0.5 (0.3 to 0.8)
I	-	-	-	-	-	-
I,II	4 (433)	15% to 29%	22.3% (15.1% to 31.6%)	94.9% (86.6% to 98.2%)	5.2 (1.4 to 13.6)	0.8 (0.7 to 0.9)
II	-	-	-	-	-	-
II,III	3 (175)	29% to 66%	64.7% (8.9% to 97.2%)	93.9% (65.0% to 99.8%)	10.5 (2.6 to 28.0)	0.4 (0.01 to 0.9)
III	1 (83)	46%	73.7%	93.3%	13	0.3
III,IV	-	-	-	-	-	-
IV	-	-	-	-	-	-

Ultrasound

Stage	N studies (N data points)	Prevalence	Sensitivity (95% CI)	Specificity (95%CI)	LR+ (95%CI)	LR-(95%CI)
Any	7 (868)	16% to 46%	53.5% (25.7% to 79.3%)	88.0% (81.0% to 92.7%)	4.5 (2.2 to 7.6)	0.5 (0.2 to 0.8)
I	3 (510)	16% to 26%	49.5% (8.9% to 90.8%)	91.9% (87.5% to 94.8%)	6.0 (1.3 to 11.3)	0.5 (0.1 to 1.0)
I,II	-	-	-	-	-	-
II	-	-	-	-	-	-

II,III	1 (97)	27%	7.7%	87.3%	0.8	1.1
III	1 (83)	46%	76.3%	93.3%	13.4	0.3
III,IV	-	-	-	-	-	-
IV	-	-	-	-	-	-

1


2

SLNB


Stage	N studies (N data points)	Prevalence	Sensitivity (95% CI)	Specificity (95%CI)	LR+ (95%CI)	LR-(95%CI)
Any	47 (19607)	9% to 41%	86.6% (84.6% to 88.4%))	100%	407 (266 to 598)	0.1 (0.1 to 0.2)
I	-	-	-	-	-	-
I,II	5 (1766)	16% to 25%	88.7% (76.1% to 95.1%)	100%	460 (104 to 1330)	0.1 (0.05 to 0.2)
II	-	-	-	-	-	-
II,III	-	-	-	-	-	-
III	-	-	-	-	-	-
III,IV	-	-	-	-	-	-
IV	-	-	-	-	-	-

3


1 **Figure 3.2 Tests for identifying positive regional nodes**



2



3



4


5

Table 3.5. Any metastasis**PET**


Stage	N studies (N data points)	Prevalence	Sensitivity (95% CI)	Specificity (95%CI)	LR+ (95%CI)	LR-(95%CI)
Any	5 (965)	23% to 90%	87.4% (38.9% to 98.7%)	88.6% (77.6% to 94.6%)	7.6 (3.6 to 14.0)	0.2 (0.02 to 0.7)
I	1 (184)	23%	20.9%	97.2%	8.6	0.8
I,II	-	-	-	-	-	-
II	-	-	-	-	-	-
II,III	-	-	-	-	-	-
III	-	-	-	-	-	-
III,IV	1 (420)	70%	70.4%	83.7%	4.4	0.4
IV	-	-	-	-	-	-

PET-CT

Stage	N studies (N data points)	Prevalence	Sensitivity (95% CI)	Specificity (95%CI)	LR+ (95%CI)	LR- (95%CI)
Any	1 (420)	71%	90.6%	77.2%	4.0	0.1
I	-	-	-	-	-	-
I,II	-	-	-	-	-	-
II	-	-	-	-	-	-
II,III	-	-	-	-	-	-
III	-	-	-	-	-	-
III,IV	-	-	-	-	-	-
IV	-	-	-	-	-	-

Figure 3.3: any metastasis

1 **Figure 3.4 Sentinel Node Positivity and Breslow thickness**



1 Clinical Outcomes

2 From one moderate quality randomised trial (Morton et al, 2014) comparing sentinel node biopsy
3 with nodal observation in a total of 1661 patients, disease free survival in patients with intermediate
4 thickness melanoma was significantly higher in the biopsy group (HR 0.75 95% CI 0.62-0.94;
5 $p=0.001$) but there was no significant difference in 10 year melanoma specific survival.

6 From one moderate quality randomised trial (Morton et al, 2014) comparing sentinel node biopsy
7 with nodal observation in a total of 1661 patients, disease free survival in patients with thick
8 melanoma was significantly higher in the biopsy group (HR 0.7 95% CI 0.5-0.96; $p=0.003$) and no
9 significant difference was observed between the groups for 10 year melanoma specific survival

10 From one moderate quality randomised trial (Morton et al, 2014) comparing sentinel node biopsy
11 with nodal observation in a total of 1661 patients, in patients with no nodal metastases (no tumour
12 on biopsy or during clinical observation), no treatment related difference in 10 year melanoma
13 specific survival rates was observed between patients in the biopsy group compared with the
14 observation group for either intermediate or thick melanomas.

15 From one systematic review and meta-analysis (Freeman et al, 2013), pooled results from six studies
16 showed that in patients with tumours $\geq 4\text{mm}$, SLN positive patients were more likely to die compared
17 with SLN negative patients (HR=2.42, 95% CI 2.00-2.92).

18 From one low quality, retrospective case series study including 1,000 patients (Voit et al, 2014), 5
19 year Kaplan-Meier estimated melanoma specific survival was 95% for patients with a negative US-
20 FNAC compared with 59% for patients with a positive US-FNAC ($p<0.001$) and the 5 year Kaplan-
21 Meier estimated disease free survival was 84% for patients with a negative US-FNAC compared with
22 33% for patients with a positive US-FNAC ($p<0.001$).

23 From one low quality, retrospective case series study including 1,000 patients (Voit et al, 2014), 5
24 year Kaplan-Meier estimated melanoma specific survival per SN tumour burden was 96% for SN
25 negative patients versus 100% for patients with metastases $<0.1\text{mm}$ in diameter. 5 year Kaplan-
26 Meier estimated melanoma specific survival for patients with metastases 0.1-1.0mm was 73%
27 ($p<0.001$). 5 year Kaplan-Meier estimated melanoma specific survival for patients with lesions
28 $>1.0\text{mm}$ was 68% ($p<0.001$), 57% ($p<0.001$) for patients with a lymph node dissection or unknown
29 SN tumour burden.

30 Corresponding disease free survival estimates were 87% for SN negative patients compared with
31 83% for patients with $<0.1\text{mm}$ lesions ($p=0.45$) versus 49% in patients with lesions 0.1-1.0mm
32 ($p<0.001$) versus 37% for patients with lesions $>1.0\text{mm}$ ($p<0.001$) versus 33% for LND or unknown SN
33 tumour burden patients ($p<0.001$).

34 From one high quality randomised trial (Faries et al, 2010) lymphoedema was significantly more
35 common in the delayed CLND group (20.4% vs. 12.4%, $p=0.04$) lymphoedema was strongly
36 associated with basin site with 9% oedema after axillary dissection and 26.6% oedema after inguinal
37 dissection ($p<0.001$).

- 1 Complications related directly to surgery occurred in 62/309 nodal basins and were strongly
- 2 associated with location of melanoma in the extremities ($p=0.0002$), specifically sentinel node
- 3 retrieval from the groin ($p=0.001$)
- 4 One retrospective case series study including 250 patients (Wasserberg et al, 2004) reported wound
- 5 complications in 42/309 basins. Independent factors significantly associated with wound infection
- 6 included inguinal SLNB ($p=0.001$) and primary lesion in the extremity ($p=0.02$)
- 7 One retrospective case series study including 250 patients (Wasserberg et al, 2004) reported nerve
- 8 related complications in 14 basins. Age younger than 50 years ($p=0.003$), axillary site ($p=0.04$) and
- 9 number of excised sentinel nodes (>2) ($p=0.02$) were found to be independent prognostic indicators
- 10 of sensory/mobility complications.

1 **GRADE Table 3.1: What is the most effective method of accurately staging melanoma in patients with clinicopathological stage I-IV melanoma?**

Quality assessment							Summary of findings				
							No of patients		Effect		Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Positive Sentinel Node Biopsy	Negative Sentinel Node Biopsy	Relative (95% CI)	Absolute	
Overall Survival (Freeman et al, 2013)											
6 (n=936 breslow depth ≥4mm)	observational studies	serious ¹	no serious inconsistency ³	no serious indirectness	no serious imprecision	none	?/393 ⁵	?/543 ⁵	HR 2.42 (2.00 to 2.92)		Very Low
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Wide excision of primary melanoma plus sentinel-node biopsy with immediate lymphadenectomy if metastases were detected	Wide excision plus post-operative nodal observation with lymphadanectomy if nodal metastases developed during observation	Relative (95% CI)	Absolute	Quality
Disease Free Survival (Morton et al, 2014)											
1(n=1661)	randomised trials	Serious ²	no serious inconsistency	no serious indirectness	no serious imprecision	none	Disease free survival was significantly higher in the biopsy group for both intermediate thickness and thick melanomas		Intermediate thickness HR 0.75 95% CI 0.62-0.94		Moderate
									Thick melanoma HR 0.7 95% CI 0.5-0.96		
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Ultrasound ± FNAC	Ultrasound ± FNAC + SLNB	Relative (95% CI)	Absolute	Quality
Disease Free Survival (Voit et al 2014)											

1(n=1000)	Observational Study	Serious ⁴	No Inconsistency	No Indirectness	No Imprecision	None			5 year Kaplan-Meier estimated disease free survival was 84% for patients with a negative US-FNAC compared with 33% for patients with a positive US-FNAC		Low
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Ultrasound ± FNAC	Ultrasound ± FNAC + SLNB	Relative (95% CI)	Absolute	Quality
Melanoma Specific Survival (Voit et al 2014)											
1 (n=1000)	Observational Study	Serious ⁴	No Inconsistency	No Indirectness	No Imprecision	None			5 year Kaplan-Meier estimated melanoma specific survival was 95% for patients with a negative US-FNAC compared with 59% for patients with a positive US-FNAC		Low
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Wide local excision + SLNB + CLND	Wide local excision + delayed CLND	Relative (95% CI)	Absolute	Quality
Adverse Events (Acute Toxicity) (Faries et al (2010))											
1(n=255)	RCT	None	No Inconsistency	No Indirectness	No Imprecision	None	lymphoedema was significantly more common in the delayed CLND group (20.4% vs. 12.4%, p=0.04) lymphoedema was strongly associated with basin site		-		High
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	SLNB	None	Relative (95% CI)	Absolute	Quality
Adverse Events (wound/sensory complications) (Wasserberg et al, 2004)											

1(n=250)	Observational Study	Serious ⁴	No Inconsistency	No Indirectness	No Imprecision	None	wound complications reported in 42/309 basins. nerve related complications reported in 14 basins.	-	Low
----------	---------------------	----------------------	------------------	-----------------	----------------	------	--	---	-----

1 ¹This was a systematic review and meta-analysis which included 29 cohort studies of which it was possible to include 6 studies in a meta-analysis. ²The was a risk of bias due to selective outcome reporting (the
2 results for the group of patients with thin melanomas were not reported). ³No serious heterogeneity ($I^2=34\%$) ⁴ Retrospective Case Series study ⁵The study does not report the number of events in each of the groups
3 just the pooled HR for the six studies which indicates that survival is better in the patients with a negative SLNB.
4

Children and Adolescents

From one retrospective study including 55 patients aged <20 years with stage I-II cutaneous melanoma (Howman-Giles et al; 2009) the SLNB positivity rate was 25% (14/55) and children aged <10 years had a higher SLNB positivity rate than those aged ≥10 years (33% versus 17%)

From one retrospective study including 55 patients aged <20 years with stage I-II cutaneous melanoma (Howman-Giles et al; 2009) overall survival was 94.1% for the total population and in the SLNB positive patients overall survival was 79%.

From one retrospective study (Toro et al; 2003) including 12 patients aged <18 years with clinically node negative melanoma no complications were reported as a result of SLNB.

GRADE Table 3.2: Should Sentinel lymph node biopsy be used for staging of melanoma in children and adolescents?

Quality assessment							
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Quality
Overall Survival							
5	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	VERY LOW
Disease Free Survival							
3	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	VERY LOW
Adverse Events							
1	observational studies	very serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	VERY LOW

¹ All studies were retrospective case series studies with very small sample sizes

² Small sample sizes in all of the studies

References

Included

- Brent-Roaten et al (2005) Sentinel Lymph Node Biopsy for Melanoma and Other Melanocytic Tumours in Adolescents *Journal of Paediatric Surgery* 40:232-235
- Butter et al (2005) Melanoma in Children and the use of sentinel lymph node biopsy *Journal of Paediatric Surgery* 40:797-800
- Faries et al (2010) The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the multicentre selective lymphadenectomy trial (I) *Annals of Surgical Oncology* 17:3324-3329
- Freeman et al (2013) Prognostic Value of Sentinel Lymph Node Biopsy Compared with that of Breslow Thickness: Implications for Informed Consent in Patients with Invasive Melanoma *Dermatologic Surgery* 39;12
- Hafner J et al (2004) Clinical and Laboratory Investigations Baseline Staging in Cutaneous Melanoma *British Journal of Dermatology* 150;677-686
- Hall B et al (2013) Fine Needle Aspiration Cytology for the Diagnosis of Metastatic Melanoma *American Journal of Clinical Pathology* 140;635-642
- Han D et al (2013) Clinicopathological predictors of sentinel lymph node metastasis in thin melanoma *Journal of Clinical Oncology* 31;35:4387-4393
- Hocevar M et al (2004) The Role of preoperative ultrasonography in reducing the number of sentinel lymph node procedures in melanoma *Melanoma Research* 14;533-536
- Howman-Giles et al (2010) Sentinel Lymph Node Biopsy in Paediatric and Adolescent Cutaneous Melanoma Patients *Annals of Surgical Oncology* 17:138-143
- Jimenez-Requena F et al (2010) Meta-analysis of the performance of ¹⁸F-FDG PET in cutaneous melanoma *European Journal of Nuclear and Molecular Imaging* 37:284-300
- Klein M et al (2000) Contribution of Whole Body F-18-FDG-PET and lymphoscintigraphy to the Assessment of Regional and Distant Metastases in Cutaneous Malignant Melanoma *Nuklearmedizin* 39;3:56-61
- Krug B et al (2008) Role of PET in the initial staging of cutaneous malignant melanoma: systematic review *Radiology* 249;3:836-844
- Lens M et al (2002) Tumour thickness as a predictor of occult lymph node metastases in patients with stage I and II melanoma undergoing sentinel lymph node biopsy *British Journal of Surgery*
- Maubec E et al (2007) F-18 fluorodeoxy D glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4mm *Melanoma Research* 17;3:147-154
- Mijnhout S et al (2001) Systematic Review of the Diagnostic Accuracy of ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography in Melanoma Patients *Cancer* 91;8:1530-1542
- Morton et al (2014) Final trial report of sentinel node biopsy versus nodal observation in melanoma *New England Journal of Medicine* 370;7:599-609

- 1 Pacella et al (2003) The Utility of Sentinel Lymph Node Biopsy in Head and Neck Melanoma in the
2 Paediatric Population *Plast. Reconstr. Surg* 112;1257
- 3 Paquet P et al (2000) An Appraisal of 18-Fluorodeoxyglucose Positron Emission Tomography for
4 Melanoma Staging *Dermatology* 200;167-169
- 5 Raval et al (2010) Use of Sentinel Lymph Node Biopsy for Melanoma in Children and Adolescents
6 *Journal of Surgical Oncology* 102:634-639
- 7 Roaten et al (2005) Sentinel Lymph node biopsy for melanoma and other melanocytic tumours in
8 adolescents *Journal of Paediatric Surgery* 40;232-235
- 9 Reindhardt M. J. Et al (2002) Value of tumour marker S-100B in Melanoma Patients: A Comparison to
10 18-FDG-PET and clinical data *Nuklearmedizin* 41;3:143-147
- 11 Rodriguez-Rivera A et al (2014) Value of positron emission tomography scan in stage III cutaneous
12 melanoma: a systematic review and meta-analysis *Surgical Oncology* 23;11-16
- 13 Sibon C et al (2007) The contribution of high resolution ultrasonography in preoperatively detecting
14 sentinel node metastases in melanoma patients *Melanoma Research* 17;4:233-238
- 15 Starrit E et al (2005) Ultrasound examination of sentinel nodes in the initial assessment of patients
16 with primary cutaneous melanoma *Annals of Surgical Oncology* 12;1:18-23
- 17 Testori A et al (2005) The Role of Ultrasound of Sentinel Nodes in the Pre and Post Operative
18 evaluation of stage I melanoma patients *Melanoma Research* 15;3:191-198
- 19 Toro J et al (2003) Sentinel Lymph node biopsy in children and adolescents with malignant
20 melanoma *Journal of Paediatric Surgery* 38;7:1063-1065
- 21 Valsecchi M et al (2011) Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients with
22 Melanoma: A Meta-analysis *Journal of Oncology* 29;11:1479-1487
- 23 Voit C et al (2014) Ultrasound guided fine needle aspiration cytology as an addendum to sentinel
24 lymph node biopsy can perfect the staging strategy in melanoma patients *European Journal of*
25 *Cancer* 50;2880-2288
- 26 Wasserberg et al (2004) Sentinel Lymph Node Biopsy (SLNB) for Melanoma is not Complication Free
27 *European Journal of Surgical Oncology* 30;851-856
- 28 Xing Y et al (2010) Contemporary Diagnostic Imaging Modalities for the Staging and Surveillance of
29 Melanoma Patients: A Meta-Analysis *Journal of the National Cancer Institute* 103;129-142
- 30 Yancovitz M et al (2007) Role of Radiologic Imaging at the Time of Initial Diagnosis of Stage T1b-T3b
31 Melanoma *Cancer* 110;5:1107-1114

32

Evidence Tables

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
Acland et al (2000) (2x2 taken from Jimenez-Requena et al, 2010)	Retrospective	High (taken from Jimenez-Requena et al, 2010)		Stage I-III	Stage I (<1.5mm/≥1.5mm /Total); Stage II (Recurrence&sate llites); Stage III and Stage IV	54	PET	Positive Histology/ Disease Progression	Scans	62	18	5	5	34
Acland et al (2000) (taken from Jimenez-Requena et al, 2010)	Retrospective	High (taken from Jimenez-Requena et al, 2010)		Stage I-IV	Melanoma metastases	54	PET	Histology and clinical follow-up mean 25 months (range 22-47 months)	Scans	62	18	5	5	34
Acland et al (2001) (2x2	Prospective	High (taken from Krug et	>1mm thick or lymphatic	Stage IB-IIIC		50	PET	Sentinel node biopsy and clinical	Patients	50	0	7	8	35

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
<i>taken from Krug et al, 2008)</i>		<i>al, 2008)</i>	invasion					follow-up of up to 13 months (range 5-26 months)						
Agnese et al (2007) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	755	SLNB	Histology		739	112	0	30	597
Aukema et al (2010) <i>(2x2 taken from Rodriguez-Rivera et al, 2014)</i>	Retrospective	Moderate (taken from Rodriguez-Rivera et al, 2014)		T1-4N1-3M0		70	PET	Biopsy, clinical follow-up, further imaging	Scans	70	26	1	4	39

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
<i>et al, 2014))</i>														
Bachter et al (2001) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	Low <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	256	SLNB	Histology		253	41	0	1	211
Basler et al (1997) <i>(2x2 taken from Hall et al, 2013)</i>	Retrospective	Moderate <i>(taken from Hall et al, 2013)</i>			Regional Lymph Nodes		FNAC	Histology/Follow-up			24	0	0	26
Bastiaansen et al (2011) <i>(2x2)</i>	Prospective	Moderate <i>(taken from</i>		T1-4N1-3M0		253	PET	Biopsy, clinical follow-up, further	Scans	253	68	12	11	162

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
<i>taken from Rodriguez-Rivera et al, 2014)</i>		<i>Rodriguez-Rivera et al, 2014))</i>						imaging						
Belhocine et al (2002) <i>(2x2 taken from Krug et al, 2008)</i>	Prospective	High <i>(taken from Krug et al, 2008)</i>	Early stage melanoma	Stage I-II		21	PET	Sentinel node biopsy and clinical follow-up 12 months	Patients	21	1	1	5	14
Berk et al (2005) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	274	SLNB	Histology		260	39	0	10	211

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
Blessing et al (1995) (2x2 taken from Krug et al, 2008)	Retrospective	Moderate (taken from Krug et al, 2008)		Stage III	Regional Lymph Nodes	19	PET	Histopathology or follow-up			28	3	10	42
Blessing et al (1995) (2x2 taken from Krug et al, 2008)	Retrospective	Moderate (taken from Krug et al, 2008)		Stage III	Regional Lymph Nodes	19	Ultrasound	Histopathology or follow-up			29	3	9	42
Blumenthal et al (2002) (2x2 taken from Valsecchi et al, 2008)	Retrospective	Moderate (taken from Valsecchi et al, 2008)	Stage IB-II	Stage IB-II	Regional Lymph Nodes	60	SLNB	Histology		60	11	0	0	49

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
<i>i et al, 2011)</i>		2011)												
Borgogoni et al (2004) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	385	SLNB	Histology		375	75	0	8	292
Brady et al (2006) <i>(2x2 taken from Krug et al, 2008)</i>	Prospective	Low <i>(Taken from Krug et al, 2008)</i>		Stage IIC-IV		103	CT		Patients	103	30	5	14	54
Cangiarella et al (2000) <i>(2x2)</i>	Retrospective	Moderate <i>(taken from Hall et al,</i>	Clinically suspicious lymph nodes		Regional Lymph Nodes	115	FNAC	Histology/Follow-up	Lymph Nodes	133	95	0	2	33

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
<i>taken from Hall et al, 2013)</i>		2013)												
Caraco et al (2004) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	331	SLNB	Histology		325	68	0	13	244
Cascinelli et al (2006) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	High <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	1108	SLNB	Histology		1108	176	0	47	885

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
Cascinelli et al (2000) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>	Stage IB-II	Stage IB-II	Regional Lymph Nodes	829	SLNB	Histology		730	141	0	40	549
Cecchi et al (2006) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	111	SLNB	Histology		111	17	0	3	91
Chakera et al (2004) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	243	SLNB	Histology		236	53	0	3	180

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
<i>from Valsecchi et al, 2011)</i>		<i>et al, 2011)</i>												
Chao et al (2002) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	1183	SLNB	Histology		1183	233	0	11	939
Clark et al (2006) <i>(2x2 taken from Krug et al, 2008)</i>	Retrospective	Moderate <i>(taken from Krug et al, 2008)</i>	T2-T4 melanoma	Stage IB-Stage IIIC		64	PET		Patients	64	2	2	15	45
Corrigan et al (2006)	Retrospective	Moderate <i>(taken</i>			Regional Lymph Nodes	149	SLNB	Histology		131	46	0	8	77

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
<i>(2x2 taken from Valsecchi et al, 2011)</i>		<i>from Valsecchi et al, 2011)</i>												
Crippa et al (2000) <i>(2x2 taken from Krug et al, 2008)</i>	Prospective	Moderate <i>(taken from Crippa et al, 2008)</i>	Clinical/Instrument detected lymph node metastases	Stage IIB-IIIC		38	PET	Lymph node dissection plus histology	Regional Lymph Nodes	56	35	3	2	16
Dalal et al (2007) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	1046	SLNB	Histology		1046	164	0	28	854

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
Dalle et al (2006) <i>(2x2 taken from Hall et al, 2013)</i>	Retrospective	Moderate <i>(taken from Hall et al, 2013)</i>			Regional Lymph Nodes		FNAC	Histology/Follow-up			56	2	1	49
Damian et al (1997) <i>(2x2 taken from Jimenez-Requena et al, 2010)</i>	Retrospective	Moderate <i>(taken from Jimenez-Requena et al, 2010)</i>	Stage II-IV	Stage II-IV	Recurrent disease	100	PET	Clinical exam, scans and/or histopathology	metastases	415	388		28	
De Giorgi et al (2007) <i>(2x2 taken from Valsecchi)</i>	Retrospective	Moderate <i>(taken from Valsecchi)</i>			Regional Lymph Nodes	104	SLNB	Histology		104		0	6	98

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
<i>from Valsecchi et al, 2011)</i>		<i>et al, 2011)</i>												
Doting et al (2002) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>	Stage I-II	Stage I-II	Regional Lymph Nodes	200	SLNB	Histology		197	48	0	2	147
Eigtved et al (2000) <i>(2x2 taken from Krug et al, 2008)</i>	Prospective	Moderate <i>(taken from Krug et al, 2008)</i>		Stage I-II		38	PET	Histopathology and clinical follow-up	Patients	38	28	4	1	5

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
Estourgie et al (2003) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Prospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	250	SLNB	Histology		250	60	0	7	183
Fincher et al (2003) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>	All stages		Regional Lymph Nodes	198	SLNB	Histology		198	38	0	1	159
Fink et al (2004) <i>(2x2 taken from Jimenez-</i>	Prospective	High <i>(taken from Jimenez-</i>	>1mm thick with no palpable	Stage IB-IIC		48	PET	Sentinel node biopsy and clinical	Patients	48	1	0	7	40

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
<i>from Krug et al, 2008)</i>		<i>Requena et al, 2010)</i>	lymph nodes					follow up 12 months						
Finkelstein et al (2004) <i>(2x2 taken from Krug et al, 2008)</i>	Prospective	High <i>(taken from Krug et al, 2008)</i>	Stage IV	Stage IV	Melanoma metastasis/Recurrent Disease	18	PET	Histopathology and clinical follow-up (median 24 months)	Lesions	94	38	6	10	40
Gad et al (2006) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	278	SLNB	Histology		273	79	0	4	190
Gershenswald et al (1998)	Retrospective	Moderate <i>(taken</i>	Primary cutaneous		Regional Lymph Nodes	317	SLNB	Histology		295	52	0	7	236

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
<i>(2x2 taken from Valsecchi et al, 2011)</i>		<i>from Valsecchi et al, 2011)</i>	melanoma											
Gipponi et al (2005) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	175	SLNB	Histology		169	38	0	6	125
Gomez-Rivera et al (2008) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	113	SLNB	Histology		113	23	0	5	85

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
<i>i et al, 2011)</i>														
Hafner et al (2004)	Prospective	High (taken from Jimenez-Requena et al, 2010)	All patients with melanoma	Stage II-III	Regional Lymph Nodes	100	PET	Histopathology and clinical follow-up 6 and 12 months		101	2	0	24	74
Hafner et al (2004)	Prospective	High (taken from Jimenez-Requena et al, 2010)	All patients with melanoma	Stage II-IV	Regional Lymph Nodes	100	Ultrasound	Sentinel node biopsy and clinical follow-up 6 months and 12 months		101	2	9	24	62
Hafner et al (2004)	Prospective	High	All patients with melanoma	Stage II-III	Regional Lymph Nodes	100	US/PET	Histopathology and clinical follow-up 6 and 12		101	3	9	23	62

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
								months						
Hafstrom et al (1980) <i>(2x2 taken from Hall et al, 2013)</i>	Retrospective	Moderate <i>(taken from Hall et al, 2013)</i>			Regional Lymph Nodes		FNAC	Histology/Follow-up			45	2	3	37
Harlow et al (2001) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>	Clinically node negative melanoma		Regional Lymph Nodes	336	SLNB	Histology		329	39	0	12	278
Havenga et al (2003) <i>(2x2</i>	Prospective	Moderate <i>(taken from Krug et</i>	>1mm thick with no palpable	Stage IB-IIC		45	PET		Regional Lymph Nodes	45	2	5	11	27

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
<i>taken from Krug et al, 2008)</i>		<i>al, 2008)</i>	lymph nodes											
Hershko et al (2006) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	64	SLNB	Histology		64	5	0	1	58
Hinz et al (2011) <i>(2x2 taken from original publication)</i>	Prospective	Low	Any cutaneous melanoma	Stage I-IV		81	Ultrasound			81	2	3	4	0

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
Hocevar et al (2004) <i>(2x2 table taken from original publication)</i>	Retrospective	Low	Unclear	Stages IA-III A	Regional Lymph Nodes	57	Ultrasound	Histology	Patients	57	10	7	4	36
Horn et al (2006) <i>(2x2 taken from Rodriguez-Rivera et al, 2014)</i>	Retrospective	Low-Moderate <i>(taken from Rodriguez-Rivera et al, 2014)</i>	Cutaneous melanoma & subclinical lymph node metastases	Stage III		33	PET	Biopsy, clinical follow-up, further imaging	Patients	33	4	5	1	23
Kettlewell et al (2006)	Prospective	Moderate <i>(taken</i>			Regional Lymph Nodes	482	SLNB			472	105	0	12	355

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
<i>(2x2 taken from Valsecchi et al, 2011)</i>		<i>from Valsecchi et al, 2011)</i>												
Klein et al (2000) <i>(2x2 table taken from original publication)</i>	Prospective	Moderate <i>(taken from Jimenez-Requena et al, 2010)</i>	Patients with cutaneous melanoma	Stage I-II	Regional Lymph Nodes	17	PET	Sentinel node biopsy and clinical follow-up of up to 22 months	Scans	20	2	0	1	17
Kokoska et al (2001)	Prospective		>1mm thick with clinically negative nodes	Stage IB-IIA		18	PET							

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
Koskivuo et al (2007) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	305	SLNB	Histology		297	50	0	5	242
Landi et al (2000) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>	Stage I-II	Stage I-II	Regional Lymph Nodes	455	SLNB	Histology		450	75	0	4	371
Longo et al (2003) <i>(taken from Jimenez-Requena)</i>	Prospective	Medium <i>(taken from Jimenez-Requena)</i>	≥1mm	Stage IB-IIIC		25	PET	Sentinel node biopsy and clinical follow-up			2		7	

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
<i>Requena et al, 2010)</i>		<i>et al, 2010)</i>						>10 months (range 10-29)						
MacFarlane et al (1998) <i>(2x2 Jimenez-Requena et al, 2010)</i>	Prospective	Moderate <i>(taken from Jimenez-Requena et al, 2010)</i>	Stage II-III	Stage II-III	Regional Lymph Nodes	23	PET	Lymph node dissection plus histology	Patients	22	10	1	2	9
Macripo et al (2004) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Prospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	274	SLNB	Histology		270	46	0	10	214

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
Manca et al (2003) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	127	SLNB	Histology		127	21	0	6	100
Mattsos et al (2008) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	422	SLNB	Histology		409	79	0	12	318
Maubec et al (2007)	Prospective		>4mm thick	Stage IIB-IV	None	25	PET		Patients	25	1	5	5	14

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
Medina-Franco et al (2001) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	54	SLNB	Histology		35	4	0	1	30
Moehrle et al (2004) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	283	SLNB	Histology		283	38	0	11	234
Morton et al (2003)	Retrospective	Moderate <i>(taken</i>			Regional Lymph Nodes	1599	SLNB	Histology		1599	322	0	33	1244

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
<i>(2x2 taken from Valsecchi et al, 2011)</i>		<i>from Valsecchi et al, 2011)</i>												
Morton et al (2006) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	High <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	769	SLNB	Histology		764	122	0	26	616
Murali et al (2007) <i>(2x2 taken from Hall et al, 2013)</i>	Retrospective	Moderate <i>(taken from Hall et al, 2013)</i>			Regional Lymph Nodes		Image guided FNAC	Histology/Follow-up			63	0	3	45

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
Murali et al (2007) <i>(2x2 taken from Hall et al, 2013)</i>	Retrospective	Moderate <i>(taken from Hall et al, 2013)</i>			Regional Lymph Nodes		Palpation guided FNAC	Histology/Follow-up			780	5	30	416
Nowecki et al (2006) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	1207	SLNB	Histology		1207	228	0	57	922
Paquet et al (2000) <i>(2x2 table taken)</i>	Retrospective	Low				24	PET	Sentinel Node biopsy and clinical follow-up of 18	scans	28	8	2	3	15

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
<i>from original publication)</i>								months						
Perry et al (1986) <i>(2x2 taken from Hall et al, 2013)</i>	Retrospective	Moderate <i>(taken from Hall et al, 2013)</i>			Regional Lymph Nodes		FNAC	Histology/Follow-up			160	3	25	65
Pfannenberget al (2007) <i>(2x2 taken from Krug et al, 2008)</i>	Prospective	N/R <i>(missing from supplementary tables of Krug et al, 2008)</i>	Stage III/IV melanoma	Stage III/IV melanoma		64	PET		Lesions	420	209	20	88	103
Pfannenberget al (2007) <i>(2x2</i>	Prospective	N/R <i>(missing from supplement</i>	Stage III/IV melanoma	Stage III/IV melanoma		64	PET-CT		Lesions	420	269	28	28	95

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
<i>taken from Krug et al, 2008)</i>		<i>entary tables of Krug et al, 2008)</i>	ma	a										
Pfluger et al (2011) <i>(2x2 taken from Rodriguez-Rivera et al, 2014)</i>	Retrospective	Low-Moderate <i>(taken from Rodriguez-Rivera et al (2014)</i>		T1-4N1-3M0		50	PET	Biopsy, clinical follow-up	Scans	232	151	6	0	75
Reinhardt et al (2002) <i>(2x2 table taken from original publication)</i>	Retrospective	Medium	>0.75mm & Clarks level III-IV		Regional Lymph Nodes/Distant Metastases	67	PET	Clinical, conventional images and/or biopsy. Clinical follow-up ≥6 months	Scans	67	60	2	0	5

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
on)														
Rex et al (2005) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	240	SLNB	Histology		240	50	0	8	182
Rodriguez et al (2000) <i>(2x2 taken from Hall et al, 2013)</i>	Retrospective	Moderate <i>(taken from Hall et al, 2013)</i>					FNAC	Histology/Follow-up			85	1	0	12
Roka et al (2005) <i>(2x2 taken from ...)</i>	Retrospective	Moderate <i>(taken from ...)</i>			Regional Lymph Nodes	309	SLNB	Histology		299	69	0	7	223

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
<i>from Valsecchi et al, 2011)</i>		<i>Valsecchi et al, 2011)</i>												
Rossi et al (2003) <i>(2x2 taken from original publication)</i>	Prospective	Low	>1mm thick cutaneous melanoma	Stage IA-IB		125	Ultrasound		Regional Lymph Nodes	140	12	0	19	109
Roulin et al (2008) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	327	SLNB	Histology		327	74	0	7	246
Schmalbach et al	Retrospective	Moderate			Regional Lymph	80	SLNB	Histology		77	14	0	3	60

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
(2003) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Active	Low <i>(taken from Valsecchi et al, 2011)</i>			Nodes									
Schoegen et al (1993) <i>(2x2 taken from Hall et al, 2013)</i>	Retrospective	Moderate <i>(taken from Hall et al, 2013)</i>			Regional Lymph Nodes		FNAC	Histology/Follow-up			217	0	5	91
Sibon et al (2007) <i>(2x2 taken from original publication)</i>	Prospective	Low	≤1mm thick or ulcerated cutaneous melanoma	Stage IA-IB		131	Ultrasound	Histology	Regional Lymph Nodes	264	10	14	58	182

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
on)			ma											
Starrit et al (2005) (2x2 table from original publication)	Prospective	Low	All patients with melanoma	All stages	None	304	Ultrasound		Patients with histologically confirmed metastases	31	5	0	26	0
Stewart et al (2005) (2x2 taken from Valsecchi et al, 2011)	Retrospective	Moderate (taken from Valsecchi et al, 2011)			Regional Lymph Nodes	178	SLNB	Histology		178	47	0	5	126
Teltzrow et al (2007)	Retrospective	Moderate (taken			Regional Lymph Nodes	106	SLNB	Histology		94	17	0	8	69

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
<i>(2x2 taken from Valsecchi et al, 2011)</i>		<i>from Valsecchi et al, 2011)</i>												
Testori et al (2005) <i>(2x2 table taken from original publication)</i>	Prospective		Stage I		Regional Lymph Nodes	88	Ultrasound	Histology	Regional Lymph Nodes	106	16	9	1	80
Testori et al (2009) <i>(2x2 taken from</i>	Prospective	Moderate <i>(taken from Valsecchi et al,</i>			Regional Lymph Nodes	1313	SLNB			1304	220	0	36	1048

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
<i>Valsecchi et al, 2011)</i>		2011)												
Tyler et al (2000) (2x2 taken from Krug et al, 2008)	Prospective	Moderate (taken from Krug et al, 2008)	Clinically evident stage III lymph node and/or in transit metastases	Stage III		95	PET	Clinical, conventional images and/or biopsy. Clinical follow-up ≥6 months	Lesions	234	144	39	21	30
Van Akkooi et al (2006) (2x2 taken from Valsecchi et al, 2011)	Retrospective	Moderate (taken from Valsecchi et al, 2011)			Regional Lymph Nodes	262	SLNB	Histology		256	77	0	6	173

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
Veit-Haibach et al (2009) (2x2 table taken from original publication)	Prospective	Moderate	Any cutaneous melanoma	Stage I-IV	N-Stage	74	PET-CT			56	48	0	8	
Veit-Haibach et al (2009) (2x2 table taken from original)	Prospective	Moderate	Any cutaneous melanoma	Stage I-IV	M-Stage	74	PET-CT			56	46	3	7	

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
publication)														
Vereecken et al (2005) (2x2 taken from Krug et al, 2008)	Prospective	High (taken from Krug et al, 2008)	Intermediate/Poor prognosis melanoma			43	PET	Sentinel node biopsy and clinical follow-up 6 months	Patients	39	4	25	6	4
Vereecken et al (2005) (2x2 taken from Krug et al, 2008)	Prospective	High (taken from Krug et al, 2008)	Intermediate/Poor prognosis melanoma			43	PET	Sentinel node biopsy and clinical follow-up 6 months	Lesions	63	4	39	6	14
Vidal Sicart et al (2003) (2x2	Retrospective	Moderate (taken from			Regional Lymph Nodes	435	SLNB			430	72	0	7	351

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
<i>taken from Valsecchi et al, 2011)</i>		<i>Valsecchi et al, 2011)</i>												
Voit et al (2000) <i>(2x2 taken from Hall et al, 2013)</i>	Retrospective	Moderate <i>(taken from Hall et al, 2013)</i>			Regional Lymph Nodes		Image guided FNAC	Histology/Follow-up			171	0	4	89
Voit et al (2000) <i>(2x2 taken from Hall et al, 2013)</i>	Retrospective	Moderate <i>(taken from Hall et al, 2013)</i>			Regional Lymph Nodes		Palpation guided FNAC	Histology/Follow-up			319	0	1	115
Voit et al (2006) <i>(2x2</i>	Prospective	Moderate	>1mm thick	Stage IB-IV		127	Ultrasound		Patients	121	27	24	7	63

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
<i>taken from original publication)</i>														
Vucetic et al (2006) (2x2 taken from Valsecchi et al, 2011)	Retrospective	Moderate (taken from Valsecchi et al, 2011))		Regional Lymph Nodes	201	SLNB	Histology		200	42	0	1	157
Voit et al (2014) (2x2 taken from original publication)	retrospective		Stage I/II melanoma ≥1.0mm Breslow thickness	Stage I/II	-	1000	Lymphoscintigraphy-US-FNAC	Different reference standards used (histopathology and cytopathology)	Patient	1000	106	8	102	784

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
								Cytology (if FNAC positive) or histopathology (SLNB)						
Vuylsteker et al (2003) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	High <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	209	SLNB	Histology		209	40	0	4	165
Wagner et al (2003) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	408	SLNB			408	85	0	4	319

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
2011)														
Wagner et al (2005) (2x2 taken from Krug et al, 2008)	Prospective	Moderate (taken from Krug et al, 2008)	>1mm thick early stage melanoma	Stage IB-IIC	Regional Lymph Node	144	PET	Sentinel node biopsy and clinical follow-up ≥ 6 months	Regional Lymph Nodes	184	9	4	34	137
Wagner et al (2005) (2x2 taken from Krug et al, 2008)	Prospective	Moderate (taken from Krug et al, 2008)	Stage I-II	Stage IB-IIC	Melanoma metastases	136	PET	Clinical , conventional images and/or biopsy		184	9	4	34	137
Wagner et al (2005) (2x2 taken from Krug et al, 2008)	Prospective	Moderate (taken from Krug et al, 2008)	Stage I-III	Stage IB-IIC	Recurrent disease	136	PET	Clinical follow-up median 41.4 months		184	9	4	34	137

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
<i>Krug et al, 2008)</i>														
Wagner et al (2011) (2x2 taken from Rodriguez-Rivera et al, 2014)	Retrospective	Low-Moderate (taken from Rodriguez-Rivera et al, 2014)		T1-4N1-3M0		46	PET	Biopsy, clinical follow-up, further imaging	Scans	46	0	6	5	35
Wagner et al (2011) (2x2 taken from Rodriguez-Rivera et al, 2014)	Retrospective	Low-Moderate (taken from Rodriguez-Rivera et al, 2014)	Histologically proven melanoma with metastatic involvement of the sentinel lymph	Stage I-IV	None	46	PET-CT	Biopsy, clinical follow-up, further imaging	Distant Metastases	46	0	6	5	35

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
			node and clinically exempt of metastases											
Wasserberg et al (2004) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	High <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	250	SLNB	Histology		236	26	0	6	204
Yancovitz et al (2007) <i>(2x2 taken from</i>	Retrospective	Low	Stage T1b-3b, clinically node negative and no distant	Stage IB-IIB		158	PET-CT		Scans	344	1	41	0	328

Study	Study Design	Study Quality	Population included	Stage Range	Subgroup Analysis	Total Number of Patients	Modality	Ref. Standard	Unit of Analysis	Total Number of units	True Positive	False Positive	False Negative	True Negative
<i>original publication)</i>			metastasis											
Yee et al (2005) <i>(2x2 taken from Valsecchi et al, 2011)</i>	Retrospective	Moderate <i>(taken from Valsecchi et al, 2011)</i>			Regional Lymph Nodes	1012	SLNB	Histology		991	145	0	22	824
Zeelen et al (1990) <i>(2x2 taken from Hall et al, 2013)</i>	Retrospective	Moderate <i>(taken from Hall et al, 2013)</i>			Regional Lymph Nodes		FNAC	Histology/Follow-up			76	0	5	42

Notes:

Jimenez-Requena et al (2010) assessed study quality using a modified version of previously developed criteria which evaluated criteria across 7 dimensions including, description of study design, description of study population, indications leading to FDG-PET use, technical and image interpretation issues, final confirmation, sensitivity & specificity data and change in management information.

Valsecchi et al (2011): Quality assessment using Methodological Index for Non-randomised Studies criteria which quantifies study quality on eight items up to a score of 16 points (0-4 Very Low; 4.5-8 Low; 8.5-12 Moderate; 12.5-16 High)

Hall et al (2013): Study quality assessed using QUADAS-2 checklist

Clinical Outcomes***Systematic Reviews***

Study	Clearly focused Question?	Includes studies relevant to review question?	Rigorous literature search?	Study quality assessed?	Adequate description of methodology?	Quality (GRADE)
Freeman et al (2013)	Yes	Yes	Yes	Yes	Yes	Very Low (due to the individual studies all being cohort studies and only 6 of the 29 studies included in the meta-analysis)

Randomised Trials

Study	Appropriate Randomisation	Appropriate Concealment	Comparable groups at baseline	Comparable Care apart from intervention	Patient Blinding	Treatment Administrator Blinding	Equal Follow-up	Equal Treatment Completion/Loss to follow up	Appropriate follow-up length	Precise definition of outcome	Valid method of measuring outcome	Investigator blinding	Quality (GRADE)
Faries et al (2010)	Yes	Yes	Yes	Yes	N/A	N/A	Yes	No	Yes	Yes	Yes	Unclear	High
Morton et al	Yes	Yes	Yes	Yes	N/A	N/A	Yes	No	Yes	Yes	Yes	Unclear	Moderate

(2014)													
------------	--	--	--	--	--	--	--	--	--	--	--	--	--

Cohort Studies

Study	Appropriate length of follow-up	Precise definition of an outcome	Valid method of measuring outcomes	Investigators blind to participants exposure to intervention?	Investigators blind to potential confounders and prognostic factors?	Quality (GRADE)
Wasserberg et al (2004)	Yes	Yes	Unclear	No	No	Very Low
Voit et al (2014)	Yes	Yes	Yes	No	No	Low

Children and Adolescents

Study	Appropriate length of follow-up	Precise definition of an outcome	Valid method of measuring outcomes	Investigators blind to participants exposure to intervention?	Investigators blind to potential confounders and prognostic factors?	Quality (GRADE)
Butter et al (2005)	No	Yes	No	No	Unclear	Very Low
Howman-Giles et al (2009)	Yes	Yes	No	No	Unclear	Very Low
Pacella et al (2003)	No	Yes	No	No	Unclear	Very Low

Study	Appropriate length of follow-up	Precise definition of an outcome	Valid method of measuring outcomes	Investigators blind to participants exposure to intervention?	Investigators blind to potential confounders and prognostic factors?	Quality (GRADE)
Roaten et al (2005)	Yes	Yes	No	No	Unclear	Very Low
Toro et al (2003)	No	Yes	No	No	Unclear	Very Low

Clinical Outcomes

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
Faries et al (2010)	Prospective Cohort (following up one arm of a randomised trial)	To investigate whether early lymph node dissection was associated with less morbidity than delayed dissection at the time of clinical recurrence	<p>N=225 patients who underwent wide local excision with SLNB and early complete lymph node dissection</p> <p>Mean Age was 50 years</p> <p>N=143 patients who underwent wide local excision alone and delayed complete lymph node dissection.</p> <p>Mean Age was 54.4 years</p>	Wide local excision + SLNB + CLND	Wide local excision + delayed CLND	<p>Acute Toxicity including: Wound separation, seroma/hematoma, haemorrhage, infection, thrombophlebitis, urinary tract infection, pneumonia and cardiac complications</p> <p>Chronic Toxicity including lymphoedema and nerve dysfunction</p> <p>Median Follow up was 5.1 years in the early CLND group and 4.9 years in the delayed CLND group.</p> <p>Regional and systemic toxicities were similar between the two groups.</p> <p><u>Systemic Toxicity</u></p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
						<p>Low systemic toxicity was reported in both groups (1 urinary tract infection, 1 pneumonia, 1 cardiac complication and 1 case of thrombophlebitis).</p> <p>Dysesthesia was reported more in the early CLND group (5.2% vs. 2.3%) but the difference was not statistically significant.</p> <p>Lymphoedema was significantly more common in the delayed CLND group (20.4% vs. 12.4%, $p=0.04$) and the difference remained significant when severity was taken into account ($p=0.03$).</p> <p>Lymphoedema was strongly associated with basin site with 9% oedema after axillary dissection and 26.6% oedema after inguinal dissection ($p<0.001$).</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
						<p>There was no indication that the benefit to early CLND in lymphoedema was limited to either the axillary or the inguinal basin.</p> <p>Patients with lymphoedema had a higher BMI than those without though the difference was not statistically significant (27.7% vs. 26.7% $p=0.21$).</p> <p>The risk of lymphoedema was greater in obese patients compared with non-obese patients though the difference was not statistically significant (20% vs. 13.9%, $p=0.21$).</p> <p>No difference was observed in the mean number of nodes evaluated in patients with lymphoedema compared with patients without lymphoedema for either axilla (mean oedema 19.6, no oedema</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
						<p>21.2 p=0.61) or for inguinal (mean: oedema 14.9, no oedema 14.2 p=0.36) basin.</p> <p>Multivariate analysis identified basin site (groin versus other) as the most powerful factor (OR 3.64, 95% CI 1.93-6.86, p<0.001) and delayed CLND (OR=1.74, 95% CI 0.93-3.25, p=0.083) showed trends toward and independent adverse effect on oedema risk.</p> <p>Length of hospital stay varied between continents. Mean length of stay was 2.8 days in the USA, 10.6 days in Europe and 9.5 days in Australia.</p> <p>Mean stay for the early CLND was 8.3 days and for delayed CLND was</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
						<p>9.9 days ($p=0.021$).</p> <p>Length of stay was longer for patients undergoing groin dissection if the deep basin was dissected (13.9 days versus 10.2 days, $p=0.009$).</p> <p>For patients undergoing superficial Dissection, length of stay was longer in the delayed group (9.8 days versus 12.3 days, $p=0.48$).</p> <p>Length of stay was directly related to age but after adjusting for age, the relationship with timing of dissection remained significant ($p=0.038$).</p>
Freeman et al (2013)	Systematic review and Meta-analysis	To determine whether SLN status provides significant prognostic information in addition to Breslow	Articles which evaluated the risk of overall survival and mortality according to SLN status in patients with melanoma.	Positive Sentinel Lymph Node Biopsy	Negative Sentinel Lymph Node Biopsy	Overall Survival

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
		thickness alone	<p>Studies conducted before 1992 were only used if they included patients treated after 1992.</p> <p>Average patient age ranged from 47-70.6 years.</p> <p>Follow-up ranged from 15-77 months</p>			<p>All included studies were cohort studies.</p> <p>A total of 29 studies were included. 4 were rated low quality 17 were rated moderate quality 8 were rated high quality</p> <p>In patients with thin melanoma (<1mm) results of the sign test showed no significant survival advantage for SLN negative patients over SLN positive patients ($p>0.99$).</p> <p>In patients with melanomas 1-2mm thick) results of the sign test showed no significant survival advantage for SLN negative patients over SLN positive patients ($p=0.62$)</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
						<p>In patients with melanomas 2-4mm) results of the sign test showed no survival advantage for SLN negative patients over SLN positive patients (p=0.25)</p> <p>In patients with melanoma greater than 4mm there was a significant survival advantage for SLN negative patients over SLN positive patients (p=0.004).</p> <p>Pooled results from six studies showed that in patients with a tumour depth ≥ 4mm, SLN positive patients were more likely to die compared with SLN negative patients (HR=2.42, 95% CI 2.00-2.92).</p>
Morton et al (2014)	Multicentre Randomised Control Trial	To determine whether sentinel-node biopsy could be used to identify patients with clinically occult nodal	Intervention Arm N=1000	Wide excision of primary melanoma plus sentinel-	Wide excision plus post-operative nodal	<p><u>Primary Outcomes</u></p> <p>Melanoma specific survival</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
		metastases and whether immediate-completion lymphadenectomy yielded better outcomes than complete lymphadenectomy performed only when nodal recurrence was revealed during observation	<p>Control Arm N=661</p> <p><u>Inclusion</u></p> <p>Patients between 18-75 years with invasive melanoma with Clark Level III and Breslow Thickness $\geq 1.00\text{mm}$ or Clark level IV or V with any Breslow thickness (confirmed by pathology)</p> <p>Primary cutaneous melanoma (head, neck, trunk, extremity, scalp, palm of hand, sole of foot or subungal skin)</p> <p>Biopsy completed no more than 10 weeks before initial clinic visit and surgery schedule within 3 months of the biopsy</p> <p>Patients with a life expectancy of at least 10 years from time of diagnosis, excluding the melanoma diagnosis</p> <p><u>Exclusion</u></p> <p>Prior wide excision of the primary with a diameter $\geq 3\text{cm}$ and the shortest</p>	node biopsy (60%) with immediate lymphadenectomy if metastases were detected	observation (40%) with lymphadenectomy if nodal metastases developed during observation	<p><u>Secondary Outcomes</u></p> <p>Disease free survival</p> <p>Incidence</p> <p>Timing</p> <p>Anatomic distribution of distant metastases</p> <p>Morbidity of procedures</p> <p>Significance of TA90 levels</p> <p>Incidence of Sentinel Node Metastases (biopsy) vs. Clinical metastases (observation)</p> <p>Accuracy of LM</p> <p><u>Follow-up</u></p> <p>Clinical exam, blood testing and chest radiography every 3 months during the first 2 years, every 4 months during year 3, every 6 months during years 4-5 and then</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
			<p>margin from the tumour edge to the excision edge was measured to be $\geq 1.5\text{cm}$; or the patient had an elliptical excision and a margin beyond the tumour edge was $\geq 1.5\text{cm}$ at the narrowest margin</p> <p>Primary cutaneous melanoma involving eye, ear or mucous membranes.</p> <p>Clinical evidence of satellite lesions, in transit, regional nodal or distant metastases</p> <p>Second primary invasive melanoma</p> <p>Any type of solid tumour or haematologic malignancy in the past 5 years (ex. T1 lesions in the past 5 years such as basal cell carcinoma, squamous cell carcinoma, in situ carcinoma of the cervix and who have not received treatment within the previous 6 months)</p> <p>Prior skin grafts, tissue transfers or flaps or lymph node dissections that may alter the lymphatic drainage pattern from a primary cutaneous</p>			<p>annually until year 10.</p> <p><u>Survival</u></p> <p><u>Thin Melanoma (1.2-1.79mm)</u></p> <p>Results not reported due to event infrequency</p> <p><u>Intermediate thickness (1.8-3.5mm)</u></p> <p>No significant difference in 10 year melanoma specific survival rates (HR for death in the biopsy group 0.84, 95% CI 0.64-1.09; $p=0.18$)</p> <p>Disease free survival was significantly higher in the biopsy group (HR 0.75 95% CI 0.62-0.94; $p=0.001$)</p> <p>10 year melanoma specific survival rate was significantly higher in patients with tumour free sentinel nodes compared with those with sentinel node metastases (HR for death from melanoma 3.09, 95% CI 2.12-4.49; $p<0.001$)</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
			<p>melanoma to the adjacent regional lymph node basins</p> <p>Previous chemotherapy, immunotherapy or radiation therapy</p> <p>Organ transplantation/receiving immunosuppressive agents as a result of transplantation</p> <p>Oral or parenteral steroids or immunosuppressive drugs in the past 6 months</p> <p>Primary or secondary immune deficiencies</p> <p>A concurrent medical condition which will affect life expectancy</p> <p>Pregnancy</p> <p>Cannot undergo SLN dissection for any reason</p> <p>1661 patients underwent randomisation</p> <p>585 patients in the intervention arm</p>			<p><u>Thick Melanoma (>3.5mm)</u></p> <p>No significant difference in the 10 year melanoma specific survival rates (HR for death in the biopsy group 1.12, 95% CI 0.76-1.67; p=0.56)</p> <p>Disease free survival was significantly higher in the biopsy group (HR 0.7 95% CI 0.5-0.96; p=0.003)</p> <p>10 year melanoma specific survival rate was significantly higher in patients with tumour free sentinel nodes compared with those with sentinel node metastases (HR for death from melanoma 1.75, 95% CI 1.07-2.87; p=0.03)</p> <p><u>Presence of Nodal Metastases</u></p> <p>The frequency of nodal metastasis across all Breslow thickness was 20.8%</p> <p><u>Intermediate thickness (1.8-3.5mm)</u></p> <p>87/500 patients in the observation</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
			<p>and 391 patients in the control arm completed the trial</p> <p>In total 215 patients were lost to follow-up, 64% of them from the intervention arm which possibly reflects a greater incentive for patients in the observation arm to continue their follow-up.</p>			<p>group had nodal metastasis at a median of 19.2 months (95% CI, 13.6-24.1).</p> <p>The estimated 10-year cumulative incidence of nodal metastasis was 19.5%</p> <p>Sentinel nodes were identified in 765/770 patients in the biopsy group and 122 patients had metastases.</p> <p>Nodal metastases were detected during observation in 31/643 patients with tumour free sentinel nodes</p> <p>The proportion of patients with nodal metastases in the biopsy group was 20% (153/765 patients) and the estimated 10 year cumulative incidence was 21.9%.</p> <p><u>Thick Melanoma (>3.5mm)</u></p> <p>44/117 patients in the observation</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
						<p>arm had nodal relapse at a median of 9.2 months (95% CI 6.4-12.2) and the estimated 10 year cumulative incidence of nodal metastasis was 41.4%</p> <p>Sentinel nodes were identified in all patients and 57/173 had nodal metastases.</p> <p>Nodal metastases were subsequently detected in 12/116 patients with initially tumour free nodes.</p> <p>The proportion of patients with nodal metastasis in the biopsy group was 39.9% and the estimated 10 year cumulative incidence of nodal metastases was 42%</p> <p><u>Survival in patients with nodal metastases</u></p> <p>There was no significant difference</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
						<p>in the distribution of prognostic factors between the two treatment groups with the exception of age among patients with thick melanomas.</p> <p><u>Intermediate thickness (1.8-3.5mm)</u></p> <p>10 year melanoma specific survival rate was 62.1±4.8% in the biopsy group compared with 41.5±5.6% in the observation group in patients with nodal metastases (HR for death from melanoma 0.56, 95% CI 0.37-0.84; p=0.006). This treatment related difference remained significant after patients with false negative sentinel nodes were included (10 year melanoma specific survival rate, 56±4.3% in the biopsy group versus 41.5±5.6% in the observation group (HR 0.67, 95% CI 0.46-0.97; p=0.04))</p> <p>In patients with no nodal metastases (no tumour on biopsy or during clinical observation), no treatment related difference in 10</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
						<p>year melanoma specific survival rates was observed (88.0±1.4% in the biopsy group versus 86.6±1.8% in the observation group; HR for death from melanoma in the biopsy group 0.89; p=0.54).</p> <p>Distant disease free survival was improved in patients receiving immediate rather than delayed lymphadenectomy (HR 0.62, 95% CI 0.42-0.91; p=0.02)</p> <p><u>Thick Melanoma (>3.5mm)</u></p> <p>No significant treatment related difference was observed for patients with thick melanomas; the 10 year melanoma-specific survival rate was 48±7.0% in the biopsy group versus 45.8±7.8% in the observation group (HR 0.92, 95% CI 0.53-1.6; p=0.78)</p> <p>In patients with no nodal metastases (no tumour on biopsy or during clinical observation), no treatment related difference in 10 year melanoma specific survival rates was observed (69.8±5.0% in</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
						<p>the biopsy group versus 76.1±5.2% in the observation group; HR for death from melanoma in the biopsy group 1.18; p=0.61).</p> <p>No significant difference was observed in distant disease free survival for patients treated with immediate versus delayed lymphadenectomy (HR 0.96, 95% CI 0.56-1.64, p=0.88)</p> <p><u>SLNB+immediate lymphadenectomy</u></p> <p>The estimated treatment effect on disease free survival was 1.17 (p<0.001) indicating an increase in survival time by a factor of 3.2.</p> <p>The estimated treatment effect on distant disease free survival was 0.73 (p=0.04) indicating an increase in survival time by a factor of 2.1</p> <p>The estimated treatment effect on melanoma specific survival was 0.68 (p=0.05) indicating an increase</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
						is survival time by a factor of 2.0.
Voit et al (2014)	Retrospective Case Series	To evaluate the increased experience with sentinel lymph node biopsy as an addition to US-FNAC	<p>N=1,000 patients</p> <p><u>Inclusion</u></p> <p>Breslow thickness at least 1.00mm or Clark IV/V, ulcerated and/or regressed</p> <p>Median Age was 62 years (mean=59)</p> <p>Median Breslow thickness was 1.57mm (mean=2.58mm)</p>	<p>US-FNAC±SNB</p> <p>All patients underwent ultrasound</p> <p>Patients with suspicious or malignant SN findings underwent FNAC</p> <p>Patients with positive FNAC or in whom ultrasound pattern could not be verified underwent SLNB</p>		<p><u>Disease Free Survival</u></p> <p><u>Melanoma-specific survival</u></p> <p>Median Follow-up was 53 months (mean=56 months)</p> <p>208 (21%) of patients had positive lymph node disease on histology</p> <p>The chance for lymph node involvement increased with increasing T-stage: 5% (15/288) for T1, 12% (37/308) for T2, 32% (73/231) for T3 and 48% (83/173) for T4 (p<0.001)</p> <p>5 year Kaplan-Meier estimated melanoma specific survival was 95% for patients with a negative US-FNAC compared with 59% for</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
						<p>patients with a positive US-FNAC ($p<0.001$).</p> <p>5 year Kaplan-Meier estimated disease free survival was 84% for patients with a negative US-FNAC compared with 33% for patients with a positive US-FNAC ($p<0.001$).</p> <p>5 year Kaplan-Meier estimated melanoma specific survival with negative Berlin morphology criteria (no malignant or suspicious ultrasound findings) was 96% versus 89% for peripheral perfusion only or central echo wandering to the rim ($p<0.001$).</p> <p>5 year Kaplan-Meier estimated melanoma specific survival with balloon shape or complete loss of central echo was 59% ($p<0.001$).</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
						<p>5 year Kaplan-Meier estimated melanoma specific survival with negative Berlin morphology criteria (no malignant or suspicious ultrasound findings) was 85% versus 74% for peripheral perfusion only or central echo wandering to the rim ($p < 0.001$).</p> <p>5 year Kaplan-Meier estimated disease specific survival with balloon shape and/or complete loss of central echo was 36% ($p < 0.001$)</p> <p>5 year Kaplan-Meier estimated melanoma specific survival per SN tumour burden was 96% for SN negative patients versus 100% for patients with metastases < 0.1mm in diameter.</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
						<p>5 year Kaplan-Meier estimated melanoma specific survival for patients with metastases 0.1-1.0mm was 73% (p<0.001)</p> <p>5 year Kaplan-Meier estimated melanoma specific survival for patients with lesions >1.0mm was 68% (p<0.001), 57% (p<0.001) for patients with a lymph node dissection or unknown SN tumour burden.</p> <p>Corresponding disease free survival estimates were 87% for SN negative patients compared with 83% for patients with <0.1mm lesions (p=0.45) versus 49% in patients with lesions 0.1-1.0mm (p<0.001) versus 37% for patients with lesions >1.0mm (p<0.001) versus 33% for LND or unknown SN tumour burden patients (p<0.001).</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
Wasserberg et al (2004)	Retrospective Case Series	To determine the incidence and severity of SLNB related complications over the long term and to identify possible risk factors	<p>N=250 patients with malignant melanoma who underwent SLNB between 1994 and 2002.</p> <p>Median age was 56.5 years (range 17-84 years)</p>	SLNB	N/A	<p>Wound Complications</p> <p>Sensory Complications</p> <p>Other Complications</p> <p>Sentinel node metastasis was a significant prognostic indicator of poor outcome compared with negative sentinel nodes: 5 year survival rate was 65% versus 89%, p=0.04).</p> <p>Complications related directly to surgery occurred in 62/309 nodal basins and were strongly associated with location of melanoma in the extremities (p=0.0002), specifically sentinel node retrieval from the groin (p=0.001)</p> <p>Wound complications were recorded in 42/309 basins.</p> <p>Open drainage was required in 6/16</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
						<p>casas.</p> <p>One severe stropoccol infection was recorded</p> <p>Independent factors significantly associated with wound infection included inguinal SLNB ($p=0.001$) and primary lesion in the extremity ($p=0.02$)</p> <p>Nerve related complications were recorded in 14 baisins.</p> <p>8 patients reported post operative pain and/or other sensory disturbances and 6 patients reported mobility limitations.</p> <p>Age younger than 50 years ($p=0.003$), axillary site ($p=0.04$) and number of excised sentinel nodes (>2) ($p=0.02$) were found to be independent prognostic indicators of sensory/mobility complications.</p> <p>3 patients had significant oedema of</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
						the leg and ankle which gradually resolved in all cases.

Children and Adolescents

Study	Study Type	Population	Setting	Aim	Intervention	Comparison	Outcomes
Howman-Giles et al (2009)	Retrospective Case Series	<p>N=55 patients aged <20 years with stage I-II cutaneous melanoma</p> <p>Median age was 17.1 years (range: 3.5-19.8 years)</p> <p><i>Location of primary tumour</i></p> <p>Trunk = 36%</p> <p>Head and neck = 30%</p> <p>Legs = 18%</p> <p>Arms = 16%</p>	Single Melanoma Unit (Australia)	To assess outcomes in young patients undergoing SLNB for intermediate thickness localised melanoma	SLNB	Histology	<p>Overall Survival</p> <p>SLNB positivity rate was 25% (14/55)</p> <p>Children aged <10 years had a higher SLNB positivity rate than those aged ≥10 years (33% versus 17%)</p> <p>Follow-up information was available for 51/55 patients</p>

Study	Study Type	Population	Setting	Aim	Intervention	Comparison	Outcomes
							<p>Median follow-up was 60 months (range, 5-143 months)</p> <p>Overall survival was 94.1% (48/51 patients)</p> <p>In the SLNB positive patients overall survival was 79%</p>
Butter et al (2005)	Retrospective Case Series	<p>N=12 patients aged <18 years with cutaneous melanoma</p> <p>Mean age at diagnosis was 8.5 years</p> <p><i>Location of primary tumour</i></p> <p>Extremity = 7</p> <p>Trunk = 4</p>	2 Children's hospitals (Montreal, Canada)	To review the experience with paediatric cutaneous melanoma and SLNB	SLNB	Only patients diagnosed after 2000 were offered SLNB (n=5 patients)	<p>Disease free survival</p> <p>Overall Survival</p> <p>4/5 patients underwent SLNB</p> <p>1/5 had thin melanoma (<1mm) and did not qualify.</p> <p>Mean 2 nodes biopsied per patient</p>

Study	Study Type	Population	Setting	Aim	Intervention	Comparison	Outcomes
		<p>Head and neck = 1</p> <p>Tumour thickness ranged from 0.8-6mm (mean = 3.5mm)</p> <p><i>Clarks Level</i></p> <p>Level 1 = 0</p> <p>Level 2 = 1</p> <p>Level 3 = 3</p> <p>Level 4 = 5</p> <p>Level 5 = 1</p>					<p>2/4 patients had positive SLNB</p> <p>2/4 had negative SLNB and after 17 months follow-up 1 remains disease free while one developed clinically positive axillary nodes 8 months after SLNB and died 18 months after SLNB.</p> <p>In patients who did not undergo SLNB (n=8), 2 underwent TLND for clinically palpable nodes; 1 had pathologically negative nodes and remains alive and disease free 9 years later.</p>
Roaten et al (2005)	Retrospective Case Series	N=20 patients aged <21 years undergoing SLNBX for melanoma or other melanocytic skin lesions		To determine outcomes and complications of children and adolescents undergoing SLNBX	SLNB		<p>Adverse events (complications) while 1 died of disease 15 months after diagnosis.</p> <p><u><i>Disease Free Survival</i></u></p> <p>Stage I: 3.9 years (n=2)</p> <p>Stage II: 7.7 years (n=6)</p>

Study	Study Type	Population	Setting	Aim	Intervention	Comparison	Outcomes
							Stage III: 2.6 years (n=4) <u>Overall survival</u> Stage I: 100% (2/2) Stage II: 83% (5/6) Stage III: 75% (3/4)
Pacella et al (2003)	Retrospective Case Series	N=7 patients aged between 4-11 years with biopsy proven melanoma (n=4) or a borderline melanocytic lesion of uncertain biologic potential (n=3). Mean age 7.6 years (range 4-11) Tumour thickness ranged from 2.8mm-8mm (mean=4.27mm)	Melanoma Clinic (USA)	To determine the clinical utility of intraoperative lymph node mapping and sentinel lymph node biopsy	SLNB		Unclear 4 patients with positive sentinel nodes underwent therapeutic lymph node dissection. Mean follow up was 14 months (94-40 months) and all 7 patients were alive and disease free.

Study	Study Type	Population	Setting	Aim	Intervention	Comparison	Outcomes
Toro et al (2003)	Retrospective Case Series	<p>N=12 patients aged <18 years with clinically node negative melanoma</p> <p>Mean age 14.1 years (range 4-18 years)</p> <p>Tumour thickness 0.36mm – 4.7mm (mean 1.65mm)</p> <p>Mean number of SLNs biopsied = 1.75 per draining basin</p>		To investigate the use of SLNB in the paediatric population focusing on its diagnostic and therapeutic implications	SLNB		<p>Recurrence</p> <p>Adverse Events (complications)</p> <p>3/12 patients had positive sentinel node biopsies and underwent completion lymph node dissection.</p> <p>One patient had a recurrence 6.1 months after CLND and died after 7.5 months.</p> <p>Median follow-up for the remaining 11 patients was 11.7 months and all patients were alive and disease free</p> <p>No complications were related to SLNB.</p>

Breslow thickness

Study	Study Type	Population	Setting	Aim	Outcomes	Quality																								
Han (2013)	Retrospective observational study	N=1250 patients entered into the sentinel lymph node working group database from 1994 to 2012 with melanomas ≤ 1mm in thickness.	Secondary or tertiary care	To determine factors predictive of sentinel lymph node micrometastases	<table><tr><th>Tumour thickness</th><th>SLNB+</th><th>N</th><th>Proportion</th></tr><tr><td>≤0.74mm</td><td>9</td><td>359</td><td>2.5%</td></tr><tr><td>0.75-1.00</td><td>56</td><td>891</td><td>6.3%</td></tr></table>	Tumour thickness	SLNB+	N	Proportion	≤0.74mm	9	359	2.5%	0.75-1.00	56	891	6.3%	Unclear how patients were entered onto the database or how patients with thin melanomas were selected for SLNB (criteria differed by individual investigator as did techniques and histopathology).												
Tumour thickness	SLNB+	N	Proportion																											
≤0.74mm	9	359	2.5%																											
0.75-1.00	56	891	6.3%																											
Lens (2002)	Systematic review	12 studies of patients (N=4218) with stage I or II melanoma who received SLNB; of at least 100 patients; published 1996 – 2001	Secondary or tertiary care	To determine the degree to which Breslow thickness predicts the presence of sentinel lymph node micrometastases	<table><tr><th>Tumour thickness</th><th>SLNB+</th><th>N</th><th>Proportion</th></tr><tr><td>≤0.75mm</td><td>2</td><td>199</td><td>1.0%</td></tr><tr><td>0.76-1.50</td><td>133</td><td>1600</td><td>8.3%</td></tr><tr><td>1.51-4.0</td><td>433</td><td>1904</td><td>22.7%</td></tr><tr><td>>4.0</td><td>183</td><td>515</td><td>35.5%</td></tr><tr><td>Total</td><td>751</td><td>4218</td><td>17.8%</td></tr></table>	Tumour thickness	SLNB+	N	Proportion	≤0.75mm	2	199	1.0%	0.76-1.50	133	1600	8.3%	1.51-4.0	433	1904	22.7%	>4.0	183	515	35.5%	Total	751	4218	17.8%	Individual study quality was not considered in this review, otherwise the methods were adequate
Tumour thickness	SLNB+	N	Proportion																											
≤0.75mm	2	199	1.0%																											
0.76-1.50	133	1600	8.3%																											
1.51-4.0	433	1904	22.7%																											
>4.0	183	515	35.5%																											
Total	751	4218	17.8%																											
Morton (2014)	Randomised trial	See clinical outcomes table above	See clinical outcomes table above	See clinical outcomes table above	<table><tr><th>Tumour thickness</th><th>SLNB+</th><th>N</th><th>Proportion</th></tr><tr><td>≤1.2mm</td><td>N.R.</td><td>N.R.</td><td>N.R.</td></tr></table>	Tumour thickness	SLNB+	N	Proportion	≤1.2mm	N.R.	N.R.	N.R.	The trial was not designed to answer this question, Data were not reported for tumour thickness																
Tumour thickness	SLNB+	N	Proportion																											
≤1.2mm	N.R.	N.R.	N.R.																											

Study	Study Type	Population	Setting	Aim	Outcomes				Quality
					1.2 – 3.5	122	765	15.9%	<1.2mm
					>3.5	57	173	32.9%	

1 **Economic Evidence Summary**

- 2 • The following databases were searched for economic evidence relevant to the PICO:
3 MEDLINE, EMBASE, COCHRANE, NHS EED. Studies conducted in OECD countries other than
4 the UK were considered (Guidelines Manual 2009).
- 5 • 303 possibly relevant papers were identified. Of these, 6 full papers relating to this topic
6 were obtained for appraisal. A further 4 papers were excluded as they were not cost-utility
7 studies. Two papers (Wilson et al (2002) and Morton et al (2009)) were included in the
8 current review of published economic evidence for this topic.
- 9 • Wilson et al was a cost-utility analysis comparing four alternative treatment strategies for
10 patients with stage II melanoma. Two different SLNB followed by tailored interferon
11 treatment strategies and two non SLNB strategies; treat all with low dose IFN or a surgery
12 only.
- 13 • The base case analysis concluded that SLNB followed by treating patients with a positive
14 result with high dose IFN and negative with low dose IFN was the most effective treatment
15 in terms of quality adjusted relapse free life-years (QArfLY). This equated to an ICER of
16 \$18,700/QArfLY compared to the surgery only approach and \$31,100 compared to only
17 treating patients with a positive SLNB. The treat all approach was deemed not cost-effective
18 as a result of extended dominance.
- 19 • Wilson et al. was deemed only partially applicable to the decision problem that we are
20 evaluating. This is primarily because the study did not consider a UK healthcare setting (USA
21 setting).
- 22 • Very serious limitations were identified with Wilson et al. Most notably, a potential conflict
23 of interest (the study was funded by a manufacturer of IFN), the duration component of the
24 QALYs used relapse free survival as opposed to overall survival and an appropriate time
25 horizon was not used.
- 26 • Morton et al was a cost-utility analysis comparing wide-excision (WEX) alone to SLNB (with
27 CLND for patients with positive SLNBs) alongside WEX in patients with primary melanoma of
28 >1mm in thickness.
- 29 • The base-case concluded that adding SLNB alongside WEX resulted in an incremental cost
30 per QALY of AU\$1,923 compared to WEX alone. This ranged from SLNB being both cheaper
31 and more effective to AU\$90,959 per QALY during sensitivity analyses. These results were
32 sensitive to the probability of distant metastasis post-intervention, the probability of nodal
33 metastasis post WEX and the cost of WEX, SLNB and delayed CLND.
- 34 • Morton et al was deemed only partially applicable to the decision problem that we are
35 evaluating. This is primarily because the study did not consider a UK setting (Australian
36 healthcare setting).
- 37 • Potentially serious limitations were identified with Morton et al most notably the lack of
38 probabilistic sensitivity analysis.

- Given the large differences in treatments considered following SLNB the results of the two studies are difficult to compare.

Volume of evidence

- 303 possibly relevant papers were identified. Of these, 6 full papers relating to this topic were obtained for appraisal. A further 4 papers were excluded as they were not cost-utility studies. Two papers (Wilson et al (2002) and Morton et al (2009)) were included in the current review of published economic evidence for this topic.
- Wilson et al was a cost-utility analysis, conducted from a US healthcare payer perspective. The study reported cost-effectiveness results in terms of cost per QArFLY over a five-year time horizon was considered for the analysis.
- Morton et al was a cost-utility analysis, conducted from an Australian healthcare system perspective. The study reported outcomes in terms of QALYs and considered a lifetime time horizon.
- No cost-utility evidence was found for non-SLNB strategies of staging patients with melanoma.
- No cost-utility studies were identified which considered a UK healthcare setting

			Selection criteria for included evidence:	
303 possibly relevant papers identified	→	297 papers excluded based on title & abstract	<ul style="list-style-type: none"> Studies that compare costs and health consequences of interventions (i.e. true cost-effectiveness analyses) Studies that included quality of life based outcomes as a measure of effectiveness Studies conducted in OECD countries were included Studies that presented incremental results or presented enough information for incremental results to be derived Studies that matched the population, interventions, comparators and outcomes specified in PICO 	
↓				
6 full text paper obtained	→	4 papers excluded based on full text		
↓				
2 papers included in evidence review				

Quality and applicability of the included studies

		<i>Applicability</i>	
		Directly applicable	Partially applicable
<i>Methodological quality</i>	Minor limitations		
	Potentially serious limitations		Morton et al. 2009
	Very serious limitations		Wilson et al. 2002

- Wilson et al and Morton et al are deemed only partially applicable to the decision problem that we are evaluating. This is primarily because the studies did not consider a UK healthcare setting. Wilson et al also did not express health effect values in terms of quality adjusted life years (QALYs).
- Very serious limitations were identified with Wilson et al. Most notably, a potential conflict of interest (the study was funded by a manufacturer of IFN), the discounting only of costs and an inappropriately short time horizon.
- Potentially serious limitations were identified Morton et al most notably the lack of probabilistic sensitivity analysis.

1 **References**

- 2 1. Wilson LS, Reyes CM, Lu C et al 'Modelling the cost-effectiveness of sentinel lymph node
3 mapping and adjuvant interferon treatment for stage II melanoma' **Melanoma Research** 12.6
4 (2002): p607-618.
- 5 2. Morton RL, Howard K, Thompson JF 'The cost-effectiveness of sentinel node biopsy in patients
6 with intermediate thickness primary cutaneous melanoma' **Annals of Surgical Oncology** 16.4
7 (2009): p929-940

8

Evidence Tables

Study	Population	Comparators	Costs	Effects	Incr costs	Incr effects	ICER	Uncertainty	Applicability	Limitations
Study 1										
Wilson et al. 2002	Hypothetical cohort of patients with Stage II malignant melanoma after surgical excision.	Treat no one with IFN, surgery and clinical observation only.	\$18,400	3.06	Reference			One-way Sensitivity Analysis For test and treat some versus surgery and test and treat appropriately versus test and treat some Reducing the cost of relapse to \$10,000 increased the ICER to \$21,900/QALY and \$35,900/QALY respectively. Increasing the cost of relapse to \$50,000 reduced the ICERs by \$14,500/QALY and \$26,100/QALY respectively Sensitivity and specificity of SLNB and the probability of dose changing toxicities were reported to have an insignificant effect on the ICER for both comparisons. Probabilistic Sensitivity Analysis (PSA) Varying across all variables for test and treat some versus surgery the median, 25th and 75th percentiles of the PSA are \$19,605, \$10,291 and \$36,659 per QALY respectively. For test and treat appropriately versus test	Partially Applicable Not conducted from a UK health service perspective.	Very Serious Limitations. Study funded by manufacturer. Inappropriate time horizon.
		Test with SLNB. Treat patients with a positive result with high dose IFN and those with a negative low dose IFN (test and treat appropriately).	\$24,200	3.37	\$5,800	0.31	\$18,700/QALY			
		Treat all with low dose IFN following surgery.	\$30,500	3.48			Extended dominated			
		Test with SLNB. Treat patients with a positive result with high dose IFN and those with a negative with surgery alone (Test and treat some)	\$33,800	3.68	\$9,600	0.31	\$31,100/QALY			

DRAFT FOR CONSULTATION

Study	Population	Comparators	Costs	Effects	Incr costs	Incr effects	ICER	Uncertainty	Applicability	Limitations
								and treat some the median, 25th and 75th percentiles \$30,229, \$16,766 and \$58,823 per QALY respectively.		
	Comments: The survival component of the QALY uses relapse free survival and not overall survival.									

Study	Population	Comparators	Costs	Effects	Incr costs ¹	Incr effects Error! Bookmark not defined.	ICER Error! Bookmark not defined.	Uncertainty	Applicability	Limitations
Study 2										
Morton et al 2009	Hypothetical cohort of patients with biopsy proven Melanoma ≥1mm	WEX	AU\$23,182	9.90 QALYs	Reference			Increasing the probability for distant metastasis post WEX to 0.02 or reducing the post WEX+SLNB probability to 0.01 resulted in SLNB+WEX becoming less costly and more effective (dominant).	Partially Applicable Not conducted from a UK health service perspective.	Potentially serious limitations Probabilistic sensitivity analysis was not performed.
		WEX+SLNB	AU\$24,045	10.34 QALYs	\$863	0.44	\$1,983/QALY	Decreasing post WEX probability to 0.01 decreases the ICER to \$90,959/QALY whilst increasing the WEX+SLNB to 0.022 increases the ICER to \$52,436/QALY. Increasing and decreasing the probability of nodal metastasis post WEX to 0.04 and 0.0275 results in WEX+SLNB becoming dominant and \$6,273/QALY respectively. Increasing the cost of delayed CLND to \$27,000 again results in WEX+SLNB becoming dominant whilst reducing the cost to \$8,717 results in an ICER of \$3,815. Increasing and decreasing the costs of WEX+SLNB between \$4,339 and \$9811 results in ICERS of \$397/QALY and \$12,976/QALY.		

DRAFT FOR CONSULTATION

Study	Population	Comparators	Costs	Effects	Incr costs ¹	Incr effectsError! Bookmark not defined.	ICERError! Bookmark not defined.	Uncertainty	Applicability	Limitations
	Comments:									

¹ Incremental values in comparison to strategy above except when ruled out through extended dominance.

Primary details	Design	Patient characteristics	Interventions	Outcome measures	Results	Comments
<i>Study 1</i>						
Author: Wilson Year: 2002 Country: USA	Type of analysis: Cost-Utility Model structure: Decision Tree Cycle length: N/A Time horizon: 5 years Perspective: Health-Care Payer Source of base-line data: The probability of metastasis was taken from a multicentre US trial validating accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma. Source of effectiveness data: Probabilities of relapse free 5 year survival were taken from four studies, three RCTs and a narrative review. The three RCTs, comparing interferon-alfa-2b were set in Austria,	Base case (population): Hypothetical cohort of patients with Stage II malignant melanoma after surgical excision. Sample size: Each patient modelled independently Age: Not reported Gender: Not reported Subgroup analysis: None	(1) Treat no one with IFN; surgery and clinical observation only. (2) Test first with SLNB. High dose IFN for positive, surgery only for negative. (3) Treat all with low-dose IFN. (4) Test first with SLNB. High dose for positive, low dose for negative.	Effectiveness (QALY): (1) Treat no one with IFN, surgery and observation only. (2) Test first with SLNB. High dose IFN for positive, surgery only for negative. (3) Treat all with low-dose IFN. (4) Test first with SLNB. High dose for positive, low dose for negative. Total costs: (1) Treat no one with IFN, surgery and observation only (2) Test first with SLNB. High dose IFN for positive, surgery only for negative. (3) Treat all with low-dose adjuvant interferon(IFN) (4) Test first with SLNB. High dose for positive, low dose for negative. ICER (cost per QALY): (2) vs (1) (3) vs (2) (4) vs (2)	3.06 3.37 3.48 3.68 \$18,400 \$24,200 \$30,500 \$33,800 \$18,700 Extended Dominated \$31 100	Funding: Roche Global Development Comments

Primary details	Design	Patient characteristics	Interventions	Outcome measures	Results	Comments
	<p>France and the USA.</p> <p>The specificity of SLNB was taken from prospective cohort study in the US (Pu et al, 1999). Sensitivity was taken from Reintegn et al (1990) a study of the order of melanoma nodal metastases.</p> <p>Source of utility data: Utility values were taken from Killbridge et al (2001) who used a standard gamble on 107 low risk US melanoma patients to evaluate different toxicities and post-treatment outcomes following IFN treatment. The valuation of these changes were by the patient group and not the general population.</p> <p>Source of cost data: Resource use for diagnostics and surgery were taken from a RCT comparing lymph node dissection and adjuvant interferon alfa-2b in a US healthcare setting (Mcmasters (2001)).</p> <p>Costs were taken from</p>			<p>Cost per Relapse-Free Year</p> <p>(2) vs (1) (3) vs (2) (4) vs (2)</p> <p>Uncertainty:</p> <p>One-way sensitivity analyses</p> <p>Cost relapse reduced to \$10000 (2) vs (1) (4) vs (2)</p> <p>Cost Relapse Increase to \$50000 (2) vs (1) (4) vs (2)</p> <p>Prob. dose-changing toxicities</p> <p>SLNB Sensitivity 0.82 to1.0 SLNB Specificity 0.96 to 1.0</p> <p>Decreasing mean utility to lower level (2)vs(1) (4)vs(2)</p> <p>Probabilistic sensitivity analysis (PSA)</p> <p>All variables (Cost per QALY)</p>	<p>\$26,000 \$28,800 \$35,700</p> <p>\$21,900/QALY \$35,900/QALY</p> <p>\$14,500/QALY \$26,100/QALY</p> <p>Reported Insignificant</p> <p>Reported Insignificant</p> <p>\$20,300/QALY \$38 ,000/QALY</p> <p>(\$19605,\$10291</p>	

Primary details	Design	Patient characteristics	Interventions	Outcome measures	Results	Comments
	<p>medicare fee schedules, average US wholesale prices. Recurrence costs were taken from Medicaid hospice rates and from a previous economic evaluation.</p> <p>Costs for drug treatment and toxicity were sourced from Tsao et al (1998) who used a modelling approach to estimate direct costs of treating cutaneous melanoma.</p> <p><u>Currency unit:</u> US\$</p> <p><u>Cost year:</u> 2001</p> <p><u>Discounting:</u> 3% Costs 0% Benefits</p>			<p>(2)vs(1) (Median,25th,75th) All variables (Cost per QALY) (4)vs(2) (Median,25th,75th)</p>	<p>,\$36659) (\$30229,\$16766 ,\$58823)</p>	

Primary details	Design	Patient characteristics	Interventions	Outcome measures	Results	Comments
<p><u>Author:</u> Morton</p> <p><u>Year:</u> 2008</p> <p><u>Country:</u> Australia</p>	<p><u>Type of analysis:</u> Cost-utility</p> <p><u>Model structure:</u> Decision Tree and Markov</p> <p><u>Cycle length:</u> 1 year</p> <p><u>Time horizon:</u> 20 years</p> <p><u>Perspective:</u> Direct Healthcare Costs. Patient QALY</p> <p><u>Source of base-line data:</u> Patient characteristics were taken from the MSLT-I trial, an Australian RCT comparing SLNB with nodal observation.</p> <p><u>Source of effectiveness data:</u> Diagnostic accuracy of SLNB was taken from the MSLT-I trial.</p> <p>A literature review was performed to identify transition probabilities. Probabilities of recurrence and probability of complications from WEX, SLNB and "immediate" CLND were taken from MSLT-I.</p> <p>Probabilities of complications from immediate CLND and for melanoma death following distant metastases were taken from retrospective studies of US patients.</p> <p><u>Source of utility data:</u> QALY weights were sourced from the</p>	<p><u>Base case (population):</u> Hypothetical cohort of patients with biopsy proven Melanoma $\geq 1\text{mm}$</p> <p><u>Sample size:</u> N/A</p> <p><u>Age:</u> Age=52</p> <p><u>Gender:</u> Didn't differentiate</p> <p><u>Subgroup analysis:</u> None</p>	<p>Wide Excision(WEX)</p> <p>Wide Excision and SLNB</p>	<p><u>Effectiveness (I):</u> <i>Life years</i> WEX WEX+SLNB</p> <p><i>QALYS</i> WEX WEX+SLNB</p> <p><u>Total costs:</u> WEX WEX+SLNB</p> <p><u>ICER (cost per):</u> LY QALY</p> <p><u>Uncertainty:</u></p> <p>Probability of distant metastases post WEX Increase to 0.2 Decrease to 0.1</p> <p>Probability Of distant metastases post SLNB Increase to 0.022 Decrease to 0.01</p> <p>Cost of WEX + SLNB Increase to \$9,811 Decrease to \$4,339</p> <p>Probability of Nodal Metastasis post WEX Increase to 0.04 Decrease to 0.0275</p> <p>Cost Delayed CLND (with complications) Increase to \$27,000 Decrease to \$8,717</p>	<p>10.45</p> <p>10.77</p> <p>9.90</p> <p>10.34</p> <p>\$23,182</p> <p>\$24,045</p> <p>\$2,770/LY</p> <p>\$1,983/QALY</p> <p>Dominant</p> <p>\$90,959/QALY</p> <p>\$52,436/QALY</p> <p>Dominant</p> <p>\$12,976/QALY</p> <p>\$397/QALY</p> <p>Dominant</p> <p>\$6,273/QALY</p> <p>Dominant</p> <p>\$3,815/QALY</p>	<p><u>Funding:</u> Not Stated</p> <p><u>Comments</u> Probabilistic sensitivity analysis not performed</p>

	<p>melanoma population or from other cancers and the general population when melanoma specific weights were not available.</p> <p><u>Source of cost data:</u> Costs were obtained from Australian Refined Diagnosis Related Groups (AR-DRG) or Australian Medicare Benefits Schedule (MBS). Resource use was calculated from 40 consecutive patients from the MSLT-1 trial.</p> <p><u>Currency unit:</u> Australian Dollars</p> <p><u>Cost year:</u> 2007</p> <p><u>Discounting:</u> 5% Costs 5% Health Benefits</p>					
--	--	--	--	--	--	--

4. Stage 0-II melanoma

4.1 Surgical Management

Review question: What is the most effective surgical treatment for stage 0-II melanoma to achieve clear margins and improved patient outcomes?

Background

Wide local excision is the treatment of choice for primary, clinically localised, melanoma. The proper clinical resection margin is based upon the Breslow thickness of the lesion. NCCN guidelines recommend for melanomas 1mm or less, wide excision with a 1cm margin whilst for localised melanomas between 2-4mm thick a 2cm margin is suggested. Thicker melanomas are associated with an increased risk of nodal and distant metastases but there is no perceived advantage in wider excision for melanomas thicker than 4mm.

The group needs to critically analyse the evidence supporting these statements and review the effectiveness of the different surgical techniques defined in the intervention aspect of the PICO.

Mohs micrographic surgery in relation to melanoma is to be assessed in relation to its outcomes as Mohs determines clear peripheral and deep margins but does not measure the clearance; in contrast to standard excision and pathological techniques.

Is it appropriate to adjust clinical resection margins to avoid significant anatomical damage e.g. free facial margins, facial nerve?

- Aesthetic and functional outcome of surgical excision and reconstruction. What evidence exists that informs us of the impact of the extent of the excision and/or reconstructive techniques eg flaps, grafts and does this vary at different anatomical sites?
- Wide local excision reduces local recurrence rate but has no statistically significant effect on survival. Evidence review as regards the validity of this statement.
- Sentinel Lymph node biopsy, a surgical procedure that identifies and removes the lymph node(s) immediately draining the area of the primary tumour for histological analysis, is subject to much debate. Whilst providing valuable prognostic information; completion lymphadenectomy, undertaken when the sentinel node is positive, has not been shown to improve survival. Critical analysis of the benefits of SNLB, taking into account the newer therapies for adjuvant treatment, needs to be assessed and contrasted with the clinical morbidity and mortality of the procedure plus the financial implications.

Question in PICO Format

Population	Intervention	Comparator	Outcomes
Patients with stage: 0 Ia Ib IIa IIb IIc melanoma	Stage 0 <ul style="list-style-type: none"> Excision with clinical margin, 2mm, 5mm, 10mm MOHS micrographic surgery Johnsons square technique No treatment Stage Ia <ul style="list-style-type: none"> Excision with clinical margin, <1cm, 1cm, 2cm, 3cm, 4cm MOHS micrographic surgery 	Each Other	1. Pathological clear margins 2. Local Recurrence 3. Regional recurrence 4. Melanoma specific Survival (5 & 10 yr) 5. Overall survival (5 & 10 yr) 6. HRQL 7. Detection of micro mets 8. Adverse events, inc: Cosmesis & surgical reconstruction,

	Stage Ib-IIc <ul style="list-style-type: none"> Excision with clinical margin <1cm, 1cm, 2cm, 3cm, 4cm 		lymphoedema after SNB
--	--	--	-----------------------

1 How will the information be searched?

Searches:	
Can we apply date limits to the search (<i>Please provide information on any date limits we can apply to the searches for this topic. This can be done for each individual intervention as appropriate</i>)	No date limits to be applied to the searches
Are there any study design filters to be used (<i>RCT, systematic review, diagnostic test</i>).	Systemic reviews, RCTs, case series (comparative studies with at least 50 patients in each comparison group; only for surgical margins below 1 cm, Mohs micrographic surgery and Johnsons squares)
List useful search terms. (<i>This can include such information as any alternative names for the interventions etc</i>)	Post surgical morbidity Stratification criteria for RCT SNB as eligibility criterion for RCT Prognosis MSLT1 MSLT2 Peg-INTRON EORTC trial melanoma 1. change in stage 2. change in management 3. clinical impact of diagnostic tests / imaging 4. impact on decision making / treatment plan

2 The Review Strategy

Evidence was identified, assessed and synthesised according to the methods outlined in the Guidelines Manual (2012). Relevant studies were identified through sifting the abstracts and excluding studies clearly not relevant to the PICO. In the case of relevant or potentially relevant studies, the full paper was ordered and reviewed, whereupon studies considered to be not relevant to the topic were excluded. Studies which were identified as relevant were critically appraised and quality assessed using GRADE methodology and NICE checklists. Data relating to the identified outcomes were extracted from the relevant studies. The data were not meta-analysed due to the difference in interventions and populations (in terms of melanoma thicknesses) of the included studies, but were instead summarised per study in tabular form, and further in GRADE tables and evidence statements.

13 Search Results

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
Medline	1946-2014	7537	909	21/05/2014
Premedline	May 19 2014	108	32	19/05/2014
Embase	1947-2014	6610	410	22/05/2014
Cochrane Library	Issue 4 of 12 April 2014	577	57	29/05/2014
Web of Science (SCI & SSCI)	1900-2014	3263	164	29/05/2014
Total References retrieved (after de-duplication): 1184				

1 Update Search

- 2 For the update search, the same search criteria/filters were applied as initial search with a date limit
3 of May 2014 onwards.


Database name	No of references found	No of references retrieved	Finish date of search
Medline	159	12	09/10/2014
Premedline	15	1	09/10/2014
Embase	104	9	09/10/2014
Cochrane Library	1	0	09/10/2014
Web of Science (SCI & SSCI)	194	5	09/10/2014
3 references found in Pubmed 09/10/2014			
Total References retrieved (after de-duplication): 29			

4 Medline search strategy (*This search strategy is adapted to each database*)

- 5 1. exp Melanoma/
- 6 2. melanoma\$.tw.
- 7 3. (maligna\$ adj1 lentigo\$).tw.
- 8 4. (hutchinson\$ adj1 (freckle\$ or melano\$)).tw.
- 9 5. dubreuilh.tw.
- 10 6. LMM.tw.
- 11 7. or/1-6
- 12 8. exp Melanoma/su
- 13 9. surgery.sh,fs.
- 14 10. Dermatologic Surgical Procedures/
- 15 11. (excision* or margin* or surger* or resection* or remov* or reconstruct*).tw.
- 16 12. Reconstructive Surgical Procedures/
- 17 13. or/8-12
- 18 14. Mohs Surgery/
- 19 15. ((micrograph* or moh*) adj3 surg*).tw.
- 20 16. chemosurg*.tw.
- 21 17. or/14-16
- 22 18. (johnson* adj2 (square* or technique* or procedure*)).tw.
- 23 19. (square adj (technique* or procedure*)).tw.
- 24 20. (geometric adj2 (technique* or procedure*)).tw.
- 25 21. *Surgical Flaps/
- 26 22. or/18-20
- 27 23. exp Sentinel Lymph Node Biopsy/
- 28 24. ((sentinel and node) adj biops*).tw.
- 29 25. (sentinel adj1 lymphadenectom*).tw.
- 30 26. ((sentinel and node) adj dissect*).tw.
- 31 27. ((sentinel and node) adj procedure).tw.

- 1 28. (SNLB or SNB).tw.
- 2 29. or/23-28
- 3 30. 13 or 17 or 22 or 29
- 4 31. 7 and 30
- 5

1 **Screening Results**



2

3 The evidence relating to the surgical excision margins of 1 cm and above for melanoma consisted of
4 one systematic review (Sladden et al 2009) of five RCTs (Balch et al, 2001; Cascinelli et al, 1998;
5 Cohn-Cedergrén et al, 2000; Khayat et al, 2003; Thomas et al, 2004) and an RCT (Gillgren et al, 2011),
6 which was published after the systematic review. No evidence relating to Mohs micrographic
7 surgery, Johnsons squares surgery and excision margins below 1 cm was identified.

Table 4.1: Characteristics of included studies

Outcome	Balch et al (2001)	Cascinelli et al (1998)	Cohn-Cedermark et al (2000)	Gillgren et al (2011)	Khayat et al (2003)	Thomas et al (2004)
Pathological clear margins	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported
Local recurrence	<u>1st relapse</u> : 2 cm (0.4%) = 4 cm (0.9%), ns <u>Anytime relapse</u> : 2 cm (2.1%) = 4 cm (2.6%), ns	<u>1st relapse</u> : 1 cm (2.6%) = 3 cm (1%), ns	<u>1st relapse</u> : 2 cm (0.2%), 5 cm (1%)	<u>1st event</u> : 2 cm (20 events) = 4 cm (9 events), HR = 2.15 (95% CI 0.97-4.77), p = 0.06	2 cm (1/161 patients), 5 cm (4/165 patients)*	<u>Local or in-transit, as a first or secondary recurrence</u> : 1 cm (37 events) = 3 cm (25 events), HR = 1.51 (95% CI 0.91-2.51), p = 0.1.
Regional recurrence	<u>5-year disease-free survival</u> : 2 cm (75%) = 4 cm (80%), p = 0.28	<u>Regional lymph nodes as 1st relapse</u> : 1 cm (6.9%), 3 cm (7.8%) <u>4-year actuarial disease-free survival</u> : 1 cm = 3 cm, p = 0.66. <u>8-year actuarial disease-free survival</u> : 1 cm (81.6%) = 3 cm (84.4%), p > 0.74.	<u>1st relapse</u> : 2 cm (14%), 5 cm (12%) <u>5-year recurrence-free survival</u> : 2 cm (81%; 95% CI 77-84%) = 5 cm (83%; 95% CI 80-86%), ns. <u>10-year recurrence-free survival</u> : 2 cm (71%; 95% CI 66-75%) = 5 cm (70%; 95% CI 65-74%), ns	<u>Regional skin metastasis as 1st event</u> : 2 cm (19 events) = 4 cm (15 events), HR = 1.25 (95% CI 0.63-2.46), p = 0.52 <u>Regional lymph node recurrence as 1st event</u> : 2 cm (100 events) = 4 cm (114 events), HR = 0.88 (95% CI 0.68-1.16), p = 0.37 <u>Any locoregional recurrence as 1st event</u> : 2 cm (139 events) = 4 cm	2 cm (8.1%), 5 cm (6.7%)* <u>10-year disease-free survival</u> : 2 cm (85%) = 5 cm (83%), p = 0.83.	<u>As a first or secondary recurrence</u> : 1 cm (149 events) = 3 cm (129 events), HR = 1.21 (95% CI 0.96-1.53), p = 0.1. <u>3-year loco-regional recurrence</u> : HR = 1.34 (95% CI 1.06-1.71), p = 0.02 for 1 cm (i.e., favouring 3 cm) <u>Loco-regional recurrence beyond 3 years</u> : HR = 0.69 (95% CI 0.36-1.37), p = 0.3.

Outcome	Balch et al (2001)	Cascinelli et al (1998)	Cohn-Cedermark et al (2000)	Gillgren et al (2011)	Khayat et al (2003)	Thomas et al (2004)
				(138 events), HR = 1 (95% CI 0.79-1.28), p = 0.96 <u>5-year recurrence-free survival</u> : 2 cm (56%; 95% CI 51-61%) = 4 cm (56%; 95% CI 51-61%), p = 0.82		
Melanoma-specific survival (5 & 10 yr)	Not reported	Not reported	<u>As first event</u> : 2 cm (16%) = 5 cm (13%), relative hazard ratio = 1.22 (95% VI 0.88-1.69, p = 0.24	<u>As 1st event?</u> : 2 cm (134 events) = 4 cm (138 events), HR = 0.99 (95% CI 0.78-1.26), p = 0.95	Not reported	<u>5-year</u> : 1 cm (128 events) = 3 cm (105 events), HR = 1.24 (95% CI 0.96-1.61), p = 0.1.
Overall survival (5-year)	2 cm (79.5%) = 4 cm (83.7%), ns.	<u>4-year actuarial survival</u> : 1 cm (96.8%) = 3 cm (96%), p = 0.58	Not reported	2 cm (65%; 95% CI 60-69%) = 4 cm (65%; 95% CI 60-70%), p = 0.69	Not reported	1 cm (144 events) = 3 cm (137 events), HR = 1.07 (95% CI 0.85-1.36), p = 0.6.
Overall survival (10-year)	2 cm (70%) = 4 cm (77%), p = 0.07	<u>8-year actuarial survival</u> : 1 cm (89.6%) = 3 cm (90.3%), p = 0.64 <u>12-year</u> : 1 cm (87.2%) = 3 cm (85.1%)	2 cm (79%; 95% CI 75-82%) = 5 cm (76%; 95% CI 72-80%), ns	<u>Swedish cohort only (N = 644)</u> : 2 cm (50%; 95% CI 44-56%) = 4 cm (50%; 95% CI 44-56%), p = 0.84	2 cm (87%) = 5 cm (86%), p = 0.56	Not reported

Outcome	Balch et al (2001)	Cascinelli et al (1998)	Cohn-Cedermark et al (2000)	Gillgren et al (2011)	Khayat et al (2003)	Thomas et al (2004)
Health-related quality of life	Not reported	Not reported	2 cm (N = 70) = 5 cm (N = 74), i^2 , ns, on all the measured EORTC QLQ-C30 functioning (physical, role, emotional, cognitive, social), symptom (fatigue, pain, insomnia) and financial difficulties scales and global quality of life; on the HAD-A (anxiety) and -D (depression) scales; and on the IES intrusion and avoidance subscales.	Not reported	Not reported	<ul style="list-style-type: none"> - Physical component (PCS), and mental component (MCS) at 1 month: Worse for 3 cm. - PCS improved significantly faster in 3 cm than in 1 cm group. - Psychological distress and attitude towards quality of medical care, treatment and illness (both at 1 month and overall); MCS overall; vocational role and extended family relations (both all time points): 1 cm = 3 cm. - Domestic and sexual role at 1 month, social role at 1 and 3 months; perception of scar at all time points: Worse for 3 cm. - Perception of scar improved significantly faster in 3 cm than in 1 cm group. - HADS-A and B: Similar to MCS results.
Detection of micro metastases	<u>In-transit metastasis (at 6-year follow up):</u> 2 cm (2.5%) = 4 cm (2.1%), ns. <u>Distant metastasis (at</u>	<u>Distant metastasis as 1st relapse:</u> 1 cm (5.6%), 3 cm (4.6%)	<u>Distant metastasis as first event:</u> 2 cm (5%) = 5 cm (7%), relative hazard ratio = 0.76 (95% VI 0.45-1.28, p =	<u>Distant metastasis as 1st event:</u> 2 cm (38 events) = 4 cm (54 events), HR = 0.71 (95% CI 0.47-	<u>Distant recurrence:</u> 2 cm (2.5%), 5 cm (6.1%)*	<u>Distant metastasis:</u> 2 cm (38 events), 5 cm (30 event)

Outcome	Balch et al (2001)	Cascinelli et al (1998)	Cohn-Cedermark et al (2000)	Gillgren et al (2011)	Khayat et al (2003)	Thomas et al (2004)
	<u>6-year follow up</u> : 2 cm (10.9%) = 4 cm (8.5%), ns.		0.29	1.08), p = 0.11		
Adverse events (incl, cosmesis & surgical reconstruction, lymphoedema after SNB)	<u>Skin grafting rate</u> : 2 cm (11%) < 4 cm (46%), p < 0.001. <u>Wound infection rate</u> : 2 cm (5.4%) = 4 cm (4.6%), ns. <u>Wound dehiscence rate</u> : 2 cm (4.6%) = 4 cm (4.2%), ns.	Not reported	<u>Problems with the scar</u> : 2 cm (12/70 patients) = 5 cm (18/74 patients), ns	Not reported	Not reported	<u>Surgical complication rates</u> : 1 cm (7.8%) ≤ 3 cm (13.9%), p = 0.05

ns = non-significant; HR = hazard ratio; *The authors report that “The type of tumor recurrence and surgery performed were independent on statistical analysis ($P = 0.22$)” (pages 1943-1944).

1 Evidence Statements

2 Surgical excision margins of 1 cm compared to surgical excision margins of ≥ 3 cm were not
 3 associated with differences in local recurrence (2 RCTs, N = 1512; low quality), melanoma-specific
 4 survival (1 RCT, N = 900; low quality), 5-year overall survival (2 RCTs, N = 1512; low quality), 10-year
 5 overall survival (1 RCT, N = 612; low quality), or distant metastasis (2 RCTs, N = 1512; low quality),
 6 whereas there was some suggestion that regional recurrence may be higher in the 1 cm group at 3
 7 years, but not later (2 RCTs, N = 1512; low quality), that the surgical complication rate may be lower
 8 in the 1 cm group (1 RCTs, N = 900; low quality), and that the two excision margins are associated
 9 with slightly different health-related quality-of-life profiles (1 RCT, N = 900; low quality).

10 Surgical excision margins of 2 cm compared to surgical excision margins of 4 cm were not associated
 11 with differences in local recurrence (2 RCTs, N = 1399; low quality), regional recurrence (2 RCTs, N =
 12 1399; low quality), melanoma-specific survival (1 RCT, N = 929; low quality), 5-year overall survival (2
 13 RCTs, N = 1399; low quality), 10-year overall survival (2 RCTs, N = 1399; low quality), distant
 14 metastasis (2 RCTs, N = 1399; low quality), or wound infection or dehiscence rates (1 RCT, N = 470;
 15 low quality) whereas the skin grating rate was higher in the 4 cm group (46%) than in the 2 cm group
 16 (11%, $p < 0.0001$; 1 RCT, N = 470; low quality).

17 Surgical excision margins of 2 cm compared to surgical excision margins of ≥ 5 cm were not
 18 associated with differences in local recurrence (2 RCTs, N = 1326; low quality), regional recurrence (2
 19 RCTs, N = 1326; low quality), melanoma-specific survival (1 RCT, N = 989; low quality), 10-year
 20 overall survival (2 RCTs, N = 1326; low quality), health-related quality-of-life (1 RCT, N = 989; low
 21 quality), distant metastasis (2 RCTs, N = 1326; low quality), or 'problems with the scar (1 RCT, N =
 22 989; low quality).

23

GRADE Table 4.1 Should excision with 1 cm clinical margin versus excision with ≥ 3 cm clinical margin

Quality assessment							Summary of findings			
							No of patients		Effect	Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Excision with 1 cm clinical margin	Excision with ≥3 cm clinical margin	Results	
Local recurrence										
2	randomised trials ¹	serious ²	no serious inconsistency	no serious indirectness	serious ³	none	N = 758	N = 754	No significant differences	LOW
Regional recurrence										
2	randomised trials ¹	serious ²	no serious inconsistency	no serious indirectness	serious ³	none	N = 758	N = 754	No significant differences, although one study showed a higher locoregional recurrence rate in 1 cm at 3 years.	LOW
Melanoma-specific survival										
1	randomised trials ⁴	serious ²	no serious inconsistency	no serious indirectness	serious ³	none	N = 453	N = 447	No significant difference	LOW
5-year overall survival										
2	randomised trials ¹	serious ²	no serious inconsistency	no serious indirectness	serious ³	none	N = 758	N = 754	No significant differences	LOW
10-year overall survival										
1	randomised trials ⁵	serious ²	no serious inconsistency	no serious indirectness	serious ³	none	N = 305	N = 307	No significant differences in 8-, or 12-year overall survival	LOW
Health-related quality-of-life										

Quality assessment							Summary of findings			
							No of patients		Effect	Quality
1	randomised trials ⁴	serious ²	no serious inconsistency	no serious indirectness	serious ³	none	N = 453	N = 447	Some apparently minor differences	LOW
Distant metastasis										
2	randomised trials ¹	serious ²	no serious inconsistency	no serious indirectness	serious ³	none	N = 758	N = 754	Appear to be similar	LOW
Adverse events										
1	randomised trials ⁴	serious ²	no serious inconsistency	no serious indirectness	serious ³	none	N = 453	N = 447	Surgical complication rate: 1 cm (7.8%) ≤ 3 cm (13.9%), p = 0.05	LOW

¹ Cascinelli et al (1998), Thomas et al (2004)

² The included studies were associated with under-reporting of a number of design features that therefore put the studies at unclear risk of bias.

³ Low event rate(s).

⁴ Thomas et al (2004)

⁵ Cascinelli et al (1998)

Excision with 2 cm clinical margin versus excision with 4 cm clinical margin

Quality assessment							Summary of findings			
							No of patients		Effect	Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Excision with 2 cm clinical margin	Excision with 4 cm clinical margin	Results	
Local recurrence										

DRAFT FOR CONSULTATION

2	randomised trials ¹	serious ²	no serious inconsistency	no serious indirectness	serious ³	none	N = 708	N = 691	No significant differences	LOW
Regional recurrence										
2	randomised trials ¹	serious ²	no serious inconsistency	no serious indirectness	serious ³	none	N = 708	N = 691	No significant differences	LOW
Melanoma-specific survival										
1	randomised trials ⁴	serious ²	no serious inconsistency	no serious indirectness	serious ³	none	N = 470	N = 459	No significant difference	LOW
5-year overall survival										
2	randomised trials ¹	serious ²	no serious inconsistency	no serious indirectness	serious ³	none	N = 708	N = 691	No significant differences	LOW
10-year overall survival										
2	randomised trials ¹	serious ²	no serious inconsistency	no serious indirectness	serious ³	none	N = 708	N = 691	No significant differences	LOW
Distant metastasis										
2	randomised trials ¹	serious ²	no serious inconsistency	no serious indirectness	serious ³	none	N = 708	N = 691	Appear to be similar	LOW
Adverse events										
1	randomised trials ⁵	serious ²	no serious inconsistency	no serious indirectness	serious ³	none	N = 238	N = 232	Skin grafting rate: 2 cm (11%) < 4 cm (46%), p < 0.001; Wound infection/dehiscence rate: 2 cm = 4 cm	LOW

¹ Balch et al (2001), Gillgren et al (2011)

² The included studies were associated with under-reporting of a number of design features that therefore put the studies at unclear risk of bias.

³ Low event rate(s).

⁴ Gillgren et al (2011)

⁵ Balch et al (2001)

Excision with 2 cm clinical margin versus excision with ≥ 5 cm clinical margin

Quality assessment							Summary of findings			
							No of patients		Effect	Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Excision with 2 cm clinical margin	Excision with ≥5 cm clinical margin	Results	
Local recurrence										
2	randomised trials ¹	serious ²	no serious inconsistency	no serious indirectness	serious ³	none	N = 643	N = 683	Appear to be similar	LOW
Regional recurrence										
2	randomised trials ¹	serious ²	no serious inconsistency	no serious indirectness	serious ³	none	N = 643	N = 683	Appear to be similar	LOW
Melanoma-specific survival										
1	randomised trials ⁴	serious ²	no serious inconsistency	no serious indirectness	serious ³	none	N = 476	N = 513	No significant difference	LOW
10-year overall survival										
2	randomised trials ¹	serious ²	no serious inconsistency	no serious indirectness	serious ³	none	N = 643	N = 683	No significant differences	LOW
Health-related quality-of-life										
1	randomised trials ⁴	serious ²	no serious inconsistency	no serious indirectness	serious ³	none	N = 476	N = 513	No significant differences	LOW
Distant metastasis										

DRAFT FOR CONSULTATION

2	randomised trials ¹	serious ²	no serious inconsistency	no serious indirectness	serious ³	none	N = 643	N = 683	Appear to be similar	LOW
Adverse events										
1	randomised trials ⁴	serious ²	no serious inconsistency	no serious indirectness	serious ³	none	N = 476	N = 513	Problems with the scar: No significant differences	LOW

¹ Cohn-Cedermark et al (2000), Khayat et al (2003)

² The included studies were associated with under-reporting of a number of design features that therefore put the studies at unclear risk of bias.

³ Low event rate(s).

⁴ Cohn-Cedermark et al (2000)

Study Quality

All the studies included in the systematic review were RCTs and these were supplemented by an additional RCT (Gillgren 2011) which had been published after the systematic review. The adequacy of the randomisation sequence generation was unclear in all the studies in the systematic review and of low risk in Gillgren et al (2011), whereas allocation concealment was considered adequate in Cohn-Cedermark (2000), Gillgren et al (2011) and Thomas (2004) and unclear in Balch et al (2001), Cascinelli et al (1998) and Khayat et al (2003). Blinding of the outcome assessment was employed for survival in Balch et al (2001), but was unclear in the remaining four studies included in the systematic review and in Gillgren et al (2011). With the exception of Cohn-Cedermark (2000), the remaining studies in the systematic review were at unclear risk of attrition bias as judged by Sladden et al (2009), while Gillgren et al (2011) was at low risk of attrition bias. Sladden et al (2009) rated all the included trials as free of selective reporting, and also reported that it was unclear whether the five included RCTs were at risk of other types of bias. Gillgren et al (2011) did not systematically record adverse events and this omission is the only indication that this study is at risk of outcome reported bias.

In summary, due to a lack of reporting in the included RCTs, it is not possible to give an overall rating of the quality of the studies included in this evidence review.

References

Included studies

Systematic review of RCTs

Sladden, M. J., et al (2009) Surgical excision margins for primary cutaneous melanoma. [Review] [59 refs]. *Cochrane Database of Systematic Reviews*, CD004835.

Balch 2001 published in 3 papers (included in Sladden et al 2009):

Balch CM, et al (2001) (Investigators from the Intergroup Melanoma Surgical Trial). Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1 - 4 mm melanomas. *Annals of surgical oncology* 8:101–8.

Balch CM, et al. (1993) Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. *Annals of surgery* 218:262–7.

Karakousis CP, et al (1996) Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. *Annals of surgical oncology*;3:446–52.

Cascinelli 1998 published in 3 papers (included in Sladden et al 2009):

Cascinelli N. (1998) Margin of resection in the management of primary melanoma. *Seminars in surgical oncology* 14:272–5.

Veronesi U, Cascinelli N. (1991) Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. *Archives of surgery*;26:438–41.

Veronesi U, et al. (1988) Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. [Erratum in: N Engl J Med 1991; 325: 292]. *The New England Journal of Medicine*;318(18):1159–62.

Cohn-Cedermark 2000 published in 3 papers (included in Sladden et al 2009):

Cohn-Cedermark G, et al. (2000) Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. *Cancer* 89:1495–1501.

Ringborg U, et al. (1996) Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm: randomized study by the Swedish Melanoma Study Group. *Cancer* 77:1809–14.

Bergenmar, M., et al (2008) Health related quality of life in patients with malignant melanoma included in a randomized study of resection margins. *Pigment Cell & Melanoma Research*, 21: 333.

Bergenmar, M., et al (2010) Surgical resection margins do not influence health related quality of life or emotional distress in patients with cutaneous melanoma: results of a prospective randomised trial. *Scandinavian Journal of Plastic & Reconstructive Surgery & Hand Surgery*, 44: 146-155.

Gillgren 2011 published in 1 paper:

Gillgren, P., et al (2011) 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. *Lancet*, 378: 1635-1642.

Khayat 2003 published in 2 papers (included in Sladden et al 2009):

Banzet P, et al. (1993) Wide versus narrow surgical excision in thin (<2mm) stage 1 primary cutaneous melanoma: long term results of a French multicentre prospective randomized trial on 319 patients. *Proceedings of the American Society of Clinical Oncology* March;12:387.

Khayat D, et al. (2003) Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). *Cancer* 97:1941–6.

Thomas 2004 published in 2 papers (included in Sladden et al 2009):

Thomas JM, et al (2004) (United Kingdom Melanoma Study Group, British Association of Plastic Surgeons, Scottish Cancer Therapy Network). Excision margins in high-risk malignant melanoma. *The New England Journal of Medicine* 350:757–66.

Newton-Bishop, J. A., et al (2004) A quality-of-life study in high-risk (thickness \geq 2 mm) cutaneous melanoma patients in a randomized trial of 1-cm versus 3-cm surgical excision margins. *Journal of Investigative Dermatology Symposium Proceedings*, 9: 152-159.

Excluded studies

(2011) Surgical excision margins for primary cutaneous melanoma: a summarised Cochrane review. *Clinical & Experimental Dermatology*, 36: 334-335.

Reason: Same as Sladden 2009

Aitken, D. R., Clausen, K., Klein, J. P., James, A. G., Aitken, D. R., Clausen, K., Klein, J. P. & James, A. G. (1983) The extent of primary melanoma excision. A re-evaluation--how wide is wide? *Annals of Surgery*, 198: 634-641.

Reason: retrospective study, only 4 out of 118 patients had excision margin $<$ 10 mm, not nohs/johnson squares

Akhtar, S., Bhat, W., Magdum, A., Stanley, P. R., Akhtar, S., Bhat, W., Magdum, A. & Stanley, P. R. W. (2014) Surgical excision margins for melanoma in situ. *Journal of Plastic, Reconstructive & Aesthetic Surgery: JPRAS*, 67: 320-323.

Reason: not in pico as this retrospective study only reports on histological margins, not clinical margins

Aloia, T. A., Gershenwald, J. E., Aloia, T. A. & Gershenwald, J. E. (2005) Management of early-stage cutaneous melanoma. [Review] [228 refs]. *Current Problems in Surgery*, 42: 460-534.

Reason: narrative review

An, K. P., Ratner, D., An, K. P. & Ratner, D. (2001) Surgical management of cutaneous malignancies. [Review] [151 refs]. *Clinics in Dermatology*, 19: 305-320.

Reason: narrative review

Anderson, K. W., Baker, S. R., Anderson, K. W. & Baker, S. R. (2003) Management of early lentigo maligna and lentigo maligna melanoma of the head and neck. [Review] [26 refs]. *Facial Plastic Surgery Clinics of North America*, 11: 93-105.

Reason: narrative review

Bachaud, J. M., Shubinski, R., Boussin, G., Chevreau, C., David, J. M., Viraben, R., Bonafe, J. L., Daly, N. J., Bachaud, J. M., Shubinski, R., Boussin, G., Chevreau, C., David, J. M., Viraben, R., Bonafe, J. L. & Daly, N. J. (1992) Stage I cutaneous malignant melanoma: risk factors of loco-regional recurrence after wide local excision and clinical perspectives. *European Journal of Surgical Oncology*, 18: 442-448.

Reason: comparisons not in pico

Balch, C. M. & Balch, C. M. (1998) The John Wayne Clinical Research Lecture. Surgical management of melanoma: results of prospective randomized trials. *Annals of Surgical Oncology*, 5: 301-309.

Reason: narrative review

- 1 Balch, C. M. & Balch, C. M. (1999) Randomized surgical trials involving elective node dissection for
2 melanoma. *Advances in Surgery*, 32: 255-270.
3 Reason: narrative review
- 4 Balch, C. M., Ross, M. I., Cascinelli, N. & Soong, S. J. (2007) Excision margins for primary cutaneous
5 melanoma - Updated pooled analysis of randomized controlled trials - Invited critique. *Archives of*
6 *Surgery*, 142: 891-893.
7 Reason: narrative review
- 8 Biran, S., Hochman, A., Walach, N., Biran, S., Hochman, A. & Walach, N. (1973) Malignant melanoma.
9 A survey of 232 cases. *Oncology*, 28: 331-342.
10 Reason: not comparative study
- 11 Bosbous, M. W., Dzwierzynski, W. W., Neuburg, M., Bosbous, M. W., Dzwierzynski, W. W. &
12 Neuburg, M. (2009) Staged excision of lentigo maligna and lentigo maligna melanoma: a 10-year
13 experience. *Plastic & Reconstructive Surgery*, 124: 1947-1955.
14 Reason: not comparative study
- 15 Breslow, A. & Breslow, A. (1978) The surgical treatment of stage I cutaneous melanoma. [Review]
16 [25 refs]. *Cancer Treatment Reviews*, 5: 195-198.
17 Reason: narrative review
- 18 Bricca, G. M., Brodland, D. G., Ren, D., Zitelli, J. A., Bricca, G. M., Brodland, D. G., Ren, D. & Zitelli, J.
19 A. (2005) Cutaneous head and neck melanoma treated with Mohs micrographic surgery. *Journal of*
20 *the American Academy of Dermatology*, 52: 92-100.
21 Reason: retrospective/prospective study with historical controls: not possible to ascertain the type
22 of surgery the historical controls were treated with in terms of surgical margins.
- 23 Brodland, D. G. & Brodland, D. G. (2000) Reconstruction conundrum #3. Excision and reconstruction
24 of recurrent lentigo maligna melanoma. *Dermatologic Surgery*, 26: 965-968.
25 Reason: not in pico
- 26 Brodland, D. G. & Brodland, D. G. (2001) The treatment of nail apparatus melanoma with Mohs
27 micrographic surgery. *Dermatologic Surgery*, 27: 269-273.
28 Reason: not in pico/not comparative study
- 29 Bruns, S. D., McGee, J. M., Phillips, J. W., Bruns, S. D., McGee, J. M. & Phillips, J. W. (2002) Current
30 treatment of cutaneous melanoma and the sentinel lymph node. [Review] [23 refs]. *Journal -*
31 *Oklahoma State Medical Association*, 95: 332-335.
32 Reason: narrative review
- 33 Bub, J. L., Berg, D., Slee, A., Odland, P. B., Bub, J. L., Berg, D., Slee, A. & Odland, P. B. (2004)
34 Management of lentigo maligna and lentigo maligna melanoma with staged excision: a 5-year
35 follow-up. *Archives of Dermatology*, 140: 552-558.
36 Reason: not comparative study
- 37 Buker, J. L., Amonette, R. A., Buker, J. L. & Amonette, R. A. (1992) Micrographic surgery. [Review] [14
38 refs]. *Clinics in Dermatology*, 10: 309-315.
39 Reason: narrative review
- 40 Cady, B., Legg, M. A., Redfern, A. B., Cady, B., Legg, M. A. & Redfern, A. B. (1975) Contemporary
41 treatment of malignant melanoma. *American Journal of Surgery*, 129: 472-482.
42 Reason: not in pico/not comparative study

- 1 Cascinelli, N. & Cascinelli, N. (1996) The role of clinical trials in assessing optimal treatment of
2 cutaneous melanoma not extending beyond the regional nodes. [Review] [49 refs]. *European Journal*
3 *of Surgical Oncology*, 22: 123-127.
4 Reason: narrative review
- 5 Chin-Lenn, L. M. (2013) Comparison of outcomes for malignant melanoma of the face treated using
6 mohs micrographic surgery and wide local excision. *Dermatologic Surgery*, 39: 1637-1645.
7 Reason: not rct, comparison not in pico (mohs v wle [nos]; retrospective, n = 151
- 8 Cochran, A. J., Bailly, C., Paul, E., Cochran, A. J., Bailly, C. & Paul, E. (2003) Optimal surgery for
9 cutaneous melanoma requires accurate and complete pathologic information. [Review] [17 refs].
10 *Facial Plastic Surgery Clinics of North America*, 11: 23-32.
11 Reason: narrative review
- 12 Cogrel, O. G. (2011) Control of excision margin by micrographic surgery (the spaghetti technique) of
13 in situ or invasive malignant lentigo: A monocentric study of 20 cases. *Nouvelles Dermatologiques*,
14 30: 49-50.
15 Reason: foreign language
- 16 Cohen, L. S. (2006) Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma
17 using mel-5 immunostaining: University of Minnesota experience: Commentary. *Dermatologic*
18 *Surgery*, 32: 696-697.
19 Reason: commentary, no original data
- 20 Coit, D. G. & Coit, D. G. (1993) The role of surgery in cutaneous malignant melanoma. [Review] [166
21 refs]. *Cancer Treatment & Research*, 65: 297-334.
22 Reason: narrative review
- 23 Demirci, H., Johnson, T. M., Frueh, B. R., Musch, D. C., Fullen, D. R. & Nelson, C. C. (2008)
24 Management of periocular cutaneous melanoma with a staged excision technique and permanent
25 sections the square procedure. *Ophthalmology*, 115: 2295-2300.
26 Reason: not in pico/not comparative study
- 27 Duffy, K. L., Truong, A., Bowen, G. M., Andtbacka, R. H., Hyngstrom, J., Bowles, T., Grossmann, K.,
28 Khong, H., Hyde, M., Florell, S. R., Bowen, A. R., Wada, D., and Grossman, D. Adequacy of 5-mm
29 surgical excision margins for non-lentiginous melanoma in situ. *Journal of the American Academy of*
30 *Dermatology* 71[4], 835-838. 2014.
31 Reason: No data
- 32 Eedy, D. J. & Eedy, D. J. (2003) Surgical treatment of melanoma. [Review] [118 refs]. *British Journal of*
33 *Dermatology*, 149: 2-12.
34 Reason: narrative review
- 35 Elder, D. E., Guerry, D., Heiberger, R. M., LaRossa, D., Goldman, L. I., Clark, W. H., Jr., Thompson, C. J.,
36 Matozzo, I., Van, H. M., Elder, D. E., Guerry, D., Heiberger, R. M., LaRossa, D., Goldman, L. I., Clark,
37 W. H. J., Thompson, C. J., Matozzo, I. & Van Horn, M. (1983) Optimal resection margin for cutaneous
38 malignant melanoma. *Plastic & Reconstructive Surgery*, 71: 66-72.
39 Reason: retrospective study, n = 105, only relevant results only describe that all six of the in-transit
40 metastases had minimal excision margins > 30 mm
- 41 Eldh, J. & Eldh, J. (1979) Excisional biopsy and delayed wide excision versus primary wide excision of
42 malignant melanoma. *Scandinavian Journal of Plastic & Reconstructive Surgery*, 13: 341-345.
43 Reason: not rct, not mohs/johnsons squares/margin <1 cm,

- 1 Erickson, C. & Miller, S. J. (2010) Treatment options in melanoma in situ: topical and radiation
2 therapy, excision and Mohs surgery. *International Journal of Dermatology*, 49: 482-491.
3 Reason: narrative review
- 4 Esmaeli, B., Youssef, A., Naderi, A., Ahmadi, M. A., Meyer, D. R., McNab, A., Collaborative Eyelid Skin
5 Melanoma Group., Esmaeli, B., Youssef, A., Naderi, A., Ahmadi, M. A., Meyer, D. R., McNab, A. &
6 Collaborative Eyelid Skin Melanoma Group. (2003) Margins of excision for cutaneous melanoma of
7 the eyelid skin: the Collaborative Eyelid Skin Melanoma Group Report. *Ophthalmic Plastic &
8 Reconstructive Surgery*, 19: 96-101.
9 Reason: not rct, <50 patients in each group
- 10 Evans, R. A. & Evans, R. A. (1995) Malignant melanoma: primary surgical management (excision and
11 node dissection) based upon pathology and staging. *Cancer*, 76: 2384-2385.
12 Reason: narrative review
- 13 Furukawa, H., Tsutsumida, A., Yamamoto, Y., Sasaki, S., Sekido, M., Fujimori, H., Sugihara, T.,
14 Furukawa, H., Tsutsumida, A., Yamamoto, Y., Sasaki, S., Sekido, M., Fujimori, H. & Sugihara, T. (2007)
15 Melanoma of thumb: retrospective study for amputation levels, surgical margin and reconstruction.
16 *Journal of Plastic, Reconstructive & Aesthetic Surgery: JPRAS*, 60: 24-31.
17 Reason: not rct, not mohs/johnson squares, comparison was ≤4 cm v >4 cm, retrospective, n = 15
- 18 Gillgren, P. (2011) A randomized multicentre trial comparing 2 versus 4-cm surgical excision margins
19 for thick (>2 mm) primary cutaneous melanoma. *Pigment Cell and Melanoma Research*, Conference:
20 1061.
21 Reason: abstract
- 22 Gillgren, P. (2012) 2-cm and 4-cm surgical excision margins did not differ for survival in cutaneous
23 melanoma > 2 mm thick. *Annals of Internal Medicine*, 156: JC5-JC7.
24 Reason: comment on gillgren rct
- 25 Grevey, S. C., Zax, R. H., McCall, M. W., Grevey, S. C., Zax, R. H. & McCall, M. W. (1995) Melanoma
26 and Mohs' micrographic surgery. [Review] [65 refs]. *Advances in Dermatology*, 10: 175-198.
27 Reason: narrative review
- 28 Haigh, P. I., DiFronzo, L. A., McCready, D. R., Haigh, P. I., DiFronzo, L. A. & McCready, D. R. (2003)
29 Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis.
30 [Review] [22 refs]. *Canadian Journal of Surgery*, 46: 419-426.
31 Reason: systematic review with same studies included as in sladden cochrane review, which is
32 included in current evidence review instead.
- 33 Harish, V., Bond, J. S., Scolyer, R. A., Haydu, L. E., Saw, R. P., Quinn, M. J., Bengner, R. S., Uren, R. F.,
34 Stretch, J. R., Shannon, K. F., Thompson, J. F., Harish, V., Bond, J. S., Scolyer, R. A., Haydu, L. E., Saw,
35 R. P. M., Quinn, M. J., Bengner, R. S., Uren, R. F., Stretch, J. R., Shannon, K. F. & Thompson, J. F. (2013)
36 Margins of excision and prognostic factors for cutaneous eyelid melanomas. *Journal of Plastic,
37 Reconstructive & Aesthetic Surgery: JPRAS*, 66: 1066-1073.
38 Reason: not rct, <50 patients in each group
- 39 Harlan, L. C. L. (2011) Trends in the treatment and survival for local and regional cutaneous
40 melanoma in a US population-based study. *Melanoma Research*, 21: 547-554.
41 Reason: not rct, comparisons not in pico
- 42 Hazan, C., Dusza, S. W., Delgado, R., Busam, K. J., Halpern, A. C., Nehal, K. S., Hazan, C., Dusza, S. W.,
43 Delgado, R., Busam, K. J., Halpern, A. C. & Nehal, K. S. (2008) Staged excision for lentigo maligna and
44 lentigo maligna melanoma: A retrospective analysis of 117 cases. *Journal of the American Academy*

- 1 *of Dermatology*, 58: 142-148.
- 2 Reason: comparison and outcome not in pico
- 3 Heaton, K. M., Sussman, J. J., Gershenwald, J. E., Lee, J. E., Reintgen, D. S., Mansfield, P. F., Ross, M.
- 4 I., Heaton, K. M., Sussman, J. J., Gershenwald, J. E., Lee, J. E., Reintgen, D. S., Mansfield, P. F. & Ross,
- 5 M. I. (1998) Surgical margins and prognostic factors in patients with thick (>4mm) primary
- 6 melanoma. *Annals of Surgical Oncology*, 5: 322-328.
- 7 Reason: not rct, not mohs/johnson squares, comparison was <2 cm v >2 cm, retrospective, n = 278
- 8 Heenan, P. J., Weeramanthri, T., Holman, C. D., Armstrong, B. K., Heenan, P. J., Weeramanthri, T.,
- 9 Holman, C. D. & Armstrong, B. K. (1985) Surgical treatment and survival from cutaneous malignant
- 10 melanoma. *Australian & New Zealand Journal of Surgery*, 55: 229-234.
- 11 Reason: comparison not in pico (0-29 mm v 30-59 mm v 60+mm)
- 12 Hilari, H., Llorca, D., Traves, V., Villanueva, A., Serra-Guillen, C., Requena, C., Llombart, B., Sanmartin,
- 13 O., Guillen, C., Nagore, E., Hilari, H., Llorca, D., Traves, V., Villanueva, A., Serra-Guillen, C., Requena,
- 14 C., Llombart, B., Sanmartin, O., Guillen, C. & Nagore, E. (2012) Conventional surgery compared with
- 15 slow Mohs micrographic surgery in the treatment of lentigo maligna: a retrospective study of 62
- 16 cases. *Actas Dermo-Sifiliograficas*, 103: 614-623.
- 17 Reason: comparison and outcome not in pico
- 18 Hill, D. C. & Gramp, A. A. (1999) Surgical treatment of lentigo maligna and lentigo maligna
- 19 melanoma. *Australasian Journal of Dermatology*, 40: 25-30.
- 20 Reason: not comparative study
- 21 Hudson, D. A. & Krige, J. E. J. (1993) Conservative Excision for Cutaneous Melanoma on the Face.
- 22 *European Journal of Plastic Surgery*, 16: 12-16.
- 23 not rct, n < 50 in each group
- 24 Hudson, L. C. (2012) 1 vs 2 cm surgical excision for 1-2 mm melanomas: Does it matter? *Annals of*
- 25 *Surgical Oncology*, Conference: February.
- 26 Reason: abstract
- 27 Hudson, L. E., Maithel, S. K., Carlson, G. W., Rizzo, M., Murray, D. R., Hestley, A. C. & Delman, K. A.
- 28 (2013) 1 or 2 cm margins of excision for T2 melanomas: do they impact recurrence or survival?
- 29 *Annals of Surgical Oncology*, 20: 346-351.
- 30 Reason: not rct, not mohs/johnson squares/margins <1 cm
- 31 Huilgol, S. C., Selva, D., Chen, C., Hill, D. C., James, C. L., Gramp, A., Malhotra, R., Huilgol, S. C., Selva,
- 32 D., Chen, C., Hill, D. C., James, C. L., Gramp, A. & Malhotra, R. (2004) Surgical margins for lentigo
- 33 maligna and lentigo maligna melanoma: the technique of mapped serial excision. *Archives of*
- 34 *Dermatology*, 140: 1087-1092.
- 35 Reason: not comparative study
- 36 Jahn, V., Breuninger, H., Garbe, C. & Moehrle, M. (2006) Melanoma of the ear: prognostic factors
- 37 and surgical strategies. *British Journal of Dermatology*, 154: 310-318.
- 38 Reason: not rct, <50 patients in each group
- 39 Jahn, V., Breuninger, H., Garbe, C., Maassen, M. M., Moehrle, M., Jahn, V., Breuninger, H., Garbe, C.,
- 40 Maassen, M. M. & Moehrle, M. (2006) Melanoma of the nose: prognostic factors, three-dimensional
- 41 histology, and surgical strategies. *Laryngoscope*, 116: 1204-1211.
- 42 Reason: not comparative study

- 1 Jejurikar, S. S., Borschel, G. H., Johnson, T. M., Lowe, L., Brown, D. L., Jejurikar, S. S., Borschel, G. H.,
2 Johnson, T. M., Lowe, L. & Brown, D. L. (2007) Immediate, optimal reconstruction of facial lentigo
3 maligna and melanoma following total peripheral margin control. *Plastic & Reconstructive Surgery*,
4 120: 1249-1255.
5 Reason: not comparative study
- 6 Jewell, W. R. & Jewell, W. R. (1991) Current status of the surgical treatment of melanoma. [Review]
7 [67 refs]. *Surgery Annual*, 23 Pt 1: 57-72.
8 Reason: narrative review
- 9 Johnson, T. M., Headington, J. T., Baker, S. R., Lowe, L., Johnson, T. M., Headington, J. T., Baker, S. R.
10 & Lowe, L. (1997) Usefulness of the staged excision for lentigo maligna and lentigo maligna
11 melanoma: the "square" procedure. *Journal of the American Academy of Dermatology*, 37: 758-764.
12 Reason: narrative review
- 13 Johnson, T. M., Sondak, V. K., Johnson, T. M. & Sondak, V. K. (2004) Melanoma margins: the
14 importance and need for more evidence-based trials. *Archives of Dermatology*, 140: 1148-1150.
15 Reason: comment on Newton-Bishop
- 16 Kanaan, Z., Mulhall, A., Mahid, S., Torres, M. L., McCafferty, M., McMasters, K. M., Hornung, C.,
17 Galandiuk, S., Kanaan, Z., Mulhall, A., Mahid, S., Torres, M. L., McCafferty, M., McMasters, K. M.,
18 Hornung, C. & Galandiuk, S. (2012) A systematic review of prognosis and therapy of anal malignant
19 melanoma: a plea for more precise reporting of location and thickness. [Review]. *American Surgeon*,
20 78: 28-35.
21 Reason: not in pico
- 22 Kanzler, M. H., Mraz-Gernhard, S., Kanzler, M. H. & Mraz-Gernhard, S. (2001) Treatment of primary
23 cutaneous melanoma. [Review] [26 refs]. *JAMA*, 285: 1819-1821.
24 Reason: narrative review
- 25 Kaufmann, R. & Kaufmann, R. (2006) Malignant melanoma--sentinel lymph node biopsy and surgical
26 procedures. [Review] [52 refs]. *Frontiers of Radiation Therapy & Oncology*, 39: 127-139.
27 Reason: narrative review
- 28 Kelly, J. W., Sagebiel, R. W., Calderon, W., Murillo, L., Dakin, R. L., Blois, M. S., Kelly, J. W., Sagebiel, R.
29 W., Calderon, W., Murillo, L., Dakin, R. L. & Blois, M. S. (1984) The frequency of local recurrence and
30 microsatellites as a guide to reexcision margins for cutaneous malignant melanoma. *Annals of*
31 *Surgery*, 200: 759-763.
32 Reason: not rct, n < 50 in each comparison group
- 33 Kirkham, N., Newton, J., Thomas, M., Kirkham, N., Newton, J. & Thomas, M. (1993) Malignant
34 melanoma excision margins. *Lancet*, 341: 184.
35 Reason: letter/comment
- 36 Krown, S. E. C. (2004) Defining Adequate Surgery for Primary Melanoma. *New England Journal of*
37 *Medicine*, 350: 823-825.
38 Reason: editorial
- 39 Kunishige, J. H., Brodland, D. G., Zitelli, J. A., Kunishige, J. H., Brodland, D. G. & Zitelli, J. A. (2012)
40 Surgical margins for melanoma in situ. *Journal of the American Academy of Dermatology*, 66: 438-
41 444.
42 Reason: not in pico/not comparative study

- 1 Lang, N. P., Stair, J. M., Degges, R. D., Thompson, C., Garner, H., Baker, G. F., Westbrook, K. C., Lang,
2 N. P., Stair, J. M., Degges, R. D., Thompson, C., Garner, H., Baker, G. F. & Westbrook, K. C. (1984)
3 Melanoma today does not require radical surgery. *American Journal of Surgery*, 148: 723-726.
4 Reason: not rct, not johnsons squares/mohs/margins < 1 cm
- 5 Lange, J. R. & Lange, J. R. (1997) The surgical management of invasive primary melanoma: an update.
6 [Review] [21 refs]. *Maryland Medical Journal*, 46: 251-254.
7 Reason: narrative review
- 8 Lens, M. B., Dawes, M., Goodacre, T., Bishop, J. A., Lens, M. B., Dawes, M., Goodacre, T. & Bishop, J.
9 A. N. (2002) Excision margins in the treatment of primary cutaneous melanoma: a systematic review
10 of randomized controlled trials comparing narrow vs wide excision. [Review] [21 refs]. *Archives of*
11 *Surgery*, 137: 1101-1105.
12 Reason: systematic review with same studies included as in sladden cochrane review, which is
13 included in current evidence review instead.
- 14 Lens, M. B., Nathan, P., Bataille, V., Lens, M. B., Nathan, P. & Bataille, V. (2007) Excision margins for
15 primary cutaneous melanoma: updated pooled analysis of randomized controlled trials. *Archives of*
16 *Surgery*, 142: 885-891.
17 Reason: systematic review with same studies included as in sladden cochrane review, which is
18 included in current evidence review instead.
- 19 Livingstone, E., Windemuth-Kieselbach, C., Eigentler, T. K., Rompel, R., Trefzer, U., Nashan, D.,
20 Rotterdam, S., Ugurel, S., Schadendorf, D., Livingstone, E., Windemuth-Kieselbach, C., Eigentler, T. K.,
21 Rompel, R., Trefzer, U., Nashan, D., Rotterdam, S., Ugurel, S. & Schadendorf, D. (2011) A first
22 prospective population-based analysis investigating the actual practice of melanoma diagnosis,
23 treatment and follow-up. *European Journal of Cancer*, 47: 1977-1989.
24 Reason: not in pico
- 25 Macdonald, C. (2013) The impact on quality of life and reconstructive need of wider excision margins
26 >1 cm for primary cutaneous melanoma. *JDDG - Journal of the German Society of Dermatology*,
27 Conference: July.
28 Reason: abstract
- 29 Mansfield, P. F., Lee, J. E., Balch, C. M., Mansfield, P. F., Lee, J. E. & Balch, C. M. (1994) Cutaneous
30 melanoma: current practice and surgical controversies. [Review] [425 refs]. *Current Problems in*
31 *Surgery*, 31: 253-374.
32 Reason: narrative review
- 33 Margolese, R. G. & Margolese, R. G. (306) Controversy in the surgical management of melanoma.
34 *Canadian Journal of Surgery*, 26: 303-304.
35 Reason: letter
- 36 Matter, M. L. (2003) Surgical treatment of malignant melanoma. *Medecine et Hygiene*, 61: 1088-
37 1097.
38 Reason: foreign language
- 39 McCall, M. W., Greenway, H. T., Mohs, F. E., McCall, M. W., Greenway, H. T. & Mohs, F. E. (1981)
40 Mohs' chemosurgery for skin cancer, microscopically controlled excision. [Review] [19 refs]. *Journal*
41 *of the Kentucky Medical Association*, 79: 613-616.
42 Reason: narrative review
- 43 McKenna, D. B., Lee, R. J., Prescott, R. J., Doherty, V. R., McKenna, D. B., Lee, R. J., Prescott, R. J. &
44 Doherty, V. R. (2004) A retrospective observational study of primary cutaneous malignant melanoma

- 1 patients treated with excision only compared with excision biopsy followed by wider local excision.
- 2 *British Journal of Dermatology*, 150: 523-530.
- 3 Reason: comparison not in pico
- 4 McLeod, M., Choudhary, S., Giannakakis, G. & Nouri, K. (2011) Surgical treatments for lentigo
- 5 maligna: a review. *Dermatol.Surg.*, 37: 1210-1228.
- 6 Reason: narrative review
- 7 Mocellin, S., Pasquali, S., Nitti, D., Mocellin, S., Pasquali, S. & Nitti, D. (2011) The impact of surgery on
- 8 survival of patients with cutaneous melanoma: revisiting the role of primary tumor excision margins.
- 9 *Annals of Surgery*, 253: 238-243.
- 10 Reason: systematic review with same studies included as in sladden cochrane review, which is
- 11 included in current evidence review instead.
- 12 Mosca, P. J., Tyler, D. S., Seigler, H. F., Mosca, P. J., Tyler, D. S. & Seigler, H. F. (2004) Surgical
- 13 management of cutaneous melanoma: current practice and impact on prognosis. [Review] [128
- 14 refs]. *Advances in Surgery*, 38: 85-119.
- 15 Reason: narrative review
- 16 Murphy, M. E., Brodland, D. G., Zitelli, J. A., Murphy, M. E., Brodland, D. G. & Zitelli, J. A. (2008)
- 17 Definitive surgical treatment of 24 skin cancers not cured by prior imiquimod therapy: a case series.
- 18 *Dermatologic Surgery*, 34: 1258-1263.
- 19 Reason: not in pico, 1/24 patients had melanoma
- 20 Neades, G. T., Hughes, L. E., Neades, G. T. & Hughes, L. E. (1990) Cure and cosmesis in the
- 21 management of primary malignant melanoma. [Review] [29 refs]. *British Journal of Cancer*, 61: 192-
- 22 194.
- 23 Reason: editorial
- 24 Neades, G. T., Orr, D. J., Hughes, L. E., Horgan, K., Neades, G. T., Orr, D. J., Hughes, L. E. & Horgan, K.
- 25 (1993) Safe margins in the excision of primary cutaneous melanoma. *British Journal of Surgery*, 80:
- 26 731-733.
- 27 Reason: comparisons not in pico (includes mixed margins, i.e., 1 or 2 cm versus 1, 2, or 3-5 cm)
- 28 Newman, L. (2001) Surgical oncology focusing on minimally invasive surgery, more randomized
- 29 clinical trials. *Journal of the National Cancer Institute*, 93: 897-899.
- 30 Reason: narrative review
- 31 Ng, A. K., Jones, W. O., Shaw, J. H., Ng, A. K., Jones, W. O. & Shaw, J. H. (2001) Analysis of local
- 32 recurrence and optimizing excision margins for cutaneous melanoma. *British Journal of Surgery*, 88:
- 33 137-142.
- 34 Reason: not rct, group size not reported by excision margin per se, but only split by excision margin
- 35 and lesion thickness with n <50 patients in each group
- 36 Nguyen, J. T., Bakri, K., Nguyen, E. C., Johnson, C. H., Moran, S. L., Nguyen, J. T., Bakri, K., Nguyen, E.
- 37 C., Johnson, C. H. & Moran, S. L. (2013) Surgical management of subungual melanoma: mayo clinic
- 38 experience of 124 cases. *Annals of Plastic Surgery*, 71: 346-354.
- 39 Reason: not rct, <50 patients in each group, not sure comparisons in pico
- 40 O'Rourke, M. G., Altmann, C. R., O'Rourke, M. G. & Altmann, C. R. (1993) Melanoma recurrence after
- 41 excision. Is a wide margin justified? *Annals of Surgery*, 217: 2-5.
- 42 Reason: not rct, comparison not in pico (15 mm or less v > 15 mm), etrospective, n = 187, not
- 43 mohs/johnson squares

- 1 Pasquali, S., Haydu, L. E., Scolyer, R. A., Winstanley, J. B., Spillane, A. J., Quinn, M. J., Saw, R. P. M.,
2 Shannon, K. F., Stretch, J. R. & Thompson, J. F. (2013) The Importance of Adequate Primary Tumor
3 Excision Margins and Sentinel Node Biopsy in Achieving Optimal Locoregional Control for Patients
4 With Thick Primary Melanomas. *Annals of Surgery*, 258: 152-157.
5 Reason: comparison not in pico (16 mm or less v > 16 mm), prospective/retrospective?, n = 632, not
6 mohs/johnson squares
- 7 Rahim, R., Charlton, F., Husain, A. & Lawrence, C. (2012) Slow Mohs surgery for lentigo maligna: a
8 follow-up study. *British Journal of Dermatology*, 167: 79.
9 Reason: abstract
- 10 Reali, U. M. (1991) Stage I cutaneous melanoma: Surgical treatment and follow-up. *Rivista Italiana di*
11 *Chirurgia Plastica*, 23: 1-6.
12 Reason: foreign language
- 13 Robinson, J. K. & Robinson, J. K. (1994) Margin control for lentigo maligna. *Journal of the American*
14 *Academy of Dermatology*, 31: 79-85.
15 Reason: not comparative study
- 16 Rogers, G. S. & Rogers, G. S. (1989) Narrow versus wide margins in malignant melanoma. *Journal of*
17 *Dermatologic Surgery & Oncology*, 15: 33-34.
18 Reason: narrative review of cascinelli rct already included.
- 19 Rosin, R. D. & Rosin, R. D. (1985) The treatment of malignant melanoma. [Review] [46 refs].
20 *European Journal of Surgical Oncology*, 11: 111-115.
21 Reason: narrative review
- 22 Schreiber, M. M. & Schreiber, M. M. (1981) Primary malignant melanoma of the skin: factors in
23 predicting prognosis and in determining initial surgical treatment. [Review] [47 refs]. *Cutis*, 27: 494-
24 498.
25 Reason: narrative review
- 26 Sladden, M. J. (2012) Sufficiency and Safety of 2-cm Excision Margin for Stage IIA Through Stage IIC
27 Cutaneous Melanoma. *Archives of Dermatology*, 148: 1197-1198.
28 Reason: comment on Gillgren
- 29 Smith, A. A., Cole, A. B., Fosko, S. W., Smith, A. A., Cole, A. B. & Fosko, S. W. (2003) Melanoma from
30 the dermatologist's perspective. [Review] [87 refs]. *Facial Plastic Surgery Clinics of North America*,
31 11: 277-286.
32 Reason: narrative review
- 33 Sondak, V. K. Z. (2014) Melanoma: MSLT-1 - Putting sentinel lymph node biopsy into context. *Nature*
34 *Reviews Clinical Oncology*, 11: 246-248.
35 Reason: review of Sondak (2014) which is not in pico
- 36 Stander, S., Assmann, K., Nashan, D., Wigbels, B., Luger, T. & Metze, D. (2000) Modified micrographic
37 surgery for malignant melanomas of the face. *Hautarzt*, 51: 826-832.
38 Reason: foreign language
- 39 Taylor, B. A. H. (1985) A policy of selective excision for primary cutaneous malignant melanoma.
40 *European Journal of Surgical Oncology*, 11: 7-13.
41 Reason: not rct, <50 patients in each group

- 1 Thomas, J. M. (1993) Width of excision of malignant melanoma of thickness 2 mm or greater. A
2 randomized study - 1 cm vs 3 cm [abstract]. *European Journal of Surgical Oncology*, 19: 497.
3 Reason: abstract
- 4 Thomas, J. M. (1994) Randomised trial of width of excision of thick cutaneous malignant melanoma.
5 *British Journal of Plastic Surgery*, 47: 581-582.
6 Reason: letter
- 7 Thomas, J. M. N. (2004) Primary tumour excision with a surrounding margin of 3 cm reduced
8 recurrence in melanomas > 2 mm thick. *Evidence-Based Medicine*, 9: 183.
9 Reason: comment on Thomas 2004
- 10 Timmons, M. J., Thomas, J. M., Timmons, M. J. & Thomas, J. M. (1993) The width of excision of
11 cutaneous melanoma. [Review] [14 refs]. *European Journal of Surgical Oncology*, 19: 313-315.
12 Reason: narrative review
- 13 Timmons, M. J. & Timmons, M. J. (1997) Selecting surgery for malignant melanoma. [Review] [15
14 refs]. *Clinical & Experimental Dermatology*, 22: 115-117.
15 Reason: narrative review
- 16 Trost, O., Danino, A. M., Dutronc, Y., Dalac, S., Lambert, D., Malka, G., Trost, O., Danino, A. M.,
17 Dutronc, Y., Dalac, S., Lambert, D. & Malka, G. (2003) Is sentinel node biopsy beneficial in melanoma
18 patients? A report on 200 patients with cutaneous melanoma (EJSO 2002; 28: 673--678). *European*
19 *Journal of Surgical Oncology*, 29: 699.
20 Reason: letter
- 21 Tseng, J. F., Tanabe, K. K., Gadd, M. A., Cosimi, A. B., Malt, R. A., Haluska, F. G., Mihm, M. C., Jr.,
22 Sober, A. J., Souba, W. W., Tseng, J. F., Tanabe, K. K., Gadd, M. A., Cosimi, A. B., Malt, R. A., Haluska,
23 F. G., Mihm, M. C. J., Sober, A. J. & Souba, W. W. (1997) Surgical management of primary cutaneous
24 melanomas of the hands and feet. *Annals of Surgery*, 225: 544-550.
25 Reason: not rct, <50 patients in each group
- 26 Urist, M. M. & Urist, M. M. (1996) Surgical management of primary cutaneous melanoma. [Review]
27 [40 refs]. *CA: a Cancer Journal for Clinicians*, 46: 217-224.
28 Reason: narrative review
- 29 van Akkooi, A. C., Voit, C. A., Verhoef, C., Eggermont, A. M., van Akkooi, A. C. J., Voit, C. A., Verhoef,
30 C. & Eggermont, A. M. M. (2010) Potential cost-effectiveness of US-guided FNAC in melanoma
31 patients as a primary procedure and in follow-up. *Annals of Surgical Oncology*, 17: 660-662.
32 Reason: letter
- 33 Veronesi, U., Cascinelli, N., Veronesi, U. & Cascinelli, N. (1985) Margins of of resection of malignant
34 melanomas that are less than the hitherto conventional "wide and deep" margins are not advisable
35 as yet. [Review] [16 refs]. *American Journal of Dermatopathology*, 7 Suppl: 123-126.
36 Reason: letter/response to other paper
- 37 Walling, H. W., Scupham, R. K., Bean, A. K., Ceilley, R. I., Walling, H. W., Scupham, R. K., Bean, A. K. &
38 Ceilley, R. I. (2007) Staged excision versus Mohs micrographic surgery for lentigo maligna and lentigo
39 maligna melanoma. *Journal of the American Academy of Dermatology*, 57: 659-664.
40 Reason: not rct, group sizes = 41 patients for staged excision and 16 patients for mohs, i.e., <50
41 patients per group

Wayne, J. D. K. (2010) Recurrence of head and neck melanoma is not affected by reducing margins of wide local excision (WLE). *Annals of Surgical Oncology*, Conference: February.

Reason: abstract

Welvaart, K., Hermans, J., Zwaveling, A., Ruiter, D. J., Welvaart, K., Hermans, J., Zwaveling, A. & Ruiter, D. J. (1986) Prognoses and surgical treatment of patients with stage I melanomas of the skin: a retrospective analysis of 211 patients. *Journal of Surgical Oncology*, 31: 79-86.

Reason: not rct, comparisons not in pico, n < 50 in one of the comparison groups

Wheatley, K., Wilson, J., Gaunt, P. & Marsden, J. (2013) Are Narrow Surgical Excision Margins for Primary Cutaneous Melanoma Safe? An Updated Systematic Review and Meta-Analysis. *Journal der Deutschen Dermatologischen Gesellschaft*, 11: 10.

Reason: abstract

Whitman, E. D. & Whitman, E. D. (2003) Surgical margins in melanoma. [Review] [18 refs]. *Facial Plastic Surgery Clinics of North America*, 11: 87-91.

Reason: narrative review

Wright, E. H., Stanley, P. R., Roy, A., Wright, E. H., Stanley, P. R. W. & Roy, A. (2010) Evaluation of sentinel lymph nodes positive for melanoma for features predictive of non-sentinel nodal disease and patient prognosis: a 49 patient series. *Journal of Plastic, Reconstructive & Aesthetic Surgery: JPRAS*, 63: e500-e502.

Reason: not in pico

Wright, F., Spithoff, K., Easson, A., Murray, C., Toye, J., McCreedy, D., Petrella, T., Melanoma Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care., Wright, F., Spithoff, K., Easson, A., Murray, C., Toye, J., McCreedy, D., Petrella, T. & Melanoma Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. (2011) Primary excision margins and sentinel lymph node biopsy in clinically node-negative melanoma of the trunk or extremities. *Clinical Oncology (Royal College of Radiologists)*, 23: 572-578.

Reason: guideline (checked for relevant included studies)

Yeung, R. S. & Yeung, R. S. (1993) Recurrent cutaneous melanoma: a surgical perspective. [Review] [129 refs]. *Seminars in Oncology*, 20: 400-418.

Reason: narrative review

Zalla, M. J., Lim, K. K., DiCaudo, D. J. & Gagnot, M. M. (2000) Mohs micrographic excision of melanoma using immunostains. *Dermatologic Surgery*, 26: 771-784.

Reason: not comparative study

Zitelli, J. A., Brown, C. & Hanusa, B. H. (1997) Mohs micrographic surgery for the treatment of primary cutaneous melanoma. *Journal of the American Academy of Dermatology*, 37: 236-245.

Exclusion reason: comparative, but only with historical controls

Zitelli, J. A. (1998) Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma: A follow-up study - Commentary. *Dermatologic Surgery*, 24: 677.

Reason: comment

Evidence Tables

Study Quality (Systematic Reviews)

	Clearly focused Question?	Includes studies relevant to review question?	Rigorous literature search?	Study quality assessed?	Adequate description of methodology?	Quality
Sladden et al (2009)	Yes	Yes	Yes	Yes	Yes	High

Study Quality (Randomised Controlled Trials)

	Appropriate method of randomisation?	Adequate allocation concealment?	Groups comparable at baseline?	Based on previous three questions, what is the likely risk (and, if high, direction) of selection bias?	Groups received same care apart from intervention?	Participants receiving care blind to treatment allocation?	Individuals administering care blind to treatment allocation?	Based on previous three questions, what is the likely risk (and, if high, direction) of performance bias?	Equal length of follow-up between the groups?	Treatment completion rates comparable between the groups (state numbers)?
Gillgren et al (2011)	Yes	Yes	Yes	Low risk	Yes	Unclear	No	Unclear risk	Yes	Yes
	Availability of outcome	Based on previous three questions,	Appropriate length of	Precise definition of	Valid and reliable method	Outcome assessors blind to	Outcome assessors blind to	Based on previous five questions, what	Quality	

	data comparable between the groups (state numbers)?	what is the likely risk (and, if high, direction) of attrition bias?	follow-up?	outcome?	used to determine outcome?	participant s' exposure to intervention?	other important confounding and prognostic factors?	is the likely risk (and, if high, direction) of detection bias?		
Gillgren et al (2011)	Yes	Low risk	Yes	Yes	Yes	Unclear	Unclear	Unclear risk	Moderate	

Study characteristics

Study	Study Type	Aim	Population	Intervention	Comparison	Further study details
Sladden et al (2009)	Systematic Review of RCTs	To assess the effects of different excision margins for primary cutaneous melanoma.	N=3297 (from 5 studies including patients with cutaneous melanoma). The five RCTs differed in interventions and populations and are therefore summarised separately below:	Narrow excision margin	Wide excision margin	

Study	Study Type	Aim	Population	Intervention	Comparison	Further study details
			<u>Balch et al (2001):</u> All patients had cutaneous melanoma of 1-4 mm thickness on trunk or limbs, with no evidence of metastatic melanoma in lymph nodes or distant sites, aged 18-81 years Exclusions: Previous cancer, chemotherapy, radiotherapy and any other adjunct to surgery; lentigo maligna	2 cm margin (N = 238)	4 cm margin (N = 232)	<ul style="list-style-type: none"> - Duration of follow up: 10 years - Multicentre, trial conducted in US, Canada, Denmark, South Africa involving 93 surgeons practising in 77 centres. - “Excision margins measured with a ruler. Lesions could be excised with a larger margin in one direction to create elliptical defect, thus easing closure. Underlying subcutaneous tissue, down to or including the underlying muscular fascia, was incorporated into the surgical specimen. Definitive resection was performed within 45 days after biopsy.” - “Local recurrence defined as a biopsy-proven first recurrence within 2 cm of the scar”. - “ ‘Each participant was also randomly assigned to receive ELND (elective lymph node dissection) or observation of the regional lymph nodes with delayed lymph node dissection only if clinically indicated.’ ‘Participants receiving ELND were evenly distributed between the two treatment arms involving surgical margins, so any survival differences that may result from ELND would not influence the survival outcome from the surgical margin issue’ “. <p>(All quotes from Sladden et al 2009, pages 20-21).</p>

Study	Study Type	Aim	Population	Intervention	Comparison	Further study details
			<p><u>Cascinelli et al (1998):</u></p> <p>All patients had cutaneous melanoma with ≤ 2 mm thickness on trunk or limbs (not fingers, toes, face); aged ≤ 65 years.</p> <p>Exclusions:</p> <p>Melanoma satellites, multiple primaries, previous cancer, impossible regular follow-up, inadequate histological documentation, biopsy > 6 weeks before definite treatment</p>	<p>1 cm margin</p> <p>(N = 305)</p>	<p>≥ 3 cm margin</p> <p>(N = 307)</p>	<ul style="list-style-type: none"> - Duration of follow-up: 12 years - Multicentre, multinational trial with recruitment from 1980 to 1985. - "Wide excision was defined as a cutaneous incision made at least 3 cm from the grossly visible margins of the melanoma or from the scar if the primary melanoma had already been biopsied; the excisions had to be 1 to 2 cm wider in the subcutaneous fat extending to muscle fascia." - "Narrow excisions were performed according to the same technique; the only difference was that the cutaneous incisions were made 1 cm from the visible margins of the primary melanoma." - "The margins were measured by the surgeon at the time of the operation. Definite surgical treatment was to be performed within 6 weeks of the primary diagnostic procedure". - "The trial was published as 3 reports: 1988, 1991, and 1998 <p>The 1988 paper states that 'local recurrences and in-transit and nodal metastases were defined as in the TNM staging system (IUAC, 1978)'The 1991 paper states that local recurrence was defined as cutaneous or subcutaneous nodules in scar or within 1 cm of scar".</p> <ul style="list-style-type: none"> - "Concomitant treatment was permitted with guidelines given for treatment in the first 5 years of follow-up: 1. Local recurrence to

Study	Study Type	Aim	Population	Intervention	Comparison	Further study details
						<p>be removed by wide local excision within 4 weeks of diagnosis;</p> <p>2. If nodal metastases, standard axillary/inguino-iliac node dissection within 4 weeks; 3. Adjuvant treatment could be given for after surgery for nodal metastases (defined pretrial); and</p> <p>4. Distant metastases to be treated with chemotherapy, in the first instance, dacarbazine".</p> <p>(All quotes from Sladden et al 2009, pages 21-22).</p>
			<p><u>Cohn-Cedermark et al (2000):</u></p> <p>All patients had cutaneous melanoma with > 0.8 mm ≤ 2 mm thickness on trunk or extremity (not fingers, feet, face); any age.</p> <p>Exclusions:</p> <p>Melanoma satellites, metastatic disease, previous cancer</p>	<p>2 cm margin</p> <p>(N = 476)</p>	<p>≥5 cm margin</p> <p>(N = 513)</p>	<p>- Duration of follow-up: 11 years overall survival), 8 years (recurrence-free survival)</p> <p>- Multicentre trial conducted in Sweden in 5 regional oncologic centres/ 39 clinics (38 hospitals) with recruitment from 1982 to 1991.</p> <p>- "Definite surgical treatment was to be performed within 6 weeks of the primary diagnostic procedure (i.e. all initially received 2 cm margin, then those randomised to wide excision received secondary procedure within 6 weeks)".</p> <p>- "Local recurrence was defined as a recurrence in the 'scar or transplant'. Other forms of recurrence are not defined".</p> <p>- "The standard salvage treatment after locoregional disease recurrence was surgery. After repeated locoregional recurrences, some participants were treated with limb perfusion. In the event of distant dissemination, chemotherapy was given at the discretion of the respective physician".</p> <p>(All quotes from Sladden et al 2009, page 23).</p>

Study	Study Type	Aim	Population	Intervention	Comparison	Further study details
			<p><u>Khayat et al (2003):</u> All patients had melanoma with ≤ 2 mm thickness on trunk, limbs, head and neck (not fingers, toes, nails); TNM stage 1; aged < 70 years. Exclusions: Melanomas arising from melanosis, lentigo, acral lesions.</p>	<p>2 cm margin (N = 167)</p>	<p>≥ 5 cm margin (N = 170)</p>	<ul style="list-style-type: none"> - Duration of follow-up: 16 years - Multicentre trial undertaken in Europe. - "Resection was performed within a month of the initial biopsy (if needed to obtain the overall 2 or 5 cm margin). Excisions extended down to the muscle fascia. Lymph node dissections not performed". - "Local disease recurrence defined as recurrence within 2 cm of the scar" - "In-transit metastases was defined as disease recurrence between the primary tumour site and the regional lymph node" - "Certain concomitant treatment was permitted. Local or regional tumours that recurred were removed surgically. Metastatic tumours were treated with chemotherapy or biochemotherapy". - "A second randomisation allocated the participant to either 12 months of adjuvant treatment with Isoprinosine or to no adjuvant treatment. Participant characteristics, including surgical margins were balanced between the 2 groups based on the immunotherapy randomisation. This second randomisation to receive or not to

Study	Study Type	Aim	Population	Intervention	Comparison	Further study details
						<p>receive Isoprinosine did</p> <p>not appear to affect the outcome of these participants. The median survival periods with</p> <p>or without the drug were 190 months and 192 months respectively (P = 0.9) and the</p> <p>disease-free survival periods were 149.5 months and 153.3 months respectively (P = 0.89)".</p> <p>(All quotes from Sladden et al 2009, pages 24-25).</p>
			<p><u>Thomas et al (2004):</u></p> <p>All patients had single, primary, localised cutaneous melanoma with ≥ 2 mm thickness on trunk or limbs (not palms of hands, soles of feet); aged ≥ 18 years.</p> <p>Exclusions:</p> <p>Previous cancer, immuno-suppressive therapy</p>	<p>1 cm margin</p> <p>(N = 453)</p>	<p>3 cm margin</p> <p>(N = 447)</p>	<p>- Duration of follow-up: 5 years</p> <p>- Multicentre trial undertaken in UK and Poland, with recruitment from 1993 to 2001</p> <p>- "Participating surgeons chose 1 of 2 primary treatment approaches. The primary tumor could be excised before randomisation, with either a 1 mm or a 1 cm margin to confirm the diagnosis and determine the thickness of the lesion. The participants were then randomly assigned to receive a 1 or 3 cm margin after the 1 mm primary excision or to receive no further treatment or an additional 2 cm margin after the 1 cm primary excision. The trial surgery was to be performed within 45 days after the primary excision, and all excisions were to extend to or include the deep fascia. Sentinal lymph node biopsy was not performed".</p>

Study	Study Type	Aim	Population	Intervention	Comparison	Further study details
						<p>- “Local recurrence defined as a recurrence within 2 cm of the scar or graft.”</p> <p>- “ In-transit recurrence was defined as a recurrence from beyond the first 2 cm of the scar or graft to the regional nodes.”</p> <p>- “All locoregional recurrences were detected clinically and confirmed by biopsy. “</p> <p>(All quotes from Sladden et al 2009, pages 25-26).</p>
Gillgren et al (2011)	Randomised controlled trial	To assess the effects of 2 cm and 4 cm excision margins for primary cutaneous melanoma thicker than 2 mm.	All patients had cutaneous melanoma with > 2 mm thickness, clinical stage 2A-C, with clinically localised disease on trunk or upper or lower extremities(not hands, foot, head-neck, anogenital region); aged ≤ 75 years. Exclusions: Previous cancer.	2 cm margin (N = 470)	4 cm margin (N = 459)	<p>- Duration of follow-up: 6.7 years overall, and 11.8 years in the Swedish cohort.</p> <p>- Multicentre trial undertaken in Sweden, Denmark, Estonia and Norway in 53 hospitals, with recruitment from 1992 to 2004.</p> <p>- “The primary excision of the tumour could be done either by an excisional biopsy (margin of 1–3 mm) or with a 2-cm margin if cutaneous melanoma was strongly suspected. Thus, patients could be allocated to receive either no further surgery (those operated on with a 2-cm margin and randomised to the 2-cm group) or to an additional wide local excision with a margin of up to either 2 cm or 4 cm. Surgical excisions were to extend to, or include, the deep fascia.... Radical surgery was to be performed within 8 weeks after the date of diagnosis”. (page 1636).</p> <p>- Local recurrence was defined as a recurrence in the scar or</p>

Study	Study Type	Aim	Population	Intervention	Comparison	Further study details
						<p>transplant.</p> <p>- “The time of an event was measured from the date of randomisation. For calculation of overall survival, the time to death was used, irrespective of cause. Patients who were diagnosed with a second cutaneous melanoma during the study were censored when analysing time to first relapse (recurrence-free survival) but were included in the overall survival analyses. For recurrence-free survival, either time to first cutaneous melanoma relapse or time to cutaneous melanoma-related death was used (whichever occurred first). Randomised patients with a new, non-lethal malignancy other than cutaneous melanoma were still included in the study, and if a cutaneous melanoma event occurred it was included in the recurrence-free survival analyses.” (pages 1637-1638)</p> <p>- Intention-to-treat analyses performed.</p> <p>- Adverse events not systematically recorded.</p>

4.2 The use of imiquimod in stage 0 melanoma and skin metastases

Review question: How effective is imiquimod in the treatment of stage 0 melanoma and skin metastases?

Background

Stage 0 Melanoma (Melanoma in situ) means the melanoma cells are only in the top surface layer of skin cells (the epidermis) and have not spread into the deeper layers.

Currently surgical excision is the treatment of choice but this can be difficult for some patients if

1. their stage 0 Melanoma is large
2. their stage 0 Melanoma is on a surgically sensitive area such as the face
3. the patients themselves have other illnesses which make them a surgical risk
4. combination of the above

As stage 0 Melanoma is confined to the top surface layer of the skin, we want to ask the question to see if imiquimod cream is as effective as surgery or other treatments such as radiotherapy, cryotherapy, laser treatment or another treatment cream called 5 FU.

Imiquimod is a cream that is applied to the skin for about 3 months every day to the stage 0 melanoma. It causes redness, irritation and could be sore. The redness and irritation clears up a couple of weeks after the cream is stopped.

Imiquimod works by changing the body's immune response and it is speculated that it can promote an immune response against Melanoma.

Another question we want to ask is if imiquimod can be used on melanoma skin metastases. This is when the original melanoma has been treated previously but then has spread to other parts of the skin, or rarely the patient may present with skin metastases and the original melanoma has yet to be found. Often the patient can have multiple skin metastases which makes treatment by surgery difficult. We want to know how good imiquimod is at treating these skin metastases and how it is tolerated by the patients.

Review question in PICO format

Population	Intervention	Comparisons	Outcomes
Patients diagnosed with melanoma Subgroups: <ul style="list-style-type: none"> • Stage 0 • Skin metastases 	Imiquimod: <ul style="list-style-type: none"> • Three times a week for 6 weeks • Daily for 5 days out of 7 for 6 weeks • Daily for 12 weeks 	<ul style="list-style-type: none"> • Surgery • Radiotherapy • Cryotherapy • 5FU • Laser • No treatment 	<ul style="list-style-type: none"> • Local control • Regional disease • Overall survival (1,5 and 10 years) • Adverse events • Cosmesis • HRQOL

1 How the information will be searched

Searches: <i>(To be Completed by subgroup lead)</i>	
Can we apply date limits to the search	Since imiquimod became available, (20 years)
Are there any study design filters to be used (RCT, systematic review, diagnostic test).	RCTs systematic reviews preferred but we may need to consider large case series
List useful search terms.	Lentigo maligna, Hutchinson's freckle, in situ melanoma, Stage 0 melanoma Melanoma skin metastases Imiquimod, aldera

2 The review strategy

What data will we extract and how will we analyse the results?	<p>Relevant studies will be identified through sifting the abstracts and excluding studies clearly not relevant to the PICO. In the case of relevant or potentially relevant studies, the full paper will be ordered and reviewed, whereupon studies considered to be not relevant to the topic will be excluded.</p> <p>Studies which are identified as relevant will be critically appraised and quality assessed using GRADE methodology and/or NICE checklists. Data relating to the identified outcomes will be extracted from relevant studies.</p> <p>If possible a meta-analysis of available study data will be carried out to provide a more complete picture of the evidence body as a whole.</p> <p>An evidence summary outlining key issues such as volume, applicability and quality of evidence and presenting the key findings from the evidence as it relates to the topic of interest will be produced.</p>
List subgroups here and planned statistical analyses.	

3

1 Search Results

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
Medline	1946-2013	183	88	03/09/2013
Premedline	30 Aug 2013	10	1	03/09/2013
Embase	1947-2013	368	99	03/09/2013
Cochrane Library	Issue 6 of 12 June 2013	3	2	04/09/2013
Web of Science (SCI & SSCI)	1900-2013	286	89	04/09/2013
Total References retrieved (after de-duplication): 144				

2 Update Search


- 3 For the update search, the same search criteria/filters were applied as initial search with a date limit
4 of September 2013 onwards.

Database name	No of references found	No of references retrieved	Finish date of search
Medline	11	4	15/10/2014
Premedline	5	4	15/10/2014
Embase	47	16	15/10/2014
Cochrane Library	0	0	15/10/2014
Web of Science (SCI & SSCI)	54	13	15/10/2014
4 references found in Pubmed 15/10/2014			
Total References retrieved (after de-duplication): 22			

5 Medline search strategy (This search strategy is adapted to each database)

- 6 1. exp Melanoma/
- 7 2. melanoma\$.tw.
- 8 3. (maligna\$ adj1 lentigo\$).tw.
- 9 4. (hutchinson\$ adj1 (freckle\$ or melano\$)).tw.
- 10 5. dubreuilh.tw.
- 11 6. LMM.tw.
- 12 7. or/1-6
- 13 8. imiquimod.tw.
- 14 9. aldara.tw.
- 15 10. zyclara.tw.
- 16 11. or/8-10
- 17 12. 7 and 11
- 18

1 **Screening Results**



2
3

1 **Evidence statements**

2 **Stage 0 melanoma (lentigo maligna)**

3 There was no evidence on the relative effectiveness of imiquimod compared with other treatments
4 for people with stage 0 melanoma.

5 Very low quality evidence suggests that when punch biopsy is used to assess treatment success,
6 complete response rates range from 73% to 87% (Buettiker *et al* 2008; Wong *et al* 2012 ; Powell *et al*
7 2009 and Naylor *et al* 2003) .

8 Very low quality evidence suggests that when wide local excision of the tumour location is used to
9 assess treatment success, complete response rates range from 53% to 64% (Ly *et al* 2011; Hyde *et al*
10 2012).

11 Very low quality evidence suggests that inflammation, erythema and irritation of the treatment area
12 are common adverse effects with imiquimod treatment in people with stage 0 melanoma.

13 Imiquimod treatment is stopped due to intolerable toxicity in between 0% and 7% of cases.

14 **Melanoma skin metastases**

15 There was no evidence on the relative effectiveness of imiquimod compared with other treatments
16 for people with melanoma skin metastases.

17 Very low quality evidence suggests that imiquimod combined with IR-laser (Li *et al* 2010) or
18 interleukin-2 (Green *et al*, 2007) can visibly clear some skin metastases in patients with melanoma.
19 Grade 3 adverse events occurred in 25% of patients in Li *et al* (2010) and 20% of patients in Green *et*
20 *al* (2007) required antibiotic treatment for local infections.

GRADE Table 4.2 imiquimod versus surgery, radiotherapy, cryotherapy, 5FU, laser or no treatment for stage 0 melanoma.

Quality assessment							No of patients		Effect		Quality
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Imiquimod	Surgery, Radiotherapy, Cryotherapy, 5FU, Laser, No treatment	Relative (95% CI)	Absolute	
Complete treatment response (Buettiker, 2008; Wong, 2012; Powell, 2009; Naylor, 2003; Ly, 2011; Hyde, 2012)											
6	observational studies ¹	no serious risk of bias	no serious inconsistency	no serious indirectness	serious ²	none	154/216 (71.3%)	-	-	-	VERY LOW
Regional disease - not reported											
0	-	-	-	-	-	none	-	-	-	-	
Overall survival - not reported											
0	-	-	-	-	-	none	-	-	-	-	
Treatment discontinued due to intolerable side effects (Powell, 2009; Naylor, 2003; Ly, 2011; Hyde, 2012)											
4	observational studies ¹	no serious risk of	no serious inconsistency	no serious indirectness	serious ²	none	7/167 (4.2%)	-	-	-	VERY LOW

Quality assessment							No of patients		Effect		Quality
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Imiquimod	Surgery, Radiotherapy, Cryotherapy, 5FU, Laser, No treatment	Relative (95% CI)	Absolute	
		bias									
Health related quality of life - not reported											
0	-	-	-	-	-	none	-	-	-	-	

¹ Case series and one RCT comparing imiquimod with and without tazarotene

² Low number of events

GRADE Table 4.3 imiquimod versus surgery, radiotherapy, cryotherapy, 5FU, laser or no treatment for melanoma skin metastases.

Quality assessment							No of patients		Effect		Quality
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Imiquimod	Surgery, Radiotherapy, Cryotherapy, 5FU, Laser, No treatment	Relative (95% CI)	Absolute	
Overall mortality (follow-up 21 to 64 months) (Li, 2010)											
1	observational studies ¹	no serious risk of bias	no serious inconsistency	serious ²	serious ³	none	6/11 (54.5%)	-	-	-	VERY LOW
Complete macroscopic response of treated metastases (per lesion) (Green, 2007)											
1	observational studies ¹	no serious risk of bias	no serious inconsistency	serious ²	serious ³	none	74/182 (40.7%)	-	-	-	VERY LOW
Complete macroscopic response of treatment site lesions (per patient) (Li, 2010)											
1	observational studies ¹	no serious risk of bias	no serious inconsistency	serious ²	serious ³	none	8/11 (72.7%)	-	-	-	VERY LOW
New metastatic lesions appearing during treatment (Green, 2007)											

Quality assessment							No of patients		Effect		Quality
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Imiquimod	Surgery, Radiotherapy, Cryotherapy, 5FU, Laser, No treatment	Relative (95% CI)	Absolute	
1	observational studies ¹	no serious risk of bias	no serious inconsistency	serious ²	serious ³	none	7/10 (70%)	-	-	-	VERY LOW
Treatment discontinued due to intolerable side effects (Green, 2007)											
1	observational studies ¹	no serious risk of bias	no serious inconsistency	serious ²	serious ³	none	0/10 (0%)	-	-	-	VERY LOW
One or more Grade 3 adverse events during treatment (Li, 2010)											
1	observational studies ¹	no serious risk of bias	no serious inconsistency	serious ²	serious ³	none	3/11 (27.3%)	-	-	-	VERY LOW
Health related quality of life - not reported											
0	-	-	-	-	-	none	-	-	-	-	

¹ case series² Treatment differs to that specified in the PICO for this question: imiquimod was combined with IR-laser (Li, 2010) or interleukin-2 (Green,2007) in the included studies.³ Low number of events

Table 4.2. Imiquimod in stage 0 melanoma

Study	N	Imiquimod regimen*	Assessment of treatment response	Complete response	Treatment failure	Treatment stopped due to toxicity	Other toxicities
Buettiker (2008)	32	Daily for 7 weeks	3mm punch biopsies only in those with residual pigmentation	25/32 (78%)	7/32 (22%)	Not reported	Telangiectasia 4/12; irritation of treatment area was common
Wong (2012)	26	3 times per week for around 20 weeks	3mm punch biopsies	19/26 (73%)	7/26 (27%)	Not reported	Inflammation, erythema and crusting were common
Powell (2009)	48	3 times per week for 6 to 10 weeks	1 or 2 X 4mm punch biopsies, adjacent to diagnostic biopsy site.	37/48 (77%)	11/48 (23%)	3/48 (6%)	Scarring 0/48; cytokine release syndrome 0/48
Naylor (2003)	30	Daily for 12 weeks	4 X 2mm punch biopsies	26/30 (87%)	4/30 (13%)	None – but treatment was paused in 10/30 due to toxicity	Irritation of treatment area, 30/30; Severe skin reaction, 10/30; Infection needing antibiotics, 5/30; cytokine release syndrome 2/30
Ly (2011)	38	5 times per week for 12 weeks	Excision of tumour area with 5mm margin	20/38 (53%)	18/38 (47%)	3/43 (7%)	Not reported

Study	N	Imiquimod regimen*	Assessment of treatment response	Complete response	Treatment failure	Treatment stopped due to toxicity	Other toxicities
Hyde (2012)	42	5 times per week for 12 weeks	Excision of tumour area with 2mm margin	27/42 (64%)	15/42 (36%)	1/46 (2%)	Not reported

*Treatment was usually intensified if there was insufficient inflammatory response

Table 4.3. Imiquimod in melanoma skin metastases

Study	N	Imiquimod treatment regimen	Additional treatments	Assessment of treatment response	Treatment response	Treatment stopped due to toxicity	Other toxicity
Green (2007)	13 (182 lesions)	Daily for 15 to 53 weeks	Interleukin-2	Macroscopic appearance and size of lesions (no histology)	Per lesion: complete response 74/182 (41%), partial response 18/182 (10%), stable disease 83/182 (29%), progressive disease 33/182 (18%)	0/10	Erythema, discharge , mild flu like symptoms, Infection needing antibiotics, 2/10;
Li (2010)	11	Twice daily for 2 weeks before and after 2 weeks of laser treatment	Infrared laser	Macroscopic appearance and size of lesions (no histology)	Best overall response for treated area: complete response 7/11 (64%), partial response 2/11 (18%), stable disease 1/11 (9%).	Not reported	Grade 3 toxicity in 25% of patients; Grade 1-2 toxicity was common

References

Included Studies

Buettiker, U. V., Yawalkar, N. Y., Braathen, L. R., Hunger, R. E., Buettiker, U. V., Yawalkar, N. Y. et al. (2008). Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients. *Archives of Dermatology*, 144, 943-945.

Green, D. S., Bodman-Smith, M. D., Dalglish, A. G., Fischer, M. D., Green, D. S., Bodman-Smith, M. D. et al. (2007). Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. *British Journal of Dermatology*, 156, 337-345.

Hyde, M. A., Hadley, M. L., Tristani-Firouzi, P., Goldgar, D., Bowen, G. M., Hyde, M. A. et al. (2012). A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions. *Archives of Dermatology*, 148, 592-596.

Li, X., Naylor, M. F., Le, H., Nordquist, R. E., Teague, T. K., Howard, C. A. et al. (2010). Clinical effects of in situ photoimmunotherapy on late-stage melanoma patients: a preliminary study. *Cancer Biology & Therapy*, 10, 1081-1087.

Ly, L., Kelly, J. W., O'Keefe, R., Sutton, T., Dowling, J. P., Swain, S. et al. (2011). Efficacy of imiquimod cream, 5%, for lentigo maligna after complete excision: a study of 43 patients. *Archives of Dermatology*, 147, 1191-1195.

Naylor, M. F., Crowson, N., Kuwahara, R., Teague, K., Garcia, C., Mackinnis, C. et al. (2003). Treatment of lentigo maligna with topical imiquimod. *British Journal of Dermatology*, 149 Suppl 66, 66-70.

Powell, A. M., Robson, A. M., Russell-Jones, R., Barlow, R. J. (2009). Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up. *British Journal of Dermatology*, 160, 994-998.

Wong, J. G., Toole, J. W., Demers, A. A., Musto, G., Wiseman, M. C., Wong, J. G. et al. (2012). Topical 5% imiquimod in the treatment of lentigo maligna. *Journal of Cutaneous Medicine & Surgery*, 16, 245-249.

Excluded studies

Alessi, S. S., Sanches, J. A., de Oliveira, W. R., Messina, M. C., Pimentel, E. R. D., & Neto, C. F. (2009). Treatment of Cutaneous Tumors with Topical 5% Imiquimod Cream. *Clinics*, 64, 961-966.
Reason: patients are already included in another publication

Baumgartner, M. (2010). Treatment of lentigo maligna with imiquimod: A follow up of 61 patients. *Melanoma Research*, Conference, June.
Reason: conference abstract only

Craythorne, E. & Lawrence, C. (2007). The use of topical imiquimod (Aldara (R)) in the treatment of lentigo maligna of the head and neck. *British Journal of Dermatology*, 157, 109-110.

- 1 Reason: Abstract
- 2 Demirci, H., Shields, C. L., Bianciotto, C. G., Shields, J. A., Demirci, H., Shields, C. L. et al. (2010).
3 Topical imiquimod for periocular lentigo maligna. *Ophthalmology*, 117, 2424-2429.
- 4 Reason: <5 patients
- 5 Ellis, L. Z., Cohen, J. L., High, W., Stewart, L., Ellis, L. Z., Cohen, J. L. et al. (2012). Melanoma in situ
6 treated successfully using imiquimod after nonclearance with surgery: review of the literature.
7 *Dermatologic Surgery*, 38, 937-946.
- 8 Reason: Narrative Review
- 9 Erickson, C., Miller, S. J., Erickson, C., & Miller, S. J. (2010). Treatment options in melanoma in situ:
10 topical and radiation therapy, excision and Mohs surgery. [Review] [79 refs]. *International Journal of*
11 *Dermatology*, 49, 482-491.
- 12 Reason: Expert Review
- 13 Fleming, C. J., Bryden, A. M., Evans, A., Dawe, R. S., Ibbotson, S. H., Fleming, C. J. et al. (2004). A pilot
14 study of treatment of lentigo maligna with 5% imiquimod cream. *British Journal of Dermatology*,
15 151, 485-488.
- 16 Reason: <10 patients
- 17 Garcia, M. S., Ono, Y., Martinez, S. R., Chen, S. L., Goodarzi, H., Phan, T. et al. (2011). Complete
18 regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional
19 interleukin 2 in combination with topical imiquimod and retinoid cream. *Melanoma Research*, 21,
20 235-243.
- 21 Reason: <10 patients
- 22 Haskett, M. (2010). Efficacy of imiquimod 5% cream for lentigo maligna as assessed following
23 complete excision - A study of 43 patients. *Pigment Cell and Melanoma Research*, Conference, 878.
- 24 Reason: less than 10 patients in study
- 25 Kai, A. (2013). Five-year recurrence rate of lentigo maligna after treatment with imiquimod
26 determined using in vivo confocal microscopy. *British Journal of Dermatology*, Conference, July.
- 27 Reason: Abstract
- 28 Kidner, T. B., Morton, D. L., Lee, D. J., Hoban, M., Foshag, L. J., Turner, R. R. et al. (2012). Combined
29 intralesional Bacille Calmette-Guerin (BCG) and topical imiquimod for in-transit melanoma. *Journal*
30 *of Immunotherapy*, 35, 716-720.
- 31 Reason: <10 patients
- 32 Ly, L. (2010). 5% imiquimod cream is not a first line treatment for lentigo maligna. *Australasian*
33 *Journal of Dermatology*, Conference, May.
- 34 Reason: phase I clinical trial in patients with advanced melanoma or renal cancer, melanoma results
35 not reported separately
- 36 Mahoney, M. H., Joseph, M. G., Temple, C., Mahoney, M. H., Joseph, M. G., & Temple, C. (2008).
37 Topical imiquimod therapy for lentigo maligna. *Annals of Plastic Surgery*, 61, 419-424.
- 38 Reason: <10 patients

- 1 McLeod, M., Choudhary, S., Giannakakis, G., Nouri, K., McLeod, M., Choudhary, S. et al. (2011).
2 Surgical treatments for lentigo maligna: a review. [Review]. *Dermatologic Surgery*, 37, 1210-1228.
3 Reason: Narrative Review
- 4 McKenna, J. K., Florell, S. R., Goldman, G. D., & Bowen, G. M. (2006). Lentigo maligna/lentigo maligna
5 melanoma: Current state of diagnosis and treatment. *Dermatologic Surgery*, 32, 493-504.
6 Reason: Narrative review
- 7 Missall, T. A. H. (2011). A case series of 14 patients with melanoma in situ, lentiginous type treated
8 with topical imiquimod therapy reveals the need for individualized regimens for successful
9 treatment. *Journal of the American Academy of Dermatology*, Conference, AB122.
10 Reason: Abstract
- 11 Murphy, M. E., Brodland, D. G., Zitelli, J. A., Murphy, M. E., Brodland, D. G., & Zitelli, J. A. (2008).
12 Definitive surgical treatment of 24 skin cancers not cured by prior imiquimod therapy: a case series.
13 *Dermatologic Surgery*, 34, 1258-1263
14 Reason: expert review
- 15 Powell, A. M., Russell-Jones, R., Barlow, R. J., Powell, A. M., Russell-Jones, R., & Barlow, R. J. (2004).
16 Topical imiquimod immunotherapy in the management of lentigo maligna. *Clinical & Experimental*
17 *Dermatology*, 29, 15-21.
18 Reason: Included in a more recent publication
- 19 Savage, P. & Horton, V. (1996). A phase I clinical trial of imiquimod, an oral interferon inducer,
20 administered daily. *British Journal of Cancer*, 74, 1482-1486.
21 Reason: surgery in patients not cured by imiquimod treatment
- 22 Salerno, E. P. W. (2012). Topical imiquimod induces immune activation and regressions of cutaneous
23 melanoma metastases. *Journal of Immunotherapy*, Conference, 751-752.
24 Reason: Abstract
- 25

Evidence Tables

Study Quality (randomized trial)

Study	Appropriate Randomisation	Appropriate Concealment	Comparable groups at baseline	Comparable Care apart from intervention	Patient Blinding	Treatment Administrator Blinding	Equal Follow-up	Equal Treatment Completion/Loss to follow up	Appropriate follow-up length	Precise definition of outcome	Valid method of measuring outcome	Investigator or blinding
Hyde et al (2012)	Yes	Unclear	Unclear	Yes	No	No	Yes	Unclear	Yes	Yes	Yes	No

Study	Study Type/Setting	Funding Source	Population	Intervention	Comparison	Risk of Bias/Applicability	Outcomes
Buettiker et al (2008)	Observational Switzerland	University of Berne	32 patients (34 lesions) Histologically confirmed facial lentigo maligna (LM), no prior treatment. Some patients were immuno-compromised (exact figure not reported)	Imiquimod 5% cream, applied to pigment areas of LM lesions. Frequency of application in most cases once or twice daily. Duration of treatment, mean 7 weeks (range 2 to 20 weeks). If no inflammatory response was seen initially, treatment was intensified or	None	Clearance histologically confirmed in 6/32 cases only Applicable to the population of interest but study has no comparator.	Mean follow up 17.2 months (range 5 to 31 months) Partial clinical clearance (residual pigmentation): 6/32 (histology confirmed complete clearance in these cases). Complete clinical clearance: 25/32 Recurrence: 1/32 Inflammatory response: severe 4/32

Study	Study Type/Setting	Funding Source	Population	Intervention	Comparison	Risk of Bias/Applicability	Outcomes										
				occlusion or cryotherapy were used.			<p>, strong 20/32, moderate 5/32, mild 3/32, none 0/32</p> <p>Adverse events: persistent telangiectasia 4/32, irritation of the treatment area (occurred but frequency was not reported).</p>										
Green et al (2007)	Observational 2003-2005 UK	Fischer Family Trust and the Cancer Vaccine Institute.	<p>13 (10 completed treatment with 182 lesions)</p> <p>Stage III-IV melanoma, multiple cutaneous or subcutaneous metastases, median age 58.5 years (range 46 to 80 years).</p>	Nightly application of imiquimod 5% cream, applied to each lesion and a 1cm margin of normal skin. After 8 weeks, or if inflammatory response was seen, frequency of application reduced to every other day. From weeks 4 to 8 interleukin-2 was injected three times a week every 2 weeks (either into the lesion N= 9 or systemically N=1)	None	<p>None Identified</p> <p>Intervention does not match the PICO (additional IL-2 treatment used), no comparator</p>	<p>Complete response (lesion became impalpable or disappeared) Partial response (50% reduction in the largest diameter of the lesion) Stable disease (<50% reduction to <20% increase in the largest diameter) Progressive disease (20% increase in the largest diameter)</p> <table><tr><td></td><td>Complete response</td><td>Partial response</td><td>Stable disease</td><td>Progressive disease</td></tr><tr><td>Per patient</td><td>0/10</td><td>0/10</td><td>1/10 (but with new lesions)</td><td>9/10</td></tr></table>		Complete response	Partial response	Stable disease	Progressive disease	Per patient	0/10	0/10	1/10 (but with new lesions)	9/10
	Complete response	Partial response	Stable disease	Progressive disease													
Per patient	0/10	0/10	1/10 (but with new lesions)	9/10													

Study	Study Type/Setting	Funding Source	Population	Intervention	Comparison	Risk of Bias/Applicability	Outcomes					
				and from week 8 onwards injected three times a week every 4 weeks. Treatment lasted between 15 and 53 weeks.			<table><tr><td>Per lesion*</td><td>74/182 (41%)</td><td>18/182 (10%)</td><td>83/182 (29%)</td><td>33/182 (18%)</td></tr></table> <p>*2% of lesions were not assessable</p> <p>New metastatic lesions appearing during the course of treatment: 7/10</p> <p>Treatment withdrawal due to intolerable toxicity: 0/10</p> <p>Treatment toxicity: All experienced erythema and/or discharge from a treated lesion. Several reported mild flu-like symptoms associated with IL-2 injections. 1/10 experienced grade 3 rigors associated with IL-2 injection.</p> <p>Local infection requiring antibiotic treatment: 2/10</p>	Per lesion*	74/182 (41%)	18/182 (10%)	83/182 (29%)	33/182 (18%)
Per lesion*	74/182 (41%)	18/182 (10%)	83/182 (29%)	33/182 (18%)								
Hyde et al (2012)	Randomised Trial 2005-2008	No financial disclosure reported	N=90 Biopsy confirmed lentigo maligna, mean age 68.2 years	All visible signs of LM were removed using shave excision 1 month before topical treatment.	All visible signs of LM were removed using shave		Protocol states 5 months of follow up after initiation of topical treatment. Per protocol analysis of patients					

Study	Study Type/Setting	Funding Source	Population	Intervention	Comparison	Risk of Bias/Applicability	Outcomes																
	USA		(range 35 to 92 years)	Imiquimod 5% cream, 5 days per week for 3 months	excision 1 month before topical treatment Imiquimod 5% cream, 5 days per week for 3 months plus tazarotene 0.1% gel 2 days per week for 3 months.		<div>completing 3 months of treatment (42/46 for monotherapy, 37/44 for combined therapy)</div> <table><tr><td></td><td>Imiquimod alone</td><td>Imiquimod + tazarotene</td><td>Relative risk (95% C.I.)</td></tr><tr><td>Complete response - no residual LM on post treatment excision of tumour footprint plus 2mm margin</td><td>27/42</td><td>29/37</td><td>0.82 [0.62, 1.09]</td></tr><tr><td>Treatment failure - residual LM on post treatment excision</td><td>15/42</td><td>8/37</td><td>1.65 [0.79, 3.45]</td></tr><tr><td>Withdrawal from trial due to toxicity</td><td>1/46</td><td>6/44</td><td>0.16 [0.02, 1.27]</td></tr></table>		Imiquimod alone	Imiquimod + tazarotene	Relative risk (95% C.I.)	Complete response - no residual LM on post treatment excision of tumour footprint plus 2mm margin	27/42	29/37	0.82 [0.62, 1.09]	Treatment failure - residual LM on post treatment excision	15/42	8/37	1.65 [0.79, 3.45]	Withdrawal from trial due to toxicity	1/46	6/44	0.16 [0.02, 1.27]
	Imiquimod alone	Imiquimod + tazarotene	Relative risk (95% C.I.)																				
Complete response - no residual LM on post treatment excision of tumour footprint plus 2mm margin	27/42	29/37	0.82 [0.62, 1.09]																				
Treatment failure - residual LM on post treatment excision	15/42	8/37	1.65 [0.79, 3.45]																				
Withdrawal from trial due to toxicity	1/46	6/44	0.16 [0.02, 1.27]																				
Li et al (2012)	Observational 2004-2008	Grants from American Cancer Society, NIH	N=11 Patients with metastatic	In situ photoimmunotherapy, which consisted of three components	None	Unclear how patients were selected for this study	Complete local response (macroscopic disappearance of treatment site lesions): 8/11 Partial local response (30% or more incomplete macroscopic reduction)																

Study	Study Type/Setting	Funding Source	Population	Intervention	Comparison	Risk of Bias/Applicability	Outcomes
	USA	and National Natural Science Foundation for China.	melanoma. Median age 69 years (range 46 to 87). Prior treatment was surgery (N=11), chemotherapy (N=3), radiotherapy (N=3), isolated limb perfusion (N=2). Performance status was 0 in all cases	applied directly to the skin metastases: topical imiquimod, injection of indocyanine green and photothermal therapy using a near-infrared laser. Treatment cycles lasted 6 weeks, patients received between 1 and 6 cycles of treatment.		Intervention does not match the PICO (additional laser treatment used), no comparator.	<p>of treatment site lesions): 3/11</p> <p>Best overall response: complete response 7/11, partial response 2/11, and stable disease 1/11.</p> <p>Grade 3 toxicity: at least one grade 3 adverse event occurred in 25 % of the patients. Rates were fatigue (9%), dyspnoea (9%), nausea (18%), anorexia (18%), skin pain (9%), and cellulitis (9%).</p> <p>Grade 4 toxicity: none reported</p> <p>Grade 1 - 2 toxicity: A wide range of grade 1 to 2 toxicities were also reported.</p> <p>Overall survival: Median survival was not reached: 12 month overall survival was 70%</p>
Ly et al (2011)	Observational Study 2004-2009	Skin Cancer Foundation; 3M Pharmaceuticals (iNova	N=43 Histologically confirmed LM of the head or neck, age	Imiquimod 5% cream applied to the lesion 5 times a week for 12 weeks, followed (4 weeks after end of	None	None identified Applicable to the population of interest but	<p>Follow-up 16 weeks (according to protocol)</p> <p>Treatment response (histologically</p>

Study	Study Type/Setting	Funding Source	Population	Intervention	Comparison	Risk of Bias/Applicability	Outcomes									
	Australia	Pharmaceuticals)	range 37 to 90 years (mean age 69 for women and 64 for men)	imiquimod treatment) by wide local excision of the LM with a 5mm margin		study has no comparator	<p>confirmed clearance of LM): 20/38.</p> <p>Treatment failure (histologically confirmed persistence of LM): 18/38</p> <p>Macroscopic clearance of LM did not completely correlate with histopathologic clearance:</p> <table><tr><td></td><td>Complete histologic clearance</td><td>Incomplete histologic clearance</td></tr><tr><td>Complete macroscopic clearance</td><td>13</td><td>7</td></tr><tr><td>incomplete macroscopic clearance</td><td>7</td><td>11</td></tr></table> <p>Treatment withdrawal due to intolerable toxicity: 3/43</p>		Complete histologic clearance	Incomplete histologic clearance	Complete macroscopic clearance	13	7	incomplete macroscopic clearance	7	11
	Complete histologic clearance	Incomplete histologic clearance														
Complete macroscopic clearance	13	7														
incomplete macroscopic clearance	7	11														

Study	Study Type/Setting	Funding Source	Population	Intervention	Comparison	Risk of Bias/Applicability	Outcomes
Naylor et al (2003)	Observational Study USA	3M Pharmaceuticals	N=30 (28 completed the 12 week treatment) Age > 18 years (mean 69 years for men, 60 for women), lentigo maligna with at least 2cm left to treat after biopsy, no suspected stage 1 melanoma. Location of LM was head in 26/30, upper extremity in 3/30 and 1/30 on the thorax.	Daily treatment with imiquimod 5% cream applied to the tumour plus a 2cm margin. Continued for 12 weeks unless rest periods were required due to intolerable irritation or impending ulceration. Treatment response was monitored using 4 2mm punch biopsies at 16 weeks.	None	None identified Applicable to the population of interest but study has no comparator	Complete treatment response (histologically confirmed absence of tumour): 26/30 Treatment failure (histologically confirmed persistent tumour): 2/30 Treatment withdrawal: 1/30 (stage 1 melanoma discovered during treatment) Treatment rest period needed due to toxicity: 10/30 Irritation at treatment site : 30/30 Severe local skin reactions : 10/30 Secondary infections requiring antibiotics: 5/30 Cytokine-release syndrome: 2/30
Powell et al (2009)	Retrospective observational study 2001-2006 UK	Not reported	N=48 Patients had histologically confirmed facial LM, not amenable to simple excision,	Imiquimod 5% applied for 8 hours, 3 times per week to the clinically affected area plus a 2 cm margin of normal skin. Treatment was	None	None identified Applicable to the population of interest but study has no comparator.	Treatment response (no clinical or histological evidence of disease): 37/48 Treatment failure (histological evidence of persistent LM): 11/48 Residual pigmentation: 8/37 (in

Study	Study Type/Setting	Funding Source	Population	Intervention	Comparison	Risk of Bias/Applicability	Outcomes
			32/48 had no prior treatment, 16/48 had persistent disease following excision, none were immunocompromised. Age 44-90 years (mean 70.6 years)	intensified if inflammatory response was not elicited			<p>treatment responders)</p> <p>Inflammatory response: , strong or moderate (15/48), mild (18/48), none (15/48)</p> <p>Discontinuation of treatment due to toxicity: 3/48</p> <p>Scarring due to imiquimod: 0/48</p> <p>Cytokine-release syndrome: 0/48</p>
Wong et al (2012)	Observational 2004-2009 Canada	Authors reported no financial disclosure.	N=27 Patients with histologically confirmed lentigo maligna. Imiquimod treatment was primary treatment in 13/27, secondary treatment in 12/27 and tertiary treatment in 1/27. Location of LM was head/neck in 26/27 and upper extremity in 1/27	Imiquimod 5% applied to the affected pigmented areas plus a 10mm margin, 3 times per week. Mean duration of treatment was 20.6 weeks (range 10.1 to 33.4 weeks). Treatment was individualised - for example frequency of application could be increase if there	None	<p>Not reported how patients were selected for the study</p> <p>Applicable to the population of interest but study has no comparator.</p>	<p>Post treatment biopsies were done on average 19.9 weeks after treatment, and patients were also followed up every 3 to 6 months after imiquimod (median follow-up not reported).</p> <p>Treatment success was defined as clinical and histopathological clearance of LM. Treatment failure was residual clinical pigmentation seen by dermoscopy or and histopathological evidence of</p>

Study	Study Type/Setting	Funding Source	Population	Intervention	Comparison	Risk of Bias/Applicability	Outcomes															
				was no inflammatory response or breaks could be taken if side effects became intolerable.			<div><div>persistent LM.</div><table><tr><th>Imiquimod Use</th><th>Treatment success</th><th>Treatment failure</th></tr><tr><td>Primary treatment</td><td>10</td><td>3</td></tr><tr><td>Secondary treatment</td><td>9</td><td>3</td></tr><tr><td>Tertiary treatment</td><td>0</td><td>1</td></tr><tr><td>Overall</td><td>19</td><td>7</td></tr></table><div>Treatment toxicity: inflammation, erythema and crusting were commonly seen (but no figures given)</div></div>	Imiquimod Use	Treatment success	Treatment failure	Primary treatment	10	3	Secondary treatment	9	3	Tertiary treatment	0	1	Overall	19	7
Imiquimod Use	Treatment success	Treatment failure																				
Primary treatment	10	3																				
Secondary treatment	9	3																				
Tertiary treatment	0	1																				
Overall	19	7																				

5. Stage III Melanoma

5.1 Surgical Management

Review question: What is the most effective surgical treatment for stage III melanoma?

Background

In this section we are not discussing the rationale for SNB but what is the most effective way to manage the nodal basin if staged by SNB. The rationale for SNB is a topic being discussed elsewhere.

The questions here are

a) Most patients with a positive sentinel node biopsy are offered a second operation to remove all the nodes in that area of the body (nodal basin) which is called Completion Lymph Node dissection, (CLND). The question we are asking is what is the benefit to this further surgery and if that surgery is beneficial for all patients.

c) Sometimes a positive sentinel node is detected in an unusual site (not in the neck, groin or axilla) which is known as an aberrant node. The question we are asking is what is the most beneficial surgery here?

Stage IIb: Macroscopic disease (melanoma that can be felt as a lump): Data indicate that surgery in the form of Therapeutic Lymph Node Dissection (TLND) is mainly to prevent the melanoma recurring in that site and does little to improve overall survival: The major areas that surgery is undertaken is

i) Neck: The question is what form of designated neck dissection (TLND) is most effective for disease in the neck. In what circumstances should removal of the parotid gland be included? How extensive does the surgery have to be?

ii) Axilla: It is felt that removal of all the glands in the axilla (Level 3 TLND dissection) is necessary for disease here. Is this the most effective surgery?

iii) Groin: This is a major area for discussion. Standard surgery for nodal disease in groin is a groin TLND (removing the nodes in superficial and deep femoral triangle). British Assoc. of Dermatology (BAD)/ British Assoc. of Plastic, Reconstructive and Aesthetic Surgeons (BAPRAS) guidelines exist for indications to extend the surgery above the inguinal ligament into the pelvic retroperitoneal space (ileoinguinal TLND). Is there indication to change these guidelines and is this surgery more effective? Are the side effects of the surgery (the morbidity) greater?

iv) Nodes can be found very occasionally in epitrochlear (elbow) and popliteal (knee) fossa. What is the most effective management here? This condition is rare

As part of surgery, should surgeons look at the effectiveness of the surgery and the side effects that result such as wound infections. There are different ways of trying to measure this? Taskforce groups have identified the following: a) Numbers of procedures by individual surgeon (NICE recommendation), b) Complications (major and minor), c) Readmission to hospital for complications, d) Mortality figures

1 Stage IIIc: Macroscopic disease with in-transit or locally recurrent disease. The management of the
2 nodal basins are identified above in i, ii and iii.

3 The management of in transit disease is part of the discussion featured in Topic I

4 * Stage IIIa Microscopic disease identified in regional nodes

5 ~ are they all identified by SLNB? What other methods are used? Links with Topic E

6 *Stage IIIb Macroscopic disease

7 ~ Neck Lymph node drainage as defined by levels for surgical clearance. Agree Parotid surgery
8 requires clarification in regard to when and how much.

9 *Both;

10 ~ Morbidity associated with all TLNDs a critical assessment especially when surgery on different
11 levels of nodes (extent of surgery) being compared.

12 Question in PICO format

Patients/population	Intervention	Comparison	Outcomes
Patients diagnosed with stage III melanoma: <ul style="list-style-type: none"> • Micro Metastatic nodal disease as detected by SLNB (inc. aberrant lymph nodes) • Palpable nodal disease (inc aberrant lymph nodes) 	<i>Micro Metastatic nodal disease</i> <ul style="list-style-type: none"> • Completion lymphadenectomy <i>Palpable nodal disease</i> <ul style="list-style-type: none"> • Standard (local) Lymphadenectomy 	<i>Micro Metastatic nodal disease</i> <ul style="list-style-type: none"> • Clinical observation • Clinical follow up using Ultrasound <i>Palpable nodal disease</i> <ul style="list-style-type: none"> • Extended Lymphadenectomy <ul style="list-style-type: none"> ○ eg inguinal versus inguinal and iliac ○ Eg modified neck vs radical ○ Eg excision aberrant node versus node and lymphadenectomy nearest basin 	1. Local Recurrence 2. Regional recurrence 3. Melanoma specific Survival (5 & 10 yr) 4. Overall survival (5 & 10 yr) 5. HRQL 6. Accurate staging 7. Adverse events long term, inc: Lymphoedema 8. Adverse Events short term surgical

13 How the information will be searched

Searches:	
Can we apply date limits to the search	The GDG did not feel that it was appropriate to apply any date limits to the searches for this topic
Are there any study design filters to be used (RCT, systematic review, diagnostic test).	
List useful search terms.	
Notes	.

1 **Search Results**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
Medline	1946-2014	4544	1134	09/06/2014
Premedline	June 04 2014	133	25	05/06/2014
Embase	1947-2014	5725	889	12/06/2014
Cochrane Library	Issue 6 of 12 June 2014	194	23	12/06/2014
Web of Science (SCI & SSCI)	1900-2014	4783	538	11/06/2014
Total References retrieved (after initial sift and de-duplication): 1599				

2 **Update Search**

- 3 For the update search, the same search criteria/filters were applied as initial search with a date limit of June
4 2014 onwards.


Database name	No of references found	No of references retrieved	Finish date of search
Medline	64	19	09/10/2014
Premedline	7	1	09/10/2014
Embase	37	5	09/10/2014
Cochrane Library	0	0	09/10/2014
Web of Science (SCI & SSCI)	232	25	09/10/2014
3 references found in Pubmed 09/10/2014			
Total References retrieved (after de-duplication): 25			

5 **Medline search strategy** (*This search strategy is adapted to each database*)

- 6 1. exp Melanoma/
7 2. melanoma\$.tw.
8 3. 1 or 2
9 4. (stage iii or stage iiia or stage iiib or stage iiic or stage 3 or stage 3a or stage 3b or stage 3c or
10 spread or metastas* or satellite* or regional or lymph* or palpable or "micro metastas*" or micro-
11 metastas* or micrometastas* or microscopic or macroscopic).tw.
12 5. Lymphatic Metastasis/

- 1 6. 4 or 5
- 2 7. 3 and 6
- 3 8. exp Lymph Node Excision/
- 4 9. Lymph Nodes/su
- 5 10. lymphadenectom*.tw.
- 6 11. CLND.tw.
- 7 12. TLND.tw.
- 8 13. ((neck or radical) adj2 (excis* or dissect* or surger* or resect*)).tw.
- 9 14. ((lymph* or node* or nodal) adj2 (dissect* or remov* or excis* or surger* or resect*)).tw.
- 10 15. or/8-14
- 11 16. exp Ultrasonography/
- 12 17. (ultraso* or sonogra* or echotomogra* or echogra*).tw.
- 13 18. 16 or 17
- 14 19. exp Aftercare/
- 15 20. (follow-up or "follow up" or followup).tw.
- 16 21. (check-up*1 or check up*1).tw.
- 17 22. surveillance.tw.
- 18 23. (aftercare or after-care).tw.
- 19 24. ((post-treatment or posttreatment) adj1 evaluat*).tw.
- 20 25. ((post-treatment or posttreatment) adj1 care).tw.
- 21 26. ((post-treatment or posttreatment) adj1 monitor*).tw.
- 22 27. or/19-26
- 23 28. 18 and 27
- 24 29. Observation/
- 25 30. Physical Examination/
- 26 31. (visual adj exam*).tw.
- 27 32. (skin adj exam*).tw.
- 28 33. (clinical adj (exam* or observ*)).tw.
- 29 34. (physical adj exam*).tw.
- 30 35. or/29-34
- 31 36. 15 or 28 or 35
- 32 37. 7 and 36
- 33
- 34

1 Screening Results



Reasons for Exclusion

Expert Reviews
Abstract Only
No Comparators
Treatment Comparisons not relevant to PICO
Population not relevant to PICO

Quality of the included studies

Systematic review of RCTs (n=0)
Systematic review of combined study designs (n=0)
Randomized controlled trial (n=0)
Prospective cross sectional study (n=0)
Case Series Studies (n=16)
Qualitative Study (n=0)

Table 5.1 Characteristics of included studies

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
Abbott et al (2013)	Retrospective Study	To compare short-term outcomes between MILND and OILND among patients with metastatic melanoma from two institutions.	N=13 MILND N=28 OILND	Minimally invasive inguinal lymph node dissection	Open Inguinal lymph node dissection	<ul style="list-style-type: none"> Adverse Events
Bamboet et al (2014)	Retrospective Study	To characterise the populations undergoing nodal observation (no CLND) and CLND; determine the pattern of initial recurrence between no CLND and CLND group; determine the melanoma specific survival of both patient groups and to characterise the outcome of no CLND patients who experience a subsequent isolated nodal recurrence	4310 patients undergoing wide local excision with SLNB N=495 (11%) with a positive SLN N=167 underwent nodal observation N=328 underwent immediate completion lymph node dissection	Completion lymph node dissection (CLND)	Nodal observation	<ul style="list-style-type: none"> Recurrence (regional,nodal, systemic, regional disease as a component of recurrence, nodal disease as a component of recurrence, systemic disease as a component of recurrence) Survival
deVries et al (2006)	Retrospective Study	To evaluate morbidity after inguinal SLNB	N=66 N=52 SLNB only	SLNB + completion	SLNB	<ul style="list-style-type: none"> Long term morbidity (lymphoedema and range of

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
		alone and inguinal SLNB with completion inguinal dissection	N=14 underwent completion lymphadenectomy (N=11 superficial + deep groin dissection and N=3 superficial groin dissection)	lymphadenectomy		motion of restrictions)
Egger et al (2014)	Retrospective study	To evaluate whether a combined inguinal and iliac/obturator dissection improved locoregional disease control and survival compared with an inguinal dissection alone in the absence of clinical and radiological evidence of pelvic lymph node metastases	N=143 patients N=100 inguinal dissections N=34 combined inguinal and iliac/obturator dissection	Inguinal Dissection	Combined inguinal and iliac/obturator dissection	<ul style="list-style-type: none"> • Overall Survival • Disease free survival
Kingham et al (2010)	Retrospective Study	To examine a group of SLNB positive patients who underwent completion lymph node dissection compared with those who did	N=313 N=271 underwent CLND N=42 no CLND SLNB+CLND	Complete lymph node dissection	No lymph node dissection	<p>Unclear appear to be:</p> <ul style="list-style-type: none"> • Recurrence <ul style="list-style-type: none"> ○ Nodal (recurrences)

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
			SLNB+salvage therapeutic lymph node dissection			<ul style="list-style-type: none"> in the draining nodal basin from the primary lesion) <ul style="list-style-type: none"> Regional (local and in-transit lesions) Systemic disease (lesions in all other locations) Survival
Kretschmer et al (2001)	Retrospective Study	To investigate the impact of inguinal versus ilio-inguinal node dissection in patients with palpable groin nodes	<p>N=104 patients with cutaneous melanoma who underwent therapeutic groin dissection.</p> <p>N=69 ilio-inguinal dissection N=35 superficial inguinal dissection</p>	Ilio-inguinal dissection	Inguinal dissection	<ul style="list-style-type: none"> Local tumour control Survival
Kretschmer et al (2004)	Retrospective Study	To investigate survival outcomes in patients with lymphatic metastases who	<p>N=937 N=314 undergoing early excision N=623 undergoing</p>	SLNB + early excision	SLNB + delayed excision	<ul style="list-style-type: none"> Overall Survival

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
		underwent early or delayed excision of regional lymph nodes	delayed excision			
O'Brien et al (1995)	Retrospective Study	To evaluate the role and efficacy of modified and selective neck dissections and adjuvant radiotherapy in treating patients with clinical metastatic melanoma	N=175 patients who had 183 neck dissections	Therapeutic Neck Dissection (Selective, Radical or modified)	Elective Neck Dissection (Selective or Modified) Elective dissections were performed when primary melanoma thickness was $\geq 1.5\text{mm}$	<ul style="list-style-type: none"> • Recurrence • Overall Survival
Singletery et al (1992)	Retrospective	To investigate whether or not a more conservative approach would offer and improved survival rate or better local and regional control.	N=264 patients N=113 with subsequent regional nodal disease N=151 who initially had regional nodal disease	Superficial femoral node dissection Iliac nodal dissection for	Combined ilio-inguinal dissection	<ul style="list-style-type: none"> • Survival

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
				<p>patients with synchronous primary melanoma</p> <p>Femoral nodal dissection six weeks later for patients with palpable groin disease</p> <p>Superficial femoral dissection or combined ilioinguinal dissection for patients who developed delayed nodal metastases.</p>		
Smith et al	Retrospective	To determine whether	N=350 patients	SLNB	SLNB +	<ul style="list-style-type: none"> Disease Specific Survival

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
(2012)	Study	CLND improves survival in patients with cutaneous melanoma of the head and neck	N=140 SLNB only N=210 SLNB +CLND		completion lymph node dissection	<ul style="list-style-type: none"> Overall Survival
Spillane et al (2014)	Retrospective Study	To establish how timing of lymphadenectomy in the course of the disease related to the interval between the diagnosis of the primary tumour and the first recurrence after lymphadenectomy.	N=1704 N=502 Immediate completion lymphadenectomy (ICL) N=214 Delayed Completion lymphadenectomy (DCL) N=709 Delayed therapeutic lymphadenectomy (DTL) N=279 Immediate therapeutic lymphadenectomy	SLNB+Immediate completion lymphadenectomy SLNB+delayed completion lymphadenectomy Observation+Delayed therapeutic lymphadenectomy	Each Other	<ul style="list-style-type: none"> Disease Free Survival Post Recurrence Survival Overall Survival

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
			(ITL)	Immediate therapeutic lymphadenectomy for clinically positive nodes		
Van der Ploeg et al (2008)	Retrospective Study	To investigate the pathological findings, the incidence of lymph node recurrences and the disease free survival in clinically node negative patients with a positive sentinel node in the groin who have undergone lymph node dissection	N=52 clinically node negative patients with cutaneous melanoma and a tumour positive sentinel node biopsy of the groin N=10 patients who did not receive further dissection due to small tumour burden in the sentinel nodes and were not included in the analysis.	Completion groin node dissection	Superficial groin node dissection	<ul style="list-style-type: none"> • Lymph Node Recurrence • Disease Free Survival
Van der ploeg et al (2012)	Retrospective Study	To evaluate the influence of immediate completion lymph node dissection (CLND) on	N=1174 patients with SN positive melanoma N=1113 underwent	CLND	No CLND	<ul style="list-style-type: none"> • Disease Specific Survival

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
		outcome in patients with SN positive melanoma	immediate CLND N=61 no CLND			
Van der ploeg et al (2011)	Retrospective Study	To evaluate the experience in patients with clinically evident metastatic melanoma to the groin who underwent combined superficial and deep groin dissection versus inguinal or superficial groin dissection	N=121 patients who underwent combined superficial and deep dissection (CGD) N=48 patients who underwent therapeutic superficial dissection (SGD) for palpable metastases to the groin	Combined superficial and deep dissection	Therapeutic superficial dissection	<ul style="list-style-type: none"> • Post operative morbidity • Regional Recurrence (Not defined) • Preoperative CT scan • Disease free survival • Overall survival
Van der ploeg et al, 2014	Retrospective Study	To compare regional recurrence free survival, distant metastases free survival and melanoma specific survival of SNB patients with observation patients in	N=2931 in the observation group N=2909 in the SLNB arm	SLNB+wide local excision	Observation + total lymph node dissection for recurrence	<ul style="list-style-type: none"> • Recurrence • Disease free Survival • Distant metastases free survival • Melanoma Specific survival

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
		a large patient cohort				
White et al (2009)	Retrospective Study	To evaluate the outcome of therapeutic neck dissection for melanoma in patients with head and neck melanoma	N=37	Radical neck dissection Modified radical dissection Selective dissection	Each Other	<ul style="list-style-type: none"> Survival

Study Quality

All studies in this review were retrospective case series studies assessed as very low quality using GRADE methodology.

The primary reason for downgrading evidence was due to the fact that was not always clear from the individual studies which AJCC stage was included and therefore there may be a question mark over the relevance of the populations to this question though due to the nature of the comparisons of interest it is considered that the risk of the populations not being directly relevant was low.

Individual studies could not be compared for consistency due to differences in outcome reporting in relation to whether studies reported on regional recurrence or local recurrence. In addition, for some outcomes, there was only a single study available so no comparisons comment can be made on consistency of results in these situations.

Not all outcomes of interest were reported in the evidence; there was no evidence relating to 'quality of life' or 'accurate staging' and the evidence relating to 'adverse events' was not comprehensive enough to report on short and long term events separately.

Evidence Statements

Sentinel Lymph node biopsy ± completion lymph node dissection

Recurrence (Local and Regional)

From one retrospective study with a total of 495 patients with a positive sentinel lymph node, there was no significant difference in median time to recurrence when comparing patients undergoing immediate completion lymph node dissection to patients undergoing nodal observation (9 months versus 12 months, $p=0.46$) (Bamboot et al, 2014).

Regional recurrence rates were not significantly different between the completion lymph node dissection (CLND) group and the observation group (18% versus 16%, $p=0.58$); however there was a statistically significant difference in nodal recurrence rates (CLND=6% versus No CLND=15%, $p=0.002$) and in systemic recurrences (CLND=27% versus Observation = 8%, $p<0.001$) (Bamboot et al, 2014).

From one retrospective study with a total of 313 patients no difference in patterns of first recurrence was observed when comparing patients who had a complete lymph node dissection and those who did not (54% versus 48%) (Kingham et al, 2010).

Melanoma Specific Survival

From one retrospective study with 1174 patients undergoing sentinel lymph node biopsy there was no significant difference in disease specific survival; 3 year disease specific survival was 74% in patients who did not undergo complete lymph node dissection ($n=61$) versus 76.9% in patients who underwent CLND ($n=1113$) while 5 year disease specific survival was 66% for patients not undergoing CLND and 66% for the CLND group (Van der Ploeg, 2012).

From one retrospective study including 495 patients with a positive sentinel lymph node, melanoma specific survival for patients who underwent immediate completion lymph node dissection was 36.5 months (median) and was not reached for patients undergoing salvage lymph node dissection ($p=0.005$). Increasing age ($p=0.006$), tumour thickness ($p=0.001$) and degree of ulceration ($p<0.001$) were all associated with higher melanoma specific survival (Bamboet et al, 2014).

One retrospective study including a total of 350 patients reported no significant difference between treatment groups (SLNB versus SLNB+CLND) in relation to disease specific survival. Age was significantly associated with an increased risk of death from melanoma in patients <60 years and tumour thickness $>2\text{mm}$ was a significant predictor of worse survival in the older age group ($\text{HR}=3.11$, $p<0.001$) (Smith et al, 2012).

Overall Survival

From one retrospective study with a total of 937 patients, overall survival was significantly better for patients undergoing sentinel lymph node biopsy and early lymph node excision compared with patients undergoing delayed excision ($p=0.002$). Estimated 3 year survival was $80.1\pm 2.8\%$ in patients positive SLNB and immediate lymph node dissection compared with $67.6\pm 1.9\%$ in patients undergoing delayed lymph node dissection and estimated 5 year survival was $62.5\pm 5.5\%$ for SLNB+immediate lymph node dissection and $50.2\pm 5.4\%$ for SLNB + delayed lymph node dissection (Kretschmer et al, 2004).

Adverse Events

From one retrospective study with a total of 66 patients who underwent sentinel lymph node biopsy with or without completion lymphadenectomy, there were no reported deaths as a result of surgical intervention. There was a significantly higher rate of post surgery complications in the SLNB+groin dissection group when compared with the SLNB only group ($p<0.001$) (deVries et al, 2006).

In one retrospective study with a total of 66 patients, a significant difference in leg volume (measure of lymphoedema) was observed with patients undergoing SLNB+groin dissection having a greater volume compared with patients undergoing SLNB only ($p<0.001$) (deVries et al, 2006).

GRADE Table 5.1: Should patients with microscopic disease detected by SLNB undergo Immediate Lymphadenectomy or Observation?

Quality assessment							Summary of findings				Quality
							No of patients		Effect		
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	SLNB+Immediate Lymphadenectomy	SLNB+Observation	Relative (95% CI)	Absolute	
Recurrence (Bamboat et al, 2014; Kingham et al, 2010)											
2 (n=808)	observational studies	serious ¹	no serious inconsistency	no serious indirectness ²	no serious imprecision	none	?/599 ³	?/209 ³	Not Pooled		Very Low
Melanoma Specific Survival (van der Ploeg et al, 2012; Bamboat et al 2014; Smith et al, 2012)											
3 (n=2019)	observational studies	serious ¹	no serious inconsistency	no serious indirectness ²	no serious imprecision	none	?/1651 ³	?/368 ³	Not Pooled		Very Low
Overall Survival (Kretschemmer et al, 2004)											
1 (n=937)	observational studies	serious ¹	no serious inconsistency	no serious indirectness ²	no serious imprecision	none	?/314 ³	?/623 ³	Estimated 3 year survival was 80.1±2.8% in patients positive SLNB and immediate lymph node dissection compared with 67.6±1.9% in patients undergoing delayed lymph node dissection		Very Low
Adverse events (deVries et al, 2006)											
1 (n=66)	observational studies	serious ¹	no serious inconsistency	no serious indirectness ²	no serious imprecision	none	?/11 ³	?/55 ³	There was a significantly higher rate of post surgery complications in the SLNB+groin dissection group when compared with the SLNB only group (p<0.001) -		Very Low

¹ Not a randomised trial ² The studies do not clearly specify what AJCC stage included patients have been assigned. ³ Event rate is not reported

Standard lymphadenectomy versus extended lymphadenectomy for palpable lymph node disease

Recurrence (local and regional)

From one retrospective study with a total of 104 patients undergoing either ilio-inguinal dissection or inguinal dissection, the type of operation did not have a significant effect on local control of the dissected lymph node (Kretschmer et al, 2001).

From one retrospective study with a total of 169 patients undergoing either combined superficial and deep groin dissection (CGD) or a therapeutic superficial groin dissection (SGD), there was no significant difference overall in rates of recurrence with 74% of CGD patients and 73% SGD patients experiencing recurrence. Regional recurrence rates were more common in the SGD group than in the CGD group though the difference was not statistically significant ($p=0.498$) (Van der Ploeg et al, 2011).

From one retrospective study with a total of 143 patients undergoing either inguinal dissection of a combined inguinal and iliac/obturator dissection, rates of pelvic lymph node recurrence did not differ significantly when considering patients with microscopic disease. For patients with macroscopic disease, pelvic node recurrence rates did not differ significantly (Egger et al, 2014).

From one retrospective study with a total of 143 patients undergoing either inguinal dissection of a combined inguinal and iliac/obturator dissection, systemic recurrence was the most common type of recurrence with 43% of patients undergoing inguinal dissection and 48% of patients undergoing combined inguinal and iliac/obturator dissection experiencing systemic recurrences. Systemic recurrences were more common in patients with macroscopic disease than in patients with microscopic disease (Egger et al, 2014).

Melanoma Specific Survival

From one retrospective study which included 52 patients undergoing completion groin node dissection or superficial groin node dissection, 5 year disease free survival was 53% in the superficial node dissection group compared with 61% in the complete groin dissection group (van der Ploeg et al, 2008).

From one retrospective study with a total of 169 patients undergoing either combined superficial and deep groin dissection (CGD) or a therapeutic superficial groin dissection (SGD) no significant difference in disease free survival was observed between the groups. 5 year estimated disease free survival rate was 15.7% in the SGD group and 18.3% in the CGD group. Considering the whole cohort, significant prognostic factors for disease free survival included number of positive superficial nodes ($HR=1.6$, 95% CI 1.03-2.51, $p=0.038$) and superficial lymph node ratio ($HR=2.33$, 95% CI 1.25-4.34, $p<0.008$) (van der Ploeg et al, 2011).

From one retrospective study with a total of 143 patients undergoing either inguinal dissection of a combined inguinal and iliac/obturator dissection, disease free survival was significantly greater in patients with macroscopic disease compared with microscopic disease ($p=0.0002$) (Egger et al, 2014).

Overall Survival

From one retrospective study which included 52 patients undergoing completion groin node dissection or superficial groin node dissection, 5 year overall survival for patients who underwent only a superficial groin node dissection was 76% (95% CI 62-95%) compared with 80% (95% CI 61-100%) for patients who underwent completion groin node dissection (van der Ploeg et al, 2008).

From a retrospective study in which 104 patients underwent either ilio-inguinal dissection or inguinal dissection, 5 year overall survival for the whole cohort was 30.4% and 10 year overall survival for the whole cohort was 18.4% and extent of lymph node dissection did not have a significant effect on survival (Kretschmer et al, 2001).

A second retrospective study in which with a total of 169 patients underwent either combined superficial and deep groin dissection (CGD) or a therapeutic superficial groin dissection (SGD) also reported no significant difference in overall survival when comparing extent of lymph node dissection (van der Ploeg et al, 2011).

From one retrospective study comparing patients who underwent femoral nodal dissection for palpable groin disease with patients who underwent an iliac nodal dissection for melanoma metastasis, no significant difference in median overall survival was observed (32.7 months versus 39.5 months, $p=0.17$) and type of groin dissection did not impact survival when stratified by tumour burden (Singletary et al, 1992).

From one retrospective study ($n=37$) comparing patients undergoing radical neck dissection, modified radical dissection or selective dissection, overall survival at 60 months was 33% with no difference observed in survival rates for the 3 different types of dissection (White et al, 1992).

Adverse Events

From one retrospective study in which 13 patients underwent minimally invasive inguinal lymph node dissection (MILND) and 28 patients underwent open inguinal lymph node dissection (OILND), operative time was significantly longer for MILND patients compared with OILND patients ($p=0.003$) but length of hospital stay was significantly shorter ($p=0.01$) and incidence of hospital readmission was higher in the OILND group (21%) than in the MILND group (7%) though the difference was not significant ($p=0.25$). Incidence of wound dehiscence ($p=0.07$) and infection ($p=0.13$) were greater in the OILND group compared with the MILND group (Abbot et al, 2013).

GRADE Table 5.2: Should patients with palpable lymph nodes undergo Superficial Lymph Node Dissection or Extended lymphadenectomy?

No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Superficial Lymph Node Dissection	Extended lymphadenectomy	Relative (95% CI)	Absolute	Quality
Recurrence (Kretschmer et al, 2001; van der Ploeg et al, 2011; Egger et al, 2014)											
3 (n=416)	observational studies	serious ¹	no serious inconsistency	no serious indirectness ²	no serious imprecision	none	?/183 ³	?/416 ³	Not Pooled ⁴		Very Low
Melanoma Specific Survival (van der Ploeg, 2008; van der Ploeg et al, 2011; Egger et al, 2014)											
3 (n=374)	observational studies	serious ¹	no serious inconsistency	no serious indirectness ²	no serious imprecision	none	?/158 ³	?/207 ³	Not Pooled ⁴		Very Low
Overall Survival (van der Ploeg, 2008; van der Ploeg et al, 2011; Kretschmer et al, 2001; Singletary et al, 1992; White et al, 1992)											
5 (n=636)	observational studies	serious ¹	no serious inconsistency	no serious indirectness ²	no serious imprecision	none	?/213 ³	?/423 ³	Not Pooled ⁴		Very Low
Adverse Events (Abbot et al, 2013)											
1 (n=41)	observational studies	serious ³	no serious inconsistency	no serious indirectness ²	no serious imprecision	none	Operative time was significantly longer for minimally invasive inguinal lymph node dissection patients compared with open inguinal lymph node dissection patients (p=0.003) but length of hospital stay was significantly shorter (p=0.01) and incidence of hospital readmission was higher in the OILND group				Very Low

¹ Not a randomised trial ² The studies do not clearly specify what AJCC stage included patients have been assigned. ³ Event rate is not reported ⁴ Data were not pooled as the individual studies were comparing different types and locations of surgical intervention

References

Included

Abbott, A. M., et al (2013) Minimally invasive inguinal lymph node dissection (MILND) for melanoma: experience from two academic centers. *Annals of Surgical Oncology* 20;1:340-345.

Bamboot, Z. M., et al (2014) Observation After a Positive Sentinel Lymph Node Biopsy in Patients with Melanoma. *Annals of Surgical Oncology* . 16-5-2014.

Reason:

de Vries, M., et al (2006) Morbidity after inguinal sentinel lymph node biopsy and completion lymph node dissection in patients with cutaneous melanoma. *Ejso* 32:7:785-789.

Egger, M. E., et al (2014) Addition of an Iliac/Obturator Lymph Node Dissection Does Not Improve Nodal Recurrence or Survival in Melanoma. *Journal of the American College of Surgeons*

Kingham, T. P., et al (2010) Outcome of patients with a positive sentinel lymph node who do not undergo completion lymphadenectomy. *Annals of Surgical Oncology* 17;2: 514-520.

Kretschmer, L., et al (2004) Patients with lymphatic metastasis of cutaneous malignant melanoma benefit from sentinel lymphonodectomy and early excision of their nodal disease. *European Journal of Cancer* 40;2:212-218.

Kretschmer, L., et al (2001) Superficial inguinal and radical ilioinguinal lymph node dissection in patients with palpable melanoma metastases to the groin--an analysis of survival and local recurrence. *Acta Oncologica* 40;1:72-78.

O'Brien C. J. Et al (1995) Radical, Modified and Selective Neck Dissection for Cutaneous Malignant Melanoma *Head and Neck* 17;232-241

Singletary, S. E., et al (1992) Surgical management of groin nodal metastases from primary melanoma of the lower extremity. *Surgery, Gynecology & Obstetrics* 174;3:195-200.

Smith, V. A., et al (2012) Completion node dissection in patients with sentinel node-positive melanoma of the head and neck. *Otolaryngology - Head & Neck Surgery* 146;4:591-599.

Spillane, A. J., et al (2014) Patterns of recurrence and survival after lymphadenectomy in melanoma patients: clarifying the effects of timing of surgery and lymph node tumor burden. *Annals of Surgical Oncology* 21;1:292-299.

van der Ploeg, I. M., et al (2008) Tumor-positive sentinel node biopsy of the groin in clinically node-negative melanoma patients: superficial or superficial and deep lymph node dissection? *Annals of Surgical Oncology* 15;5:1485-1491

van der Ploeg, A. P., et al (2011) Therapeutic surgical management of palpable melanoma groin metastases: superficial or combined superficial and deep groin lymph node dissection. *Annals of Surgical Oncology* 18;12: 3300-3308.

van der Ploeg, A. P. T. (2012) Prognosis in patients with sentinel node-positive melanoma without immediate completion lymph node dissection. *British Journal of Surgery* 99;10:1396-1405.

van der Ploeg, A. P., et al (2014) Outcome following sentinel node biopsy plus wide local excision versus wide local excision only for primary cutaneous melanoma: analysis of 5840 patients treated at

1 a single institution. *Annals of Surgery* 260;1:149-157

3 White, N., et al (2009) Lymphadenectomy for melanoma in the clinically N1 neck: radical, modified
4 radical, or selective? *Journal of Craniofacial Surgery* 20;2:385-388.

5 *Excluded Studies*

7 Aziz, A. I. M. (1995) Malignant melanoma of the vulva: Limited local excision versus radical
8 vulvectomy. *Contemporary Reviews in Obstetrics and Gynaecology* 7;2:101-105.
9 *Reason: Not relevant to PICO*

10 Baas, P. C., et al (1992) Groin dissection in the treatment of lower-extremity melanoma. Short-term
11 and long-term morbidity. *Archives of Surgery* 127;3:281-286
12 *Reason: No Comparison*

13 Badgwell, B., et al (2007) Pelvic lymph node dissection is beneficial in subsets of patients with node-
14 positive melanoma. *Annals of Surgical Oncology* 14;10:2867-2875.
15 *Reason: Population not relevant to PICO (No SLNB)*

16 Balch, C. M. and Balch, C. M.(1998) The John Wayne Clinical Research Lecture. Surgical management
17 of melanoma: results of prospective randomized trials. *Annals of Surgical Oncology* 5;4:301-309.
18 *Reason: Narrative Review*

19 Blazer, D. G., Sondak, V. K., and Sabel, M. S. (2007) Surgical therapy of cutaneous melanoma.
20 *Seminars in Oncology* 34;3:270-280.
21 *Reason: Narrative Review*

22 Cascinelli, N., et al (1998) Immediate or delayed dissection of regional nodes in patients with
23 melanoma of the trunk: a randomised trial. WHO Melanoma Programme. *Lancet* 351;9105:793-796.
24 *Reason: Population/comparison not relevant to PICO*

25 Chan, A. D., et al (2000) Judging the therapeutic value of lymph node dissections for melanoma.
26 *Journal of the American College of Surgeons* 191;1:16-22.
27 *Reason: No Comparative Analysis*

28 Clary, B. M., et al (2001) Early recurrence after lymphatic mapping and sentinel node biopsy in
29 patients with primary extremity melanoma: a comparison with elective lymph node dissection.
30 *Annals of Surgical Oncology* 8;4:328-337.
31 *Reason: Not relevant to PICO*

32 Corsetti, R. L., et al (2000) Thin < or = 1 mm level III and IV melanomas are higher risk lesions for
33 regional failure and warrant sentinel lymph node biopsy. *Annals of Surgical Oncology* 7;6:456-460.
34 *Reason: Not relevant to PICO*

35 De Stefani, S., et al (2010). Inguinal Lymphadenectomy for Penile Cancer and Melanoma: Our
36 Experience with 22 Cases. *Anticancer Research* 30;4:1480-1481.
37 *Reason: Abstract*

38 de Vries, M., et al (2009) Quality of life after axillary or groin sentinel lymph node biopsy, with or
39 without completion lymph node dissection, in patients with cutaneous melanoma. *Annals of Surgical*
40 *Oncology* 16;10:2840-2847.
41 *Reason: Population not relevant to PICO*

- 1 Egberts, F., et al (2011) Risk evaluation in cutaneous melanoma patients undergoing lymph node
2 dissection: impact of POSSUM. *Annals of the Royal College of Surgeons of England* 93;7:514-522.
3 *Reason: Comparison not relevant to PICO (Palpable nodes versus non-palpable nodes)*
- 4 Essner, R., et al (2006) Surgical management of the groin lymph nodes in melanoma in the era of
5 sentinel lymph node dissection. *Archives of Surgery* 141;9:877-882.
6 *Reason: Population not relevant to PICO*
- 7 Faries, M. B. Et al (2010) The impact on morbidity and length of stay of early versus delayed
8 complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy
9 Trial (I). *Annals of Surgical Oncology* 17;12:3324-3329.
10 *Reason: Comparison not relevant to PICO*
- 11 Fisher, S. R. and Fisher, Samuel R. (2002) Elective, therapeutic, and delayed lymph node dissection
12 for malignant melanoma of the head and neck: analysis of 1444 patients from 1970 to 1998.
13 *Laryngoscope* 112;1: 99-110.
14 *Reason: Comparison not relevant to PICO (compares stage)*
- 15 Fisher, S. R. and Fisher, S. R. (1989) Cutaneous malignant melanoma of the head and neck.
16 *Laryngoscope* 99;8:Pt 1:822-836.
17 *Reason: Population not relevant to PICO*
- 18 Fortner, J. G. et al (1964) Results Of Groin Dissection For Malignant Melanoma In 220 Patients.
19 *Surgery* 55, 485-494. 1964.
20 *Reason: Narrative Review*
- 21 Gadd, M. A. Coitet al (1992) Recurrence patterns and outcome in 1019 patients undergoing axillary
22 or inguinal lymphadenectomy for melanoma. *Archives of Surgery* 127;12:1412-1416.
23 *Reason: No comparator*
- 24 Geltzeiler, M. Givi. (2011) Regional control of head and neck melanoma with selective neck
25 dissection. *Otolaryngology - Head and Neck Surgery Conference*[var.pagings]
26 *Reason: Abstract*
- 27 Ghussen, F. and Kruger, I. Lymphadenectomy in Patients Suffering from Melanomas of the
28 Extremities - A Prospective-Study on 220 Patients. *Aktuelle Chirurgie* 23;6:232-235. 1988.
29 *Reason:*
- 30 Glumac, N., et al (2012) Inguinal or inguino-iliac/obturator lymph node dissection after positive
31 inguinal sentinel lymph node in patients with cutaneous melanoma. *Radiology & Oncology* 46;3:
32 258-264.
33 *Reason: Population not relevant to PICO*
- 34 Gumport, S. L. M.(1959)Treatment of 126 cases of malignant melanoma: Long term results. *Annals*
35 *of Surgery* 150[6], 989-992.
36 *Reason: No Data*
- 37 Hotz, G., et al (1986) Prophylactic Lymph-Node Dissection in the Treatment of Cutaneous Malignant-
38 Melanoma - A Study of Matched Pairs. *Hautarzt* 37;10:554-559.
39 *Reason: Foreign Language*

- 1 Hyngstrom, J. R. R. (2011) Prospective assessment of lymphedema following lymph node surgery for
2 melanoma. *Annals of Surgical Oncology Conference*[var.pagings]
3 *Reason: Abstract*
- 4 Ingvar, C. et al (1984) Morbidity following prophylactic and therapeutic lymph node dissection for
5 melanoma--a comparison. *Tumori* 70;6:529-533.
6 *Reason: Comparison not relevant to PICO*
- 7 Karakousis, C. P et al (1991). Survival after groin dissection for malignant melanoma. *Surgery*
8 109;2:119-126.
9 *Reason: Comparison not relevant to PICO*
- 10 Karakousis, C. P., et al (1983) Lymphedema after groin dissection. *American Journal of Surgery*
11 145;2:205-208..
12 *Reason:No useable data*
- 13 Kelemen, P. R., Wanek, et al (1999) Lymph node biopsy does not impair survival after therapeutic
14 dissection for palpable melanoma metastases. *Annals of Surgical Oncology* 6;2:139-143.
15 *Reason: Comparison not relevant to PICO*
- 16 Kretschmer, L., et al (2008) Postoperative morbidity of lymph node excision for cutaneous
17 melanoma-sentinel lymphonodectomy versus complete regional lymph node dissection. *Melanoma*
18 *Research* 18;1:16-21.
19 *Reason: Comparison not relevant to PICO (palpable versus non-palpable nodes)*
- 20 Kunte, C., et al (2011) Analysis of predictive factors for the outcome of complete lymph node
21 dissection in melanoma patients with metastatic sentinel lymph nodes. *Journal of the American*
22 *Academy of Dermatology* 64;4:655-662.
23 *Reason:*
- 24 Leiter, U., et al (2010) Sentinel lymph node dissection in primary melanoma reduces subsequent
25 regional lymph node metastasis as well as distant metastasis after nodal involvement. *Annals of*
26 *Surgical Oncology* 17;1:129-137.
27 *Reason: Comparison not relevant to PICO*
- 28 Lens, M. B., et al (2002). Elective lymph node dissection in patients with melanoma: systematic
29 review and meta-analysis of randomized controlled trials. [Review] [20 refs]. *Archives of Surgery*
30 137;4:458-461.
31 *Reason: Population not relevant to PICO*
- 32 Livingstone E.Windemuth-Kieselbach. (2011) A first prospective population-based analysis
33 investigating the actual practice of melanoma diagnosis, treatment and follow-up. *European Journal*
34 *of Cancer* 47;13:1977-1989.
35 *Reason: Not relevant to PICO*
- 36 Mann, G. B., (1999) Does the extent of operation influence the prognosis in patients with melanoma
37 metastatic to inguinal nodes? *Annals of Surgical Oncology* 6;3:263-271.
38 *Reason: Comparison not relevant to PICO*
- 39 Martin, B. M., et al (2014) Oncologic outcomes of patients undergoing videoscopic inguinal
40 lymphadenectomy for metastatic melanoma. *Journal of the American College of Surgeons* 218;4,
41 620-626.
42 *Reason: Not relevant to PICO*

- 1 Milton, G. W. et al (1968) Radical dissection of the inguinal and iliac lymph-nodes for malignant
2 melanoma of the leg. *British Journal of Surgery* 55;9:641-648
3 *Reason: Narrative Review*
- 4 Morton, D. L., et al (2007) Can completion lymph node dissection be avoided for a positive sentinel
5 node in melanoma? *Annals of Surgical Oncology* 14;9:2437-2439.
6 *Reason: Narrative Review*
- 7 Morton, D. L., et al (2006) Sentinel-node biopsy or nodal observation in melanoma. *New England*
8 *Journal of Medicine* 355;13:1307-1317.
9 *Reason: Using more recent publication*
- 10 Morton, DL et al (2014) Final trial report of sentinel node biopsy versus nodal observation in
11 melanoma *The New England Journal of Medicine* 370;7:599-609
12 *Reason: Each arm of the trial is relevant to an element of the PICO but the overall comparison is not*
13 *relevant and the results are not reported in a manner which allows inclusion.*
- 14 Mozzillo, N.(2013) Superficial and deep lymph node dissection for stage III cutaneous melanoma:
15 Clinical outcome and prognostic factors. *World Journal of Surgical Oncology* 11.
16 *Reason: Comparison not relevant to PICO*
- 17 Nagaraja, V., et al (2013) Is complete lymph node dissection after a positive sentinel lymph node
18 biopsy for cutaneous melanoma always necessary? A meta-analysis. *European Journal of Surgical*
19 *Oncology* 39;7:669-680.
20 *Reason: Not relevant to PICO (prognostic)*
- 21 Nagaraja, V. (2012) Is completion lymph node dissection after a positive sentinel lymph node biopsy
22 for cutaneous melanoma always necessary? A meta-analysis and systematic review. *Asia-Pacific*
23 *Journal of Clinical Oncology Conference*[var.pagings]
24 *Reason: Abstract*
- 25 Neuss, H., et al (2010) Postoperative surgical complications after radical axillary lymph node
26 dissection in melanoma disease result in increased pain. *International surgery* 95;2:166-171.
27 *Reason: Comparison not relevant to PICO*
- 28 Neuss, H., et al (2010) Influence of Surgical Complications on the Level of Pain after Radical
29 Inguinal/Iliacal Lymph Node Dissection. *Acta Chirurgica Belgica* 110;3:308-312.
30 *Reason: Comparison not relevant to PICO*
- 31 Nowecki, Z. I., et al (2008) The survival benefit to patients with positive sentinel node melanoma
32 after completion lymph node dissection may be limited to the subgroup with a primary lesion
33 Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3). *Annals of Surgical*
34 *Oncology* 15;8:2223-2234.
35 *Reason: Comparison not relevant to PICO*
- 36 O'Brien, C. J., et al (1994) Evaluation of 107 therapeutic and elective parotidectomies for cutaneous
37 melanoma. *American Journal of Surgery* 168;5:400-403.
38 *Reason: Not relevant to PICO*
- 39 O'Brien, C. J., et al (1995) Radical, modified, and selective neck dissection for cutaneous malignant
40 melanoma. *Head & Neck* 17;3:232-241.
41 *Reason: Not relevant to PICO*

- 1 O'Brien, C. J., Gianoutsos, M. P., and Morgan, M. J. (1992) Neck Dissection for Cutaneous Malignant-
2 Melanoma. *World Journal of Surgery* 16;2:222-226.
3 *Reason: Comparisons not relevant to PICO*
- 4 O'Brien, et al (1991) Experience with 998 cutaneous melanomas of the head and neck over 30 years.
5 *American Journal of Surgery* 162;4:310-314.
6 *Reason: Not relevant to PICO*
- 7 O'Driscoll, D. O'Leary. (2012) Patterns of metastatic recurrence following inguinal lymph node
8 dissection in melanoma. *Irish Journal of Medical Science Conference*[var.pagings]
9 *Reason: Abstract*
- 10 Pasquali S.Mozzillo. (2013) The extent of radical lymph node dissection influences survival of
11 patients with melanoma. *Annals of Surgical Oncology Conference*[var.pagings], S116-S117.
12 *Reason: Abstract*
- 13 Pasquali, S., et al (2010) Early (sentinel lymph node biopsy-guided) versus delayed
14 lymphadenectomy in melanoma patients with lymph node metastases : personal experience and
15 literature meta-analysis. [Review] [30 refs]. *Cancer* 116;5:1201-1209.
16 *Reason: Comparison not relevant to PICO*
- 17 Pilko, G., Besic, N., Zgajnar, J., and Hocevar, M. (2011) Prognostic heterogeneity after the excision of
18 lymph node metastases in patients with cutaneous melanoma. *Surgical Oncology-Oxford* 20;1:26-34.
19 *Reason: Comparison not relevant to PICO (palpable versus non-palpable)*
- 20 Reintgen, D. S. et al (1983) Efficacy of elective lymph node dissection in patients with intermediate
21 thickness primary melanoma. *Annals of Surgery* 198;3:379-385.
22 *Reason: Population not relevant to PICO*
- 23 Ricard, A. S., et al (2007) Management of lymph nodes in head and neck melanoma: a retrospective
24 study of 25 cases. *Revue de Stomatologie et de Chirurgie Maxillo-Faciale* 108;6:505-508.
25 *Reason: Foreign Language*
- 26 Rompel, R. Et al (1995) Elective lymph node dissection in primary malignant melanoma: a matched-
27 pair analysis. *Melanoma Research* 5;3:189-194.
28 *Reason: Population not relevant to PICO*
- 29 Roses, D. F., Harris, et al (1981). Regional lymph node dissection for malignant melanoma of the
30 extremities. *Surgery* 89;6: 654-659
31 *Reason: Population not relevant to PICO*
- 32 Rossi, C. R., et al (2014) The number of excised lymph nodes is associated with survival of melanoma
33 patients with lymph node metastasis. *Annals of Oncology* 25;1:240-246.
34 *Reason: Not relevant to PICO*
- 35 Rossi, C. R., et al (2014) Number of Excised Lymph Nodes as a Quality Assurance Measure for
36 Lymphadenectomy in Melanoma. *JAMA Surgery* .
37 *Reason: Comparisons not relevant to PICO*
- 38 Rutkowski, P. Nowecki. (2010) The analysis of the outcomes and factors related to iliac-obturator
39 involvement in cutaneous melanoma patients after completion lymph node dissection (CLND) due to
40 positive sentinel lymph node (SLN) biopsy and after therapeutic LND (TLND) due to clinically

- 1 detected inguinal metastases. *European Journal of Surgical Oncology Conference*[var.pagings], 800.
- 2 *Reason: Abstract*
- 3 Serpell, J. W., et al (2003) Radical lymph node dissection for melanoma. *ANZ Journal of Surgery*
- 4 73;5:294-299.
- 5 *Reason: Not relevant to PICO*
- 6 Shah, J. P. Et al (1970). Incontinuity versus discontinuous lymph node dissection for malignant
- 7 melanoma. *Cancer* 26[3], 610-614.
- 8 *Reason: Population not relevant to PICO*
- 9 Slingluff, C. L., et al (1994) Surgical management of regional lymph nodes in patients with melanoma.
- 10 Experience with 4682 patients. *Annals of Surgery* 219;2:120-130.
- 11 *Reason: No Comparator*
- 12 Spillane, A. (2013)The ideal extent of groin lymphadenectomy for metastatic melanoma to inguinal
- 13 lymph nodes is still controversial: Feasibility of the proposed ANZMTG eagle FM trial. JDDG - *Journal*
- 14 *of the German Society of Dermatology Conference*[var.pagings]
- 15 *Reason: Abstract*
- 16 Spillane, A. J. H. (2011) Inguinal or ilio-inguinal dissection for metastatic melanoma in groin lymph
- 17 nodes-a randomized trial is still required. *Pigment Cell and Melanoma Research*
- 18 *Conference*[var.pagings], 1067-1068.
- 19 *Reason:Abstract*
- 20 Spillane, A. J., et al (2008). Defining lower limb lymphedema after inguinal or ilio-inguinal dissection
- 21 in patients with melanoma using classification and regression tree analysis. *Annals of Surgery*
- 22 248;2:286-293.
- 23 *Reason: Comparison not relevant to PICO*
- 24 Spillane, A. J. T. (2010) A minimally invasive groin radical lymph node dissection based on two
- 25 incisions for melanoma: A pilot study. *Pigment Cell and Melanoma Research*
- 26 *Conference*[var.pagings], 975.
- 27 *Reason: Abstract*
- 28 Teymoortash, A. Hoch. (2010) Postoperative morbidity after different types of selective neck
- 29 dissection. *Laryngoscope* 120;5: 924-929.
- 30 *Reason: Not relevant to PICO*
- 31 Thomas, J. M. H. (2008) Multivariable analysis comparing outcome after sentinel node biopsy or
- 32 therapeutic lymph node dissection in patients with melanoma (Br J Surg 2007; 94: 1293-1299).
- 33 *British Journal of Surgery* 95;5:664.
- 34 *Reason: Comment*
- 35 Trias, M., et al (1998) Extraperitoneal laparoscopically assisted ilioinguinal lymphadenectomy for
- 36 treatment of malignant melanoma. *Archives of Surgery* 133;3:272-274.
- 37 *Reason: Not relevant to PICO*
- 38 Tsutsumida, A. (2013) Is level I and II dissection adequate for patients with positive axillary sentinel
- 39 lymph nodes in melanoma. JDDG - *Journal of the German Society of Dermatology*
- 40 *Conference*[var.pagings],
- 41 *Reason: Abstract*

- 1 van Akkooi, A. C., et al (2007) Multivariable analysis comparing outcome after sentinel node biopsy
2 or therapeutic lymph node dissection in patients with melanoma. *British Journal of Surgery* 94;10
3 1293-1299.
4 *Reason: Comparison not relevant to PICO*
- 5 van der Ploeg, A. P. T. (2010) Surgical management of palpable melanoma groin metastases: The
6 necessity of deep groin lymph node dissection. *Pigment Cell and Melanoma Research*
7 *Conference*[var.pagings], 983.
8 *Reason: Abstract*
- 9 van der Ploeg, I. M., et al. Evaluation of lymphatic drainage patterns to the groin and implications for
10 the extent of groin dissection in melanoma patients. *Annals of Surgical Oncology* 16;11:2994-2999.
11 *Reason: Outcomes not relevant to PICO*
- 12 Veenstra, H. J., V. (2010) Completion lymph node dissection in melanoma patients with a tumor-
13 positive sentinel node does not increase the rate of local/regional recurrences. *Annals of Surgical*
14 *Oncology Conference*[var.pagings]
15 *Reason: Abstract*
- 16 Vigato E.Dalla Pozza.(2013) Completion lymph node dissection after a positive sentinel node biopsy
17 in malignant melanoma: Necessary or not? A preliminary report. *JDDG - Journal of the German*
18 *Society of Dermatology Conference*[var.pagings]
19 *Reason: Abstract*
- 20 von Kanel, O. E. C. (2005) One-stage versus two-stage lymph node dissection after investigation of
21 sentinel lymph node in cutaneous melanoma: A comparison of complications, costs, hospitalization
22 times, and operation times. *European Journal of Plastic Surgery* 27;7:347-350.
23 *Reason: Population not relevant to PICO*
- 24 Wasif, N., Faries, M. B., and Morton, D. L. (2009) Survival in Node-Positive Melanoma Patients
25 Correlates with Extent of Lymph Node Dissection. *Annals of Surgical Oncology* 16:102-103.
26 *Reason:*
- 27 Wevers, K. P., et al (2012) Therapeutic lymph node dissection in melanoma: different prognosis for
28 different macrometastasis sites? *Annals of Surgical Oncology* 19;12:3913-3918.
29 *Reason: Comparison not relevant to PICO*
- 30 Wong, S. L., et al (2006) Melanoma patients with positive sentinel nodes who did not undergo
31 completion lymphadenectomy: a multi-institutional study. *Annals of Surgical Oncology* 13;6:809-816.
32 *Reason: No Comparator*
- 33 Yu E.Spillane. (2010) Morbidity rates associated with inguinal sentinel lymph node biopsy and
34 inguinal lymph node dissection. *Asia-Pacific Journal of Clinical Oncology Conference*[var.pagings],
35 *Reason: Abstract*

Evidence Tables

	Appropriate length of follow-up	Precise definition of an outcome	Valid method of measuring outcomes	Investigators blind to participants exposure to intervention?	Investigators blind to potential confounders and prognostic factors?	Quality (GRADE)
Abbott et al (2013)	Yes (median follow-up was different for both groups, however outcomes were short-term post-operative and survival outcomes were not compared due to this difference in follow-up times)	Yes	Yes	No	No	Very Low
Bamboet et al (2014)	Yes	Yes	Yes	No	No	Very Low
deVries et al (2006)	Yes	Yes	Yes	No	No	Very Low
Egger et al (2014)	Yes	Yes	Yes	No	No	Very Low

O'Brien et al (2014)	Yes	Yes	Yes	No	No	Very Low
Kingham et al (2010)	Yes	Yes	Yes	No	No	Very Low
Kretschmer et al (2001)	Yes	Yes	Yes	No	No	Very Low
Kretschmer et al (2004)	Yes	Yes	Yes	No	No	Very Low
Singletary et al (1992)	Yes	Yes	Yes	No	No	Very Low
Smith et al (2012)	Yes	Yes	Yes	No	No	Very Low
Spillane et al (2014)	Yes	Yes	Yes	No	No	Very Low
Van der Ploeg et al (2008)	Yes	Yes	Yes	No	No	Very Low
Van der ploeg et al (2011)	Yes	Yes	Yes	No	No	Very Low
Van der ploeg et al (2012)	Yes	Yes	Yes	No	No	Very Low
Van der ploeg et al (2014)	Yes	Yes	Yes	No	No	Very Low
White et al (2009)	Yes	Yes	Yes	No	No	Very Low

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
Abbott et al (2013)	<p>Retrospective Study</p> <p>Data for minimally invasive inguinal lymph node dissection was collected prospectively from 2010-2012</p> <p>Data relating to open inguinal lymph node dissection was retrospective and collected from 2002-2011</p> <p>2 tertiary academic centres (USA)</p>	To compare short-term outcomes between MILND and OILND among patients with metastatic melanoma from two institutions.	<p>N=13 MILND</p> <p>N=28 OILND</p>	Minimally invasive inguinal lymph node dissection	Open Inguinal lymph node dissection	<p>5 months for MILND (median)</p> <p>13 months for OILND (median)</p>	<p>Operative time was significantly longer for MLND compared with OILND (245 mins versus 138 mins, $p=0.003$)</p> <p>Median blood loss was similar for both cohorts (MLND 30cc versus OILND 25 cc, $p=0.07$) and no blood transfusions were administered.</p> <p>Length of hospital stay was significantly shorter in the MLND cohort compared with the OILND cohort (1 day versus 2 days, $p=0.01$)</p> <p>Median disease free survival and overall survival could not be compared due to the difference in median follow up times.</p> <p>Total median number of lymph nodes pathologically identified in the lymphadenectomy specimen was</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p>significantly higher in MILND cases than in OILND cases (11 nodes versus 8 nodes, $p=0.03$).</p> <p>Infection incidence was reduced in the MILND cohort compared with the OILND cohort though the difference was not statistically significant (1 versus 8, $p=0.13$).</p> <p>5/8 infections in the OILND cohort required re-admission to hospital.</p> <p>Incidence of wound dehiscence was greater in the OILND group compared with the MILND group (4 versus 0, $p=0.07$)</p> <p>Incidence of hospital readmission was higher in the OILND cohort compared with the MILND cohort (21% versus 7%, $p=0.25$)</p> <p>None of the MILND patients developed a VTE while 2 patients in the OILND group</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p>developed a postoperative VTE (p=0.32)</p> <p>Drain duration did not differ between the MILND group and the OILND group (28 days versus 24 days, p=0.25)</p> <p>Post-operative seroma rates did not differ between the MILND group and the OILND group (38% versus 21%, p=0.26).</p>
Bamboat et al (2014)	Retrospective Study Single institute (USA)	To characterise the populations undergoing nodal observation (no CLND) and CLND; determine the pattern of initial recurrence between no CLND and CLND group; determine the melanoma specific survival of both patient groups and to characterise	4310 patients undergoing wide local excision with SLNB N=495 (11%) with a positive SLN N=167 underwent nodal observation N=328	Completion lymph node dissection (CLND)	Nodal observation	No-CLND=23 months (median) CLND=80 months (median)	<p>The no-CLND group had a greater percentage of patients with groin node involvement (43 versus 36%, p=0.03) and fewer with axillary basin involvement (29 versus 42%, p=0.03)</p> <p>14% of patients in the no-CLND group had more than one nodal basin involvement versus 10% in the CLND group.</p> <p>There was no difference in the median number of lymph nodes examined (N=2,</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
		the outcome of no CLND patients who experience a subsequent isolated nodal recurrence	<p>underwent immediate completion lymph node dissection</p> <p><i>Exclusions</i> Patients with stage IV disease on extent of disease work up Patients undergoing nodal observation under MLST-II were excluded</p>				<p>p=0.17) or percentage of patients with a single positive SLN (80% no CLND versus 75% CLND, p=0.23)</p> <p>In 66% of the no-CLND group, the reason for not undergoing CLND was patient decision, while in 22% of the cohort the reason was physician decision.</p> <p>In 4% of the cohort, patient co-morbidities was the cited reason.</p> <p><u>Recurrence</u></p> <p>81 patients (49%) in the no-CLND group and 179 patients (55%) undergoing CLND recurred.</p> <p>Median time to recurrence was not significantly different ; 9 months versus 12 months (p=0.46).</p> <p>Sites of first recurrence: Regional recurrence rates between the groups: No CLND=16%</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p>versus CLND 18%, $p=0.58$</p> <p>Nodal Recurrence: No CLND=15% versus CLND 6%, $p=0.002$</p> <p>Systemic recurrence: No CLND=8% versus 27% CLND, $p<0.001$</p> <p>Median disease specific survival was not reached for no CLND versus 110 months in the CLND group ($p=0.09$)</p> <p>Recurrence free survival was significantly higher in the CLND group (34.5 versus 21 months, $p=0.02$).</p> <p>In patients who developed systemic disease as first recurrence, median disease free survival was 46 months for the no-CLND group versus 35 months for the CLND group ($p=0.98$).</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p>Comparing DSS i patients undergoing immediate CLND with a positive NSLN with those in the no CLND group who developed node only recurrence and went on to salvage lymphadenectomy. Patients undergoing salvage lymphadenectomy (n=19) had a more favourable melanoma specific survival (CLND median DSS=36.5 months versus not reached for salvage LND, p=0.005)</p> <p>On multivariable analysis factors associated with higher melanoma specific survival included increasing age (p=0.006), tumour thickness (p=0.001) and ulceration (p<0.001).</p>
deVries et al (2006)	<p>Retrospective Study</p> <p>Patients were treated between 1995 and 2003</p> <p>University</p>	To evaluate morbidity after inguinal SLNB alone and inguinal SLNB with completion inguinal dissection	<p>N=66</p> <p>N=52 SLNB only</p> <p>N=14 underwent completion lymphadenectomy (N=11 superficial +</p>	SLNB + completion lymphadenectomy	SLNB	51 months (median) (4-94 months)	<ul style="list-style-type: none"> Long term morbidity (lymphoedema and range of motion of restrictions) <p><u>Complications</u></p> <p>No patient died as a result of surgical intervention.</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
	Medical Centre, Netherlands		<p>deep groin dissection and N=3 superficial groin dissection)</p> <p><i>Exclusions:</i></p> <ul style="list-style-type: none"> • Treatment for local or locoregional recurrence at the time of the study • Bilateral SLNB • Undergoing follow-up elsewhere • Pre-existing functional limitations • Previous 				<p>3 patients developed complications after inguinal SLNB</p> <p>4 patients developed wound infection after SLNB+groin dissection</p> <p>After SLNB alone, there were 3 complications versus 7 after SLNB+groin dissection ($p<0.001$)</p> <p><u>Volume</u></p> <p>In patients who underwent inguinal SLNB, no volume difference was observed between patients with primary melanoma on the trunk compared with primary melanoma on the leg ($p=0.4$)</p> <p>Volume difference was observed between primary closure of the excision wound and closure with a free skin graft ($p=0.044$)</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
			<p>operations on the extremity concerned</p> <ul style="list-style-type: none"> • Pre-existing volume difference between the two extremities • Severe comorbidity such as dementia, disseminated disease or patients receiving palliative care 				<p>A significant volume difference was observed ($p<0.001$) between patients undergoing SLNB and patients undergoing SLNB+groin dissection.</p> <p><u>Functional Outcome</u></p> <p>The average difference in degrees was significantly higher in the SLNB+groin dissection group for flexion of the hip ($p=0.011$)</p>
Egger et al (2014)	Retrospective study Population	To evaluate whether a combined inguinal and iliac/obturator dissection improved	<p>N=143 patients</p> <p>N=100 inguinal</p>	Inguinal Dissection	Combined inguinal and iliac/obturat	39 months (median)	<ul style="list-style-type: none"> • Overall Survival • Disease free survival

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
	included in the Sunbelt clinical trial were included along with patients in the University of Louisville melanoma database.	locoregional disease control and survival compared with an inguinal dissection alone in the absence of clinical and radiological evidence of pelvic lymph node metastases	dissections N=34 combined inguinal and iliac/obturator dissection		or dissection		<p>Median number of lymph nodes removed was 11 (2-37).</p> <p>For inguinal dissection the median number of lymph nodes removed was 11 (3-33) and for combined iliac/obturator dissection the median number of lymph nodes removed was 22 (10-51).</p> <p><u>Microscopic Disease</u></p> <p>94/134 patients (70%) underwent an inguinal dissection for microscopic (SLN positive) disease. 12 of these patients underwent combined inguinal and iliac/obturator dissection.</p> <p>The rate of tumour positive pelvic lymph nodes when a combined inguinal and iliac/obturator dissection was performed for microscopic disease was 25% (3/12).</p> <p>Recurrence rates in the pelvic lymph nodes</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p>were similar between inguinal dissection and combined inguinal and iliac/obturator dissection (12% versus 17%, $p=0.66$).</p> <p>Complication rates were similar between inguinal dissection and combined inguinal and iliac/obturator dissection (29% versus 27%, $p=0.89$).</p> <p>There was no significant difference in the rate of lymphoedema between the inguinal dissection and combined inguinal and iliac/obturator dissection groups (15.9% versus 27.3%, $p=0.35$)</p> <p><u>Macroscopic Disease</u></p> <p>22/40 patients (55%) with macroscopic disease underwent a combined inguinal and iliac/obturator dissection.</p> <p>The rate of tumour positive pelvic nodes was 55% (12/22) when combined dissection</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p>was performed for macroscopic disease.</p> <p>There was no significant difference in the recurrence rates between inguinal lymph node dissection and combined dissection (11% versus 5%).</p> <p>Complication rates were not significantly different between the inguinal dissection group and the combined lymph node dissection group (33% versus 32%, $p=0.92$).</p> <p>There was no significant difference in the rates of lymphoedema between the inguinal dissection and combined lymph node dissection group (16.7% versus 9.1%, $p=0.47$).</p> <p>Overall rate of positive pelvic lymph nodes in all patients undergoing combined inguinal and iliac/obturator dissection was 44.1%.</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p>No statistically significant risk factors for tumour positive pelvic lymph nodes were identified which could identify patients at high risk for pelvic lymph node metastases in patients without a priori clinical knowledge or radiological evidence of metastases.</p> <p>5-year lymph node recurrence-free survival rate was 77%.</p> <p>Pelvic node recurrence rates did not differ significantly between all inguinal dissections compared with combined inguinal and iliac/obturator dissection (12% versus 8.9%, $p=0.61$).</p> <p>Inguinal or pelvic node recurrences after inguinal dissection or combined inguinal and ilia/obturator dissection were often associated with systemic recurrences; 60%</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p>of patients with a nodal recurrence also suffered systemic recurrence.</p> <p>Systemic recurrence was the most common type of recurrence (43% for inguinal dissection and 48% for combined inguinal and iliac/obturator dissection).</p> <p>Systemic recurrences were higher in the macroscopic group compared with the microscopic group (40% versus 31%).</p> <p>There was no difference in pelvic node recurrence-free survival or disease free survival for inguinal dissection alone compared with inguinal and iliac/obturator dissection when stratified by indication (microscopic versus macroscopic nodal disease)</p> <p>Disease free survival was greater for microscopic disease ($p=0.0002$).</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p>5 year overall survival rates ($p=0.0163$)</p> <p>Microscopic disease/Inguinal lymph node dissection = 72%</p> <p>Microscopic disease/Inguinal and Iliac/Obturator lymph node dissection =68%</p> <p>Macroscopic disease/Inguinal lymph node dissection=51%</p> <p>Macroscopic disease/Inguinal and Iliac/obturator lymph node dissection=44%</p> <p>No difference in overall survival was observed when comparing inguinal dissection with inguinal and iliac/obturator dissection when stratified by indication.</p>
Kingham et al (2010)	Retrospective Study Patients were treated between 1992	To examine a group of SLNB positive patients who underwent completion lymph node dissection	N=313 N=271 underwent CLND N=42 no CLND	Complete lymph node dissection	No lymph node dissection	No CLND=32 months (median) CLND=43	Unclear appear to be: <ul style="list-style-type: none"> • Recurrence • Survival

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
	and 2008 Netherlands Cancer Institute	compared with those who did	SLNB+CLND SLNB+salvage therapeutic lymph node dissection			months (median)	<p>There was a statistically significant difference between location of melanoma in patients who did not undergo CLND compared with those who did ($p<0.01$)</p> <p>Lower extremity: 40% versus 13%</p> <p>Trunk: 26% versus 45%</p> <p>Head and Neck: 17% versus 8%</p> <p>Upper Extremity: 12% versus 32%</p> <p>There was a statistically significant increase in patients who did not undergo CLND in more recent periods (1992-2000 versus 2001-2008).</p> <p>Patients who did not undergo CLND had significantly higher median age and a significant difference between the location</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p>of melanomas</p> <p>No difference was observed in the pattern of first recurrence between patients who had a CLND and those who did not (CLND 54% versus No CLND 48%)</p> <p>Median interval recurrence was similar in the two groups (CLND: 14 months versus No CLND: 13 months)</p> <p>There was no significant difference in the location of first recurrence</p> <p>Median relapse free survival was 35 months for the no –CLND group and 36 months for the CLND group ($p=0.63$). <i>In this analysis, patients who did not undergo CLND but had metastasis on SLNB were removed ($n=5$).</i></p>
Kretschmer et al	Retrospective Study	To investigate survival outcomes in	N=937 N=314	SLNB + early excision	SLNB + delayed	From primary diagnosis 32	<ul style="list-style-type: none"> Overall Survival

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
(2004)	<p>Five clinical centres in Germany</p> <p>SLNEs were performed between 1993 and 2002</p> <p>DLNDs were performed between 1983 and 2002</p>	<p>patients with lymphatic metastases who underwent early or delayed excision of regional lymph nodes</p>	<p>undergoing early excision N=623</p> <p>undergoing delayed excision</p> <p>Study does not exclusively include stage III patients though it is not clear from the paper what the distribution of stages might be.</p> <p><i>Inclusions</i> Patients with loco-regional cutaneous metastases prior to lymph node excision</p>		excision	<p>months (median)</p> <p>3-94 months (range) in patients with positive SLN biopsy</p> <p>121 months (median)</p> <p>4-324 months (range) in patients with DLND</p> <p>Patients were routinely monitored at 3 month intervals for the first 2 years and every 6</p>	<p>A significantly higher number of metastatic lymph nodes were excised in patients with DLND compare with patients having ELND (2.45 ± 2.35 nodes versus 1.54 ± 1.42 nodes; $p < 0.00001$).</p> <p>Overall survival was significantly better for patients with SLND and early diagnosis of lymph node metastases ($p = 0.002$).</p> <p>Estimated 3 year overall survival rate was $80.1 \pm 2.8\%$ in patients with positive SLNs and $67.6 \pm 1.9\%$ in patients with DLND.</p> <p>5 year overall survival rates: 62.5 ± 5.5 and $50.2 \pm 5.4\%$</p> <p>On multivariate analysis , SLNE was an independent prognostic factor of overall survival ($p = 0.000052$)</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
			<i>Exclusions</i> Patients with clinically detectable distant metastases at the time of DLND were excluded			months for the next 3 years and annually thereafter.	
Kretschmer et al (2001)	Retrospective Study Patients were operated on between September 1983 and August 1994 University Hospital, Germany	To investigate the impact of inguinal versus ilio-inguinal node dissection in patients with palpable groin nodes	N=104 patients with cutaneous melanoma who underwent therapeutic groin dissection. N=69 ilio-inguinal dissection N=35 superficial inguinal	Ilio-inguinal dissection	Inguinal dissection This was a highly selected group of patients (elderly patients with cardiopulmonary risk factors in particular those with	68 months (median) 28-141 months (range) Follow-up closed in March 1998	<ul style="list-style-type: none"> Local tumour control Survival Median interval from the date of lymphadenectomy to reviewing the data was 127 months (range 42-177) Overall 5 year survival was 30.4% Overall 10 year survival was 18.4% Patients with only 1-2 nodes had a median survival of 14 months and a 5 year survival

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
			dissection		small groin metastases; some patients with very thick primary melanomas or patients presenting with lymph node and locoregional cutaneous metastases)		<p>of 41.4%</p> <p>Patients with more than two involved nodes or iliac metastases had a median survival of 14 months and a 5 year overall survival of 13.9%</p> <p>Univariate analysis showed a statistically significant difference between the two groups (crude relative risk=2.4; 95% CI, 1.5-3.7, p=0.0006)</p> <p>Extent of lymph node dissection did not have a significant effect on survival.</p> <p>There was a significant difference in survival between patients with superficial and pelvic nodal involvement compared with patients with only superficial lymph node metastases (p=0.008)</p> <p>In patients undergoing ilioinguinal</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p>dissections, 34.8% had metastatic involvement of both superficial and pelvic nodes. Median survival was 12 months for these patients, overall 3 year survival rate was 25% and overall 5 year survival rate was 6.2%</p> <p>Median survival was 30 months and 5 year survival rate was 36.7% for patients with superficial lymph node metastases.</p> <p>33.6% of patients relapsed into the dissected lymph node basin.</p> <p>Median time between inguinal lymphadenectomy and groin recurrence was 9 months (range 1-34).</p> <p>Median survival after groin recurrence was 10 months.</p> <p>Type of operation (inguinal versus ilioinguinal dissection) did not influence</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							local control of the dissected lymph node basin.
O'Brien et al (1995)	Retrospective Study	To evaluate the role and efficacy of modified and selective neck dissections and adjuvant radiotherapy in treating patients with clinical metastatic melanoma	N=175 patients who had 183 neck dissections	Therapeutic Neck Dissection (Selective, Radical or modified)	<p>Elective Neck Dissection (Selective or Modified)</p> <p>Elective dissections were performed when primary melanoma thickness was $\geq 1.5\text{mm}$</p>	Median follow-up time was 42 months (12-80 months)	<p>Lymph nodes were histologically positive in 80% of 183 dissection specimens</p> <p>A total of 72/75 (43%) therapeutic neck dissections were positive compared with 8/108 (8%) elective dissections.</p> <p>A total of 92 patients had a therapeutic or elective parotidectomy with their neck dissection.</p> <p>Significant surgical complications occurred in 16 (9%) patients and there was one post-operative death.</p> <p>26 patients received post-operative radiotherapy following histologically positive dissections.</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results						
							<p>Recurrence of metastatic melanoma developed in 19/183 dissected necks or parotids representing a cumulative 5 year control rate of 86%.</p> <p>Time to recurrence ranged from 2 months to 51 months after initial dissection.</p> <p>15/19 recurrences occurred within 1 year of lymphadenectomy.</p> <p>Recurrence rate following histologically positive dissection was 17% compared with 5% after histologically negative dissections.</p> <p>Incidence of recurrence was not affected by the number of positive nodes or presence of extracapsular spread.</p> <p><i>Recurrence in the neck or parotid following Therapeutic Dissection</i></p> <table><tr><td></td><td>n</td><td>2 yr F/U</td><td>Irradiated</td><td>Recurrence</td><td>%</td></tr></table>		n	2 yr F/U	Irradiated	Recurrence	%
	n	2 yr F/U	Irradiated	Recurrence	%								

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results																																																						
							<table><tr><td>RND</td><td>32</td><td>29</td><td>14</td><td>4</td><td>14</td></tr><tr><td>MRND</td><td>15</td><td>12</td><td>2</td><td>0</td><td>0</td></tr><tr><td>SND</td><td>28</td><td>22</td><td>8</td><td>5</td><td>23</td></tr><tr><td>Paroti decto my</td><td>19</td><td>17</td><td>13</td><td>4</td><td>24</td></tr></table> <p><i>Elective Dissection</i></p> <table><tr><td></td><td>n</td><td>2 yr F/U</td><td>Irradia ted</td><td>Recurr ence</td><td>%</td></tr><tr><td>RND</td><td>2</td><td>2</td><td>0</td><td>0</td><td>0</td></tr><tr><td>MRND</td><td>17</td><td>14</td><td>1</td><td>1</td><td>7</td></tr><tr><td>SND</td><td>89</td><td>79</td><td>1</td><td>4</td><td>5</td></tr><tr><td>Paroti decto my</td><td>73</td><td>63</td><td>0</td><td>1</td><td>1.5</td></tr></table> <p>There were 2 recurrences in the 27 node positive dissections treated with adjuvant radiotherapy (7%) compared with 12/53 (23%) recurrences in node dissections</p>	RND	32	29	14	4	14	MRND	15	12	2	0	0	SND	28	22	8	5	23	Paroti decto my	19	17	13	4	24		n	2 yr F/U	Irradia ted	Recurr ence	%	RND	2	2	0	0	0	MRND	17	14	1	1	7	SND	89	79	1	4	5	Paroti decto my	73	63	0	1	1.5
RND	32	29	14	4	14																																																								
MRND	15	12	2	0	0																																																								
SND	28	22	8	5	23																																																								
Paroti decto my	19	17	13	4	24																																																								
	n	2 yr F/U	Irradia ted	Recurr ence	%																																																								
RND	2	2	0	0	0																																																								
MRND	17	14	1	1	7																																																								
SND	89	79	1	4	5																																																								
Paroti decto my	73	63	0	1	1.5																																																								

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p>which did not receive radiotherapy.</p> <p>At time of follow-up, 52 patients had developed distant metastases (39 node positive and 13 node negative).</p> <p>Median time to development of distant metastases was 8 months in node positive patients compared with 22 months among node negative patients.</p> <p>Cumulative 5 year survival was 50% and was significantly higher for patients having elective dissection compared with therapeutic dissection (due to the fact that almost all patients having therapeutic dissections had histological node involvement).</p> <p>5 year survival rate was 61% for node negative patients and 38% for node positive patients.</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							Patients with 2 or more involved nodes had similar but poorer survival compared with patients with <2 involved nodes.
Singletery et al (1992)	Retrospective University Hospital (USA)	To investigate whether or not a more conservative approach would offer and improved survival rate or better local and regional control.	N=264 patients N=113 with subsequent regional nodal disease N=151 who initially had regional nodal disease Patients were treated from 1948-1987	Superficial femoral node dissection Iliac nodal dissection for patients with synchronous primary melanoma Femoral nodal dissection six weeks later for patients with palpable	Combined ilio-inguinal dissection	142 (1-411) months (median)	<ul style="list-style-type: none"> Survival <p>No difference was observed in the survival rate of patients who initially had nodal metastases and patients who subsequently developed nodal disease (p=0.12).</p> <p>No significant difference in median overall survival time was observed among patients with superficial femoral or radical groin dissection (32.7 months versus 39.5 months, p=0.17)</p> <p>Type of groin dissection did not affect survival when stratified by tumour burden (1 positive node, p=0.06; 2 or more nodes, p=0.16; extra nodal, p=0.13)</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
				groin disease Superficial femoral dissection or combined ilioinguinal dissection for patients who developed delayed nodal metastases.			The majority of tumour relapse from melanom were distant metastases. 15% of all patients had a recurrence within the nodal basin after operation with a higher proportion occurring in the superficial femoral dissection group than in the radical surgical treatment group though the difference was likely related to the extent of tumour burden than to the extent of surgery.
Smith et al (2012)	Retrospective Study Patients treated between January 1998 and December 2007	To determine whether CLND improves survival in patients with cutaneous melanoma of the head and neck	N=350 patients N=140 SLNB only N=210 SLNB +CLND <i>Exclusions</i> No nodal	SLNB	SLNB + completion lymph node dissection	SLNB = 26 months (median) SLNB+CLND=24 months (median)	<ul style="list-style-type: none"> • Disease Specific Survival • Overall Survival Disease specific survival was analysed in two seperate age groups (patients age <60 years and patients ≥60 years) Type of lymph node procedure was not associated with improved disease specific survival in either age group (p=0.56).

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
			metastasis No SLNB Missing data regarding the quantity of examined or positive nodes				<p>Age was significantly associated with disease specific survival with an increased risk of death from melanoma in the younger age group (4.5% per additional year of age at diagnosis, $p=0.016$).</p> <p>Tumour thickness .2mm was the only significant predictor of worse survival in the older age group ($HR=3.11$, $p<0.001$).</p> <p>Disease specific survival for the whole cohort did not differ significantly for CLND patients (log rank $p>0.2$).</p> <p>In patients with a poorer prognosis (tumour >2mm thick and/or ulcerated), CLND did not significantly affect survival.</p> <p>For patients with the best prognosis, survival was statistically different based on</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p>surgical procedure in both age groups:</p> <p>CLND was associate with improved survival in patients age <60 (p=0.039)</p> <p>CLND was associated with worse survival in patients aged ≥60 (p=0.023)</p> <p>In low risk patients who had at least 3 SLN harvested of which only 1 was positive for metastasis, CLND significantly reduced the risk of death from melanoma in patients <60 years (p=0.003)</p> <p>In patients ≥60 years, CLND was associated with significantly poorer survival (p=0.028).</p>
Spillane et al (2014)	Retrospective Study Melanoma Institute Australia Patients treated	To establish how timing of lymphadenectomy in the ciourse if the disease related to the interval between the diagnosis of the primary tumour and	N=1704 N=502 Immediate completion lymphadenectomy (ICL)	SLNB+Immediate completion lymphadenectomy SLNB+delaye	Each Other	69 months (median) after melanoma diagnosis (95% CI 66-73months)	<ul style="list-style-type: none"> • Disease Free Survival • Post Recurrence Survival • Overall Survival <p>Recurrence occurred in 48% of all patients at a median time of 57 months (95% CI 49-</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
	between 1992 and 2010	the first recurrence after lymphadenectomy.	<p>N=214 Delayed Completion lymphadenectomy (DCL)</p> <p>N=709 Delayed therapeutic lymphadenectomy (DTL)</p> <p>N=279 Immediate therapeutic lymphadenectomy (ITL)</p> <p>Patients with proven single cutaneous melanoma managed with lymphadenectomy before any other recurrence</p>	<p>d completion lymphadenectomy</p> <p>Observation +Delayed therapeutic lymphadenectomy</p> <p>Immediate therapeutic lymphadenectomy for clinically positive nodes</p>			<p>65)</p> <p><u>Site of First Recurrence</u></p> <p>Local=3.8%</p> <p>In-transit=7.4%</p> <p>Nodal=7.3%</p> <p>Distant metastases=29.5%</p> <p>Disease free survival was significantly different between the four treatment groups (p=0.001)</p> <p>Median disease free survival times (months):</p> <p>ICL=68 (95% CI, not reached)</p> <p>DCL=48 (95% CI 39-56)</p> <p>DTL=82 (95% CI 66-97)</p> <p>ITL=16 (95% CI, 14-19)</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
			events				<p>Extranodal spread was the only independent prognostic factor for all four treatment groups (multivariate analysis)</p> <p>TNM N stage was a significant independent predictor of disease free survival in all groups apart from the DCL group.</p> <p><u>Disease Free Survival</u></p> <p>Disease free survival after 5 years was significantly different when comparing ICL (n=113) and DTL (n=283) groups (p=0.005) a difference that remained significant after multivariate analysis. Hazards Ratio=2.57; 95% CI, 1.14-5.85, p=0.023).</p> <p>TNM N-stage remained a significant predictor of disease free survival after 5 years:</p> <p>N2 versus N1: HR 2.20, 95% CI, 1.75-5.88,</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p>p<0.001</p> <p>N3 versus N1: HR 3.16, 95% CI 1.69-5.92, p<0.001</p> <p><u>Postrecurrence Survival</u></p> <p>In patients who experienced relapse after lymphadenectomy, median post recurrence survival for the whole cohort was 9 months (95% CI 7-10 months).</p> <p>Median PRS by site (p<0.001):</p> <p>Local/In-transit= 18 months (95% CI 14-21 months)</p> <p>Nodal= 18 months (95% CI 11-24 months)</p> <p>Distant metastases= 7 months (95% CI 6-8 months)</p> <p>Patients in the ICL group had significantly longer PRS compared with patients in other</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p>treatment groups (log rank $p<0.001$)</p> <p><i><u>PRS times by treatment group</u></i></p> <p>ICL=14 months (95% CI 7.2-10.7)</p> <p>DCL=8 months (95% CI 6.3-9.7)</p> <p>DTL=9 months (95% CI 7.2-10.7 months)</p> <p>ITL= 9 months (95% CI 6.7-11.3 months)</p> <p>ICL versus DCL $p<0.001$</p> <p>ICL versus DTL $p<0.001$</p> <p>ICL versus ITL, $p<0.001$</p> <p>DCL versus DTL $p=0.424$</p> <p>DCL versus ITL $p=0.769$</p> <p>DTL versus ITL $p=0.179$</p> <p>On multivariate analysis, distant site of first recurrence was a significant prognostic</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p>factor for all treatment options except DCL.</p> <p><u>Overall Survival</u></p> <p>There were 675 deaths due to melanoma (39.6%) and median survival from time of primary melanoma diagnosis was 91.7 months (95% CI 80.7-102.9).</p> <p>Overall survival was significantly different across clinical scenarios ($p<0.001$)</p> <p><u>Median Survival by treatment option</u></p> <p>ICL=not reached</p> <p>DCL=71.1 months (95% CI 45.8-96.4)</p> <p>DTL=101.3 months (95% CI 86.1-116.0)</p> <p>ITL=29.2 months (95% CI 22.7-35.8)</p> <p>Extranodal spread and TNM N stage were</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p>significantly associated with overall survival.</p> <p>For patients surviving beyond 5 years, overall survival was significantly different when comparing the ICL group and DTL groups ($p=0.012$)</p> <p>TNM N stage was the only predictor of overall survival in patients surviving >5 years.</p> <p>N2 versus N1 HR=2.37, 95% CI 1.354.14, $p=0.002$</p> <p>N3 versus N1 HR=4.15, 95% CI 2.387.24, $p<0.001$)</p>
Van der Ploeg et al (2008)	Retrospective Study Patients treated between June 1996 and April 2007	To investigate the pathological findings, the incidence of lymph node recurrences and the disease free survival in clinically node negative	N=52 clinically node negative patients with cutaneous melanoma and a tumour positive sentinel node	Completion groin node dissection	Superficial groin node dissection	61 months (median)	<ul style="list-style-type: none"> • Lymph Node Recurrence • Disease Free Survival <p>At 5 years 77% of all patients were alive (95% CI 62-95%) and 56% were disease free (95% CI 40-80%)</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
		patients with a positive sentinel node in the groin who have undergone lymph node dissection	biopsy of the groin N=10 patients who did not receive further dissection due to small tumour burden in the sentinel nodes and were not included in the analysis.				5 year survival for patients who underwent only superficial dissection was 76% (95% CI 56-100%) and 5 year disease free survival was 53% (95% CI 31-90%) 5 year survival for patients who underwent combined superficial and deep dissection was 80% (95% CI 61-100%) and 5 year disease free survival was 61% (95% CI 39-96%)
Van der ploeg et al (2011)	Retrospective Study One University Medical Centre (Netherlands) Surgery was carried out between 1991 and 2009	To evaluate the experience in patients with clinically evident metastatic melanoma to the groin who underwent combined superficial and deep groin dissection versus inguinal or	N=121 patients who underwent combined superficial and deep dissection (CGD) N=48 patients who underwent	Combined superficial and deep dissection	Therapeutic superficial dissection	20 months (median) for all patients 45 months (median) for survivors.	<ul style="list-style-type: none"> • Post operative morbidity • Regional Recurrence • Preoperative CT scan • Disease free survival • Overall survival <p><u>Post-operative Morbidity</u></p> <p>Median hospital stay was 6 days (3-27) for patients with CGD and 6 days (2-32) for patients with SGD.</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
		superficial groin dissection	<p>therapeutic superficial dissection (SGD) for palpable metastases to the groin</p> <p><i>Exclusions</i> Patients who underwent sentinel lymph node biopsy</p> <p>Adjuvant radiotherapy was given to 16 patients</p>				<p>There were no significant differences in post-operative morbidities between CGD and SGD patients ($p>0.05$).</p> <p>There was a trend towards more chronic lymphoedema in the CGD group (25.6% versus 14.6%, $p=0.154$)</p> <p><u>Recurrence</u></p> <p>There no statistically significant difference in disease free survival time or time to regional relapse between SGD and CGD patients.</p> <p>Overall recurrence rate was 73% (90/121) for SGD patients and 74% (35/48) for CGD patients.</p> <p>At the time of last follow-up 67% of CGD patients and 65% of SGD patients had died.</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p>Regional recurrence rates were more common in the SGD group than in CGD group (21% versus 16%, $p=0.498$).</p> <p>Pelvic recurrence rates were 10% in both groups.</p> <p>Median time to first recurrence was 7.6 months (1-96) for CGD patients and 6 months (1-42) for SGD patients ($p=0.677$).</p> <p><u>Survival Analysis</u></p> <p>There was no significant difference in disease free survival and overall survival when comparing CGD patients and SGD patients.</p> <p>5 year estimated disease free survival rate was 15.7% for SGD patients and 18.3% for</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p>CGD patients.</p> <p>5 year estimated overall survival rate was 28.7% for SGD patients and 33% for CGD patients.</p> <p><u>Univariate Analysis</u></p> <p>Number of positive superficial nodes was a significant prognostic factor for Disease free survival (HR=1.85, 95% CI 1.21-2.84, p=0.005) and for overall survival (HR=1.6, 95% CI 1.03-2.51, p=0.038) and (HR=2.36, 95% CI 1.50-3.71, p=0.0005)</p> <p>Superficial lymph node ratio was a significant prognostic factor for disease free survival (HR 2.33, 95% CI 1.25-4.34, p<0.008) and for overall survival HR=3.16, 95% CI 1.68-5.94, p<0.001).</p> <p>In SGD patients only, the largest diameter of</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p>the positive lymph node was significant for overall survival (HR=3.10, 95% CI 1.07-8.98, p=0.037)</p> <p>In CGD patients only, superficial lymph node ratio (HR=5.9, 95% CI 2.21-15.76, p<0.001); more than three positive lymph nodes (HR=2.29, 96% CI 1.34-3.91, p=0.002) and presence of involved deep lymph nodes (HR=2.25, 95% CI 1.38-3.66, p=0.001) were poor prognostic factors for overall survival.</p> <p>In CGD patients only, superficial lymph node ratio (HR=4.64, 95% CI 1.70-12.65, p<0.003); more than three positive lymph nodes (HR=1.96, 96% CI 1.19-3.22, p=0.008) and presence of involved deep lymph nodes (HR=1.61, 95% CI 1.02-2.55, p=0.041) were poor prognostic factors for disease free survival.</p> <p>5-year estimated DFS and OS rates for positive deep lymph nodes were 9.1% and</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p>12.5% respectively.</p> <p>5 year estimated disease free survival rates for positive superficial lymph nodes only in CGD patients were 21.5% and 39.7%.</p> <p>5 year estimated disease free survival rates for the number of positive lymph nodes was 23.7% for 1, 12.0% for 2-3 and 11.2% for ≥ 4 involved nodes.</p> <p>5 year estimated overall survival rates for the number of positive superficial lymph nodes was 23.7% for 1, 12% for 2-3 and 11.2% for ≥ 4 involved nodes.</p> <p>5 year estimated overall survival rates for the number of positive superficial lymph nodes was 42.6% for 1, 25.8% for 2-3 and 17% for ≥ 4 involved nodes.</p>
Van der ploeg et	Retrospective Study	To evaluate the influence of	N=1174 patients with	CLND	No CLND	48 (25-70) months	<ul style="list-style-type: none"> Disease Specific Survival

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
al (2012)	<p>10 European cancer centres collaborating in the EORTC Melanoma Group</p> <p>Matched pair analysis was carried out with patients from the study group matched with those in the control group according to age, breslow thickness, tumour ulceration, rotterdam criteria, Dewar criteria, S classification and RDC criteria.</p>	immediate completion lymph node dissection (CLND) on outcome in patients with SN positive melanoma	<p>SN positive melanoma N=1113 underwent immediate CLND</p> <p>N=61 no CLND</p>			<p>(median) in the no CLND group</p> <p>34 (20-60) months (median) in the CLND group</p> <p>44 months (median) in the 61 matched patients who underwent CLND</p>	<p>CLND was not a significant prognostic factor for disease specific survival (HR=0.89, 95% CI 0.58-1.37, p=0.6)</p> <p>In matched pair analysis CLND did not significantly influence disease specific survival (HR=0.86, 95% CI 0.46-1.61, p=0.64)</p> <p>CLND had no significant influence on prognosis in any of the models adjusting for prognostic imbalance in baseline factors.</p> <p>There was a trend towards improved outcome for patients who underwent CLND compared with those who did not.</p> <p>Model 1. HR=0.81, 95% CI 0.52-1.25, p=0.34)</p> <p>Model 2. HR=0.82, 95% CI 0.53-1.27, p=0.377)</p> <p>Model 3: HR=0.74, 95% CI 0.48-1.16,</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p>p=0.189)</p> <p>Model 4: HR=0.73, 95% CI, 0.47-1.14, p=0.169)</p> <p>Subgroup analyses showed no significant benefit of CLND after correcting for age, breslow thickness and tumour ulceration.</p> <p>3 year disease specific survival was 74% in patients who did not undergo CLND compared with 76.9% for patients who did.</p> <p>5 year disease specific survival was 66% for patients who did not undergo CLND compared with 66.9% for those who did.</p> <p>In the matched pair analysis rates for the 61 patients who underwent CLND were 79% and 69% (HR=0.86, 95% CI 0.46-1.61, p=0.64)</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
Van der ploeg et al, 2014	Retrospective Study	To compare regional recurrence free survival, distant metastases free survival and melanoma specific survival of SNB patients with observation patients in a large patient cohort	N=2931 in the observation group N=2909 in the SLNB arm	SLNB+wide local excision	Observation + total lymph node dissection for recurrence	Mean follow up for observation patients was 54.2 months (median, 40 months) Mean follow-up for SLNB patients was 53.4 months (median, 44 months)	<p>There were significant differences in baseline characteristics between the SNB and observation groups:</p> <p>SNB group had younger patients and melanomas of a nodular subtype.</p> <p>Observation group contained more young patients and more melanomas less than 1mm in thickness, with a lower mitotic rate and located in head and neck sites.</p> <p><i>Recurrence</i></p> <p>Site of first recurrence was significantly different in the two groups (SNB=distant metastases; Observation=regional node metastases p<0.001)</p> <p>Median time to first recurrence was 38 months (range: 1-215 months) for SNB patients and 31 months (range: 1-223 months) for observation patients</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p>There were significantly fewer regional node recurrences in the SNB group compared with the observation group (p=0.047)</p> <p>Tumours <1mm with ulceration, Clark level IV or V invasion or a mitotic rate of 1 or more per millimetre square – there were significantly fewer regional node recurrences in the SNB group (p=0.047)</p> <p>Tumours =1mm – There was no significant difference in regional node recurrence between the groups</p> <p>Tumours >1mm thick – there were significantly more regional node recurrences in the SNB group compared with the observation group (p<0.001)</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p>There was no significant difference between the groups in the proportion of distant metastases as first recurrences for patients with tumours <1mm and 1mm thick while for tumours >1mm there were significantly more distant metastases as first recurrences in the SNB group (p=0.018).</p> <p>There were significantly fewer recurrences of any type in the SNB group compared with the observation group for patients with melanoma >1mm (p<0.001).</p> <p><i>Disease Free and Distant metastases free survival</i></p> <p>SNB showed improved disease free survival (p<0.001) but no difference in distant metastases free survival (univariate analysis).</p> <p>In patients with T2 or T3 melanomas (>1.0-</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p>4.0mm) SNB patients demonstrated improved DMFS compared with the observation group (p=0.021).</p> <p>After adjustment for prognostic factors, the SNB group had significantly better disease free survival (HR=1.40, 95% CI 1.23-1.58, p<0.001);</p> <p>Regional lymph node control (HR=3.23, 95% CI 2.66-3.94, p<0.001) and distant metastasis free survival for T2 and T3 subgroups (HR=1.23, 95% CI 1.01-1.5, p=0.041) were significantly better in the observation group.</p> <p><i>Melanoma specific survival</i></p> <p>No significant difference in MSS between the groups (p=0.560)</p> <p>5 year MSS was 85% for SNB patients and 85.8% for observation.</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p>MSS was better for patients in the SNB group with tumours >1mm thick ($p=0.012$) and in patients with T2 and T3 melanomas (>1.0-4mm, $p=0.011$).</p> <p>5 year MSS for patients with T2 and T3 melanoma was 86.8% for the SNB group and 85.3% for the observation group.</p> <p>No significant difference in overall MSS when adjusting for known prognostic factors.</p> <p><i>SN positive versus SN Negative</i></p> <p>Sentinel node status was an independent prognostic factor for DFS (HR=3.04, 95% CI 2.50-3.70, $p<0.001$) and for MSS (HR=2.97, 95% CI, 2.34-3.77, $p<0.001$).</p> <p>5 year DFS rate for SN positive patients was 81.4% and 5 year MSS rate was 88.9%</p> <p>5 year DFS rate for SN negative patients was 51.2% and 5 year MSS rate was 63.8%.</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p><i>SNB with Early CLND versus Observation with late TLND</i></p> <p>394/2909 patients were SN positive and received CLND.</p> <p>There were positive non SN in 77 (19.5%) of patients.</p> <p>89/2515 (3.5%) patients had regional node recurrence as first recurrence and underwent delayed lymphadenectomy.</p> <p>SN false negative rate was 18.4%.</p> <p>417 patients in the observation group recurred in the regional node field and received a delayed TLND.</p> <p>Mean number of positive nodes in patients receiving CLND was 1.69 compared with 2.92 for patients in the observation group and 2.57 for SN false negative patients at the time of delayed lymphadenectomy</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p>($p < 0.001$).</p> <p>15.2% of early CLND patients had N3 disease compared with 32.5% in the observation group and 29.2% in the SN false negative group ($p < 0.001$).</p> <p>SN positive patients having early CLND had significantly better DMFS compared with observation patients undergoing delayed LND (Obs HR=1.36, 95% CI 1.08-1.72, $p = 0.01$).</p> <p>DMFS was significantly different for the SN positive group compared with the observation group for patients with T2 and T3 melanomas (Obs HR=1.36, 95% CI 1.01-1.84, $p = 0.042$).</p> <p>MSS was not significantly influenced by early CLND or delayed TLND.</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
							<p>5 year MSS estimates were 64.1% for CLND patients and 60.5% for TLND patients (p=0.144).</p> <p>5 year MSS estimates for T2 and T3 patients were 68.3% after CLND and 62.7% after delayed TLND</p>
White et al (2009)	<p>Retrospective Study</p> <p>2 Plastic Surgery Units in University hospitals in the UK (Coventry and Warwickshire NHS trust and Birmingham NHS trust)</p>	To evaluate the outcome of therapeutic neck dissection for melanoma in patients with head and neck melanoma	<p>N=37</p> <p><i>Inclusions</i> Patients with a single involved node based on clinical or radiological investigation</p> <p><i>Exclusions</i> Patients undergoing concomitant deep pelvic</p>	<p>Radical neck dissection</p> <p>Modified radical dissection</p> <p>Selective dissection</p>	Each Other	<p>46 months (mean)</p> <p>Patients with less than 18 months follow-up were excluded</p>	Overall survival at 60 months was 33% with no difference observed in survival rates for the 3 different types of dissection.

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Follow Up	Outcomes & Results
			lymphadenectomy or isolated limb perfusion				

1 5.2 Adjuvant radiotherapy

2 **Review question: What is the effectiveness of adjuvant radiotherapy to the resected**
 3 **lymph node basin for stage III melanoma in people who have undergone curative**
 4 **resection?**

5 **Question in PICO format**

Patients/population	Intervention	Comparison	Outcomes
Patients who have undergone a curative resection for stage III melanoma: <ul style="list-style-type: none"> • Neck • Axilla • Groin 	<ul style="list-style-type: none"> • Adjuvant Radiotherapy to the resected lymph node basin 	<ul style="list-style-type: none"> • No Adjuvant Radiotherapy 	1 Local recurrence 2 Melanoma specific survival 3 Lymphoedema 4 Metastases free survival 5 Adverse events 6 Overall survival

6 **How the information will be searched**

Searches:	
Can we apply date limits to the search (<i>Please provide information on any date limits we can apply to the searches for this topic. This can be done for each individual intervention as appropriate</i>)	
Are there any study design filters to be used (<i>RCT, systematic review, diagnostic test</i>).	There are 1 or 2 RCT but don't look at Lymphoedema and therefore it would not be appropriate to apply filters
List useful search terms. (<i>This can include such information as any alternative names for the interventions etc</i>)	TROG trial (Radiotherapy trial) The Lancet Oncology, Volume 13, Issue 6, Pages 589 - 597, June 2012 Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial

1 **The review strategy**

2 Any additional information to be added by subgroup lead

What data will we extract and how will we analyse the results?	<p>Relevant studies will be identified through sifting the abstracts and excluding studies clearly not relevant to the PICO. In the case of relevant or potentially relevant studies, the full paper will be ordered and reviewed, whereupon studies considered to be not relevant to the topic will be excluded.</p> <p>Studies which are identified as relevant will be critically appraised and quality assessed using GRADE methodology and/or NICE checklists. Data relating to the identified outcomes will be extracted from relevant studies.</p> <p>If possible a meta-analysis of available study data will be carried out to provide a more complete picture of the evidence body as a whole.</p> <p>An evidence summary outlining key issues such as volume, applicability and quality of evidence and presenting the key findings from the evidence as it relates to the topic of interest will be produced.</p>
List subgroups here and planned statistical analyses.	

3

4 **Search Results**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
Medline	1946-2013	322	53	16/09/2013
Premedline	13 Sep 2013	2	0	16/09/2013
Embase	1947-2013	572	38	16/09/2013
Cochrane Library	Issue 6 of 12 June 2013	7	4	17/09/2013
Web of Science (SCI & SSCI)	1900-2013	350	36	17/09/2013
Total References retrieved (after de-duplication): 72				

5 **Update Search**


6 For the update search, the same search criteria/filters were applied as initial search

Database name	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	21	4	10/10/2014
<i>Premedline</i>	0	0	10/10/2014
<i>Embase</i>	114	4	10/10/2014
<i>Cochrane Library</i>	0	0	10/10/2014
<i>Web of Science (SCI & SSCI)</i>	41	10	10/10/2014
Total References retrieved (after de-duplication): 8			

Medline search strategy (This search strategy is adapted to each database)

1. exp Melanoma/
2. melanoma\$.tw.
3. 1 or 2
4. Radiotherapy, Adjuvant/
5. (radiotherap* adj adjuvant).tw.
6. (adjuvant adj (radiation or irradiation)).tw.
7. or/4-6
8. exp Surgical Procedures, Operative/
9. surgery.fs.
10. *Lymph Node Excision/
11. (surg* or resect* or operat* or excision* or excised or lymphadenectom* or dissection*).tw.
12. or/8-11
13. 3 and 7 and 12

Screening Results



Reasons for Exclusion

Expert Reviews
Abstract Only
No Comparators
Treatment Comparisons not relevant to PICO
Population not relevant to PICO

Quality of the included studies

Systematic review of RCTs (n=0)
Systematic review of combined study designs (n=0)
Randomized controlled trial (n=2)
Prospective cross sectional study (n=0)
Case Series Studies (n=1)
Qualitative Study (n=0)

Table 5.3 Characteristics of included studies

Study	Study Type	Population	Aim	Intervention	Comparison	Outcomes
Burmeister et al (2012)	Randomised Controlled Trial	248	To assess the effect of adjuvant radiotherapy on lymph-node field control in patients who underwent therapeutic lymphadenectomy for metastatic melanoma in regional lymph nodes	Adjuvant radiotherapy of 48 Gy in 20 fractions	Observation	<ul style="list-style-type: none"> • Lymph Node field relapse • Acute toxic effects • Relapse free survival • Overall survival
Burmeister et al (2006)	Retrospective Case Series	234	To prospectively evaluate the role of post-operative radiation therapy to the nodal basin in patients having features which would put them at high risk of recurrence	Adjuvant radiotherapy (48 Gy reference dose in 20 daily fractions, 5 times per week over 4 weeks)	None	<ul style="list-style-type: none"> • Late Toxicity • Relapse
Creagan et al (1978)	Randomised Controlled Trial	56	To assess the role of post-operative radiation therapy directed to the regional node area in patients undergoing lymphadenectomy for metastatic melanoma	Adjuvant radiotherapy	Observation	<ul style="list-style-type: none"> • Disease free interval
Guadagnolo et al (2014)	Retrospective Case Series	130	To evaluate outcomes, specifically with respect of adjuvant radiotherapy for patients with desmoplastic melanoma	Adjuvant Radiotherapy	No radiotherapy	<ul style="list-style-type: none"> • Overall Survival • Disease Specific Survival
Strom et al	Retrospective	277	To analyse the impact of adjuvant	Wide local excision +	Wide local	<ul style="list-style-type: none"> • Local Control

Study	Study Type	Population	Aim	Intervention	Comparison	Outcomes
(2014)			post operative radiotherapy on local recurrence rates in patients with desmoplastic melanoma	adjuvant radiotherapy	excision alone	<ul style="list-style-type: none"> • Locoregional Control • Distant Metastases Rate • Toxicity

Evidence Statements

One randomised trial with a total of 248 patients (Burmeister et al, 2012) reported a significantly lower risk of lymph-node field relapse in patients treated with radiotherapy compared to patients in the observation arm: HR=0.47 (95% CI, 0.28-0.81) p=0.005. [Low Quality Evidence] A second retrospective cohort study (Strom et al, 2014) reported improved local control in patients treated with adjuvant radiotherapy (HR=0.15, 95% CI 0.06-0.39, p=0.001) and poorer local control was significantly associated with male sex, Clarks level V and positive resection margins [Very Low Quality Evidence]

From one retrospective observational study including 130 patients, 5 year actuarial melanoma specific survival was 84% and 10 year actuarial melanoma specific survival was 80% for the whole cohort [Very Low Quality Evidence]

From two randomised trials with a total of 304 patients (Burmeister et al, 2012; Creagan et al, 1978) no significant difference in relapse free survival between patients in radiotherapy arm versus the observation arm was reported [Low Quality Evidence]

From one randomised trial with a total of 56 patients (Creagan et al, 1978) median disease free survival was 43 months for irradiated patients versus 30 months for surgery alone (p=0.15) [Low Quality Evidence]

One randomised trial (Burmeister et al, 2012) reported no statistically significant difference in overall survival for patients receiving adjuvant radiotherapy compared with patients in the observation arm: HR 1.35 (95% CI; 0.94-1.92) p=0.12. [Low Quality Evidence]

One prospective case series study followed patients treated with adjuvant radiotherapy for a median of 58.4 months (range 21.2-158 months) and reported that radiotherapy was well tolerated in most patients with lymphoedema being the most significant. 9% of patients with axillary disease and 19% of patients with ilio-inguinal disease experienced grade 3 lymphoedema [Very Low Quality Evidence].

GRADE Profile 5.3: Should adjuvant radiotherapy of the resected lymph node basin vs. observation be used in patients with stage III melanoma who have undergone curative resection ?

Quality assessment							Summary of findings				
							No of patients		Effect		Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Adjuvant Radiotherapy of the resected lymph node basin	Observation	Relative (95% CI)	Absolute	
Lymph node field relapse (Burmeister et al, 2012)											
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	20/109 (18.3%)	34/108 (31.5%)	HR 0.47 (0.28 to 0.81)	152 fewer per 1000 (from 51 fewer to 214 fewer)	LOW
Local Control (Strom et al, 2014)											
1	Observational Study	Very Serious ³	No serious inconsistency	no serious indirectness	No serious imprecision	none	36/277 patients failed locally (details not reported according to treatment)		HR 0.15 (0.06 to 0.39)		VERY LOW

Melanoma Specific Survival (Guadagnolo et al, 2013)(
1	Observational Study	Serious ⁴	No serious inconsistency	no serious indirectness	No serious imprecision	None	5 year actuarial melanoma specific survival 84% for the whole cohort 10 year actuarial melanoma specific survival 80% for the whole cohort				VERY LOW
Relapse free survival/Disease Free Survival (Burmeister et al, 2012 and Creagan et al, 1978)											
2	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	Serious ⁴	none	79/149 (53%)	86/155 (55.5%)	not pooled	not pooled	LOW
Lymphoedema (Burmeister et al, 2006)											
1	observational studies	Serious ⁵⁵	no serious inconsistency	no serious indirectness	no serious imprecision	none	Grade 3-4 lymphoedema reported in a total of 19 patients (Axilla=9%; Inguinal=19%)				VERY LOW
Early Adverse Events (surgical) (Burmeister et al, 2012)											
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	19 patients reported grade 3-4 dermatitis resulting from radiotherapy (head&neck n=3; axilla n=10; ilio-inguinal n=6) 2 patients reported grade 3-4 pain resulting from radiotherapy to the axilla				LOW

Overall Survival (Burmeister et al, 2012)											
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	66/122 (54.1%)	55/126 (43.7%)	HR 1.35 (0.94 to 1.92)	102 more per 1000 (from 20 fewer to 231 more)	LOW
Late Toxicity (Burmeister et al, 2006)											
1	observational studies	Serious ⁶	no serious inconsistency	no serious indirectness	no serious imprecision	none	0/0 (0%)	0/0 (0%)	RR 0 (0 to 0)	0 fewer per 1000 (from 0 fewer to 0 fewer)	VERY LOW
								0%		0 fewer per 1000 (from 0 fewer to 0 fewer)	

¹ There was no blinding in this trial, however it is not possible to blind patients and investigators due to the nature of the comparison

² There was reduced power in the study due to the number of ineligible patients which were excluded. Analysis was carried out on the intent to treat population.

³ Retrospective observational study comparing wide local excision + adjuvant radiotherapy with wide local excision alone in which patients receiving adjuvant radiotherapy were highly selected according to clinical features.

⁴ Retrospective observational study reporting disease specific survival rates with no confidence intervals or p values

⁵ There was reduced power in the Burmeister study due to the number of ineligible patients which were excluded. Analysis was carried out on the intent to treat population. The Creagan study was also under powered and had a high number of ineligible patients which were not analysed. Analysis in the Creagan study was not carried out in the intent to treat population.

⁶ Prospective observational study with no comparison group

1 Evidence Summaries

2 A single randomised trial (Burmeister et al 2012) comparing adjuvant radiotherapy with observation
3 following therapeutic lymphadenectomy. The trial randomised 250 patients on a 1:1 basis and
4 planned analysis was on intent to treat basis, however 2 patients (1 from each group) withdrew
5 consent soon after randomisation and were excluded. In addition there were 41 major protocol
6 infringements in 31 patients which resulted in investigators carrying out analysis in both the intent
7 to treat population and the eligible population. The results presented in this review are from the
8 intent-to treat population with the quality of the evidence down-graded to reflect the possible
9 impact of the protocol violations on outcomes.

10 The median potential follow up time in the intention to treat population was 40 months (IQR 27-55)
11 and in patients who were not lost to follow up the range was 14-80 months (Burmeister et al 2012).

12 Lymph node field relapse as first relapse occurred in 20/122 (16%) of patients treated with adjuvant
13 radiotherapy versus 40/126 (32%) of patients in the observation arm: HR=0.47 (95% CI 0.28-0.81),
14 p=0.005 (Burmeister et al 2012).

15 In the radiotherapy arm 76/122 (63%) relapsed with melanoma at any site compared with 85/126
16 (68%) in the observation arm. Relapse free survival in the intent to treat population showed no
17 significant difference for patients in the adjuvant radiotherapy arm compared with the observation
18 arm: HR=0.90 (95% CI, 0.66-1.22), p=0.53 (Burmeister et al 2012)

19 There was reportedly no significant difference in time to distant relapse (as a first relapse or any
20 relapse) between the radiotherapy arm and observation arm, though these data are not shown for
21 the intent to treat population (Burmeister et al 2012).

22 Median survival was 32 months in the adjuvant radiotherapy arm compared with 47 months in the
23 observation arm. Although this difference was not statistically significant (HR=1.35 (95% CI 0.94-
24 1.92), p=0.12, there may be some clinical significance to this result (Burmeister et al 2012).

25 Analysis of potential prognostic factors indicated that extranodal spread (none vs. Limited vs.
26 Extensive) was the only independent risk factor for lymph node field relapse: HR=1.77 per degree of
27 spread (95% CI, 1.26-2.49), p=0.001 (Burmeister et al 2012).

28 A second randomised trial (Creagan et al, 1978) compared patients receiving adjuvant radiotherapy
29 following lymphadenectomy for metastatic melanoma with patients undergoing surgery alone. The
30 study included a total of 56 patients, 27 of whom were randomized to receive adjuvant
31 radiotherapy.

32 Median time to recurrence was 20 months for patients treated with radiotherapy versus 9 months
33 for patients treated with surgery alone though the difference was not significant (p=0.07) (Creagan
34 et al, 1978).

35 Median survival in the irradiated group was 33 months versus 22 months for surgery alone though
36 again the difference was not significant (p=0.09) For patients with a single involved node, median
37 survival was 43 months for irradiated patients versus 30 months following surgery alone (p=0.15)
38 (Creagan et al, 1978).

- 1 A total of 8/27 patients treated with radiotherapy and 6/29 patients treated with surgery alone
- 2 reported lymphoedema (Creagan et al, 1978).
- 3 One prospective case series study with a total of 234 patients reported that radiation therapy was
- 4 generally well tolerated in most patients. Lymphoedema was reported to be the most significant late
- 5 toxic effect with 9% of patients with axillary disease and 19% of patients with ilio-inguinal disease
- 6 reporting grade 3 changes, though no patient reported grade 4 disease (Burmeister et al, 2006).
- 7 The most common grade 1-2 late toxicities included skin changes, subcutaneous changes and
- 8 lymphoedema (Burmeister et al, 2006).
- 9

References

Included Studies

Burmeister BH et al (2012) Adjuvant radiotherapy versus observation alone for patients at risk of lymph node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial *Lancet Oncology* 13:589-597

Burmeister BH et al (2006) A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma – Trans Tasman Radiation Oncology Group (TROG) Study 96.06 *Radiotherapy and Oncology* 81: 136-142

Creagan, E. T., et al (1978) Adjuvant radiation therapy for regional nodal metastases from malignant melanoma: a randomized, prospective study. *Cancer* 42;5:2206-2210

Guadagnolo, B. A et al (2014) The role of adjuvant radiotherapy in the local management of desmoplastic melanoma. *Cancer* 120;9:1361-1368. Strom, T., et al (2014) Radiotherapy influences local control in patients with desmoplastic melanoma. *Cancer* 120;9:1369-1378.

Excluded Studies

Agrawal, S., et al (2008). Therapeutic lymphadenectomy alone versus adjuvant radiotherapy for regional nodal metastases from melanoma. *Journal of Clinical Oncology* 26;15.
Reason: Abstract Only

Agrawal, S., (2009) The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. *Cancer* 115;24:5836-5844.
Reason: Population/Outcomes not relevant to PICO

Arora, A et al (2005) Wide excision without radiation for desmoplastic melanoma. *Cancer* 104;7:1462-1467.
Reason: No radiotherapy

Ballo, M. T., et al Radiotherapy for cutaneous malignant melanoma: rationale and indications. [Review] [65 refs]. *Oncology (Williston Park)* 18;1:99-107.
Reason: Expert Review

Ballo, M. T., et al (2002) Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. *Journal of Clinical Oncology* 20;23: 4555-4558.
Reason: Not relevant to PICO

Ballo, M. T., et al (2002) Adjuvant irradiation for axillary metastases from malignant melanoma. *International Journal of Radiation Oncology, Biology, Physics* 52;4:964-972.
Reason: No comparator

Ballo, M. T., et al (2003). Radiation therapy for malignant melanoma. [Review] [88 refs]. *Surgical Clinics of North America* 83;2:323-342.
Reason: Expert Review

- 1 Ballo, M. T et al (2003) Adjuvant irradiation for cervical lymph node metastases from melanoma.
- 2 Cancer 97;7:1789-1796.
- 3 Reason: No Comparator
- 4 Ballo, M. T., et al (2004) A critical assessment of adjuvant radiotherapy for inguinal lymph node
- 5 metastases from melanoma. Annals of Surgical Oncology 11;12:1079-1084.
- 6 Reason: No Comparator
- 7 Ballo, M. T., et al (2005) Melanoma metastatic to cervical lymph nodes: Can radiotherapy replace
- 8 formal dissection after local excision of nodal disease? Head & Neck 27;8:718-721.
- 9 Reason: No Data
- 10 Ballo, M. T., et al (2006) Combined-modality therapy for patients with regional nodal metastases
- 11 from melanoma. International Journal of Radiation Oncology, Biology, Physics 64;1:106-113.
- 12 Reason: Comparison not relevant to PICO
- 13 Ballo, M. T. G. (2009) Adjuvant radiation therapy for patients with cervical lymph node metastases
- 14 from malignant melanoma. American Journal of Hematology/ Oncology 8;7
- 15 Reason: Expert Review
- 16 Bastiaannet, E., et al (2005) Radiation therapy following lymph node dissection in melanoma
- 17 patients: treatment, outcome and complications. [Review] [48 refs]. Cancer Treatment Reviews
- 18 31;1:18-26
- 19 Reason: Expert Review
- 20 Beadle, B. M., et al (2009) Radiation therapy field extent for adjuvant treatment of axillary
- 21 metastases from malignant melanoma. International Journal of Radiation Oncology, Biology, Physics
- 22 73;5:1376-1382.
- 23 Reason: No Comparator
- 24 Berk, L. B. and Berk, Lawrence B.(2008) Radiation therapy as primary and adjuvant treatment for
- 25 local and regional melanoma. [Review] [48 refs]. Cancer Control 15;3:233-238.
- 26 Reason: Expert Review
- 27 Bibault, J. E., et al (2011) Adjuvant radiation therapy in metastatic lymph nodes from melanoma.
- 28 Radiation Oncology 6;12.
- 29 Reason: No Data
- 30 Bigault, O. (2009) Post-operative radiation therapy in the adjuvant setting to assess local control for
- 31 in-transit melanoma. Journal of Medical Imaging and Radiation Oncology Conference[var.pagings],
- 32 Reason: Not relevant to PICO
- 33 Burmeister, B. H., et al (1995) Radiation therapy for nodal disease in malignant melanoma. World
- 34 Journal of Surgery 19;3:369-371.
- 35 Reason: Not systematic

- 1 Burmeister, B. H et al (2002) Radiation therapy following nodal surgery for melanoma: an analysis of
2 late toxicity. ANZ Journal of Surgery 72;5:344-348
3 Reason: Population included elsewhere
- 4 Burmeister, B. H. (2009) Adjuvant radiotherapy improves regional control in melanoma patients
5 after lymphadenectomy: Results of an intergroup randomised trial (TROG 02.01/anzmtg 01.02).
6 Journal of Medical Imaging and Radiation Oncology Conference[var.pagings],
7 Reason: Abstract Only
- 8 Chang, D. T., et al (2006) Adjuvant radiotherapy for cutaneous melanoma: comparing
9 hypofractionation to conventional fractionation. International Journal of Radiation Oncology,
10 Biology, Physics 66;4:1051-1055.
11 Reason: Not relevant to PICO
- 12 Conill, C., et al (2007) Toxicity of combined treatment of adjuvant irradiation and interferon alpha2b
13 in high-risk melanoma patients. Melanoma Research 17;5:304-309.
14 Reason: Not relevant to PICO
- 15 Conill, C et al (2009) Loco-regional control after postoperative radiotherapy for patients with
16 regional nodal metastases from melanoma. Clinical & Translational Oncology: Official Publication of
17 the Federation of Spanish Oncology Societies & of the National Cancer Institute of Mexico 11;10:688-
18 693.
19 Reason: Not Randomised
- 20 Dhungel, B. (2010) Hypofractionated radiation following surgical resection of malignant melanoma.
21 International Journal of Radiation Oncology Biology Physics Conference[var.pagings], S618-S619.
22 Reason: Abstract Only
- 23 Dzhabarov, F. R., et al (2011) [The usefulness of neo- and adjuvant therapy in the treatment of
24 cutaneous melanoma]. [Russian]. Voprosy Onkologii 57;4:521-524.
25 Reason: Not relevant to PICO
- 26 Fenig, E., et al (1999) Role of radiation therapy in the management of cutaneous malignant
27 melanoma. American Journal of Clinical Oncology 22;2:184-186.
28 Reason: Not relevant to PICO
- 29 Finkelstein, S. E., et al (2008) The Florida melanoma trial I: A prospective multi-center phase I/II trial
30 of post-operative hypofractionated adjuvant radiotherapy with concurrent interferon-alpha in the
31 treatment of advanced stage III melanoma. International Journal of Radiation Oncology Biology
32 Physics 72;1:S108.
33 Reason: Not relevant to PICO
- 34 Foote, M., et al (2012) An innovative approach for locally advanced stage III cutaneous melanoma:
35 radiotherapy, followed by nodal dissection. Melanoma Research 22;3:257-262.
36 Reason: Not relevant to PICO

- 1 Foote, M. C et al (2008) Desmoplastic melanoma: the role of radiotherapy in improving local control.
2 ANZ Journal of Surgery 78;4:273-276.
3 Reason: Not relevant to PICO
- 4 Fox, M. C et al (2013) Management options for metastatic melanoma in the era of novel therapies: a
5 primer for the practicing dermatologist: part I: Management of stage III disease. Journal of the
6 American Academy of Dermatology 68;1:1-9.
7 Reason: Expert Review
- 8 Fuhrmann, D., et al (2001) Should adjuvant radiotherapy be recommended following resection of
9 regional lymph node metastases of malignant melanomas? British Journal of Dermatology 144[1],
10 66-70. 2001. England.
11 Reason: Not Randomised
- 12 Geere, S. L. B. (2012) Management of loco-regionally recurrent melanoma. Cancer Forum 36[3].
13 Reason: Expert Review
- 14 Geltzeiler, M. (2011) Regional control of head and neck melanoma with selective neck dissection.
15 Otolaryngology - Head and Neck Surgery Conference[var.pagings],
16 Reason: No relevant data
- 17 Gibbs, Pet al (2001) Management of primary cutaneous melanoma of the head and neck: The
18 University of Colorado experience and a review of the literature. [Review] [35 refs]. Journal of
19 Surgical Oncology 77;3:179-185.
20 Reason: No adjuvant radiotherapy
- 21 Gojkovic-Horvat, A., et al (2012) Adjuvant radiotherapy for palpable melanoma metastases to the
22 groin: when to irradiate? International Journal of Radiation Oncology, Biology, Physics 83;1:310-316.
23 Reason:No Comparator
- 24 Goldner, G. (2013) [Adjuvant radiotherapy following lymphadenectomy for malignant melanoma
25 significantly improves local control][German]. Strahlentherapie und Onkologie 189;1:95-96.
26 Reason: Check data (likely expert review)
- 27 Guadagnolo, B. A. and Zagars, G. K. (2009) Adjuvant radiation therapy for high-risk nodal metastases
28 from cutaneous melanoma. Lancet Oncology 10;4:409-416.
29 Reason: Expert Review
- 30 Guadagnolo, B. A., et al (2010) Role of postoperative irradiation for patients with bilateral cervical
31 nodal metastases from cutaneous melanoma: a critical assessment. Head & Neck 32;6:708-713.
32 Reason: No Comparator
- 33 Gyorki, D. E., et al (2004) Concurrent adjuvant radiotherapy and interferon-alpha2b for resected high
34 risk stage III melanoma -- a retrospective single centre study. Melanoma Research 14;3:223-230.
35 Reason: Not relevant to PICO

- 1 Hamming-Vrieze, O., et al (2009) Regional control of melanoma neck node metastasis after selective
2 neck dissection with or without adjuvant radiotherapy. Archives of Otolaryngology -- Head & Neck
3 Surgery 135;8:795-800.
4 Reason: Not Randomised
- 5 Hazard, L. J., et al (2002) Combined adjuvant radiation and interferon-alpha 2B therapy in high-risk
6 melanoma patients: the potential for increased radiation toxicity. International Journal of Radiation
7 Oncology, Biology, Physics 52;3:796-800.
8 Reason: Comparison not relevant to PICO
- 9 Henderson, M. A. B.(2009) Adjuvant radiotherapy and regional lymph node field control in
10 melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG
11 01.02/TROG 02.01). Journal of Clinical Oncology Conference[var.pagings], LBA9084.
12 Reason: Abstract Only
- 13 Henderson, M. A. B. (2013) Adjuvant radiotherapy after lymphadenectomy in melanoma patients:
14 Final results of an intergroup randomized trial (ANZMTG 0.1.02/TROG 02.01). Journal of Clinical
15 Oncology Conference[var.pagings].
16 Reason: Abstract Only
- 17 Homsj, J., et al (2007) Melanoma of the anal canal: a case series. Diseases of the Colon & Rectum
18 50;7:1004-1010.
19 Reason: Not relevant to PICO
- 20 Kavanagh, D., et al (2005) Adjuvant therapies in the treatment of stage II and III malignant
21 melanoma. [Review] [89 refs]. Surgeon Journal of the Royal Colleges of Surgeons of Edinburgh &
22 Ireland 3;4:245-256.
23 Reason: Expert Review
- 24 Kelly, P., et al (2011) Sphincter-sparing local excision and hypofractionated radiation therapy for
25 anorectal melanoma: a 20-year experience. Cancer 117;20:4747-4755.
26 Reason: Not relevant to PICO
- 27 Khan, N., et al (2011) The evolving role of radiation therapy in the management of malignant
28 melanoma. [Review]. International Journal of Radiation Oncology, Biology, Physics 80;3:645-654.
29 Reason: Expert Review
- 30 Lee, R. J., et al (2000) Nodal basin recurrence following lymph node dissection for melanoma:
31 implications for adjuvant radiotherapy. International Journal of Radiation Oncology, Biology, Physics
32 46;2: 467-474.
33 Reason: No Radiotherapy
- 34 Mendenhall, W. M., et al (2008) Adjuvant radiotherapy for cutaneous melanoma. [Review] [54 refs].
35 Cancer 112;6:1189-1196.
36 Reason: Expert Review

- 1 Mendenhall, W. M., et al (2013) Surgery and adjuvant radiotherapy for cutaneous melanoma
2 considered high-risk for local-regional recurrence. American Journal of Otolaryngology 34;4:320-322.
3 Reason: Population not relevant to PICO
- 4 Moncrieff, M. D., et al (2008) Adjuvant postoperative radiotherapy to the cervical lymph nodes in
5 cutaneous melanoma: is there any benefit for high-risk patients? Annals of Surgical Oncology
6 15;11:3022-3027.
7 Reason:
- 8 Moozar, K. L., et al (2003) Anorectal malignant melanoma: treatment with surgery or radiation
9 therapy, or both. Canadian Journal of Surgery 46;5:345-349.
10 Reason: Not relevant to PICO
- 11 Moros, M. L., et al (2004). Primary malignant melanoma of the vagina. Poor response to radical
12 surgery and adjuvant therapy. European Journal of Obstetrics, Gynecology, & Reproductive Biology
13 113;2:248-250.
14 Reason:Single Case
- 15 O'Brien, C. J., et al (1995) Radical, modified, and selective neck dissection for cutaneous malignant
16 melanoma. Head & Neck 17;3:232-241
17 Reason: Not Randomised
- 18 O'Brien, C. J., et al (1997) Adjuvant radiotherapy following neck dissection and parotidectomy for
19 metastatic malignant melanoma. Head & Neck 19;7:589-594.
20 Reason: Not Randomised
- 21 Phipps, A. R., et al (1992). The Effect of Immediately Preoperative Adjuvant Radiotherapy in the
22 Surgical-Treatment of Primary Cutaneous Malignant-Melanoma. British Journal of Plastic Surgery
23 45;1:30-33.
24 Reason: No data
- 25 Pinkham, M. B., et al (2013) Stage III melanoma in the axilla: patterns of regional recurrence after
26 surgery with and without adjuvant radiation therapy. International Journal of Radiation Oncology,
27 Biology, Physics 86;4:702-708.
28 Reason: Not randomised
- 29 Ramakrishnan, A. S. M.(2008) Optimizing local control in anorectal melanoma. Indian Journal of
30 Cancer 45;1:13-19.
31 Reason: Not relevant to PICO
- 32 Rao, N. G., et al (2011) The role of radiation therapy in the management of cutaneous melanoma.
33 [Review]. Surgical Oncology Clinics of North America 20;1:115-131.
34 Reason: Expert Review
- 35 Ridge, J. A. (2000) Adjuvant radiation after lymph node dissection for melanoma. Annals of Surgical
36 Oncology 7;8:550-551.
37 Reason: No data

- 1 Shen, P., et al (2000). Is adjuvant radiotherapy necessary after positive lymph node dissection in
2 head and neck melanomas? *Annals of Surgical Oncology* 7;8:554-559.
3 Reason: Not Randomised
- 4 Sherriff, J. (2012) Adjuvant nodal radiation therapy for malignant melanoma with single region nodal
5 metastasis. *Journal of Radiation Oncology* 1;4:373-380.
6 Reason: Not primary melanoma
- 7 Stevens, G., (2000) Locally advanced melanoma: results of postoperative hypofractionated radiation
8 therapy. *Cancer* 88;1:88-94.
9 Reason: Not relevant to PICO
- 10 Strojan, P., et al (2010) Melanoma metastases to the neck nodes: role of adjuvant irradiation.
11 *International Journal of Radiation Oncology, Biology, Physics* 77;4:1039-1045. .
12 Reason: Not Randomised
- 13 Strojan, P. (2010) Adjuvant radiotherapy for palpable melanoma metastases to the groin: When if at
14 all to irradiate? *Radiotherapy and Oncology Conference*[var.pagings],
15 Reason: Abstract Only
- 16 Strom, E. A et al (1995) Adjuvant radiation therapy after axillary lymphadenectomy for metastatic
17 melanoma: toxicity and local control. *Annals of Surgical Oncology* 2;5:445-449.
18 Reason: No Data
- 19 Testori, A., et al (2009) Surgery and radiotherapy in the treatment of cutaneous melanoma. *Annals*
20 *of Oncology* 20, 22-29.
21 Reason: Expert Review
- 22 Van Der Bol, W. (2010) Treatment of clinically positive cervical lymph nodes by local excision and
23 adjuvant radiotherapy in frail and elderly patients with metastatic melanoma. *European Journal of*
24 *Surgical Oncology Conference*[var.pagings], 907.
25 Reason: Abstract Only
- 26 Vongtama, R., et al (2003) Efficacy of radiation therapy in the local control of desmoplastic malignant
27 melanoma. *Head & Neck* 25;6:423-428.
28 Reason: Population not relevant to PICO
- 29 Wasif, N., et al (2003). Desmoplastic melanoma - the step-child in the melanoma family? *Journal of*
30 *Surgical Oncology* 103;2:158-162.
31 Reason: Not relevant to PICO

Evidence Tables

Study Quality

	Appropriate length of follow-up	Precise definition of an outcome	Valid method of measuring outcomes	Investigators blind to participants exposure to intervention?	Investigators blind to potential confounders and prognostic factors?	Quality (GRADE)
Burmeister et al (2012)	Unclear	Yes	Yes	No	Unclear	Low
Burmeister et al (2006)	Yes	Yes	Yes	Unclear	Unclear	Very Low
Creagan et al (1978)	Unclear	Yes	Yes	Unclear	Unclear	Low
Guadagnolo et al (2013)	Yes	Yes	Yes	Unclear	Unclear	Very Low
Strom et al (2014)	Yes	Yes	Yes	Unclear	Unclear	Low

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and results
Burmeister et al (2012)		Clinical Trial	250 patients <u>Inclusion criteria:</u> Palpable metastatic lymph	Radiotherapy (48Gy in 20 fractions)	Observation	Median follow up was 40 months with patients followed up once every 3 months for 2 years and	<u>Outcomes</u> <i>Primary:</i> Lymph node field relapse as first relapse

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and results
		16 hospitals in Australia, New Zealand, the Netherlands and Brazil.	<p>node field disease Complete cervical, axillary or inguinal lymphadenectomy High risk of further lymph-node field relapse ECOG performance status of 0-1 Aged 18 years or older Life expectancy in the absence of melanoma of 2 years or more Staged by CT scan of lymph node field, chest abdomen or pelvis and CT or MRI of brain Serum LDH concentration less than 1.5 the upper limit of normal Normal FBC and biochemistry Informed consent</p> <p><u>Exclusion criteria:</u> Concurrent or previous history of local, in transit or distant relapse Impalpable (Including detected by SLNB) lymph node field relapse Had cancer previously (unless diagnosed more than 5 years before with estimated risk recurrence of less than 10%)</p>			then every 6 months until 5 years and then annually thereafter.	<p><i>Secondary</i> Acute toxic effects Relapse free survival Overall survival</p>
Burmeister et al (2006)	To prospectively evaluate the role of post-operative radiation therapy to the nodal basin in patients considered	8 centres in Australia and New Zealand	<p>N=234 patients</p> <p><u>Inclusion Criteria</u> Histologically confirmed malignant melanoma involving regional lymph</p>	Prescribed regimen was 48Gy reference dose in 20 daily	N/A	Median follow-up was 58.4 months (range 21.2-158 months)	<p><u>Primary</u> Late Toxicity</p> <p><u>Secondary</u> Relapse</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and results
	to be at high risk of regional recurrence.		<p>nodes or extranodal soft tissues in the lymph node basin.</p> <p>Disease limited to the area of resection, completely macroscopically resected with no evidence of distant metastases</p> <p>ECOG performance status 0-1</p> <p>Full blood counts and biochemistry within normal limits</p> <p><u>Exclusion Criteria</u></p> <p>None provided</p>	fractions, 5 times/week over 4 weeks with radiation to commence within 3 months of surgery.			Survival
Creagan et al (1978)		January 1972 to July 1977	<p>82 patients were entered in the study.</p> <p>A total of 17 patients were considered to be ineligible to take part and a further 9 patients were later excluded for various reasons leaving a total of 56 patients analysed.</p> <p>N=27 receiving radiation and N=29 having surgery alone</p> <p><u>Inclusion criteria:</u></p> <p>Biopsy proven melanoma in regional nodes associated with primary lesions on the trunk, extremities or with</p>	Surgery+Radio therapy	Surgery		Disease free interval Survival

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and results
			<p>unknown primaries. No clinical or laboratory evidence of dissemination</p> <p><u>Exclusion criteria:</u> Previous radiotherapy to node bearing areas Concomitant chemotherapy or immunotherapy</p>				
Guadagnolo et al (2013)	To evaluate outcomes, specifically with respect of adjuvant radiotherapy for patients with desmoplastic melanoma	<p>Retrospective Case Series</p> <p>Single Centre (USA)</p> <p>1985-2009</p>	<p>N=130 patients with non-metastatic, desmoplastic melanoma</p> <p>Median age 66 years (21-97)</p>	<p>Adjuvant radiotherapy</p> <p>Median total dose was 30Gy (30-60Gy)</p> <p>Median fractional dose was 6Gy per fraction (2-6Gy)</p> <p>Interval between surgery and radiotherapy ranged from 1 month to 60</p>	No adjuvant radiotherapy	Median Follow-up for patients still alive at last follow up was 6.6 years (11 months – 24 years)	<p>Management of primary lesion using surgery alone was accomplished in 59 patients (45%) and using surgery and adjuvant radiotherapy in 71 patients (55%).</p> <p>At time of last follow-up, 53 patients had died for a median survival of 11.8 years.</p> <p>5 year actuarial overall survival was 69%</p> <p>10 year actuarial overall survival was 53%</p> <p>5 year actuarial Disease Specific Survival was 84%</p> <p>10 year actuarial disease specific survival was 80%</p> <p>5 year actuarial disease free survival was 72%</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and results
				<p>months (median 7 months)</p> <p>(the decision to use adjuvant radiotherapy was at the discretion of the treating physician and practice patterns varied)</p>			<p>10 year actuarial disease free survival was 70%</p> <p>Lymph node involvement was a significant predictor of poor disease specific survival ($p<0.0001$) as was positive/uncertain resection margins ($p=0.03$) even when adjusting for postoperative radiotherapy.</p> <p>35/130 patients (27%) developed disease recurrence</p> <p>19 patients (15%) developed local recurrence for an actuarial local recurrence rate of 17% at 5 years and beyond.</p> <p>Actuarial rate of lymph node recurrence at 5 years was 11% and at 10 years was 14%.</p> <p>There was no significant difference in lymph node recurrence between patients with pure and mixed desmoplastic melanoma (12% versus 11% at 5 years, $p=0.81$).</p> <p>21% of patients developed distant metastases at a median of 19 months (1.8-103 months) for an actuarial rate of distant metastases development of 20% at 5 years and 25% at 10 years).</p> <p>Patients presenting with involved lymph nodes at the time of diagnosis were at higher risk of distant</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and results
							<p>metastases than those who did not ($p<0.0001$).</p> <p>Median overall survival and disease specific survival after first recurrence was 20 months.</p> <p>14/59 (24%) patients who underwent surgery without adjuvant radiotherapy experienced local recurrence compared with 5/71 patients (7%) who were treated with adjuvant radiotherapy.</p> <p>Factors found to be significant predictors of improved local control included receipt of post-operative radiotherapy ($p=0.03$) and negative resection margins ($p=0.008$).</p> <p>Patients with perineural invasion and who received postoperative radiotherapy had significantly better local control compared with those who did not receive adjuvant radiotherapy (91% versus 63% at 10 years, $p=0.02$).</p> <p>21 patients (16%) experienced surgical complications, with 11 considered moderate in severity.</p> <p>10 patients experienced surgical complications which were considered to be severe.</p> <p>Actuarial rate of surgical complications was 16% at 5 years and median time to surgical complication was 1</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and results
							<p>months (0-16 months).</p> <p>15/71 patients (21%) who received adjuvant radiotherapy experienced a radiotherapy related complication at a median time of 19 months (1month-12.5 years).</p> <p>Actuarial rates of significant radiotherapy related complications (moderate-severe) were 18% at 5 years and 22% at 10 years.</p>
Strom et al (2014)	To analyse the impact of adjuvant post operative radiotherapy on local recurrence rates in patients with desmoplastic melanoma	Retrospective Single Centre (USA) 1989-2010	<p>N=277 patients with desmoplastic melanoma</p> <p>Median age=68 years (16-96)</p> <p>Median Breslow thickness=3.9mm (0.5-35mm)</p> <p><i>Exclusions</i></p> <p>Patients presenting with distant disease or locally recurrent disease</p> <p>Patients who declined surgery or who received</p>	Wide local excision + adjuvant radiotherapy	Wide local excision alone	Median follow-up was 43.1 months	<p>N=113 patients received post-operative radiotherapy.</p> <p>Patients with head and neck tumours, Clark level V or tumours >4mm in thickness were significantly more likely to have received adjuvant radiotherapy.</p> <p>33 patients (12%) had pathologically proven regional lymph node involvement.</p> <p><i>Local Control</i></p> <p>36/277 patients (13%) failed locally – median time to failure was 14 months (2-113 months)</p> <p>Adjuvant radiotherapy was associated with improved</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and results
			<p>radiotherapy prior to surgery</p> <p>Patients with no treatment records</p>				<p>local control (HR=0.15, 95% CI 0.06-0.39, p=0.001)</p> <p>Poorer local control was found to be associated with:</p> <p>male sex [HR=3.8, 95% CI 1.3-11.2, p=0.01]</p> <p>Clark level V [HR=2.3, 95% CI 1.0-4.9, p=0.04]</p> <p>Positive resection margins [HR=6.6, 95% CI 2.8-15.7, p<0.001]</p> <p>28/164 (17%) who did not receive adjuvant radiotherapy developed local recurrence compared with only 8/113 (7%) of patients who received adjuvant radiotherapy.</p> <p>1 year actuarial local control rate with radiotherapy was 96% and without radiotherapy was 91%</p> <p>5 year actuarial local control rate with radiotherapy was 95% and without radiotherapy was 76%</p> <p>35 patients had a positive resection margin and 237 patients had a negative margin (5 had an unknown margin status).</p> <p>10/35 patients (29%) with positive margins developed local recurrence compared with 24/237 patients (10%)</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and results
							<p>with negative resection margins ($p<0.001$)</p> <p><i>Positive Resection Margins</i></p> <p>22/35 patients received adjuvant radiotherapy</p> <p>3/22 developed local recurrence compared with 7/13 (54%) of patients who had no adjuvant radiotherapy ($p=0.003$).</p> <p><i>Negative Resection Margins</i></p> <p>89/237 patients received adjuvant radiotherapy</p> <p>5/89 patients (6%) developed local recurrence compared with 19/148 (13%) of patients who did not receive adjuvant radiotherapy.</p> <p>Patients with negative margins and high risk features, including a head and neck location, Breslow depth $>4\text{mm}$ or Clark level V tumour had significantly improved local control with the use of radiotherapy and a $\geq 10\%$ difference in the absolute rates of local control.</p> <p><i>Locoregional Control</i></p> <p>21/264 patients developed a regional disease recurrence.</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and results
							<p>Patients treated with adjuvant radiotherapy had significantly improved locoregional control [Hr=0.20, 95% CI 0.10-0.40, p<0.001].</p> <p>40/164 patients (24%) who did not receive local/regional radiotherapy developed a locoregional recurrence compared with 15/113 patients (13%) who did.</p> <p>Other variables significantly associated with poorer locoregional control included: age >70 years [HR=2.4, 95% CI 1.3-4.2, p=0.003]</p> <p>Breslow depth >4mm [HR=2.5, 95% CI, 1.4-4.7, p=0.003]</p> <p>Positive Resection Margins [HR=4.6, 95% CI 2.3-9.1, p<0.001].</p> <p><i>Positive resection margins</i></p> <p>23% had a locoregional recurrence with radiotherapy versus 69% without (p=0.002)</p> <p><i>Negative Resection Margins</i></p> <p>10% experienced a locoregional recurrence with radiotherapy compared with 20% without (p=0.06).</p>

Study	Aim	Setting	Population	Intervention	Comparison	Follow-up	Outcomes and results
							<p>Patient age >70, Breslow depth >4mm and no radiotherapy were found to be associated with poorer locoregional control in patients with negative resection margins ($p<0.05$).</p> <p>In patients with high risk features, variables associated with significantly improved locoregional control with adjuvant radiotherapy included male sex and patients with deeper tumours, pure desmoplasia or perineural invasion.</p> <p><i>Distant Metastasis Rate and Salvage Surgery</i></p> <p>63/277 patients developed distant metastases with a median time from wide local excision of 17 months (2-121 months)</p> <p><i>Toxicity</i></p> <p>Common acute side effects included skin erythema, pain and fatigue</p> <p>Long term side effects included skin fibrosis, telangiectasis and skin pigment changes.</p>

5.3 In transit metastases

Review question: What is the most effective treatment for in transit melanoma metastases (for example, surgery, isolated limb infusion, isolated limb perfusion, palliative radiotherapy, cryotherapy, electro-chemotherapy or the laser)?

Background

In-transit melanoma are metastases located in the regional dermal and subdermal lymphatics which between >2cm from the excision scar and the regional nodes. The risk of developing in transit metastases is directly related to the stage of the disease. In the absence of extensive disease, surgery is treatment of choice for single or a small number of multiple metastases. Many patients will relapse, and for those with intermittent recurrence of a few metastases the morbidity associated with surgical resection is generally considered acceptable. Increase frequency of relapse or significant number of in transit nodules generally suggests alternative regional or systemic approaches should be considered. There are a wide variety of potential approaches.

It will be important to compare the different effectiveness and toxicities of regional methods of treating in transit metastases, and whether certain treatments would be favoured in certain circumstances. In particular it will be important to assess the local control rates compared with morbidity of the intervention. The role of new targeted and immunotherapy in unresectable in transit metastases compared with currently available regional therapies is not well defined compared with current options and is evolving rapidly.

Question in PICO format

Patients/population	Intervention	Comparison	Outcomes
Patients with in-transit melanoma metastases: <ul style="list-style-type: none"> Limb Not limb (Trunk, head/neck) Number of lesions/dept h/diameter 	<ul style="list-style-type: none"> Surgical excision Amputation Isolated limb infusion Isolated limb perfusion Radiotherapy Cryotherapy Electrochemotherapy Co2 Laser Topical agents (Inc. Imiquimod) 	<ul style="list-style-type: none"> Each Other Systemic Chemotherapy (inc. targeted) 	1. Local Control (partial response/complete response) 2. Melanoma specific Survival 3. Overall Survival (5 & 10yr) 4. Time to next treatment 5. Adverse Events 6. HRQL
Notes	For each study, report what diagnostics were used if possible		

How the information will be searched

Searches:	
Can we apply date limits to the search (<i>Please provide information on any date limits we can apply to the searches for this topic. This can be done for each individual intervention as appropriate</i>)	The GDG did not feel it appropriate to apply any date limits to this topic.

Are there any study design filters to be used (<i>RCT, systematic review, diagnostic test</i>).	The GDG did not feel is appropriate to apply any filters to this topic as there will not be randomised trials available for all comparisons
List useful search terms. (<i>This can include such information as any alternative names for the interventions etc</i>)	None given

1 The review strategy

2 Any additional information to be added by subgroup lead

What data will we extract and how will we analyse the results?	<p>Relevant studies will be identified through sifting the abstracts and excluding studies clearly not relevant to the PICO. In the case of relevant or potentially relevant studies, the full paper will be ordered and reviewed, whereupon studies considered to be not relevant to the topic will be excluded.</p> <p>Studies which are identified as relevant will be critically appraised and quality assessed using GRADE methodology and/or NICE checklists. Data relating to the identified outcomes will be extracted from relevant studies.</p> <p>If possible a meta-analysis of available study data will be carried out to provide a more complete picture of the evidence body as a whole.</p> <p>An evidence summary outlining key issues such as volume, applicability and quality of evidence and presenting the key findings from the evidence as it relates to the topic of interest will be produced.</p>
List subgroups here and planned statistical analyses.	

3 Search Results

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
Medline	1946-2013	1406	136	24/09/2013
Premedline	16 Sep 2013	14	7	25/09/2013
Embase	1947-2013	342	157	25/09/2013
Cochrane Library	Issue 6 of 12 June 2013	222	9	25/09/2013

Web of Science (SCI & SSCI)	1900-2013	445	148	30/09/2013
Total References retrieved (after de-duplication): 266				

1 Update Search

2 For the update search, the same search criteria/filters were applied as initial search


Database name	No of references found	No of references retrieved	Finish date of search
Medline	12	12	10/10/2014
Premedline	1	1	10/10/2014
Embase	49	30	10/10/2014
Cochrane Library	0	0	10/10/2014
Web of Science (SCI & SSCI)	65	39	10/10/2014
Total References retrieved (after de-duplication): 36			

3 Medline search strategy (*This search strategy is adapted to each database*)

- 4 1. exp Melanoma/
- 5 2. melanoma\$.tw.
- 6 3. (maligna\$ adj1 lentigo\$).tw.
- 7 4. (hutchinson\$ adj1 (freckle\$ or melano\$)).tw.
- 8 5. dubreuilh.tw.
- 9 6. LMM.tw.
- 10 7. or/1-6
- 11 8. exp Dermatologic Surgical Procedures/
- 12 9. (excis\$ or margin\$ or surg\$ or remov\$ or amputat* or operat* or dissection* or
- 13 lymphadenectom*).tw.
- 14 10. Chemotherapy, Cancer, Regional Perfusion/
- 15 11. Dacarbazine/ or dacarbazine.tw.
- 16 12. temozolomide.tw.
- 17 13. (limb* adj (infusion or perfusion)).tw.
- 18 14. Melphalan/ or melphalan.tw.
- 19 15. Tumor Necrosis Factor-alpha/
- 20 16. (tumo?r necrosis factor or tnfa or tnfa or cachectin or cachexin).tw.
- 21 17. Interferons/ or interferon*.tw.
- 22 18. Injections, Intralesional/
- 23 19. ((intra lesional or intralesional) adj (therap* or injection*)).tw.
- 24 20. exp Cryotherapy/
- 25 21. cryotherap*.tw.
- 26 22. Electrochemotherapy/
- 27 23. electrochemo*.tw.
- 28 24. Electroporation/
- 29 25. (electropor* or electro - por* or electropor* or electro - permeab*).tw.
- 30 26. Laser Therapy/
- 31 27. laser.tw.
- 32 28. imiquimod.tw.
- 33 29. Administration, Cutaneous/
- 34 30. Radiotherapy/

31. (radiotherap* or radiat* or irradiat*).tw.
32. or/8-31
33. Neoplasm Metastasis/
34. (in-transit adj2 (metasta* or disease*)).tw.
35. 33 or 34
36. 7 and 35
37. 32 and 36

Screening Results



Reasons for Exclusion

Expert Reviews
Abstract Only
No Comparators
Treatment Comparisons not relevant to PICO
Population not relevant to PICO

Quality of the included studies

Systematic review of RCTs (n=0)
Systematic review of combined study designs (n=1)
Randomized controlled trial (n=0)
Prospective cross sectional study (n=0)
Case Series Studies (n=7)
Qualitative Study (n=0)

Table 5.4 Characteristics of included studies

Study	Study Type	Population	Aim	Intervention	Comparison	Diagnostics	Outcomes
Caraco et al (2013)	Retrospective Case Series	N=60 with relapse and refractory cutaneous melanoma or in-transit disease	To analyse the short and long term responses of lesions treated with electrochemotherapy with intravenous injection of bleomycin in melanoma patients with in-transit disease or distant cutaneous metastases	Electrochemotherapy		N/R	<ul style="list-style-type: none"> Response rates
Fotopoulos et al (1998)	Retrospective Case Series	N= 33 patients with loco-regional recurrence of whom 21 patients had in-transit melanoma	To investigate the role of surgical treatment for survival in patients with loco-regional recurrences	Surgical Excision	None	N/R	<ul style="list-style-type: none"> Survival
Kandamany et al (2009)	Observational Case series	N=16 patients with cutaneous and superficial melanoma metastases too numerous or recurring too frequently for surgical excision	Not Clear from the study	CO2 laser	None	N\R	<ul style="list-style-type: none"> Survival
Hill et al (1993)	Observational case series	N=60 patients with cutaneous and superficial subcutaneous metastasis of malignant melanoma	To investigate the place of CO2 laser ablation of cutaneous or sub-cutaneous deposits of malignant melanoma	CO2 laser	None	N\R	<ul style="list-style-type: none"> Development of extraregional disease Overall Survival
Mali et al (2013)	Systematic Review and meta-analysis	N=22 studies with melanoma patients	To investigate the effectiveness of electrochemotherapy in patients with cutaneous and sub-cutaneous	Electrochemotherapy	Chemotherapy where available	N\R	<ul style="list-style-type: none"> Response Rates (Complete and Partial)

Study	Study Type	Population	Aim	Intervention	Comparison	Diagnostics	Outcomes
			tumours				
Ricotti et al (2014)	Prospective, non-randomised study	N=30 patients affected by 654 metastatic nodules from melanoma	To evaluate the efficacy, long-term tolerability and long-term efficacy of electrochemotherapy in the treatment of advanced cutaneous and subcutaneous melanoma	Electrochemotherapy	None	N/R	<ul style="list-style-type: none"> • Resposne Rates
Seegenschmidt et al (1999)	Retrospective Case Series	N=57 patients with stage UICC III melanoma of which an unclear number had in-transit melanoma	To analyse the 20 year clinical experience with radiotherapy treatment with respect to different endpoints and prognostic factors.	Radiotherapy	None	N/R	<ul style="list-style-type: none"> • Response Rates • Survival
Sharma et al (2012)	Retrospective case series	N=214 patients with in-transit melanoma undergoing either ILI or HILP for the first time	To summarise the patterns of recurrence following a complete response to HILP and ILI and to evaluate whether the regional treatment modality producing a complete response influences the probability and/or timing of local recurrence or overall survival	Hyperthermic Isolated Limb Perfusion	Isolated Limb Infusion	PET/CT	<ul style="list-style-type: none"> • Response Rates • Recurrence • Overall Survival

1 Evidence Statements

2 Electrochemotherapy

3 One systematic review and meta-analysis (Mali et al, 2013) reported a complete response rate of
4 56.8% and an objective response rate of 80.6% for patients with melanoma who were treated with
5 electrochemotherapy [Very Low]

6 CO2 laser

7 Two observational case series studies with a total of 76 patients and 5059 lesions (Hill et al (1993);
8 Kandamany et al (2009)) reported survival in patients treated with CO2 laser. Overall survival at 12
9 months was 67% (40/60) (Hill et al, 1993) and disease free survival at 12 months was 62.5% (10/16)
10 (Kandamany et al, 2009) [Very Low]

11 Radiotherapy

12 One retrospective case series with a total of 57 patients with stage UICC III, of which a small subset
13 had in-transit melanoma, were treated with radiotherapy (Seegenschmiedt et al, 1999). A total of
14 44% of stage UICC III patients had a complete response while 21% of stage UICC III patients showed
15 progressive disease. [Very Low]

16 Surgical Excision

17 One retrospective case series with a total of 33 patients treated for loco-regional metastases of the
18 lower extremities (Fotopoulos et al, 1998) reported a median disease free survival of 16 months (1-
19 104 months) and median overall survival of 31 months (2-264 months). [Very Low]

20 Isolated limb perfusion versus isolated limb infusion

21 One retrospective case series (Sharma et al; 2012) reported a significantly higher rate of complete
22 response in patients treated with HILP compared with patients treated with ILI (44% versus 28%;
23 $p=0.01$). [Very Low]

24 At 3-year follow-up following a complete response to treatment; a single retrospective case series
25 (Sharma et al; 2012) reported a recurrence rate of 65% (95% CI 43%-79%) for patients treated with
26 HILP compared with a recurrence rate of 85% (95% CI 53%-94%) for patients treated with ILI. Time to
27 first recurrence was longer for HILP (23 vs. 8 months, $p=0.02$) [Very Low]

28 In patients achieving complete response to treatment, in field recurrence rates were 44% (95% CI
29 16%-58%) for HILP compared with 56% (95% CI 30%-72%) for ILI. Median time to in field recurrence
30 was not statistically significantly different (HILP 46 months vs. ILI 25 months; $p=0.15$). [Very Low]

31 In patients achieving complete response to out of field recurrence rate was 44% (95% CI 23%-60%)
32 for HILP compared with 77% (95% CI 51%-89%) for ILI. Time to out field recurrence was longer for
33 HILP (42 versus 14 months, $p=0.02$) [Very Low]

34 In patients achieving complete response, there was no statistically significant difference in median
35 overall survival between HILP and ILI (100 vs. 39 months, $p=0.10$). [Very Low]

GRADE Table 5.4: Should surgical excision be used in patients with in transit melanoma?

Quality assessment							Summary of Findings				Quality
local control											
0	no evidence available										
Melanoma specific survival											
0	no evidence available										
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Surgical Excision	None	Relative (95% CI)	Absolute	Quality
Overall Survival (Fotopoulos et al, 1998)											
1 (n=33)	observational studies	serious ¹	no serious inconsistency	serious ²	serious ³	none	/33 ⁴	No comparison	Median overall survival of 31 months (2-264 months)-		Very Low
Time to next treatment											
0	no evidence available										
Adverse Events											
0	no evidence available										
Health Related Quality of Life											
0	no evidence available										

¹ This is a retrospective case series study with no comparison to surgical excision. ² Not all patients in the study had in-transit melanoma ³Very small numbers of relevant patients in the study and wide ranges in survival times ⁴Event rate not reported

GRADE Table 5.5: Should Amputation be used in patients with in-transit melanoma?

Quality assessment							Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	
Local Control							

0	no evidence available	
Melanoma Specific Survival		
0	no evidence available	
Overall Survival		
0	no evidence available	
Time to next treatment		
0	no evidence available	
Adverse Events		
0	no evidence available	
Health Related Quality of Life		
0	no evidence available	

GRADE Table 5.6: Should cryotherapy be used in patients with in-transit melanoma?

Quality assessment							Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	
Local Control							
0	no evidence available						

Melanoma Specific Survival		
0	no evidence available	
Overall Survival		
0	no evidence available	
Time to next treatment		
0	no evidence available	
Adverse Events		
0	no evidence available	
Health Related Quality of Life		
0	no evidence available	

GRADE Table 5.7: Should Radiotherapy be used in patients with in transit melanoma?

Quality assessment							Summary of findings				Quality
							No of patients		Effect		
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Radiotherapy		Relative (95% CI)	Absolute	
Local Control (Seegenschmiedt et al, 1999)											
1 (n=57; 24 patients with in-transit metastases)	observational studies	serious ¹	no serious inconsistency	serious ²	serious ³	none		No compar ison	44% of stage UICC III patients had a complete response while 21% of stage UICC III patients showed progressive disease	Very Low	
Melanoma Specific Survival											

0	no evidence available										
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Radiotherapy	None	Relative (95% CI)	Absolute	Quality
Overall Survival (Seegenschmiedt et al, 1999)											
1 (n=57; 24 patients with in-transit metastases)	observational studies	serious ¹	no serious inconsistency	serious	serious ³	none		No Comparison	Patients with in-transit metastases* had a median survival of 19 months; 1 year survival was 69±17% and 5 year survival was 32±20%.		Very Low
Time to next treatment											
0	no evidence available										
Adverse Events											
0	no evidence available										
Health Related Quality of Life											
0	no evidence available										

¹This is a retrospective case series study with no comparison to radiotherapy ²The study included patients without in-transit melanoma ³The numbers of patients with in-transit melanoma included in the study was a small proportion of the total patient numbers ⁴Study states that N=33 patients had in-transit metastases and n=24 patients had regional lymph node metastases however the table within the study states n=33 patients had regional lymph node metastases and n=24 patients had in-transit metastases. It is not clear which is the correct number of patients for each.

GRADE Table 5.8: Should Imiquimod be used in patients with in-transit melanoma?

Quality assessment							Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	
Local Control							
0	no evidence available						
Melanoma Specific Survival							
0	no evidence available						

Overall Survival		
0	no evidence available	
Time to next treatment		
0	no evidence available	
Adverse Event		
0	no evidence available	
Health Related Quality of Life		
0	no evidence available	

GRADE Table 5.9: Should Electrochemotherapy be used in patients with in transit melanoma?

Quality assessment							Summary of findings				Quality
							No of patients		Effect		
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Electrochemot herapy	control	Relative (95% CI)	Absolute	
Local Control (Mali et al, 2013)											
22 (150 patients with 920 tumours)	observational studies	serious ¹	serious ²	serious ³	serious	None		No Comparison	A complete response rate of 56.8% and an objective response rate of 80.6% for patients with melanoma who were treated with electrochemotherapy	VERY LOW	
Melanoma Specific Survival - not measured											
0	-	-	-	-	-	None			- -		
Time to next treatment - not measured											
0	-	-	-	-	-	None			-		
Adverse Events - not measured											
0	-	-	-	-	-	None			-		

Health Related Quality of Life - not measured										
0	-	-	-	-	-	None			-	

¹ Studies are not randomised trials, many are retrospective studies and case series with a high risk of bias ² Response to treatment varied widely across the individual studies (0%-100% for complete response) ³ The studies included in the review included patients other than those with in-transit melanoma

GRADE Table 5.10: Should CO2 laser be used in patients with in transit melanoma?

Quality assessment							Summary of findings				Quality
							No of patients		Effect		
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	CO2 laser	control	Relative (95% CI)	Absolute	
Local Control (Hill et al, 1993; Kandamany et al, 2009)											
2 (76 patients with 5059 lesions)	observational studies	serious ¹	no serious inconsistency	serious ²	serious ³	none		No Comparison	Not Pooled	Very Low	
Melanoma Specific Survival - not measured											
0	-	-	-	-	-	none	-	-	-		
Time to next treatment - not measured											
0	-	-	-	-	-	none	-	-	-		
Adverse Events - not measured											
0	-	-	-	-	-	none	-	-	-		
Health Related Quality of Life - not measured											
0	-	-	-	-	-	none	-	-	-		

¹ Non-randomised studies with no comparator and small numbers (n=76 patients total) ² Patients with all stages of Melanoma are included in one of the studies ³ Numbers are too small for precise results to be obtained

GRADE Table 5.11: Should Isolated Limb Perfusion vs. Isolated Limb Infusion be used in Patients with in-transit melanoma?

Quality assessment							Summary of findings				Quality
							No of patients		Effect		
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Isolated Limb Perfusion	Isolated Limb Infusion	Relative (95% CI)	Absolute	
Response Rates (Sharma et al, 2012)											
1 (n=214)	observational studies	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	?/81 ³	?/133 ³	-complete response rate of 44% for patients receiving first time hyperthermic	Very Low	

									isolated limb perfusion (HILP) compared with a complete response rate of 28% for patients undergoing first time isolated limb infusion	
3 Year Recurrence Rate (Sharma et al, 2012)										
1(n=214)	observational studies	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	?/81 ³	?/133 ³	HILP: 65% (95% CI 43-79%) ILI: 85% (95% CI 53-94%).	Very Low
Overall Survival (Sharma et al, 2012)										
1 (n=214)	Observational studies	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	?/81 ³	?/133 ³	In patients achieving complete response, no statistically significant difference in median overall survival between HILP and ILI (100 vs. 39 months)	Low

¹ Retrospective analysis of a prospective database ² Only patients who achieved complete response were evaluated for recurrence resulting in small numbers of patients and events ³ Event rate not reported

1 Evidence Summaries

2 There were a number of interventions of interest in this topic for which no evidence was found including surgical
3 incision, amputation, imiquimod, cryotherapy and immunotherapy. For the remaining interventions the available
4 evidence varied in quantity and quality.

5 Electrochemotherapy

6 One systematic review and meta-analysis investigated the effectiveness of electrochemotherapy in cutaneous or
7 subcutaneous tumours, including melanoma. A total of 22 studies, none of which were randomised trials,
8 reported response rates for melanoma. These studies included all types of melanoma and not just in transit and
9 therefore there are some concerns over the applicability of the data for this topic (Mali et al, 2013). Complete
10 response rate with electrochemotherapy (with either bleomycin or cisplatin) was 56.8% and the objective
11 response rate (CR+PR) was 80.6%.

12 A further two observational studies (Caraco et al, 2013 and Ricotti et al, 2014) reported response rates in
13 patients treated with Electrochemotherapy. Ricotti et al (2014) reported and objective response in 100% of
14 patients (complete response in 20%) while Caraco et al reported and objective response rate of 86.6% for all
15 treated lesions.

16 CO₂ Laser

17 Two observational case series studies reported on the use of CO₂ laser for the treatment of cutaneous and
18 superficial subcutaneous melanoma (Hill et al (1993) and Kandamany et al (2009)). Neither study was
19 comparative and reported only on the survival of patients treated with CO₂ laser with no information on any of
20 the other outcomes of interest.

21 Radiotherapy

22 One retrospective case series investigated the use of radiotherapy for the treatment of melanoma, including 24
23 patients with in-transit melanoma (Seegenschmiedt et al, 1999).

24 A total of 44/57 (77%) patients with stage UICC III melanoma had a local tumour response to radiotherapy with
25 25 complete responses. Five patients showed no change and 8 patients had progressive disease.

26 Patients with in-transit metastases* had a median survival of 19 months; 1 year survival was 69±17% and 5 year
27 survival was 32±20%.

28 *Study states that N=33 patients had in-transit metastases and n=24 patients had regional lymph node
29 metastases however the table within the study states n=33 patients had regional lymph node metastases and
30 n=24 patients had in-transit metastases. It is not clear which is the correct number of patients for each.

31 Surgery

32 One retrospective case series study reported on 33 patients who developed a loco-regional relapse following
33 treatment for primary tumour located on the lower extremity; 21 patients had in-transit metastases (Fotopoulos
34 et al, 1998). Five year disease free survival for the total population was 12% and overall survival was 58%
35 following surgical treatment of metastases.

36 Median disease free survival was reported to be 16 months (1-104 months) and median overall survival was
37 reported to be 31 months (2-264 months).

38 There was a statistically significant difference in median disease free survival for patients undergoing surgery
39 with curative intent compared with those undergoing palliative surgery (p<0.01). In patients who underwent

surgery with curative intent (n=25); median disease free survival was 22 months (4-104 months) and in patients who underwent surgery with palliative intent median disease free survival was 5 months (1-24 months)

There was a statistically significant difference in median overall survival for patients undergoing surgery with curative intent compared with those undergoing palliative surgery ($p<0.02$). In patients who underwent surgery with curative intent; median overall survival was 46 months (5-264 months) and in patients who underwent surgery with palliative intent median overall survival was 17 months (5-45 months).

Hyperthermic Isolated limb perfusion versus Isolated limb infusion

One retrospective case series analysing data from a prospective database reported a complete response rate of 44% (36/81) for patients receiving first time hyperthermic isolated limb perfusion (HILP) compared with a complete response rate of 28% (37/133) for patients undergoing first time isolated limb infusion. Partial response rates were 9% (7/81) for HILP and 13% (17/133) for ILI and stable disease was reported in 11% for both HILP (9/81) and ILI (15/133) (Sharma et al: 2012).

In patients recording a complete response to initial treatment, the recurrence rate at 3 year follow up for HILP was 65% (95% CI 43-79%) compared with 85% (95% CI 53-94%). The in-field recurrence rate was 41% (95% CI 16-58%) for HILP compared with 56% (95% CI 30-72%) for ILI. Outfield recurrence rate was 44% (95% CI 23-60%) for HILP compared with 77% (95% CI 51%-89%) for ILI.

The median time to first recurrence was significantly longer in the HILP group compared with the ILI group (23 months versus 8 months, $p=0.02$). Median time to out of field recurrence was significantly longer in the HILP arm (42 versus 14 months, $p=0.02$) but there was no statistically significant difference in the time to in field recurrence between the two groups (46 versus 25 months, $p=0.15$).

Median survival time was longer in the HILP group, though this did not achieve statistical significance (100 versus 39, $p=0.010$).

1 **References**

2 *Included Studies*

- 3 Caraco, C., et al (2013) Long-lasting response to electrochemotherapy in melanoma patients with cutaneous
4 metastasis. *Bmc Cancer* 13..
- 5 Fotopoulos P et al (1998) Prognosis after surgical treatment of loco-regional recurrences from malignant
6 melanoma located to the lower extremities *Regional Cancer Treatment* 9;4:227-230
- 7 Kandamany N. et al (2009) Carbon dioxide laser ablation as first line management of in transit cutaneous
8 malignant melanoma metastases *Lasers in Medical Science* 24;3:411-414
- 9 Hill S. Et al (1993) Treatment of cutaneous metastases from malignant melanoma using the carbon dioxide laser
10 *European Journal of Surgical Oncology* 19;173-177
- 11 Mali et al (2013) Antitumour effectiveness of electrochemotherapy: A systematic review and meta-analysis
12 *European Journal of Surgical Oncology* 39; 4-16
- 13 Ricotti, F., et al (2014) Electrochemotherapy: an effective local treatment of cutaneous and subcutaneous
14 melanoma metastases. *Dermatologic Therapy* 27;3:148-152
- 15 Seegenschmiedt M et al (1999) Palliative radiotherapy for recurrent and metastatic malignant melanoma:
16 prognostic factors for tumour response and long-term outcome: A 20 year experience *International Journal of*
17 *Radiation Oncology, Biology Physics* 44:3;607-618
- 18 Sharma K et al (2012) Patterns of recurrence following complete response to regional chemotherapy for in transit
19 melanoma *Annals of Surgical Oncology* 19;8:2563-2571

20 *Excluded Studies*

- 21 Alexander, H. R., (2010) Analysis of factors influencing outcome in patients with in-transit malignant melanoma
22 undergoing isolated limb perfusion using modern treatment parameters. *Journal of Clinical Oncology* 28;1:114-
23 118.
- 24 Reason: No Comparator
- 25 Alexander, H. R., Fraker, D. L., and Bartlett, D. L. (1996) Isolated limb perfusion for malignant melanoma.
26 *Seminars in Surgical Oncology* 12;6: 416-428.
- 27 Reason: Expert Review
- 28 Allen, B. J., et al (2011). Analysis of patient survival in a Phase I trial of systemic targeted alpha-therapy for
29 metastatic melanoma. *Immunotherapy* 3;9:1041-1050.
- 30 Check relevance
- 31 Algazi, A. P. S. (2010) Treatment of cutaneous melanoma: Current approaches and future prospects. *Cancer*
32 *Management and Research* 2;1:197-211.
- 33 Reason: Expert Review
- 34 Aloia, T. A., et al (2005) Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor
35 response. *Archives of Surgery* 140;11:1115-1120.
- 36 Reason: No comparator/Included in systematic review

- 1 Andersson, A. Pet al (1992). [Hyperthermic regional perfusion in malignant melanoma of an extremity]. [Review]
2 [30 refs] [Danish]. *Ugeskrift for Laeger* 154;41:2815-2819.
3 Reason: Expert Review
- 4 Ariyan, S., et al (1998). Safety and efficacy of isolated perfusion of extremities for recurrent tumor in elderly
5 patients. *Surgery* 123;3:335-343.
6 Reason: No Comparator
- 7 Ariyan, S., et al (1997). Regional isolated perfusion of extremities for melanoma: a 20-year experience with drugs
8 other than L-phenylalanine mustard. *Plastic & Reconstructive Surgery* 99;4:1023-1029.
9 Reason: No Comparator
- 10 Augustine, C. K., et al (2010). Gene expression signatures as a guide to treatment strategies for in-transit
11 metastatic melanoma. *Molecular Cancer Therapeutics* 9;4:779-790.
12 Reason: Not relevant to PICO
- 13 Bagge, R. O., Mattsson, J., and Hafstrom, L. Regional hyperthermic perfusion with melphalan after surgery for
14 recurrent malignant melanoma of the extremities - Long-term follow-up of a randomised trial. *International*
15 *Journal of Hyperthermia* 30[5], 295-298. 2014.
- 16 Barbour, A. P., et al (2009) Isolated limb infusion for malignant melanoma: predictors of response and outcome.
17 *Annals of Surgical Oncology* 16;12:3463-3472.
18 Reason: Not relevant to PICO
- 19 Bartlett, D. L., et al (1997) . Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with
20 extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. *Cancer* 80;11: 2084-2090.
21 Reason: No comparator
- 22 Beasley, G. M., et al (2008) Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-
23 tolerated but less effective alternative to hyperthermic isolated limb perfusion. *Annals of Surgical Oncology*
24 15;8:2195-2205.
25 Reason No comparison
- 26 Beasley, G. M. and Tyler, D. S. (2011) Treatment of in-transit melanoma: an opportunity to discover critical
27 knowledge. *Oncology* (Williston.Park) 25;14:1351-2, 1355
28 Reason: Expert Review
- 29 Beasley, G. M., et al (2011) Prospective Multicenter Phase II Trial of Systemic ADH-1 in Combination With
30 Melphalan via Isolated Limb Infusion in Patients With Advanced Extremity Melanoma. *Journal of Clinical*
31 *Oncology* 29;9:1210-1215.
32 Reason: Not relevant to PICO
- 33 Beasley, G. M., et al (2009) A multi-institutional experience of isolated limb infusion: defining response and
34 toxicity in the US. *Journal of the American College of Surgeons* 208;5:706-715.
35 Reason: No Comparator
- 36 Beasley, G. M et al (2009) A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb
37 infusion in patients with locally advanced in-transit malignant melanoma. *Cancer* 115;20: 4766-4774.
38 Reason: Not relevant to PICO

- 1 Beasley, G. M., et al (2012). A phase I multi-institutional study of systemic sorafenib in conjunction with regional
2 melphalan for in-transit melanoma of the extremity. *Annals of Surgical Oncology* 19;12:3896-3905.
3 Reason: Not relevant to PICO
- 4 Belli, F., et al (1992). Treatment of recurrent in transit metastases from cutaneous melanoma by isolation
5 perfusion in extracorporeal circulation with interleukin-2 and lymphokine activated killer cells. A pilot study.
6 *Melanoma Research* 2;4:263-271.
7 N=6/No comparator
- 8 Bigault, O. (2009) Post-operative radiation therapy in the adjuvant setting to assess local control for in-transit
9 melanoma. *Journal of Medical Imaging and Radiation Oncology Conference*[var.pagings]
10 Reason: Abstract Only
- 11 Boesch, C. E., et al (2010) Long-term outcome of hyperthermic isolated limb perfusion (HILP) in the treatment of
12 locoregionally metastasised malignant melanoma of the extremities. *International Journal of Hyperthermia*
13 26;1:16-20.
14 Reason: No comparator
- 15 Bonerandi, J. J. and Bonerandi, J. J. (1995) [After excision of primary melanoma should an initial evaluation be
16 performed? Point of view of a French dermatologist]. [Review] [36 refs] [French]. *Annales de Dermatologie et de*
17 *Venereologie* 122;5:289-291.
18 Reason: Expert Review
- 19 Bong, A. B. B. (2002) Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases
20 of malignant melanoma. *Dermatology* (Basel, Switzerland) 205;2:135-138.
21 Reason: No comparator
- 22 Boyd, K. U., Wehrli, et al (2011) Intra-lesional interleukin-2 for the treatment of in-transit melanoma. *Journal of*
23 *Surgical Oncology* 104;7:711-717.
24 Reason: Intervention not relevant to PICO
- 25 Brown, C. D. Z. (1995) The prognosis and treatment of true local cutaneous recurrent malignant melanoma.
26 *Dermatologic Surgery* 21;4:285-290. 1995.
27 Reason: Not relevant to PICO
- 28 Burmeister, B. H., et al (2012) Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node
29 field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. *The Lancet Oncology*
30 13;6:589-597.
31 Reason: Population not relevant to PICO
- 32 Buzaid, A. C et al (1998) Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with
33 local-regional metastases. *Melanoma Research* 8;6: 549-556.
34 Reason: Not relevant to PICO
- 35 Buzaid, A. et al (1994) Pilot study of preoperative chemotherapy with cisplatin, vinblastine, and dacarbazine in
36 patients with local-regional recurrence of melanoma. *Cancer* 74;9: 2476-2482.
37 Reason: Not relevant to PICO
- 38 Damian, D. L., Saw, R. P. M., and Thompson, J. F. Topical Immunotherapy with Diphencyprone for in Transit and
39 Cutaneously Metastatic Melanoma. *Journal of Surgical Oncology* 109[4], 308-313. 2014.

- 1 Campana, L. and Chiarion-Sileni, V. (2013) Case-matched series of electrochemotherapy versus isolated limb
2 perfusion in extremity melanoma. *JDDG - Journal of the German Society of Dermatology Conference*[var.pagings]
3 Reason: Abstract Only
- 4 Campana, L. G. P. (2010) Electrochemotherapy: Clinical outcome and predictive factors from a single institution
5 experience on 50 melanoma patients. *Annals of Surgical Oncology Conference*[var.pagings],
6 Reason: Abstract Only
- 7 Casara, D., et al (2007) Real-time monitoring during TNF isolated limb perfusion followed by systemic low-dose
8 interferon therapy in patients with in-transit melanoma metastases. *European Journal of Nuclear Medicine and*
9 *Molecular Imaging* 34;S188.
10 Reason: Not relevant to PICO
- 11 Cashin, R. P., et al (2008) Advanced cutaneous malignant melanoma: a systematic review of economic and
12 quality-of-life studies. [Review] [33 refs]. *Value in Health* 11;2:259-271.
13 Reason: Not relevant to PICO
- 14 Cascinelli, N., et al (1986) Regional non-nodal metastases of cutaneous melanoma. *European Journal of Surgical*
15 *Oncology* 12;2: 175-180.
16 Reason: Not relevant to PICO
- 17 Couture, J. and Couture, J.(1982) Melanoma: the management of local recurrence and in-transit metastasis.
18 *Canadian Journal of Surgery* 25[6], 698-700.
19 Reason: Expert Review
- 20 Cascinelli, N., et al (1998). Immediate or delayed dissection of regional nodes in patients with melanoma of the
21 trunk: a randomised trial. WHO Melanoma Programme. *Lancet* 351;9105:793-796.
22 Reason: Population not relevant to PICO
- 23 Cavaliere, R., et al (1992) Hyperthermic antitlastic perfusion in the treatment of local recurrence or "in-transit"
24 metastases of limb melanoma. [Review] [35 refs]. *Seminars in Surgical Oncology* 8;6:374-380.
25 Reason: Expert Review
- 26 Cavalcanti, A. (2007) Carcinological results of perfusions of isolates members under extracorporeal circulation
27 (PMI-CEC) for metastase treatment in transit of melanomas. *Bulletin du Cancer* 94;6:525.
28 Reason: Abstract Only
- 29 Cavalcanti, A et al (2013) One hundred fifty six isolated limb perfusion (ILP) in melanoma patients with in-transit
30 metastases. *Journal der Deutschen Dermatologischen Gesellschaft* 11, 57.
31 Reason: Abstract Only
- 32 Cemazar, M. Todorovic, V. (2011) The effect of electrochemotherapy on metastatic potential of human
33 melanoma cells SK-Mel28. *Cancer Research Conference*[var.pagings].
34 Reason: Not relevant to PICO
- 35 Chai, C. Y., et al (2012) A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma
36 of extremities. *Annals of Surgical Oncology* 19;5:637-1643.
37 Reason: Not relevant to PICO (treatment sequences)
- 38 Chakera, A. H., et al (2008) In-transit sentinel nodes must be found: implication from a 10-year follow-up study in
39 melanoma. *Melanoma Research* 18;5:359-364.
40 Reason: Not relevant to PICO

- 1 Chan, L. K. W. and Quaba, A. A. (2012) Improving the quality of life in Melanoma - The role of the CO2 laser.
2 *Journal of Cosmetic and Laser Therapy* 14;1:43-47.
3 Reason: Expert Review
- 4 Chin-Lenn, L., Temple-Oberle, C., and McKinnon, J (2013). Isolated Limb Infusion for Melanoma In-Transit
5 Metastases: Experience at Two Canadian Centres. *Annals of Surgical Oncology* 20;S93-S94.
6 Reason: No data
- 7 Chun, J. Y., et al (2011). Technique and outcomes of isolated limb infusion for locally advanced malignant
8 melanoma--a radiological perspective. *Clinical Radiology* 66;12:1175-1180.
9 Reason: N=11 & no comparator
- 10 Clemente-Ruiz de, Almiron A., et al (2012) [Risk factors for in-transit metastasis in patients with cutaneous
11 melanoma]. [Spanish]. *Actas Dermo-Sifiliograficas* 103;3:207-213.
12 Reason: Not relevant to PICO
- 13 Coleman, A., et al (2009) Optimizing regional infusion treatment strategies for melanoma of the extremities.
14 *Expert Review of Anticancer Therapy* 9;11:1599-1609.
15 Reason: Expert Review
- 16 Colombo, G. Et al (2010) Electrochemotherapy. European Surgical Research Conference[var.pagings], 236.
17 Reason: Expert Review
- 18 Cornett, W. R., et al (2007). Is there any reason to delay introduction of tumor necrosis factor in the management
19 of in transit metastasis of unresectable melanoma? Reply. *Journal of Clinical Oncology* 25;9:1149-1151.
20 Reason: Comment
- 21 Cornett, W. R., et al (2006) Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan
22 alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group trial
23 Z0020. *Journal of Clinical Oncology* 24;25: 4196-4201.
24 Reason: Comparison not relevant to PICO
- 25 Da Ponte, P. F. F. (2009) Isolated limb perfusion for melanoma in-transit metastases: A single center experience.
26 *Skin Cancer* 24;3:91-101.
27 Reason: Not relevant to PICO
- 28 Davar, D., Tarhini et al (2013) Adjuvant immunotherapy of melanoma and development of new approaches using
29 the neoadjuvant approach.[Erratum appears in Clin Dermatol. 2013 Jul-Aug;31(4):501]. *Clinics in Dermatology*
30 31;3:237-250.
31 Reason: Expert Review
- 32 De Cian, F., et al (1996) Conventional isolated hyperthermic antitlastic perfusion in the treatment of recurrent
33 limb melanoma. *Anticancer Research* 16;4A:2017-2024.
34 Reason: No comparator/n=20 relevant patients
- 35 De Cian, F., et al (1994) [Isolated hyperthermic antitlastic perfusion in recurrent melanoma of the extremities].
36 [Italian]. *Minerva Chirurgica* 49;7-8: 681-691.
37 Reason: N=14 relevant patients
- 38 Defty, C. L. and Marsden, J. R. (2012) Melphalan in regional chemotherapy for locally recurrent metastatic
39 melanoma. *Current Topics in Medicinal Chemistry* 12;1:53-60.
40 Reason: Expert Review

- 1 Dehesa, L. A., V. (2009) Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis
2 with intralesional interleukin-2. *Actas Dermo-Sifiliograficas* 100;7:571-585.
3 Reason: N=7
- 4 Deroose, J. P., et al (2012) 20 years experience of TNF-based isolated limb perfusion for in-transit melanoma
5 metastases: TNF dose matters. *Annals of Surgical Oncology* 19;2:627-635.
6 Reason: No comparator
- 7 Deroose, J. P., et al (2011) Long-term outcome of isolated limb perfusion with tumour necrosis factor- for
8 patients with melanoma in-transit metastases. *British Journal of Surgery* 98;11:1573-1580.
9 Reason: No comparator
- 10 Deroose, J. P., et al (2011) Isolated limb perfusion for melanoma in-transit metastases: developments in recent
11 years and the role of tumor necrosis factor alpha. [Review]. *Current Opinion in Oncology* 23[2], 183-188.
12 Reason: Expert Review
- 13 Desmedt, E., et al (2009) [Detection of melanoma relapse: a retrospective study of 100 patients]. [French].
14 *Annales de Dermatologie et de Venereologie* 136;11:767-771.
15 Reason: Not relevant to PICO
- 16 Dewar, D. J. and Powell, B. W. E. M.(2003) Sentinel node biopsy in patients with in-transit recurrence of
17 malignant melanoma. *British Journal of Plastic Surgery* 56;4:415-417.
18 Reason: Case Reports
- 19 Di Filippo, F., (2003) [Anti-blastic hyperthermic perfusion in the treatment of melanoma of the extremities in the
20 loco-regional diffusion phase]. [Italian]. *Tumori* 89;4 Suppl:241-243.
21 Check relevance/data
- 22 Di Filippo, F. (2009) Prognostic factors influencing tumor response, locoregional control and survival, in
23 melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb
24 perfusion. *In Vivo* 23;2:347-352.
25 Reason: No comparator
- 26 Di Filippo, F., et al (2006) Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit
27 melanoma metastasis. *In Vivo* 20;6A:739-742.
28 Reason: No comparator/Poor Data
- 29 Dubois, R. W et al (2001) Developing indications for the use of sentinel lymph node biopsy and adjuvant high-
30 dose interferon alfa-2b in melanoma. [Review] [30 refs]. *Archives of Dermatology* 137;9:1217-1224.
31 Reason: Expert Review
- 32 Eggermont, A. M. M., et al (2008) The Rotterdam experience difficult surgical cases: isolated limb perfusions with
33 TNF-alpha and melphalan in melanoma patients with multiple in transit metastases. *Pigment Cell & Melanoma*
34 *Research* 21;2:277.
35 Reason: Abstract Only
- 36 Eggermont, A. M., et al (2003). The role of isolated limb perfusion for melanoma confined to the extremities.
37 [Review] [81 refs]. *Surgical Clinics of North America* 83;2:371-384
38 Reason: Expert Review
- 39 Eggermont, A. M. M.(2003) Current uses of isolated limb perfusion in the clinic and a model system for new
40 strategies. *Lancet Oncology* 4;7:429-437.
41 Reason:Expert Review

- 1 Eggermont, A. M. and Eggermont, A. M. (1996) Treatment of melanoma in-transit metastases confined to the
2 limb. [Review] [65 refs]. *Cancer Surveys* 26;335-349.
3 Reason: Expert Review
- 4 Eroglu, A. (1999) Isolated limb perfusion with cisplatin in malignant melanoma: Turkish experience. *Journal of B*
5 *U.ON.* 4;2:137-142.
6 Reason: N=14 relevant patients (group 2)
- 7 Elias, E. G. S. (2013) Consequential administration of intralesional (intratumoral) GM-CSF and IL-2 in the
8 management of metastatic and primary invasive cutaneous melanoma. *Journal of Clinical Oncology*
9 Conference[*var.pagings*].
10 Reason: Not relevant to PICO
- 11 Eton, O et al (1999). Pilot study of intra-arterial cisplatin and intravenous vinblastine and dacarbazine in patients
12 with melanoma in-transit metastases. *Melanoma Research* 9;5:483-489
13 Reason: Comparison not relevant to PICO
- 14 Farre Alegre, D. R. D. (2012) Regional treatment of locally advanced melanoma and soft tissue sarcomas of the
15 extremities with isolated limb perfusion in hyperthermic conditions with alfa-tumour necrotic factor and
16 mephalan-Our experience in eleven years. *European Journal of Surgical Oncology Conference*[*var.pagings*], 772.
17 Reason: Abstract Only
- 18 Farricha, V., V.(2010) Electrochemotherapy: A technique for multiple approaches in the treatment of locally
19 advanced melanoma. *Melanoma Research Conference*[*var.pagings*],
20 Reason: No data
- 21 Feldman, A. L., et al (1999) Management of extremity recurrences after complete responses to isolated limb
22 perfusion in patients with melanoma. *Annals of Surgical Oncology* 6;6:562-567.
23 Reason: Outcomes not relevant to PICO
- 24 Fox, M. C., et al (2013) Management options for metastatic melanoma in the era of novel therapies: a primer for
25 the practicing dermatologist: part I: Management of stage III disease. *Journal of the American Academy of*
26 *Dermatology* 68;1:1-9.
27 Reason: No data
- 28 Fraker, D. L. and Fraker, Douglas L.(2004) Management of in-transit melanoma of the extremity with isolated
29 limb perfusion. [Review] [35 refs]. *Current Treatment Options in Oncology* 5;3:173-184
30 Reason: Expert Review
- 31 Fraker, D. L., et al (1996). Treatment of patients with melanoma of the extremity using hyperthermic isolated
32 limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor
33 dose-escalation study. *Journal of Clinical Oncology* 14;2:479-489.
34 Reason: Comparison not relevant to PICO
- 35 Fraker, D. L.(1997) Surgical issues in the management of melanoma. *Current Opinion in Oncology* 9;2:183-188.
36 Reason: Expert Review
- 37 Furukawa, H. (2012) Tailored excision of in-transit metastatic melanoma based on indocyanine green
38 fluorescence lymphography. *European Journal of Plastic Surgery* 35;4:329-332.
39 Reason: No data
- 40 Garioch, J. and Moncrieff, M. (2013) Topical Diphencyprone for the Treatment of in Transit Melanoma
41 Metastases of the Skin: Experience of a Single UK Skin Cancer Centre. *Journal der Deutschen Dermatologischen*
Melanoma: DRAFT evidence review (January 2015)

- 1 *Gesellschaft* 11:65-66.
- 2 Reason: No data
- 3 Garcia, E. D. S. (1999) Treatment of malignant melanoma. *Annals of Pharmacotherapy* 33;6:730-738.
- 4 Reason: Expert Review
- 5 Garbe, C. Isolated limb perfusion of metastatic malignant melanoma of the extremity worthwhile? *European*
- 6 *Journal of Cancer* 32A;10:1635-1638.Reason: Expert Review
- 7 Garrido-Laguna, I., Ponz, M., and Espinos, J. (2007) Is there any reason to delay introduction of tumor necrosis
- 8 factor in the management of in transit metastasis of unresectable melanoma? *Journal of Clinical Oncology*
- 9 25;9:1149.
- 10 Reason: Abstract Only
- 11 Gattuso, J. M., Waters, R., and Thomas, J. M. (1990) A Preliminary-Report of Treatment for In-Transit Metastatic
- 12 Melanoma with A Carbon-Dioxide Laser. *British Journal of Cancer* 61;1:158.
- 13 Reason: Abstract Only
- 14 Gaudy, C., et al (2006) Randomized controlled study of electrochemotherapy in the local treatment of skin
- 15 metastases of melanoma. *Journal of Cutaneous Medicine & Surgery* 10;3:115-121.
- 16 Reason: In systematic review
- 17 Geere, S. L. B. (2012) Management of loco-regionally recurrent melanoma. *Cancer Forum* 36;3
- 18 Reason: Expert Review
- 19 Gerlini, G., et al (2013). Dendritic cells recruitment in melanoma metastasis treated by electrochemotherapy.
- 20 *Clinical & Experimental Metastasis* 30;1:37-45.
- 21 Reason: Not relevant to PICO
- 22 Gimbel, M. I., (2008) Therapy for unresectable recurrent and in-transit extremity melanoma. [Review] [83 refs].
- 23 *Cancer Control* 15;3:225-232.
- 24 Reason: Expert Review
- 25 Gohl, J., et al (2009). [Malignant melanoma]. [German]. *Chirurg* 80;6:559-567.
- 26 Reason: No data
- 27 Green, D. S., et al (2008) Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and
- 28 restore the Th1/Th2 balance in patients with metastatic melanoma. *British Journal of Dermatology* 159;3:606-
- 29 614.
- 30 Reason: Outcomes not relevant to PICO
- 31 Grotz, T. E., et al (2011) In-transit melanoma: an individualized approach. *Oncology* (Williston.Park) 25;14:1340-
- 32 1348.
- 33 Reason: No data
- 34 Grubbs, E. G., (2004) In-transit melanoma: The role of alkylating-agent resistance in regional therapy. *Journal of*
- 35 *the American College of Surgeons* 199;3:419-427.
- 36 Reason: Not relevant to PICO
- 37 Grunhagen, D. J., et al (2005) Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and
- 38 melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. *Annals of*
- 39 *Surgical Oncology* 12;8:609-615.
- 40 Reason: No comparator

- 1 Grunhagen, D. J., et al (2004) One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in
2 melanoma patients with multiple in-transit metastases. *Annals of Surgery* 240;6:939-947.
3 Reason: No comparator
- 4 Grunhagen, D. J., et al (2006) The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in
5 patients with metastatic sarcoma and melanoma. *Cancer* 106;1:156-162
6 Reason: Population not relevant to PICO
- 7 Grunhagen, D. J., et al (2006) Isolated limb perfusion for melanoma patients--a review of its indications and the
8 role of tumour necrosis factor-alpha. [Review] [108 refs]. *European Journal of Surgical Oncology* 32;4:371-380.
9 Reason: Expert Review
- 10 Guida, M.(2009) Electrochemotherapy (ECT) for the treatment of superficial tumor localizations. *Journal of Clinical*
11 *Oncology Conference*[var.pagings], e13526.
12 Reason: Population not relevant to PICO
- 13 Hallock, A., et al (2011) Is radiotherapy an effective treatment option for recurrent metastatic malignant
14 melanoma? A case report of short-course, large-fraction radiation and a literature review. *Canadian Journal of*
15 *Plastic Surgery* 19;4:153-155.
16 Reason: Single Case
- 17 Han, D., et al (2011). Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb
18 infusion and percutaneous hepatic perfusion. *Expert Opinion on Drug Metabolism and Toxicology* 7;11:1383-
19 1394.
20 Reason: Expert Review
- 21 Hauschild, A. (2001) Safety margins for the primary surgical excision of malignant melanoma. Proposals based on
22 controlled clinical trials. *Hautarzt* 52;11:1003-1010.
23 Reason: Expert Review
- 24 Hayes, A. J., et al (2007) Meirion. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for
25 advanced melanoma and soft-tissue sarcoma. *Annals of Surgical Oncology* 14;1:230-238.
26 Reason: Not relevant to PICO
- 27 Hayes, A. J., et al (2004). Management of in-transit metastases from cutaneous malignant melanoma. *British*
28 *Journal of Surgery* 91;6: 673-682.
29 Reason: Expert Review
- 30 Hoekstra, H. J. and Hoekstra, H. J. (2008) The European approach to in-transit melanoma lesions. [Review] [58
31 refs]. *International Journal of Hyperthermia* 24;3:227-237.
32 Reason: Expert Review
- 33 Hohenberger, W., et al (1994) [Extremity perfusion in malignant melanoma]. [Review] [31 refs] [German]. *Chirurg*
34 65;3:175-185.
35 Reason: Expert Review
- 36 Hohenberger, W., Meyer, T., and Gohl, J.(1994) Isolation Perfusion in Malignant-Melanoma. *Chirurg* 65;3:175-
37 185.
38 Reason: Expert Review
- 39 Hoekstra, H. J., et al (1993) Toxicity of hyperthermic isolated limb perfusion with cisplatin for recurrent
40 melanoma of the lower extremity after previous perfusion treatment. *Cancer* 72;4:1224-1229.
41 Reason: Not relevant to PICO

- 1 Hsueh, E. C., et al (1999) Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with
2 in-transit melanoma metastases. *Cancer* 85;10:2160-2169..
3 Reason: Intervention not relevant to PICO
- 4 Isolated Limb Perfusion and Isolated Limb Infusion for Malignant Lesions of the Extremities. *Current Problems in*
5 *Surgery* 48;6:371-430.2011
6 Reason: No data
- 7 Jiang, B. S., Beasley, G. M., Speicher, P. J., Mosca, P. J., Morse, M. A., Hanks, B., Salama, A., and Tyler, D. S.
8 Immunotherapy Following Regional Chemotherapy Treatment of Advanced Extremity Melanoma. *Annals of*
9 *Surgical Oncology* 21[8], 2525-2531. 2014.
- 10 Jones, R. F., et al (1972). Total integumentectomy of the leg for multiple in-transit metastases of melanoma.
11 *American Journal of Surgery* 123;5:588-590.
12 Reason: No dataJose
- 13 Kam, P. C. A. and Thompson, J. F. (2010) Isolated limb infusion with melphalan and actinomycin D in melanoma
14 patients: factors predictive of acute regional toxicity. *Expert Opinion On Drug Metabolism & Toxicology* 6;9:1039-
15 1045.
16 Reason: Expert Review
- 17 Kandamany, N. and Mahaffey, P. (2008) Carbon dioxide laser ablation for the management of in-transit
18 cutaneous malignant melanoma metastases. *Journal of Plastic Reconstructive and Aesthetic Surgery* 61;9:1111-
19 1113.
20 Reason: Expert Review
- 21 Kang, J. C., et al (2005) lymphadenectomy does not increase the incidence of in-transit metastases in primary
22 melanoma. *Journal of Clinical Oncology* 23;21:4764-4770.
23 Reason: Not relevant to PICO
- 24 Karakousis, C. P., et al (1997). Tourniquet infusion chemotherapy for extremity in-transit lesions in malignant
25 melanoma. *Annals of Surgical Oncology* 4;6:506-510.
26 Reason: Not relevant to PICO (dose comparison)
- 27 Keilholz, U., et al (2005). Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic
28 melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of
29 Cancer Melanoma Group. *Journal of Clinical Oncology* 23;27:6747-6755.
30 Reason: Not relevant to PICO
- 31 Kidner, T. B., et al (2012). Combined intralesional Bacille Calmette-Guerin (BCG) and topical imiquimod for in-
32 transit melanoma. *Journal of Immunotherapy* 35;9:716-720.
33 Reason: Intervention not relevant to PICO
- 34 Kirov, K. (2011) Electro-immunotherapy with BCG of superficial in-transit melanoma metastases. *Melanoma*
35 *Research Conference*[var.pagings],
36 Reason: Not relevant to PICO
- 37 Kofler, R. et al (1994) Late metastasis of malignant cutaneous melanoma. *Der Hautarzt; Zeitschrift fur*
38 *Dermatologie, Venerologie, und verwandte Gebiete* 45;3:145-148.
39 Reason: N=3
- 40 Koops, H. S., et al (1998) Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a
41 multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant
Melanoma: DRAFT evidence review (January 2015)

- 1 Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and
2 the North American Perfusion Group Southwest Oncology Group-8593. *Journal of Clinical Oncology* 16;9:2906-
3 2912.
4 Reason: Not relevant to PICO (Population)
- 5 Krementz, E. T. and Krementz, E. T. (1986) Lucy Wortham James lecture. Regional perfusion. Current
6 sophistication, what next? *Cancer* 57;3:416-432.
7 Reason: Expert Review
- 8 Kretschmer, L., et al (2005) lymphonodectomy does not increase the risk of loco-regional cutaneous metastases
9 of malignant melanomas. *European Journal of Cancer* 41;4:531-538.
10 Reason: Not relevant to PICO
- 11 Kretschmer, L et al (2005) High incidence of in-transit metastases after sentinel node biopsy in patients with
12 melanoma (Br F Surg 2004; 91 : 1370-1371). *British Journal of Surgery* 92;2:253-254.
13 Reason: Not relevant to PICO
- 14 Kretschmer, L., et al (2002) Locoregional cutaneous metastasis in patients with therapeutic lymph node
15 dissection for malignant melanoma: risk factors and prognostic impact. *Melanoma Research* 12;5: 499-504.
16 Reason: Not relevant to PICO
- 17 Kretschmer, L., et al (2006) Factors predicting the risk of in-transit recurrence after sentinel lymphonodectomy in
18 patients with cutaneous malignant melanoma. *Annals of Surgical Oncology* 13;8:1105-1112.
19 Reason: Not relevant to PICO
- 20 Kroon, H. M., Moncrieff, M., Kam, P. C. A., and Thompson, J. F.(2008) Outcomes Following Isolated Limb Infusion
21 for Melanoma. A 14-Year Experience. *Annals of Surgical Oncology* 15;11:3003-3013.
22 Reason: No Comparator
- 23 Kroon, H. M. and Thompson, J. F. (2009) Isolated Limb Infusion: A Review. *Journal of Surgical Oncology*
24 100;2:169-177.
25 Reason: Expert Review
- 26 Kroon, B. B. R., et al (2008) Isolated limb perfusion for melanoma. *Surgical Oncology Clinics of North America*
27 17;4:785
28 Reason: No data
- 29 Kroon, H. M. (2009) Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and
30 actinomycin D in melanoma patients. *Annals of Surgical Oncology* 16;5:1184-1192.
31 Reason: No comparator
- 32 Kroon, H. M., Huismans, A. M., Kam, P. C. A., and Thompson, J. F. Isolated Limb Infusion with Melphalan and
33 Actinomycin D for Melanoma: A Systematic Review. *Journal of Surgical Oncology* 109[4], 348-351. 2014.
- 34 Kruijff, S. (2011) Salvage surgery for a giant melanoma on the back. *Rare Tumors* 3;3:90-91.
35 Reason: Single Case
- 36 Lasithiotakis, K., et al (2010) Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue
37 sarcomas: feasibility and reproducibility in a multi-institutional Hellenic collaborative study. *Oncology Reports*
38 23;4:1077-1083.
39 Reason: No Comparator

- 1 Leiter, U., et al (2010) Sentinel lymph node dissection in primary melanoma reduces subsequent regional lymph
2 node metastasis as well as distant metastasis after nodal involvement. *Annals of Surgical Oncology* 17;1:129-137
3 Reason: Not relevant to PICO
- 4 Lejeune, F. J., et al (1977). Hyperthermic isolation-perfusion with melphalan, a preliminary appraisal of local and
5 general effects in malignant melanoma. *Tumori* 63;3:289-298.
6 Reason: N=4 relevant patients
- 7 Lejeune, F. J., et al (1983) Objective regression of unexcised melanoma in-transit metastases after hyperthermic
8 isolation perfusion of the limbs with melphalan. *Recent Results in Cancer Research* 86:268-276.
9 Reason: No comparator
- 10 Lejeune, F. J., et al (1998). Clinical applications of TNF-alpha in cancer. [Review] [42 refs]. *Current Opinion in*
11 *Immunology* 10;5:573-580.
12 Reason: Expert Review
- 13 Lejeune, F. J., et al (1980). Efficacy of Isolation-Perfusion of the Limbs with Phenyl Alanin Mustard and
14 Hyperthermia on in Transit Metastasis of Malignant-Melanoma. *European Surgical Research* 12, 120-121
15 Reason: No data
- 16 Lejeune, F. J. et al (2000) Treatment of in-transit metastases of melanoma by isolated limb perfusion. *Oncologie*
17 2;1:85-89.
18 Expert Review
- 19 Lejeune, F. J. L. Et al (1994) Clinical experience with high-dose tumor necrosis factor alpha in regional therapy of
20 advanced melanoma. *Circulatory Shock* 43;4:191-197.
21 Reason: Not relevant to PICO
- 22 Lidsky, M. E., (2013) Predicting disease progression after regional therapy for in-transit melanoma. *JAMA Surgery*
23 148;6:493-498.
24 Reason: Not relevant to PICO
- 25 Lienard, D., et al (1992) In transit metastases of malignant melanoma treated by high dose rTNF alpha in
26 combination with interferon-gamma and melphalan in isolation perfusion. *World Journal of Surgery* 16;2:234-
27 240.
28 Reason: No comparator
- 29 Lienard, D., et al (1993) High-Dose of Rtnf-Alpha, Rifn-Gamma and Melphalan in Isolation Perfusion Produce 90-
30 Percent Complete Response in Melanoma in Transit Metastases. Tumor Necrosis Factor : *Molecular and Cellular*
31 *Biology and Clinical Relevance* , 233-238.
- 32 Lienard, D., et al (1994) Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha),
33 interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study.
34 *Melanoma Research* ; Suppl 1
35 Reason: Not relevant to PICO
- 36 Lienard, D., et al (1999) Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or
37 without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized
38 phase II study. *Melanoma Research* 9;5: 491-502.
39 Check relevance of comparison

- 1 Lienard, D., et al (1998) Isolated limb perfusion in primary and recurrent melanoma: indications and results.
2 *Seminars in Surgical Oncology* 14;3:202-209
3 Reason: No comparator
- 4 Lienard, D., et al (1992). High-dose recombinant tumor necrosis factor alpha in combination with interferon
5 gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. *Journal of Clinical*
6 *Oncology* 10;1:52-60.
7 Reason: Population not relevant to PICO
- 8 Lukacs, L. and Lukacs, L. (1992) Loco-regional renewal of malignant melanomas. I. Local recurrence satellites and
9 in-transit nodes. *Acta Chirurgica Hungarica* 33;3-4: 325-334.
10 Reason: Not relevant to PICO
- 11 Lyo, V., et al (2012) In-Transit Intramammary Sentinel Lymph Nodes From Malignant Melanoma of the Trunk.
12 *Annals of Surgery* 255;1: 122-127.
13 Reason: Not relevant to PICO
- 14 Marsden, J. (2010) Management of in-transit limb metastases in melanoma: State of the art. Melanoma Research
15 Conference[*var.pagings*],
16 Reason: No data
- 17 Martin-Algarra, S.(2004) Isolated hyperthermic limb perfusion in melanoma. *Skin Cancer* 19[4], 245-260.
18 Reason: Expert Review
- 19 Martiniuk, F., et al (2010) TH17 is Involved in the Remarkable Regression of Metastatic Malignant Melanoma to
20 Topical Diphencyprone. *Journal of Drugs in Dermatology* 9;11:1368-1372.
21 Reason: Not relevant to PICO
- 22 Mattsson, J. (2012) Isolated limb perfusion for sarcoma and melanoma. *European Journal of Surgical Oncology*
23 *Conference[*var.pagings*]*, 801
24 Reason: Abstract Only
- 25 McClaine, R. J., et al (2012) Quality of life outcomes after isolated limb infusion. *Annals of Surgical Oncology*
26 19;5:1373-1378.
27 Reason: No Comparator
- 28 Mendenhall, W. M., et al (2013) Surgery and adjuvant radiotherapy for cutaneous melanoma considered high-
29 risk for local-regional recurrence. *American Journal of Otolaryngology* 34;4:320-322.
30 Reason: Not relevant to PICO
- 31 Meyer, T., Gohl, J., Meyer, T., and Gohl, J (2001). [Regional chemotherapy--perfusion of the extremities].
32 [German]. *Kongressband/Deutsche Gesellschaft fur Chirurgie* 118; 200-204.
33 Reason: Expert Review
- 34 Mian, R et al (2001) A. Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion.
35 *Canadian Journal of Surgery* 44;3:189-192.
36 Reason: N=9/No comparator
- 37 Minor, D. R. A.(1985) A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for
38 melanoma. *Cancer* 55;11:2638-2644.
39 Reason: No comparator

- 1 Moeller, M. G., et al (2008). Toxicities associated with hyperthermic isolated limb perfusion and isolated limb
2 infusion in the treatment of melanoma and sarcoma. *International Journal of Hyperthermia* 24[3], 275-289.
3 Reason: No data
- 4 Mohs, F. E. (1986) Micrographic surgery for satellites and in-transit metastases of malignant melanoma. *Journal*
5 *of Dermatologic Surgery and Oncology* 12;5:471-476
6 N=5
- 7 Moller, M. G., et al (2009). Electrochemotherapy as an adjunct or alternative to other treatments for
8 unresectable or in-transit melanoma. [Review] [204 refs]. *Expert Review of Anticancer Therapy* 9;11:1611-1630.
9 Reason: Expert Review
- 10 Moreno-Ramirez, D., et al (2010) A. Isolated Limb Perfusion for Malignant Melanoma: Systematic Review on
11 Effectiveness and Safety. *The Oncologist* 15;4:416-427.
12 Reason: No comparator
- 13 Moreno-Ramirez, D., et al (2009) [Study and treatment of locally advanced melanoma]. [Review] [48 refs]
14 [Spanish]. *Actas Dermo-Sifiliograficas* 100;9:767-779.
15 Reason: Expert Review
- 16 Muchmore, J. H. K. (1986) Isolated perfusion of extremities for metastatic melanoma from an unknown primary
17 lesion. *Southern Medical Journal* 79;3:288-290.
18 Reason: No Comparator
- 19 Murali, R. Moncrieff. (2010) The prognostic value of tumor mitotic rate and other clinicopathologic factors in
20 patients with locoregional recurrences of melanoma. *Annals of Surgical Oncology* 17;11:2992-2999.
21 Reason: Not relevant to PICO
- 22 Nathanson, L., et al (1998). Active specific immunotherapy with polyvalent melanoma cell vaccine (PMCV) in
23 patients with in transit (UICC Stage N2b) melanoma metastases. *17Th International Cancer Congress*, Vol 1 and
24 2:439-443.
25 Reason: Not relevant to PICO
- 26 Neto, J. P. D., Mauro, A. C. C., Molina, A. S., Nishinari, K., Zurstrassen, C. E., Costa, O. F., Belfort, F. A., Facure, L.,
27 and Fregnani, J. H. Isolated limb infusion with hyperthermia and chemotherapy for advanced limb malignancy:
28 factors influencing toxicity. *Anz Journal of Surgery* 84[9], 677-682. 2014.
- 29 Nooijen, P. T., et al (1998) Complete response of melanoma-in-transit metastasis after isolated limb perfusion
30 with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological
31 study of the delayed-type reaction pattern. *Cancer Research* 58;21:4880-4887
32 Reason: No comparator
- 33 Noorda, E. M., et al (2004). Isolated limb perfusion for unresectable melanoma of the extremities. *Archives of*
34 *Surgery* 139;11:1237-1242.
35 Reason: No comparator
- 36 Noorda, E. M., et al (2004) Isolated limb perfusion prolongs the limb recurrence-free interval after several
37 episodes of excisional surgery for locoregional recurrent melanoma. *Annals of Surgical Oncology* 11;5: 491-499.
38 Reason: No comparator
- 39 Noorda, E. M., et al (2003) Prognostic factors for survival after isolated limb perfusion for malignant melanoma.
40 *European Journal of Surgical Oncology* 29;10:916-921.
41 Reason: Not relevant to PICO

- 1 Olofsson, R. (2011) Long-term Follow-up of all isolated limb perfusions for in-transit metastasis of malignant
2 melanoma in sweden during 25 years. *Annals of Surgical Oncology* Conference[var.pagings]
3 Reason: No comparator
- 4 Olofsson, R., et al (2013). Melan-A specific CD8+ T lymphocytes after hyperthermic isolated limb perfusion: a
5 pilot study in patients with in-transit metastases of malignant melanoma. *International Journal of Hyperthermia*
6 29;3:234-238.
7 Reason: Not relevant to PICO
- 8 Olofsson, R., Mattsson, J., and Lindner, P.(2013) Long-term follow-up of 163 consecutive patients treated with
9 isolated limb perfusion for in-transit metastases of malignant melanoma. *International Journal of Hyperthermia*
10 29;6:551-557.
11 Reason: Abstract Only
- 12 Oni, G.(2009) Spontaneous regression of subcutaneous in-transit malignant melanoma deposits of the lower leg
13 after treatment with the carbon dioxide laser. *Clinical and Experimental Dermatology* 34;8: e650-e652.
14 Reason: Single Case
- 15 Ortin-Perez, J., et al (2008). [In-transit sentinel lymph nodes in malignant melanoma. What is their importance?].
16 [Spanish]. *Revista Espanola de Medicina Nuclear* 27;6: 424-429.
17 Reason: Not relevant to PICO
- 18 Ozawa, A et al (2012) Immunohistological analysis of in-transit metastasis in a patient with advanced melanoma
19 treated with combination therapy of cytosine guanine dinucleotide oligodeoxynucleotide, dacarbazine and beta-
20 interferon: A case report. *Journal of Dermatology* 39;12:1035-1037.
21 Reason: Single Case
- 22 Pais Costa, S. R. C. (2008) Popliteal lymphadenectomy for treating metastatic melanoma: Case report. *Sao Paulo*
23 *Medical Journal* 126[4], 232-235.
24 Reason: Single Case
- 25 Pace, M., Gattai, R., Mascitelli, E. M., and Millanta (2011) L. Results of Isolated Lower Limb Perfusion for Loco-
26 Regional Advanced/Recurrent Melanoma Using Borderline True Hyperthermia Plus Additional Bolus of
27 Melphalan. A Critical Analysis of Homogeneous Cases. *Journal of Surgical Oncology* 104;7:718-723.
28 Reason: No Comparator
- 29 Padsis, J., et al (2010). Pharmacotherapy of regional melanoma therapy. *Expert Opinion on Pharmacotherapy*
30 11;1:79-93.
31 Reason: Expert Review
- 32 Papadia, F., et al (2013) Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine
33 fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity
34 melanoma. *Journal of Surgical Oncology* 107;2:173-179.
35 Reason: No Comparator
- 36 Pannucci, C. J., et al (2012) The role of full-thickness scalp resection for management of primary scalp melanoma.
37 *Annals of Plastic Surgery* 69;2:165-168.
38 Reason: Not relevant to PICO
- 39 Pasquali, S., et al (2010) Early (sentinel lymph node biopsy-guided) versus delayed lymphadenectomy in
40 melanoma patients with lymph node metastases: personal experience and literature meta-analysis (Provisional

- 1 abstract). *Cancer* 116;5:1201-1209.
- 2 Reason: Not relevant to PICO
- 3 Paulsen, I. F., Chakera, A. H., Drejoe, J. B., Klyver, H., Dahlstrom, K., Oturai, P. S., Mortensen, J., Hesse, B.,
- 4 Schmidt, G., Drzewiecki, K., Paulsen, Ida Felbo, Chakera, A. H., Drejoe, Jennifer Berg, Klyver, Helle, Dahlstrom,
- 5 Karin, Oturai, Peter Sandor, Mortensen, Jann, Hesse, Birger, Schmidt, Grethe, and Drzewiecki, Krzysztof. Tumour
- 6 response after hyperthermic isolated limb perfusion for locally advanced melanoma. *Danish Medical Journal*
- 7 61[1], A4741. 2014.
- 8 Pawlik, T. M., et al (2005) The risk of in-transit melanoma metastasis depends on tumor biology and not the
- 9 surgical approach to regional lymph nodes. *Journal of Clinical Oncology* 23;21:4588-4590.
- 10 Reason: No data
- 11 Pawlik, T. M., et al (2005) Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy.
- 12 *Annals of Surgical Oncology* 12;8:587-596.
- 13 Reason: Not relevant to PICO
- 14 Pawlik, T. M., et al (2005). Low risk of in-transit metastasis in patients with cutaneous melanoma undergoing
- 15 sentinel lymph node biopsy. *Journal of Clinical Oncology* 23;21:4588-4590.
- 16 Reason: Not relevant to PICO
- 17 Pfohler, C., et al (2004) Complete remission of cutaneous satellite and in-transit metastases. After intralesional
- 18 therapy with interleukin-2 in two patients with malignant melanoma. *Hautarzt* 55;2:171-175.
- 19 Reason: No data
- 20 Pilati, P., et al (2004). Hypoxic antitlastic stop-flow limb perfusion: clinical outcome and pharmacokinetic findings
- 21 of a novel treatment for in transit melanoma metastases. *Oncology Reports* 12;4:895-901.
- 22 Reason: N=5
- 23 Posner, M. C., et al(1995) Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma.
- 24 *The Cancer Journal from Scientific American* 1;4:274-280.
- 25 Reason: N=6
- 26 Raja, C., et al (2007) Interim analysis of oxicity and response in phase 1 trial of systemic targeted alpha therapy
- 27 for metastatic melanoma. *Cancer Biology & Therapy* 6;6:846-852.
- 28 Reason: No relevant data
- 29 Raymond, A. K., et al (2011) Current Trends in Regional Therapy for Melanoma: Lessons Learned from 225
- 30 Regional Chemotherapy Treatments between 1995 and 2010 at a Single Institution. *Journal of the American*
- 31 *College of Surgeons* 213;2:306-316.
- 32 Reason: No comparator
- 33 Read, R. (2013) The role of lymphadenectomy in patients who develop in-transit melanoma metastases. JDDG -
- 34 *Journal of the German Society of Dermatology* Conference[var.pagings],
- 35 Reason: Not relevant to PICO
- 36 Read, R., Haydu et al (2012) In-transit Melanoma Metastases: Incidence, Prognostic Importance and Implications
- 37 for Patient Staging. *Annals of Surgical Oncology* 19: S23.
- 38 Reason: No data
- 39 Roberts, M. S., et al (2001) Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for
- 40 recurrent localized limb malignancy. *Melanoma Research* 11;4: 423-431
- 41 Reason: No data

- 1 Robinson, D. W., Jr et al (2012) Health-related quality of life among patients with metastatic melanoma: results
2 from an international phase 2 multicenter study. *Melanoma Research* 22;1:54-62.
3 Reason: Not relevant to PICO
- 4 Rodriguez-Cuevas, S., et al (2001) Electrochemotherapy in primary and metastatic skin tumors: phase II trial using
5 intralesional bleomycin. *Archives of Medical Research* 32;4:273-276.
6 Reason: Not relevant to PICO
- 7 Romics, L., et al (2011). Initial experiences with isolated limb perfusion for unresectable melanoma of the limb.
8 *Irish Journal of Medical Science* 180;2:517-520.
9 Reason: No COmparator
- 10 Roses, D. F., et al (1983) Local and in-transit metastases following definitive excision for primary cutaneous
11 malignant melanoma. *Annals of Surgery* 198;1: 65-69.
12 Reason: Not relevant to PICO
- 13 Ross, M. I. and Ross, Merrick I. (2008) Current status of hyperthermic limb perfusion for in-transit melanoma.
14 [Review] [50 refs]. *International Journal of Hyperthermia* 24;3:205-217.
15 Reason: Expert Review
- 16 Ross, M. I. (2011) Intralesional therapy: Local/regional control and implications for systemic response. *Pigment*
17 *Cell and Melanoma Research Conference*[var.pagings], 1010.
18 Reason: No data
- 19 Rossi, C. R., et al (2007) A pilot study on TNF based hyperthermic perfusion followed by low-dose TNF in patients
20 with in-transit metastasis from melanoma. *Annals of Surgical Oncology* 14;2:8-9.
21 Reason: No data
- 22 Rossi, C. R., et al (2008) TNF-based isolated limb perfusion followed by consolidation biotherapy with systemic
23 low-dose interferon alpha 2b in patients with in-transit melanoma metastases: a pilot trial. *Annals of Surgical*
24 *Oncology* 15;4:1218-1223.
25 Reason: Intervention not relevant to PICO
- 26 Rossi, C. R., et al (2010) Long-term results of melphalan-based isolated limb perfusion with or without low-dose
27 TNF for in-transit melanoma metastases. *Annals of Surgical Oncology* 17;11:3000-3007.
28 Reason: No Comparator
- 29 Rossi, C. R., et al (2004) Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and
30 melphalan for bulky in-transit melanoma metastases. *Annals of Surgical Oncology* 11;2:173-177.
31 Reason: No Comparator
- 32 Rossi, C. R., et al (2003) TNF-based limb perfusion for cutaneous melanoma in transit metastases: suggestions for
33 modification of the perfusional schedule.[Erratum appears in J Exp Clin Cancer Res. 2006 Sep;25(3):preceding
34 table of contents Note: Ribello, D [corrected to Rubello, D]]. *Journal of Experimental & Clinical Cancer Research*
35 22;4 Suppl:103-107.
36 Check relevance
- 37 Rossi, C. R., et al (2002). Isolated limb perfusion in locally advanced cutaneous melanoma. *Seminars in Oncology*
38 29;4:400-409.
39 Reason: No Comparator

- 1 Ruschulte, H.(2013) Anesthesia management of patients undergoing hyperthermic isolated limb perfusion with
2 melphalan for melanoma treatment: An analysis of 17 cases. *BMC Anesthesiology* 13 ;15
3 Reason: Not relevant to PICO
- 4 Russell-Jones, R. (2004) Completion lymphadenectomy may not increase in-transit disease in malignant
5 melanoma [5]. *British Medical Journal* 329;7477:1288-1289.
6 Reason: No data
- 7 Rutkowski, P et al (2006). In transit/local recurrences in melanoma patients after sentinel node biopsy and
8 therapeutic lymph node dissection. *European Journal of Cancer* 42;2:159-164.
9 Reason: Not relevant to PICO
- 10 Salemi, M., et al (2012) Proapoptotic Genes Are Downregulated in a Patient With Melanoma and Repeated In-
11 Transit Metastases. *American Journal of Dermatopathology* 34:4:454-455.
12 Reason: Not relevant to PICO
- 13 Salerno, E. P. W. (2012) Topical imiquimod induces immune activation and regressions of cutaneous melanoma
14 metastases. *Journal of Immunotherapy Conference*[var.pagings], 751-752.
15 Reason:Abstract Only
- 16 Santillan, A. A., et al (2009) Predictive factors of regional toxicity and serum creatine phosphokinase levels after
17 isolated limb infusion for melanoma: a multi-institutional analysis. *Annals of Surgical Oncology* 16;9:2570-2578.
18 Reason: Not relevant to PICO
- 19 Savoia, P., et al (2009). Skin metastases of malignant melanoma: a clinical and prognostic survey. *Melanoma*
20 *Research* 19;5:321-326.
21 Reason: Not relevant to PICO
- 22 Schlag, P. M., et al (1995). [Isolated extremity perfusion with tumor necrosis factor and melphalan.An option for
23 treatment of satellite or in transit metastasis of malignant melanoma]. [German]. *Hautarzt* 46[5], 361-362.
24 Reason: Expert Review
- 25 Schlag, P. M. and Kettelhack, C. (1995) Isolated Limb Perfusion with Tumor-Necrosis-Factor and Melphalan -
26 Option for Treatment of Satellitosis Or in Transit Metastasis of Malignant-Melanoma. *Hautarzt* 46[5], 361-362.
27 Reason: Expert Review
- 28 Schnabel, T. (1992) Radiotherapy and simultaneous intra-arterial dacarbazine infusion in the treatment of in
29 transit metastases of malignant melanoma. *Regional Cancer Treatment* 4;5-6:258-259.
30 Reason: Single Case
- 31 Schneider-Burrus, S. (2009) Operative treatment of malignant melanomas. *Onkologe* 15;8:750-757
32 Reason: No data
- 33 Schraffordt Koops, H. (1977) Regional perfusion for recurrent malignant melanoma of the extremities. *American*
34 *Journal of Surgery* 133[2], 221-224.
35 Reason: No comparator
- 36 Seegenschmiedt, M. H., et al (1999). [Long term results following radiation therapy of locally recurrent and
37 metastatic malignant melanoma]. [German]. *Hautarzt* 50;8:572-579.
38 Reason: N=24/possible duplicate
- 39 Seegenschmiedt, M. H., et al (1999) [Locally recurrent and metastatic malignant melanoma. Long-term results
40 and prognostic factors after percutaneous radiotherapy]. [German]. *Strahlentherapie und Onkologie* 175;9:450-

- 1 457
- 2 Reason: N=24 relevant patients
- 3 Sersa, G. (2006) The state-of-the-art of electrochemotherapy before the ESOPE study; advantages and clinical
- 4 uses. *European Journal of Cancer*, Supplement 4;11:52-59.
- 5 Reason: No data
- 6 Shekhel, T., Glick, R. M., and Cranmer, L. D. (2009) In-Transit Metastasis From Melanoma Presenting as
- 7 Lymphangiectasis: A Case Report. *Cutis* 84;3:151-158.
- 8 Reason: Single Case
- 9 Sherrill, B. (2013) Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with
- 10 stage III/IV melanoma. *British Journal of Cancer* 109;1:8-13
- 11 Reason: Not relevant to PICO
- 12 Shibata S. (2005) Evaluation of clinical prognosis of stage II and III melanoma patients treated with hyperthermic
- 13 isolated limb perfusion (HILP). *Nishinohon Journal of Dermatology* 67;2:147-151.
- 14 Reason: Not relevant to PICO
- 15 Squires, M. H., III and Delman, K. A. (2013) Current treatment of locoregional recurrence of melanoma. *Current*
- 16 *Oncology Reports* 15;5:465-472.
- 17 Reason: No data
- 18 Stadler, R et al (2000). Management of regional metastases. [Review] [21 refs]. *Clinical & Experimental*
- 19 *Dermatology* 25;6:490-496.
- 20 Reason: Expert Review
- 21 Stehlin, J. S., Jr., et al (1966). Melanomas of the extremities complicated by in-transit metastases. *Surgery,*
- 22 *Gynecology & Obstetrics* 122;1:3-14.
- 23 Reason: Expert Review
- 24 Strobbe, L. J. A., et al (1997). Carbon dioxide laser for cutaneous melanoma metastases: indications and
- 25 limitations. *European Journal of Surgical Oncology* 23;5:435-438.
- 26 Reason: No Comparator
- 27 Suojarvi, N. J., et al (2012) Outcome following local recurrence or in-transit metastases in cutaneous melanoma.
- 28 *Melanoma Research* 22;6: 447-453.
- 29 Reason: Not relevant to PICO
- 30 Suzuki, T. (1995) Two cases of in-transit metastases of malignant melanoma successfully treated with
- 31 cryosurgery. *Skin Cancer* 10;1:53-59.
- 32 N=2
- 33 Takkenberg, R. B., et al (2005) Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma
- 34 patients. *Journal of Surgical Oncology* 91;2:107-111.
- 35 Reason: Not relevant to PICO
- 36 Tavaniello, B. (2010) Electrochemotherapy for primary or metastatic skin tumours: A single institution
- 37 experience. *European Surgical Research Conference*[var.pagings], 237
- 38 Reason: Abstract Only
- 39 Temple-Oberle, C. F., Byers, B. A., Hurdle, V., Fyfe, A., and Mckinnon, J. G. Intra-Lesional Interleukin-2 Therapy for
- 40 In Transit Melanoma. *Journal of Surgical Oncology* 109[4], 327-331. 2014.

- 1 Terando, A. M. and Carson, W. E., (2011) III. Individualized local treatment strategies for in-transit melanoma.
2 *Oncology* (Williston.Park) 25;14:1355, 1360.
3 Reason: No data
- 4 Testori, A., et al (2011) Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb
5 infusion. [Review]. *Journal of Surgical Oncology* 104;4: 397-404.
6 Reason: Expert Review
- 7 Testori, A., et al (2011) Local and intralesional therapy of in-transit melanoma metastases. [Review]. *Journal of*
8 *Surgical Oncology* 104[4], 391-396. 2011.
9 Reason: Expert Review
- 10 Testori, A et al (2012) Alternatives for the treatment of local advanced disease: electrochemotherapy, limb
11 perfusion, limb infusion, intralesional IL2. What is the role? *Dermatologic Therapy* 25;5: 443-451.
12 Reason: No data
- 13 Testori, A., V. (2012) Treatment of in-transit metastasis: Perfusion (ILP), infusion (IP) and electro-chemotherapy
14 (ECT). *European Journal of Surgical Oncology Conference*[var.pagings], 739-740.
15 Reason: No data
- 16 Testori, A., et al (2009) Surgery and radiotherapy in the treatment of cutaneous melanoma. [Review] [99 refs].
17 *Annals of Oncology* 20;Suppl 6:vi22-vi29.
18 Reason: Expert Review
- 19 Thirlwell, C. (2008) Melanoma - Part 2: Management. *BMJ* 337;7682:1345-1348.
20 Reason: Not relevant to PICO
- 21 Tokgoz, S., et al (2012). Factors predicting iliac metastasis and overall survival in malignant melanoma of the
22 lower extremities. *Acta Chirurgica Belgica* 112;3:189-194.
23 Reason: Not relevant to PICO
- 24 Tsuchida, Y. (1997) Six cases of in-transit metastasis on acral lentiginous melanoma. *Japanese Journal of Plastic*
25 *and Reconstructive Surgery* 40;10:969-976.
26 Reason: Not relevant to PICO
- 27 Turley, R. S., et al (2011) Regional treatment strategies for in-transit melanoma metastasis. [Review]. *Surgical*
28 *Oncology Clinics of North America* 20;1:79-103.
29 Reason: Expert Review
- 30 Turley, R. S., et al (2012) Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel
31 Approach to Augment Regional Chemotherapy for In-Transit Melanoma. *Clinical Cancer Research* 18;12: 3328-
32 3339.
33 Reason: Not relevant to PICO
- 34 Utikal, J. (2006) Complete remission of multiple satellite and in-transit melanoma metastases after sequential
35 treatment with isolated limb perfusion and topical imiquimod [9]. *British Journal of Dermatology* 155;2:488-491.
36 Reason: Combination treatment not relevant to PICO
- 37 van Der Veen, A. H., et al (2000). An overview on the use of TNF-alpha: our experience with regional
38 administration and developments towards new opportunities for systemic application. [Review] [116 refs].
39 *Anticancer Research* 20;5B:3467-3474.
40 Reason: Expert Review

- 1 Van Etten, B., et al (2004). Repeat isolated limb perfusions (ILP) with tumor necrosis factor-alpha (TNF) and
2 melphalan are highly effective in melanoma patients with multiple in-transit metastases who have failed prior
3 ILPs. *Annals of Surgical Oncology* 11;2:S77.
4 Reason: Abstract Only
- 5 Vaglini, M., et al (1994). Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion
6 with tumour necrosis factor-alpha (TNF-alpha), melphalan and interferon-gamma (IFN-gamma). Dose-finding
7 experience at the National Cancer Institute of Milan. *Melanoma Research* 4;Suppl 1:35-38.
8 Reason: Not relevant to PICO
- 9 Vaglini, M., et al (1994). Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose
10 alpha-tumor necrosis factor, gamma-interferon, and melphalan. *Cancer* 73;2:483-492.
11 Reason: No comparator/Case Reports
- 12 Vaglini, M., et al (1995) Isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine-
13 activated killer cells in the treatment of in-transit metastases from limb cutaneous melanoma. *Annals of Surgical*
14 *Oncology* 2;1:61-70.
15 Reason: Not relevant to PICO
- 16 Veenstra, H. J et al (2010) Reevaluation of the locoregional recurrence rate in melanoma patients with a positive
17 sentinel node compared to patients with palpable nodal involvement. *Annals of Surgical Oncology* 17;2:521-526.
18 Reason: Not relevant to PICO
- 19 Vendettuoli, D., et al (2010) Role of surgery in patients with metastases from melanoma. A case report. *Annali*
20 *Italiani di Chirurgia* 81;6:453-455.
21 Reason: Single Case
- 22 Villani, F., et al (1995) Pulmonary toxicity of alpha tumor necrosis factor in patients treated by isolation perfusion.
23 *Journal of Chemotherapy* 7;5:452-454.
24 Reason: Poor Data
- 25 Villani, F., et al (1995) Cardiac and pulmonary effects of alpha tumor necrosis factor administered by isolation
26 perfusion. *Tumori* 81;3:197-200.
27 Reason: Poor Data (possible duplicate)
- 28 Von Nida, J. Successful treatment of in-transit melanoma metastases using topical 2-4 dinitrochlorobenzene.
29 *Australasian Journal of Dermatology* 44;4:277-280.
30 Reason: Single Case
- 31 Walther, W. Et al (2007) Phase I trial of non-viral jet injection gene transfer into in transit metastases from
32 melanoma and skin metastases from breast cancer. *Human Gene Therapy* 18;10:994.
33 Reason: Not relevant to PICO
- 34 Wessels, R. (2010) CO2-laser treatment for cutaneous malignant melanoma metastases. *European Journal of*
35 *Surgical Oncology Conference*[var.pagings], 908.
36 Reason: Abstract Only
- 37 Weide, B., Eigentler, T. K., Pflugfelder, A., Zelba, H., Martens, A., Pawelec, G., Giovannoni, L., Ruffini, P. A., Elia, G.,
38 Neri, D., Gutzmer, R., Becker, J. C., and Garbe, C. Intralesional Treatment of Stage III Metastatic Melanoma
39 Patients with L19-IL2 Results in Sustained Clinical and Systemic Immunologic Responses. *Cancer Immunology*
40 *Research* 2[7], 668-678. 2014.

- 1 Weichenthal, M. and Chiarion-Sileni, V. Intermittent intensified high-dose intravenous interferon alpha 2b
2 (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Pooled analysis of two randomized phase III
3 trials (NCT00226408 and ISRCTN75125874) with 980 patients. *Journal of Clinical Oncology*
4 Conference[*var.pagings*]. 2013.
- 5 Weide, B., et al (2013) Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time
6 of stage III diagnosis. *PLoS One* 8;4: e63137.
7 Reason: Not relevant to PICO
- 8 Weide, B., et al (2010) High Response Rate After Intratumoral Treatment With Interleukin-2 Results From a Phase
9 2 Study in 51 Patients With Metastasized Melanoma. *Cancer* 116;17:4139-4146.
10 Reason: Not relevant to PICO
- 11 Wolf, I. H et al (2004) Locoregional cutaneous metastases of malignant melanoma and their management.
12 *Dermatologic Surgery* 30;2 Pt 2:244-247.
13 Reason: Expert Review
- 14 Wong, J., Chen, Y. A., Fisher, K. J., Beasley, G. M., Tyler, D. S., and Zager, J. S. Resection of Residual Disease after
15 Isolated Limb Infusion (ILI) Is Equivalent to a Complete Response after ILI-Alone in Advanced Extremity
16 Melanoma. *Annals of Surgical Oncology* 21[2], 650-655. 2014.
17 Wong, J. (2011) A standardized approach to isolated limb infusion for in-transit melanoma on the extremities:
18 Perioperative data and outcomes. *Pigment Cell and Melanoma Research Conference*[*var.pagings*], 1072-1073.
19 Reason: Abstract Only
- 20 Wong, J. H., et al (1990). Natural history and selective management of in transit melanoma. *Journal of Surgical*
21 *Oncology* 44;3:146-150.
22 Reason: Not relevant to PICO
- 23 Wouters, J., et al (2012) Gene expression changes in melanoma metastases in response to high-dose
24 chemotherapy during isolated limb perfusion. *Pigment Cell & Melanoma Research* 25;4:454-465.
25 Reason: Not relevant to PICO
- 26 Yao, K. A., et al (2003) Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent
27 melanoma? *Annals of Surgery* 238;5:743-747. 2003.
28 Reason: Not relevant to PICO
- 29 Zager, J. S., Puleo, C. A., and Sondak, V. K. (2011) What is the Significance of the In Transit or Interval Sentinel
30 Node in Melanoma? *Annals of Surgical Oncology* 18;12: 3232-3234.
31 Reason: No data
- 32 Zogakis, T. G., et al (2001) Factors affecting survival after complete response to isolated limb perfusion in
33 patients with in-transit melanoma. *Annals of Surgical Oncology* 8;10:771-778.
34 Reason: No Comparator

35

Evidence Tables

Study Quality

	Appropriate and clearly focused	Type of studies you consider relevant to the guideline review question	Literature search is sufficiently rigorous	Study quality is assessed and reported	Adequate description of the methodology	Quality (GRADE)
Mali et al (2013)	Yes	Yes	Yes	Yes	Yes	Very Low

	Appropriate length of follow-up	Precise definition of an outcome	Valid method of measuring outcomes	Investigators blind to participants exposure to intervention?	Investigators blind to potential confounders and prognostic factors?	Quality (GRADE)
Caraco et al (2013)	Unclear	Yes	Yes	No	No	Very Low
Fotopoulos et al 1998	Unclear	Yes	Yes	No	No	Very Low
Hill et al (1993)	Unclear	Yes	Yes	No	No	Very Low
Kadamany et al (2009)	Unclear	Yes	Yes	No	No	Very Low
Ricotti et al (2014)	Unclear	Yes	Yes	No	No	Very Low
Seegenschmiedt et al (1999)	Unclear	Yes	Yes	No	No	Very Low

Sharma et al 2012	Unclear	Yes	Yes	No	No	Very Low
-------------------	---------	-----	-----	----	----	----------

Study	Aim	Population	Intervention	Comparison	Follow-up	Outcomes and results
Caraco et al (2013)	To analyse the short and long term responses of lesions treated with electrochemotherapy with intravenous injection of bleomycin in melanoma patients with in-transit disease or distant cutaneous metastases	N=60 with relapse and refractory cutaneous melanoma or in-transit disease	Electrochemotherapy	None	Median follow-up was 27.5 months (range 6-67 months)	<p>21 patients had recurrent cutaneous disease or in-transit disease of the trunk</p> <p>35 patients had in transit disease of an inferior limb</p> <p>4 patients had cutaneous disease in the head and neck area</p> <p>Treatment was well tolerated with the most frequent side effects being mild pain in 22 patients and myalgia in 8 patients.</p> <p>No systemic adverse events were recorded</p> <p>Necrosis of treated lesions occurred in 18 patients</p> <p>3 months after Electrochemotherapy, 23 patients recorded a partial response, 29 recorded a complete response and 8 recorded no change or progressive disease.</p> <p>Objective response rate was 86.6% for all treated lesions.</p> <p>13 patients experienced a long lasting response to Electrochemotherapy after one session and were free of disease after mean follow-up of 27.5 months.</p>

Study	Aim	Population	Intervention	Comparison	Follow-up	Outcomes and results
Fotopoulos et al 1998	To investigate the role of surgical treatment for survival in patients with loco-regional recurrences	N=33 patients who developed a loco-regional relapse after removal of a primary tumour located to the lower extremity. 12 patients had a local recurrence while 21 had in-transit metastases. In transit was defined as cutaneous or subcutaneous recurrences occurring between the scar or skin graft after surgery for the primary tumour and the regional lymph nodes (groin). Median age was 67 years (18-85 years) and there were 26 females and 7 males.	Surgical Excision	None	Median observation time was 31 months (5 months -22 years)	Survival
Hill et al (1993)	To investigate the place of CO2 laser ablation of cutaneous or sub-cutaneous deposits of malignant melanoma	N= 60 patients with cutaneous and superficial subcutaneous metastases of malignant melanoma.	Co2 laser	None	Not reported	Development of extraregional disease Overall Survival
Kadamany et al (2009)	Not Clear – appears to be effectiveness of CO2 laser	N=16 patients with cutaneous and superficial melanoma metastases too numerous or recurring too frequently for surgical excision	Co2 laser	None	Not Reported	Survival
Mali et al (2013)	To investigate the effectiveness of electrochemotherapy (ECT) in cutaneous or subcutaneous tumour.	N=413 patients with 1894 tumours were included in the review. N=150 with 922 tumours patients with melanoma were included in the review (22 studies) <u>Inclusion criteria:</u> <ul style="list-style-type: none"> Studies with information about single session ECT of cutaneous or subcutaneous tumours performed on human patients using bleomycin or cisplatin administered intratumorally or intravenously. 	Electrochemotherapy	Chemotherapy (where available)	Not reported	Response of individual tumours to a single session of ECT (or control treatment) evaluated according to WHO or RECIST criteria and classified as complete response (CR), partial response (PR), no change (NC) or progressive disease (PD). Objective Response (CR+PR) and No Response (NC+PD) were also evaluated.

Study	Aim	Population	Intervention	Comparison	Follow-up	Outcomes and results
		<ul style="list-style-type: none"> Studies with data for number of patients and tumours, tumour response (evaluated at least 4 weeks after treatment) chemotherapeutic drug, route of drug administration and tumour type. <p><i>For inclusion in meta-analysis,</i></p> <ul style="list-style-type: none"> studies with data for control tumours (i.e. tumours treated with chemotherapeutic drug or electroporation pulses only or no treatment) studies with data for at least two different histological types of tumours <p><u>Exclusion criteria:</u> No specific exclusion criteria given</p>				
Ricotti et al (2014)	To evaluate the efficacy, long-term tolerability and long-term efficacy of electrochemotherapy in the treatment of advanced cutaneous and subcutaneous melanoma	N=30 patients affected by 654 metastatic nodules from melanoma	Electrochemotherapy	None	Median follow-up was 20 months	<p><i>First ECT</i></p> <p>Average number of lesions treated per patient was 21.8 (4-54)</p> <p>Size of lesion ranged from 0.2cm²-10cm²</p> <p>100% of patients recorded an objective response (complete or partial)</p> <p>Complete response was achieved in 6 patients (20%) and partial response was achieved in 24 patients (80%).</p> <p>Partial response was 31.09% for patients with 1-25 lesions and 33.85% for patients with >26 lesions.</p>

Study	Aim	Population	Intervention	Comparison	Follow-up	Outcomes and results
						<p>Partial response was 79.116% for nodules $\geq 1\text{cm}^2$.</p> <p>48/63 (76.19%) nodules 1-5cm^2 had a partial response</p> <p>9/9 (100%) nodules 5-10cm^2 had a partial response</p> <p>Following second ECT, PR for nodules sized $\geq 1\text{cm}^2$ was 73.68%.</p> <p>PR was reported in 68.75% of nodules 1-5cm^2</p> <p>PR was reported in 100% of nodules $>5\text{cm}^2$</p> <p>PR was achieved in 157/360 (26.9%) of nodules 0.2-0.5cm^2 after first ECT and in 31/157 (19.74%) nodules after second ECT.</p> <p>50/360(13.8%) nodules 0.2-0.5cm^2 achieved PR on first ECT and 0 nodules at second ECT.</p> <p>111/222 (50%) nodules 0.6-1cm^2 achieved partial response after first ECT and 33/111 (29.72%) after second ECT.</p> <p>Overall PR rate after first ECT was 32.72% (95% CI 29-36%) (214/654 nodules).</p> <p>214 nodules were retreated and overall PR rate was 34.11% (95% CI 28-41%) (73/214).</p> <p>1 month after second ECT, 581/654 lesions had</p>

Study	Aim	Population	Intervention	Comparison	Follow-up	Outcomes and results
						<p>achieved complete response.</p> <p>After median 20 month follow-up, CR was achieved in 9/20 patients and PR in 5/20 surviving patients.</p> <p>Stable or progressive disease was recorded in 6 patients.</p> <p>Local tumour control rate at 24 months was 72%.</p>
Seegenschmiedt et al (1999)	To analyse the 20 year clinical experience with radiotherapy treatment with respect to different endpoints and prognostic factors.	<p>N=121 patients referred for external radiotherapy of which 24 patients were referred due to in-transit metastases.</p> <p>N=57 patients with stage UICC III (including the 24 patients with in-transit metastases) were referred for radiotherapy to reduce or prevent tumour related symptoms and improve quality of life.</p>	Radiotherapy	None		<p>Response Rates</p> <p>Survival</p>
Sharma et al 2012	To summarise the patterns of recurrence following a complete response to HILP and ILI and to evaluate whether the regional treatment modality producing a complete response influences the probability and/or timing of local recurrence or overall survival	<p>From 1995-2011, N= 214 patients undergoing HILP or ILI for the first time for in transit melanoma; 81 HILPs and 133 ILIs.</p> <p><u>Inclusion Criteria</u> Patients with AJCC stage IIIB, IIIC or IV with known outside disease resected before regional treatment.</p> <p><u>Exclusion Criteria</u> None given</p>	Hyperthermic Isolated Limb Perfusion	Isolated Limb Infusion		<p>Response Rates</p> <p>Recurrence</p> <p>Survival</p> <p>PET-CT was used to evaluate disease status prior to therapy and to detect local and systemic recurrences. Patients treated from 2005 underwent PET-CT scans prior to regional chemotherapy, every 3 months for a year and every 6 months thereafter. Pathological confirmation via punch biopsies, fine needle aspiration, CT guided biopsies or surgical resections were performed when possible.</p>

6. Stage IV Melanoma

6.1 Localised treatments for metastatic stage IV melanoma

Review question: How effective is surgery, ablative treatments or stereotactic radiotherapy for people with stage IV melanoma with oligometastatic disease?

Background

A wide variety of treatment modalities have been used to treat metastatic melanoma, i.e. a melanoma which is spread through the bloodstream to reach distant sites. The commonest metastatic sites for melanoma to spread to are liver, lungs, brain and bone. Melanoma can also spread to other skin sites giving tumours under the skin at subcutaneous nodules. Unfortunately with melanoma, spread can also occur almost anywhere in the body, including sites that other cancers do not usually spread to, such as the gastrointestinal tract or the heart.

All the many local treatments which have been used, and several new approaches are in development or at the clinical trials stage, have in common the aim of removing the melanoma metastases completely, and so reducing the risk of recurrence at that particular site, while reducing to a minimum the side-effects or morbidity of using that particular treatment. Therefore some techniques such as the emerging advanced radiotherapy techniques are more appropriate to use for brain metastasis where the inevitable morbidity of any surgical approach, might be too high a cost for the palliation achieved. In contrast, surgical techniques using surgery, laser ablation or localised electro-chemotherapy would be much more appropriate for the palliation of multiple subcutaneous melanoma metastases, than any of even the new radiotherapy techniques.

Surgical management of distant malignant melanoma deposits has been used for hundreds of years but these techniques are still developing with increased use of laser treatments and the development of electro-chemotherapy. Advances in imaging and diagnostic techniques has allowed for more precise surgical intervention improving palliation and decreasing morbidity.

Stereotactic radiosurgery, introduced in the last two decades allows for the treatment of metastases in a much reduced number of fractions and by being able to deliver highly focused radiation treatments to very precise target areas with much reduced dose to surrounding normal tissues reduces treatment morbidity and the number of patient attendances required for treatment. Other new technologies for treating melanoma metastases include CyberKnife and other Intensity Modulation RadioTherapy approaches.

Radiation can also be used by delivering radioactive particles to the melanoma metastases and using different techniques so that these particles are preferentially taken up within the melanoma cells. As well as targeting these metastases individually the tumours blood supply can be compromised by radioembolisation using radioactive agents to block the tumours feeding arterial supply and it also places a decaying radiation source close to the tumour itself.

The major challenge with all of these new and not some new techniques is that there are very few comparative trials telling us which modality is best in which particular clinical situation and metastatic site.

Question in PICO format

Patients/population	Intervention	Comparison	Outcomes
Patients with stage IV melanoma: With oligometastatic	Surgery Stereotactic radiotherapy Image guided ablative techniques:	Each other Systemic treatment Radiotherapy Symptom control	Overall Survival (1, 5 & 10yr) Melanoma specific survival

disease	Radio frequency ablation (RFA) Microwave Cryotherapy Radiologically guided embolisation Chemoembolisation For completeness consider adding in the electroporation 'nano knife' and HIFU techniques	Observation alone	Metastases free survival Adverse Events HRQL tumour necrosis sometimes called complete or incomplete tumour ablation or primary or secondary effectiveness rates
---------	---	-------------------	--

1

2

1 **Search Results**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	1998-2013	1510	519	28/10/2013
<i>Premedline</i>	1998-2013	632	105	29/10/2013
<i>Embase</i>	1998-2013	2671	991	05/11/2013
<i>Cochrane Library</i>	1998-2013	478	43	30/10/2013
<i>Web of Science (SCI & SSCI)</i>	1998-2013	4254*	908	08/11/2013
*Database error with Web of Science – giving different search totals				
Total References retrieved (after de-duplication): 1631				

2 **Update Search**

3 For the update search, the same search criteria/filters were applied as initial search

Database name	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	200	48	10/10/2014
<i>Premedline</i>	31	11	10/10/2014
<i>Embase</i>	961	127	13/10/2014
<i>Cochrane Library</i>	27	2	13/10/2014
<i>Web of Science (SCI & SSCI)</i>	659	94	13/10/2014
12 references found in Pubmed 10/10/2014			
Total References retrieved (after de-duplication): 115			


4 Abstracts for 1745 papers were screened for their relevance for the review question and 1654 papers were
5 excluded leaving 90 papers to be ordered and the full text screened (figure 1). From these 90 papers 15 were
6 relevant (table 3) and included in the evidence review and 74 papers were excluded (table 4). There were a
7 number of papers which were excluded because they are not specific to melanoma and the studies contain
8 patients with metastases from a range of different primary cancers. It was important to select papers specific to
9 melanoma as the effect of treatments on melanoma metastases may be different to other cancers.

10 From the 15 relevant melanoma studies 7 were concerning brain metastases, 1 examined lung metastases, 1
11 examined adrenal metastases, 2 examined liver metastases, 1 examined abdominal metastases, and 3 studies
12 were not specific to any particular metastasis location but contained a wide range of melanoma patients with
13 various metastases.

14 All 15 studies investigated the effect of surgery, 4 also investigated stereotactic radiotherapy and 1 study
15 identified looked at surgery with or without ablation.

1 **Screening Results**

2



3

4

1 **Evidence statements**

2 ***Overall survival***

3 The effectiveness of surgery, ablative treatments or stereotactic radiotherapy for people with stage IV melanoma
4 with oligometastatic disease is unclear from the evidence in the 14 included papers.

5 *Surgery and/or Stereotactic Radiotherapy*

6 Very low quality evidence suggests that patients who receive surgery and/or stereotactic radiotherapy have
7 greater median survival compared to patients who do not receive these treatments (Table 2: grade profiles) but
8 these studies are at high risk of selection bias [Very Low Quality Evidence].

9 *Surgery versus No Surgery*

10 There were a number of papers comparing survival in patients who received surgery compared to those who did
11 have not surgery for a number of different metastases – brain, lung, adrenal, liver and abdominal. There were
12 also 2 papers that examined this in patient cohorts with a range of different metastases locations. All these
13 papers demonstrated that patients having surgery survived longer than those who did not have surgery [Very
14 Low to Low Quality Evidence].

15 *Surgery versus Supportive Care, Chemotherapy, WBRT and chemotherapy and/or WBRT*

16 These studies for brain metastases showed that surgery gives better results with regards to overall survival than
17 supportive care, chemotherapy, WBRT and chemotherapy and/or WBRT; STR resulted in longer median overall
18 survival than chemotherapy and WBRT; treatment with STR or surgery resulted in longer median overall survival
19 than WBRT and supportive care. There were 2 studies comparing surgery and STR and they demonstrated little
20 difference in overall survival between these two treatments. One study found that surgery increased survival by
21 0.3 months compared to STR and the other study found that STR increased survival by 1.71 months compared to
22 surgery.

23 *Surgery + Ablation versus Ablation alone*

24 A single study reported on patients undergoing surgery with ablation or ablation alone and reported a 5 year
25 overall survival rate of 6.6% in the non-surgical group compared with 30% in the surgical group ($p < 0.001$) though
26 outcomes did not differ significantly by type of surgery (resection, ablation, resection with ablation).

27 To what extent the longer median survival associated with surgery and stereotactic radiotherapy is related to the
28 treatment itself or to selection of patients with better performance status is unclear. All 14 studies are
29 retrospective cohort studies and all have a high patient selection bias. Also the studies do not aim to compare
30 treatment modalities but to show that the treatment investigated (usually surgery) in suitable patients can
31 confer a survival advantage - many of the studies compare surgery vs. no surgery, but the no surgery group is
32 made up of patients undergoing a range of different treatments or no treatment at all.

33

34 ***Adverse Events***

Two studies provided low quality evidence about adverse events. In Bushbaum et al (2002) radiotherapy for brain metastases (either STR or WBRT) was associated with acute complications (swelling requiring steroid treatment or seizures) in 10/70 patients (14%) but no symptomatic radiation necrosis was reported. Surgery was associated with acute complications requiring hospitalization in 6/25 (24%) patients. These complications included infection, haemorrhage and central nervous system deficits. In Gutman et al (2001) surgery for abdominal metastases was associated with a 14% rate of major complications (sepsis, evisceration or pulmonary embolism) and mortality rate of 3% within 30 days of surgery.

Metastases free survival

In Bushbaum et al (2002) brain metastases recurred locally in 2/10 patients (20%) treated with local therapy only (surgery or STR) and 4/24 patients (17%) treated with WBRT alone.

HRQOL

Health related quality of life was not reported although there was low quality evidence from one study (Gutman et al, 2001) that surgery provides better symptom relief in patients with abdominal metastases. 23% of patients treated using surgery were symptom free for at least 1 year compared with a typical symptom free period of 1 month in those treated without surgery.

Melanoma specific survival

No comparative evidence was identified relating to this outcome.

Tumour necrosis

No comparative evidence was identified relating to this outcome.

GRADE table 6.1: Should surgery vs. no surgery be used for stage IV melanoma with oligometastatic disease?

Quality assessment							Summary of findings				
							No of patients		Effect		Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	surgery	no surgery	Relative (95% CI)	Absolute	
Overall survival: brain metastases											
2	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	no serious imprecision	none	163	292	-	Overall median survival was 5.4 - 7.7 months longer in patients that underwent surgery compared to those who did not have surgery.	VERY LOW
Serious adverse events: brain metastases											
1	observational study ¹	very serious ²	no serious inconsistency	no serious indirectness	serious imprecision ³	none	6/25 (24%)	10/70 (15%)	-	90 fewer adverse events per 1000 treated in the non surgery group – but the types of adverse events were different.	VERY LOW
Overall survival: lung metastases											
1	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	serious imprecision ³	none	26	96	-	Overall median survival was 27 months longer in patients that underwent surgery compared to those who did not have surgery.	VERY LOW
Overall survival: adrenal metastases											
1	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	serious imprecision ³	None	16	163	-	Overall median survival was 11 months longer in patients that underwent surgery compared to those who did not have surgery.	VERY LOW
Overall survival: liver metastases											
2	observational studies	very serious ²	no serious inconsistency	no serious indirectness	serious imprecision ³	none	39	907	-	Overall median survival was 17 - 22 months longer in patients that underwent surgery compared to those who did not have surgery.	VERY LOW

Overall survival: abdominal metastases											
1	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	serious imprecision ³	none	96	155	-	Overall median survival was 6 months longer in patients that underwent surgery compared to those who did not have surgery.	VERY LOW
Serious adverse events: abdominal metastases											
1	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	serious imprecision ³	none	13/96 (14%)	-	-	Cannot calculate because adverse events were not reported for the non surgical patients.	VERY LOW
Symptom free at 1 year: abdominal metastases											
1	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	serious imprecision ³	none	22/96 (23%)	-	-	Symptom free rate at 1 year not reported for non-surgical group – although authors state that such patients were rarely symptom free for more than a month.	VERY LOW
Overall survival: mixed metastases											
	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	no serious imprecision	none	151	318	-	Overall median survival was 12.3 - 13 months longer in patients that underwent surgery compared to those who did not have surgery.	VERY LOW

¹ retrospective cohort study² High bias due to patient selection for surgery³ Low number of events or patients**Grade Table 6.2: Should surgery vs. chemotherapy be used for stage IV melanoma with oligometastatic disease?**

Quality assessment							Summary of findings				
							No of patients		Effect		Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	surgery	chemotherapy	Relative (95% CI)	Absolute	
Overall survival: brain metastases											
2	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	serious imprecision ³	none	42	55	-	Overall median survival was 4 - 7 months longer in patients treated with surgery compared to those	VERY LOW

										treated with chemotherapy.	
--	--	--	--	--	--	--	--	--	--	----------------------------	--

¹ retrospective cohort study² Serious risk of bias due to patient selection for treatment³ Low number of events or patients**Grade Table 6.3: Should surgery vs. supportive care be used for stage IV melanoma with oligometastatic disease?**

Quality assessment							Summary of findings				
							No of patients		Effect		Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	surgery	supportive care	Relative (95% CI)	Absolute	
Overall survival: brain metastases											
4	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	no serious imprecision	none	120	336	-	Overall median survival was 4 - 10 months longer in patients treated with surgery compared to those that had supportive care only.	VERY LOW

¹ retrospective cohort studies² serious risk of bias due to patient selection for treatment**Grade Table 6.4: Should surgery vs. stereotactic radiotherapy be used for stage IV melanoma with oligometastatic disease?**

Quality assessment							Summary of findings				
							No of patients		Effect		Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	surgery	stereotactic radiotherapy	Relative (95% CI)	Absolute	
Overall survival: brain metastases											
2	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	serious imprecision ³	none	73	43	-	Overall median survival was -1.71 – 0.3 months longer in patients treated with surgery compared to those treated with stereotactic radiotherapy.	VERY LOW

¹ Retrospective cohort study² High risk of bias due to patient selection for treatment

³ Low number of events or patients**Grade Table 6.5: Should surgery vs. WBRT be used for stage IV melanoma with oligometastatic disease?**

Quality assessment							Summary of findings				
							No of patients		Effect		Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	surgery	WBRT	Relative (95% CI)	Absolute	
Overall survival: brain metastases											
4	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	serious imprecision ³	none	125	418	-	Overall median survival was 4.2 - 9 months longer in patients treated with surgery compared to those treated with WBRT.	VERY LOW

¹ retrospective cohort study² High risk of bias due to patient selection for treatment**Grade Table 6.6: Should surgery vs. chemotherapy and/or WBRT be used for stage IV melanoma with oligometastatic disease?**

Quality assessment							Summary of findings				
							No of patients		Effect		Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	surgery	chemotherapy and/or WBRT	Relative (95% CI)	Absolute	
Overall survival: brain metastases											
1	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	serious imprecision ³	none	32	75	-	Overall median survival was 2 months longer in patients treated with surgery compared to those treated with chemotherapy and/or WBRT.	VERY LOW

¹ retrospective cohort study² High risk of bias due to patient selection for treatment³ Low number of events or patients**Grade Table 6.7: Should STR vs. chemotherapy be used for stage IV melanoma with oligometastatic disease?**

Quality assessment							Summary of findings			
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	No of patients		Effect	

No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	STR	chemotherapy	Relative (95% CI)	Absolute	
Overall survival: brain metastases											
1	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	serious imprecision ³	None	17	38	-	Overall median survival was 3.7 months longer in patients treated with STR compared to those treated with chemotherapy.	VERY LOW

¹ retrospective cohort study² High risk of bias due to patient selection for treatment³ Low number of events or patients**Grade Table 6.8: Should STR vs. WBRT be used for stage IV melanoma with oligometastatic disease?**

Quality assessment							Summary of findings				
							No of patients		Effect		Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	STR	WBRT	Relative (95% CI)	Absolute	
Overall survival: brain metastases											
1	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	serious imprecision ³	none	17	54	-	Overall median survival was 4.8 months longer in patients treated with STR compared to those treated with WBRT.	VERY LOW

¹ retrospective cohort study² High risk of bias due to patient selection for treatment³ Low number of events or patients**Grade Table 6.9: Should STR or surgery vs. supportive care be used for stage IV melanoma with oligometastatic disease?**

Quality assessment							Summary of findings				
							No of patients		Effect		Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	STR or surgery	supportive care	Relative (95% CI)	Absolute	
Overall survival: brain metastases											
1	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	serious imprecision ³	none	10	3	-	Overall median survival was 3.7 months longer in patients treated with STR or surgery compared to	VERY LOW

										those that had supportive care only.	
--	--	--	--	--	--	--	--	--	--	--------------------------------------	--

¹ retrospective cohort study² High risk of bias due to patient selection for treatment³ Low number of events or patients**Grade Table 6.10: Should STR or surgery vs. WBRT be used for stage IV melanoma with oligometastatic disease?**

Quality assessment							Summary of findings				
							No of patients		Effect		Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	STR or surgery	WBRT	Relative (95% CI)	Absolute	
Overall survival: brain metastases											
1	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	serious imprecision ³	none	10	25	-	Overall median survival was 2.5 months longer in patients treated with STR or surgery compared to those treated with WBRT.	VERY LOW
Recurrence of metastasis at local site: brain metastases											
1	observational study ¹	very serious ²	no serious inconsistency	no serious indirectness	serious imprecision ³	none	2/10 (20%)	4/24 (17%)	-	30 more recurrences per 1000 treated in the non surgery group	VERY LOW

¹ retrospective cohort study² High bias due to patient treatment selection³ Low number of events or patients**Grade Table 6.11: Should surgery with or without ablation be used to treat oligometastatic disease**

Quality assessment							Summary of findings				Quality
							No of patients		Effect		
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Surgery±Ablation	No Surgery	Relative (95% CI)	Absolute	
Overall survival: any metastases											

1	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	no serious imprecision	none	Not reported	Not reported		<p>Median overall survival was 8 months in the non surgical group compared with 24.8 months in the non-surgical group.</p> <p>5 year overall survival was 6.6% in the non-surgical group compared with 30% in the surgical group (p<0.001)</p> <p>Outcomes did not differ significantly by type of surgery (resection, ablation, resection with ablation)</p>	VERY LOW
---	------------------------------------	---------------------------	--------------------------	-------------------------	------------------------	------	--------------	--------------	--	--	----------

¹Retrospective Cohort Study²High risk of bias due to treatment selection

1 **References**

- 2 Buchsbaum, J. C., Suh, J. H., Lee, S. Y., Chidel, M. A., Greskovich, J. F. & Barnett, G. H. (2002) Survival by radiation
3 therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain
4 metastases from malignant melanoma: a retrospective study. *Cancer*, 94: 2265-2272.
- 5 Faries, M. B., Leung, A., Morton, D. L., Hari, D., Lee, J. H., Sim, M. S., Bilchik, A. J., Faries, Mark B., Leung, Anna,
6 Morton, Donald L., Hari, Danielle, Lee, Ji Hey, Sim, Myung shin, and Bilchik, Anton J. A 20-year experience of
7 hepatic resection for melanoma: is there an expanding role? *Journal of the American College of Surgeons* 219[1],
8 62-68. 2014.
- 9 Fife, K. M., Colman, M. H., Stevens, G. N., Firth, I. C., Moon, D., Shannon, K. F., Harman, R., Petersen-Schaefer, K.,
10 Zacest, A. C., Besser, M., Milton, G. W., McCarthy, W. H. & Thompson, J. F. (2004) Determinants of outcome in
11 melanoma patients with cerebral metastases. *Journal of Clinical Oncology*, 22: 1293-1300.
- 12 Konstadoulakis, M. M., Messaris, E., Zografos, G., Androulakis, G. & Karakousis, C. (2000) Prognostic factors in
13 malignant melanoma patients with solitary or multiple brain metastases. Is there a role for surgery? *Journal of*
14 *Neurosurgical Sciences*, 44: 211-218.
- 15 Meier, S., Baumert, B. G., Maier, T., Wellis, G., Burg, G., Seifert, B. & Dummer, R. (2004) Survival and prognostic
16 factors in patients with brain metastases from malignant melanoma. *Onkologie*, 27: 145-149.
- 17 Panagiotou, I. E., Brountzos, E. N., Kelekis, D. A., Papathanasiou, M. A. & Bafaloukos, D. I. (2005) Cerebral
18 metastases of malignant melanoma: contemporary treatment modalities and survival outcome. *Neoplasma*, 52:
19 150-158.
- 20 Raizer, J. J., Hwu, W.-J., Panageas, K. S., Wilton, A., Baldwin, D. E., Bailey, E., Von, A. C., Lamb, L. A., Alvarado, G.,
21 Bilsky, M. H. & Gutin, P. H. (2008) Brain and leptomeningeal metastases from cutaneous melanoma: Survival
22 outcomes based on clinical features. *Neuro-Oncology*, 10: 199-207.
- 23 Ricotti, F., Giuliadori, K., Cataldi, I., Campanati, A., Ganzetti, G., Ricotti, G., and Offidani, A. Electrochemotherapy:
24 an effective local treatment of cutaneous and subcutaneous melanoma metastases. *Dermatologic Therapy* 27[3],
25 148-152. 2014.
- 26 Stone, A., Cooper, J., Koenig, K. L., Golfinos, J. G. & Oratz, R. (2004) A comparison of survival rates for treatment
27 of melanoma metastatic to the brain. *Cancer Investigation*, 22: 492-497.
- 28 Neuman, H. B., Patel, A., Hanlon, C., Wolchok, J. D., Houghton, A. N. & Coit, D. G. (2007) Stage-IV melanoma and
29 pulmonary metastases: factors predictive of survival. *Annals of Surgical Oncology*, 14: 2847-2853.
- 30 Collinson, F. J., Lam, T. K., Bruijn, W. M. J., De Wilt, J. H. W., Lamont, M., Thompson, J. F. & Kefford, R. F. (2008)
31 Long-term survival and occasional regression of distant melanoma metastases after adrenal metastasectomy.
32 *Annals of Surgical Oncology*, 15: 1741-1749.
- 33 Rose DM, Essner R, Hughes MD, Tang PC, Bilchik A, Wanek LA et al. (2001) Surgical resection for metastatic
34 melanoma to the liver. *Arch Surg* 136: 950–955.
- 35 Chua T, Saxena A, Morris DL. (2010) Surgical metastasectomy in AJCC stage IV M1c melanoma with
36 gastrointestinal and liver metastases. *Ann Acad Med Singapore* 39: 634–639.
- 37 Gutman, H., Hess, K. R., Kokotsakis, J. A., Ross, M. I., Guinee, V. F. & Balch, C. M. (2001) Surgery for abdominal
38 metastases of cutaneous melanoma. *World Journal of Surgery*, 25: 750-758.
- 39 Meyer, T., Merkel, S., Goehl, J. & Hohenberger, W. (2000) Surgical therapy for distant metastases of malignant
40 melanoma. *Cancer*, 89: 1983-1991.
- 41 Ollila, D. W., Hsueh, E. C., Stern, S. L. & Morton, D. L. (1999) Metastasectomy for recurrent stage IV melanoma.
42 *Journal of Surgical Oncology*, 71: 209-213.

- 1 *Excluded Studies*
- 2 Abuodeh, Y., Tsai, Y., Chinnaiyan, P., Sarangkasiri, S., Jain, S. & Yu, H. M. (2012) Review of patients with brain
- 3 metastasis treated with fractionated stereotactic radiation therapy to surgical resection cavity. *International*
- 4 *Journal of Radiation Oncology Biology Physics*, 84: S287-S288.
- 5 Reason: Conference abstract., Mixed population of different cancers including 12 melanomas.
- 6 Adam, R. & Chiche, L. (2013) Liver metastases from melanoma. *Digestive and Liver Disease*, 45: S240-S241.
- 7 Reason: Conference abstract.
- 8 Agrawal, S., Yao, T. J. & Coit, D. G. (1999) Surgery for melanoma metastatic to the gastrointestinal tract. *Annals of*
- 9 *Surgical Oncology*, 6: 336-344.
- 10 Reason: Retrospective study that only looks at 68 of the 7965 patients with melanoma
- 11 Ahmad, Z. K., Hussain, S., Orusz, S. & Corrie, P. (2010) Single centre retrospective review of melanoma patients
- 12 receiving whole brain radiotherapy (WBRT) for metastatic disease. *Radiotherapy and Oncology*, 96: S362-S363.
- 13 Reason: Conference abstract - poster
- 14 Ammirati, M., Cobbs, C. S., Linskey, M. E., Paleologos, N. A., Ryken, T. C., Burri, S. H., Asher, A. L., Loeffler, J. S.,
- 15 Robinson, P. D., Andrews, D. W., Gaspar, L. E., Kondziolka, D., McDermott, M., Mehta, M. P., Mikkelsen, T., Olson,
- 16 J. J., Patchell, R. A. & Kalkanis, S. N. (2010) The role of retreatment in the management of recurrent/progressive
- 17 brain metastases: a systematic review and evidence-based clinical practice guideline. *Journal of Neuro-Oncology*,
- 18 96: 85-96.
- 19 Reason: Not specific to melanoma.
- 20 Aoyama, T., Mastrangelo, M. J., Berd, D., Nathan, F. E., Shields, C. L., Shields, J. A., Rosato, E. L., Rosato, F. E. &
- 21 Sato, T. (2000) Protracted survival after resection of metastatic uveal melanoma. *Cancer*, 89: 1561-1568.
- 22 Reason: Primary uveal melanoma – not to be covered (according to scope).
- 23 Aubin, J.-M., Rekman, J., Fairfull-Smith, R., Mimeault, R., Balaa, F. & Martel, G. (2012) Hepatic resection for
- 24 metastatic malignant melanoma: A systematic review. *HPB*, 14: 411.
- 25 Reason: Conference abstract.
- 26 Aubin, J. M., Rekman, J., Vandenbroucke-Menu, F., Lapointe, R., Fairfull-Smith, R. J., Mimeault, R., Balaa, F. K. &
- 27 Martel, G. (2013) Systematic review and meta-analysis of liver resection for metastatic melanoma. [Review].
- 28 *British Journal of Surgery*, 100: 1138-1147.
- 29 Reason: Not relevant to PICO
- 30 Ballo, M. T., Bonnen, M. D., Garden, A. S., Myers, J. N., Gershenwald, J. E., Zagars, G. K., Schechter, N. R.,
- 31 Morrison, W. H., Ross, M. I. & Kian, A. K. (2003) Adjuvant irradiation for cervical lymph node metastases from
- 32 melanoma. *Cancer*, 97: 1789-1796.
- 33 Reason: Not stage IV with oligometastatic disease
- 34 Ballo, M. T., Garden, A. S., Myers, J. N., Lee, J. E., Diaz, E. M., Jr., Sturgis, E. M., Morrison, W. H., Gershenwald, J.
- 35 E., Ross, M. I., Weber, R. S. & Ang, K. K. (2005) Melanoma metastatic to cervical lymph nodes: Can radiotherapy
- 36 replace formal dissection after local excision of nodal disease? *Head & Neck*, 27: 718-721.
- 37 Reason: Not stage IV with oligometastatic disease.
- 38 Banfill, K. E., Bownes, P. J., St Clair, S. E., Loughrey, C. & Hatfield, P. (2012) Stereotactic radiosurgery for the
- 39 treatment of brain metastases: Impact of cerebral disease burden on survival. *British Journal of Neurosurgery*, 26:
- 40 674-678.

- 1 Reason: Not specific to melanoma
- 2 Barney, B. M., Olivier, K. R., Wilson, Z. C., Miller, R. C., Macdonald, O. K., Brown, P. D., Foote, R. L. & Markovic, S.
3 N. (2011) Clinical outcomes and toxicity using Stereotactic Body Radiotherapy (SBRT) for stage IV melanoma.
4 *International Journal of Radiation Oncology Biology Physics*, 81: S687.
- 5 Reason: Conference abstract.
- 6 Bashir, A., Hodge, C. J., Jr., Dababneh, H., Hussain, M., Hahn, S., and Canute, G. W. Impact of the number of
7 metastatic brain lesions on survival after Gamma Knife radiosurgery. *Journal of Clinical Neuroscience* . 15-7-2014.
- 8 Reason: Not Melanoma
- 9 Beadle, B. M., Guadagnolo, B. A., Ballo, M. T., Lee, J. E., Gershenwald, J. E., Cormier, J. N., Mansfield, P. F., Ross,
10 M. I. & Zagars, G. K. (2009) Radiation Therapy Field Extent for Adjuvant Treatment of Axillary Metastases From
11 Malignant Melanoma. *International Journal of Radiation Oncology Biology Physics*, 73: 1376-1382.
- 12 Reason: Not stage IV with oligometastatic disease.
- 13 Boasberg, P. D., O'Day, S. J., Kristedja, T. S., Martin, M., Wang, H., Deck, R., Shinn, K., Ames, P., Tamar, B. &
14 Petrovich, Z. (2003) Biochemotherapy for metastatic melanoma with limited central nervous system
15 involvement. *Oncology*, 64: 328-335.
- 16 Reason: Study looking at effect of biochemotherapy.
- 17 Brown, R. E., Bower, M. R., Metzger, T. L., Scoggins, C. R., McMasters, K. M., Hahl, M. J., Tatum, C. & Martin, R. C.
18 G. (2011) Hepatectomy after hepatic arterial therapy with either yttrium-90 or drug-eluting bead chemotherapy:
19 Is it safe? *HPB*, 13: 91-95.
- 20 Reason: Mixed population of different cancers.
- 21 Caraco, C., Mozzillo, N., Marone, U., Simeone, E., Benedetto, L., Di, Monta G., Di Cecilia, M. L., Botti, G., Ascierto,
22 P. A., Caraco, Corrado, Mozzillo, Nicola, Marone, Ugo, Simeone, Ester, Benedetto, Lucia, Di Monta, Gianluca, Di
23 Cecilia, Maria Luisa, Botti, Gerardo, and Ascierto, Paolo Antonio. Long-lasting response to electrochemotherapy
24 in melanoma patients with cutaneous metastasis. *BMC Cancer* 13, 564. 2013.
- 25 Reason: Not Melanoma
- 26 Cashin, R. P., Lui, P., Machado, M., Hemels, M. E., Corey-Lisle, P. K. & Einarson, T. R. (2008) Advanced cutaneous
27 malignant melanoma: a systematic review of economic and quality-of-life studies (DARE structured abstract).
28 *Value in Health*, 11: 259-271.
- 29 Reason: Economic and quality of life studies.
- 30 Chua, T. C., Scolyer, R. A., Kennedy, C. W., Yan, T. D., McCaughan, B. C. & Thompson, J. F. (2012) Surgical
31 management of melanoma lung metastasis: an analysis of survival outcomes in 292 consecutive patients. *Annals*
32 *of Surgical Oncology*, 19: 1774-1781.
- 33 Reason: Not study looking at effectiveness of the treatment.
- 34 Clarke, J. W., Register, S., McGregor, J. M., Grecula, J. C., Mayr, N. A., Wang, J. Z., Li, K., Gupta, N., Kendra, K. L.,
35 Olencki, T. E., Cavaliere, R., Sarkar, A. & Lo, S. S. (2010) Stereotactic radiosurgery with or without whole brain
36 radiotherapy for patients with a single radioresistant brain metastasis. *American Journal of Clinical Oncology*, 33:
37 70-74.
- 38 Reason: Mixed population:
- 39
- 40 Connolly, E. P. M. Involved field radiation therapy after surgical resection of solitary brain metastases - Mature
41 results. *Neuro-Oncology* 15[5], 589-594. 2013.

- 1 Reason: Not Melanoma
- 2 Concalves, M., Passos, A., Moreira, A. & Oliveira, J. (2009) Malignant melanoma brain metastases - A single
3 institution experience. *European Journal of Cancer, Supplement*, 7: 502.
- 4 Reason: Conference abstract - poster
- 5 Conill, C., Valduvieto, I., Domingo-Domenech, J., Arguis, P., Vidal-Sicart, S. & Vilalta, A. (2009) Loco-regional
6 control after postoperative radiotherapy for patients with regional nodal metastases from melanoma. *Clinical &*
7 *translational oncology*, 11: 688-693.
- 8 Reason: Not stage IV with oligometastatic disease
- 9 Dalrymple-Hay, M. J., Rome, P. D., Kennedy, C., Fulham, M. & McCaughan, B. C. (2002) Pulmonary metastatic
10 melanoma -- the survival benefit associated with positron emission tomography scanning. *European Journal of*
11 *Cardio-Thoracic Surgery*, 21: 611-614.
- 12 Reason: Not relevant to PICO
- 13 Dyer, M. A., Arvold, N. D., Chen, Y. H., Pinnell, N. E., Mitin, T., Lee, E. Q., Hodi, F. S., Ibrahim, N., Weiss, S. E., Kelly,
14 P. J., Floyd, S. R., Mahadevan, A., and Alexander, B. M. The role of whole brain radiation therapy in the
15 management of melanoma brain metastases. *Radiation Oncology* 9. 2014.
- 16 Reason: Not Melanoma
- 17 Fogarty, G., Morton, R. L., Vardy, J., Nowak, A. K., Mandel, C., Forder, P. M., Hong, A., Hruby, G., Burmeister, B.,
18 Shivalingam, B., Dhillon, H. & Thompson, J. F. (2011) Whole brain radiotherapy after local treatment of brain
19 metastases in melanoma patients--a randomised phase III trial. *BMC Cancer*, 11: 142.
- 20 Reason: No results reported
- 21 Fogarty, G., Vardy, J. & Nowak, A. (2011) Whole brain radiotherapy following local treatment of 1-3 intracranial
22 metastases of melanoma - A phase III trial (Anzmtg 01/07; TROG 08/05). *Asia-Pacific Journal of Clinical Oncology*,
23 7: 44.
- 24 Reason: Conference abstract.
- 25 Gonzalez-Martinez, J., Hernandez, L., Zamorano, L., Sloan, A., Levin, K., Lo, S., Li, Q. & Diaz, F. (2002) Gamma knife
26 radiosurgery for intracranial metastatic melanoma: a 6-year experience. *Journal of Neurosurgery*, 97: Suppl-8.
- 27 Reason: Brief report
- 28 Hasegawa, T., Kondziolka, D., Flickinger, J. C., Germanwala, A. & Lunsford, L. D. (1026) Brain metastases treated
29 with radiosurgery alone: an alternative to whole brain radiotherapy? *Neurosurgery*, 52: 1318-1326.
- 30 Reason: Not specific to melanoma
- 31 Herfarth, K. K., Izwekova, O., Thilmann, C., et al.. (2003) Linac-based radiosurgery of cerebral melanoma
32 metastases. Analysis of 122 metastases treated in 64 patients. *Strahlentherapie und Onkologie*, 179: 366-371.
- 33 Reason: No comparisons
- 34 Ivanova, D. Single brain metastases: Radiotherapy alone or combined with neurosurgery? Supportive Care in
35 Cancer Conference[[var.pagings](#)], June. 2013.
- 36 Reason: Abstract
- 37 Jung, E. W., Delly, F., Rakowski, J., Mittal, S., Tang, K., Kim, H. & Jagannathan, J. (2012) Repeated stereotactic
38 radiosurgery for progressive brain metastases from melanoma after initial treatment. *International Journal of*
39 *Radiation Oncology Biology Physics*, 84: S629.
- 40 Reason: Conference abstract.

- 1 Kalkanis, S. N., Kondziolka, D., Gaspar, L. E., Burri, S. H., Asher, A. L., Cobbs, C. S., Ammirati, M., Robinson, P. D.,
2 Andrews, D. W., Loeffler, J. S., McDermott, M., Mehta, M. P., Mikkelsen, T., Olson, J. J., Paleologos, N. A.,
3 Patchell, R. A., Ryken, T. C. & Linskey, M. E. (2010) The role of surgical resection in the management of newly
4 diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. *Journal of Neuro-*
5 *Oncology*, 96: 33-43.
6 Reason: Not specific to melanoma.
- 7 Kim, J. M., Losina, E., Bono, C. M., Schoenfeld, A. J., Collins, J. E., Katz, J. N. & Harris, M. B. (2012) Clinical outcome
8 of metastatic spinal cord compression treated with surgical excision +/- radiation versus radiation therapy alone:
9 A systematic review of literature. *Spine*, 37: 78-84.
10 Reason: Not specific to melanoma.
- 11 Kim, H., Jung, T. Y., Kim, I. Y., Jung, S., Moon, K. S., Park, S. J., Kim, Hyool, Jung, Tae Young, Kim, In Young, Jung,
12 Shin, Moon, Kyung Sub, and Park, Seung Jin. The usefulness of stereotactic radiosurgery for radioresistant brain
13 metastases. *Journal of Korean Neurosurgical Society* 54[2], 107-111. 2013.
14 Reason: Not Melanoma
- 15 Kis, E., Olah, J., Ocsai, H., Baltas, E., Gyulai, R., Kemeny, L. & Horvath, A. R. (2011) Electrochemotherapy of
16 Cutaneous Metastases of Melanoma-A Case Series Study and Systematic Review of the Evidence. *Dermatologic*
17 *Surgery*, 37: 816-824.
18 Reason: Electrochemotherapy not in PICO
- 19 Koay, E. J., Bucheit, A. D., Jakob, J. A., Hyun, E. D., Settle, S. H., Brown, P. D., Davies, M. A. & Sulman, E. P. (2012)
20 Correlation of BRAF and NRAS mutation status with tumor characteristics and treatment outcomes in melanoma
21 patients with brain metastasis. *Journal of Clinical Oncology*, 30.
22 Reason: Conference abstract.
- 23 Kocher, M., Maarouf, M., Bendel, M., Voges, J., Muller, R. P. & Strum, V. (2004) Linac radiosurgery versus whole
24 brain radiotherapy for brain metastases - A survival comparison based on the RTOG recursive partitioning analysis.
25 *Strahlentherapie und Onkologie*, 180: 263-267.
26 Reason: Not specific to melanoma
- 27 Lee, D. S., White, D. E., Hurst, R., Rosenberg, S. A. & Yang, J. C. (1998) Patterns of relapse and response to
28 retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based
29 immunotherapy. *The cancer journal from Scientific American*, 4: 86-93.
30 Reason: Mixed population
- 31 Lee, M. K. J. Is stereotactic radiosurgery under-utilised in the treatment of surgically excisable cerebral
32 metastases? *British Journal of Neurosurgery* 27[5], 658-661. 2013.
33 Reason: Not Melanoma
- 34 Lo, S. S., Clarke, J. W., Grecula, J. C., McGregor, J. M., Mayr, N. A., Cavaliere, R., Kendra, K. L., Gupta, N., Wang, J.
35 Z., Sarkar, A. & Olencki, T. E. (2011) Stereotactic radiosurgery alone for patients with 1-4 radioresistant brain
36 metastases. *Medical Oncology*, 28: Suppl-44.
37 Reason: Mixed population
- 38 Lopez, E. Frameless stereotactic radiosurgery for brain metastases using image guided radiotherapy (IGRT).
39 *European Journal of Cancer Conference*[var.pagings], September. 2013
40 Reason: Not Melanoma
- 41 Mali, B., Jarm, T., Snoj, M., Sersa, G., and Miklavcic, D. Antitumor effectiveness of electrochemotherapy: A
42 systematic review and meta-analysis. *Ejso* 39[1], 4-16. 2013

- 1 Reason: Not Melanoma
- 2 Memon, K., Kuzel, T. M., Vouche, M., Atassi, R., Lewandowski, R. J., and Salem, R. Hepatic yttrium-90
3 radioembolization for metastatic melanoma: a single-center experience. *Melanoma Research* 24[3], 244-251.
4 2014.
- 5 Reason: Not Melanoma
- 6 Miller, D., Zappala, V., El, H. N., Livingstone, E., Schadendorf, D., Sure, U. & Sandalcioglu, I. E. (2013) Intracerebral
7 metastases of malignant melanoma and their recurrences--a clinical analysis. *Clinical Neurology & Neurosurgery*,
8 115: 1721-1728.
- 9 Reason: No comparison
- 10 Minniti, G., D'Angelillo, R. M., Scaringi, C., Trodella, L. E., Clarke, E., Matteucci, P., Osti, M. F., Ramella, S., Enrici, R.
11 M., and Trodella, L. Fractionated stereotactic radiosurgery for patients with brain metastases. *Journal of Neuro-*
12 *Oncology* 117[2], 295-301. 2014.
- 13 Reason: Not Melanoma
- 14 Morton, D. L., Stern, S. & Elashoff, R. (2011) Surgical resection for melanoma metastatic to distant sites. *Annals of*
15 *Surgical Oncology*, 18: S21.
- 16 Reason: Conference abstract.
- 17 Narayana, A., Mathew, M., Tam, M., Kannan, R., Madden, K. M., Golfinos, J. G., Parker, E. C., Ott, P. A. & Pavlick,
18 A. C. (2013) Vemurafenib and radiation therapy in melanoma brain metastases. *Journal of Neuro-Oncology*, 113:
19 411-416.
- 20 Reason: Study not relevant to PICO.
- 21 Nieweg, O. Combination treatment for irresectable melanoma masses. *European Journal of Cancer*
22 *Conference*[var.pagings], September. 2013.
- 23 Reason: Abstract
- 24 Olson, J. J., Paleologos, N. A., Gaspar, L. E., Robinson, P. D., Morris, R. E., Ammirati, M., Andrews, D. W., Asher, A.
25 L., Burri, S. H., Cobbs, C. S., Kondziolka, D., Linskey, M. E., Loeffler, J. S., McDermott, M., Mehta, M. P., Mikkelsen,
26 T., Patchell, R. A., Ryken, T. C. & Kalkanis, S. N. (2010) The role of emerging and investigational therapies for
27 metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics
28 (DARE structured abstract). *Journal of Neuro-Oncology*, 96: 115-142.
- 29 Reason: No discussion of local treatments.
- 30 Pennacchioli, E., Gandini, S., Verrecchia, F., Tosti, G., Spadola, G., Baldini, F., Mosconi, M., Ferrucci, P. & Testori,
31 A. (2011) Surgery in stage IV melanoma patients: Results from a single institution. *Pigment Cell and Melanoma*
32 *Research*, 24: 1066-1067.
- 33 Reason: Conference abstract.
- 34 Peterson, H. E., Larson, E. W., Fairbanks, R. K., Mackay, A. R., Lamoreaux, W. T., Call, J. A., Carlson, J. D., Ling, B.
35 C., Demakas, J. J., Cooke, B. S., Peressini, B., and Lee, C. M. Gamma knife treatment of brainstem metastases.
36 *International Journal of Molecular Science* 15[6], 9748-9761. 2014.
- 37 Reason: Not Melanoma
- 38 Pflugfelder, A., Kochs, C., Blum, A., et al. (2001) Malignant melanoma S3-guideline "diagnosis, therapy and follow-
39 up of melanoma". *Journal der Deutschen Dermatologischen Gesellschaft*, 11: Suppl-116.
- 40 Reason: Guidelines

- 1 Plana, M., Pons, V. F., Caminal, J. M., Pera, J., Fernandes, I. C., Perez, F. J., Garcia, D. M., X, Gutierrez, C., Jimenez,
2 L. & Piulats, J. M. (2010) Metastatic uveal melanoma: Is there a role for conventional chemotherapy? A single
3 experience based on 58 patients. *Journal of Clinical Oncology*, 28.
4 Reason: Not relevant to PICO
- 5 Pollock, B. E., Brown, P. D., Foote, R. L., Stafford, S. L. & Schomberg, P. J. (2003) Properly selected patients with
6 multiple brain metastases may benefit from aggressive treatment of their intracranial disease. [Review] [32 refs].
7 *Journal of Neuro-Oncology*, 61: 73-80.
8 Reason: Not specific to melanoma.
- 9 Pons, F., Plana, M., Caminal, J. M., Pera, J., Fernandes, I., Perez, J., Garcia-Del-Muro, X., Marcoval, J., Penin, R.,
10 Fabra, A. & Piulats, J. M. (2011) Metastatic uveal melanoma: is there a role for conventional chemotherapy? - A
11 single center study based on 58 patients. [Review]. *Melanoma Research*, 21: 217-222.
12 Reason: Primary uveal melanoma – not to be covered (according to scope)
- 13 Rades, D., Hornung, D., Blanck, O., Martens, K., Khoa, M. T., Trang, N. T., Huppe, M., Terheyden, P., Gliemroth, J.,
14 and Schild, S. E. Stereotactic radiosurgery for newly diagnosed brain metastases. *Strahlentherapie und Onkologie*
15 190[9], 786-791. 2014.
16 Reason: Not Melanoma
- 17 Rades, D., Sehmis, L., Huttenlocher, S., Blank, O., Hornung, D., Terheyden, P., Gliemroth, J., and Schild, S. E.
18 Radiosurgery Alone for 1-3 Newly-diagnosed Brain Metastases from Melanoma: Impact of Dose on Treatment
19 Outcomes. *Anticancer Research* 34[9], 5079-5082. 2014.
20 Reason: Not Melanoma
- 21 Rades, D., Hornung, D., Blanck, O., Martens, K., Khoa, M. T., Trang, N. T., Huppe, M., Terheyden, P., Gliemroth, J.,
22 and Schild, S. E. Stereotactic radiosurgery for newly diagnosed brain metastases: comparison of three dose levels.
23 *Strahlentherapie und Onkologie* 190[9], 786-791. 2014.
24 Reason: Not Melanoma
- 25 Rezvi, U. Judicious use of radiosurgery (SRS) may change the ultimate patterns of failure in patients with brain
26 metastasis from melanoma. *Neuro-Oncology Conference*[var.pagings], November. 2013
27 Reason: Abstract
- 28 Ricotti, F., Giuliadori, K., Cataldi, I., Campanati, A., Ganzetti, G., Ricotti, G., and Offidani, A. Electrochemotherapy:
29 an effective local treatment of cutaneous and subcutaneous melanoma metastases. *Dermatologic Therapy* 27[3],
30 148-152. 2014.
31 Reason: Intervention not relevant to PICO
- 32 Richtig, E., Ludwig, R., Kerl, H. & Smolle, J. (2005) Organ- and treatment-specific local response rates to systemic
33 and local treatment modalities in stage IV melanoma. *British Journal of Dermatology*, 153: 925-931.
34 Reason: Not oligometastatic disease.
- 35 Rivoire, M., De, C. F., Meeus, P., Gignoux, B., Frering, B. & Kaemmerlen, P. (2000) Cryosurgery as a means to
36 improve surgical treatment of patients with multiple unresectable liver metastases. *Anticancer Research*, 20:
37 3785-3790.
38 Reason: Not specific to melanoma.
- 39 Rutter, C. E., Giesen, E., Yu, J. B., Bindra, R. S., Kluger, H. M. & Chiang, V. L. (2013) Influence of braf and nras
40 mutations on distant intracranial recurrence and survival in metastatic melanoma following radiosurgery.
41 *International Journal of Radiation Oncology Biology Physics*, 87: S275.
42 Reason: Conference abstract.

- 1 Sanki, A., Scolyer, R. A. & Thompson, J. F. (2009) Surgery for melanoma metastases of the gastrointestinal tract:
2 Indications and results. *European Journal of Surgical Oncology*, 35: 313-319.
3 Reason: NO relevant Comparisons
- 4 Sasse, A. D., Sasse, E. C., Clark-Luciana, G. O., Ulloa, L. & Clark-Otavio, A. C. (2007) Chemoimmunotherapy versus
5 chemotherapy for metastatic malignant melanoma. *Cochrane.Database.of Systematic.Reviews*.
6 Reason: No discussion of local treatment.
- 7 Schneebaum, S. (2011) For patients with distant metastases - Surgery is first choice of treatment. *European*
8 *Journal of Cancer*, 47: S14.
9 Reason: Conference abstract.
- 10 Sia, J., Paul, E., Dally, M., and Ruben, J. Stereotactic radiosurgery for 318 brain metastases in a single Australian
11 centre: The impact of histology and other factors. *Journal of Clinical Neuroscience* . 7-10-2014.
12 Reason: Not Melanoma
- 13 Solari, N., Spagnolo, F., Ponte, E., Quaglia, A., Lillini, R., Battista, M., Queirolo, P., and Cafiero, F.
14 Electrochemotherapy for the Management of Cutaneous and Subcutaneous Metastasis: A Series of 39 Patients
15 Treated With Palliative Intent. *Journal of Surgical Oncology* 109[3], 270-274. 2014.
16 Reason: Not Melanoma
- 17 Soon, Yu Yang, Tham-Ivan, Weng Keong, Lim, Keith H., Koh, Wee Yao, and Lu, Jiade J. Surgery or radiosurgery plus
18 whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases. *Cochrane Database of*
19 *Systematic Reviews* . 2014.
20 Reason: Not Melanoma
- 21 Strojanc, P., Jancar, B., Cemazar, M., Perme, M. P. & Hocevar, M. (2010) Melanoma Metastases to the Neck
22 Nodes: Role of Adjuvant Irradiation. *International Journal of Radiation Oncology Biology Physics*, 77: 1039-1045.
23 Reason: Not relevant to PICO
- 24 Tait, I. S., Yong, S. M. & Cuschieri, S. A. (2002) Laparoscopic in situ ablation of liver cancer with cryotherapy and
25 radiofrequency ablation. *British Journal of Surgery*, 89: 1613-1619.
26 Reason: Mixed population
- 27 Tauceri, F., Mura, G., Roseano, M., Framarini, M., Ridolfi, L. & Verdecchia, G. M. (2009) Surgery and adjuvant
28 therapies in the treatment of stage IV melanoma: our experience in 84 patients. *Langenbecks Archives of Surgery*,
29 394: 1079-1084.
30 Reason: No relevant comparison
- 31 Vecchio, S., Spagnolo, F., Merlo, D. F., Signori, A., Acquati, M., Pronzato, P., and Queirolo, P. The treatment of
32 melanoma brain metastases before the advent of targeted therapies: associations between therapeutic choice,
33 clinical symptoms and outcome with survival. *Melanoma Research* 24[1], 61-67. 2014.
34 Reason: Not Melanoma
- 35 Wang, S., Zhao, Z., Barber, B. & Wagner, V. (2012) Surgery, radiation, and systemic therapies in patients with
36 metastatic melanoma. *Value in Health*, 15: A232-A233.
37 Reason: Conference abstract.
- 38 Wiggendaad, R., Verbeek-de, K. A., Mast, M., Molenaar, R., Kal, H. B., Nijeholt, G., Vecht, C. & Struikmans, H.
39 (2012) Local progression and pseudo progression after single fraction or fractionated stereotactic radiotherapy
40 for large brain metastases. A single centre study. *Strahlentherapie und Onkologie*, 188: 696-701.
41 Reason: Mixed Population

- 1 Xing, M., Prajapati, H. J., Dhanasekaran, R., Lawson, D. H., Kokabi, N., Eaton, B. R., and Kim, H. S. Selective
- 2 Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With
- 3 Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort
- 4 Study. American Journal of Clinical Oncology . 7-8-2014.
- 5 Reason: Not Melanoma

6

Evidence tables

Study Quality

	method of allocation to treatment groups was unrelated to potential confounding factors	Attempts were made within the design or analysis to balance the comparison groups for potential confounders	Comparable at baseline	The comparison groups received the same care apart from the intervention(s) studied	Participants blind to treatment allocation	Treatment administrators blind to treatment allocation	Equal follow up	Appropriate length of follow-up	Precise definition of an outcome	Valid method of measuring outcomes	Investigators blind to participants exposure to intervention?	Investigators blind to potential confounders and prognostic factors?
Buchsbaum et al 2002	No	No	No	No	No	No	No	Yes	Yes	Yes	No	No
Chua et al 2010	No	No	No	No	No	No	No	Yes	Yes	Yes	No	No
Collinson et al 2008	No	No	No	No	No	No	No	Yes	Yes	Yes	No	No
Fife et al 2004	No	No	No	No	No	No	No	Yes	Yes	Yes	No	No
Gutman et al 2001	No	No	No	No	No	No	No	Yes	Yes	Yes	No	No
Konstadoulakis et al 2000	No	No	No	No	No	No	No	Yes	Yes	Yes	No	No
Meier et al 2004	No	No	No	No	No	No	No	Yes	Yes	Yes	No	No
Meyer et al., 2000	No	No	No	No	No	No	No	Yes	Yes	Yes	No	No
Neuman et al 2007	No	No	No	No	No	No	Yes	Yes	Yes	Yes	No	No
Ollila et al., 1999	No	No	No	No	No	No	Yes	Yes	Yes	Yes	No	No
Panagiotou et al 2005	No	No	No	No	No	No	Yes	Yes	Yes	Yes	No	No
Raizer et al 2008	No	No	No	No	No	No	Yes	Yes	Yes	Yes	No	No
Rose et al 2001	No	No	No	No	No	No	Yes	Yes	Yes	Yes	No	No
Stone et al 2004	No	No	No	No	No	No	Yes	Yes	Yes	Yes	No	No

BRAIN METASTASES

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS				NOTES
Buchsbaum, J. C., Suh, J. H., Lee, S. Y., Chidel, M. A., Greskovich, J. F. & Barnett, G. H. (2002) Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. <i>Cancer</i> , 94: 2265-2272.	Retrospective	74					Risk of Bias – HIGH. Patient selection bias. Survival benefit of combination therapy likely due to selection bias – clinicians had selected patients for treatment in a fashion that correlated with the RTOG RPA schema.
			Treatment	No. patients	median survival (months)	No. patients with brain metastases recurrence	
			Combined therapy (local + WBRT)	36	8.8	18	
			Local therapy alone (surgery or SRS)	10	4.8	2	
			WBRT alone	25	2.3	4	
			No treatment	3	1.1	-	
			Combined vs. other p<0.0001				

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS				NOTES
			WBRT alone v Combined therapy (local + WBRT)	2.39 2	1.161-4.929	0.0180	
			Local therapy alone (surgery or SRS) v Combined therapy (local + WBRT)	1.44 0	0.648-3.197	0.3703	
			Acute complications				
				Complications	No. patients		
			Surgery (alone or with WBRT)	6 (24%)	25		
			WBRT or STR	10 (14%)	70		
			Radiation: 0 patients symptomatic radiation necrosis				
			Surgery (alone or with WBRT) – acute complications: 1 infection, 2 haemorrhages, 3 central nervous system deficits. No long term complications.				

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS				NOTES																											
Fife, K. M., Colman, M. H., Stevens, G. N., Firth, I. C., Moon, D., Shannon, K. F., Harman, R., Petersen-Schaefer, K., Zacest, A. C., Besser, M., Milton, G. W., McCarthy, W. H. & Thompson, J. F. (2004) Determinants of outcome in melanoma patients with cerebral metastases. <i>Journal of Clinical Oncology</i> , 22: 1293-1300.	Retrospective	686 patients, As of June 2003 646 had died as a result of melanoma.	<table><tr><th>Treatment</th><th>No. patients</th><th>median survival (months)</th></tr><tr><td>surgery and postoperative radiotherapy</td><td>158</td><td>8.9</td></tr><tr><td>surgery alone</td><td>47</td><td>8.7</td></tr><tr><td>radiotherapy alone</td><td>236</td><td>3.4</td></tr><tr><td>supportive care alone</td><td>210</td><td>2.1</td></tr></table> <table><tr><th>Treatment</th><th>HR</th><th>CI</th><th>p</th></tr><tr><td>Surgery v supportive care</td><td>0.436</td><td>0.308-0.619</td><td><0.001</td></tr><tr><td>Radiotherapy v supportive care</td><td>0.851</td><td>0.698-1.038</td><td>0.111</td></tr></table>				Treatment	No. patients	median survival (months)	surgery and postoperative radiotherapy	158	8.9	surgery alone	47	8.7	radiotherapy alone	236	3.4	supportive care alone	210	2.1	Treatment	HR	CI	p	Surgery v supportive care	0.436	0.308-0.619	<0.001	Radiotherapy v supportive care	0.851	0.698-1.038	0.111	<p>Risk of Bias – HIGH.</p> <p>Patient selection bias.</p> <p>Median survival was dependent on treatment, which in turn was dependent on patient selection.</p> <p>Patients were selected for active treatment on the basis of having a single cerebral metastasis, cerebral metastases with no evidence of metastatic disease elsewhere, or a younger age.</p>
Treatment	No. patients	median survival (months)																																
surgery and postoperative radiotherapy	158	8.9																																
surgery alone	47	8.7																																
radiotherapy alone	236	3.4																																
supportive care alone	210	2.1																																
Treatment	HR	CI	p																															
Surgery v supportive care	0.436	0.308-0.619	<0.001																															
Radiotherapy v supportive care	0.851	0.698-1.038	0.111																															

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS				NOTES																
			<table><tr><td>Surgery and radiotherapy v supportive care</td><td>0.346</td><td>0.273-0.439</td><td><0.001</td></tr></table>				Surgery and radiotherapy v supportive care	0.346	0.273-0.439	<0.001													
Surgery and radiotherapy v supportive care	0.346	0.273-0.439	<0.001																				
Konstadoulakis, M. M., Messaris, E., Zografos, G., Androulakis, G. & Karakousis, C. (2000) Prognostic factors in malignant melanoma patients with solitary or multiple brain metastases. Is there a role for surgery? <i>Journal of Neurosurgical Sciences</i> , 44: 211-218.	Retrospective	136	<table><tr><th>Treatment</th><th>No. patients</th><th>median survival (months)</th><th>1 year survival</th></tr><tr><td>surgery</td><td>32</td><td>5</td><td>28.13%</td></tr><tr><td>radiotherapy and/or chemotherapy</td><td>75</td><td>3</td><td>6.67%</td></tr><tr><td>No treatment</td><td>29</td><td>1</td><td>3.45%</td></tr></table> <p>One year survival of patients treated surgically was significantly better than patients who received radiotherapy and/or chemotherapy or who had no treatment. p=0.006.</p>				Treatment	No. patients	median survival (months)	1 year survival	surgery	32	5	28.13%	radiotherapy and/or chemotherapy	75	3	6.67%	No treatment	29	1	3.45%	<p>Risk of Bias – HIGH.</p> <p>Patient selection bias.</p> <p>Survival was dependent on treatment, which in turn was dependent on patient selection.</p>
Treatment	No. patients	median survival (months)	1 year survival																				
surgery	32	5	28.13%																				
radiotherapy and/or chemotherapy	75	3	6.67%																				
No treatment	29	1	3.45%																				
Meier, S., Baumert, B. G., Maier, T., Wellis, G., Burg, G., Seifert, B.	Retrospective	100 patients	<table><tr><th>Treatment</th><th>No.</th><th>median survival</th><th>1 year</th></tr></table>				Treatment	No.	median survival	1 year	<p>Risk of Bias – HIGH.</p> <p>Patient selection bias.</p>												
Treatment	No.	median survival	1 year																				

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS				NOTES
& Dummer, R. (2004) Survival and prognostic factors in patients with brain metastases from malignant melanoma. <i>Onkologie</i> , 27: 145-149.	e						Survival was dependent on treatment, which in turn was dependent on patient selection.
				patients	(months)	survival	
			Surgery	37	10.6	31%	
			No surgery	63	2.9	3%	
			p<0.0001				
			Treatment	No. patients	median survival (months)	1 year survival	
			Radiosurgery	17	10.3	35%	
			No radiosurgery	83	3.9	9%	
			p=0.002				
			Treatment	No. patients	median survival (months)	1 year survival	
WBRT/PBRT	54	5.5	19%				
No WBRT/PBRT	46	2.6	7%				
p=0.009							

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS				NOTES																				
			<table><tr><th>Treatment</th><th>HR</th><th>CI</th><th>p</th></tr><tr><td>WBRT/PBRT</td><td>0.45</td><td>0.29-0.70</td><td>0.0004</td></tr><tr><td>surgery</td><td>0.30</td><td>0.19-0.49</td><td><0.0001</td></tr><tr><td>radiosurgery</td><td>0.31</td><td>0.17-0.55</td><td><0.0001</td></tr><tr><td>chemotherapy</td><td>0.43</td><td>0.27-0.70</td><td>0.0006</td></tr></table>				Treatment	HR	CI	p	WBRT/PBRT	0.45	0.29-0.70	0.0004	surgery	0.30	0.19-0.49	<0.0001	radiosurgery	0.31	0.17-0.55	<0.0001	chemotherapy	0.43	0.27-0.70	0.0006	
Treatment	HR	CI	p																								
WBRT/PBRT	0.45	0.29-0.70	0.0004																								
surgery	0.30	0.19-0.49	<0.0001																								
radiosurgery	0.31	0.17-0.55	<0.0001																								
chemotherapy	0.43	0.27-0.70	0.0006																								
Panagiotou, I. E., Brountzos, E. N., Kelekis, D. A., Papathanasiou, M. A. & Bafaloukos, D. I. (2005) Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome. <i>Neoplasma</i> , 52: 150-158.	Retrospective	64	<table><tr><th>Treatment</th><th>No. patients</th><th>median survival (months)</th></tr><tr><td>Surgery followed by radiotherapy</td><td>5</td><td>12</td></tr><tr><td>Temozolomide as first line treatment and radiotherapy</td><td>17</td><td>5</td></tr></table>				Treatment	No. patients	median survival (months)	Surgery followed by radiotherapy	5	12	Temozolomide as first line treatment and radiotherapy	17	5	Risk of Bias – HIGH. Patient selection bias. Survival was dependent on treatment. Patient characteristics											
Treatment	No. patients	median survival (months)																									
Surgery followed by radiotherapy	5	12																									
Temozolomide as first line treatment and radiotherapy	17	5																									

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS			NOTES																
			after cerebral disease progression			influenced selection of treatment modality.																
			radiotherapy alone																			
			supportive care only																			
			Surgery vs non surgery groups: p=0.0011																			
<table><tr><th>Treatment</th><th>HR</th><th>SE</th><th>p</th></tr><tr><td>supportive care only</td><td></td><td></td><td></td></tr><tr><td>Surgery/radiotherapy</td><td>9.6831</td><td>7.0301</td><td>0.0053</td></tr><tr><td>whole brain irradiation</td><td>0.4099</td><td>1.1010</td><td>0.7097</td></tr><tr><td>Temozolomide/ radiotherapy</td><td>4.1874</td><td>2.2236</td><td>0.5497</td></tr></table>			Treatment	HR	SE	p	supportive care only				Surgery/radiotherapy	9.6831	7.0301	0.0053	whole brain irradiation	0.4099	1.1010	0.7097	Temozolomide/ radiotherapy	4.1874	2.2236	0.5497
Treatment	HR	SE	p																			
supportive care only																						
Surgery/radiotherapy	9.6831	7.0301	0.0053																			
whole brain irradiation	0.4099	1.1010	0.7097																			
Temozolomide/ radiotherapy	4.1874	2.2236	0.5497																			

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS			NOTES
Raizer, J. J., Hwu, W.-J., Panageas, K. S., Wilton, A., Baldwin, D. E., Bailey, E., Von, A. C., Lamb, L. A., Alvarado, G., Bilsky, M. H. & Gutin, P. H. (2008) Brain and leptomeningeal metastases from cutaneous melanoma: Survival outcomes based on clinical features. <i>Neuro-Oncology</i> , 10: 199-207.	Retrospective	Brain metastases from 355 melanoma patients.				Risk of Bias – HIGH. Patient selection bias. Patients treated with surgery and RS had the longest survival. However a selection bias most certainly contributed to this result in that patients treated with surgery and/or RS likely had a lower intracranial tumour burden and controlled or absent extracranial disease and were likely healthier overall compared with patients receiving WBRT or supportive care.
			Treatment	No. patients	median survival (months)	
			None	83	2.04	
			WBRT alone	100	3.98	
			RS alone	26	9.87	
			Surgery alone	36	8.16	
			WBRT + RS	20	9.44	
			Surgery + WBRT	58	8.81	
			Surgery + RS	20	13.75	
			Surgery + WBRT + RS	12	10.2	
Brain metastasis directed therapies improve survival compared with supportive care only.						
Patients treated with surgery and RS had the longest survival.						

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS			NOTES
Stone, A., Cooper, J., Koenig, K. L., Golfinos, J. G. & Oratz, R. (2004) A comparison of survival rates for treatment of melanoma metastatic to the brain. <i>Cancer Investigation</i> , 22: 492-497.	Retrospective	91 patients with brain metastases from malignant melanoma	Gamma knife stereotactic radiosurgery plus WBRT (n=8) and patients treated with surgery plus WBRT (n=16) median survival 10.9 months vs radiation alone (n=59) median survival 3.6 months			Risk of Bias – HIGH. Patient selection bias. Patients treated with Gamma knife stereotactic radiosurgery or surgery plus radiation therapy were younger, less likely to present with symptoms and presented with fewer metastases to the brain than patients treated with radiation therapy alone.
			Treatment	No. patients	median survival (months)	
			Gamma knife stereotactic radiosurgery plus WBRT	8	10.9	
			surgery plus WBRT	16		
			WBRT alone	59	3.6	

LUNG METASTASES

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS				NOTES
Neuman, H. B., Patel, A., Hanlon, C., Wolchok, J. D., Houghton, A. N. & Coit, D. G. (2007) Stage-IV melanoma and pulmonary metastases: factors predictive of survival. <i>Annals of Surgical Oncology</i> , 14: 2847-2853.	Retrospective	122	Treatment	No. patients	median survival (months)	5 year survival	Selection bias. Patients undergoing surgery were more likely to be younger, have localised rather than regional disease prior to presentation with distant metastases and have a single metastatic focus.
			Surgery	26	40	29%	
			No surgery	96 (82 systemic therapy; 14 no treatment)	13	NR	

ADRENAL METASTASES

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS	NOTES									
Collinson, F. J., Lam, T. K., Bruijn, W. M. J., De Wilt, J. H. W., Lamont, M., Thompson, J. F. & Kefford, R. F. (2008) Long-term survival and occasional regression of distant melanoma metastases after adrenal metastasectomy. <i>Annals of Surgical Oncology</i> , 15: 1741-1749.	Retrospective	186 patients with adrenal gland metastases from melanoma.	<table><tr><th>Treatment</th><th>No. patients</th><th>median survival (months)</th></tr><tr><td>adrenalectomy</td><td>23</td><td>16</td></tr><tr><td>non surgical treatment</td><td>163</td><td>5</td></tr></table> <p>p<0.00001</p>	Treatment	No. patients	median survival (months)	adrenalectomy	23	16	non surgical treatment	163	5	High selection bias. Patients were selected for surgery on the basis of the extent of the disease, the resectability of any concomitant metastases, general fitness and performance status.
Treatment	No. patients	median survival (months)											
adrenalectomy	23	16											
non surgical treatment	163	5											

LIVER METASTASES

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS					NOTES																				
Rose DM, Essner R, Hughes MD, Tang PC, Bilchik A, Wanek LA <i>et al.</i> (2001) Surgical resection for metastatic melanoma to the liver. <i>Arch Surg</i> 136: 950–955.	Retrospective	1750 patients with hepatic metastases, of whom 34 underwent exploration with intent to resect the metastases (24 underwent hepatic resection (18 complete resection and 6 incomplete) and 10 underwent exploration but not resection).	<table><tr><th>Treatment</th><th>No. patients</th><th>median survival (months)</th><th>3 year survival</th><th>5 year survival</th></tr><tr><td>Surgical resection</td><td>24</td><td>28</td><td>41%</td><td>29%</td></tr><tr><td>Exploration only</td><td>10</td><td>4</td><td>NR</td><td>NR</td></tr><tr><td>Non-operative treatment</td><td>899</td><td>6</td><td>NR</td><td>4%</td></tr></table>					Treatment	No. patients	median survival (months)	3 year survival	5 year survival	Surgical resection	24	28	41%	29%	Exploration only	10	4	NR	NR	Non-operative treatment	899	6	NR	4%	High selection bias. Outcomes for all 1750 patients with hepatic metastases not reported.
Treatment	No. patients	median survival (months)	3 year survival	5 year survival																								
Surgical resection	24	28	41%	29%																								
Exploration only	10	4	NR	NR																								
Non-operative treatment	899	6	NR	4%																								
Chua T, Saxena A, Morris DL. (2010) Surgical metastasectomy in AJCC stage IV M1c melanoma with gastrointestinal and liver metastases. <i>Ann Acad Med Singapore</i> 39: 634–639.	Retrospective	23 patients with gastrointestinal/ liver metastases	<table><tr><th>Treatment</th><th>No. patients</th><th>median survival (months)</th><th>1 year survival</th><th>3 year survival</th></tr><tr><td>surgery</td><td>15</td><td>21</td><td>60%</td><td>40%</td></tr><tr><td>No surgery (clinical trials/system</td><td>8</td><td>4</td><td>NR</td><td>NR</td></tr></table>					Treatment	No. patients	median survival (months)	1 year survival	3 year survival	surgery	15	21	60%	40%	No surgery (clinical trials/system	8	4	NR	NR	High selection bias. Patients were deemed inappropriate for surgery if their disease was considered unresectable, or if they had other metastatic sites that were untreated.					
Treatment	No. patients	median survival (months)	1 year survival	3 year survival																								
surgery	15	21	60%	40%																								
No surgery (clinical trials/system	8	4	NR	NR																								

			ic therapies)					

ABDOMINAL METASTASES

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS	NOTES									
Gutman, H., Hess, K. R., Kokotsakis, J. A., Ross, M. I., Guinee, V. F. & Balch, C. M. (2001) Surgery for abdominal metastases of cutaneous melanoma. <i>World Journal of Surgery</i>, 25: 750-758.	Retrospective	251 melanoma patients who developed intra abdominal metastases	<p>96 patients underwent 119 laparotomies</p> <p>51 underwent non-surgical intervention (i.e., endoscopic or percutaneous procedures)</p> <p>116 were treated medically only without any invasive procedure.</p> <table border="1"><thead><tr><th>Treatment</th><th>No. patients</th><th>median survival (months)</th></tr></thead><tbody><tr><td>Surgery (laparotomy)</td><td>96</td><td>11</td></tr><tr><td>non surgical treatment</td><td>155</td><td>5</td></tr></tbody></table> <p>p<0.0001</p> <p>23% of patients treated with surgery were symptom free for at least 1 year and 16% remained asymptomatic for more than 2 years. Patients with non-surgical interventions only rarely remained asymptomatic for more than 1 month.</p> <p>Major postoperative complications (septicaemia,</p>	Treatment	No. patients	median survival (months)	Surgery (laparotomy)	96	11	non surgical treatment	155	5	<p>Selection bias.</p> <p>Metastases were from a wide range of abdomen locations e.g., small bowel, liver, stomach, colon, pancreas, etc.</p>
Treatment	No. patients	median survival (months)											
Surgery (laparotomy)	96	11											
non surgical treatment	155	5											

			abdominal sepsis, evisceration, pulmonary embolism) in 14% of surgical patients, and 18% had minor complications (wound infection, deep vein thrombosis, pneumonia). The mortality rate at 30 days after surgery was 3.2%.	
--	--	--	--	--

MIXED METASTASES

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS	NOTES
Faries et al (2014)	Retrospective	<p>N=58 patients considered candidates for surgery (resection with or without ablation)</p> <p>Represents 5.4% of total population of melanoma patients with metastatic liver disease</p>	<p>Surgery + Ablation versus Ablation Only</p> <p>Overall survival and disease free survival were better in the surgical group compared with the non-surgical group.</p> <p>Median OS was 8 months in the non-surgical group compared with 24.8 months in the surgical group. 5 year OS rate was 6.6% in the non-surgical group compared with 30% in the surgical group (p<0.001).</p> <p>Outcomes did not differ significantly by type of surgery (resection, ablation, resection/ablation)</p> <p>Outcomes for patients who underwent concomitant resection of extrahepatic metastases were not significantly worse than those with liver only disease.(p=0.14)</p> <p>Patients who underwent systemic treatment with disease stabilisation before surgery had favourable overall and disease free survival compared with those who did not (p=0.01).</p> <p>Overall survival was found to be independently associated with completeness of surgical treatment [HR=3.4, 95% CI 1.4-8.1, p=0.007) and to stabilisation of disease on previous systemic therapy [HR=0.38, 95% CI 0.19-0.78, p=0.008).</p> <p>Disease free survival was associated with completeness of surgery [HR=5.1, 95% CI 2-12.9, p=0.0007).</p>	

Meyer, T., Merkel, S., Goehl, J. & Hohenberger, W. (2000) Surgical therapy for distant metastases of malignant melanoma. <i>Cancer</i> , 89: 1983-1991.	Retrospective	444 consecutive patients with distant melanoma metastases	<table><tr><th>Treatment</th><th>No. patients</th><th>median survival (months)</th><th>2 year survival</th></tr><tr><td>Surgery with curative resection</td><td>111</td><td>17</td><td>36.1%</td></tr><tr><td>Surgery with palliative resection</td><td>63</td><td>6</td><td>12.7%</td></tr><tr><td>Conservative treatment (systemic chemotherapy and/or immunotherapy with various drugs or supportive care)</td><td>270</td><td>4</td><td>8.1%</td></tr></table>	Treatment	No. patients	median survival (months)	2 year survival	Surgery with curative resection	111	17	36.1%	Surgery with palliative resection	63	6	12.7%	Conservative treatment (systemic chemotherapy and/or immunotherapy with various drugs or supportive care)	270	4	8.1%	Risk of Bias – HIGH. Patient selection bias.
Treatment	No. patients	median survival (months)	2 year survival																	
Surgery with curative resection	111	17	36.1%																	
Surgery with palliative resection	63	6	12.7%																	
Conservative treatment (systemic chemotherapy and/or immunotherapy with various drugs or supportive care)	270	4	8.1%																	
Ollila, D. W., Hsueh, E. C., Stern, S. L. & Morton, D. L. (1999) Metastasectomy for recurrent stage IV melanoma. <i>Journal of Surgical Oncology</i> , 71: 209-213.	Retrospective	131 patients who developed recurrent stage IV melanoma	<table><tr><th>Treatment</th><th>No. patients</th><th>median survival (months)</th><th>5 year survival</th></tr><tr><td>complete metastasectomy</td><td>40</td><td>18.2</td><td>20%</td></tr></table>	Treatment	No. patients	median survival (months)	5 year survival	complete metastasectomy	40	18.2	20%	Risk of Bias – HIGH. Patient selection bias. Patients managed non-operatively had multiple brain or liver metastases and/or involvement of								
Treatment	No. patients	median survival (months)	5 year survival																	
complete metastasectomy	40	18.2	20%																	

			palliative surgical procedure	43	12.5	7%	more than 3 anatomic sites.
			nonsurgical management	48	5.9	2.1%	

6.2 Localised treatment for brain metastases

Review question: What is the effectiveness of local treatment using surgery or radiotherapy compared with systemic drug therapy or supportive care in the management of brain metastases in people with stage IV melanoma?

Background

A wide variety of treatment modalities have been used to treat metastatic melanoma, i.e. a melanoma which is spread through the bloodstream to reach distant sites. The commonest metastatic sites for melanoma to spread to are liver, lungs, brain and bone. Melanoma can also spread to other skin sites giving tumours under the skin at subcutaneous nodules. Unfortunately with melanoma, spread can also occur almost anywhere in the body, including sites that other cancers do not usually spread to, such as the gastrointestinal tract or the heart.

All the many local treatments which have been used, and several new approaches are in development or at the clinical trials stage, have in common the aim of removing the melanoma metastases completely, and so reducing the risk of recurrence at that particular site, while reducing to a minimum the side-effects or morbidity of using that particular treatment. Therefore some techniques such as the emerging advanced radiotherapy techniques are more appropriate to use for brain metastasis where the inevitable morbidity of any surgical approach, might be too high a cost for the palliation achieved. In contrast, surgical techniques using surgery, laser ablation or localised electro-chemotherapy would be much more appropriate for the palliation of multiple subcutaneous melanoma metastases, than any of even the new radiotherapy techniques.

Surgical management of distant malignant melanoma deposits has been used for hundreds of years but these techniques are still developing with increased use of laser treatments and the development of electro-chemotherapy. Advances in imaging and diagnostic techniques has allowed for more precise surgical intervention improving palliation and decreasing morbidity.

Stereotactic radiosurgery, introduced in the last two decades allows for the treatment of metastases in a much reduced number of fractions and by being able to deliver highly focused radiation treatments to very precise target areas with much reduced dose to surrounding normal tissues reduces treatment morbidity and the number of patient attendances required for treatment. Other new technologies for treating melanoma metastases include CyberKnife and other Intensity Modulation RadioTherapy approaches.

Radiation can also be used by delivering radioactive particles to the melanoma metastases and using different techniques so that these particles are preferentially taken up within the melanoma cells. As well as targeting these metastases individually the tumours blood supply can be compromised by radioembolisation using radioactive agents to block the tumours feeding arterial supply and it also places a decaying radiation source close to the tumour itself.

The major challenge with all of these new and not some new techniques is that there are very few comparative trials telling us which modality is best in which particular clinical situation and metastatic site.

Question in PICO format

Patients/population	Intervention	Comparison	Outcomes
---------------------	--------------	------------	----------

People with stage IV melanoma & brain metastases	<ul style="list-style-type: none"> • Surgery • Stereotactic Radiotherapy • Whole brain radiotherapy 	<ul style="list-style-type: none"> • <i>Each other</i> • Systemic drug therapy (chemotherapy and/or immunotherapy) • Supportive Care 	<ol style="list-style-type: none"> 1. Symptom Control 2. Survival (1 yr) 3. HRQL 4. Adverse events
--	--	---	--

1

2 **Search Results**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	1946-2013	831	419	14/11/2013
<i>Premedline</i>	November 19 2013	71	46	20/11/2013
<i>Embase</i>	1974-2013	2084	808	19/11/2013
<i>Cochrane Library</i>	As per database	68	18	19/11/2013
<i>Web of Science (SCI & SSCI)</i>	1900-2013	1294	516	21/11/2013
Total References retrieved (after de-duplication): 1043				


3 **Update Search**

4 For the update search, the same search criteria/filters were applied as initial search with a date limit of
 5 November 2013 onwards.

Database name	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	37	28	14/10/2014
<i>Premedline</i>	10	7	14/10/2014
<i>Embase</i>	361	105	14/10/2014
<i>Cochrane Library</i>	6	2	14/10/2014
<i>Web of Science (SCI & SSCI)</i>	184	87	14/10/2014
2 references found in Pubmed 14/10/2014			
Total References retrieved (after de-duplication): 69			

6 Abstracts for 1112 papers were screened for their relevance for the review question and 1068 papers were
 7 excluded leaving 44 papers to be ordered and the full text screened (figure 1). From these 44 papers 12 were
 8 relevant (table 3) and included in the evidence review and 32 papers were excluded (table 4). There were a
 9 number of papers which were excluded because they are not specific to melanoma and the studies contain
 10 patients with brain metastases from a range of different primary cancers. It was important to select papers
 11 specific to melanoma as the effect of treatments on melanoma metastases may be different to other cancers.
 12

1 Screening Results



2

1 **Evidence statements**

2 ***Overall survival***

3 All 12 studies examined the effect of treatment on survival and they all found increased survival in patients who
4 underwent local treatment such as surgery or stereotactic radiotherapy compared to systemic drug therapy
5 and/or supportive care. All 12 studies included a mix of patients with both single and multiple metastases.

6 Two retrospective studies analysed the effect of treatment on patients with single or multiple metastases
7 separately (Katz, 1981; Eigentler et al 2011) and they both found surgery to be associated with a significantly
8 longer survival compared with other treatment modalities for patients with a single brain metastasis. This benefit
9 was no longer detectable when considering patients with multiple brain metastases [Very Low Quality Evidence].

10 The effectiveness of local treatment compared with systemic drug therapy or supportive care in the management
11 of brain metastases in people with stage IV melanoma is unclear from the evidence in the 12 included papers. 11
12 of the studies suggest that local treatment is more effective in terms of increased median survival (Table 2: grade
13 profiles) [Very Low Quality Evidence].

14 Extracting data from the different studies demonstrated that in terms of increased survival surgery gives better
15 results than supportive care, chemotherapy, WBRT and chemotherapy and/or WBRT. There was no difference in
16 overall survival between surgery and STR, however only one study compared these treatments. STR resulted in
17 longer overall survival than chemotherapy and WBRT (there were no studies comparing STR with supportive care
18 or chemotherapy and/or WBRT). WBRT resulted in increased survival compared to supportive care. Whether
19 WBRT gives better results than chemotherapy is uncertain as one study showed that WBRT did result in
20 increased survival compared to chemotherapy, but 2 other studies demonstrated longer survival with
21 chemotherapy than WBRT.

22 In one retrospective study of 157 patients treated with stereotactic radiotherapy with and without WBRT (Dyer
23 et al, 2014), death occurred in 135 patients (92%) with a median overall survival of 7.3 months. On multivariate
24 analysis extensive extracranial metastases [HR=1.78, 95% CI 1.25-2.53, p=0.001] and Karnofsky Performance
25 status 50-80 (versus 90-100) [HR=1.52, 95% CI 1.08-2.15, p=0.02] were associated with poorer survival. The use
26 of up front whole brain radiotherapy was associated with treatment centre (p<0.0001) and multiple brain
27 metastases (p<0.0001) [Very Low Quality Evidence]

28 To what extent the longer median survival associated with local treatment using surgery or radiotherapy
29 compared with systemic drug therapy or supportive care is related to the treatment itself or to selection of
30 patients with better performance status is unclear. All 12 studies are retrospective cohort studies and all have
31 undergone patient selection that is biased toward treating patients with more favourable prognoses with local
32 treatments such as surgery. Prospective studies are required to overcome selection bias and confirm the results
33 observed by these retrospective studies.

34 ***Symptom control***

35 There was very low quality evidence from two studies reporting improvement in neurological symptoms
36 following surgery or radiotherapy. One study found similar rates of improvement in neurological symptoms with
37 50% of patients experiencing improvement in at least 1 neurological symptom following surgery and 54% of
38 patients experiencing improvement after whole brain radiotherapy (Sampson, 1998). Another study found that
39 surgery improved neurological symptoms in 70% patients compared to radiotherapy which improved symptoms
40 in 42% of patients (Katz 1981).

41 ***Adverse events***

1 Very low quality evidence from two studies suggests that serious treatment related adverse events are more
2 likely with surgery than radiotherapy. In Sampson et al (1998) 12/139 (9%) patients treated with surgery had
3 treatment-related serious complications (including death) compared with 2/180 (1%) treated with whole brain
4 radiotherapy. In Katz et al (1981) there was a serious adverse event rate of 1/10 (10%) with surgery compared
5 with 0/52 (0%) in the whole brain radiotherapy group.

6 ***Health related quality of life***

7 This outcome was not reported in the included studies.
8

Grade Table 6.12: Should surgery vs. chemotherapy be used for stage IV melanoma & brain metastases?

Quality assessment							Summary of findings				
							No of patients		Effect		Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	surgery	chemotherapy	Relative (95% CI)	Absolute	
overall survival											
3	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	serious imprecision ³	none	94	260	-	Overall median survival was 4 - 7 months longer in patients treated with surgery compared to those treated with chemotherapy.	⊕○○○ VERY LOW

¹ retrospective cohort study² Serious risk of bias due to patient selection for treatment³ Low event rate or low number of patients**Grade Table 6.13: Should surgery vs. supportive care be used for stage IV melanoma & brain metastases?**

Quality assessment							Summary of findings				
							No of patients		Effect		Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	surgery	supportive care	Relative (95% CI)	Absolute	
overall survival											
3	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	serious imprecision ³	none	84	253	-	Overall median survival was 4 - 10 months longer in patients treated with surgery compared to those undergoing supportive care.	⊕○○○ VERY LOW

¹ retrospective cohort studies² serious risk of bias due to patient selection for treatment³ Low event rate or low number of patients

Grade Table 6.14: Should surgery vs. stereotactic radiotherapy be used for stage IV melanoma & brain metastases?

Quality assessment							Summary of findings				
							No of patients		Effect		Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	surgery	stereotactic radiotherapy	Relative (95% CI)	Absolute	
overall survival											
1	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	serious imprecision ³	none	37	17	-	Overall median survival was 0.3 months longer in patients treated with surgery compared to those treated with STR.	⊕○○○ VERY LOW

¹ Retrospective cohort study² High bias due to patient selection for treatment³ Low event rate or low number of patients**Grade table 6.15: Should surgery vs. WBRT be used for stage IV melanoma & brain metastases?**

Quality assessment							Summary of findings				
							No of patients		Effect		Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	surgery	WBRT	Relative (95% CI)	Absolute	
overall survival											
5	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	no serious imprecision	none	149	527	-	Overall median survival was 2.5 – 11.5 months longer in patients treated with surgery compared to those treated with WBRT.	⊕○○○ VERY LOW
Symptom control (improvement in at least 1 neurological symptom)											
2	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	serious imprecision ³	none	149	232	-	Symptoms improved in 50 – 70% of patients treated with surgery compared to 42 -54% of patients treated with WBRT.	⊕○○○ VERY LOW
Serious complications											

2	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	serious imprecision ³	none	13/149 (9%)	2/232 (1%)	-	80 per 1000 more with surgery than with WBRT	⊕○○○ VERY LOW
---	------------------------------------	---------------------------	--------------------------	-------------------------	----------------------------------	------	-------------	------------	---	--	------------------

¹ retrospective cohort study² High bias due to patient selection for treatment³ Low event rate or low number of patients**Grade Table 6.16: Should surgery vs. chemotherapy and/or WBRT be used for stage IV melanoma & brain metastases?**

Quality assessment							Summary of findings				
							No of patients		Effect		Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	surgery	chemotherapy and/or WBRT	Relative (95% CI)	Absolute	
overall survival											
1	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	serious imprecision ³	none	32	75	-	Overall median survival was 2 months longer in patients treated with surgery compared to those treated with chemotherapy and/or WBRT.	⊕○○○ VERY LOW

¹ retrospective cohort study² High bias due to patient selection for treatment³ Low event rate or low number of patients**Grade Table 6.17: Should STR vs. chemotherapy be used for stage IV melanoma & brain metastases?**

Quality assessment							Summary of findings				
							No of patients		Effect		Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	STR	chemotherapy	Relative (95% CI)	Absolute	
overall survival											
1	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	serious imprecision ³	none	17	38	-	Overall median survival was 3.7 months longer in patients treated with STR compared to those treated with chemotherapy.	⊕○○○ VERY LOW

¹ retrospective cohort study² High bias due to patient selection for treatment³ Low event rate or low number of patients**Grade Table 6.18: Should WBRT vs. chemotherapy be used for stage IV melanoma & brain metastases?**

Quality assessment							Summary of findings				
							No of patients		Effect		Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	WBRT	chemotherapy	Relative (95% CI)	Absolute	
overall survival											
3	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	no serious imprecision	none	262	260	-	Overall median survival was 3.7 months longer in patients treated with WBRT compared to those treated with chemotherapy in one study. However, for 2 studies overall median survival was 1.1 - 2 months longer in patients treated with chemotherapy compared to those treated with WBRT.	⊕○○○ VERY LOW

¹ retrospective cohort studies² High bias due to patient selection for treatment**Grade Table 6.19: Should WBRT vs. supportive care be used for stage IV melanoma & brain metastases?**

Quality assessment							Summary of findings				
							No of patients		Effect		Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	WBRT	supportive care	Relative (95% CI)	Absolute	
overall survival											
3	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	no serious imprecision	none	289	227	-	Overall median survival was 1 – 1.3 months longer in patients treated with WBRT compared to those undergoing supportive care.	⊕○○○ VERY LOW

¹ retrospective cohort study² High bias due to patient selection for treatment

Grade Table 6.20: Should WBRT vs. STR be used for stage IV melanoma & brain metastases?

Quality assessment							Summary of findings				
							No of patients		Effect		
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	WBRT	STR	Relative (95% CI)	Absolute	
overall survival											
1	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	serious imprecision ³	none	54	17	-	Overall median survival was 4.8 months longer in patients treated with STR compared to those treated with WBRT.	⊕○○○ VERY LOW

¹ retrospective cohort study² High bias due to patient selection for treatment³ Low event rate or low number of patients**Grade Table 6.21: Should STR or surgery vs. supportive care be used for stage IV melanoma & brain metastases?**

Quality assessment							Summary of findings				
							No of patients		Effect		
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	STR or surgery	supportive care	Relative (95% CI)	Absolute	
overall survival											
1	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	serious imprecision ³	none	10	3	-	Overall median survival was 3.7 months longer in patients treated with STR or surgery compared to those undergoing supportive care.	⊕○○○ VERY LOW

¹ retrospective cohort study² High bias due to patient selection for treatment³ Low event rate or low number of patients**Grade Table 6.22: Should STR or surgery vs. WBRT be used for stage IV melanoma & brain metastases?**

Quality assessment							Summary of findings				
							No of patients		Effect		Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	STR or surgery	WBRT	Relative (95% CI)	Absolute	
overall survival											
1	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	serious imprecision ³	none	10	25	-	Overall median survival was 2.5 months longer in patients treated with STR or surgery compared to those treated with WBRT.	⊕○○○ VERY LOW

¹ retrospective cohort study² High bias due to patient treatment selection³ Low event rate or low number of patients**Grade Table 6.23: Should STR or surgery vs. chemotherapy and/or WBRT be used for stage IV melanoma & brain metastases?**

Quality assessment							Summary of findings				
							No of patients		Effect		Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	STR or surgery	chemotherapy and/or WBRT	Relative (95% CI)	Absolute	
overall survival											
1	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	no serious imprecision	none	122	92	-	Overall median survival was 3 months longer in patients treated with STR or surgery compared to those treated with chemotherapy and/or WBRT.	⊕○○○ VERY LOW

¹ retrospective cohort study² High bias due to patient selection for treatment**Grade Table 6.24: Should STR with or without WBRT be used for stage IV melanoma & brain metastases?**

Quality assessment							Summary of findings		
							No of patients	Effect	Quality

No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	STR	STR+WBRT	Relative (95% CI)	Absolute	
overall survival											
1	observational studies ¹	very serious ²	no serious inconsistency	no serious indirectness	no serious imprecision	none	147 (numbers not reported for each treatment separately)			Death occurred in 92% of patients with a median overall survival was 7.3 months	VERY LOW

¹ retrospective cohort study² High bias due to patient selection for treatment

References

Included Studies

- Bremer, A. M., West, C. R. & Didolkar, M. S. (1978) An evaluation of the surgical management of melanoma of the brain. *Journal of Surgical Oncology*, 10: 211-219.
- Buchsbaum, J. C., Suh, J. H., Lee, S. Y., Chidel, M. A., Greskovich, J. F. & Barnett, G. H. (2002) Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. *Cancer*, 94: 2265-2272.
- Dyer, M. A., Arvold, N. D., Chen, Y. H., Pinnell, N. E., Mitin, T., Lee, E. Q., Hodi, F. S., Ibrahim, N., Weiss, S. E., Kelly, P. J., Floyd, S. R., Mahadevan, A., and Alexander, B. M. The role of whole brain radiation therapy in the management of melanoma brain metastases. *Radiation Oncology* 9. 2014.
- Eigentler, T. K., Figl, A., Krex, D., Mohr, P., Mauch, C., Rass, K., Bostroem, A., Heese, O., Koelbl, O., Garbe, C., Schadendorf, D. & Dermatologic Cooperative Oncology Group and the National Interdisciplinary Working Group on Melanoma (2011) Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. *Cancer*, 117: 1697-1703.
- Fife, K. M., Colman, M. H., Stevens, G. N., Firth, I. C., Moon, D., Shannon, K. F., Harman, R., Petersen-Schaefer, K., Zacest, A. C., Besser, M., Milton, G. W., McCarthy, W. H. & Thompson, J. F. (2004) Determinants of outcome in melanoma patients with cerebral metastases. *Journal of Clinical Oncology*, 22: 1293-1300.
- Katz, H. R. (1981) The relative effectiveness of radiation therapy, corticosteroids, and surgery in the management of melanoma metastatic to the central nervous system. *International Journal of Radiation Oncology Biology Physics*, 7: 897-906.
- Konstadoulakis, M. M., Messaris, E., Zografos, G., Androulakis, G. & Karakousis, C. (2000) Prognostic factors in malignant melanoma patients with solitary or multiple brain metastases. Is there a role for surgery? *Journal of Neurosurgical Sciences*, 44: 211-218.
- Meier, S., Baumert, B. G., Maier, T., Wellis, G., Burg, G., Seifert, B. & Dummer, R. (2004) Survival and prognostic factors in patients with brain metastases from malignant melanoma. *Onkologie*, 27: 145-149.
- Panagiotou, I. E., Brountzos, E. N., Kelekis, D. A., Papathanasiou, M. A. & Bafaloukos, D. I. (2005) Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome. *Neoplasma*, 52: 150-158.
- Sampson J, Carter J, Friedman A, et al. (1998) Demographics, prognosis and therapy in 702 patients with brain metastases from malignant melanoma. *J Neurosurg* 88, 11-20.
- Selek, U., Chang, E. L., Hassenbusch, S. J., III, Shiu, A. S., Lang, F. F., Allen, P., Weinberg, J., Sawaya, R. & Maor, M. H. (2004) Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. *International Journal of Radiation Oncology, Biology, Physics*, 59: 1097-1106.
- Zacest, A. C., Besser, M., Stevens, G., Thompson, J. F., McCarthy, W. H. & Culjak, G. (2002) Surgical management of cerebral metastases from melanoma: outcome in 147 patients treated at a single institution over two decades. *Journal of Neurosurgery*, 96: 552-558.

Excluded Studies

- Ahmed, K. A., Freilich, J. M., Abuodeh, Y., Figura, N., Patel, N., Sarangkasiri, S., Chinnaiyan, P., Yu, H. H. M., Etame, A. B., and Rao, N. G. Fractionated stereotactic radiotherapy to the post-operative cavity for radioresistant and radiosensitive brain metastases. *Journal of Neuro-Oncology* 118[1], 179-186. 2014.
- Reason: Not Melanoma
- Anderson, D. & Flynn, K. (1997) Stereotactic radiosurgery for metastases to the brain: a systematic review of published studies of effectiveness (DARE structured abstract). *Database of Abstracts of Reviews of Effects.*, 16

- 1 Reason: Abstract
- 2 Bindal, R. K., Sawaya, R., Leavens, M. E. & Lee, J. J. (1993) Surgical-Treatment of Multiple Brain Metastases.
3 *Journal of Neurosurgery*, 79: 210-216.
- 4 Reason: Not Melanoma
- 5 Blesa, J. M. G., Pulido, E. G., Pulla, M. P. & Candel, V. A. (2009) Treatment options for metastatic melanoma. A
6 systematic review. *Cancer Therapy*, 7: 188-199.
- 7 Reason: Not Melanoma
- 8 Bottoni, U., Clerico, R., Paolino, G., Ambrifi, M., Corsetti, P. & Calvieri, S. (2013) Predictors and survival in patients
9 with melanoma brain metastases. *Medical Oncology*, 30: 466.
- 10 Reason: No Brain Metastases
- 11 Brady, L. W., Mancall, E. L., Lee, D. K., Neff, L. B., Shockman, A. T., Faust, D. S., Antoniades, J., Prasasvinichai, S.,
12 Torpie, R. J. & Glassburn, J. R. (1974) Predictors and survival in patients with melanoma brain metastases.
13 *Radiologia Clinica et Biologica*, 43: 40-47.
- 14 Reason: Not melanoma
- 15 Concalves, M., Passos, A., Moreira, A. & Oliveira, J. (2009) Malignant melanoma brain metastases - A single
16 institution experience. *European Journal of Cancer, Supplement*, 7: 502.
- 17 Reason: Abstract
- 18 DiBiase, S. J., Chin, L. S. & Ma, L. (2002) Influence of gamma knife radiosurgery on the quality of life in patients
19 with brain metastases. *American Journal of Clinical Oncology*, 25: 131-134.
- 20 Reason: Not melanoma
- 21 Eigentler, T. K., Figl, A., Krex, D., Mohr, P., Kurschat, P., Tilgen, W., Bostroem, A., Heese, O., Garbe, C. &
22 Schadendorf, D. (2009) Multicenter study on prognostic factors in 692 patients with brain metastases of
23 malignant melanoma. *Journal of Clinical Oncology*, 27: 9081.
- 24 Reason: Abstract
- 25 Feuvret, L., Vinchon, S., Martin, V., Lamproglou, I., Halley, A., Calugaru, V., Chea, M., Valery, C. A., Simon, J. M.,
26 Mazon, J. J., Feuvret, L., Vinchon, S., Martin, V., Lamproglou, I., Halley, A., Calugaru, V., Chea, M., Valery, C. A.,
27 Simon, J. M., and Mazon, J. J. Stereotactic radiotherapy for large solitary brain metastases. *Cancer*
28 *Radiotherapie* 18[2], 97-106. 2014.
- 29 Reason: Not Melanoma
- 30 Fogarty, G., Morton, R. L., Vardy, J., Nowak, A. K., Mandel, C., Forder, P. M., Hong, A., Hruby, G., Burmeister, B.,
31 Shivalingam, B., Dhillon, H. & Thompson, J. F. (2011) Whole brain radiotherapy after local treatment of brain
32 metastases in melanoma patients--a randomised phase III trial. *BMC Cancer*, 11: 142
- 33 Reason: Study Protocol
- 34 Jung, E. W., Delly, F., Rakowski, J., Mittal, S., Tang, K., Kim, H. & Jagannathan, J. (2012) Repeated stereotactic
35 radiosurgery for progressive brain metastases from melanoma after initial treatment. *International Journal of*
36 *Radiation Oncology Biology Physics*, 84: S629.
- 37 Reason: Abstract
- 38 Kalani, M. Y. S., Filippidis, A. S., Kalani, M. A., Sanai, N., Brachman, D., McBride, H. L., Shetter, A. G. & Smith, K. A.
39 (2010) Gamma Knife surgery combined with resection for treatment of a single brain metastasis: preliminary
40 results. *Journal of Neurosurgery*, 113: 90-96.
- 41 Reason: Not Melanoma

- 1 Kocher, M., Maarouf, M., Bendel, M., Voges, J., Muller, R. P. & Strum, V. (2004) Linac radiosurgery versus whole
2 brain radiotherapy for brain metastases - A survival comparison based on the RTOG recursive partitioning analysis.
3 *Strahlentherapie und Onkologie*, 180: 263-267.
4 Reason: Not melanoma
- 5 Krause, U., Psathakis, D., Assenmacher, S. & Erhard, J. (1993) Indications for Metastasectomy in Malignant-
6 Melanoma. *Tumordiagnostik & Therapie*, 14: 138-142.
7 Reason: Foreign Language
- 8 Kreth, F. W., Warnke, P. C. & Ostertag, C. B. (1993) Stereotaxic Interstitial Radiosurgery and Percutaneous
9 Radiotherapy for Treatment of Cerebral Metastases. *Nervenarzt*, 64: 108-113.
10 Reason: Foreign Language
- 11 Lagerwaard F, Levendag P, Nowak P, et al. (1999) Identification of prognostic factors in patients with brain
12 metastases: A review of 1292 patients. *Int J Radiat Oncol Biol Phys* 43, 795-803.
13 Reason: Not Melanoma
- 14 Lowe, M. C., Cavitt, A., Shelton, J., Crocker, I. R., Pan, L., Lawson, D. H., Carlson, G. W., Delman, K. A. & Rizzo, M.
15 (2010) The role of radio-surgery in patients with metastatic melanoma to the brain. *Journal of Clinical Oncology*,
16 28.
17 Reason: Abstract
- 18 Osei-Boateng, K., Venur, V. A., Dahiya, S., Du, L., Garje, R., Elson, P., Chao, S. T. & Ahluwalia, M. S. (2013) Graded
19 prognostic assessment index for melanoma with brain metastases (MBM). *Journal of Clinical Oncology*, 31.
20 Reason: Abstract
- 21 Ostertag, C. B. & Kreth, F. W. (1995) Interstitial I-125 Radiosurgery for Cerebral Metastases. *British Journal of*
22 *Neurosurgery*, 9: 593-603.
23 Reason: Not Melanoma
- 24 Patchell, R. A., Tibbs, P. A., Regine, W. F., Dempsey, R. J., Mohiuddin, M., Kryscio, R. J., Markesbery, W. R., Foon,
25 K. A. & Young, B. (1998) Postoperative radiotherapy in the treatment of single metastases to the brain - A
26 randomized trial. *Jama-Journal of the American Medical Association*, 280: 1485-1489.
27 Reason: Not Melanoma
- 28 Rezvi, U. Judicious use of radiosurgery (SRS) may change the ultimate patterns of failure in patients with brain
29 metastasis from melanoma. *Neuro-Oncology Conference*[var.pagings], November. 2013.
30 Reason:Abstract
- 31 Rhomberg, W., Eiter, H., Boehler, F., Saely, C. & Strohal, R. (2005) Combined razoxane and radiotherapy for
32 melanoma brain metastases. A retrospective analysis. *Journal of Neuro-Oncology*, 74: 295-299.
33 Reason: Not relevant to PICO
- 34 Rutigliano, M. J., Lunsford, L. D., Kondziolka, D., Strauss, M. J., Khanna, V. & Green, M. (1995) The Cost-
35 Effectiveness of Stereotaxic Radiosurgery Versus Surgical Resection in the Treatment of Solitary Metastatic Brain-
36 Tumors. *Neurosurgery*, 37: 445-453.
37 Reason: Not relevant to PICO
- 38 Schackert, G., Steinmetz, A., Meier, U. & Sobottka, S. B. (2001) Surgical management of single and multiple brain
39 metastases: Results of a retrospective study. *Onkologie*, 24: 246-255.
40 Reason: Not Melanoma

- 1 Schadendorf, D., Hauschild, A., Ugurel, S., Thielke, A., Egberts, F., Kreissig, M., Linse, R., Trefzer, U., Vogt, T.,
2 Tilgen, W., Mohr, P. & Garbe, C. (2006) Dose-intensified bi-weekly temozolomide in patients with asymptomatic
3 brain metastases from malignant melanoma: a phase II DeCOG/ADO study. *Annals of Oncology*, 17: 1592-1597.
4 Reason: Not relevant to PICO
- 5 Tsao, M. N., Lloyd, N. S., Wong, R. K. S., Rakovitch, E., Chow, E. & Laperriere, N. (2005) Radiotherapeutic
6 management of brain metastases: A systematic review and meta-analysis. *Cancer Treatment Reviews*, 31: 256-
7 273.
8 Reason: Not Melanoma
- 9 Tsao MN, Lloyd N, Wong RK, Chow E, Rakovitch E, Laperriere N, Xu W, Sahgal A. (2012) Whole brain radiotherapy
10 for the treatment of newly diagnosed multiple brain metastases. *Cochrane Database Syst Rev*. 2012 Apr
11 18;4:CD003869.
12 Reason: Not Melanoma
- 13 Varlotto, J. M., Flickinger, J. C., Niranjana, A., Bhatnagar, A. K., Kondziolka, D. & Lunsford, L. D. (2003) Analysis of
14 tumor control and toxicity in patients who have survived at least one year after radiosurgery for brain
15 metastases. *International Journal of Radiation Oncology, Biology, Physics*, 57: 452-464.
16 Reason: Not Melanoma
- 17 Vecchio, S., Spagnolo, F., Merlo, D. F., Signori, A., Acquati, M., Pronzato, P., and Queirolo, P. The treatment of
18 melanoma brain metastases before the advent of targeted therapies: associations between therapeutic choice,
19 clinical symptoms and outcome with survival. *Melanoma Research* 24[1], 61-67. 2014.
20 Reason: Not Melanoma
- 21 Wang, S., Zhao, Z., Barber, B. & Wagner, V. J. (2012) Surgery, radiation, and systemic therapies in patients with
22 metastatic melanoma. *Journal of Clinical Oncology*, 30.
23 Reason: Abstract
- 24 Wiggensraad, R., Verbeek-de, K. A., Kal, H. B., Taphoorn, M., Vissers, T. & Struikmans, H. (2011) Dose-effect
25 relation in stereotactic radiotherapy for brain metastases: a systematic review (DARE structured abstract).
26 *Radiotherapy and Oncology*, 98: 292-297.
27 Reason: Not Melanoma

28

Evidence Tables

Study Quality

	method of allocation to treatment groups was unrelated to potential confounding factors	Attempts were made within the design or analysis to balance the comparison groups for potential confounders	Comparable at baseline	The comparison groups received the same care apart from the intervention(s) studied	Participants blind to treatment allocation	Treatment asministrators blind to treatment allocation	Equal follow up	Appropriate length of follow-up	Precise definition of an outcome	Valid method of measuring outcomes	Investigators blind to participants exposure to intervention?	Investigators blind to potential confounders and prognostic factors?
Bremer et al 1978	No	No	No	No	No	No	Yes	Yes	Yes	Yes	No	No
Buchsbaum et al 2002	No	No	No	No	No	No	Yes	Yes	Yes	Yes	No	No
Eigentler et al 2011	No	No	No	No	No	No	Yes	Yes	Yes	Yes	No	No
Fife et al 2004	No	No	No	No	No	No	Yes	Yes	Yes	Yes	No	No
Katz 1981	No	No	No	No	No	No	Yes	Yes	Yes	Yes	No	No
Konstadoulakis et al 2000	No	No	No	No	No	No	Yes	Yes	Yes	Yes	No	No
Meier et al 2004	No	No	No	No	No	No	Yes	Yes	Yes	Yes	No	No
Panagiotou et al 2005	No	No	No	No	No	No	Yes	Yes	Yes	Yes	No	No
Sampson et al 1998	No	No	No	No	No	No	Yes	Yes	Yes	Yes	No	No
Selek et al 2004	No	No	No	No	No	No	Yes	Yes	Yes	Yes	No	No
Zacest et al 2002	No	No	No	No	No	No	Yes	Yes	Yes	Yes	No	No

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS	NOTES									
Bremer, A. M., West, C. R. & Didolkar, M. S. (1978) An evaluation of the surgical management of melanoma of the brain. <i>Journal of Surgical Oncology</i> , 10: 211-219.	Retrospective	32 Multiple brain metastases: 13 Single brain metastases: 19	Overall survival	Risk of Bias – HIGH. Patient selection bias. Median survival was dependent on treatment, which in turn was dependent on patient selection No surgery group contains a mix of patients with different alternative treatments.									
			<table><tr><th>Treatment</th><th>No. patients</th><th>median survival (months)</th></tr><tr><td>Surgery</td><td>19</td><td>5-6</td></tr><tr><td>No surgery</td><td>13</td><td>1</td></tr></table>		Treatment	No. patients	median survival (months)	Surgery	19	5-6	No surgery	13	1
			Treatment		No. patients	median survival (months)							
			Surgery		19	5-6							
No surgery	13	1											
Intratumor haemorrhage (at autopsy) by surgery													
<table><tr><th>Treatment</th><th>Intra tumour hemorrhage</th><th>No. patients</th></tr><tr><td>Surgery</td><td>10 (53%)</td><td>19</td></tr><tr><td>No surgery</td><td>8 (62%)</td><td>13</td></tr></table>	Treatment	Intra tumour hemorrhage	No. patients	Surgery	10 (53%)	19	No surgery	8 (62%)	13				
Treatment	Intra tumour hemorrhage	No. patients											
Surgery	10 (53%)	19											
No surgery	8 (62%)	13											
			Intratumor haemorrhage (at autopsy) by chemotherapy										
			<table><tr><th>Treatment</th><th>Intra tumour hemorrhage</th><th>No. patients</th></tr><tr><td>Chemotherapy</td><td>13 (62%)</td><td>21</td></tr><tr><td>No chemotherapy</td><td>5 (45%)</td><td>11</td></tr></table>	Treatment	Intra tumour hemorrhage	No. patients	Chemotherapy	13 (62%)	21	No chemotherapy	5 (45%)	11	
Treatment	Intra tumour hemorrhage	No. patients											
Chemotherapy	13 (62%)	21											
No chemotherapy	5 (45%)	11											

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS				NOTES
Buchsbaum, J. C., Suh, J. H., Lee, S. Y., Chidel, M. A., Greskovich, J. F. & Barnett, G. H. (2002) Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. <i>Cancer</i> , 94: 2265-2272.	Retrospective	74 Multiple brain metastases: 60 Single brain metastases: 14					Risk of Bias – HIGH. Patient selection bias. Survival benefit of combination therapy likely due to selection bias – clinicians had selected patients for treatment in a fashion that correlated with the RTOG RPA schema.
			Treatment	No. patients	median survival (months)		
			Combined therapy (local + WBRT)	36	8.8		
			Local therapy alone (surgery or SRS)	10	4.8		
			WBRT alone	25	2.3		
			No treatment	3	1.1		
			Combined vs. other p<0.0001				
			Treatment	HR	CI	p	
			No treatment v Combined therapy (local + WBRT)	7.928	1.680-37.409	0.0089	
WBRT alone v Combined therapy (local + WBRT)	2.392	1.161-4.929	0.0180				
Local therapy alone (surgery or SRS) v Combined	1.440	0.648-3.197	0.3703				

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS	NOTES				
			<table><tr><td>therapy (local + WBRT)</td><td></td><td></td><td></td></tr></table> <p>Complications:</p> <p>Radiation: 0 patients symptomatic radiation necrosis</p> <p>Surgery (alone or with WBRT) – acute complications: 1 infection, 2 haemorrhages, 3 central nervous system deficits. No long term complications.</p>	therapy (local + WBRT)				
therapy (local + WBRT)								

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS	NOTES
Dyer, M. A., Arvold, N. D., Chen, Y. H., Pinnell, N. E., Mitin, T., Lee, E. Q., Hodi, F. S., Ibrahim, N., Weiss, S. E., Kelly, P. J., Floyd, S. R., Mahadevan, A., and Alexander, B. M. The role of whole brain radiation therapy in the management of melanoma brain metastases. Radiation Oncology 9. 2014.	Retrospective Case Series	147	<p>Stereotactic radiotherapy and WBRT</p> <p>Stereotactic radiotherapy alone</p> <p>56 patients had distant failure prior to any local failure</p> <p>20 patients had distant and local failure at the same time</p> <p>27 patients had local failure first</p> <p>Distant intracranial progression occurred in 59% of patients</p> <p>Median time to progression was 4.3 months.</p> <p><i>Multivariate Analysis</i></p> <p>Age >60 HR=0.64 (0.41-0.99, p=0.05)</p> <p>>1 brain metastases HR=1.90 (1.18-3.06, p=0.008)</p> <p>Omission of upfront WBRT HR=2.24 (1.27-3.94, p=0.005)</p> <p>In patients with multiple brain metastases median time to distant intracranial progression was 2 months in patients who did not receive upfront WBRT compared with 6 months in patients who were treated with upfront WBRT (p=0.003).</p>	<p>Risk of Bias – HIGH.</p> <p>Patient selection bias.</p> <p>The use of up front whole brain radiotherapy was associated with treatment centre (p<0.0001) and multiple brain metastases (p<0.0001)</p> <p>Median number of brain metastasis for patients receiving up front WBRT was 4 (IQR 3-5) and for patients stereotactic radiotherapy alone was 1 (IQR 1-2).</p>

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS	NOTES
			<p>Median time to progression in patients with solitary brain metastases was approximately 5 months in both treatment groups.</p> <p>Death occurred in 135 patients (92%) with a median overall survival of 7.3 months.</p> <p>On multivariate analysis extensive extracranial metastases [HR=1.78, 95% CI 1.25-2.53, p=0.001] and Karnofsky Performance status 50-80 (versus 90-100) [HR=1.52, 95% CI 1.08-2.15, p=0.02] were associated with poorer survival.</p>	

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS	NOTES																				
Eigentler, T. K., Figl, A., Krex, D., Mohr, P., Mauch, C., Rass, K., Bostroem, A., Heese, O., Koelbl, O., Garbe, C., Schadendorf, D. & Dermatologic Cooperative Oncology Group and the National Interdisciplinary Working Group on Melanoma (2011) Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. <i>Cancer</i> , 117: 1697-1703.	Retrospective	672 Multiple brain metastases: 397 Single brain metastases: 249	<p>For patients with a single brain metastasis, neurosurgery and STR were both found to be associated with a significantly longer survival compared with other treatment modalities such as WBRT and/or systemic therapy.</p> <p>However, this benefit is no longer detectable when considering patients with limited disease (<3 metastases)</p> <p>Treatment for single brain metastases:</p> <table><tr><th>Treatment</th><th>No. patients</th><th>median survival (months)</th></tr><tr><td>STR or surgery (complete resection)</td><td>122</td><td>9</td></tr><tr><td>WBRT and/or chemotherapy</td><td>92</td><td>6</td></tr></table> <p>p=0.036</p> <table><tr><th>Treatment</th><th>HR</th><th>CI</th><th>p</th></tr><tr><td>STR or surgery v WBRT and/or chemotherapy</td><td>1.5</td><td>1.1-1.9</td><td>0.0061</td></tr></table> <p>Page 676 of 886</p> <p>Treatment for limited brain disease (<3 metastases):</p> <table><tr><th>Treatment</th><th>No. patients</th><th>median survival</th></tr></table>	Treatment	No. patients	median survival (months)	STR or surgery (complete resection)	122	9	WBRT and/or chemotherapy	92	6	Treatment	HR	CI	p	STR or surgery v WBRT and/or chemotherapy	1.5	1.1-1.9	0.0061	Treatment	No. patients	median survival	<p>Risk of Bias – HIGH.</p> <p>Patient selection bias.</p>
Treatment	No. patients	median survival (months)																						
STR or surgery (complete resection)	122	9																						
WBRT and/or chemotherapy	92	6																						
Treatment	HR	CI	p																					
STR or surgery v WBRT and/or chemotherapy	1.5	1.1-1.9	0.0061																					
Treatment	No. patients	median survival																						

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS	NOTES																															
<p>Fife, K. M., Colman, M. H., Stevens, G. N., Firth, I. C., Moon, D., Shannon, K. F., Harman, R., Petersen-Schaefer, K., Zacest, A. C., Besser, M., Milton, G. W., McCarthy, W. H. & Thompson, J. F. (2004) Determinants of outcome in melanoma patients with cerebral metastases. <i>Journal of Clinical Oncology</i>, 22: 1293-1300.</p>	Retrospective	<p>686 patients,</p> <p>As of June 2003 646 had died as a result of melanoma.</p> <p>Multiple brain metastases: 173 Single brain metastases: 178</p>	<table><tr><th>Treatment</th><th>No. patients</th><th>median survival (months)</th></tr><tr><td>surgery and postoperative radiotherapy</td><td>158</td><td>8.9</td></tr><tr><td>surgery alone</td><td>47</td><td>8.7</td></tr><tr><td>radiotherapy alone</td><td>236</td><td>3.4</td></tr><tr><td>supportive care alone</td><td>210</td><td>2.1</td></tr></table> <table><tr><th>Treatment</th><th>HR</th><th>CI</th><th>p</th></tr><tr><td>Surgery v supportive care</td><td>0.436</td><td>0.308-0.619</td><td><0.001</td></tr><tr><td>Radiotherapy v supportive care</td><td>0.851</td><td>0.698-1.038</td><td>0.111</td></tr><tr><td>Surgery and radiotherapy v supportive care</td><td>0.346</td><td>0.273-0.439</td><td><0.001</td></tr></table>	Treatment	No. patients	median survival (months)	surgery and postoperative radiotherapy	158	8.9	surgery alone	47	8.7	radiotherapy alone	236	3.4	supportive care alone	210	2.1	Treatment	HR	CI	p	Surgery v supportive care	0.436	0.308-0.619	<0.001	Radiotherapy v supportive care	0.851	0.698-1.038	0.111	Surgery and radiotherapy v supportive care	0.346	0.273-0.439	<0.001	<p>Risk of Bias – HIGH.</p> <p>Patient selection bias.</p> <p>Median survival was dependent on treatment, which in turn was dependent on patient selection.</p> <p>Patients were selected for active treatment on the basis of having a single cerebral metastasis, cerebral metastases with no evidence of metastatic disease elsewhere, or a younger age.</p>
Treatment	No. patients	median survival (months)																																	
surgery and postoperative radiotherapy	158	8.9																																	
surgery alone	47	8.7																																	
radiotherapy alone	236	3.4																																	
supportive care alone	210	2.1																																	
Treatment	HR	CI	p																																
Surgery v supportive care	0.436	0.308-0.619	<0.001																																
Radiotherapy v supportive care	0.851	0.698-1.038	0.111																																
Surgery and radiotherapy v supportive care	0.346	0.273-0.439	<0.001																																

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS	NOTES

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS	NOTES																																				
<p>Katz, H. R. (1981) The relative effectiveness of radiation therapy, corticosteroids, and surgery in the management of melanoma metastatic to the central nervous system. <i>International Journal of Radiation Oncology Biology Physics</i>, 7: 897-906.</p> <p>Melanoma: DRAFT evidence review (January 2015)</p>	Retrospective	63 Multiple brain metastases: 25 Single brain metastases: 38	<p>Surgical excision of solitary brain metastases produces better results than radiotherapy alone.</p> <p>Overall survival: <i>Solitary brain metastases:</i></p> <table><tr><th>Treatment</th><th>No. patients</th><th>median survival (months)</th><th>1 year survival</th></tr><tr><td>surgery</td><td>8</td><td>14.7</td><td>50%</td></tr><tr><td>radiotherapy</td><td>29</td><td>3.2</td><td>n/a</td></tr></table> <p><i>multiple brain metastases:</i></p> <table><tr><th>Treatment</th><th>No. patients</th><th>median survival (months)</th><th>1 year survival</th></tr><tr><td>surgery</td><td>2</td><td>2</td><td>0</td></tr><tr><td>radiotherapy</td><td>23</td><td>2.2</td><td>n/a</td></tr></table> <p>Improvement in neurological symptoms</p> <table><tr><th></th><th>Improved after treatment</th><th>No. patients</th></tr><tr><td>Surgery</td><td>7 (70%)</td><td>10</td></tr><tr><td>WBRT</td><td>22 (42%)</td><td>52</td></tr></table> <p>Life threatening complications or death during treatment or 30 days post treatment. Page 679 of 886</p> <table><tr><th></th><th>Complications or death</th><th>No. patients</th></tr></table>	Treatment	No. patients	median survival (months)	1 year survival	surgery	8	14.7	50%	radiotherapy	29	3.2	n/a	Treatment	No. patients	median survival (months)	1 year survival	surgery	2	2	0	radiotherapy	23	2.2	n/a		Improved after treatment	No. patients	Surgery	7 (70%)	10	WBRT	22 (42%)	52		Complications or death	No. patients	<p>Risk of Bias – HIGH.</p> <p>Patient selection bias.</p>
Treatment	No. patients	median survival (months)	1 year survival																																					
surgery	8	14.7	50%																																					
radiotherapy	29	3.2	n/a																																					
Treatment	No. patients	median survival (months)	1 year survival																																					
surgery	2	2	0																																					
radiotherapy	23	2.2	n/a																																					
	Improved after treatment	No. patients																																						
Surgery	7 (70%)	10																																						
WBRT	22 (42%)	52																																						
	Complications or death	No. patients																																						

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS				NOTES																								
Konstadoulakis, M. M., Messaris, E., Zografos, G., Androulakis, G. & Karakousis, C. (2000) Prognostic factors in malignant melanoma patients with solitary or multiple brain metastases. Is there a role for surgery? <i>Journal of Neurosurgical Sciences</i> , 44: 211-218.	Retrospective	136 Multiple brain metastases: 75 Single brain metastases: 56	<table><tr><th>Treatment</th><th>No. patients</th><th>median survival (months)</th><th>1 year survival</th></tr><tr><td>surgery</td><td>32</td><td>5</td><td>28.13%</td></tr><tr><td>radiotherapy and/or chemotherapy</td><td>75</td><td>3</td><td>6.67%</td></tr><tr><td>No treatment</td><td>29</td><td>1</td><td>3.45%</td></tr></table> <p>One year survival of patients treated surgically was significantly better than patients who received radiotherapy and/or chemotherapy or who had no treatment. p=0.006.</p>				Treatment	No. patients	median survival (months)	1 year survival	surgery	32	5	28.13%	radiotherapy and/or chemotherapy	75	3	6.67%	No treatment	29	1	3.45%	Risk of Bias – HIGH. Patient selection bias. Survival was dependent on treatment, which in turn was dependent on patient selection.								
Treatment	No. patients	median survival (months)	1 year survival																												
surgery	32	5	28.13%																												
radiotherapy and/or chemotherapy	75	3	6.67%																												
No treatment	29	1	3.45%																												
Meier, S., Baumert, B. G., Maier, T., Wellis, G., Burg, G., Seifert, B. & Dummer, R. (2004) Survival and prognostic factors in patients with brain metastases from malignant melanoma. <i>Onkologie</i> , 27: 145-149.	Retrospective	100 patients Multiple brain metastases: 56 Single brain metastases: 41	<table><tr><th>Treatment</th><th>No. patients</th><th>median survival (months)</th><th>1 year survival</th></tr><tr><td>Surgery</td><td>37</td><td>10.6</td><td>31%</td></tr><tr><td>No surgery</td><td>63</td><td>2.9</td><td>3%</td></tr></table> <p>p<0.0001</p> <table><tr><th>Treatment</th><th>No. patients</th><th>median survival (months)</th><th>1 year survival</th></tr><tr><td>Radiosurgery</td><td>17</td><td>10.3</td><td>35%</td></tr><tr><td>No radiosurgery</td><td>83</td><td>3.9</td><td>9%</td></tr></table>				Treatment	No. patients	median survival (months)	1 year survival	Surgery	37	10.6	31%	No surgery	63	2.9	3%	Treatment	No. patients	median survival (months)	1 year survival	Radiosurgery	17	10.3	35%	No radiosurgery	83	3.9	9%	Risk of Bias – HIGH. Patient selection bias. Survival was dependent on treatment, which in turn was dependent on patient selection.
Treatment	No. patients	median survival (months)	1 year survival																												
Surgery	37	10.6	31%																												
No surgery	63	2.9	3%																												
Treatment	No. patients	median survival (months)	1 year survival																												
Radiosurgery	17	10.3	35%																												
No radiosurgery	83	3.9	9%																												

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS	NOTES																																
			<p>p=0.002</p> <table><tr><th>Treatment</th><th>No. patients</th><th>median survival (months)</th><th>1 year survival</th></tr><tr><td>WBRT/PBRT</td><td>54</td><td>5.5</td><td>19%</td></tr><tr><td>No WBRT/PBRT</td><td>46</td><td>2.6</td><td>7%</td></tr></table> <p>p=0.009</p> <table><tr><th>Treatment</th><th>HR</th><th>CI</th><th>p</th></tr><tr><td>WBRT/PBRT</td><td>0.45</td><td>0.29-0.70</td><td>0.0004</td></tr><tr><td>surgery</td><td>0.30</td><td>0.19-0.49</td><td><0.0001</td></tr><tr><td>radiosurgery</td><td>0.31</td><td>0.17-0.55</td><td><0.0001</td></tr><tr><td>chemotherapy</td><td>0.43</td><td>0.27-0.70</td><td>0.0006</td></tr></table>	Treatment	No. patients	median survival (months)	1 year survival	WBRT/PBRT	54	5.5	19%	No WBRT/PBRT	46	2.6	7%	Treatment	HR	CI	p	WBRT/PBRT	0.45	0.29-0.70	0.0004	surgery	0.30	0.19-0.49	<0.0001	radiosurgery	0.31	0.17-0.55	<0.0001	chemotherapy	0.43	0.27-0.70	0.0006	
Treatment	No. patients	median survival (months)	1 year survival																																	
WBRT/PBRT	54	5.5	19%																																	
No WBRT/PBRT	46	2.6	7%																																	
Treatment	HR	CI	p																																	
WBRT/PBRT	0.45	0.29-0.70	0.0004																																	
surgery	0.30	0.19-0.49	<0.0001																																	
radiosurgery	0.31	0.17-0.55	<0.0001																																	
chemotherapy	0.43	0.27-0.70	0.0006																																	

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS	NOTES																					
Panagiotou, I. E., Brountzos, E. N., Kelekis, D. A., Papathanasiou, M. A. & Bafaloukos, D. I. (2005) Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome. <i>Neoplasma</i> , 52: 150-158.	Retrospective	64 Multiple brain metastases: 47 Single brain metastases: 14	<table><tr><th>Treatment</th><th>No. patients</th><th>median survival (months)</th></tr><tr><td>Surgery followed by radiotherapy</td><td>5</td><td>12</td></tr><tr><td>Temozolomide as first line treatment and radiotherapy after cerebral disease progression</td><td>17</td><td>5</td></tr><tr><td>radiotherapy alone</td><td>28</td><td>3</td></tr><tr><td>supportive care only</td><td>14</td><td>2</td></tr></table>	Treatment	No. patients	median survival (months)	Surgery followed by radiotherapy	5	12	Temozolomide as first line treatment and radiotherapy after cerebral disease progression	17	5	radiotherapy alone	28	3	supportive care only	14	2	Risk of Bias – HIGH. Patient selection bias. Survival was dependent on treatment. Patient characteristics influenced selection of treatment modality.						
			Treatment	No. patients	median survival (months)																				
			Surgery followed by radiotherapy	5	12																				
			Temozolomide as first line treatment and radiotherapy after cerebral disease progression	17	5																				
			radiotherapy alone	28	3																				
			supportive care only	14	2																				
			Surgery vs non surgery groups: p=0.0011																						
			<table><tr><th>Treatment</th><th>HR</th><th>SE</th><th>p</th></tr><tr><td>supportive care only</td><td></td><td></td><td></td></tr><tr><td>Surgery/radiotherapy</td><td>9.6831</td><td>7.0301</td><td>0.0053</td></tr><tr><td>whole brain irradiation</td><td>0.4099</td><td>1.1010</td><td>0.7097</td></tr><tr><td>Temozolomide/ radiotherapy</td><td>4.1874</td><td>2.2236</td><td>0.5497</td></tr></table>	Treatment	HR	SE	p	supportive care only				Surgery/radiotherapy	9.6831	7.0301	0.0053	whole brain irradiation	0.4099	1.1010		0.7097	Temozolomide/ radiotherapy	4.1874	2.2236	0.5497	
			Treatment	HR	SE	p																			
			supportive care only																						
Surgery/radiotherapy	9.6831	7.0301	0.0053																						
whole brain irradiation	0.4099	1.1010	0.7097																						
Temozolomide/ radiotherapy	4.1874	2.2236	0.5497																						

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS	NOTES																														
Sampson J, Carter J, Friedman A, et al. (1998) Demographics, prognosis and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88, 11-20.	Retrospective	702 patients Multiple brain metastases: 234 Single brain metastases: 151	<p>Overall survival</p> <table><tr><th>Treatment</th><th>No. patients</th><th>median survival (months)</th></tr><tr><td>surgery and postoperative radiotherapy</td><td>87</td><td>8.9</td></tr><tr><td>surgery alone</td><td>52</td><td>6.5</td></tr><tr><td>radiotherapy alone</td><td>180</td><td>4.0</td></tr><tr><td>systemic palliative chemotherapy</td><td>205</td><td>1.3</td></tr><tr><td>No treatment</td><td>178</td><td>n/a</td></tr></table> <p>Improvement in neurological symptoms</p> <table><tr><th></th><th>Improved after treatment</th><th>No. patients</th></tr><tr><td>Surgery</td><td>69 (50%)</td><td>139</td></tr><tr><td>WBRT</td><td>96 (54%)</td><td>180</td></tr></table> <p>Life threatening complications or death during treatment or 30 days post treatment.</p> <table><tr><th></th><th>Complications or</th><th>No. patients</th></tr></table>	Treatment	No. patients	median survival (months)	surgery and postoperative radiotherapy	87	8.9	surgery alone	52	6.5	radiotherapy alone	180	4.0	systemic palliative chemotherapy	205	1.3	No treatment	178	n/a		Improved after treatment	No. patients	Surgery	69 (50%)	139	WBRT	96 (54%)	180		Complications or	No. patients	<p>Risk of Bias – HIGH.</p> <p>Patient selection bias.</p> <p>Survival was dependent on treatment, which in turn was dependent on patient selection.</p>
Treatment	No. patients	median survival (months)																																
surgery and postoperative radiotherapy	87	8.9																																
surgery alone	52	6.5																																
radiotherapy alone	180	4.0																																
systemic palliative chemotherapy	205	1.3																																
No treatment	178	n/a																																
	Improved after treatment	No. patients																																
Surgery	69 (50%)	139																																
WBRT	96 (54%)	180																																
	Complications or	No. patients																																

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS			NOTES												
			<table><tr><td></td><td>death</td><td></td></tr><tr><td>Surgery</td><td>12 (9%)</td><td>139</td></tr><tr><td>WBRT</td><td>2(1%)</td><td>180</td></tr></table>				death		Surgery	12 (9%)	139	WBRT	2(1%)	180				
	death																	
Surgery	12 (9%)	139																
WBRT	2(1%)	180																
Selek, U., Chang, E. L., Hassenbusch, S. J., III, Shiu, A. S., Lang, F. F., Allen, P., Weinberg, J., Sawaya, R. & Maor, M. H. (2004) Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. <i>International Journal of Radiation Oncology, Biology, Physics</i> , 59: 1097-1106.	Retrospective	103 Multiple brain metastases: 42 Single brain metastases: 61	<table><tr><th>Treatment</th><th>No. patients</th><th>median overall survival (months)</th></tr><tr><td>SRS alone</td><td>61</td><td>7.5</td></tr><tr><td>SRS + initial WBRT</td><td>12</td><td>3.7</td></tr><tr><td>Salvage SRS after</td><td>30</td><td>5.4</td></tr></table>			Treatment	No. patients	median overall survival (months)	SRS alone	61	7.5	SRS + initial WBRT	12	3.7	Salvage SRS after	30	5.4	Risk of Bias – HIGH. Patient selection bias. Patient selection was generally biased toward treating patients with more favourable prognoses with initial SRS alone and reserving WBRT or surgery for salvage therapy, whereas patients with more
Treatment	No. patients	median overall survival (months)																
SRS alone	61	7.5																
SRS + initial WBRT	12	3.7																
Salvage SRS after	30	5.4																

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS	NOTES																					
			<table><tr><td>WBRT</td><td></td><td></td></tr></table> <p>Initial SRS alone is an effective treatment modality for cerebral melanoma when applied to selected patients with small lesions.</p> <p>Complications:</p> <p>Local failure occurred in 20 cases:</p> <p>SRS alone: 12 tumours</p> <p>SRS+WBRT: 3 tumours</p> <p>Salvage SRS after WBRT: 5 tumours</p> <p>Requiring surgical resection owing to tumour progression, bleeding into lesion, or necrosis.</p>	WBRT			advanced metastatic brain disease were treated with WBRT with or without SRS.																		
WBRT																									
Zacest, A. C., Besser, M., Stevens, G., Thompson, J. F., McCarthy, W. H. & Culjak, G. (2002) Surgical management of cerebral metastases from melanoma: outcome in 147 patients treated at a single institution over two decades. <i>Journal of Neurosurgery</i> , 96: 552-558.	Retrospective	147 patients with 174 craniotomies Multiple brain metastases: 23 Single brain metastases: 124	<table><tr><th>Treatment</th><th>No. patients</th><th>median survival (months)</th></tr><tr><td>Surgery</td><td>9</td><td>1</td></tr><tr><td>Surgery/WBRT</td><td>102</td><td>9</td></tr><tr><td>Surgery/WBRT/chemo</td><td>33</td><td>11</td></tr><tr><td>Surgery/chemo</td><td>3</td><td>?</td></tr><tr><td>Repeated craniotomy</td><td>24</td><td>15</td></tr><tr><td>Surgery/WBRT /radiosurgery</td><td>2</td><td>5</td></tr></table>	Treatment	No. patients	median survival (months)	Surgery	9	1	Surgery/WBRT	102	9	Surgery/WBRT/chemo	33	11	Surgery/chemo	3	?	Repeated craniotomy	24	15	Surgery/WBRT /radiosurgery	2	5	Risk of Bias – HIGH. Patient selection bias. Survival was dependent on treatment, which in turn was dependent on patient selection.
Treatment	No. patients	median survival (months)																							
Surgery	9	1																							
Surgery/WBRT	102	9																							
Surgery/WBRT/chemo	33	11																							
Surgery/chemo	3	?																							
Repeated craniotomy	24	15																							
Surgery/WBRT /radiosurgery	2	5																							

PAPER	TYPE OF STUDY	No. PATIENTS	TREATMENT COMPARISONS	NOTES
			<p>Postoperative morbidity (not reported by treatment group) included:</p> <p>4 postoperative hematomas requiring operation</p> <p>8 wound infections (6 of which required repeated craniotomy)</p> <p>7 pulmonary emboli</p> <p>5 deep venous thromboses</p> <p>4 urinary tract or lung infections</p>	

6.3 The role of systemic anticancer therapy

Review question: What is the effectiveness of systemic anticancer therapy compared with supportive care in the treatment (first and second line) of patients with stage IV metastatic melanoma?

Background

Systemic therapy is playing an ever more important role in the multidisciplinary management of metastatic melanoma. With the development of new targeted treatments and immune therapies the role of chemotherapy has shifted and selection of the most appropriate therapy must now take into account the mutational status of the tumour, tumour load, pace of disease and treatment availability (see Table 11.1).

Table 6.1 Factors determining treatment selection of systemic therapy

	Mutation	Response rate	Onset of Action	Durable response	Availability in the UK (July 2013)
Targeted treatment(s)	yes	high	days	no	BRAF mutated, 1st or 2nd line
Immunotherapy	no	low	months	yes	2nd line
Chemotherapy	no	low	weeks	no	Any

Targeted treatment and immunotherapy have taken over many of the previous traditional roles of chemotherapy, however, it will remain a treatment choice for patients in whom targeted treatments and immunotherapy are not considered options. Targeted treatment is only useful in the presence of a tumour mutation, whilst the onset of actions for immunotherapy is in the order of months which may preclude treatment in patient with high disease burden and/or rapidly progressing disease. At present, immunotherapy with anti-CTLA4 antibodies is only available as second line treatment in Europe and therefore chemotherapy is the treatment of choice in patients with BRAF wild type melanoma. Chemotherapy is also an option where targeted treatment or immunotherapy has failed.

Dacarbazine chemotherapy has been the standard of care for over 20 years. Temozolomide is an analogue of dacarbazine also currently also in widespread use, particularly in patients with brain metastases. It will be important to compare dacarbazine with temozolamide in order establish if there is any advantage of temozolamide over dacarbazine in terms of efficacy or toxicity, or if there are any special situations in which one drug would be favoured. Carboplatin and paclitaxel are also used in the UK.

Question in PICO format

Patients/population	Intervention	Comparator	Outcomes
Patients diagnosed with	Dacarbazine	Each other	Symptom control

stage IV melanoma: <ul style="list-style-type: none"> • Location of metastases • Age • Tumour mutation Status • Previous systemic therapy • Performance status • AJCC stage 4 subgroup 	Temozolomide Carboplatin Paclitaxel Carboplatin + paclitaxel	Supportive care	Overall Survival (1 yr, 2 yr) Median OS PFS Response status HRQOL Adverse events
--	---	-----------------	---

1 How the information will be searched

Searches:	
Can we apply date limits to the search (<i>Please provide information on any date limits we can apply to the searches for this topic. This can be done for each individual intervention as appropriate</i>)	The GDG did not feel there were any dates which could be applied to these searches.
Are there any study design filters to be used (<i>RCT, systematic review, diagnostic test</i>).	Due to the nature of the topic under investigation, the GDG felt that it was appropriate to limit the evidence to systematic reviews/meta-analysis and randomized controlled trials
List useful search terms. (<i>This can include such information as any alternative names for the interventions etc</i>)	No additional information to add

2

3 The review strategy

What data will we extract and how will we analyse the results?	<p>Relevant studies will be identified through sifting the abstracts and excluding studies clearly not relevant to the PICO. In the case of relevant or potentially relevant studies, the full paper will be ordered and reviewed, whereupon studies considered to be not relevant to the topic will be excluded.</p> <p>Studies which are identified as relevant will be critically appraised and quality assessed using GRADE methodology and/or NICE checklists. Data relating to the identified outcomes will be extracted from relevant studies.</p> <p>If possible a meta-analysis of available study data will be carried out to provide a more complete picture of</p>
--	--

	<p>the evidence body as a whole.</p> <p>An evidence summary outlining key issues such as volume, applicability and quality of evidence and presenting the key findings from the evidence as it relates to the topic of interest will be produced.</p>
List subgroups here and planned statistical analyses.	<p>If the data are reported, the GDG would like to see the effectiveness of treatment according to the following subgroups:</p> <ul style="list-style-type: none"> • Location of metastases • Age • Tumour mutation Status • Previous systemic therapy • Performance status • AJCC stage 4 subgroup

1 Search results

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	1946-2013	897	224	05/08/2013
<i>Premedline</i>	24 Jun 2013	16	5	06/08/2013
<i>Embase</i>	1947-2013	2260	139	13/08/2013
<i>Cochrane Library</i>	Issue 6 of 12 June 2013	335	184	06/08/2013
<i>Web of Science (SCI & SSCI)</i>	1900-2013	938	192	07/08/2013
Total References retrieved (after de-duplication): 453				

2 Update Search

- 3 For the update search, the same search criteria/filters were applied as initial search with a date limit
- 4 of August 2013 onwards.

Database name	No of references found	No of references retrieved	Finish date of search

Medline	36	19	08/10/2014
Premedline	3	2	08/10/2014
Embase	157	18	08/10/2014
Cochrane Library	1	1	08/10/2014
Web of Science (SCI & SSCI)	149	36	08/10/2014
Pubmed	6	6	08/10/2014
Total References retrieved (after de-duplication): 40			

1 Medline search strategy (*This search strategy is adapted to each database*)

1. exp Melanoma/
2. melanoma\$.tw.
3. 1 or 2
4. Dacarbazine/
5. (dacarbazine or DTIC or deticine or (imidazole adj carboxamide) or dticdome or nsc45388 or nsc-45388 or decarbazine or icdt or biocarbazine).tw.
6. 4 or 5
7. (temozolomide or temodal or temodar or ccrg81045 or mb39831 or methazolastone or nsc362856 or nsc-362856 or temomedac or temoxol).tw.
8. Carboplatin/
9. (carboplatin or (cis-diammine adj cyclobutanedicarboxylato adj platinum) or CBDCA or ribocarbo or nealorin or neocarbo or paraplatin or carboplat* or paraplattine or carbosin or carbotec or ercar or JM-8 or JM8 or nsc-241240 or nsc241240 or platinwas or blastocarb).tw.
10. 8 or 9
11. Paclitaxel/
12. (paclitax* or paclitac* or paxene or anzatax or abraxane or nsc125973 or nsc-125973 or 7-epi-taxol or taxol or praxel or paxene or onxol).tw.
13. 11 or 12
14. 6 or 7 or 10 or 13
15. 3 and 14

Screening Results



Reasons for Exclusion

- Expert Reviews
- Abstract Only
- No Comparators
- Treatment Comparisons not relevant to PICO
- Population not relevant to PICO

Quality of the included studies

- Systematic review of RCTs (n=1)
- Systematic review of combined study designs (n=0)
- Randomized controlled trial (n=4)
- Prospective cross sectional study (n=0)
- Case Series Studies (n=0)
- Qualitative Study (n=0)

Table 6.2: Characteristics of included studies

Study	Study Type	Population	Aim	Intervention	Comparison	Outcomes
Crosby et al (2013)	Systematic Review	No relevant studies identified for inclusion	To investigate the efficiency of systemic anticancer therapy for the treatment of metastatic melanoma	Systemic Anticancer therapy in the form of cytotoxic chemotherapy with/without immunotherapy	Best Supportive Care or Placebo	<ul style="list-style-type: none"> • Overall Survival • Progression Free survival • Quality of Life • Response Rates • Treatment Morbidity • Health Economics
Kiebert et al (2003)	Randomised Trial	N=305	To provide further details of the Health Related Quality of Life results	Temozolomide	Dacarbazine	<ul style="list-style-type: none"> • Health Related Quality of Life
Middleton et al (2000)	Randomised Trial	N=305	To compare the effectiveness of temozolomide versus dacarbazine for the treatment of metastatic melanoma	Temozolomide (n=146)	Dacarbazine (n=141)	<ul style="list-style-type: none"> • Overall Survival • Time to progression • Objective Response Rate • Quality of Life
Patel et al (2011)	Randomised Trial	N=859 patients randomised	To determine whether an extended schedule and escalated dose of temozolomide is more effective treatment for metastatic melanoma than standard dose of dacarbazine	Temozolomide (n=429)	Dacarbazine (n=430)	<ul style="list-style-type: none"> • Overall Survival • Progression Free Survival • Response to Treatment • Safety

Study	Study Type	Population	Aim	Intervention	Comparison	Outcomes
Zimpfer-Rechner et al (2003)	Randomised Trial	N=34	To compare the response rate of patients receiving paclitaxel with and without carboplatin	Paclitaxel	Paclitaxel + Carboplatin	<ul style="list-style-type: none"> • Overall Survival • Progression Free Survival • Response Rates • Toxicity

Evidence Statements

Systemic Anticancer Therapy versus Best Supportive Care

From one Cochrane Review (Crosby et al; 2013) there was no evidence comparing the use of systemic anticancer therapy with best supportive care alone for any of the outcomes of interest (GRADE Profile 1).

Dacarbazine versus Temozolomide

Evidence from two randomised trials (Middleton *et al*, 2000 and Patel *et al*, 2010) suggests similar overall survival for patients treated with temozolomide when compared to those treated with dacarbazine. The pooled hazard ratio (HR) for death from any cause was 0.96 (95% CI 0.84 to 1.09), translating to an absolute improvement in median overall survival of 0.33 months with temozolomide [Moderate].

Evidence from two randomised trials (Middleton *et al*, 2000 and Patel *et al*, 2010) that patients treated with temozolomide have better progression free survival (PFS) than those treated with dacarbazine. The pooled HR for disease progression was 0.87 (95% CI 0.77 to 0.98) translating to an absolute improvement in median progression free survival of 0.28 months with temozolomide. This hazard ratio combined with the control arm PFS data from Patel *et al* (2010) suggests 6 month progression free survival of 27% with temozolomide treatment compared to 22% with dacarbazine [Moderate].

Two randomised controlled trials (Middleton et al; 2000 & Patel et al; 2011) indicate that there is no significant difference in responses to treatment for patients treated with temozolomide compared with patients treated with dacarbazine (OR for complete response: 1.48 (0.59-3.70); OR for partial response: 1.39 (0.94-2.06)) [Moderate]

Two randomised controlled trials (Middleton et al; 2000 & Patel et al; 2011) reported that the rate of Grade 3-4 adverse events ranged from 35%-38% in patients treated with temozolomide compared with 29%-36% for patients treated with dacarbazine [Moderate]

Paclitaxel versus Paclitaxel + Carboplatin

From one phase II randomised trial with 40 participants (Zimpfer-Rechner et al, 2003), the median overall survival time was 218 days for patients treated with paclitaxel versus 209 days for patients treated with paclitaxel + carboplatin [Low].

From one phase II randomised trial with 40 participants (Zimpfer-Rechner et al, 2003), the median progression free survival time was 54 days for patients treated with paclitaxel versus 57 days for patients treated with paclitaxel + carboplatin [Low].

GRADE Table 6.25: Should Systemic Anti-cancer treatments (Dacarbazine, Temozolomide, Carboplatin, Paclitaxel, Paclitaxel+Carboplatin) vs. Best Supportive Care be used in patients with metastatic melanoma?

Quality assessment						
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations
Overall Survival - not reported						
0 ¹	-	-	-	-	-	none
Progression free survival - not reported						
0 ¹	-	-	-	-	-	none
Median Survival - not reported						
0 ¹	-	-	-	-	-	none
Response Rates - not reported						
0 ¹	-	-	-	-	-	none
Health Related Quality of Life - not reported						
0 ¹	-	-	-	-	-	none
Symptom Control - not measured						
0	-	-	-	-	-	none
Adverse Events - not measured						

0	-	-	-	-	-	none
---	---	---	---	---	---	------

¹ Cochrane Review of RCTs comparing systemic anti-cancer therapy with best supportive care (Crosby et al, 2013)

GRADE Table 6.26: Should Temozolomide vs. Dacarbazine be used in patients with metastatic melanoma?

Quality assessment							Summary of findings				
							No of patients		Effect		Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Temozolomide	Dacarbazine	Relative (95% CI)	Absolute	
Overall Mortality (Patel et al, 2011; Middleton et al, 2000)											
2	randomised trials	Serious ²	no serious inconsistency	no serious indirectness ⁵	no serious imprecision	none	585 ⁴	579 ⁴	HR 0.96 (0.84-1.09)	Median overall survival 0.33 months longer with temozolomide (from 0.7 months shorter to 1.5 months longer)	MODERATE
Disease Progression (Patel et al, 2011; Middleton et al, 2000)											
2	randomised trials	serious ²	no serious inconsistency	no serious indirectness ⁵	no serious imprecision	none	508/585 (87%)	505/579 (87%)	HR 0.87 (0.77-0.98)	Median progression free survival was 0.28	MODERATE

										months longer with temozolomide (from 1 months shorter to 0.04 months longer)	
Partial Response (Patel et al, 2011; Middleton et al, 2000)											
2	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	67/557 (12%)	48/537 (8.9%)	OR 1.39 (0.94 to 2.06)	31 more per 1000 (from 5 fewer to 79 more)	MODERATE
								9.1%		31 more per 1000 (from 5 fewer to 80 more)	
Complete Response (Patel et al, 2011; Middleton et al, 2000)											
2	randomised trials	Serious ¹	no serious inconsistency	no serious indirectness	no serious imprecision	none	12/557 (2.2%)	8/547 (1.5%)	OR 1.48 (0.59 to 3.7)	7 more per 1000 (from 6 fewer to 37 more)	MODERATE
								2%		9 more per 1000 (from 8 fewer to 50)	

										more)	
Health Related Quality of Life³ (Kiebert et al 2003))											
1	randomised trials	serious ^{1,2}	no serious inconsistency	no serious indirectness	no serious imprecision	none					MODERATE
Grade 3-4 Adverse Events (Patel et al, 2011; Middleton et al, 2000)											
2	randomised trials	Serious ^{1,2}	no serious inconsistency	no serious indirectness	no serious imprecision	none	Rate ranged from 35%-38% in 585 patients	Rate ranged from 29%-36% in 579 patients			MODERATE

¹ There is a lack of information provided in the methodology to adequately assess factors such as allocation concealment or blinding.

² Two randomised trials compared temozolomide with dacarbazine however it was not possible to conduct a meta-analysis of the results.

³ This study reports the Health Related Quality outcome measured as part of the Middleton et al, 2000 trial, in more detail. The quality assessment has been based on the information provided both in this publication and also in the original trial publication.

⁴ Number of deaths was not reported in Middleton, but hazard ratios were reported so meta-analysis was still possible

⁵ Patel et al included patients with mucosal melanoma which is not covered by the scope of the guideline. However, as the rates of mucosal melanoma are lower than for other types of melanoma, it was considered that the numbers of patients in the trial with mucosal melanoma would be low enough as to not impact the results and so the evidence was not downgraded for indirectness.

GRADE Table 6.26: Should Paclitaxel vs. Paclitaxel + Carboplatin be used in patients with metastatic melanoma?

Quality assessment							Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	
Tumour Response							

1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	LOW
Overall Survival							
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	LOW
Progression Free Survival							
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	LOW
Toxicity							
1	randomised trials	serious ¹	no serious inconsistency	no serious indirectness	serious ²	none	LOW

¹ Phase II trial - small numbers with no details on method of randomisation

² A sample size of 242 patients was required to assure statistical significance however the study planned to initially recruit 40 patients in order to evaluate response and as the response rates were <10% in each arm, recruitment to the trial was stopped early .

Evidence Summaries

Systemic Anticancer Treatment versus Best Supportive Care

A single Cochrane Review (Crosby et al, 2013) sought to compare a variety of systemic anticancer treatments for metastatic cutaneous melanoma with best supportive care; treatments of interest included cytotoxic chemotherapy and immunotherapy with or without hormone therapy. The review found no randomised trials comparing the effects of systemic therapies for metastatic cutaneous melanoma with best supportive care or placebo.


Dacarbazine versus Temozolomide

Evidence from two randomised trials (Middleton *et al*, 2000 and Patel *et al*, 2010) suggests similar overall survival for patients treated with temozolomide when compared to those treated with dacarbazine. The pooled hazard ratio (HR) for death from any cause was 0.96 (95% CI 0.84 to 1.09) [Moderate].

Evidence from two randomised trials (Middleton *et al*, 2000 and Patel *et al*, 2010) that patients treated with temozolomide have better progression free survival (PFS) than those treated with dacarbazine. The pooled HR for disease progression was 0.87 (95% CI 0.77 to 0.98). This hazard ratio combined with the control arm PFS data from Patel *et al* (2010) suggests 6 month progression free survival of 27% with temozolomide treatment compared to 22% with dacarbazine [Moderate].


Median overall survival was 9.1 months for patients randomised to temozolomide and 9.4 months for patients in the dacarbazine arm. This compares favourably to a second trial (Middleton et al, 2000) in which the median overall survival time was 7.7 months for patients randomised to temozolomide versus 6.4 months for patients randomised to dacarbazine.

Figure 6.1: Overall Mortality



(1) Number of deaths was not reported in this study.

Figure 6.2: Disease Progression



(1) The rate of disease progression was not reported clearly; we assumed that patients not treated or ineligible progressed.

Response to treatment was measured in both trials (Middleton et al, 2000; Patel et al, 2011) with a similar rate of response observed for both treatments.

Figure 6.3: Complete Response to treatment





Figure 6. 4: Partial Response to treatment



Health related quality of life was reported in detail in one study (Kiebert et al, 2003) using a self administered EORTC QLQ-C30 with health related quality of life summarised at weeks 12 and 24 to account for the differences in treatment cycle durations. Baseline health related quality of life scores were available for 251/305 with no significant difference between the treatment groups at baseline observed.

At week 12, HQRL data were available for 50 patients in the temozolomide arm and 31 patients in the dacarbazine arm; patients in the temozolomide arm reported significantly better physical functioning and less fatigue and sleep disturbances compared with patients in the dacarbazine arm and at 24 weeks all subscales with the exception of diarrhoea were better for patients in the temozolomide arm though data were only available for 22 patients in the temozolomide arm and 8 patients in the dacarbazine arm.

For patients in the temozolomide arm there was a statistically significant improvement in emotional functioning ($p \leq 0.001$) at week 12. There were improvements in role, cognitive and social functioning also, however the overall change in global HRQL (all functioning scales) was negligible.

For patients in the dacarbazine arm, functioning at week 12 decreased in all functioning scales apart from emotional functioning which showed improvement.

Patients in the temozolomide arm reported a reduction in pain, sleep disturbance and appetite loss and increased fatigue, nausea and vomiting, dyspnoea, constipation and diarrhoea.

1 In the dacarbazine arm, patients reported reductions in nausea and vomiting, pain, loss of appetite
2 and diarrhoea and increased fatigue, dyspnoea, sleep disturbance, constipation and financial impact.

3 Paclitaxel vs. Paclitaxel + Carboplatin

4 A single, phase II randomised trial (Zimpfer-Rechner et al, 2003) compared the effectiveness of
5 paclitaxel with and without carboplatin in the treatment of patients with histologically advanced
6 metastatic melanoma. Prior to recruiting the full sample of 242 patients, the study initially recruited
7 40 patients in order to evaluate response to treatment however 6 patients were not included in the
8 analysis due to protocol violations (n=4) and not receiving treatment (n=2). The overall response rate in
9 this initial patient sample was <10% in both arms and so recruitment to the study was halted.

10 No major clinical responses to treatment were observed and only 8 patients were classified as stable
11 disease. Following 8 weeks 11/18 patients treated with paclitaxel and 12/16 patients treated with
12 paclitaxel + carboplatin showed evidence of progressive disease.

13 All 34 randomised patients were included in the per protocol analysis and median overall survival
14 time, calculated from treatment initiation to time of death, was similar for both arms (218 days for
15 patients treated with paclitaxel and 209 days for patients treated with paclitaxel + carboplatin).

16 Median progression free survival time was 54 days in the paclitaxel arm and 57 days in the paclitaxel
17 + carboplatin arm.

18 Toxicity, assessed according to the WHO grading system was more pronounced in the paclitaxel +
19 carboplatin arm though overall, toxicity was mild and both treatments were well tolerated.
20 Haematological toxicity, particularly leucopenia, was frequently observed during the first treatment
21 cycle but less so in the second and third treatment cycles. Overall, grade III/IV leucopenia was
22 observed in 4/22 administered treatment cycles in the paclitaxel arm and in 6/20 administered
23 cycles in the paclitaxel + carboplatin arm.

24

References

Included

Crosby et al (2013) Systemic treatments for metastatic cutaneous melanoma *Cochrane Database of Systematic Reviews*

Kiebert et al (2003) Health related quality of life in patients with advance metastatic melanoma: results of a randomised phase III study comparing temozolomide with dacarbazine *Cancer Investigation* 21(6);821-829

Middleton et al (2000) Randomised phase III study of temozolomide versus dacarbazine in the treatment of patients with advances metastatic malignant melanoma *Journal of Clinical Oncology* 18;1:158-166

Patel et al (2011) Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032) *European Journal of Cancer* 47; 1476-1483

Zimpfer-Rechner et al (2003) Randomised phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG) *Melanoma Research* 13;531-536

Excluded

Agarwala, S. S., et al (1999) A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. *Cancer* 85[9], 1979-1984. 1-5-

Reason: Comparison not relevant to PICO

Atkins, M. B et al (2002) A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. *Clinical Cancer Research* 8[10], 3075-3081

Reason: Not relevant to PICO

Agarwala, S. S et al (2004) Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. *Journal of Clinical Oncology* 22[11], 2101-2107. 1-6-

Reason: None comparative study

Bafaloukos D et al (2004). The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. *Melanoma Research* 14[4], 289-294.

Reason: N=6 relevant patients

Bedikian, A. Y et al (2004) Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma. *Melanoma Research* 14[1], 63-66.

Reason: None comparative study

- 1
- 2 Bedane, C et al (2013) Treatment patterns and outcomes in patients with advanced melanoma in
- 3 France. *Current Medical Research and Opinion* [Jul 26], epub ahead of print.
- 4 Reason: No useable data
- 5 Blesa, J. M. G (2009). Treatment options for metastatic melanoma. *A systematic review. Cancer*
- 6 *Therapy* 7[ISSUE A], 188-199.
- 7 Reason: No relevant data reported
- 8 Boeckmann, L. Thoms.(2009) Modulation of the efficacy of temozolomide and dacarbazine
- 9 melanoma treatment by DNA-repair factors in vivo and in vitro. *International Journal of Clinical*
- 10 *Pharmacology and Therapeutics* 47[1], 33-35.
- 11 Reason: Not relevant to PICO
- 12 Chang, A et al (1993). Phase II trial of carboplatin in patients with metastatic malignant melanoma. A
- 13 report from the Eastern Cooperative Oncology Group. *American Journal of Clinical Oncology* 16[2],
- 14 152-155
- 15 Reason: None comparative study
- 16 Chang, W (2013) Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus
- 17 cutaneous metastatic melanoma. *Melanoma Research* 23[2], 147-151.
- 18 Reason: Comparison not relevant to PICO
- 19 Carbone, P. P. and Costello, W. (1976) Eastern Cooperative Oncology Group studies with DTIC (NSC-
- 20 45388). SO: *Cancer treatment reports* 60[2], 193-198.
- 21 Reason: Comparison not relevant to PICO
- 22 Casper, E. S., et al (1990). Phase II trial of carboplatin in patients with advanced melanoma.
- 23 *Investigational New Drugs* 8[2], 187-190.
- 24 Reason: None comparative study
- 25 Danson, S et al (2003) Randomized phase II study of temozolomide given every 8 hours or daily with
- 26 either interferon alfa-2b or thalidomide in metastatic malignant melanoma. *Journal of Clinical*
- 27 *Oncology* 21[13], 2551-2557. 1-7
- 28 Reason: Comparison not relevant to PICO
- 29 Eigentler, T. K et al (2003) Palliative therapy of disseminated malignant melanoma: a systematic
- 30 review of 41 randomised clinical trials. [Review] [70 refs]. *Lancet Oncology* 4[12], 748-759.
- 31 Reason: Interventions and comparisons not relevant to PICO
- 32 Fisher, R. A., et al (2010). Malignant melanoma (metastatic). Clinical Evidence 2010, 2010.
- 33 Reason: Relevant studies already identified and included as appropriate
- 34 Hellman, K., et al (1990). Phase II study of carboplatin in malignant melanoma. SO: *Ann-Oncol*
- 35 1[Suppl], 128.
- 36 Reason: Abstract Only

Hill, G. J., et al (1974). Chemotherapy of malignant melanoma with dimethyl traizeno imidazole carboxamide (DITC) and nitrosourea derivatives (BCNU, CCNU). SO: *Annals of surgery* 180[2], 167-174.

Reason: Comparison not relevant to PICO

Hauke, R. J., et al (2013) Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Research Consortium. *Melanoma Research* 23;6:468-473.

Reason: Not relevant to PICO

Huncharek, M et al (2001). Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. *Melanoma Research* 11[1], 75-81.

Reason: Comparator not relevant to PICO

Hodi, F. S et al (2002). Phase II study of paclitaxel and carboplatin for malignant melanoma. *American Journal of Clinical Oncology* 25[3], 283-286.

Reason: None comparative study

Jiang, G., Li, R. H., Sun, C., Jia, H. Y., Lei, T. C., and Liu, Y. Q. Efficacy and safety between temozolomide alone and temozolomide-based double therapy for malignant melanoma: a meta-analysis. *Tumor Biology* 35[1], 315-322. 2014.

Lebbe, C et al (2011) Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: A retrospective, longitudinal survey (MELODY study). *European Journal of Cancer* 48[17], 3205-3214.

Reason: No relevant data can be extracted

Lorigan, P et al (2013) Treatment patterns, outcomes, and resource utilisation of patients with metastatic melanoma in the U.K.: the MELODY study. *British Journal of Dermatology* [Jul 16], epub ahead of print.

Reason: No relevant data

Luce, J. K et al (1970) Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide(NSC-45388). *Cancer Chemotherapy Reports - Part 1* 54[2], 119-124.

Reason: Non comparative study

Lui, P et al (2007) Treatments for metastatic melanoma: synthesis of evidence from randomized trials. [Review] [68 refs]. *Cancer Treatment Reviews* 33[8], 665-680.

Reason: Comparisons not relevant to PICO

Ma, C. and Armstrong, A. W. (2014) Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. *Journal of Dermatological Treatment* 25;5:401-408.

Reason: Not relevant to PICO

Ma, C. and Armstrong, A.(2013) Severe Adverse Events from the Treatment of Advanced Melanoma: A Systematic Review of Severe Side Effects Associated with Ipilimumab, Vemurafenib, Interferon Alfa-2b, Dacarbazine, and Interleukin-2. *Journal of Dermatological Treatment* [Jun 14], epub ahead of print.

Reason: Any relevant data included in other studies

MacNeil, J. S.(2008) Temozolomide fails to improve survival in EORTC trial. *Oncology Report* [WINTER 2008], 48.

Reason: Comment

Middleton, M. R et al (2000). Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.[Erratum appears in J Clin Oncol 2000 Jun;18(11):2351]. *Journal of Clinical Oncology* 18[1], 158-166.

Reason: Comparison not relevant to PICO

National Horizon Scanning Centre. Temozolomide (Temodal) for advanced metastatic melanoma: horizon scanning technology briefing (Structured abstract). Health Technology Assessment Database [3], 5. 2007. National Horizon Scanning Centre (NHSC).

Reason: No data

O'Day, S et al (2007) Subgroup analysis of efficacy and safety analysis of a randomized, double-blinded controlled phase 2 study of STA-4783 in combination with paclitaxel in patients with metastatic melanoma. *Archives of Dermatological Research* 299[5-6], 294.

Reason: Abstract Only

Paul, M. J., et al (2002) Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. *Melanoma Research* 12[2], 175-178.

Reason: Retrospective non-comparative study

Perrin, C., Pracht, M., Talour, K., Adamski, H., Cumin, I., Porneuf, M., Talarmin, M., Mesbah, H., Audrain, O., Moignet, A., Lefeuvre-Plesse, C., and Lesimple, T. Metastatic melanoma: Results of 'classical' second-line treatment with cytotoxic chemotherapies. *Journal of Dermatological Treatment* 25[5], 396-400. 2014.

Pflugfelder, A et al (2011) Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma. *PLoS ONE [Electronic Resource]* 6[2], e16882.

Reason: None comparative study

Quirt, I et al (2007) Temozolomide for the treatment of metastatic melanoma: a systematic review. [Review] [36 refs]. *The Oncologist* 12[9], 1114-1123.

Reason: Comparisons not relevant to PICO

Rietschel, P. Wolchok (2008). Phase II study of extended-dose temozolomide in patients with melanoma. *Journal of clinical oncology* : official journal of the American Society of Clinical Oncology 26[14], 2299-2304.

Reason: None comparative study

1 Reintgen, D. and Saba, H (1993). Chemotherapy for Stage-4 Melanoma - A 3-Year Experience with
2 Cisplatin, Dtic, Bcnu, and Tamoxifen. *Seminars in Surgical Oncology* 9[3], 251-255.

3 Reason: Intervention not relevant to PICO

4 Rosenberg, S. A., (1999) Prospective randomized trial of the treatment of patients with metastatic
5 melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination
6 with interleukin-2 and interferon alfa-2b. *Journal of Clinical Oncology* 17[3], 968-975.

7 Reason: Comparison not relevant to PICO

8 Rusthoven, J. J., et al (1996). Randomized, double-blind, placebo-controlled trial comparing the
9 response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with
10 metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. *Journal of Clinical*
11 *Oncology* 14[7], 2083-2090.

12 Reason: Interventions not relevant to PICO

13 Steffens, T. A., et al (1991) A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of
14 high-dose, cisplatin-based therapy for metastatic melanoma. *Cancer* 68[6], 1230-1237.

15 Reason: Intervention not relevant to PICO

16 Rao, R. D et al (2006) Combination of paclitaxel and carboplatin as second-line therapy for patients
17 with metastatic melanoma. *Cancer* 106[2], 375-382

18 Reason: None comparative study.

19 Robinson, D. W (2012) Health-related quality of life among patients with metastatic melanoma:
20 results from an international phase 2 multicenter study. *Melanoma Research* 22[1], 54-62.

21 Reason: Treatment comparisons not relevant to PICO

22 Schadendorf, D. Hauschild. (2006) Dose-intensified bi-weekly temozolomide in patients with
23 asymptomatic brain metastases from malignant melanoma: A phase II DeCOG/ADO study. *Annals of*
24 *Oncology* 17[10], 1592-1597.

25 Reason: Comparison not relevant to PICO

26 Teimouri, F.(2012) Evaluation of the efficacy and side effects of dacarbazine in comparison to
27 temozolomide therapies in treatment of malignant melanoma. a meta-analysis. *Value in Health*
28 *Conference*[var.pagings], A411.

29 Reason: Abstract

30 Teimouri, F et al (2013) Efficacy and side effects of dacarbazine in comparison with temozolomide in
31 the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients. *Melanoma*
32 *Research* [Jul 20], epub ahead of print.

33 Reason: Not relevant to PICO

34 Walker, L et al (2005) Phase II trial of weekly paclitaxel in patients with advanced melanoma.
35 *Melanoma Research* 15[5], 453-459

36 Reason: None comparative study

- 1 Yi, J. H et al (2011) Dacarbazine-based chemotherapy as first-line treatment in noncutaneous
- 2 metastatic melanoma: multicenter, retrospective analysis in Asia. *Melanoma Research* 21[3], 223-
- 3 227.
- 4 Reason: Interventions not relevant to PICO

- 5 Zhu, W., et al (2014) Temozolomide for treatment of brain metastases: A review of 21 clinical trials.
- 6 [Review]. *World Journal of Clinical Oncology* 5;1:19-27
- 7 Reason: Not relevant to PICO

Evidence Tables

Study Quality

Systematic Reviews

	Appropriate and clearly focused question that is relevant to the guideline review question	Studies relevant to the guideline review question	Literature search is sufficiently rigorous to identify all the relevant studies	Study quality is assessed and reported	An adequate description of the methodology used is included, and the methods used are appropriate to the question
Crosby et al (2013)	Yes	Yes	Yes	Yes	Yes

Randomised Trials

Study	Appropriate Randomisation	Appropriate Concealment	Comparable groups at baseline	Comparable Care apart from intervention	Patient Blinding	Treatment Administrator Blinding	Equal Follow-up	Equal Treatment Completion/Loss to follow up	Appropriate follow-up length	Precise definition of outcome	Valid method of measuring outcome	Investigator blinding
Middleton et al (2000)	Unclear	Unclear	Yes	Yes	No	No	Unclear	Unclear	Yes	Yes	Yes	Unclear
Patel et al (2011)	Yes	Unclear	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Unclear
Kiebert et al (2003)	Unclear	Unclear	Yes	Yes	No	No	Yes	Unclear	Unclear	Unclear	Yes	Unclear


Zimpfer-Rechner et al (2003)	Unclear	Unclear	Yes	Unclear	No	No	Yes	Yes	Unclear	Yes	Yes	Unclear
-------------------------------------	---------	---------	-----	---------	----	----	-----	-----	---------	-----	-----	---------

Economic Evidence Summary

- The following databases were searched for economic evidence relevant to the PICO: MEDLINE, EMBASE, COCHRANE, NHS EED. Studies conducted in OECD countries other than the UK were considered (Guidelines Manual 2009).
- 303 possibly relevant papers were identified. Of these, 2 full papers relating to this topic were obtained for appraisal. A further 1 paper was excluded as it was not applicable to the PICO. Therefore only one paper (Hillner et al. 2000) was included in the current review of published economic evidence for this topic.
- The study was a cost-effectiveness analysis of temozolomide (TEM) versus dacarbazine (DTIC) which reported the results in terms of incremental cost per life year gained. Typically papers which do not report quality of life based outcomes are excluded but given the paucity of economic evidence on this topic an exception was made.
- Hillner et al. is deemed only partially applicable to the decision problem that we are evaluating. This is primarily because the study did not consider a UK setting (US healthcare setting) and did not express health outcomes in terms of quality adjusted life years (QALYs).
- Very serious limitations were identified with Hillner et al. Most notably, a potential conflict of interest was identified (as the study was funded by the manufacturer of temozolomide) and probabilistic sensitivity analysis (PSA) was not conducted.
- The base case suggested that treating with TEM over DTIC would cost \$36 990 per life-year gained although this varied from temozolomide being dominated (more costly, less effective) to \$18 670 per life-year gained when the 2.5% and 97.5% confidence interval estimates for effectiveness were used. No analyses using quality adjusted life-years (QALYs) were presented.

Volume of evidence

- 303 possibly relevant papers were identified. Of these, 2 full papers relating to this topic were obtained for appraisal. A further 1 paper were excluded as it was not applicable to the PICO. Therefore only one paper (Hillner et al. 2000) was included in the current review of published economic evidence for this topic.
- Hillner et al was an cost-effectiveness analysis, conducted from a US healthcare payer perspective using effectiveness data from a RCT set in Europe and Australia
- The study reported cost-effectiveness results in terms of cost per life-year gained. No analyses using quality adjusted life-years (QALYs) were presented.



1 Quality and applicability of the included studies

		<i>Applicability</i>	
		Directly applicable	Partially applicable
<i>Methodological quality</i>	Minor limitations		
	Potentially serious limitations		
	Very serious limitations		Hillner et al. 2000

- Hillner et al. is deemed only partially applicable to the decision problem that we are evaluating. This is primarily because the study did not consider a UK setting and did not express health effect values in terms of quality adjusted life years (QALYs).
- Very serious limitations were identified with Hillner et al. Most notably, a potential conflict of interest was identified (as the study was partially funded by the manufacturer of temozolomide) and probabilistic sensitivity analysis (PSA) was not conducted.

8 References

Hillner BE, Agarwala S, Middleton MR. 'Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma' *Journal of Clinical Oncology* 18.7 (2000): p1474-80

Evidence Tables

Modified GRADE profiles for included economic studies

Study	Population	Comparators	Costs	Effects	Incr costs	Incr effects	ICER	Uncertainty	Applicability	Limitations
Hillner et al. 2000	Patients with advanced, metastatic malignant melanoma who are previously untreated for metastatic disease.	Intravenous DTIC once a day for 5 days with a starting dose of 250mg/m ² repeated every 21 days.	\$3 697	8.6 months mean survival	Reference			One-way Sensitivity Analysis One-way sensitivity analyses were conducted with incremental cost per life-year gained ranging from \$15 600 to TEM being dominated compared to DTIC	Partially Applicable Not conducted from a UK health service perspective.	Very Serious Limitations. Study funded by manufacturer.
		Orally administered TEM once a day for 5 days with a starting dose of 200mg/m ² repeated every 28 days.	\$6 902	9.6 months mean survival	\$3 205	0.087 years survival	\$36 990 per Life Year gained.	Threshold Sensitivity Analysis Threshold sensitivity analysis showed that TEM could be increased to \$1 805 per course and still be cost-effective at a WTP of \$50 000 per life-year gained.	QALY results not presented (life years only).	PSA not conducted.
Comments: Papers which do not report quality of life based outcomes are typically excluded from the review of economic evidence. However, given the paucity of economic evidence on this topic an exception was made.										

Primary details	Design	Patient characteristics	Interventions	Outcome measures	Results	Comments
<i>Study 1</i>						
Author: Hillner Year: 2000 Country: USA	Type of analysis: Cost-effectiveness analysis (CEA) using life years as the effectiveness measure. Model structure: N/A Cycle length: N/A	Base case (population): Patients with advanced, metastatic malignant melanoma who are previously untreated for metastatic disease with a WHO performance status of either 0,1 or 2. Sample size:	1. Intravenous DTIC once a day for 5 days with a starting dose of 250mg/m ² repeated every 21 days. 2. Orally administered TEM once a day for 5 days with a starting dose of 200mg/m ² repeated every 28 days.	Effectiveness (Survival months): Mean DTIC (ITT Group) TEM (ITT Group) Median DTIC (ITT Group) TEM (ITT Group) DTIC (Eligible Patients)	8.6 9.6 6.4 7.7 5.9	Funding: Unrestricted grant from Schering-Plough Corporation and Faculty Research Award from American Cancer Society.

Primary details	Design	Patient characteristics	Interventions	Outcome measures	Results	Comments
	<p><u>Time horizon:</u> Lifetime</p> <p><u>Perspective:</u> Base case: US Healthcare Payer Perspective Sensitivity Analysis: Societal</p> <p><u>Source of base-line data:</u> Baseline data taken from Middleton et al (2000) trial described below.</p> <p><u>Source of effectiveness data:</u> Effectiveness data was taken from the Middleton et al trial. This was an open label trial conducted at 34 European and Australian centres comparing intravenous DTIC to TEM. The studied enrolled 260 patients with final analysis after 210 deaths. The cost-effectiveness analysis used a difference in mean survival of 1.04 months for TEM compared to DTIC.</p> <p><u>Source of utility data:</u> No health related quality of life weightings were used.</p> <p><u>Source of cost data:</u> The price of TEM was estimated based on the 1999 Food and Drug Administration approval for treatment of adults with refractory anaplastic astrocytoma.</p> <p>Drug costs were taken from 1999 US wholesale prices. Insurance reimbursement costs were used for the cost of preparation of solution.</p>	<p>DTIC (n=149) TEM (n=156)</p> <p><u>Age (Median):</u> DTIC=58.8 years TEM=58.5 years</p> <p><u>Gender (Male):</u> DTIC=54% TEM=63%</p> <p><u>Subgroup analysis:</u> None Performed</p>		<p>TEM (Eligible Patients) DTIC (Treated Eligible) TEM (Treated Eligible)</p> <p><u>Total costs:</u></p> <p>Base Case: TEM DTIC DTIC High Cost DTIC Low Cost</p> <p>2.5% Lower Limit Increased Survival (-13 days) TEM DTIC DTIC High Cost DTIC Low Cost</p> <p>97.5% Upper Limit Increased Survival (76 days) TEM DTIC DTIC High Cost DTIC Low Cost</p> <p><u>ICER (cost per LY):</u> <i>TEM versus</i> Base Case DTIC DTIC Lower Limit DTIC Upper Limit</p> <p>2.5% Lower Limit Increased Survival (-13 days) DTIC DTIC Lower Limit DTIC Upper Limit</p> <p>97.5% Upper Limit Increased Survival (76 days) DTIC DTIC Lower Limit DTIC Upper Limit</p> <p><u>Uncertainty:</u></p>	<p>7.9 5.7 7.9</p> <p>\$6 902 \$3 697 \$5 403 \$1 717</p> <p>\$6 902 \$4 567 \$6 674 \$2 121</p> <p>\$6 902 \$2 982 \$4 359 \$444</p> <p>\$36 690 \$17 300 \$59 830</p> <p>Dominated Dominated Dominated</p> <p>\$18 670 \$12 110 \$30 750</p>	<p><u>Comments</u> DTIC High Cost estimate includes nonmedical costs i.e. lost wages</p>

Primary details	Design	Patient characteristics	Interventions	Outcome measures	Results	Comments
	<p>Costs to family members providing transportation assistance and emotional support were estimated from Hayman et al (1996).</p> <p><u>Currency unit:</u> US\$</p> <p><u>Cost year:</u> Drug costs:1999 Other costs not stated.</p> <p><u>Discounting:</u> No discounting performed.</p>			<p>Deterministic Sensitivity Analysis TEM price reduced from \$1500 to \$1000 TEM reduced \$1000 high cost DTIC ITT median survival used Treated eligible population</p> <p>Threshold Sensitivity Analysis Cost per course TEM to be Cost-effective for threshold \$50000/LY</p>	<p>\$15 600 Dominant \$29 590 \$21 370</p> <p>\$1 805</p>	

7. Follow-up

7.1 Frequency and duration of follow-up?

Review question: In asymptomatic patients who have undergone treatment with curative intent for melanoma, what is the optimal method, frequency and duration of follow-up?

Background

After a melanoma is treated, patients have regular checkups. The reason for this is to look for signs of

1. melanoma coming back around the scar (local recurrence)
2. melanoma spreading to lymph nodes or other parts of the body
3. any new melanomas that may develop

At the moment follow up depends on how deep the melanoma was initially and is as follows

Stage 0- no follow up after initial treatment and results

Stage 1A- 2-4 appointments in 12 months then discharged

Stage 1b-2 every 3 months for 3 years then every 6 months for another 2 years

Stage 3 and over every 3 months for five years

Do any of these things alter the long term outcomes for patients and what do patients prefer?

Does follow up make a difference to the outcomes for patients or are we seeing patients too often without making a difference.

Question in PICO format

Patients/population	Intervention	Comparison	Outcomes
Asymptomatic patients who have undergone treatment for melanoma with curative intent	<ul style="list-style-type: none"> Intensive follow-up packages (follow up setting primary/secondary care) HCP – dermatologists, plastic surgeons, dermatology CNS, skin cancer CNS, oncologist, maxofacial surgeons, MDT's, Imaging (There are a variety of ways we can image for cancer. 95% of the time we use CT. The alternatives are PET-CT and total body MRI, Ultrasound) 	<ul style="list-style-type: none"> Less intensive follow-up packages No follow-up (each other) No imaging 	<ol style="list-style-type: none"> Survival Stage at recurrence Time to Recurrence Patient preference HRQL Adverse events Cost of imaging Radiation
Stage <ul style="list-style-type: none"> Ia Ib-II III IV 			

1 How the information will be searched

Searches:	
Can we apply date limits to the search	The GDG did not feel that it was appropriate to apply any date limits to the searches for this topic
Are there any study design filters to be used (RCT, systematic review, diagnostic test).	All study designs were considered as it was felt that there would not be much available in the form of randomised trials. In addition some elements of the question would require diagnostic studies while other elements would require more qualitative evidence to inform the outcomes of interest.
List useful search terms.	None provided
Notes	Two searches were performed for L1 and L2, one with follow up terms and one with imaging terms, to best retrieve possible relevant references for the asymptomatic population. The results of Topics L1 and L2 were combined into one Reference Manager database due to the high duplication of results between the searches.

2 Search Results

3 Follow-up

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
Medline	1946-2013	106	25	20/11/2013
Premedline	19 Nov 2013	4	0	20/11/2013
Embase	1947-2013	163	27	20/11/2013
Cochrane Library	Issue 11 of November 2013	47	2	20/11/2013
Web of Science (SCI & SSCI)	1900-2013	107	15	20/11/2013

4 Imaging

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
Medline	1946-2013	115	27	26/11/2013
Premedline	25 Nov 2013	7	1	26/11/2013
Embase	1947-2013	200	33	26/11/2013
Cochrane Library	Issue 11 of November 2013	47	2	26/11/2013
Web of Science (SCI & SSCI)	1900-2013	165	15	26/11/2013

5 Total References retrieved (after de-duplication) for L1 and L2 combined: 53

1 **Update Search**

2 For the update search, the same search criteria/filters were applied as initial search

3 **Topic L1 and L2 Follow up**

Database name	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	4	1	08/10/2014
<i>Premedline</i>	3	1	08/10/2014
<i>Embase</i>	22	1	08/10/2014
<i>Cochrane Library</i>	2	0	08/10/2014
<i>Web of Science (SCI & SSCI)</i>	42	1	08/10/2014
Total References retrieved (after de-duplication): 3			

4 **Topic L1 and L2 Imaging**

Database name	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	4	1	08/10/2014
<i>Premedline</i>	3	1	08/10/2014
<i>Embase</i>	32	0	08/10/2014
<i>Cochrane Library</i>	2	0	08/10/2014
<i>Web of Science (SCI & SSCI)</i>	21	1	08/10/2014
Total References retrieved (after de-duplication): 3			

5 **Medline search strategy** (*This search strategy is adapted to each database*)6 **Follow-up**


- 7 1. exp Melanoma/
- 8 2. melanoma\$.tw.
- 9 3. (maligna\$ adj1 lentigo\$).tw.
- 10 4. (hutchinson\$ adj1 (freckle\$ or melano\$)).tw.
- 11 5. dubreuilh.tw.
- 12 6. LMM.tw.
- 13 7. or/1-6
- 14 8. (asymptom* or symptomless or no symptoms or no symptom or clinically silent).tw.
- 15 9. ((absence or absent or without) adj1 (sign*1 or symptom*)).tw.
- 16 10. Asymptomatic Diseases/
- 17 11. or/8-10

- 1 12. 7 and 11
- 2 13. (follow-up or "follow up" or followup).tw.
- 3 14. (check-up*1 or check up*1).tw.
- 4 15. surveillance.tw.
- 5 16. exp Aftercare/
- 6 17. (aftercare or after-care).tw.
- 7 18. ((post-treatment or posttreatment) adj1 evaluation*).tw.
- 8 19. ((post-treatment or posttreatment) adj1 care).tw.
- 9 20. ((post-treatment or posttreatment) adj1 monitoring).tw.
- 10 21. ((post-treatment or posttreatment) adj1 surveillance).tw.
- 11 22. or/13-21
- 12 23. 12 and 22
- 13

14 **Imaging**

- 15 1. exp Melanoma/
- 16 2. melanoma\$.tw.
- 17 3. (maligna\$ adj1 lentigo\$).tw.
- 18 4. (hutchinson\$ adj1 (freckle\$ or melano\$)).tw.
- 19 5. dubreuilh.tw.
- 20 6. LMM.tw.
- 21 7. or/1-6
- 22 8. (asymptom* or symptomless or no symptoms or no symptom or clinically silent).tw.
- 23 9. ((absence or absent or without) adj2 (sign*1 or symptom*)).tw.
- 24 10. Asymptomatic Diseases/
- 25 11. or/8-10
- 26 12. 7 and 11
- 27 13. exp Magnetic Resonance Imaging/
- 28 14. "magnetic resonance imaging".tw.
- 29 15. (MRI or MR*2 or NMR*1 or MP-MR* or MPMR*).tw.
- 30 16. ((magnet* or mr*) adj (imaging or exam* or scan* or spectroscop*)).tw.
- 31 17. diagnostic imaging/
- 32 18. exp TOMOGRAPHY, X-RAY COMPUTED/
- 33 19. "comput* tomograph*".tw.
- 34 20. (comput* adj (axial or assisted) adj tomograph*).tw.
- 35 21. ((ct or cat) adj scan*).tw.
- 36 22. exp TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON/
- 37 23. spect.tw.
- 38 24. "single photon emission computed tomography".tw.
- 39 25. exp Tomography, Emission-Computed/
- 40 26. (PET or PET-CT).tw.
- 41 27. or/13-26
- 42 28. 12 and 27

1 **Screening Results**



Reasons for Exclusion

- No Follow-up schedules/information
- Treatment Comparisons not relevant to PICO
- Population not relevant to PICO
- Expert Review
- Foreign Language
- Single Case Reports

Quality of the included studies

- Systematic review of RCTs (n=0)
- Systematic review of combined study designs (n=0)
- Randomized controlled trial (n=1)
- Prospective cross sectional study (n=0)
- Case Series Studies (n=13)
- Qualitative Study (n=0)

2

3

Table 7.1 Characteristics of included studies

Study	Study Design	Population	Follow-up Protocol	Outcomes	Comment
Abbott et al	Retrospective Case Series	N=34 AJCC stage III who underwent at least one annual surveillance PET/CT	<ul style="list-style-type: none"> Clinical exam every 3 months post diagnosis Annual PET/CT 	<ul style="list-style-type: none"> Detection of Recurrence 	All patients were followed up for at least 6 months post PET/CT scan
Beasley et al	Retrospective Case Series	N=97 patients with stage IIIB-IV melanoma	<ul style="list-style-type: none"> Initial 3 month evaluation (physical examination) followed every 3 months for 1 year and every 6 months thereafter to determine progression free survival Initial PET-CT within 30 days of initial treatment, every 3 months for the first year and every 6 months thereafter 	<ul style="list-style-type: none"> Detection of Recurrence Survival 	PET CT is the focus for this study
Garbe et al (2003)	Retrospective Case Series	N=2,008 patients with stage I-IV melanoma at diagnosis	<ul style="list-style-type: none"> Follow up exams every 3 months in the first 5 years and every 6 months thereafter until year 10. Extensive education regarding the clinical characteristics of melanoma and its metastases, self examination and recognition of the signs and symptoms of recurrence. Visits included a complete history, skin inspection and clinical examination of the resection site and lymphatic drainage areas . Abdominal sonography, chest x-ray and blood tests every 12 months in stage I-II disease and every 6 months 	<ul style="list-style-type: none"> Detection of metastasis or second primary melanoma Survival 	

			<ul style="list-style-type: none"> in stage III disease. Sonographic examination of the resected tumour scar, lymphatic drainage area and regional node regions every 12 months in stage I melanoma, every 6 months in stage II melanoma and every 3-6 months in stage III melanoma. 		
Hofmann et al	Retrospective Case Series	N=661 patients with stage I-IV melanoma at diagnosis	<ul style="list-style-type: none"> Stage I/II patients – physician visits every 3 months during the first 5 years and every 6 months thereafter until end of year 8 or recurrence Annual chest x-ray and sonography of the abdomen Lymph node sonography of peripheral nodes every 6 months Stage III/IV follow-up was extended by increasing the frequency of diagnostic imaging – 6 monthly chest x-ray and abdominal sonography and 3 monthly lymph node sonography. 	<ul style="list-style-type: none"> Time to Recurrence 	
Kottschade et al	Retrospective Case Series	N=106 patients with resected stage III-IV melanoma	<ul style="list-style-type: none"> Not clearly identified though the purpose of the review appears to be PET 	<ul style="list-style-type: none"> Detection of Recurrence 	
Koskivuo et al	Retrospective Case Series	N= 30 patients with AJCC stage IIB-IIIC adult melanoma who were free of any clinical signs of metastases	<ul style="list-style-type: none"> Regular follow-up schedule including whole body CT at the time of initial surgery and clinical exam every 3-6 months during the first 5 years. 	<ul style="list-style-type: none"> Detection of recurrence Diagnostic Accuracy of Imaging 	

			<ul style="list-style-type: none"> • Annual Chest X-Ray and blood tests • Secondary CT and physical exam performed concurrently with PET • In addition a whole body FDG-PET 7-24 months after primary surgery 		
Leiter et al (2012)	Retrospective Study	N=33,384 (stage I-III)	<p>Every 3 months during the first 5 years and every 6 months during years six to ten.</p> <p>Follow-up includes:</p> <ul style="list-style-type: none"> • Whole body skin exam • Lymph node ultrasound 1-2 times a year • Blood examinations of tumour marker protein S100β and lactate dehydrogenase in patients with melanoma thickness ≥ 1mm 	<ul style="list-style-type: none"> • Overall Survival • Secondary Melanoma Free survival • Recurrence Free survival 	
Meyers et al (2009)	Retrospective Case Series	N=118 stage II or SLN positive stage III melanoma	<ul style="list-style-type: none"> • A written copy of the follow-up schedule was provided to all patients • Follow-up exam with a health care provider (surgical oncologist, dermatologist, surgical nurse practitioner) every 3 months for the first 3 years, every 6 months in years 3-5 and annually to year ten. • For patients with stage II melanoma exam should include full body 	<ul style="list-style-type: none"> • Time to Recurrence • Detection of Recurrence • Survival 	

			<p>examination of skin and lymph node basins, annual blood work, annual chest x-ray</p> <ul style="list-style-type: none"> For patients with stage III melanoma follow-up should additionally include annual body and brain imaging in years 1-3 		
Mooney et al	Retrospective Case Series	N=154 stage I-II	<ul style="list-style-type: none"> No. of visits Physical Exam Lab tests Chest radiographs 	<ul style="list-style-type: none"> Follow up setting 	
Morton et al	Case Series	N=108 AJCC stage III A/B with a positive SLNB	<ul style="list-style-type: none"> Chest X-Ray every 6 months for 5 years and annually for 5 years thereafter 	<ul style="list-style-type: none"> Time to Recurrence 	
Murchie et al	Randomised Controlled Trial		<ul style="list-style-type: none"> 	<ul style="list-style-type: none"> Patient Satisfaction Guideline Adherence 	
Poo-Hwu et al	Retrospective Case Series	N=419 patients with stage I-III melanoma with pathologically confirmed melanoma and no evidence of disease following surgery.	<ul style="list-style-type: none"> Follow-up schedule was dependant on AJCC stage at diagnosis with each visit to include history taking, physical exam, complete blood count and liver function tests. Annual Chest X-Ray for stage I-II and 6 monthly chest X-Rays for stage III for the first 5 years Patients with Stage III had a baseline CT scan with follow-up CT scans obtained in 6-12 	<ul style="list-style-type: none"> Survival 	

			months in the event of abnormal findings not clearly indicative of metastatic disease		
Rinne et al	Retrospective Case Series	N=48 patients with high risk melanoma in whom PET was performed for re-staging as part of follow-up	<ul style="list-style-type: none"> Chest Radiograph, abdominal sonography, high res ultrasound of regional lymph nodes, X-Ray CT of thorax and abdomen, contrast MRI of the brain 	<ul style="list-style-type: none"> Diagnostic Accuracy of Imaging 	PET is the focus of this study and it appears that patients were followed up using standard techniques and PET was additionally carried out in patients with suspicious findings on the standard follow-up imaging. No data are presented for the other imaging modalities.
Romano et al (2010)	Retrospective study	N=340 total Stage IIIA=95 Stage IIIB=155 Stage IIIC=90	<ul style="list-style-type: none"> Physical exam every 3 months for the first 2 years and every 6 months thereafter (no end time specified) Follow-up included medical oncology visits, surgical and dermatologic visits CT scans, CBCs, comprehensive panels and lactate dehydrogenase were obtained before the follow-up visits 	<ul style="list-style-type: none"> Time and site of first recurrence Method of detection Overall Survival 	

1 **Quality of the Evidence**

2 Fourteen studies (1 RCT and 13 case series studies) were identified as relevant to this topic. The
3 reported follow-up schedules and protocols were broadly similar across the individual studies in
4 terms of timing of follow-up and components of follow-up, with variation in timing occurring mostly
5 in year one of follow-up depending on the stage of melanoma at diagnosis.

6 Overall quality of the evidence for this topic was considered to be very low on GRADE assessment
7 for all clinical outcomes of interest. For diagnostic outcomes, the quality of evidence was considered
8 to be very low based on assessment using the QUADAS checklist.

9 **Evidence Statements**

10 **Follow-up Schedules**

11 Follow up schedules varied across the individual studies and within the individual studies depending
12 on the stage at diagnosis of primary melanoma, though all follow-up protocols consisted of clinic
13 visits or physician exams and chest x-ray at regular intervals.

14 **Follow up setting**

15 One randomised trial assessed the impact of GP led follow-up on patient satisfaction and guideline
16 adherence. The overall findings from the trial suggested that GP lead follow-up improved patient
17 satisfaction and was more guideline compliant than hospital based follow up and that the health
18 status and psychological well-being of patients was not adversely affected (Murchie et al 2010).

19 Patient satisfaction was assessed using a 15 point questionnaire which had been developed for use
20 in a randomised trial of GP-led follow-up for breast cancer patients and was administered at
21 baseline, 3 months, 6 months and 12 months No significant difference in patient satisfaction was
22 observed at baseline though at follow-up there were statistically significant differences between the
23 groups on 6 of the 15 aspects assessed. Members of the intervention group were significantly more
24 likely to think that it was 'easier to get through by phone if you need to' and they felt that they could
25 usually see a doctor on the same day if needed and that they would usually be seen by a doctor
26 within 20 minutes of their appointment time. The intervention group also reported feeling that the
27 doctor 'examines you thoroughly when necessary' and 'always prescribes medication if you need it.
28 In addition, patients in the intervention groups were more likely to report being seen by 'a doctor
29 that knows you well' (Murchie et al, 2010).

30 Health status and psychological well being was assessed using a SF-36 and the HADS questionnaires
31 and no significant differences were recorded between the groups at baseline or at follow-up
32 (Murchie et al, 2010).

33 In the year before the study, adherence to local guidelines was 84.9% in the intervention group and
34 85.4% in the control group. At follow-up however there was a significant difference in adherence to
35 local guidelines ($p=0.02$); adherence had increased to 98.1% in the intervention group while
36 adherence decreased in the control group to 80.9% (Murchie et al, 2010).

1 **Detection of Recurrence**

2 One retrospective study analysed how each first relapse was detected during follow-up in a total of
3 340 patients with stage III melanoma. 62% of local and in-transit recurrences, 49% of nodal
4 recurrences and 37% of systemic recurrences were patient detected. Physical Exam (physician)
5 detected 36% of local and in-transit recurrences, 26% of nodal recurrences and 9% of systemic
6 recurrences.

7 37% of patients detected systemic relapse by noticing a new tumour or new symptoms
8 63% of patients had asymptomatic systemic relapse and radiological tests identified recurrence in
9 53% of these patients (CT scans 72%) (Romano et al, 2010).

10 One retrospective case series study reported a sensitivity of 100% for PET in the patient by patient
11 analysis, compared with 84.6% for conventional imaging; overall specificity was 95.5% versus 68.2%.
12 Accuracy of PET was 97.9% versus 77.1. In the lesion by lesion analysis, PET sensitivity was 91.8%
13 compared with 57.5% for conventional imaging, specificity was 94.4% compared with 45% and
14 accuracy was 92.1% compared with 55.7% for conventional imaging % (Rinne et al, 1998).

15 In a retrospective case series study of 106 patients diagnosed with stage III-IV melanoma PET
16 successfully identified an additional 12 cases of asymptomatic recurrences which were amenable to
17 complete surgical resection, representing an additional 25% of cases compared with patients whose
18 follow-up did not include PET (Kottschade et al, 2009).

19 In a retrospective study of 30 stage IIB-IIIC patients, six out of seven recurrences observed were
20 upstaged by FDG PET. Recurrence influenced treatment plans in all cases; three patients underwent
21 surgery with curative intent while four patients with inoperable recurrent disease received
22 chemotherapy and/or interferon (Koskivuo et al, 2007).

23 In a retrospective study following up 118 patients treated for melanoma, no statistically significant
24 difference was observed between patients seeking care for symptomatic recurrence compared with
25 patients whose recurrence was asymptomatic (patient detected, physician detected or detected by
26 routine imaging). (Meyers et al, 2009).

27 **Time to Recurrence**

28 From two retrospective case series studies (Mooney et al 1998 & Hoffmann et al, 2002) 71%-90.7%
29 of recurrences were recorded in the first 5 years of follow-up.

30 In a retrospective case series with a sample size of 108, there was no significant difference in median
31 time to diagnosis for asymptomatic pulmonary metastases (chest x-ray) and symptomatic pulmonary
32 metastases detected during clinical visits ($p=0.30$). Median time to diagnosis of pulmonary
33 metastasis was 24 months (95% CI 12-41 months) and median time to the diagnosis of pulmonary
34 disease by clinical follow-up was 16 months (95% CI 10-30 months) (Morton et al, 2009)

35 From one retrospective case series study including 118 patients, median time to recurrence was 14
36 months (2-88 months) and there was no significant difference in time to recurrence when comparing
37 stage II and stage II patients (Meyers et al, 2009).

From one retrospective study including 33,384 patients treated for stage I-III primary melanoma and undergoing follow-up, median recurrence free survival time was 44 months (IQR 19-85) and median follow-up time to diagnosis of secondary melanoma was 21 months (IQR 4-61) (Leiter et al, 2012).

Survival

From one retrospective study with 340 stage III melanoma patients, overall 5-year survival from time of first relapse was 20%, in stage IIIA and IIIB patients and 11% in stage IIIC patients. Regional relapse was associated with longer overall survival than systemic relapse ($p<0.001$). Symptomatic relapse was associated with shorter survival compared with relapse discovered by physical exam or radiological imaging. $RR=2.31$, 95% $CI=1.68-3.18$, $p<0.001$ (Romano et al, 2010).

From one retrospective study ($n=33,384$) 5 year melanoma specific survival was 91.9% (95% CI 91.5-92.2) and 10 year melanoma specific survival was 87.2% (95% CI 86.6-87.8) (Leiter et al, 2012)

From a prospective cohort study of 2,008 patients treated for primary melanoma, early detection of recurrence was associated with a higher survival rate for patients with stage I-II melanoma with a 76% overall survival rate at 3 years compared with 38% for late detection ($p<0.0001$). Early detection was similarly associated with an overall survival rate at 3 years for stage III patients (60% versus 18%; $p<0.0001$) (Garbe et al, 2003).

From one retrospective case series with 154 patients treated for stage I-II, no significant difference in disease-free survival interval (28 months and 23 months respectively, $p=0.15$) however a statistically significant difference in survival following detection of recurrence was observed. Median disease free survival was 12 months for symptomatic recurrences compared with 24 months for asymptomatic recurrences ($p=0.02$)
5-year overall survival was similar for both groups: $46\pm11\%$ for any symptomatic recurrences and $47\pm12\%$ for any asymptomatic recurrences ($p=0.26$) (Mooney et al, 1998).

From one retrospective case series study with 419 patients treated for stage I-III melanoma, patients with loco-regional recurrences had a better survival rate compared to patients with distant recurrences (median survival was 34 months versus 13 months; $p=0.03$) (Poo-Hwu et al, 1999). Similarly in a second retrospective case series, following up 118 patients treated for stage II or III melanoma, median survival after recurrence was 22 months for patients with loco-regional disease compared with 7 months for patients with distant recurrence ($p<0.0001$) (Meyers et al, 2009).

From one retrospective case series study with 419 patients treated for stage I-III melanoma, median survival was 27 months compared with 14.5 months for patient detected (symptomatic) recurrences for patients with disease recurrence detected at routine examination (asymptomatic) ($p=0.02$. controlled for stage, symptomatic versus asymptomatic and local versus distant recurrences) (Poo-Hwu et al, 1999).

A second retrospective case series study following up 118 patients treated for stage II or III melanoma, reported no statistically significant difference in survival for patients with a symptomatic recurrence compared with patients who had asymptomatic recurrence ($p=0.2$) (Meyers et al, 2009)

A retrospective case series, following up 118 patients treated for stage II or III melanoma reported no statistically significant different in survival for patients who detected their recurrence compared

with patients whose recurrence was physician detected or detected on routine imaging (p=0.6) (Meyers et al, 2009)

Diagnostic Efficacy of Imaging

From one case series study including 48 patients diagnosed with high risk melanoma and undergoing PET for re-staging; overall sensitivity of PET was 100% compared with 84.6% for conventional imaging, overall specificity was 95.5% versus 68.2%. Accuracy of PET was 97.9% versus 77.1% in the patient by patient analysis. While in the lesion by lesion analysis, PET sensitivity was 91.8% compared with 57.5% for conventional imaging, specificity was 94.4% compared with 45% and accuracy was 92.1% compared with 55.7% for conventional imaging (Rinne et al, 1998).

One retrospective case series study including 30 patients with stage IIB-IIIC melanoma, PET sensitivity was 86%, specificity was 96%, positive predictive value was 86% and negative predictive value was 9% for melanoma recurrence (Koskivuo et al, 2007).

GRADE Table 7.1: What method, duration and frequency of follow-up should be used in patients who have undergone treatment for melanoma and who are asymptomatic?

Quality assessment							Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	
Time to Recurrence							
6	observational studies	serious ¹	serious ²	no serious indirectness	no serious imprecision	none	VERY LOW
Detection of recurrence							
8	observational studies	serious ¹	serious ²	no serious indirectness	no serious imprecision	none	VERY LOW
Overall Survival							
6	observational studies	serious ¹	serious ²	no serious indirectness	no serious imprecision	none	VERY LOW

¹ All studies were retrospective reviews² Studies varied in their follow-up schedules, protocols and frequencies. Length of follow-up varied across the studies Definitions of symptomatic and asymptomatic recurrences varied.

Table 7.2: Follow-up protocols for each of the included studies

Follow Up Element	Year 1	Year 2	Year 3	Year 4	Year 5	Year 6 onwards
Mooney et al (1998) N=154						
Physical Exam	3 monthly	4 monthly	6 monthly	6 monthly	6 monthly	Annually
Chest X-Ray	3 monthly	4 monthly	6 monthly	6 monthly	6 monthly	Annually
Laboratory Tests	3 monthly	6 monthly	6 monthly	6 monthly	6 monthly	Annually
CT	Some patients underwent routine CT after first recurrence but no details were provided					
PET-CT	Not Applicable					
MRI	Not Applicable					
Morton et al (2009) N=108						
Physical Exam	6 monthly	6 monthly	6 monthly	6 monthly	6 monthly	6 monthly until year 8, then annually.
Chest X-Ray	6 monthly	6 monthly	6 monthly	6 monthly	6 monthly	6 monthly until year 8, then annually.
Laboratory Tests	Not Applicable					
Chest CT	If chest x-ray showed findings suspicious of pulmonary metastases					
PET	If chest x-ray showed findings suspicious of pulmonary metastases					
PET-CT	Not Applicable					
MRI	Not Applicable					
Histology	If chest x-ray showed findings suspicious of pulmonary metastases					
Abbot et al (2011) N=34, stage III						
Clinical Exam	Every 3 months for at least six months					
PET-CT	Annually with the first PET-CT scan happening between 12-23 months following diagnosis of stage III disease in asymptomatic patients					
Rinne et al (1998) N=48 relevant patients						
Chest X-Ray	No details Provided					
Abdominal Ultrasound	No details Provided					
High Res ultrasound of regional lymph nodes	No details Provided					
X-Ray/CT of the thorax and abdomen	No details Provided					
Contrast MRI of the brain	No details Provided					
PET-CT	Performed within 3 weeks of initial diagnosis					

Poo-Hwu et al (1999) N=373						
History taking						
Stage I	6 monthly	6 monthly	6 monthly	Annually	Annually	Annually
Stage II	4 monthly	4 monthly	4 monthly	6 monthly	6 monthly	Annually
Stage III	3 monthly	3 monthly	3 monthly	6 monthly	6 monthly	Annually
Physical Exam						
Stage I	6 monthly	6 monthly	6 monthly	Annually	Annually	Annually
Stage II	4 monthly	4 monthly	4 monthly	6 monthly	6 monthly	Annually
Stage III	3 monthly	3 monthly	3 monthly	6 monthly	6 monthly	Annually
Blood counts and liver function tests						
Stage I	6 monthly	6 monthly	6 monthly	Annually	Annually	Annually
Stage II	4 monthly	4 monthly	4 monthly	6 monthly	6 monthly	Annually
Stage III	3 monthly	3 monthly	3 monthly	6 monthly	6 monthly	Annually
Chest X-Ray						
Stage I	Annually	Annually	Annually	Annually	Annually	Annually
Stage II	Annually	Annually	Annually	Annually	Annually	Annually
Stage III	6 monthly	6 monthly	6 monthly	6 monthly	6 monthly	Annually
CT scans	6-12 months only if there were abnormal findings initially that were not clearly indicative of metastatic disease					
Kottschade et al (2009) N=106						
PET/PET CT	At least 2 PET scans performed less than 1 year apart as part of regular clinical follow-up (No other details of follow-up protocol have been provided but included physical exam, CT or MRI scanning and plain film X-ray)					
Koskivuo et al (2007) N=30						
Whole Body CT	A baseline CT scan was taken at the time of initial surgery and a secondary scan and physical exam were performed concurrently with FDG PET.					
Clinical Follow-up	Every 3-6 months	Every 3-6 months	Every 3-6 months	Every 3-6 months	Every 3-6 months	Annually
Chest X-Ray	Every 3-6 months	Every 3-6 months	Every 3-6 months	Every 3-6 months	Every 3-6 months	Annually
Blood Tests	Every 3-6 months	Every 3-6 months	Every 3-6 months	Every 3-6 months	Every 3-6 months	Annually
FDG-PET	7-24 months after primary surgery, independently of the regular follow-up schedule.					
Hoffman et al (2002) N=561						
Physician Visits	3 monthly	3 monthly	3 monthly	3 monthly	3 monthly	Every 6 months until year 8 or recurrence

DRAFT FOR CONSULTATION

Chest X-ray and sonography of the abdomen						
Stage I/II	Annually	Annually	Annually	Annually	Annually	Annually
Stage III/IV	6 monthly	6 monthly	6 monthly	6 monthly	6 monthly	6 monthly
Lymph node sonography						
Stage I/II	6 monthly	6 monthly	6 monthly	6 monthly	6 monthly	6 monthly
Stage III/IV	3 monthly	3 monthly	3 monthly	3 monthly	3 monthly	3 monthly
Beasley et al (2012) N=97						
Physician Visits	3 monthly	6 monthly	6 monthly	6 monthly	6 monthly	6 monthly
PET-CT	3 monthly	6 monthly	6 monthly	6 monthly	6 monthly	6 monthly
Meyers et al (2009) N=118						
Clinical Follow Up	3 monthly	3 monthly	6 monthly	6 monthly	6 monthly	Annually to year 10
Laboratory Tests)						
Stage II	Annually	Annually	Annually	Annually	Annually	Annually
Body and brain imaging (CT of chest abdomen pelvis prior to 2003; whole body PET/CT post 2003; MRI for brain)						
Stage III	Annually	Annually	Annually			
Murchie et al (2010) N=142						
Romano et al (2010) N=340 (stage III)						
Medical Oncology Visits (Physical Exam)	3 monthly	3 monthly	6 monthly	6 monthly	6 monthly	
Surgical & Dermatological Visits	3 monthly	3 monthly	6 monthly	6 monthly	6 monthly	
CT scans	3 monthly	3 monthly	6 monthly	6 monthly	6 monthly	
Laboratory tests	3 monthly	3 monthly	6 monthly	6 monthly	6 monthly	
Leiter et al (2012) N=33.384 (stage I-III)						
Physical Exam	3 monthly	3 monthly	3 monthly	3 monthly	3 monthly	6 monthly until 10 years
Lymph node ultrasound	1-2 times a year					
Imaging techniques	1-2 times a year					
Blood Examinations	1-2 times a year					
Garbe et al (2003) N=2008 (all stages)						
Physician Visits (including full skin exam, clinical exam of	3 monthly	3 monthly	3 monthly	3 monthly	3 monthly	6 monthly until 10 years

DRAFT FOR CONSULTATION

scar of primary resection, lymphatic drainage areas and all lymphatic regions)							
Abdominal sonography and chest X-Ray	Stage I-II	12 monthly	12 monthly	12 monthly	12 monthly	12 monthly	12 monthly
	Stage III	6 monthly	6 monthly	6 monthly	6 monthly	6 monthly	6 monthly
Blood Tests	Stage I-II	12 monthly	12 monthly	12 monthly	12 monthly	12 monthly	12 monthly
	Stage III	6 monthly	6 monthly	6 monthly	6 monthly	6 monthly	6 monthly
Sonographic exam of the resected tumour scar, ;lymphatic drainage area and regional node regions	Stage I	12 monthly	12 monthly	12 monthly	12 monthly	12 monthly	
	Stage II	6 monthly	6 monthly	6 monthly	6 monthly	6 monthly	
	Stage III	3-6 monthly	3-6 monthly	3-6 monthly	3-6 monthly	3-6 monthly	

Evidence Summary

Follow-up Schedules

In total, 12 studies reported some details of the follow-up protocol that patients followed after treatment for their primary melanoma. Details reported varied in terms of the timings of the follow-up and the components of follow-up though all protocols were broadly similar in that clinician visits with physical exam and some form of imaging at regular intervals formed the basis for follow-up.

Follow up schedule for the cohort included physician visits with chest radiographs every 3 months for the first year following diagnosis, every 4 months during the second year, every 6 months during years 3-5 and annually thereafter. Full blood cell counts and liver function tests were obtained on average, every 3 months in the first year, every 6 months during years 2-5 and annually thereafter. For patients in whom recurrence was detected, surveillance was increased resulting in physician visits every 2-3 months in the first year, every 4 months in the 2-4 years, every 6 months in year five and annually thereafter (Mooney et al, 1998).

Patients were followed up every 6 months for seven years and the follow-up schedule included physician exam followed by chest x-ray. For patients with findings suspicious of pulmonary metastases, chest CT was carried out within a week of chest x-ray and PET and fine needle biopsy carried out within a month to confirm findings (Morton et al, 2009).

Patients were followed up clinically every 3 months with and surveillance PET-CT annually for the first 36 months of follow-up. All patients in the study have been followed up for at least 6 months following surveillance PET-CT. (Abbot et al, 2011).

Patients with stage I disease were followed up every 6 months for the first 3 years and annually thereafter; patients with stage II disease were followed up every 4 months for the first 3 years, 6 monthly in year 4 and annually thereafter and patients with stage III disease were followed up every 3 months for the first 3 years, 6 monthly in year 4 and 5 and annually thereafter. Follow-up protocol included history taking, physical examination, complete blood counts and liver function tests. Chest x-rays were obtained annually for stage I and II patients and every 6 months for stage III patients and all patients with stage III disease had a baseline CT scan (Poo-Hwu et al, 1999).

Standard follow up included chest x-ray, abdominal ultrasound, high resolution ultrasound of the regional lymph nodes, X-ray/CT of the thorax and abdomen, and contrast MRI of the brain. No details were provided regarding the timing of follow-up for patients in this study. PET-CT was used in addition to the standard follow-up methods for the purpose of restaging. And was performed within 3 weeks either for the purpose of primary staging or for restaging during follow-up (Rinne et al, 1998)

A total of 30 patients with stage IIB-IIIC melanoma were followed up regularly with a protocol which included whole body CT at the time of initial surgery and clinical exam every 3-6 months for the first 5 years. Follow-up also included annual chest x-ray and blood tests. A whole body PET-CT scan was performed 7-24 months after primary surgery along with a secondary CT and physical exam (Koskivuo et al, 2007).

1 Patients with stage III-IV melanoma were followed up regularly by physical exam, CT or MRI scanning
 2 and plain film X-ray. In addition, patients also had at least 2 PET scans performed less than a year
 3 apart (Kottschade et al, 2009).

4 One study of 661 patients with stage I-IV melanoma reported a follow-up schedule that was
 5 dependent on the stage at diagnosis. All patients had physician visits every 3 months during the first
 6 5 years and every 6 months between years 5-8. Stage I-II patients had annual chest x-ray and
 7 abdominal sonography and lymph node sonography every 6 months whereas patients with stage III-
 8 IV disease the frequency of imaging was increased to 6 months for chest x-ray and 3 months for
 9 abdominal sonography and lymph node sonography (Hofmann et al, 2002).

10 97 patients with stage IIIB-IV melanoma were followed-up with an initial 3 month evaluation
 11 consisting of physical exam and were subsequently followed every 3 months for 1 year and every 6
 12 months thereafter. Patients had a PET-CT scan within 30 days of initial treatment and again every 3
 13 months for the first year and every 6 months thereafter (Beasley et al, 2012).

14 118 patients with stage II or III melanoma were followed up with a 3 monthly clinic follow-up for the
 15 first three years, 6 monthly visits for years 3-5 and annual visits until year 10. Physical exam included
 16 full-body examination of the skin and lymph node basins. For stage II patients, follow-up also
 17 included annual laboratory tests and for stage III patients, annual body and brain imaging was
 18 carried out in years 1-3 of follow-up. All patients were provided with a written copy of the
 19 recommended follow-up schedule and routine follow-up was with a health care provider such as
 20 surgical oncologist, dermatologist or surgical nurse practitioner (Meyers et al, 2009).

21 340 patients with stage III melanoma were followed up with 3 monthly medical oncology visits for
 22 the first 2 years and 6 monthly thereafter. The study did not specify an end date for follow up of the
 23 patients. Follow up also included surgical and dermatological visits and CT scans and laboratory tests
 24 prior to clinic visits (Romano et al, 2010).

25 From one retrospective study with 33,384 patients, guidelines recommend follow-up every 3 months
 26 during the first 5 years and every 6 months during years six to ten with follow-up to includes whole
 27 body skin exam, lymph node ultrasound and blood examinations of tumour marker protein S100 β
 28 and lactate dehydrogenase in patients with melanoma thickness ≥ 1 mm 1-2 times a year (Leiter et al,
 29 2012).

30 One study prospectively followed up 2,008 patients treated for primary melanoma with frequency of
 31 follow up exams differing according to stage of melanoma at diagnosis; All patients were followed
 32 up every 3 months in the first 5 years and every 6 months thereafter until year 10 and there was a
 33 focus on educating patients regarding the clinical characteristics of melanoma and its metastases,
 34 self examination and recognition of the signs and symptoms of recurrence. Visits included a
 35 complete history, skin inspection and clinical examination of the resection site and lymphatic
 36 drainage areas. Abdominal sonography, chest x-ray and blood tests every 12 months in stage I-II
 37 disease and every 6 months in stage III disease. Follow-up also included sonographic examination of
 38 the resected tumour scar, lymphatic drainage area and regional node regions every 12 months in
 39 stage I melanoma, every 6 months in stage II melanoma and every 3-6 months in stage III melanoma
 40 (Garbe et al, 2003).

Time to Recurrence

Early recurrence (within 5 years) occurred in 130 patients while late recurrence (post 5 years) occurred in 24 patients with 88% of symptomatic recurrences and 82% of asymptomatic recurrences occurring early.

For asymptomatic patient, the majority of pulmonary first recurrences were found within the first 5 years after diagnosis: 18% in years 0-2, 53% in years 3-5 and 29% in years 6-10.

Median time between last normal chest radiograph and abnormal chest radiograph indicating recurrent disease was 5 months (1-30 months) (Mooney et al, 1998)

There was no significant difference in median time to diagnosis for asymptomatic pulmonary metastases (chest x-ray) and symptomatic pulmonary metastases detected during clinical visits ($p=0.30$). Median time to diagnosis of pulmonary metastasis was 24 months (95% CI 12-41 months) and median time to the diagnosis of pulmonary disease by clinical follow-up was 16 months (95% CI 10-30 months) (Morton et al, 2009)

From one retrospective case series study, the median time to detection of recurrence by stage was 22 months (2-60.5 months) for stage I; 13.2 months (2.4-71 months) for stage II and 10.6 months (2.3-53.8 months) for stage III (table 12.3)

Stage	Recurrences (%)	Median time to recurrence between initial visit and diagnosis (range)
I	9 (5%)	22 months (2-60.5 months)
II	35 (40%)	13.2 months (2.4-71 months)
III	34 (54%)	10.6 months (2.3-53.8 months)

Table 7.3: Recurrence by stage (Poo-Hwu et al, 1999)

From one retrospective case series study, 12/26 recurrences detected by PET were amenable to surgical resection. One patient elected not to undergo surgery and all 11 patients who had surgery had a subsequent recurrence. Median time to subsequent recurrence was 4.7 months (median follow-up was 1.1 years).

32/42 (75%) of recurrences detected by methods other than PET were suitable for resection; all but 4 of the 32 patients who underwent resection had a second recurrence. Median time to second recurrence was 5.9 months (Kottschade et al, 2009).

In one retrospective case series, 95/127 first relapses were detected in the follow up of patients with 75 (77.3%) recurrences observed in the first 3 years. In total, 88 (90.7%) relapses were detected within the first 5 years of follow-up.

93 patients with surgically resected loco-regional metastases were enrolled in the follow-up program of whom 60 (64.5%) had a relapse within a median time of 7.8 months (Hoffman et al, 2002)

43/118 (36%) patients developed recurrence during the follow-up period (27 stage II and 16 stage III) with a median time to recurrence of 14 months (2-88 months). 38/43 (88%) developed recurrence within 36 months of initial diagnosis. There was no significant difference in time to recurrence when comparing stage II and stage III patients (Meyers et al, 2009).

In one retrospective study ($n=33,384$), recurrences were recorded in 4,999 patients (Stage I=7.1%, Stage II=32.5%, Stage III=51%) and median recurrence free survival time was 44 months (IQR 19-85).

10 year recurrence free survival was 78.9% (95% CI 73.1-90.5) for the whole cohort. There was a significant difference in 10 year recurrence free survival according to stage at diagnosis; for stage I it was 89%, for stage II it was 56.9% and for stage III it was 36% ($p<0.001$) (Leiter et al, 2012).

Locoregional recurrence accounted for 37.4%, regional lymph node recurrence accounted for 39.5% and distant metastases for 23% of recurrences (Leiter et al, 2012).

Detection of Recurrence

One retrospective study analysed how each first relapse was detected during follow-up in a total of 340 patients with stage III melanoma. 62% of local and in-transit recurrences, 49% of nodal recurrences and 37% of systemic recurrences were patient detected. Physical Exam (physician) detected 36% of local and in-transit recurrences, 26% of nodal recurrences, 9% of systemic recurrences.

37% of patients detected systemic relapse by noticing a new tumour or new symptoms

63% of patients had asymptomatic systemic relapse and radiological tests identified recurrence in 53% of these patients (CT scans 72%) (Romano et al, 2010).

In Stage IIIA, lung and liver were the most common sites of first relapse and 4 patients experienced first relapse to CNS. For Stage IIIB lung and liver were again the most common site of first relapse while 7% experienced first relapse to CNS. In this patient group the majority of relapse occurred by 23 months.

In Stage IIIC, systemic relapse was evenly distributed among skin/subcutaneous, nodal, lung, liver, brain and bone, 13% of patients experienced first relapse to CNS and the majority of relapse occurred by 18 months.

When looking at the site specific risk of relapse, overall 5 year risk of relapse at any site for stage IIIA was 48%, stage IIIB was 71% and for stage IIIC was 85%.

One retrospective study estimated the time point after which the site specific risk of first relapse at a given site was $\leq 5\%$. In stage IIIA patients, the site specific risk of first relapse dropped to $\leq 5\%$ at 31 months for local/in transit, 24 months for nodal, 32 months for systemic (non-brain) sites.

In stage IIIB patients, the site specific risk of first relapse dropped to $\leq 5\%$ at 22 months for local/in transit, 14 months for nodal, 40 months for systemic (non-brain) sites and in stage IIIC patients, the site specific risk of first relapse dropped to $\leq 5\%$ at 7 months for local/in transit and 40 months for systemic (non-brain) sites (Romano et al, 2010).

In one cohort study ($n=2,008$ melanoma patients), 71% ($n=165$) of recurrences were detected and confirmed by a physician during regular follow-up examinations compared with 12% ($n=29$) detected outside of regular follow-up exams. 13% ($n=31$) were patient detected and confirmed during regular scheduled follow-up compared with only 3% ($n=8$) patient detected outside of regular follow-up (Garbe et al, 2003).

Symptomatic (patient detected) first recurrence occurred in 89/154 (58%) of cases while asymptomatic (physician detected) first recurrence occurred in 65/154 (42%) of cases

Recurrences were detected by physical exam in 72% of cases and of these 57% were detected by the patient or family member while 43% were detected by the physician

Constitutional symptoms (pain, weight loss, malaise, neurological symptoms or combination) indicated 17% of recurrences

1 Chest radiograph detected the remaining 11% of recurrences
2 Complete cell counts and liver function tests were never the sole indicator of recurrence
3 Diagnosis of symptomatic disease occurred at 55% of unscheduled visits and 43% of scheduled visits
4 while 2% of the visits unclassified.
5 All asymptomatic recurrences were detected during regularly scheduled follow-up appointments
6 Of the 65 first recurrences detected by physicians, 74% were discovered on physical examination
7 and 26% by chest radiograph.
8 There were 84 second recurrences (55% symptomatic; 36% asymptomatic; 8% unclassified). A total
9 of 53% of asymptomatic recurrences were detected on physical exam, 40% on chest radiograph and
10 7% on CT scan.
11 Chest radiographs detected 30 recurrences in 26 patients (17 first, 12 second and 1 third recurrence)
12 whereas screening chest or abdominal CT detected only 6 recurrences (Mooney et al, 1998).

13 30/108 patients had suspicious or highly probable findings on their chest x-rays however only 11/23
14 had a positive biopsy result giving a sensitivity of 48% (95% CI 27%-68%) for serial chest x-rays. It is
15 not clear whether the remaining 7 patients underwent biopsy though from the flow chart it seems 7
16 patients died from their disease (Morton et al, 2009).

17 A total of 78 patients experienced recurrence of which 34 (44%) were developed symptoms which
18 indicated recurrence and 44 (56%) were diagnosed by procedures performed during a scheduled
19 visit (Poo-Hwu et al, 1999).
20 There were 39 loco-regional recurrences of which 20 were detected by the patient.
21 There were 39 distant recurrences of which 25 were detected by the physician
22 Physicians detected 44/78 (56%) of all recurrences and the most common method of detection was
23 history taking or physical examination (25/44). Abnormal chest x-ray detected 8 recurrences while
24 10 recurrences were detected using other imaging methods (CT or MRI) which were obtained due to
25 abnormal findings on the baseline CT scan or due to suspicious findings on physical exam
26 Laboratory results were abnormal in 38 patients at the time of recurrence however there was only 1
27 patient for whom abnormal lab results were the sole indicator of recurrence (Poo-Hwu et al, 1999).

28 A total of 68/106 (64%) patients had recurrences during the course of the study period.
29 Asymptomatic recurrences, detected by PET scanning alone, accounted for 25% of recurrences
30 compared with symptomatic recurrences detected by other methods (Kottschade et al, 2009)
31 32/42 (75%) of recurrences detected by methods other than PET were suitable for resection; all but
32 4 of the 32 patients who underwent resection had a second recurrence. Median time to second
33 recurrence was 5.9 months.
34 PET successfully identified an additional 12 cases of asymptomatic recurrences which were
35 amenable to complete surgical resection, representing an additional 25% of cases compared with
36 patients whose follow-up did not include PET (Kottschade et al, 2009).

37 At initial staging, 2554 imaging procedures were performed in 561 patients yielding 31 metastases
38 (true positive) and 202 false positive results which resulted in further examinations.
39 During follow-up of stage I/II patients, 30 metastases were detected by the patient resulting in early
40 clinic visits while the remaining 45 metastases were detected by the clinician.
41 Patient history and physical examination was the most successful diagnostic tool for both initial
42 staging and follow-up of patients detecting approximately 70% of all relapses compared with lymph

node sonography which detected between 15-20%, chest x-ray and sonography of the abdomen which detected less than 10% when used for routine follow-up in stage I/II and stage III patients (Hoffman et al, 2002).

Twenty patients with microscopic stage III disease underwent sentinel lymph node biopsy followed by lymph node dissection with a follow-up PET-CT performed annually for a mean follow-up time of 35 months (range: 21-54 months). Ten patients (10%) developed recurrences detected on PET-CT and one patient developed a local recurrence which was not picked up on PET-CT.

Eight patients underwent a second PET-CT scan and at the time of publication, none had evidence of malignant disease.

Fourteen patients developed clinically detectable stage III disease and underwent surveillance PET-CT with a mean follow-up time of 34 months (range: 15-24 months) and four patients were found to have developed recurrences that were first picked up by PET-CT (Abbot et al, 2011).

FDG-PET/ CT demonstrated complete response in 19/32 (59%) patients with the remaining patients showing FDG activity but no physical or pathological evidence of disease. An additional 5/64 (8%) were classified as complete responders by FDG-PET/CT however these patients showed persistent disease on physical and/or pathological examination.

51 patients were identified as having had out of field disease at a median time after ILI of 212 days (range: 34- 1013). FDG-PET/CT identified a second site of distant disease in 23/51 patients at a median time of 468 days (range: 82-944) (Beasley et al, 2012).

Initial recurrence was detected on self-examination in 16 patients who were otherwise asymptomatic, 13 patients developed symptoms which led to the detection of recurrence, 10 patients had recurrence detected by the physician during routine follow-up exam, 3 patients had recurrence detected on routine imaging and one patient had high LDH levels which resulted in the detection of regional lymph node basin recurrence. No statistically significant difference was observed between patients seeking care for symptomatic recurrence compared with patients whose recurrence was asymptomatic (patient detected, physician detected or detected by routine imaging). (Meyers et al, 2009).

Survival

Comparing symptomatic and asymptomatic recurrences showed no significant difference in disease-free survival interval (28 months and 23 months respectively, $p=0.15$) however a statistically significant difference in survival following detection of recurrence was observed. Median disease free survival was 12 months for symptomatic recurrences compared with 24 months for asymptomatic recurrences ($p=0.02$).

5-year overall survival was similar for both groups: $46\pm 11\%$ for any symptomatic recurrences and $47\pm 12\%$ for any asymptomatic recurrences ($p=0.26$) (Mooney et al, 1998).

Median survival time in patients undergoing surgery ($n=9$) for pulmonary metastasis was 24 months (95% CI 21-27 months) versus 7 months (95% CI 5-9 months) in patients refusing surgery or who were unresectable. The remaining patients received chemotherapy and median survival for these patients was 18 months (95% CI 0-37 months).

There was no significant difference in survival between surgical and non-surgical groups ($p=0.42$) (Mooney et al, 1998).

	5-year	10-year	15-year
No Recurrence	92%±2%;	85%±3%	77%±4%
Recurrence	46%±8%	17%±6%	14%±6%

Table 7.4 The development of any recurrence significantly affected survival (Mooney et al, 1998).

Median survival for symptomatic patients was 36 months (95% CI 18-46 months) compared with 42 months (95% CI, 24-84 months) in the asymptomatic group (p=0.53) (Morton et al, 2009)

5 year overall survival rates were 95% for stage I, 72% for stage II and 52% for stage III (Poo-Hwu et al, 1999)

Patients with loco-regional recurrences had a better survival rate compared to patients with distant recurrences (median survival was 34 months versus 13 months; p=0.03).

For patients with disease recurrence detected at routine examination (asymptomatic) median survival was 27 months compared with 14.5 months for patient detected (symptomatic) recurrences (p=0.02. controlled for stage, symptomatic versus asymptomatic and local versus distant recurrences).

The estimated 6-month hazard rates for death or recurrence after the date of first visit were 0.0044 for stage I, 0.0088 for stage II and 0.0278 for stage III (Poo-Hwu et al, 1999).

No difference was observed in survival between patients with symptomatic relapse compared with asymptomatic relapse (p=0.643) however there was a greater number of patients with symptomatic relapse (105 vs. 20) (Hoffman et al, 2002)

Median time to progression for complete responders was 2.66 years. 3 year disease free rate was 62.2% (95% CI: 40.1%-96.4%) for patients who were classified complete responders by both clinical/pathological examination and FDG-PET/CT compared with only 29.4% (95% CI: 9.9%-87.2%) for the complete responders who had residual FDG-PET/CT activity (Beasley et al, 2012).

Median survival after recurrence was 22 months for patients with loco-regional disease compared with 7 months for patients with distant recurrence (p<0.0001).

There was no statistically significant difference in survival for patients with a symptomatic recurrence compared with patients who had asymptomatic recurrence (p=0.2)

There was no statistically significant different in survival for patients who detected their recurrence compared with patients whose recurrence was physician detected or detected on routine imaging (p=0.6) (Meyers et al, 2009)

From one retrospective study (n=33,384), the hazards ratio for first recurrences remained stable in stage IA patients ($\leq 1:125$; 1 case/125 persons/year for 10 years). In stage IB an increased HR was observed during the first 36 months (1:37 – 1:40) with overlapping CI after 10 years

In stage II there was a decline (1:7 – 1:13) during the first 36 months and decreased to 1:40 after 8 years

In stage III there was a sharp decline during the first 36 months (1:3 – 1:10) and dropped to 1:30 after nine years.

From 3 years onwards there was no significant difference between stage II and III

The hazard to develop a recurrence decreased significantly with the follow up time for stages I, II, III and IB (p<0.05) but no significant decline was observed for stage IA (p=0.654)

The hazard ratio for secondary melanoma decreased from 1:222 – 1:769 after 3 years of follow-up (p=0.049) (Leiter et al, 2012).

One cohort study reported that for patients with stage I or II disease at diagnosis, early discovery of melanoma metastasis was beneficial with 76% overall survival rate after 3 years versus 38% survival rate for late detection. Early detection of metastasis was also beneficial for patients with stage III disease at diagnosis, overall survival rate after 3 years for early detection was 60% versus 18% for late detection (Garbe et al, 2003).

Diagnostic Efficacy of Imaging

PET detected 9 lymph node metastases in 4 patients which had not been picked up by conventional methods (Rinne et al, 1998)

PET detected 112 lesions in 48 patients compared with 79 detected by conventional imaging methods. PET was false positive for one lesion compared with conventional imaging which was false positive for 10.

PET was false negative for 10 metastases compared with conventional imaging which was false positive for 51 metastases.

In the patient by patient analysis, overall sensitivity of PET was 100% compared with 84.6% for conventional imaging, overall specificity was 95.5% versus 68.2%. Accuracy of PET was 97.9% versus 77.1%.

In the lesion by lesion analysis, PET sensitivity was 91.8% compared with 57.5% for conventional imaging, specificity was 94.4% compared with 45% and accuracy was 92.1% compared with 55.7% for conventional imaging (Rinne et al, 1998).

Analysis by different region showed both PET and conventional imaging to have 100% specificity and accuracy for the detection of brain metastases (n=15/15). For neck lymph nodes, sensitivity, specificity and accuracy was 100% for PET compared with 66%, 100% and 84% for conventional imaging.

PET had a sensitivity of 69.9%, specificity of 100% and accuracy of 81.1% for the detection of lung metastases compared with 87%, 100% and 91.9% for conventional imaging.

For detection of liver metastases, PET had a sensitivity, specificity and accuracy of 100% compared with 60%, 86.6% and 80% for conventional imaging.

For imaging of the abdominal lymph nodes, PET had 100% sensitivity, specificity and accuracy compared with conventional imaging which had 83.3% sensitivity, 100% specificity and 94.7% accuracy. PET also showed higher sensitivity (100% vs. 26.6%), specificity (94.4% vs. 77.7%) and accuracy (97% vs. 54.5%) compared with conventional imaging.

For peripheral lymph nodes, PET showed higher sensitivity (97.1% vs. 51.4%), specificity (100% vs. 92.9%) and accuracy (97.9% vs. 63.3%) compared with conventional imaging (Rinne et al, 1998).

There were 7 recurrences observed in the study population and six of them were upstaged by FDG PET. One patient presented with a negative finding at first scanning and was regarded as a false negative after a positive finding on further scanning

Recurrence influenced treatment plans in all cases; three patients underwent surgery with curative intent while four patients with inoperable recurrent disease received chemotherapy and/or interferon

- 1 PET sensitivity was 86%, specificity was 96%, positive predictive value was 86% and negative
- 2 predictive value was 9% for melanoma recurrence (Koskivuo et al, 2007).
- 3 At initial staging, imaging procedures detected synchronous metastases in 31/561 patients, 27 of
- 4 whom were upstaged to stage IIIA/B disease (Hoffman et al, 2002).
- 5 Overall 5-year survival from time of first relapse was 20%, in stage IIIA and IIIB patients and 11% in
- 6 stage IIIC patients.
- 7 Regional relapse was associated with longer overall survival than systemic relapse ($p < 0.001$)
- 8 Symptomatic relapse was associated with shorter survival compared with relapse discovered by
- 9 physical exam or radiological imaging. RR=2.31, 95% CI=1.68-3.18, $p < 0.001$
- 10

References

Included Studies

- Abbott, R. A., et al (2011) The role of positron emission tomography with computed tomography in the follow-up of asymptomatic cutaneous malignant melanoma patients with a high risk of disease recurrence. *Melanoma Research* 21;5:446-449.
- Beasley, G. M., et al (2012). A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma. *Annals of Surgery* 256;2:350-356.
- Garbe C. et al (2003) Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy *Journal of Clinical Oncology* 21;3:520-529
- Hofmann, U., et al (2002) Primary staging and follow-up in melanoma patients--monocenter evaluation of methods, costs and patient survival. *British Journal of Cancer* 87;2:151-157
- Koskivuo, I. O., et al (2007) Whole body positron emission tomography in follow-up of high risk melanoma. *Acta Oncologica* 46;5:685-690.
- Kottschade, L. A. S.(2009) Positron emission tomography in early detection of relapse in high-risk melanoma patients: A retrospective review. *Community Oncology* 6;8:344-347.
- Leiter U. et al (2012) Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry *Journal of the American Academy of Dermatology* 66:37-45
- Meyers, M. O., et al (2009) Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. *Annals of Surgical Oncology* 16;4:941-947.
- Murchie et al (2010) Patient satisfaction with GP-led melanoma follow-up: a randomised controlled trial *British Journal of Cancer* 102;1447-1455
- Morton, R. L., Craig, J. C., and Thompson, J. F. (2009) The role of surveillance chest X-rays in the follow-up of high-risk melanoma patients. *Annals of Surgical Oncology* 16;3:571-577
- Murchie et al (2010) Patient satisfaction with GP-led melanoma follow-up: a randomised controlled trial *British Journal of Cancer* 102;1447-1455
- Poo-Hwu, W. J., Ariyan, S., Lamb, L., Papac, R., Zelterman, D., Hu, G. L., Brown, J., Fischer, D., Bolognia, J., and Buzaid, A. C. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. *Cancer* 86[11], 2252-2258. 1-12-1999.
- Romano E. Et al (2010) Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines *Journal of Clinical Oncology* 28:3042-3047
- Rinne, D., Baum, R. P., Hor, G., and Kaufmann, R.(1998) Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. *Cancer* 82:9;1664-1671

Excluded Studies

Abbott, R. and Harries, M.(2009) Positron-emission tomography with computed tomography (PET/CT) in melanoma follow-up. *British Journal of Dermatology Conference*[var.pagings].
Reason: Abstract Only

Baker, J. J. M.(2011) Routine restaging PET/CT and detection of recurrence in sentinel lymph node positive stage III melanoma. *Annals of Surgical Oncology Conference*[var.pagings]
Reason: Abstract Only

Buzaid, A. C. T. (1995) Role of computed tomography in the staging of patients with local-regional metastases of melanoma. *Journal of Clinical Oncology* 13:8;2104-2108.
Reason: No brain metastases data

Cromwell, K. D., et al (2012) Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review. *Melanoma Research* 22;5:376-385
Reason: No useable data

Danielsen, M., (2013) Positron emission tomography in the follow-up of cutaneous malignant melanoma patients: a systematic review. [Review]. *American Journal of Nuclear Medicine and Molecular Imaging* 4;1:17-28.
Reason: Narrative Review

DeRose, E. R., et al (2011) Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanoma. *Melanoma Research* 21;4:364-369.
Reason: No brain metastases data

Kuvshinoff, B. W., Kurtz, C., and Coit, D. G.(1997) Computed tomography in evaluation of patients with stage III melanoma. *Annals of Surgical Oncology* 4:3;252-258.
Reason: No brain metastases data

Francken, A. B., et al (2007) Detection of first relapse in cutaneous melanoma patients: Implications for the formulation of evidence-based follow-up guidelines. *Annals of Surgical Oncology* 14;6:1924-1933.
Reason: No brain metastases data

Miranda, E. P., et al (2004) Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease. *Archives of Surgery* 139;8:831-836.
Reason: Not a follow-up population

Mooney, M. M., et al (1997) Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences: a cost-effectiveness analysis. *Cancer* 80;6:1052-1064.
Reason: No brain metastases data

Orfaniotis, G., et al (2012) Findings of computed tomography in stage IIB and IIC melanoma: a six-year retrospective study in the South-East of Scotland. *Journal of Plastic, Reconstructive and Aesthetic Surgery* 65;9:1216-1219.
Reason: Comparison not relevant to PICO

Panagiotou, I. E. B. (2001) Evaluation of imaging studies at the initial staging and during follow-up of patients with local-regional malignant melanoma. *Journal of B U.ON* 64:411-414.
Reason: No useable data

1 Rueth, N. M., et al (2013) Is Surveillance Imaging Effective for Detecting Surgically Treatable
2 Recurrences in Patients With Melanoma? A Comparative Analysis of Stage-Specific Surveillance
3 Strategies. *Annals of Surgery* [Oct 3], epub ahead of print.

5 Romano, E. and Scordo, M. (2009) Characteristics of first relapse in stage III melanoma patients with
6 no evidence of disease (NED): Guidelines for follow-up. *Journal of Clinical Oncology*
7 Conference[var.pagings], 9069.
8 Reason: No brain metastases data

9 Tsao, H., et al (2004) Early detection of asymptomatic pulmonary melanoma metastases by routine
10 chest radiographs is not associated with improved survival. *Archives of Dermatology* 140;1:67-70.
11 Reason: No brain metastases data
12 Weiss, M., et al (1995) Utility of follow-up tests for detecting
13 recurrent disease in patients with malignant melanomas. *JAMA* 274:21;1703-1705.
Reason: No useable data

Evidence Tables

Study Quality (Randomised Trials)

Study	Appropriate Randomisation	Appropriate Concealment	Comparable groups at baseline	Comparable Care apart from intervention	Patient Blinding	Treatment Administrator Blinding	Equal Follow-up	Equal Treatment Completion/Loss to follow up	Appropriate follow-up length	Precise definition of outcome	Valid method of measuring outcome	Investigator or blinding	Quality (GRADE)
Murchie et al	Yes	No	Yes	Yes	No	No	Yes	Yes	No	Yes	Unclear	Unclear	Moderate

Study Quality (Cohort Studies)

	Appropriate length of follow-up	Precise definition of an outcome	Valid method of measuring outcomes	Investigators blind to participants exposure to intervention?	Investigators blind to potential confounders and prognostic factors?	Risk of Bias	Quality
Abbot et al	Yes	Yes	Yes	No	No	High	Low
Beasley et al (2012)	Unclear	Yes	Yes	No	Unclear	High Risk of bias, particularly in relation to population selection	Low
Garbe et al (2003)	Unclear	Yes	Yes	No	Unclear	High	Low

	Appropriate length of follow-up	Precise definition of an outcome	Valid method of measuring outcomes	Investigators blind to participants exposure to intervention?	Investigators blind to potential confounders and prognostic factors?	Risk of Bias	Quality
Kottschade et al	Unclear	Yes	N/A	No	No	<p>There were several limitations to this study which may increase the risk of bias.</p> <p>The frequency of PET scanning was not uniform with an average of one scan every six months, though timings varied individually and all PET scans were not performed on the same scanner.</p> <p>For some patients, other methods of radiographic surveillance were interposed between scheduled PET</p>	Low

	Appropriate length of follow-up	Precise definition of an outcome	Valid method of measuring outcomes	Investigators blind to participants exposure to intervention?	Investigators blind to potential confounders and prognostic factors?	Risk of Bias	Quality
						scans.	
Leiter et al (2012)	Yes	Yes	Yes	No	No	Retrospective Case Series Study	Moderate
Meyers et al (2009)	Unclear	Yes	Yes	No	No	Retrospective study with a highly selected population (single institute and all evaluated by SLNB) which may not be reflective of a wider population scenario.	Low
Mooney et al	Yes	Yes	Yes	N/A	N/A	Retrospective analysis of medical records from a single centre means this is a highly selected population. The investigators however state that	Low

	Appropriate length of follow-up	Precise definition of an outcome	Valid method of measuring outcomes	Investigators blind to participants exposure to intervention?	Investigators blind to potential confounders and prognostic factors?	Risk of Bias	Quality
						the patient and tumour characteristics and overall survival rates parallel those of patients with local cutaneous melanoma in the SEER database over a comparable period of time and consider the results are generalisable to the US population however whether this is true for the UK population is not clear.	
Poo-Hwu et al	Unclear	Yes	Yes	No	No	Patients were followed up for a minimum of two years; it is not	Low

	Appropriate length of follow-up	Precise definition of an outcome	Valid method of measuring outcomes	Investigators blind to participants exposure to intervention?	Investigators blind to potential confounders and prognostic factors?	Risk of Bias	Quality
						<p>clear whether this length follow-up is appropriate to accurately assess recurrence. Some studies suggest that the majority of recurrence/disease progression occurs within the first two years following treatment for primary melanoma however, so this may be appropriate. In fact, in this study, most recurrences occurred within the first two years (79%) with 47% occurring in the first year and 32%</p>	

	Appropriate length of follow-up	Precise definition of an outcome	Valid method of measuring outcomes	Investigators blind to participants exposure to intervention?	Investigators blind to potential confounders and prognostic factors?	Risk of Bias	Quality
						in the second year.	
Romano et al (2010)	Yes	Yes	Yes	No	No	Retrospective Analysis	Low

Study Quality (diagnostic Studies)

	Was a consecutive or random sample of patients enrolled?	Was a case-control design avoided?	Did the study avoid inappropriate exclusions?	Were the index test results interpreted without knowledge of the results of the reference standard?	If a threshold was used, was it pre-specified?	Is the reference standard likely to correctly classify the target condition?	Were the reference standard results interpreted without knowledge of the results of the index test?	Was there an appropriate interval between index test(s) and reference standard?	Did all patients receive a reference standard?	Did patients receive the same reference standard?	Were all patients included in the analysis?
Hofmann et al	No	Yes	Unclear	No	N/A	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
Koskivuo et al	Yes	Yes	Yes	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Yes

Morton et al	Yes	Yes	Yes	Yes	N/A	Yes	N/A	Yes	No	Yes	Yes
Rinne et al	Yes	Yes	Yes	Yes	N/A	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
Abbott et al	To evaluate the role of PET/CT as a surveillance tool in patients with AJCC stage 3 primary cutaneous melanoma	Retrospective Case Series	<p>N=34 AJCC stage III who underwent at least one annual surveillance PET/CT</p> <p>N=20 patients with microscopic stage 3 disease who underwent sentinel lymph node biopsy followed by lymph node dissection.</p>	<ul style="list-style-type: none"> Clinical exam every 3 months post diagnosis Annual PET/CT 	<p><u>Patients with microscopic stage 3 disease</u></p> <p>Mean follow-up time from diagnosis until most recent clinical review was 38 months (21-54 months)</p> <p><u>Patients with macroscopic stage 3 disease</u></p> <p>Mean follow-up time from diagnosis of stage 3 disease to most recent clinical review was 34 months (15-52)</p>	<ul style="list-style-type: none"> Detection of Recurrence <p><u>Patients with microscopic stage 3 disease</u></p> <p>2/20 patients developed recurrences first detected on surveillance PET/CT</p> <p>One patient developed a local recurrence within 1 month which was not picked up PET/CT but was picked up on clinical review.</p> <p><u>Patients with macroscopic stage 3 disease</u></p> <p>4/14 patients developed recurrences that were picked up on PET/CT (3 on initial PET/CT and</p>	All PET exams covered skull base to upper thigh.

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
						1 on their second surveillance PET/CT).	
Beasley et al	To compare how response to ILI as assessed by FDG-PET/CT correlates with clinical and pathological response and to evaluate the use of FDG-PET/CT as a surveillance tool for the detection of systemic recurrence	Retrospective Case Series	<p>N=97 patients with stage IIIB-IV melanoma</p> <p>Patients undergoing ILI at 2 institutions were included if they had a FDG-PET/CT scan within 30 days of ILI treatment and at 3 month intervals for the first year and 6 month intervals thereafter.</p>	<ul style="list-style-type: none"> Initial 3 month evaluation (physical examination) followed every 3 months for 1 year and every 6 months thereafter to determine progression free survival Initial PET-CT within 30 days of initial treatment, every 3 months for the first year and every 6 months thereafter 	Median time between the pre-treatment scan and first scan post ILI was 117 days (range: 45-265).	<ul style="list-style-type: none"> Detection of Recurrence Survival 	Highly selected population – only patients undergoing isolated limb infusion are included so the population
Garbe et al (2003)	To determine the effectiveness	Retrospective Case Series	<ul style="list-style-type: none"> N=2,008 patients with stage I-IV melanoma at diagnosis 	<ul style="list-style-type: none"> Follow up exams every 3 months in the 	Unclear but all patients appear to have at least	<ul style="list-style-type: none"> Detection of metastasis or second 	Early recurrence (metastasis)

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
	of follow-up procedures in a large cohort of patients treated for melanoma for the early detection of developing metastasis	<p>Patients treated between August 1996 and August 1998</p> <p><u>Exclusions</u></p> <p>Patients who had not previously undergone observation of their disease and who were referred with suspected metastasis</p> <p>Patients who had discontinued previous follow-up and returned with possible metastasis</p>		<p>first 5 years and every 6 months thereafter until year 10.</p> <ul style="list-style-type: none"> • Extensive education regarding the clinical characteristics of melanoma and its metastases, self examination and recognition of the signs and symptoms of recurrence. • Visits included a complete history, skin inspection and clinical examination of the resection site and lymphatic drainage areas 	25 months	<p>primary melanoma</p> <ul style="list-style-type: none"> • Survival <p><u>Detection of Recurrence and second melanomas</u></p> <ul style="list-style-type: none"> • 233 disease recurrences were detected in 112 patients with stage I-III melanoma. • In 39/233 recurrences, the patient initially suspected recurrence with 31/39 diagnoses established during subsequent follow-up examinations. • 71% of 	was defined as organ or lymph node metastases of no more than 2cm in diameter with less than 10 individual nodes being affected and simultaneously with an indication for surgery with curative intent.

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
				<ul style="list-style-type: none"> Abdominal sonography, chest x-ray and blood tests every 12 months in stage I-II disease and every 6 months in stage III disease. Sonographic examination of the resected tumour scar, lymphatic drainage area and regional node regions every 12 months in stage I melanoma, every 6 months in stage II melanoma and every 3-6 months in 		<p>recurrences were detected and confirmed on scheduled follow-up examinations</p> <ul style="list-style-type: none"> 12% of recurrences were discovered by physicians not participating in the melanoma follow-up schedule who were consulted for other reasons. 62 newly developed second primaries were identified in 46 patients; a single second primary was detected in 36 patients, 2 second 	

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
				stage III melanoma.		<p>primaries in 6 patients and 3-4 second primaries in 4 patients.</p> <p><i>Contribution of history and physical examination</i></p> <p>Case history and physical exam detected almost 50% of all recurrences and 80% of metastases detected on clinical examination consisted of local recurrences, satellite or in-transit metastasis or regional lymph node metastasis.</p>	

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
						<p><i>Lymph node sonography</i></p> <ul style="list-style-type: none"> • 3,490 lymph node examinations were carried out during the follow-up period. 5% revealed a suspicion of metastasis and 9% required repeated sonography. • <1% of lymph node sonography results in stage IA were suggestive of metastasis • >20% of lymph node sonography results were 	

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
						<p>suggestive of metastasis in stage IV patients.</p> <ul style="list-style-type: none"> 76% of the lymph node sonographies that were considered suspicious for metastasis were confirmed positive on further examination. <p><i>Chest x-ray and abdominal sonography</i></p> <ul style="list-style-type: none"> A total of 2,396 chest x-rays were performed with a suspicion of 	

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
						<p>metastasis in only 14 patients (12 confirmed as true-positives).</p> <ul style="list-style-type: none"> A total of 2,464 abdominal scans were carried out with only 0.8% resulting in a suspicion of metastasis. <p><i>Blood Tests and Additional Technical Investigations</i></p> <ul style="list-style-type: none"> An additional 4048 technical investigations (primarily blood tests) were carried out but were 	

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
						<p>rarely the first proof of metastasis.</p> <ul style="list-style-type: none"> • In patients developing metastases, LDH and AP levels were found to be elevated in 16.4% and 12.5% of patients and both percentages were significantly higher than in patients without metastasis ($p<0.0001$). • CT scanning confirmed metastasis in 14% of stage II patients, 23% 	

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
						<p>in stage III disease and 40% in stage IV disease.</p> <p><i>Impact on Relapse Detection</i></p> <ul style="list-style-type: none"> Almost 50% of all disease recurrence was detected on physical exam. <p>Stage I=55.6%</p> <p>Stage II=51%</p> <p>Stage III=48.2%</p> <p>Stage IV=13.3%</p> <ul style="list-style-type: none"> Lymph node 	

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
						<p>sonography was responsible for the detection of 14% of all recurrences as part of routine follow-up. The detection rate was highest for recurrences in stage II patients (22.4%)</p> <ul style="list-style-type: none"> • Abdominal sonography detected only 4% of all recurrences <p><i>Early and Late detection of recurrences and</i></p>	

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
						<p><i>their impact on overall survival</i></p> <p>48% of metastasis were classified as early discoveries and 52% were classified as late discoveries.</p> <p>Rate of detection of metastasis at an early stage of development varied according to examination method used:</p> <p>Lymph node sonography=71%</p> <p>Clinical examination=56%</p>	

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
						<p>CT scans=30 %</p> <p>Chest X-ray & Abdominal ultrasound=25%</p> <p>Patients with metastasis detected early and at later stages were estimated to have highly significant overall survival rates ($p<0.0001$).</p> <p>In patients with stage I or II disease, early discovery of</p>	

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
						<p>melanoma metastasis was beneficial with 76% overall survival rate after 3 years versus 38% survival rate for late detection.</p> <p>In stage III disease, overall survival rate after 3 years for early detection was 60% versus 18% for late detection.</p>	
Hofmann et al	To evaluate records of patient with stage I-III melanoma who had been seen and followed up at a single institute to determine clinical and	Retrospective Case Series Single Institute	<p>N=661 patients with stage I-IV melanoma at diagnosis</p> <ul style="list-style-type: none"> • 630 stage I/II, • 27 stage IIIA/B, • 4 stage IV patients at the time of first diagnosis. 	<ul style="list-style-type: none"> • Stage I/II patients – physician visits every 3 months during the first 5 years and every 6 months thereafter until end of year 8 or 		<ul style="list-style-type: none"> • Time to Recurrence 	<ul style="list-style-type: none"> •

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
	cost effectiveness of imaging.			recurrence <ul style="list-style-type: none"> • Annual chest x-ray and sonography of the abdomen • Lymph node sonography of peripheral nodes every 6 months • Stage III/IV follow-up was extended by increasing the frequency of diagnostic imaging – 6 monthly chest x-ray and abdominal sonography and 3 monthly lymph node sonography. 			
Kottscha de et al		Case Series	N=106 patients with resected stage III-IV melanoma <i>Exclusions:</i> Patients did not have sufficient time intervals	<ul style="list-style-type: none"> • Not clearly identified though the purpose of the review appears to be PET 		<ul style="list-style-type: none"> • Detection of Recurrence 	

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
			between PET scans.				
Koskivuo et al	To determine the clinical impact of FDG-PET to detect clinically silent metastases in the follow-up of patients with high risk melanoma.	Case Series Single Institute, patients treated between March 2004 and November 2005	N= 30 patients with AJCC stage IIB-IIIC adult melanoma who were free of any clinical signs of metastases	<ul style="list-style-type: none"> Regular follow-up schedule including whole body CT at the time of initial surgery and clinical exam every 3-6 months during the first 5 years. Annual Chest X-Ray and blood tests Secondary CT and physical exam performed concurrently with PET In addition a whole body FDG-PET 7-24 months after primary surgery 		Index Test: PET Reference Test: Unclear <ul style="list-style-type: none"> Detection of recurrence Diagnostic Accuracy of Imaging 	
Leiter et al (2012)		Retrospective Study	N=33,384 (stage I-III)	every 3 months during the first 5		<ul style="list-style-type: none"> Overall Survival 	

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
				<p>years and every 6 months during years six to ten.</p> <p>Follow-up includes:</p> <ul style="list-style-type: none"> • Whole body skin exam • Lymph node ultrasound 1-2 times a year • Blood examinations of tumour marker protein S100β and lactate dehydrogenase in patients with melanoma thickness $\geq 1\text{mm}$ 		<ul style="list-style-type: none"> • Secondary Melanoma Free survival • Recurrence Free survival 	
Meyers et al (2009)	To evaluate the method of detection of recurrent melanoma in patients with stage II-III melanoma	Retrospective Case Series Single Institution review of patients from 1997-2005,	<p>N=118 stage II or SLN positive stage III melanoma</p> <p><i>Inclusions</i> Patients who underwent surgical treatment for AJCC stage II or stage III</p>	<ul style="list-style-type: none"> • A written copy of the follow-up schedule was provided to all patients • Follow-up exam with a health care 	Minimum follow-up of 2 years	<ul style="list-style-type: none"> • Time to Recurrence • Detection of Recurrence • Survival 	From 1997-2003, CT of the chest/abdomen/pelvis was used routinely however from 2003 onwards

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
	<p>who were initially evaluated by SLNB.</p> <p>Does a rigid follow-up schedule with a health care professional have any impact on the method of detection of recurrence?</p> <p>Does the use of imaging in stage III patients have any impact on the detection of recurrence?</p>		cutaneous melanoma and were evaluated by SLNB and underwent routine follow-up .	<p>provider (surgical oncologist, dermatologist, surgical nurse practitioner) every 3 months for the first 3 years, every 6 months in years 3-5 and annually to year ten.</p> <ul style="list-style-type: none"> • For patients with stage II melanoma exam should include full body examination of skin and lymph node basins, annual blood work, annual chest x-ray • For patients with stage III melanoma follow-up 			whole body PET/CT scan was available and became the imaging method of choice.

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
				should additionally include annual body and brain imaging in years 1-3			
Mooney at al		<p>Case Series</p> <p>Medical records between 1971-1995 from a single institution in the United States</p>	<p>N=154 stage I-II</p> <p>~98% of patients were seen within 2 months of initial biopsy diagnosis and of these: 22% were diagnosed between 1971-1979 46% were diagnosed between 1980-1989 32% were diagnosed between 1990-1995</p> <p>AJCC T classification of local tumours based on Breslow thickness (94%) or Clarks Level (6%) at diagnosis was as follows: pT1=29% pTII=27% pTIII=26% pT4=7%</p> <p>Primary tumours were treated with surgical</p>	<ul style="list-style-type: none"> No. of visits Physical Exam Lab tests Chest radiographs 	<p>6.1 years for the whole cohort (median)</p> <p>7.1 years for patients alive and disease free at the time of the study (median).</p> <p>55 months for patients with recurrence (median)</p>	<ul style="list-style-type: none"> Time to Recurrence Survival <p>Early recurrence (within 5 years) occurred in 130 patients while late recurrence (post 5 years) occurred in 24 patients with 88% of symptomatic recurrences and 82% of asymptomatic recurrences occurring early.</p> <p>For asymptomatic patient, the majority of pulmonary first recurrences were found within the</p>	<p>Symptomatic recurrence was defined as recurrence detected by a patient or family member while asymptomatic recurrences were defined as those detected by a physician.</p>

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
			excision: wide radical excision 70%; wide radical excision with elective lymph node dissection 22%; others 8%.			<p>first 5 years after diagnosis: 18% in years 0-2, 53% in years 3-5 and 29% in years 6-10.</p> <p>Median time between last normal chest radiograph and abnormal chest radiograph indicating recurrent disease was 5 months (1-30 months)</p> <p>Symptomatic (patient detected) first recurrence occurred in 89/154 (58%) of cases while asymptomatic (physician detected) first recurrence occurred in 65/154 (42%) of cases</p> <p>Recurrences were</p>	

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
						<p>detected by physical exam in 72% of cases and of these 57% were detected by the patient or family member while 43% were detected by the physician</p> <p>Constitutional symptoms (pain, weight loss, malaise, neurological symptoms or combination) indicated 17% of recurrences</p> <p>Chest radiograph detected the remaining 11% of recurrences</p> <p>Complete cell counts and liver function tests were never the sole indicator of recurrence</p> <p>Diagnosis of symptomatic</p>	

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
						<p>disease occurred at 55% of unscheduled visits and 43% of scheduled visits while 2% of the visits unclassified. All asymptomatic recurrences were detected during regularly scheduled follow-up appointments</p> <p>Of the 65 first recurrences detected by physicians, 74% were discovered on physical examination and 26% by chest radiograph. There were 84 second recurrences (55% symptomatic; 36% asymptomatic; 8% unclassified). A total of 53% of asymptomatic recurrences were</p>	

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
						<p>detected on physical exam, 40% on chest radiograph and 7% on CT scan. Chest radiographs detected 30 recurrences in 26 patients (17 first, 12 second and 1 third recurrence) whereas screening chest or abdominal CT detected only 6 recurrences</p> <p>Comparing symptomatic and asymptomatic recurrences showed no significant difference in disease-free survival interval (28 months and 23 months respectively, $p=0.15$) however a statistically</p>	

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
						significant difference in survival following detection of recurrence was observed. Median disease free survival was 12 months for symptomatic recurrences compared with 24 months for asymptomatic recurrences (p=0.02) 5-year overall survival was similar for both groups: 46%±11% for any symptomatic recurrences and 47%±12% for any asymptomatic recurrences (p=0.26)	
Morton et al (2009)	To evaluate the accuracy of detecting asymptomatic	Case Series	N=108 AJCC stage III A/B with a positive SLNB	<ul style="list-style-type: none"> Chest X-Ray every 6 months for 5 years and 		<ul style="list-style-type: none"> Time to Recurrence <p>There was no</p>	In some cases a biopsy of suspected lung lesions

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
	pulmonary metastases by surveillance chest x-rays in melanoma patients with a positive sentinel lymph node biopsy.		<p><i>Exclusions</i></p> <ul style="list-style-type: none"> • <18 years • evidence of satellite, in-transit, regional nodal or distant disease at the time of SLNB. • Patients with a history of melanoma or previous treatment for melanoma with chemotherapy or radiotherapy 	<p>annually for 5 years thereafter</p> <ul style="list-style-type: none"> • Histopathology from fine-needle biopsy of a lung lesion. • Patients also had Chest CT and PET scans 		<p>significant difference in median time to diagnosis for asymptomatic pulmonary metastases (chest x-ray) and symptomatic pulmonary metastases detected during clinical visits ($p=0.30$). Median time to diagnosis of pulmonary metastasis was 24 months (95% CI 12-41 months) and median time to the diagnosis of pulmonary disease by clinical follow-up was 16 months (95% CI 10-30 months)</p> <p>30/108 patients had suspicious or highly probable findings on their</p>	was not undertaken if widespread metastatic disease was observed on PET or CT scans

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
						chest x-rays however only 11/23 had a positive biopsy result giving a sensitivity of 48% (95% CI 27%-68%) for serial chest x-rays. It is not clear whether the remaining 7 patients underwent biopsy though from the flow chart it seems 7 patients died from their disease	
Murchie et al		Randomised Controlled Trial		•	•	<ul style="list-style-type: none"> • Patient Satisfaction • Guideline Adherence 	•
Poo-Hwu et al	To evaluate the time interval between initial visit and diagnosis of recurrence	Case Series Single institution from January 1988-1994.	N=419 patients with stage I-III melanoma with pathologically confirmed melanoma and no evidence of disease following surgery. <i>Exclusions:</i>	<ul style="list-style-type: none"> • Follow-up schedule was dependant on AJCC stage at diagnosis with each visit to include history taking, 	Minimum follow up of 2 years	<ul style="list-style-type: none"> • Survival 	•

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
	<p>To determine if recurrence was detected during a scheduled visit by a physician or recognised by the patient between visits by self examination or symptoms</p> <p>To determine which procedures identified recurrence in asymptomatic patients</p> <p>To determine where was the site of recurrence</p> <p>To determine survival after recurrence</p> <p>To determine whether the</p>		<ul style="list-style-type: none"> Patients with stage IV disease or non-cutaneous disease Patients with inadequate medical records or follow-up. In total, 46 patients were excluded leaving 373 patients to be included in analysis. <ul style="list-style-type: none"> 193 (52%) of patients had stage I disease (stage IA=84; stage IIB=109) 117 (31%) of patients had stage II disease (stage IIA=85; stage IIB=109) 63 (17%) of patients had stage III disease 	<p>physical exam, complete blood count and liver function tests.</p> <ul style="list-style-type: none"> Annual Chest X-Ray for stage I-II and 6 monthly chest X-Rays for stage III for the first 5 years Patients with Stage III had a baseline CT scan with follow-up CT scans obtained in 6-12 months in the event of abnormal findings not clearly indicative of metastatic disease 			

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
	patient developed another primary melanoma						
Rinne et al	To analyse the sensitivity, specificity and accuracy of PET as compared with conventional tumour staging methods.	Case Series	N=48 patients with high risk melanoma in whom PET was performed for re-staging as part of follow-up	<ul style="list-style-type: none"> Chest Radiograph, abdominal sonography, high res ultrasound of regional lymph nodes, X-Ray CT of thorax and abdomen, contrast MRI of the brain 		Index Test: PET Reference Test: Histology/clinical detection of recurrence Diagnostic Accuracy of Imaging	<ul style="list-style-type: none">
Romano et al (2010)		Retrospective study	N=340 total Stage IIIA=95 Stage IIIB=155 Stage IIIC=90	<ul style="list-style-type: none"> Physical exam every 3 months for the first 2 years and every 6 months thereafter (no end time specified) Follow-up included medical 		<ul style="list-style-type: none"> Time and site of first recurrence Method of detection Overall Survival 	<ul style="list-style-type: none">

Study	Aim	Study Design & Setting	Population	Follow-up Protocol	Follow-Up	Outcomes and Results	Comment
				<p>oncology visits, surgical and dermatologic visits</p> <ul style="list-style-type: none"> • CT scans, CBCs, comprehensive panels and lactate dehydrogenase were obtained before the follow-up visits 			


1 Economic Evidence Summary

- 2 • The following databases were searched for economic evidence relevant to the PICO:
3 MEDLINE, EMBASE, COCHRANE, NHS EED. Studies conducted in any OECD country were
4 considered (Guidelines Manual 2009).
- 5 • 303 possibly relevant papers were identified. Of these, eight full papers relating to this topic
6 were obtained for appraisal. A further four papers were excluded for not reporting an
7 incremental analysis and two further papers were excluded as not being relevant to the
8 PICO. Two papers (Mooney et al (1997) and Krug et al (2009)) were included in the current
9 review of published economic evidence for this topic.
- 10 • Mooney et al was a cost-utility analysis comparing a strategy of adding annual CXR screening
11 for local, regional or metastatic recurrence to usual follow-up in patients diagnosed with
12 intermediate-thickness, local, cutaneous melanoma.
- 13 • When both costs and health benefits were discounted at 5% the addition of annual CXR
14 screening to usual follow-up resulted in an ICER of \$215,000 per QALY compared to usual
15 follow-up. During one-way sensitivity analysis the lowest ICER was \$109,000 when the
16 increase in survival benefit from surgery for lung recurrences was increased from 8 months
17 to 15 months. Shortening the duration follow-up with CXRs reduced the ICER but still always
18 resulted in a cost per QALY in excess of \$100,000, above common thresholds for cost-
19 effectiveness, when compared to usual follow-up.
- 20 • Mooney et al. was deemed only partially applicable to the decision problem that we are
21 evaluating. This is primarily because the study did not consider a UK healthcare setting (USA
22 setting).
- 23 • Very serious limitations were identified with Mooney et al. including not all relevant costs
24 being included in the analysis and lack of probabilistic sensitivity analysis.
- 25 • Krug et al was a cost-effectiveness analysis comparing the use of FDG PET-CT versus whole
26 body CT during follow-up in patients with resected stage IIc and stage III melanoma where
27 there is suspicion of pulmonary metastasised melanoma. The study reported effectiveness
28 outcomes in terms of cost per life month gained. Typically papers which do not report
29 quality of life based outcomes are excluded but given the paucity of economic evidence on
30 this topic an exception was made.
- 31 • The base-case concluded that the inclusion of PET-CT was both cost saving and health
32 improving with a reduction in costs of €1,048 and an increase in survival of 0.2 life months.
33 During probabilistic sensitivity analysis in 71.0% of iterations PET-CT was both cost saving
34 and health improving whilst it was cost increasing and health decreasing in 22.6% of trials.
- 35 • Krug et al was deemed only partially applicable to the decision problem that we are
36 evaluating. This is primarily because the study did not consider a UK setting (Belgian
37 healthcare setting).

- Potentially serious limitations were identified with Krug et al most notably the lack of transparency around the clinical inputs used in the model.
- Given the fundamental differences in the interventions considered the studies were not compared.

Volume of evidence

- 303 possibly relevant papers were identified. Of these, 8 full papers relating to this topic were obtained for appraisal. A further 4 papers were excluded as they only reported costs and 2 were excluded as they were not relevant to the PICO. Two papers (Mooney et al (1997) and Krug et al (2010)) were included in the current review of published economic evidence for this topic.
- Mooney et al was a cost-utility analysis, conducted from a US healthcare payer perspective. The study reported cost-effectiveness results in terms of cost per QALY over a 20 year time horizon.
- Krug et al was a cost-utility analysis, conducted from a Belgian healthcare payer perspective. The study reported outcomes in terms of QALYs over a 10 year time horizon.
- No cost-effectiveness evidence was identified comparing setting (primary/secondary care) of follow-up or healthcare professional conducting follow-up.
- No cost-effectiveness studies were identified which considered a UK healthcare setting.



1 Quality and applicability of the included studies

		<i>Applicability</i>	
		Directly applicable	Partially applicable
<i>Methodological quality</i>	Minor limitations		
	Potentially serious limitations		Krug et al. 2010
	Very serious limitations		Mooney et al. 1997

- Mooney et al and Krug et al are deemed only partially applicable to the decision problem that we are evaluating. This is primarily because the studies did not consider a UK healthcare setting. Krug et al also did not express health effect values in terms of quality adjusted life years (QALYs).
- Very serious limitations were identified with Mooney et al. including not all relevant costs being included in the analysis and lack of probabilistic sensitivity analysis.
- Potentially serious limitations were identified with Krug et al most notably the lack of transparency around the clinical inputs used in the model.

10 References

- Mooney MM, Mettling C, Michalek AM et al 'Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences: a cost-effectiveness analysis' **Cancer** 80.6 (1997): p1052-1064.
- Krug B, Crott R, Roch I et al 'Cost-effectiveness analysis of FDG PET-CT in the management of pulmonary metastases from malignant melanoma' **Acta Oncologica** 49.2 (2010): p192-200.

Evidence Tables

Modified GRADE profiles for included economic studies

Study	Population	Comparators	Costs	Effects	Incr costs	Incr effects	ICER	Uncertainty	Applicability	Limitations
Study 1										
Mooney et al. 2000	Hypothetical cohort of patients diagnosed with intermediate-thickness [Clark's level III], local, cutaneous melanoma	Usual follow-up.	Not reported	Not reported	Reference			One-way Sensitivity Analysis One-way sensitivity analyses were conducted with ICER ranging from \$109,000/QALY to \$765,000/QALY for the lifetime (20year) screening option. When altering the frequency and total duration of the screening program the ICER ranged from \$143,000 to \$240, 000. Screening was always more costly and effective.	Partially Applicable	Very Serious Limitations.
		Usual follow-up plus life-long annual CXR for local, regional or metastatic recurrence.	Not reported	Not Reported	\$755 ²	0.035 QALYs ²	\$215 000		Not conducted from a UK perspective.	
Comments:										

¹ Calculated by NCC-C health economist from reported data

Study	Population	Comparators	Costs	Effects	Incr costs	Incr effects	ICER	Uncertainty	Applicability	Limitations
Study 2										
Krug et al 2010	Patients with resected stage IIc and stage III malignant melanoma.	Follow-up with suspected pulmonary metastases being examined with whole body CT.	\$4 384	90.41 Life months	Reference		Error! Bookmark not defined.	Probabilistic Sensitivity Analysis: PET-CT was dominant in 71.0% of iterations and dominated in 22.6% of iterations versus WB-CT.	Partially Applicable Not conducted from a UK health service perspective.	Potentially serious limitations
		Follow-up with suspected pulmonary metastases being examined with fluorine-18 fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) with X-Ray computed tomography(CT)	\$3 438	90.61 Life Months	-€946	0.20	PET-CT dominant (Both cost saving and health improving).			

Comments:

Primary details	Design	Patient characteristics	Interventions	Outcome measures	Results	Comments
-----------------	--------	-------------------------	---------------	------------------	---------	----------

<i>Study 1</i>					
Author: Mooney	Type of analysis: Cost-Utility	Base case (population): Hypothetical cohort of patients diagnosed with intermediate-thickness [Clark's level III], local, cutaneous melanoma	1) Usual follow-up	Incremental cost-effectiveness Ratio (Cost per QALY)³	Funding: National Institutes of Health Comments
Year: 1997	Model structure: Markov Model		2) Usual follow-up plus life-long annual CXR for local, regional or metastatic recurrence	Health benefits discounted 5%	
Country: US	Cycle length: 1 year	Sample size: Hypothetical Cohort		Basecase	\$215,000
	Time horizon: 20 Years	Age (Mean): 52 years		Benefit reduced 3 months survival	\$765,000
	Perspective: US Healthcare Payer	Gender: 53% Male		Benefit increased 15 months survival	\$109,000
	Source of base-line data: % of detected cases amenable to surgery, annual probabilities of recurrence and systemic recurrence and asymptomatic lung recurrences are taken from Roswell Park Cancer Institute (RCPI) data. The RCPI data is a retrospective cohort study consisting of a cohort of 1004 patients who presented between 1971 to 1995 with local, cutaneous melanoma.			Low recurrence probability	\$309,000
				High recurrence probability	\$164,000
				CXR reduced \$30	\$180,000
				CXR increased \$80	\$306,000
				Specificity CXR reduced 90%	\$292,000
				Specificity CXR increased 98%	\$166,000
				Reduce surgical candidates 40%	\$280,000
				Increase surgical candidates 70%	\$177,000
				% Asymptomatic lung recurrences reduce	\$277,000
				% Asymptomatic lung recurrences increase	
				% systemic recurrences decrease	\$195,000
				% systemic recurrences increases	\$268,000
				Surgical morbidity decreased 0 months	\$180,000
				Surgical morbidity increased 2 months	\$188,000
				Discount rates cost 3%	\$251,000
				Discount rates cost 6%	\$244,000
				Discount rate health 5%	\$203,000
				Annual cost increase 5%	\$195,000
				Annual cost increase 8%	\$198,000
					\$235,000
				Program length	
				5 years	
				5 years ⁴	\$168,000
				10 years	\$143,000
				10 years ⁴	\$174,000
				20 years ⁴	\$156,000
				20 years ⁵	\$198,000
					\$240,000
				Health benefits not discounted	

³ Changes in % lost to follow-up, growth rate for costs, discount rate for costs, mortality rate and cost of chest CT scans also considered with impact being reported as less than 10% change in ICER. No figures were reported.

⁴ Chest X-Ray every 6 months in years 1-2.

⁵ Chest x-ray screening annually with a decrease of 50% in the sensitivity of the screening regimen in years 1-5

Source of utility data:

Utility values were taken from two previous cost-effectiveness studies of metastatic breast cancer and hepatitis B. In these studies clinical opinion was used to estimate utility scores for complete remission and progressive disease.

Source of cost data:

Costs were taken from various sources in the medical literature.

The cost of chest x-ray (CXR) was taken from medicare reimbursement costs.

Currency unit: US\$

Cost year: 1996

Discounting:

Costs: 5% per annum

Benefits: 0%, 5%

Base case	
Benefit reduced 3 months survival	\$165,000
Benefit increased 15 months survival	\$589,000
Low recurrence probability	\$82,000
High recurrence probability	\$242,000
CXR reduced \$30	\$124,000
CXR increased \$80	\$138,000
Specificity CXR reduced 90%	\$235,000
Specificity CXR increased 98%	\$224,000
Reduce surgical candidates 40%	\$128,000
Increase surgical candidates 70%	\$216,000
% Asymptomatic lung recurrences reduce	\$137,000
% Asymptomatic lung recurrences increase	\$212,000
% systemic recurrences decrease	
% systemic recurrences increases	\$151,000
Surgical morbidity decreased 0 months	\$205,000
Surgical morbidity increased 2 months	\$139,000
Discount rates cost 3%	\$145,000
Discount rates cost 6%	\$193,000
Annual cost increase 5%	\$187,000
Annual cost increase 8%	\$156,000
	\$152,000
<i>Program length</i>	\$181,000
<i>5 years</i>	
<i>5 years⁴</i>	
<i>10 years</i>	\$147,000
<i>10 years⁴</i>	\$125,000
<i>20 years⁴</i>	\$143,000
<i>20 years⁵</i>	\$128,000
	\$152,000
	\$174,000

Incremental cost-effectiveness Ratio(Cost per Life Year)

Health benefits discounted 5%

Base case	
Benefit reduced 3 months survival	
Benefit increased 15 months survival	\$199,000
Low recurrence probability	\$721,000
High recurrence probability	\$100,000
CXR reduced \$30	\$286,000
CXR increased \$80	\$151,000
Specificity CXR reduced 90%	\$166,000
Specificity CXR increased 98%	\$283,000
Reduce surgical candidates 40%	\$269,000

Increase surgical candidates 70%	\$154,000
% Asymptomatic lung recurrences reduce	\$259,000
% Asymptomatic lung recurrences increase	\$164,000
% systemic recurrences decrease	\$255,000
% systemic recurrences increases	
Surgical morbidity decreased 0 months	\$180,000
Surgical morbidity increased 2 months	\$248,000
Discount rates cost 3%	\$166,000
Discount rates cost 6%	\$173,000
Discount rate health 5%	\$232,000
Annual cost increase 5%	\$225,000
Annual cost increase 8%	\$188,000
	\$179,000
<i>Program length</i>	\$183,000
	\$217,000
<i>5 years</i>	
<i>5 years⁴</i>	
<i>10 years</i>	
<i>10 years⁴</i>	\$155,000
<i>20 years⁴</i>	\$132,000
<i>20 years⁵</i>	\$161,000
	\$144,000
	\$183,000
Health benefits not discounted	\$220,000
Base case	
Benefit reduced 3 months survival	
Benefit increased 15 months survival	
Low recurrence probability	\$150,000
High recurrence probability	\$540,000
CXR reduced \$30	\$74,000
CXR increased \$80	\$219,000
Specificity CXR reduced 90%	\$112,000
Specificity CXR increased 98%	\$125,000
Reduce surgical candidates 40%	\$213,000
Increase surgical candidates 70%	\$203,000
% Asymptomatic lung recurrences reduce	\$116,000
% Asymptomatic lung recurrences increase	\$195,000
% systemic recurrences decrease	\$124,000
% systemic recurrences increases	\$192,000
Surgical morbidity decreased 0 months	
Surgical morbidity increased 2 months	\$137,000
Discount rates cost 3%	\$186,000
Discount rates cost 6%	\$126,000
Annual cost increase 5%	\$131,000
Annual cost increase 8%	\$175,000
	\$169,000
<i>Program length</i>	\$141,000

	\$138,000
5 years	\$164,000
5 years ⁴	
10 years	
10 years ⁴	
20 years ⁴	\$133,000
20 years ⁵	\$113,000
	\$130,000
	\$116,000
	\$138,000
	\$157,000

Changes in % lost to follow-up, growth rate for costs, discount rate for costs, mortality rate and cost of chest CT scans also considered with impact being reported as less than 10% change in ICER. No figures were reported.

¹ Chest X-Ray every 6 months in years 1-2.

¹ Chest x-ray screening annually with a decrease of 50% in the sensitivity of the screening regimen in years 1-5

Primary details	Design	Patient characteristics	Interventions	Outcome measures	Results	Comments
<i>Study2</i>						
<u>Author:</u> Krug <u>Year:</u> 2010 <u>Country:</u> Belgium	<u>Type of analysis:</u> Cost-Effectiveness <u>Model structure:</u> Markov Model <u>Cycle length:</u> Monthly <u>Time horizon:</u> 10 Year <u>Perspective:</u> Belgium healthcare system <u>Source of base-line data:</u> Not Stated <u>Source of effectiveness data:</u> Base-line data has been taken from published sources and confirmed by	<u>Base case (population):</u> Patients with resected stage IIc and stage III malignant melanoma. <u>Sample size:</u> Hypothetical Cohort <u>Age (Median):</u> Not Stated <u>Gender:</u> Not stated	1) Follow-up with suspected pulmonary metastases being examined with whole body CT (WB-CT). 2) Follow-up with suspected pulmonary metastases being examined with fluorine-18 fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) with X-Ray computed tomography(CT)	<u>Effectiveness (Life Months):</u> <u>Basecase:</u> PET-CT WB-CT <u>Undiscounted effects:</u> PET-CT WB-CT <u>Total costs:</u> <u>Basecase:</u> PET-CT WB-CT <u>ICER (cost per Life Month):</u> <u>Basecase:</u> PET-CT versus WB-CT <u>Undiscounted effects:</u> PET-CT versus WB-CT	90.61 90.42 97.15 96.93 \$3 438 \$4 384 Dominant Dominant	<u>Funding:</u> <u>Comments</u> Derivation of clinical inputs unclear. Demographics of group not reported.

expert opinion. Detailed explanation of choosing and use of the clinical inputs has not been presented.

The probability of developing pulmonary metastasis was derived from data from the Duke Comprehensive Cancer Centre as large US database.

Source of utility data:

N/A

Source of cost data:

Unit costs were taken from the public prices of RIZIV/INAMI as published by the Health Insurance institute Belgium. As video assisted thoracoscopy was not priced the surgery cost was based on stapled wedge resection, lobectomy, segmentectomy or pneumectomy.

Resource use was taken from standardised administrative databases of 19 hospitals between 2005 and 2006.

Currency unit:

Euro(€)

Cost year:

2009

Discounting:

Costs:3.5% per Annum

LMG:1.5% per Annum

Uncertainty:

Probabilistic Sensitivity Analysis:

PET-CT was dominant in 71.0% of iterations and dominated in 22.6% of iterations versus WB-CT

7.2 Brain Imaging

Review question: In patients with melanoma who are undergoing body imaging as part of follow-up and who have no neurological signs or symptoms, should brain imaging be included?

Background

Patients with node positive or metastatic body disease are at risk of additional metastases within the brain. The probability of a patient having brain metastases increases with increasing stage of disease. A patient with large volume metastatic disease within the chest, abdomen and pelvis is at greater risk of having occult brain metastatic disease compared to a patient who has one involved node. Some centres will routinely image the brain when completing body CT whilst others do not. Detecting asymptomatic metastatic brain disease may facilitate earlier treatment either with radiotherapy or chemotherapy. Questions to consider include:

1. What is the probability of having brain metastases when imaging the body?
2. What threshold / probability do we choose when deciding to image the brain?
3. Is the threshold that triggers body imaging the same threshold we should use to trigger brain imaging?
4. Is there an effective treatment for brain metastases that can delay the onset of symptoms and / or improve survival in asymptomatic patients?

Question in PICO format

Patients/population	Intervention	Comparison	Outcomes
Asymptomatic Patients who have undergone treatment for melanoma with curative intent, undergoing imaging for follow up..	Imaging for brain metastasis in addition to chest, abdo, pelvis.	chest, abdo, pelvis and no imaging for brain metastasis	Survival (Lead time bias may be an issue here that is difficult to quantify.) Identification of malignant brain metastases HRQL

How the information will be searched

Searches:	
Can we apply date limits to the search	The GDG did not feel that it was appropriate to apply date limits to the searches
Are there any study design filters to be used (RCT, systematic review, diagnostic test).	The GDG felt that randomised trials would be the most important study type to answer this question however they were aware that it was unlikely that such a trial existed and therefore considered it inappropriate to apply and study design filters to the searches.
List useful search terms.	None provided

1 The review strategy

What data will we extract and how will we analyse the results?	<p>Relevant studies will be identified through sifting the abstracts and excluding studies clearly not relevant to the PICO. In the case of relevant or potentially relevant studies, the full paper will be ordered and reviewed, whereupon studies considered to be not relevant to the topic will be excluded.</p> <p>Studies which are identified as relevant will be critically appraised and quality assessed using GRADE methodology and/or NICE checklists. Data relating to the identified outcomes will be extracted from relevant studies.</p> <p>If possible a meta-analysis of available study data will be carried out to provide a more complete picture of the evidence body as a whole.</p> <p>An evidence summary outlining key issues such as volume, applicability and quality of evidence and presenting the key findings from the evidence as it relates to the topic of interest will be produced.</p>
List subgroups here and planned statistical analyses.	Nothing to add

2 Search Results

- 3 Two searches were performed for L2, one with follow up terms and one with imaging terms, to best
 4 retrieve possible relevant references for the asymptomatic population.
 5 The results of Topics L2 were combined into one Reference Manager database due to the high
 6 duplication of results between the searches.

7 Follow-up

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	1946-2013	106	25	20/11/2013
<i>Premedline</i>	19 Nov 2013	4	0	20/11/2013
<i>Embase</i>	1947-2013	163	27	20/11/2013
<i>Cochrane Library</i>	Issue 11 of November 2013	47	2	20/11/2013
<i>Web of Science (SCI & SSCI)</i>	1900-2013	107	15	20/11/2013

1 **Imaging**

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	1946-2013	115	27	26/11/2013
<i>Premedline</i>	25 Nov 2013	7	1	26/11/2013
<i>Embase</i>	1947-2013	200	33	26/11/2013
<i>Cochrane Library</i>	Issue 11 of November 2013	47	2	26/11/2013
<i>Web of Science (SCI & SSCI)</i>	1900-2013	165	15	26/11/2013

2 Total References retrieved (after de-duplication): 53

3 **Update Search**

4 For the update search, the same search criteria/filters were applied as initial search

5 **Topic L1 and L2 Follow up**

Database name	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	4	1	08/10/2014
<i>Premedline</i>	3	1	08/10/2014
<i>Embase</i>	22	1	08/10/2014
<i>Cochrane Library</i>	2	0	08/10/2014
<i>Web of Science (SCI & SSCI)</i>	42	1	08/10/2014
Total References retrieved (after de-duplication): 3			

6 **Topic L1 and L2 Imaging**

Database name	No of references found	No of references retrieved	Finish date of search
<i>Medline</i>	4	1	08/10/2014
<i>Premedline</i>	3	1	08/10/2014
<i>Embase</i>	32	0	08/10/2014
<i>Cochrane Library</i>	2	0	08/10/2014
<i>Web of Science (SCI & SSCI)</i>	21	1	08/10/2014
Total References retrieved (after de-duplication): 3			

7 **Medline search strategy (Follow-up)**

8 1. exp Melanoma/

9 2. melanoma\$.tw.

10 3. (maligna\$ adj1 lentigo\$).tw.


11 4. (hutchinson\$ adj1 (freckle\$ or melano\$)).tw.

- 1 5. dubreuilh.tw.
- 2 6. LMM.tw.
- 3 7. or/1-6
- 4 8. (asymptom* or symptomless or no symptoms or no symptom or clinically silent).tw.
- 5 9. ((absence or absent or without) adj1 (sign*1 or symptom*)).tw.
- 6 10. Asymptomatic Diseases/
- 7 11. or/8-10
- 8 12. 7 and 11
- 9 13. (follow-up or "follow up" or followup).tw.
- 10 14. (check-up*1 or check up*1).tw.
- 11 15. surveillance.tw.
- 12 16. exp Aftercare/
- 13 17. (aftercare or after-care).tw.
- 14 18. ((post-treatment or posttreatment) adj1 evaluation*).tw.
- 15 19. ((post-treatment or posttreatment) adj1 care).tw.
- 16 20. ((post-treatment or posttreatment) adj1 monitoring).tw.
- 17 21. ((post-treatment or posttreatment) adj1 surveillance).tw.
- 18 22. or/13-21
- 19 23. 12 and 22

20 **Medline search strategy (Imaging)**

- 21 1. exp Melanoma/
- 22 2. melanoma\$.tw.
- 23 3. (maligna\$ adj1 lentigo\$).tw.
- 24 4. (hutchinson\$ adj1 (freckle\$ or melano\$)).tw.
- 25 5. dubreuilh.tw.
- 26 6. LMM.tw.
- 27 7. or/1-6
- 28 8. (asymptom* or symptomless or no symptoms or no symptom or clinically silent).tw.
- 29 9. ((absence or absent or without) adj2 (sign*1 or symptom*)).tw.
- 30 10. Asymptomatic Diseases/
- 31 11. or/8-10
- 32 12. 7 and 11
- 33 13. exp Magnetic Resonance Imaging/
- 34 14. "magnetic resonance imaging".tw.
- 35 15. (MRI or MR*2 or NMR*1 or MP-MR* or MPMR*).tw.
- 36 16. ((magnet* or mr*) adj (imaging or exam* or scan* or spectroscop*)).tw.
- 37 17. diagnostic imaging/
- 38 18. exp TOMOGRAPHY, X-RAY COMPUTED/
- 39 19. "comput* tomograph*".tw.
- 40 20. (comput* adj (axial or assisted) adj tomograph*).tw.
- 41 21. ((ct or cat) adj scan*).tw.
- 42 22. exp TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON/
- 43 23. spect.tw.
- 44 24. "single photon emission computed tomography".tw.
- 45 25. exp Tomography, Emission-Computed/
- 46 26. (PET or PET-CT).tw.
- 47 27. or/13-26
- 48 28. 12 and 27

1 **Screening Results**



Reasons for Exclusion

- Did not include brain imaging
- Treatment Comparisons not relevant to PICO
- Population not relevant to PICO

Quality of the included studies

- Systematic review of RCTs (n=0)
- Systematic review of combined study designs (n=0)
- Randomized controlled trial (n=0)
- Prospective cross sectional study (n=0)
- Case Series Studies (n=0)
- Qualitative Study (n=0)

2
3

4 **Evidence Statements**

5 None of the studies identified for this topic included brain imaging as part of the follow-up
6 protocols for asymptomatic patients.

7

References

Excluded Studies

- Abbott, R. A., et al (2011) The role of positron emission tomography with computed tomography in the follow-up of asymptomatic cutaneous malignant melanoma patients with a high risk of disease recurrence. *Melanoma Research* 21;5:446-449.
- Abbott, R. and Harries, M.(2009) Positron-emission tomography with computed tomography (PET/CT) in melanoma follow-up. *British Journal of Dermatology Conference*[var.pagings].
Reason: Abstract Only
- Baker, J. J. M.(2011) Routine restaging PET/CT and detection of recurrence in sentinel lymph node positive stage III melanoma. *Annals of Surgical Oncology Conference*[var.pagings]
Reason: Abstract Only
- Beasley, G. M., et al (2012). A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma. *Annals of Surgery* 256;2:350-356.
- Buzaid, A. C. T. (1995) Role of computed tomography in the staging of patients with local-regional metastases of melanoma. *Journal of Clinical Oncology* 13;8:2104-2108.
Reason: No brain metastases data
- Cromwell, K. D., et al (2012) Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review. *Melanoma Research* 22;5:376-385
Reason: No useable data
- Danielsen, M., (2013) Positron emission tomography in the follow-up of cutaneous malignant melanoma patients: a systematic review. [Review]. *American Journal of Nuclear Medicine and Molecular Imaging* 4;1:17-28.
Reason: Narrative Review
- DeRose, E. R., et al (2011) Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanoma. *Melanoma Research* 21;4:364-369.
Reason: No brain metastases data
- Francken, A. B., et al (2007) Detection of first relapse in cutaneous melanoma patients: Implications for the formulation of evidence-based follow-up guidelines. *Annals of Surgical Oncology* 14;6:1924-1933.
Reason: No brain metastases data
- Garbe C. et al (2003) Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy *Journal of Clinical Oncology* 21;3:520-529
- Hofmann, U., et al (2002) Primary staging and follow-up in melanoma patients--monocenter evaluation of methods, costs and patient survival. *British Journal of Cancer* 87;2:151-157
- Kuvshinoff, B. W., Kurtz, C., and Coit, D. G.(1997) Computed tomography in evaluation of patients with stage III melanoma. *Annals of Surgical Oncology* 4;3:252-258.
Reason: No brain metastases data

- 1 Koskivuo, I. O., et al (2007) Whole body positron emission tomography in follow-up of high risk
2 melanoma. *Acta Oncologica* 46;5:685-690.
- 3 Kottschade, L. A. S.(2009) Positron emission tomography in early detection of relapse in high-risk
4 melanoma patients: A retrospective review. *Community Oncology* 6;8:344-347.
- 5 Leiter U. et al (2012) Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of
6 33,384 patients in the German Central Malignant Melanoma Registry *Journal of the American*
7 *Academy of Dermatology* 66:37-45
- 8 Meyers, M. O., et al (2009) Method of detection of initial recurrence of stage II/III cutaneous
9 melanoma: analysis of the utility of follow-up staging. *Annals of Surgical Oncology* 16;4:941-
10 947. Murchie et al Miranda, E. P., et al (2004) Routine imaging of asymptomatic melanoma patients
11 with metastasis to sentinel lymph nodes rarely identifies systemic disease. *Archives of Surgery*
12 139;8:831-836.
- 13 Reason: Not a follow-up population
- 14 Mooney, M. M., et al (1997) Life-long screening of patients with intermediate-thickness cutaneous
15 melanoma for asymptomatic pulmonary recurrences: a cost-effectiveness analysis. *Cancer*
16 80;6:1052-1064.
- 17 Reason: No brain metastases data
- 18 Mooney, M. M., (1998) Impact on survival by method of recurrence detection in stage I and II
19 cutaneous melanoma. *Annals of Surgical Oncology* 5;1:54-63.
- 20 Morton, R. L., Craig, J. C., and Thompson, J. F. (2009) The role of surveillance chest X-rays in the
21 follow-up of high-risk melanoma patients. *Annals of Surgical Oncology* 16;3:571-577
- 22 Murchie et al (2010) Patient satisfaction with GP-led melanoma follow-up: a randomised controlled
23 trial *British Journal of Cancer* 102;1447-1455
- 24 Orfaniotis, G., et al (2012) Findings of computed tomography in stage IIB and IIC melanoma: a six-
25 year retrospective study in the South-East of Scotland. *Journal of Plastic, Reconstructive and*
26 *Aesthetic Surgery* 65;9:1216-1219.
- 27 Reason: Comparison not relevant to PICO
- 28 Panagiotou, I. E. B. (2001) Evaluation of imaging studies at the initial staging and during follow-up of
29 patients with local-regional malignant melanoma. *Journal of B U.ON* 64:411-414.
- 30 Reason: No useable data
- 31 Poo-Hwu, W. J., Ariyan, S., Lamb, L., Papac, R., Zelterman, D., Hu, G. L., Brown, J., Fischer, D.,
32 Bologna, J., and Buzaid, A. C. Follow-up recommendations for patients with American Joint
33 Committee on Cancer Stages I-III malignant melanoma. *Cancer* 86[11], 2252-2258. 1-12-1999.
- 34 Rinne, D., Baum, R. P., Hor, G., and Kaufmann, R.(1998) Primary staging and follow-up of high risk
35 melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results
36 of a prospective study of 100 patients. *Cancer* 82;9:1664-1671
- 37 Romano E. Et al (2010) Site and timing of first relapse in stage III melanoma patients: implications for
38 follow-up guidelines *Journal of Clinical Oncology* 28:3042-3047

- 1 Rueth, N. M., et al (2013) Is Surveillance Imaging Effective for Detecting Surgically Treatable
- 2 Recurrences in Patients With Melanoma? A Comparative Analysis of Stage-Specific Surveillance
- 3 Strategies. *Annals of Surgery* [Oct 3], epub ahead of print.

- 4 Romano, E. and Scordo, M. (2009) Characteristics of first relapse in stage III melanoma patients with
- 5 no evidence of disease (NED): Guidelines for follow-up. *Journal of Clinical Oncology*
- 6 Conference[var.pagings], 9069.
- 7 Reason: No brain metastases data

- 8 Tsao, H., et al (2004) Early detection of asymptomatic pulmonary melanoma metastases by routine
- 9 chest radiographs is not associated with improved survival. *Archives of Dermatology* 140;1:67-70.
- 10 Reason: No brain metastases dataWeiss, M., et al (1995) Utility of follow-up tests for detecting
- 11 recurrent disease in patients with malignant melanomas. *JAMA* 274:21;1703-1705.
- 12 Reason: No useable data

- 13

Review question: Where imaging is indicated, is CT or MRI the most appropriate method of imaging for brain metastasis as part of follow-up for asymptomatic patients?

Background

Both MRI and CT can be used to image the brain. Both techniques are readily available in most hospitals. Body staging is routinely completed with CT and in selected patients PET-CT. Imaging the brain using CT during the CT body examination is more convenient to the patient. In addition this would be quicker and cheaper as compared to completing body imaging and a separate MRI brain study. An additional brain MRI may result in two separate hospital visits for the patient. MRI is however more accurate in detecting and characterizing brain pathology.

Question in PICO format

Patients/population	Intervention	Comparison	Outcomes
Asymptomatic Patients who have undergone treatment for melanoma with curative intent, undergoing imaging for follow up.	CT for brain imaging	MRI for brain imaging	Identification of brain metastases HRQL Survival Number of metastases

How the information will be searched

Searches:	
Can we apply date limits to the search	The GDG did not feel that it was appropriate to apply date limits to the searches
Are there any study design filters to be used (RCT, systematic review, diagnostic test).	The GDG felt that randomised trials would be the most important study type to answer this question however they were aware that it was unlikely that such a trial existed and therefore considered it inappropriate to apply and study design filters to the searches.
List useful search terms.	None provided

1 The review strategy

What data will we extract and how will we analyse the results?	<p>Relevant studies will be identified through sifting the abstracts and excluding studies clearly not relevant to the PICO. In the case of relevant or potentially relevant studies, the full paper will be ordered and reviewed, whereupon studies considered to be not relevant to the topic will be excluded.</p> <p>Studies which are identified as relevant will be critically appraised and quality assessed using GRADE methodology and/or NICE checklists. Data relating to the identified outcomes will be extracted from relevant studies.</p> <p>If possible a meta-analysis of available study data will be carried out to provide a more complete picture of the evidence body as a whole.</p> <p>An evidence summary outlining key issues such as volume, applicability and quality of evidence and presenting the key findings from the evidence as it relates to the topic of interest will be produced.</p>
List subgroups here and planned statistical analyses.	Nothing to add

2 Search Results

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
Medline	1946-2013	13	7	27/11/2013
Premedline	26 Nov 2013	1	0	27/11/2013
Cochrane Library	Issue 11 of November 2013	0	0	27/11/2013
Embase	1947-2013	33	11	27/11/2013
Web of Science (SCI & SSCI)	1900-2013	35	3	27/11/2013
Total References retrieved (after de-duplication): 10				


Database name	No of references found	No of references retrieved	Finish date of search
Medline	0	0	08/10/2014
Premedline	0	0	08/10/2014
Embase	7	0	08/10/2014
Cochrane Library	2	0	08/10/2014
Web of Science (SCI & SSCI)	18	0	08/10/2014
Total References retrieved (after de-duplication): 0			

1 **Medline search strategy** (*This search strategy is adapted to each database*)

- 2 1. exp Melanoma/
- 3 2. melanoma\$.tw.
- 4 3. (maligna\$ adj1 lentigo\$).tw.
- 5 4. (hutchinson\$ adj1 (freckle\$ or melano\$)).tw.
- 6 5. dubreuilh.tw.
- 7 6. LMM.tw.
- 8 7. or/1-6
- 9 8. (asymptom* or symptomless or no symptoms or no symptom or clinically silent).tw.
- 10 9. ((absence or absent or without) adj2 (sign*1 or symptom*)).tw.
- 11 10. Asymptomatic Diseases/
- 12 11. or/8-10
- 13 12. 7 and 11
- 14 13. exp Neoplasm Metastasis/
- 15 14. exp central nervous system neoplasms/
- 16 15. exp Brain/
- 17 16. 14 or 15
- 18 17. 13 and 16
- 19 18. ((brain or cereb* or intracranial or meninge* or central nervous system) adj3 (metastas* or
- 20 spread or involvement or carcinosis)).tw.
- 21 19. 17 or 18
- 22 20. exp Magnetic Resonance Imaging/
- 23 21. "magnetic resonance imaging".tw.
- 24 22. (MRI or MR*2 or NMR*1 or MP-MR* or MPMR*).tw.
- 25 23. ((magnet* or mr*) adj (imaging or exam* or scan* or spectroscop*)).tw.
- 26 24. diagnostic imaging/
- 27 25. exp TOMOGRAPHY, X-RAY COMPUTED/
- 28 26. "comput* tomograph*".tw.
- 29 27. (comput* adj (axial or assisted) adj tomograph*).tw.
- 30 28. ((ct or cat) adj scan*).tw.
- 31 29. exp TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON/

30. spect.tw.
31. "single photon emission computed tomography".tw.
32. exp Tomography, Emission-Computed/
33. (PET or PET-CT).tw.
32. or/18-31
34. 12 and 19 and 32

Screening Results



Reasons for Exclusion

No Comparators
Treatment Comparisons not relevant to PICO
Population not relevant to PICO

Quality of the included studies

Systematic review of RCTs (n=0)
Systematic review of combined study designs (n=0)
Randomized controlled trial (n=0)
Prospective cross sectional study (n=0)
Case Series Studies (n=0)
Qualitative Study (n=0)

Evidence Statements

No evidence was identified comparing CT scans to MRI scans for the identification of brain metastases in asymptomatic patients treated for melanoma.

References

Excluded

Holtas, S., Cronqvist, S., Holtas, S., and Cronqvist, S. (1981) Cranial computed tomography of patients with malignant melanoma. *Neuroradiology* 22:3;123-127.

Reason: No Comparator

Weisberg, L. A.(1985) Computerized tomographic findings in intracranial metastatic malignant melanoma. *Computerized Radiology* 9:6;365-372.

Reason: No Comparator

Merimsky, O., et al (1992) Cerebral metastatic melanoma: correlation between clinical and CT findings. *Melanoma Research* 2:5-6;385-391.

Reason: No Comparator

Reider-Groswasser, I., et al (1996). Computed tomography features of cerebral spread of malignant melanoma. *American Journal of Clinical Oncology* 19:1;49-53.

Reason: Not relevant to PICO

Schlamann, M., et al (2008). [Cerebral MRI in neurological asymptomatic patients with malignant melanoma]. [German]. *Rofo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin* 180:2;143-147.

Reason: No comparator/Foreign Language

Zukauskaitė, R., et al (2013) Asymptomatic brain metastases in patients with cutaneous metastatic malignant melanoma. *Melanoma Research* 23;1:21-26.

Reason: No comparison

Buzaid, A. C., et al (1995) Role of computed tomography in the staging of patients with local-regional metastases of melanoma. *Journal of Clinical Oncology* 13;8:2104-2108.

Reason: Population not relevant to PICO

Miranda, E. P., et al (2004) Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease. *Archives of Surgery* 139;8:831-836.

Reason: Population not relevant to PICO

Fogarty, G. B., Tartaguia, C., Fogarty, G. B., and Tartaguia, C. (2006) The utility of magnetic resonance imaging in the detection of brain metastases in the staging of cutaneous melanoma. *Clinical Oncology (Royal College of Radiologists)* 18;4:360-362.

Reason: Not follow-up patients/No comparator

Noor, R. (2010). Frequency of radiologically confirmed brain metastasis from time of diagnosis of stage IV disease in patients with melanoma. *Journal of Clinical Oncology Conference*[var.pagings].

Reason: Abstract Only

8. Other management issues during follow-up

8.1 Managing suboptimal vitamin D levels

Review question: How should sub-optimal vitamin D levels be managed in people with melanoma (including supplements and monitoring)?

Background

The relationship between Vitamin D, sun exposure, cancer and malignant melanoma is complicated and not well understood. What we do know is that normal vitamin D levels are needed to ensure good healthy bones and that Vitamin D can be made in the body in response to exposure to sunshine. We also know that often, when patients are diagnosed with melanoma, they will be given advice to avoid excess sunshine because people worry about a link between exposure to the sun and the development of skin cancer. What is also confusing is that there seem to be some studies that suggest that low levels of Vitamin D are associated with melanomas that don't have such a good outlook and are more likely to cause problems. So we need to find out whether we should be measuring Vitamin D levels in patients with melanoma when they are first diagnosed and, if the results are low, whether we should be offering patients vitamin D supplements or not. This whole problem is made even more complicated by the fact that we are not really sure what the best levels of Vitamin D are, the amount of sunshine that is needed to ensure the right amount of vitamin D is made in the body and how best to give Vitamin D supplements to people who are short of this vitamin.

Question in PICO Format

Population	Intervention	Comparator	Outcomes
Patients with melanoma & deficient or insufficient levels of vitamin D: Vitamin 25-Hydroxy Vitamin D ₂ D ₃ levels	<ul style="list-style-type: none"> Vitamin D supplements Vitamin D level supplements & monitoring Vitamin D level monitoring Dietary intervention Lifestyle advice ((including sun exposure advice at specific times of the day e.g. early morning / late afternoon: see Genomel & BAD websites) 	<ul style="list-style-type: none"> No supplements No monitoring Sun avoidance advice 	<ol style="list-style-type: none"> Overall Survival Evidence of impaired bone health Cardiovascular disease?

How will the information be searched?

Searches:	
Can we apply date limits to the search (<i>Please provide information on any date limits we can apply to the searches for this topic. This can be done for each individual intervention as appropriate</i>)	No date limits to be applied to the searches

Are there any study design filters to be used (<i>RCT, systematic review, diagnostic test</i>).	<p>Any study type but preferably</p> <ul style="list-style-type: none"> • Meta-analysis vitamin D supplementation trials • Systematic review vitamin D and bone health • Systematic review vitamin D and cancer survival <p>Systematic reviews metabolic syndrome or cardiovascular disease</p>
List useful search terms. (<i>This can include such information as any alternative names for the interventions etc</i>)	<p>Vitamin D</p> <p>Definition of vitamin D insufficiency/deficiency</p> <p>Vitamin D levels and skin type (levels reported to be lower in white people with skin which burns rather than white people who do not burn i.e. people at risk of melanoma (with fair skin)</p> <p>25 hydroxyvitamin D₂/D₃</p>

1

2 The Review Strategy

3 Relevant studies will be identified through sifting the abstracts and excluding studies clearly not
4 relevant to the PICO. In the case of relevant or potentially relevant studies, the full paper will be
5 ordered and reviewed, whereupon studies considered to be not relevant to the topic will be
6 excluded.

7 Studies which are identified as relevant will be critically appraised and quality assessed using GRADE
8 methodology and NICE checklists. Data relating to the identified outcomes will be extracted from
9 relevant studies.

10 If possible a meta-analysis of available study data will be carried out to provide a more complete
11 picture of the evidence body as a whole.

12 An evidence summary outlining key issues such as volume, applicability and quality of evidence and
13 presenting the key findings from the evidence as it relates to the topic of interest will be produced.

14 Search Results

Database name	Dates Covered	No of references found	No of references retrieved	Finish date of search
Medline	1946-2013	224	74	03/12/2013
Premedline		24	13	03/12/2013
Embase	1947-2013	518	184	04/12/2013
Cochrane Library	Issue 6 of 12 June 2013 (all	64	6	02/12/2013

	years)			
Web of Science (SCI & SSCI)	1900-2013	529	166	06/12/2013
Total References retrieved (after de-duplication): 281				

1 Update Search


- 2 For the update search, the same search criteria/filters were applied as initial search with a date limit
- 3 of December 2013 onwards.

Database name	No of references found	No of references retrieved	Finish date of search
Medline	26	10	15/10/2014
Premedline	6	2	15/10/2014
Embase	91	19	15/10/2014
Cochrane Library	1	0	15/10/2014
Web of Science (SCI & SSCI)	95	10	15/10/2014
1 reference found in Pubmed 15/10/2014			
Total References retrieved (after de-duplication): 12			

4 Medline search strategy (*This search strategy is adapted to each database*)

- 5 1. exp Melanoma/
- 6 2. melanoma*.tw.
- 7 3. (maligna* adj1 lentigo*).tw.
- 8 4. (Hutchinson* adj1 (freckle* or melano*)).tw.
- 9 5. dubreuilh.tw.
- 10 6. LMM.tw.
- 11 7. or/1-6
- 12 8. Vitamin D/
- 13 9. vitamin d.tw.
- 14 10. (Calciol or Cholecalciferol* or Hydroxycholecalciferol* or Hydroxyvitamins D or Hydroxyvitamin D
- 15 or Calcidiol or 25-Hydroxyvitamin D3 or 25 Hydroxyvitamin D3 or 25-Hydroxycholecalciferol or 25
- 16 Hydroxycholecalciferol or Hidroferol or Calcifediol or Calderol or Dedrogyl or Dihydroxyvitamin D or
- 17 Dihydroxycholecalciferol or Bocatriol or Calcitriol or Calcijex or Decostriol or MC1288 or MC-1288 or
- 18 MC 1288 or Osteotriol or Renatriol or Rocaltrol or Silkis or Sitriol or Soltriol or Tirocal or 25-
- 19 dihydroxy-20-epi-Vitamin D3 or Calciferol* or Ergocalciferol* or Hydroxyvitamin D2 or Ercalcidiol* or
- 20 Hydroxyergocalciferol or Dihydrotachysterin or Tachystin or Calcamine or Deparal or Ricketon or
- 21 Trivitan or Vigorsan or Diaverene or Hydroxycalcidiol or Secalciferol* or Dihydroxycholecalciferol or
- 22 Delakmin or Calcidiol*).tw.
- 23 11. or/8-10
- 24 12. 7 and 11
- 25

1 **Screening Results**



Reasons for Exclusion

- Expert Reviews
- Abstract Only
- No Comparators
- Treatment Comparisons not relevant to PICO
- Population not relevant to PICO

Quality of the included studies

- Systematic review of RCTs (n=0)
- Systematic review of combined study designs (n=1)
- Randomized controlled trial (n=0)
- Prospective cross sectional study (n=0)
- Case Series Studies (n=6)
- Qualitative Study (n=0)

2

3

4 The evidence relating to the management of vitamin D levels in melanoma patients consisted of one
5 systematic review (Gandini et al 2008) and a number of cohort studies and case-control studies
6 (Rosso et al, 2007; Nurnberg et al, 2009; Newton-Bishop et al, 2009; Gandini et al, 2013; Davies et al,
7 2011; Idorn et al, 2011). .

Table 8.1: Characteristics of included studies

Study	Study Type	Population	Aim	Intervention	Comparison	Outcomes
Rosso et al (2007)	Cohort study (Retrospective analysis of a Case-Control Study)	Cases = 260 Controls = 416	To investigate survival in a cohort of melanoma patients with detailed information on sun exposure and other risk factors	Interviews using a questionnaire which included socio-demographic variables including age at diagnosis, sex, level of education and occupation, host factors including pigmentation and skin reaction to sun exposure and sun exposure history.		Not clearly stated though appears to be survival
Gandini et al (2008)	Systematic Review and Meta-analysis	N=6 studies (721 cutaneous melanoma cases, 4084 non-melanoma skin cancer)	To investigate whether Fokl and BsmI, 25(OH)D serum levels and intake of vitamin D impact skin cancer risk.	Vitamin D intake Estimates using Vitamin D intake in food were chosen over intake from supplementation. Estimates in the individual studies were adjusted for age, hair colour and family history of cutaneous melanoma (Wienstock, 1992) and for age, sex, dysplastic nevi, education and skin type (Millen, 2004).		Dose-response effect of vitamin D intake on melanoma risk
Nurnberg et al (2009)	Case-Control Study	Cases=205 patients with histologically proven cutaneous melanoma Controls=141 (71 volunteers visiting the Dept of Dermatology;	To evaluate the possible association of a direct measure of vitamin D status, serum vitamin D levels and an indirect measure of vitamin D status (UV-exposure) on the incidence and	Self-administered questionnaire		Not clearly stated (association of vitamin D levels with a number of factors as outlined in the aim of the study)

Study	Study Type	Population	Aim	Intervention	Comparison	Outcomes
		70 patients of the Dept of Orthopaedic Surgery)	clinical outcome of melanoma patients.			
Newton-Bishop et al (2009)	Retrospective Pilot Study Prospective Cohort Study	Retrospective Pilot Study: N=271 patients with melanoma Relapsers=131 Non-relapsers=169	To test the findings from a retrospective pilot study that vitamin D may protect against melanoma recurrence	Patient reported questionnaire collecting data on regular use of vitamins, minerals, fish oils, fibre or other food supplements 1 year prior to interview).		Risk of relapse
		Prospective Cohort Study: n=872 patients with stage I-IIIa melanoma		Relapse/Survival data collected via annual patient questionnaire, cancer registry and clinical notes. Patient reported height and weight used to calculate BMI. Serum 25(OH)D levels measured		
Davies et al (2011)	Case-Control Study	Cases=960 Controls=513	Not clearly stated but seems to be to investigate the effect of a number of factors including supplementation, sun	Questionnaire and telephone interview collecting data on sun exposure including: Weekday exposure and weekend exposure in sunny and in colder weather Holiday sun exposure at low and higher latitudes		Predictors of blood vitamin D concentrations

Study	Study Type	Population	Aim	Intervention	Comparison	Outcomes
			exposure and sunscreen use on blood vitamin D concentrations.			
Idorn et al (2011)	Descriptive Case-Control Study	Cases=42 Controls=26	To assess changes in UVR exposure in patients with cutaneous melanoma using objective surrogate parameters	Interviews about sun exposure behaviour		Changes in UV exposure in patients with cutaneous melanoma according to time of diagnosis.
Gandini et al (2013)	Cohort Study (2 groups, i retrospective , 1 prospectivee)	N=742	To investigate if different indicators of UV exposure, collected before and after diagnosis are associated with Breslow Thickness and recurrence	Self administered questionnaire at initial diagnosis	Self administered questionnaire during follow-up Median time from diagnosis to questionnaire: 2.6 years (1-6 years interquartile range)	Melanoma Recurrence

Study Quality

All studies included in the review were cohort studies or case-control studies and one systematic review and meta-analysis of case-control studies. There was a high degree of heterogeneity between the studies in relation to the methodology, populations and outcomes and none of the studies could be considered to directly report on the comparisons of interest in the PICO and the outcomes reported were not those listed in the PICO

Inconsistency could not be assessed as the degree of heterogeneity across the individual studies means that it would not be appropriate to make any direct comparisons between the results of individual studies.

Many of the studies considered the potential effect of confounders when conducting the analysis and adjusted for a range of potential confounders however the list of potential confounders was varied across the individual studies. It is possible that a dose-response relationship might exist between vitamin D levels and melanoma risk however the evidence is too poor and limited to upgrade the quality of evidence on this basis.

Many of the studies relied on self-reporting of data through the use of questionnaires and therefore there is a high risk of recall bias. Many of the studies also reported their outcomes based on the whole population in the study rather than separately by cases and controls.

Evidence Statements

One very low quality case-control study reported that patients who had serum vitamin levels <10ng/ml had earlier distant disease compared with patients serum levels >20ng/ml though the difference was not statistically significant (24.37 months versus 29.47; $p=0.641$) (Nurnberg et al. 2009).

Moderate quality evidence from a prospective cohort study including 872 patients, reported that, after adjusting for age, sex, Townsend score, tumour site, Breslow thickness and BMI on multivariate analysis, higher serum vitamin D levels showed a protective effect for relapse free survival (HR=0.79, 95% CI 0.64-0.96) and overall survival (HR=0.83, 95% CI 0.68-1.02) per 20nmol/L increase in serum vitamin D levels (Newton-Bishop et al, 2009).

Moderate quality evidence from one prospective cohort study indicates uncertainty over whether Vitamin D supplementation affects relapse free survival (HR=0.81, 95% CI 0.56-1.17) or overall survival (HR=0.71; 95% CI 0.47-1.09) (Newton-Bishop et al, 2009) .

Moderate quality evidence from one prospective cohort study reported no evidence of a harmful effect of high serum levels of vitamin D with no adverse events observed at the highest levels of vitamin D (Newton-Bishop et al, 2009).

Moderate quality evidence from one prospective cohort study reported that inheritance of the BsmI A allele was associated with a poorer outcome from melanoma in patients with low vitamin D levels but not in those with high vitamin D levels (p for interaction=0.02) (Newton-Bishop et al, 2009).

Moderate quality evidence from a systematic review and meta-analysis indicates a possible protective effect for cutaneous melanoma when comparing the highest versus lowest intake of vitamin D supplements (Summary relative risk 0.63; 95% CI 0.42-0.94) (Gandini et al, 2008).

GRADE Table 8.1 How should sub-optimal levels of vitamin D be managed in patients with melanoma

Quality assessment							Quality
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	
Distant Disease (Nurnberg et al. 2009).							
1	observational studies	serious ¹	No serious inconsistency	no serious indirectness	no serious imprecision	none	VERY LOW
Relapse Free Survival (Newton-Bishop et al, 2009)							
1	observational studies	serious ¹	No serious inconsistency	no serious indirectness	no serious imprecision	none	MODERATE
Adverse Events (Newton-Bishop et al (2009)							
1	observational studies	serious ¹	No serious inconsistency	no serious indirectness	no serious imprecision	none	MODERATE

¹ All studies were retrospective reviews

Evidence Summary

Vitamin D and 25(OH)D serum levels in melanoma patients

In a hospital based case-control study evaluating the possible association of a direct measure of vitamin D status, serum vitamin D levels and an indirect measure of vitamin D status (UV-exposure) on the incidence and clinical outcome of melanoma patients., both groups showed a high level of vitamin D deficiency (defined as serum 25(OH)D levels <20ng/ml) with 78.1% of melanoma patients and 63.1% of controls deficient. Median 25(OH)d serum levels were not significantly different in melanoma patients as compared with controls (14.3 ng/ml versus 15.6 ng/ml p=0.44 (Nurnberg et al, 2009).

In melanoma patients specifically, younger patients had a significantly higher median serum 25(OH)D level compared with the older population (p=0.053) (Nurnberg et al, 2009).

The study found no statistically significant associations when 25(OH)D levels were compared with respect to age, gender or body mass index (Nurnberg et al, 2009).

In a prospective cohort study investigating whether vitamin D may protect against melanoma recurrence (Newton-Bishop et al, 2009), serum vitamin D levels varied with season and, taking 60nmol/L as optimal, the majority of patients had suboptimal levels (64%). Serum vitamin D levels were also found to be lower in younger patients (p<0.001; adjusted for sex, month of venipuncture and BMI)

Reported vitamin D supplementation was associated with higher serum vitamin D levels while increased Breslow thickness was associated with lower serum vitamin D levels (adjusted for age, sex, body mass index and month sampled).

	Mean serum vitamin D levels	95% CI	P value
BMI			
<24.9	54 nmol/L	51-56 nmol/L	<0.005
24.9-29.9	55 nmol/L	53-57 nmol/L	
>29.9	48 nmol/L	24.9-29.9 nmol/L	
Reported Vitamin D Supplementation			
Supplementation	60 nmol/L	57-63 nmol/L	0.001
No Supplementation	50 nmol/L	48-52 nmol/L	
Breslow Thickness (mm)			
<0.75	55.8 nmol/L	52.5-59.0 nmol/L	0.002
0.75-1	54.9 nmol/L	52.0-57.8 nmol/L	

1-2	53.7 nmol/L	51.3-56.2nmol/L	
2-3	51.6 nmol/L	47.8-55.4nmol/L	
>3	48.5 nmol/L	44.8-52. nmol/L	

Table 8.2: Mean Serum Vitamin D levels in melanoma patients (data from Newton-Bishop et al, 2009)

5(OH)D serum levels and solar UV-exposure

25(OH)D serum levels were significantly associated with sun-exposure; patients with infrequent sun exposure in the previous two years had lower levels compared with those who had more frequent exposure (Nurnberg et al, 2009).

In a UK population based case control study investigating the effect of a number of factors including supplementation, sun exposure and sunscreen use on blood vitamin D concentrations. (Davies et al, 2011), vitamin D level was found to vary by season with higher mean levels vitamin recorded during the summer months.

For most comparisons under investigation, little difference was observed between cases and control with the strongest association seen between vitamin D levels overall and holiday exposure at low latitudes (adjusted mean levels increased by 9.1 units between the lowest and highest group of exposure) (Davies et al, 2011).

A strong association was observed between vitamin D levels and average weekend exposure in recent warmer months, with weaker correlations with daily exposure and average holiday exposure. Individuals with greater sun sensitivity had lower overall vitamin D levels and increased freckling on the shoulders (surrogate for greater habitual sun exposure in the fair skinned) was associated with higher levels. There was a strong positive association between freckling and higher reported levels of sun exposure (Davies et al, 2011).

Use of low protection sun screen compared with no sunscreen was associated with higher levels of serum vitamin D in the total dataset (adjusted estimate 5.72, p=0.002) though no effect of high SPF sunscreen use was observed.

In the total dataset (cases and controls) the LOESS curve increased to a plateau of just under 60nmol/L in individuals reporting an average of 5hours per day of weekend sun exposure for non-sensitive phenotypes. A lower plateau was reached for individuals reporting an average of 6 hours per day of weekend sun exposure. In melanoma cases not taking supplements the 60 nmol/L plateau was reached after 6hour average exposure in those with non-sensitive phenotypes but was not reached at all in sun-sensitive individuals.

The 60nmol/L plateau was reached in those taking vitamin D supplements irrespective of sun exposure (Davies et al, 2011).

In participants reporting more than 5hours in the sun at weekends, there was a mean difference of 14.7nmol/L in levels for participants who were homozygous for the variant allele in the gene coding for the vitamin D binding protein (rs2282679) (Davies et al, 2011).

In a case-control study assessing changes in UVR exposure in patients with cutaneous melanoma using objective surrogate parameters (Idorn et al, 2011), recently diagnosed patients had significantly higher winter serum vitamin D compared with controls ($p=0.02$, $R^2=0.60$) and patients diagnosed within the past year ($p=0.01$) indicating higher UVR exposure dose the summer before melanoma diagnosis.

Serum vitamin D was significantly lower in recently diagnosed patients compared with controls ($p=0.005$, $R^2=0.51$) and patients diagnosed in the past ($p=0.008$) indicating a lower UVR exposure in the first summer following diagnosis while no difference between the groups in summer serum vitamin D levels (Idorn et al 2011).

Idorn et al (2011) reported that prior to diagnosis of cutaneous melanoma, recently diagnosed patients used sunscreen more often than patients diagnosed in the past ($p<0.04$) and controls ($p=0.02$, $R^2=0.81$).

A significant group variance was observed in solarium use between the 3 groups ($p=0.05$) with a higher percentage of recently diagnosed patients reporting the use of a solarium.

Gardening was reportedly more frequent in patients diagnosed in the past ($p=0.008$) and this group also reported more days of gardening than the rest of the participants ($p=0.002$) (Idorn et al, 2011).

Idorn et al (2011) reported a significant group variance in the severity and frequency of sunburn after diagnosis; patients diagnosed in the past reported only mild sunburn ($p=0.04$) and fewer episodes of sunburn ($p=0.03$) than the rest of the participants.

Recently diagnosed patients used a significantly higher sun protection factor ($p=0.002$, $R^2=0.83$) and had significantly more days using sunscreen ($p=0.02$, $R^2=0.66$) than did controls.

25(OH)D serum levels in stage I versus stage IV melanoma

Patients with stage I melanoma had significantly higher serum 25(OH)D levels when compared with patients with stage IV melanoma ($p=0.006$) (Nurnberg et al, 2009).

Tumour thickness in primary cutaneous melanoma

Patients with serum 25(OH)D levels $<10\text{ng/ml}$ had thicker primary cutaneous melanomas compared with patients with serum levels $>20\text{ng/ml}$ (2.55mm versus 1.5mm; $p=0.078$) (Nurnberg et al, 2009).

In a cohort study investigating if different indicators of UV exposure, collected before and after diagnosis are associated with Breslow Thickness and recurrence Gandini et al (2013) reported that ulcerated cutaneous melanoma and cutaneous melanoma diagnosis during the summer were more common in those without holidays. Breslow categories were associated with holidays, the proportion of thick melanomas ($>4\text{mm}$) was significantly lower in patients having holidays compared with no holidays (8% versus 20%, p for trend 0.002).

A significant negative association between very thick melanomas and number of weeks of holidays (p for trend 0.001) was observed and after adjustment for confounding factors (age, gender, education, grade of clinician at visit, history of NMSC and season at diagnosis) there was significant association between holidays before diagnosis and lower Breslow thickness ($p=0.003$) (Gandini et al, 2011).

Sun exposure during peak hours, history of NMSC, sun bed use, cutaneous melanoma body site, skin type, and season of diagnosis were not found to be significantly associated with Breslow thickness while holidays were significantly associated with Breslow thickness in a dose-response manner ($p=0.007$) (Gandini et al, 2013).

Gandini et al (2013) reported a significant interaction between the effect of holidays: women had a significantly lower Breslow thickness if they had a history of holidays ($p=0.004$) whereas for men this protective effect was not significant ($p=0.88$).

Melanoma Recurrence

In a cohort study investigating if different indicators of UV exposure, collected before and after diagnosis are associated with Breslow Thickness and recurrence Gandini et al (2013) reported a median follow-up of 44 months (range 1-72) for group 1 and 40 months (range 2-75) for group 2. Overall, 6% of patients had a melanoma recurrence and 5% had a second primary cancer. Holiday before diagnosis was not associated with risk of recurrence ($HR=4.19$, 95% CI 0.53-33.36, $p=0.18$).

For holidays during follow-up the 5-year cumulative incidence of melanoma recurrences was 8% for those having holidays after diagnosis compared to 17% for those without ($HR=0.30$, 95% CI 0.10-0.87).

A dose response relationship was observed between the risk of melanoma recurrence and number of weeks of holidays: the hazards ratio for up to 2 weeks of holidays compared with no holidays was 0.74 (95% CI 0.16-3.45) and for more than 2 weeks of holidays compared with no holidays was 0.28 (95% CI 0.08-0.98) (Gandini et al, 2013).

Distant metastatic disease

Patients who had serum levels $<10\text{ng/ml}$ had earlier distant disease compared with patients serum levels $>20\text{ng/ml}$ (24.37 months versus 29.47; $p=0.641$) (Nurnberg et al, 2009).

Season of diagnosis and clinical outcome

In patients diagnosed in the summer the median time between primary excision and lymphogenous metastasis was 13.7 months compared to 1.2 months in patients diagnosed in autumn ($p=0.486$) (Nurnberg et al, 2009).

For distant metastasis in patients diagnosed in autumn median time between primary excision and distant metastasis was 14.2 months compared with 31.7 months for patients diagnosed in the summer ($p=0.057$) (Nurnberg et al, 2009).

	Median serum 25(OH)D level	P value
Age		
14-34 years	16.95ng/ml	0.053
>65 years	14.3 ng/ml	

	Median serum 25(OH)D level	P value
Sun Exposure in previous 2 years		
<50 days	8.16ng/ml	0.001
>150	25.90ng/ml	
Disease Stage		
Stage Ia/b	16.40ng/ml	0.006
Stage IV	13.10ng/ml	

Table 8.3: Median Serum Vitamin D levels (reported in Nurnberg et al, 2009)

Vitamin D Intake from food and/or supplementation

From one systematic review and meta-analysis, summary relative risk indicates a possible protective effect for cutaneous melanoma when comparing the highest versus lowest intake (0.92; 95% CI 0.25-3.44) however the I^2 of 71 indicates high heterogeneity. Taking out the oldest study removed the heterogeneity and the summary relative risk shows a significant positive effect (0.63; 95% CI 0.42-0.94). Dose response estimates suggested a protective effect of cutaneous melanoma when excluding the oldest study and inclusion of non-melanoma skin cancer in the analysis did not show any indication of an association with vitamin D intake (Gandini et al, 2008).

In a retrospective pilot study, median time from diagnosis to relapse was 6.6 years (range 3.1-28.1 years) and for non-relapsers was 7.4 years (range, 3.2-31.7 years) and 38% of relapsers and 47% of non-relapsers reported using any supplements before relapse (OR=0.7; 95% CI 0.4-1.2) (Newton-Bishop et al 2009).

31% of relapsers and 38% of non-relapsers reported regular use intake of vitamin D in the year prior to interview (OR=0.6; 95% CI, 0.4-1.1; p=0.09). Serum vitamin D levels were significantly higher in patients reporting the use of vitamin D supplements (mean 54 nmol/L; 95% CI, 51-58 nmol/L) compared with those not taking supplements (mean, 43 nmol/L; 95% CI, 40-47 nmol/L) but no significant difference was observed in serum vitamin D levels between relapsers and non-relapsers (p=0.3) (Newton-Bishop et al 2009).

In a UK population based case control study investigating the effect of a number of factors including supplementation, sun exposure and sunscreen use on blood vitamin D concentrations. (Davies et al, 2011), participants who were homozygous for the variant allele in the gene coding for the vitamin D binding protein (rs2282679) had lower mean seasonally adjusted serum vitamin D levels when compared with wild type (on average 11.8nmol/L lower). Stratification of the data by exposures, genotype appeared to be most strongly associated with supplementation; wild type participants who were supplementing had serum vitamin D levels 18.8nmol/L higher than homozygous participants on average.

In a prospective cohort study investigating whether vitamin D may protect against melanoma recurrence (Newton-Bishop et al, 2009), univariate analysis suggested that increases of 20nmol/L in

- 1 serum vitamin D levels were associated with a reduced risk of relapse (HR=0.75; 95% CI, 0.64-0.90)
 2 and overall survival (HR=0.80; 95% CI 0.68-0.96) across all seasons. After adjusting for age, sex,
 3 Townsend score, tumour site, Breslow thickness and BMI on multivariate analysis, higher serum
 4 vitamin D levels showed a protective effect for relapse free survival (HR=0.79, 95% CI 0.64-0.96) and
 5 overall survival (HR=0.83, 95% CI 0.68-1.02) per 2020nmol/L increase in serum vitamin D levels.

25 hydroxyvitamin D₃ level (Per 20nmol/L increase)				
	Relapse from melanoma		Overall Death	
	Hazard Ratio	95% CI	Hazard Ratio	95% CI
January – March	0.72	0.56-0.96	0.72	0.54-0.96
April-June	0.85	0.67-1.08	0.80	0.62-1.06
July-September	0.77	0.63-0.96	0.85	0.70-1.04
October-December	0.77	0.60-0.98	0.82	0.64-1.04

- 6 On univariate analysis, Vitamin D supplementation showed no significant effect on relapse free
 7 survival (HR=0.81, 95% CI 0.56-1.17) or on overall survival (HR=0.71; 95% CI 0.47-1.09) and there was
 8 no evidence of an effect of VDR genotype on outcome (Newton-Bishop et al, 2009).
- 9 There was no evidence of a harmful effect of high serum levels of vitamin D and no adverse events
 10 were observed at the highest levels of vitamin D.
- 11

References

Included

- Rosso, S., Sera, F., Segnan, N., and Zanetti, R. (2008) Sun exposure prior to diagnosis is associated with improved survival in melanoma patients: Results from a long-term follow-up study of Italian patients. *European Journal of Cancer* 44;9:1275-1281.
- Gandini, S., et al (2009). Vitamin D and skin cancer: a meta-analysis. [Review] [52 refs]. *European Journal of Cancer* 45;4:634-641.
- Newton Bishop, J. A., et al (2009) Serum vitamin D levels, VDR, and survival from melanoma. *Journal of Clinical Oncology* 27;15 SUPPL. 1:9016.
- Nurnberg, B., et al (2009) Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients. *Anticancer Research* 29;9:3669-3674.
- Davies, J. R., et al (2011) The determinants of serum vitamin D levels in participants in a melanoma case-control study living in a temperate climate. *Cancer Causes & Control* 22;0:1471-1482.
- Idorn, L. W., Philipsen, P. A., and Wulf, H. C. (2011) Sun exposure before and after a diagnosis of cutaneous malignant melanoma: estimated by developments in serum vitamin D, skin pigmentation and interviews. *British Journal of Dermatology* 165;1:164-170.
- Gandini, S., et al (2013) Sunny Holidays before and after Melanoma Diagnosis Are Respectively Associated with Lower Breslow Thickness and Lower Relapse Rates in Italy. *PLoS ONE* [Electronic Resource] 8;11:e78820.
- Excluded*
- Afzal, S., Nordestgaard, B. G., and Bojesen, S. E. (2013) Plasma 25-hydroxyvitamin D and risk of non-melanoma and melanoma skin cancer: a prospective cohort study. *Journal of Investigative Dermatology* 133;3:629-636.
Reason: Population not relevant to PICO
- Bade, B., et al (2012). Low serum 25-hydroxyvitamin D concentrations are associated with increased risk for melanoma and unfavourable prognosis. *Experimental Dermatology* 21;3:e15.
Reason: Abstract Only
- Boniol, M., Armstrong, B. K., and Dore, J. F. (2006) Variation in incidence and fatality of melanoma by season of diagnosis in New South Wales, Australia. *Cancer Epidemiology Biomarkers & Prevention* 15;3:524-528.
Reason: Outcomes not relevant to PICO
- Buttiglieri, C., et al (2011) Prognostic role of vitamin d status and efficacy of vitamin D supplementation in cancer patients: a systematic review. [Review]. *The Oncologist* 16;9:1215-1227
Reason: Only included in melanoma study which was picked up and reviewed independently
- Caini, S., et al (2014). Vitamin D and melanoma and non-melanoma skin cancer risk and prognosis: A comprehensive review and meta-analysis. *European Journal of Cancer* 50;15:2649-2658
Reason: No useable data

- 1 Cornwell, M. L., et al (1992) Prediagnostic serum levels of 1,25-dihydroxyvitamin D and malignant
2 melanoma. *Photodermatology, Photoimmunology & Photomedicine* 9;3:109-112.
3 Reason: Not relevant to PICO
- 4 Delong, L., et al (2010). Vitamin D levels and oral supplementation update in patients with skin
5 cancer. *Journal of Investigative Dermatology* 130;S66.
6 Reason: Abstract Only
- 7 Denzer, N., Vogt, T., and Reichrath, J. (2011) Vitamin D receptor (VDR) polymorphisms and skin
8 cancer: A systematic review. *Dermato-endocrinology* 3;3:205-210.
9 Reason: Narrative Review
- 10 El, Hayderi L., et al (2011). Seasonal variations in vitamin D levels in melanoma patients: A single-
11 center prospective pilot comparative study. *Melanoma Research* 21;e14-e15.
12 Reason: Abstract Only
- 13 Failla, V., et al (2012) Seasonal variations in vitamin D levels in melanoma patients: a single-centre
14 prospective pilot comparative study. *Journal of the European Academy of Dermatology &*
15 *Venereology* 26;5:651-653.
16 Reason: Comparison not relevant to PICO
- 17 Field, S., et al (2013) Do vitamin A serum levels moderate outcome or the protective effect of
18 vitamin D on outcome from malignant melanoma? *Clinical Nutrition* 32;6:1012-1016.
19 Reason: Not relevant to PICO
- 20 Field, S., et al (2013). A clinical audit of the effect of targeted advice and vitamin D supplementation
21 on serum vitamin D levels in patients with melanoma. *British Journal of Dermatology* 169; 43.
22 Reason: Abstract Only
- 23 Freedman, D. M., et al (2010) Serum 25-hydroxyvitamin D and cancer mortality in the NHANES III
24 study (1988-2006). *Cancer Research* 70;21:8587-8597.
25 Reason: Population not relevant to PICO
- 26 Gambichler, T., et al (2013) Serum 25-hydroxyvitamin D serum levels in a large German cohort of
27 patients with melanoma. *British Journal of Dermatology* 168;3:625-628.
28 Reason: Not relevant to PICO
- 29 Gandini, S., et al (2013) Could sunny holidays improve melanoma prognosis? *JDDG - Journal of the*
30 *German Society of Dermatology* 11;1.
31 Reason: Abstract Only
- 32 Gandini, S., et al (2009). Why vitamin D for cancer patients? *Ecancermedicalscience* 3;160.
33 Reason: Population not relevant to PICO
- 34 Gupta, D., et al (2011). A. Prevalence of serum vitamin D deficiency and insufficiency in cancer:
35 Review of the epidemiological literature. *Experimental and Therapeutic Medicine* 2;2:181-193.
36 Reason: Not relevant to PICO
- 37 Hill, N., et al (2010) Vitamin D levels and oral supplementation in patients with skin cancer. *Journal*
38 *of the American Academy of Dermatology* 62;3 SUPPL. 1:AB66.
39 Reason: Abstract Only

- 1 Hutchinson, P. E., et al (2010) Higher serum 25-hydroxy vitamin D3 levels at presentation are
2 associated with improved survival from melanoma, but there is no evidence that later prevailing
3 levels are protective. *Journal of Clinical Oncology* 28;27:e492-e493.
4 Reason: Letter
- 5 Kumar, R., et al (2012) The impact of sun protective behavior and vitamin D supplementation on
6 vitamin D level in melanoma patients. *Journal of Clinical Oncology* 30;15 SUPPL. 1
7 Reason: Abstract Only
- 8 Lazzeroni, M., et al (2013). Vitamin D supplementation and cancer: Review of randomized controlled
9 trials. *Anti-Cancer Agents in Medicinal Chemistry* 13;1:118-125.
10 Reason: Population not relevant to PICO
- 11 Mandelcorn-Monson, R et al (2011) Sun exposure, vitamin D receptor polymorphisms FokI and BsmI
12 and risk of multiple primary melanoma. *Cancer Epidemiology* 35;6: e105-e110.
13 Reason: Comparison not relevant to PICO
- 14 Marks, R., et al (1995) The Effect of Regular Sunscreen Use on Vitamin-D Levels in An Australian
15 Population - Results of A Randomized Controlled Trial. *Archives of Dermatology* 131;4:415-421.
16 Reason: Not Melanoma
- 17 MacKie, R. M. (2010) Serum vitamin D levels in melanoma patients in Scotland. *Pigment Cell and*
18 *Melanoma Research* 23;6:894.
19 Reason: Abstract Only
- 20 Major, J. M., et al (2012) Pre-diagnostic circulating vitamin D and risk of melanoma in men. *PLoS ONE*
21 [Electronic Resource] 7;4: e35112.
22 Reason: Not relevant to PICO
- 23 Millen, A. E., et al (2004) Diet and melanoma in a case-control study. *Cancer Epidemiology,*
24 *Biomarkers & Prevention* 13;6:1042-1051.
25 Reason: Included in Systematic Review
- 26 Miller, P. E., et al (2009) Dietary supplement use in adult cancer survivors. *Oncology Nursing Forum*
27 36;1:61-68.
28 Reason: Not relevant to PICO
- 29 Mocellin, S. and Nitti, D (2008). Vitamin D receptor polymorphisms and the risk of cutaneous
30 melanoma: a systematic review and meta-analysis. [Review] [49 refs]. *Cancer* 113;9:2398-2407.
31 Reason: Not relevant to PICO (Population comparisons/outcomes)
- 32 Meyskens, F. L., et al (1988) Randomized phase III trial of high dose vitamin A versus placebo for
33 stage I malignant melanoma [abstract]. *Proceedings of the American Society of Clinical Oncology*
34 7;247
35 Reason: Abstract Only
- 36 Newton-Bishop, J. A., et al (2009) Serum 25-hydroxyvitamin D3 levels are associated with breslow
37 thickness at presentation and survival from melanoma. *Journal of Clinical Oncology* 27;32:5439-
38 5444.
39 Reason: Abstract Only
- 40 Ogbah, Z., et al (2013). Serum 25-hydroxyvitamin D3 levels and vitamin D receptor variants in
41 melanoma patients from the Mediterranean area of Barcelona: 25-hydroxyvitamin D3 levels and

- 1 VDR variants in melanoma patients from Barcelona. *BMC Medical Genetics* 14;1:26.
- 2 Reason: Not relevant to PICO
- 3 Pandit, T., et al (2011) The effect of malignant melanoma on serum 25(OH)vitamin d levels in elderly
- 4 patients. *Journal of the American Geriatrics Society* 59;S55-S56.
- 5 Reason: Abstract Only
- 6 Pilz, S., et al (2013) Vitamin D and cancer mortality: Systematic review of prospective
- 7 epidemiological studies. *Anti-Cancer Agents in Medicinal Chemistry* 13;1:107-117.
- 8 Reason: Narrative Review
- 9 Pongprutthipan, M., Alam, M., and Kim, N. (2012) Comparison of 25-hydroxy vitamin D level in white
- 10 women receiving vitamin D supplementation and not receiving supplementation: A randomized
- 11 controlled trial. *Journal of the American Academy of Dermatology* 66;4 SUPPL. 1:AB174. 2012.
- 12 Reason: Abstract Only
- 13 Reichrath, J., et al (2004) No evidence for reduced 25-hydroxyvitamin D serum level in melanoma
- 14 patients. *Cancer Causes & Control* 15;1:97-98.
- 15 Reason: Letter
- 16 Reichrath, J. (2011) Serum levels of 25(OH)D and VDR polymorphisms in malignant melanoma:
- 17 Results from pilot studies in Homburg. *Anticancer Research* 31;4:1498.
- 18 Reason: Abstract Only
- 19 Reeder, A. I., Jopson, J. A., and Gray, A. R. (2012) "Prescribing sunshine": a national, cross-sectional
- 20 survey of 1,089 New Zealand general practitioners regarding their sun exposure and vitamin D
- 21 perceptions, and advice provided to patients. *BMC Family Practice* 13;85.
- 22 Reason: Not relevant to PICO
- 23 Rhodes, L. E., et al (2010) Recommended Summer Sunlight Exposure Levels Can Produce Sufficient
- 24 (≥ 20 ng ml⁻¹) but Not the Proposed Optimal (≥ 32 ng ml⁻¹) 25(OH)D Levels at UK Latitudes.
- 25 *Journal of Investigative Dermatology* 130;5:1411-1418.
- 26 Reason: Not relevant to PICO
- 27 Suppa, M., et al (2011) Determinants of melanoma risk in a large case-control study: The role of skin
- 28 aging and vitamin D. *Melanoma Research* 21;e6.
- 29 Reason: Abstract
- 30 Tang, J. Y., et al (2011) Calcium plus vitamin D supplementation and the risk of nonmelanoma and
- 31 melanoma skin cancer: post hoc analyses of the women's health initiative randomized controlled
- 32 trial. *Journal of Clinical Oncology* 29;22:3078-3084.
- 33 Reason: Not relevant to PICO
- 34 van der Pols, J. C., et al (2013) Vitamin D status and skin cancer risk independent of time outdoors:
- 35 11-year prospective study in an Australian community. *Journal of Investigative Dermatology* 133;3:
- 36 637-641.
- 37 Reason: Not enough melanoma data
- 38 Weinstock, M. A., et al (1992) Case-control study of melanoma and dietary vitamin D: implications
- 39 for advocacy of sun protection and sunscreen use. *Journal of Investigative Dermatology* 98;5:809-
- 40 811.
- 41 Reason: Population not relevant to PICO

Evidence Tables***Study Quality (Systematic Reviews)***

	Clearly focused Question?	Includes studies relevant to review question?	Rigorous literature search?	Study quality assessed?	Adequate description of methodology?	Quality
Gandini et al (2008)	Yes	Yes	Yes	Unclear	Yes	Moderate

Study Quality (Cohort Studies)

	Appropriate length of follow-up	Precise definition of an outcome	Valid method of measuring outcomes	Investigators blind to participants exposure to intervention?	Investigators blind to potential confounders and prognostic factors?	Quality
Gandini et al (2013)	Unclear	Unclear	Yes	Unclear	Unclear	Low
Newton-Bishop et al (2009)	Yes	Yes	Yes	Unclear	Unclear	Moderate
Rosso et al (2008)	Yes	No	Unclear	No	No	Very Low

Study Quality (case-control studies)

	Clearly focused Question	Comparable populations for cases and Controls?	Same Exclusion Criteria for cases and controls?	Participation Rate for cases and controls	Participants and non-participants compared?	Cases clearly defined and differentiated from controls	Clearly established that cases are not controls	Measures to prevent influence of primary knowledge	Exposure measured in standard, valid method	Confounders identified	Confidence Intervals provided	Quality
Nurnberg et al (2009)	Yes	Unclear	Unclear	Unclear	No	Yes	Yes	Unclear	Yes	No	No	Very Low
Davies et al (2011)	Yes	Unclear	Unclear	Unclear	No	Yes	Yes	Unclear	Unclear	Yes	No (standard error)	Very Low
Idorn et al (2011)	Yes	Unclear	Yes	Cases: 35% (31/89) Controls: 27% (15/56)	No	Yes	Yes	Unclear	Unclear	No	No (qualitative reporting)	Very Low

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
Rosso et al (2007)	Cohort study (Retrospective analysis of a Case-Control Study) Population based (Turin, Italy)	To investigate survival in a cohort of melanoma patients with detailed information on sun exposure and other risk factors	N= 260/305 patients with a histological diagnosis of cutaneous melanoma (Participation Rate: 85%) N=186 female/74 male (recruitment of females extended to allow for investigation of the role of oral contraceptives in melanoma). Mean Age: 56 years (12-92) Follow Up: Median 17 years (1 month – 21 years)	Interviews using a questionnaire which included socio-demographic variables including age at diagnosis, sex, level of education and occupation, host factors including pigmentation and skin reaction to sun exposure and sun exposure history.		Not clearly stated though appears to be survival 3.5% (9) of participants lost to follow-up. No significant differences in baseline characteristics Univariate Analysis <u>No significant associations:</u> Sunscreen Use: HR=0.96 (95% CI, 0.41-1.4) Sunburn in childhood: HR 0.96 (95% CI 0.51-1.8) Lifelong exposure: HR 1.4 (95% CI, 0.79-2.5) Sports: HR 0.64 (95% CI, 0.32-1.3) Hobbies: HR: 0.60 (95% CI, 0.27-1.3) Outdoor Work/chronic sun exposure: HR 1.3 (95% CI, 0.65-2.5)

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
						<p>1-59 weeks spent at the beach (lifetime) versus not visiting the beach: HR 0.41 (95% CI, 0.18-0.90) (decreased risk of death from melanoma)</p> <p>>60 weeks at the beach (lifetime) versus not visiting the beach: HR 0.39 (95% CI, 0.19-0.79; p=0.015) (decreased risk of death from melanoma)</p> <p>Multivariate Analysis</p> <p>Effects of lesion thickness, number of weeks spent lifetime on the beach, age, sex and education.</p>
Nurnberg et al (2009)	Case-Control Study Hospital Based	To evaluate the possible association of a direct measure of	Cases=205 patients with histologically proven cutaneous melanoma	Self-administered questionnaire		Not clearly stated (association of vitamin D levels with a number of factors as outlined in the aim of the study)

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
	(Germany)	vitamin D status, serum vitamin D levels and an indirect measure of vitamin D status (UV-exposure) on the incidence and clinical outcome of melanoma patients.	Controls=141 (71 volunteers visiting the Dept of Dermatology; 70 patients of the Dept of Orthopaedic Surgery)			<p><u><i>Vitamin D and 25(OH)D serum levels in melanoma patients and controls</i></u></p> <p>Both groups showed a high level of vitamin D deficiency (defined as serum 25(OH)D levels <20ng/ml) with 78.1% of melanoma patients and 63.1% of controls deficient.</p> <p>Median 25(OH)d serum levels were not significantly different in melanoma patients as compared with controls (14.3 ng/ml versus 15.6 ng/ml p=0.44).</p> <p>No statistically significant associations were found when 25(OH)D levels were compared with respect to age, gender or body mass index.</p> <p>In melanoma patients younger patients had a significantly higher median serum 25(OH)D level compared with the older population (p=0.053)</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
						<p><u>25(OH)D serum levels and solar UV-exposure</u></p> <p>25(OH)D serum levels were significantly associated with sun-exposure; patients with infrequent sun exposure in the previous two years had lower levels compared with those who had more frequent exposure.</p> <p><u>25(OH)D serum levels in stage I versus stage IV melanoma</u></p> <p>Patients with stage I melanoma had significantly higher serum 25(OH)D levels when compared with patients with stage IV melanoma (p=0.006)</p> <p><u>Tumour thickness in primary cutaneous melanoma</u></p> <p>Patients with serum 25(OH)D levels <10ng/ml had thicker primary cutaneous melanomas compared with patients with serum levels >20ng/ml (2.55mm versus 1.5mm; p=0.078).</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
						<p><u>Distant metastatic disease</u></p> <p>Patients who had serum levels <10ng/ml had earlier distant disease compared with patients serum levels >20ng/ml (24.37 months versus 29.47; p=0.641)</p> <p><u>Season of diagnosis and clinical outcome</u></p> <p>In patients diagnosed in the summer the median time between primary excision and lymphogenous metastasis was 13.7 months compared to 1.2 months in patients diagnosed in autumn (p=0.486).</p> <p>For distant metastasis in patients diagnosed in autumn median time between primary excision and distant metastasis was 14.2 months compared with 31.7 months for patients diagnosed in the summer (p=0.057)</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
Newton-Bishop et al (2009)	Retrospective Pilot Study	To test the findings from a retrospective pilot study that vitamin D may protect against melanoma recurrence	Retrospective Pilot Study: N=271 patients with melanoma	Patient reported questionnaire collecting data on regular use of vitamins, minerals, fish oils, fibre or other food supplements 1 year prior to interview).		Measured serum vitamin D use
	Prospective Cohort Study		Relapsers=131 Non-relapsers=169			<p>Measured serum vitamin D use was higher in patients reporting vitamin D supplementation compared with not taking vitamin D supplements:</p> <p>Mean: 54nmol/L (95% CI 51-58nmol/L) vs. 43nmol/L (95% CI 40-47nmol/L); p=0.0001)</p> <p>Non-relapsers had higher serum vitamin D levels compared with non-relapsers:</p> <p>Mean: 49nmol/L (95% CI 45-52nmol/L) vs. 46nmol/L (95% CI 41-50nmol/L); p=0.3</p>
	Population based (Northern England)		Prospective Cohort Study: n=872 patients with stage I-IIIa melanoma	<p>Relapse/Survival data collected via annual patient questionnaire, cancer registry and clinical notes.</p> <p>Patient reported height and weight used to calculate BMI.</p> <p>Serum 25(OH)D levels measured</p>		<p>Risk of relapse</p> <p>Univariate Analysis</p> <p>Increases of 20nmol/L in serum vitamin D levels were associated with a reduced risk of relapse and better overall survival consistently across seasons:</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
						<p>Relapse Free Survival: HR=0.75 (95% CI, 0.64-0.90)</p> <p>Overall Survival: HR=0.80 (95% CI, 0.68-0.96)</p> <p>Reported vitamin D supplementation showed no statistically significant effect on outcome:</p> <p>Relapse Free Survival: HR=0.81 (95% CI 0.56-1.17)</p> <p>Overall Survival: HR=0.71 (95% CI 0.47-1.09)</p> <p>Multivariate Analysis</p> <p>Adjustment for age, sex, townsend score, tumour site, breslow thickness, and BMI</p> <p>Relapse free survival: HR=0.79 (95% CI, 0.64-0.96)</p> <p>Overall Survival: HR=0.83 (95% CI, 0.68-1.02)</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
Gandini et al (2013)	Cohort Study (2 groups, i retrospective, 1 prospective) Hospital based (Milan, Italy)	To investigate if different indicators of UV exposure, collected before and after diagnosis are associated with Breslow Thickness and recurrence	N=742 patients with cutaneous melanoma, two cohorts of patients with no overlap Group at diagnosis N=289 Group during follow-up N=402 Median age at diagnosis: 47 years (IQR: 37-60) Thick Melanoma (Breslow >1mm): 55% (n=378)	Self administered questionnaire at initial diagnosis	Self administered questionnaire during follow-up Median time from diagnosis to questionnaire: 2.6 years (1-6 years interquartile range)	Melanoma Recurrence Ulcerated melanoma and melanoma diagnosis during summer months were more frequent in those without holidays Breslow categories were associated with holidays: The proportion of thick melanomas was significantly lower among patients having holidays versus patients not having holidays 8% versus 2%; p for trend=0.002). Very thick melanomas were negatively associated with number of weeks of holiday in a dose-response manner (no sunny holiday, 1-2 weeks per year and >2 weeks per year) p for trend = 0.001) <u>Melanoma Recurrence</u>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
						<p>Median follow-up was 44 months (range 1-72) for group 1 and 40 months (range 2-75) for group 2. Overall, 6% of patients had a melanoma recurrence and 5% had a second primary cancer.</p> <p>Holiday before diagnosis was not associated with risk of recurrence (HR=4.19, 95% CI 0.53-33.36, p=0.18)</p> <p>For holidays during follow-up the 5-year cumulative incidence of melanoma recurrences was 8% for those having holidays after diagnosis compared to 17% for those without (HR=0.30, 95% CI 0.10-0.87).</p> <p>A dose response relationship was observed between the risk of melanoma recurrence and number of weeks of holidays: the hazards ratio for up to 2 weeks of holidays compared with no holidays was 0.74 (95% CI 0.16-3.45) and for more than 2 weeks of holidays compared with no holidays was 0.28 (95% CI 0.08-0.98).</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
Gandini et al (2008)	Systematic Review and Meta-analysis	<p>To investigate whether Fokl and BsmI, 25(OH)D serum levels and intake of vitamin D impact skin cancer risk (only vitamin D intake is relevant to the current topic).</p> <p><u>Data abstraction included:</u></p> <p>Study characteristics (year of publication, study design, location, exclusion of subjects among controls and adjustments for confounders)</p> <p>Exposure evaluation (laboratory methods to detect</p>	<p>N=721 (from 3 studies including patients with cutaneous melanoma)</p> <p>Weinstock et al (1992): Hospital based case-control study – 165 cases</p> <p>Millen et al (2004): hospital based case-control study – 497 cases</p> <p>Vincenti et al(2005): Population based case-control study – 59 cases</p>	<p>Vitamin D intake</p> <p>Estimates using Vitamin D intake in food were chosen over intake from supplementation.</p> <p>Estimates in the individual studies were adjusted for age, hair colour and family history of cutaneous melanoma (Weinstock, 1992) and for age, sex, dysplastic nevi, education and skin type (Millen, 2004).</p>		<p>Dose-response effect of vitamin D intake on melanoma risk</p> <p>Vitamin D intake highest versus lowest levels</p> <p><u>Individual study estimates:</u></p> <p>Weinstock et al (1992) RR: 1.80 (0.90-3.50)</p> <p>Millen et al (2004) RR 0.61 (0.40-0.95)</p> <p>Vincenti et al (2005) RR 0.76 (0.23-2.50)</p> <p><u>Pooled Estimates</u></p> <p>RR 0.92 (0.25-.044), p=0.03; I²=71</p> <p>RR 0.63 (0.42-0.94); p=0.73, I²=0 (Excluding Weinstock)</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
		<p>VDR polymorphisms, dietary assessment method used for vitamin D intake, time of evaluation with respect to diagnosis, values of vitamin D intake, supplementation used).</p> <p>Study Population (number & sources of cases and controls, sub-type of cases, history of familial melanoma or other cancers, gender, race)</p> <p>VDR estimates (number of cases and controls genotypes for specific polymorphisms, case and control genotype)</p>				

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
		frequency, reported RR's with 95% CI) Vitamin D intake (number of cases and controls for each category of vitamin D intake and reported RR' with 95% CI)				
Davies et al (2011)	Case-Control Study	Not clearly stated but seems to be to investigate the effect of a number of factors including supplementation, sun exposure and sunscreen use on blood vitamin D concentrations.	Cases=960 patients diagnosed with melanoma	Questionnaire and telephone interview collecting data on sun exposure including: Weekday exposure and weekend exposure in sunny and in colder weather Holiday sun exposure at low and higher latitudes		Predictors of blood vitamin D concentrations <u><i>Vitamin D levels and Sun Exposure</i></u> The strongest association was seen between vitamin D levels overall and holiday exposure at low latitudes (adjusted mean levels increased by 9.1 units between the lowest and highest group of exposure). Strong association between vitamin D levels and average weekend exposure in recent warmer months, with weaker correlations with daily exposure and average holiday exposure.
	Population based (UK) Recruitment was within 3-6 months of melanoma diagnosis were possible.		Controls=513 (same sex, 5 year age group recruited through the family doctor of the cases and siblings of cases)			

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
						<p>Individuals with greater sun sensitivity had lower overall vitamin D levels and increased freckling on the shoulders (surrogate for greater habitual sun exposure in the fair skinned) was associated with higher levels. There was a strong positive association between freckling and higher reported levels of sun exposure.</p> <p>Use of low protection sun screen compared with no sunscreen was associated with higher levels of serum vitamin D in the total dataset (adjusted estimate 5.72, $p=0.002$) though no effect of high SPF sunscreen use was observed.</p> <p>In the total dataset (cases and controls) the LOESS curve increased to a plateau of just under 60nmol/L in individuals reporting an average of 5 hours per day of weekend sun exposure for non-sensitive phenotypes. A lower plateau was reached for individuals reporting an average of 6 hours per day of weekend sun exposure.</p> <p>In melanoma cases not taking supplements the</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
						<p>60 nmol/L plateau was reached after 6hour average exposure in those with non-sensitive phenotypes but was not reached at all in sun-sensitive individuals.</p> <p>The 60nmol/L plateau was reached in those taking vitamin D supplements irrespective of sun exposure.</p> <p>Serum vitamin D levels were an estimated 5.79 units lower in participants (total dataset) carrying 1 copy of rs2282679 ($p<0.0001$) and 10.8 units lower in participants carrying two copies of the minor allele ($p<0.0001$) when compared with homozygotes for the common allele.</p> <p>Participants who were homozygous for the variant allele in the gene coding for the vitamin D binding protein (rs2282679) had lower mean seasonally adjusted serum vitamin D levels when compared with wild type (on average 11.8nmol/L lower). Stratification of the data by exposures, genotype appeared to me most strongly associated with supplementation; wild type</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
						<p>participants who were supplementing had serum vitamin D levels 18.8nmol/L higher than homozygous participants on average.</p> <p>In participants reporting more than 5hours in the sun at weekends, there was a mean difference of 14.7nmol/L in levels for homozygotes.</p>
Idorn et al (2011)	Descriptive Case-Control Study	To assess changes in UVR exposure in patients with cutaneous melanoma using objective surrogate parameters	Cases=42	Interviews about sun exposure behaviour		<p>Changes in UV exposure in patients with cutaneous melanoma according to time of diagnosis.</p> <p><u>Interview 1: Sun exposure before diagnosis</u></p> <p>Prior to diagnosis of cutaneous melanoma, recently diagnosed patients used sunscreen more often than patients diagnosed in the past ($p<0.04$) and controls ($p=0.02$, $R^2=0.81$)</p> <p>A significant group variance was observed in solarium use between the 3 groups ($p=0.05$) with a higher percentage of recently diagnosed patients reporting the use of a solarium.</p> <p><u>Interview 2: Sun exposure after diagnosis</u></p>
			Controls=26			

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
						<p>Gardening was more frequent in patients diagnosed in the past ($p=0.008$) and this group also reported more days of gardening than the rest of the participants ($p=0.002$).</p> <p>No significant group variance was observed when comparing recently diagnosed patients with each of the two other groups.</p> <p>There was significant group variance in the severity and frequency of sunburn after diagnosis; patients diagnosed in the past reported only mild sunburn ($p=0.04$) and fewer episodes of sunburn ($p=0.03$) than the rest of the participants.</p> <p>No significant group variance was observed when comparing recently diagnosed patients with each of the two other groups.</p> <p>Recently diagnosed patients used a significantly higher sun protection factor ($p=0.002$, $R^2=0.83$) and had significantly more days using sunscreen ($p=0.02$, $R^2=0.66$) than did controls.</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
						<p><u>Serum vitamin D concentrations</u></p> <p>Recently diagnosed patients had significantly higher winter serum vitamin D compared with controls ($p=0.02$, $R^2=0.60$) and patients diagnosed within the past year ($p=0.01$) indicating higher UVR exposure dose the summer before melanoma diagnosis.</p> <p>Serum vitamin D was significantly lower in recently diagnosed patients compared with controls ($p=0.005$, $R^2=0.51$) and patients diagnosed in the past ($p=0.008$) indicating a lower UVR exposure in the first summer following diagnosis.</p> <p>No difference between the groups in summer serum vitamin D levels.</p> <p><u>Pigment Protection Factor</u></p> <p>Recently diagnosed patients were matched to controls according to constitutive skin pigmentation and had almost identical C-PPF whereas patients diagnosed in the past had</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
						<p>significantly lower C-PPF compared with controls ($p=0.03$).</p> <p>Summer F-PPF and F-ΔPPF were lower in recently diagnosed patients compared with controls and patients diagnosed in the past indicating a lower UVR exposure dose the summer after diagnosis.</p> <p><u>Correlations between vitamin D and pigment protection factor</u></p> <p>Summer serum vitamin D and summer F-PPF were positively correlated ($p=0.003$, $R^2=0.19$) when considering all participants.</p> <p>Serum vitamin D and F-ΔPPF were positively correlated ($p=0.04$, $R^2=0.09$)</p> <p>Winter serum vitamin D and winter F-PPF showed no correlation.</p> <p><u>Relation between questions from interview 2 and vitamin D and pigment protection factor</u></p> <p>Higher summer 25(OH)D, Δ25(OH)D, summer F-PPF and F-ΔPPF were related to higher sun</p>

Study	Study Type/Setting	Aim	Population	Intervention	Comparison	Outcomes
						exposure, less use of sunscreen and lower SPF.

8.2 Concurrent Drug Therapies

Review question: What is the most effective approach to the management of risks to patients associated with concurrent drug therapies used to treat other conditions, which may affect the prognosis from melanoma (for example, immunosuppressants, levadopa, metformin, HRT, COCP)?

Background

Melanoma patients may receive a number of drugs as treatment for concurrent medical illnesses. These drugs may have effects which could be harmful in terms of the melanoma or conversely potentially helpful. The use of immune-suppressants for auto-immune disease is important but may be deleterious in terms of survival if patients have also had a melanoma. Non-steroidal anti-inflammatory drugs are associated with improved outcomes from cardiovascular disease and they could also improve survival from cancer theoretically at least as a result of suppression of the grumbling inflammation which is thought to accompany the obesity related chronic inflammation syndrome. In this question we will review the evidence that concurrent exposures may affect melanoma risk. It is likely that there will be more data on risk of new cancers in patients receiving a given drug than data on the likelihood of relapse from melanoma in patients treated with the drug in question. Others have extrapolated from one (risk of new cancers) to the other (risk of recurrence) which is far from perfect but may be all that can be done currently.

Question in PICO Format

Population	Intervention	Comparator	Outcomes
Patients diagnosed with melanoma and are at risk due to concurrent therapies at any time.	Choice of drug to treat concurrent medical problem. <ul style="list-style-type: none"> Duration of treatment (concurrent treatment) Number of Agents (Drug list for immunosuppressant, Levadopa, Metformin, HRT, COCP)	Each other (stopping/reducing dose, changing)	Overall Survival Progression free survival QoL Melanoma specific survival Concurrent disease specific survival

How the information will be searched

Searches:	
Can we apply date limits to the search	The GDG did not feel that it was appropriate to apply any date limits to the searches for this topic
Are there any study design filters to be used (RCT, systematic review, diagnostic test).	
List useful search terms.	Immunosuppressive drugs and Cancer ... and specific drugs e.g. azathioprine or anti TNF

	NSAIDs or aspirin and Cancer Metformin and melanoma Levodopa and melanoma risk Melanoma and parkinsons B blockers and melanoma HRT and melanoma Contraceptive pill and melanoma Some reviews seem to be addressed to specific concurrent diseases e.g. immunosuppression for inflammatory bowel disease e.g. risk of cancer after organ transplant
Notes	Include studies with mixed skin cancer populations (BCC/SCC/Melanoma) if available and either report only melanoma patients if possible or downgrade the quality of the evidence for indirectness Duration of treatment (concurrent treatment) Number of Agents

1 Search Results

2 Literature search details

Database name	Dates Covered	No of references found	Finish date of search
Medline	1946-2013	3580	24/04/2014
Premedline	Apr 23 2014	93	24/04/2014
Embase	1947-2013	8811	28/04/2014
Cochrane Library	Issue 4 of 12 April 2014	83	23/04/2014
Web of Science (SCI & SSCI)	1900-2013	3775	24/04/2014
Total References retrieved (after initial sift and de-duplication): 409			

1 Update Search

- 2 For the update search, the same search criteria/filters were applied as initial search with a date limit
3 of April 2014 onwards.


Database name	No of references found	No of references retrieved	Finish date of search
Medline	79	4	15/10/2014
Premedline	1	0	15/10/2014
Embase	148	4	15/10/2014
Cochrane Library	0	0	15/10/2014
Web of Science (SCI & SSCI)	223	15	15/10/2014
1 reference found in Pubmed 15/10/2014			
Total References retrieved (after de-duplication): 22			

4 Medline search strategy (This search strategy is adapted to each database)

- 5 1. exp Melanoma/
- 6 2. melanoma\$.tw.
- 7 3. (maligna\$ adj1 lentigo\$).tw.
- 8 4. (hutchinson\$ adj1 (freckle\$ or melano\$)).tw.
- 9 5. dubreuilh.tw.
- 10 6. LMM.tw.
- 11 7. or/1-6
- 12 8. (acetylsalicylic acid or aspirin).tw.
- 13 9. Aspirin/
- 14 10. 8 or 9
- 15 11. exp Anti-inflammatory Agents, Non-Steroidal/
- 16 12. (((non?steroidal or non-steroidal) adj (anti?inflammatory or anti-inflammatory or
- 17 antinflammatory)) or NSAID*).tw.
- 18 13. (Aceclofenac or Acemetacin or Celecoxib or Dexibuprofen or Dexketoprofen or Diclofenac or
- 19 Etodolac or Etoricoxib or Fenbufen or Fenoprofen or Flurbiprofen or Ibuprofen or Indometacin or
- 20 Ketoprofen or Mefenamic acid or Meloxicam or Nabumetone or Naproxen or Piroxicam or Sulindac
- 21 or Tenoxicam or Tiaprofenic acid or tolfenamic acid or clotam rapid).tw.
- 22 14. or/11-13
- 23 15. exp Adrenergic beta-Antagonists/
- 24 16. (propranolol or angilol or inderal-la or half-inalderal or inderal or bedranol or progranol or slo-pro
- 25 or acebutolol or sectral or atenolol or tenormin or bisoprolol or cardicor or emcor or carvedilol or
- 26 eucardic or celiprolol or celectol or co-tenidone or tenoret or tenoretic or esmolol or brevilobol or
- 27 labetalol or trandate or metoprolol or betaloc or lopresor or nadolol or corgard or nebivolol or
- 28 nebilet or hypoloc or oxprenolol or trasicor or slow-trasicor or pindolol or visken or sotalol or beta-
- 29 cardone or sotacor or timolol or betim).tw.
- 30 17. (beta adj3 block*).tw.
- 31 18. (b adj3 block*).tw.

- 1 19. (beta adj2 antagonist*).tw.
- 2 20. or/15-19
- 3 21. Contraceptive Agents/
- 4 22. Contraceptive Agents, Female/
- 5 23. exp Contraceptives, Oral/
- 6 24. exp Menstruation-Inducing Agents/
- 7 25. (Loestrin20 or Mercilon or Femodette or Brevinor or Cilest or Eugynon30 or Loestrin30 or
- 8 Microgynon30 or Norimin or Norinyl-1 or Ovranelle or Ovysmen or Yasmin or Femodene or
- 9 Marvelon or Minulet or BiNovum or Logynon or Qlaira or Synphase or Triadene or Tri-Minulet or
- 10 Trinordial or TriNovum or Evra patch or Cerazette or Femulen or Micronor or Microval or Neogest or
- 11 Norgeston or Noriday or Medroxyprogesterone acetate or Depo-provera or Norethisterone enantate
- 12 or Noristerat or Etonogestrel-releasing implant or Implanon or Nexplanon or Mirena).tw.
- 13 26. ((progestogen* or progestin* or progestagen* or estrogen* or oestrogen* or combined) adj3
- 14 contracepti*).tw.
- 15 27. or/21-26
- 16 28. exp Hormone Replacement Therapy/
- 17 29. ((hormon* or oestrogen* or estrogen* or oestradiol or estradiol or progesteron* or progestin or
- 18 progestagen*) and replacement).tw.
- 19 30. hormone substitution.tw.
- 20 31. hrt.tw.
- 21 32. ((hormon* or oestrogen* or estrogen* or oestradiol or estradiol or progesteron* or progestin or
- 22 progestagen*) adj2 (therap* or treatment*)).tw.
- 23 33. or/28-32
- 24 34. exp Immunosuppressive Agents/
- 25 35. (immunosuppressant* or immunosuppressive agent* or immune-suppressant*).tw.
- 26 36. (6-Mercaptopurine or Antilymphocyte serum or Azaserine or Azathioprine or Busulfan or
- 27 Cladribine or Coformycin or Cyclophosphamide or Cyclosporin* or Ciclosporin* or Cytarabine or
- 28 Ellipticine* or Fluorouracil or Gliotoxin or Methotrexate or Muromonab-CD3 or Sirolimus or
- 29 Tacrolimus or Thalidomide or Thioinosine or Triamcinolone Acetonide).tw.
- 30 37. or/34-36
- 31 38. Metformin/
- 32 39. (metformin or glucophage or dimethylbiguanidine or dimethylguanylguanidine).tw.
- 33 40. 38 or 39
- 34 41. Levodopa/
- 35 42. (l 34 dihydroxyphenylalanine or l-dopa or l-34-dihydroxyphenylalanine or arodopa or 3-hydroxy-
- 36 l-tyrosine or l dopa or 3 hydroxy l tyrosine or dopaflex or dopar or levodopa or levopa).tw.
- 37 43. 41 or 42
- 38 44. exp Parkinson Disease/
- 39 45. (parkinson* or parkinson's or hemiparkinson* or hemi-parkinson* or antiparkinson* or anti-
- 40 Parkinson*).tw.
- 41 46. exp Parkinsonian Disorders/
- 42 47. (parkinsonian disorders or parkinsonian syndrome).tw.
- 43 48. paralysis agitan*.tw.
- 44 49. hypokinetic rigid syndrome.tw.
- 45 50. or/44-49
- 46 51. 10 or 14 or 20 or 27 or 33 or 37 or 40 or 43 or 50
- 47 52. 7 and 51
- 48

1 Screening Results



2

3 Evidence Statements

4 Hormone replacement therapy (HRT)

5 Low quality evidence from an observational study of 206 patients with melanoma followed up for a
 6 median of 10.6 years (MacKie and Bray, 2004) suggests a lower overall mortality rate in those
 7 receiving HRT than in those not receiving HRT (mortality rate 1.2% versus 3.3%; HR=0.17, 95% CI
 8 0.05 to 0.62).

9 No evidence was found about the effect of hormone replacement therapy on progression free
 10 survival, quality of life, melanoma specific survival or concurrent disease specific survival in patients
 11 with melanoma.

12 Indirect evidence comes from studies comparing the rates of melanoma in women receiving
 13 hormone therapy to those not receiving such therapy:

- 14 • Low quality evidence from 8 case control and 2 cohort studies including 110113 patients
 15 (Gandini et al, 2011) suggests uncertainty over whether hormone replacement therapy is
 16 associated with an increased risk of melanoma, OR 1.16 (95% CI 0.93 to 1.44).
- 17 • Moderate quality evidence from a randomized trial of hormone replacement therapy (Tang
 18 et al, 2011) suggests uncertainty about the relative rates of melanoma, HR = 0.92 (95% CI
 19 0.61 to 1.37; HRT versus no HRT).
- 20 • The evidence from these studies suggests that, even at the upper limit of the effect
 21 confidence interval, the absolute increase in melanoma risk is likely to be small.

1 Oral contraceptives

2 No evidence was found about the effect of oral contraceptives on outcomes in patients with
3 melanoma.

4 Indirect evidence comes from studies comparing the rates of melanoma in women taking oral
5 contraceptives therapy to those not taking oral contraceptives. Low quality evidence from 4 cohort
6 and 16 case control studies including 301347 women (Gandini et al, 2011) suggests that oral
7 contraceptive use is not associated with an increased risk of melanoma, OR 1.04 (95% CI 0.92 to
8 1.18).

9 β -blockers

10 Low quality evidence comes from three cohort studies (De Giorgi et al, 2013; Livingston et al, 2013;
11 Lemeshow et al, 2011) including 4641 patients with melanoma, 557 of whom had received
12 treatment with β -blockers. Pooling the adjusted hazards ratios suggests better overall survival in
13 those treated with β -blockers (HR = 0.80, 95%CI 0.67 to 0.94). One study (De Giorgi et al, 2013) also
14 reported better disease free survival (defined as the time to melanoma recurrence or death from
15 any cause) in the group taking β -blockers (rate of recurrence or death was 2.5% versus 8%; HR =
16 0.03, 95% CI 0.01 to 0.17).

17 Immunosuppressive therapy

18 No evidence was found about the use of immunosuppressive therapy in transplant patients with
19 melanoma.

20 One systematic review of low quality, retrospective studies reported that transplant recipients had a
21 pooled estimate of 2.4 times (95% CI 2.0-2.9) the risk of melanoma when compared with the general
22 population ($I^2=46\%$, $p=0.04$). Adjusting for type of organ graft and most recent year of transplant in
23 the cohort reduced the I^2 to 0%. (Dahlke et al (2014).

24 Low quality indirect evidence comes from the rates of melanoma in two observational studies
25 including 3686 kidney or heart transplant patients receiving immunosuppressive therapy (Jensen et
26 al, 1999; Bastiaannet et al, 2007). The standardized incidence ratio (SIR) ranged from 1.7 to 3.4
27 suggesting an increased risk of melanoma in this population. The evidence from these studies
28 suggests if 1000 patients were treated for a year with immunosuppressive therapy we would expect
29 one additional melanoma (assuming an incidence rate of 0.5 per 1000 in the untreated population).

30 Metformin for type 2 diabetes

31 No evidence was found about the use of metformin therapy in patients with melanoma and type 2
32 diabetes.

33 Low quality indirect evidence comes from a systematic review of 2 randomised trials of metformin
34 for type 2 diabetes (Franciosi et al 2013), including 6576 patients followed over 4 to 5 years of
35 treatment. There was uncertainty over whether metformin increased or decreased the rate of
36 melanoma compared to other treatments (0.08% versus 0.15%; OR = 0.87, 95%CI 0.36 to 2.66).

Levodopa

No evidence was found about the use of levodopa therapy in patients with melanoma and Parkinson's disease.

Very low quality indirect evidence comes from a screening study of 2106 patients with Parkinson's disease (Bertoni et al, 2010), 1786 of whom had previously been treated with levodopa. There was uncertainty over whether levodopa treatment was associated with an increased or decreased prevalence of melanoma compared to other treatments (4.3% versus 5%; OR = 0.84, 95%CI 0.48 to 1.47).

Methotrexate

No evidence was found about the use of treatments for rheumatoid arthritis in patients with melanoma.

Very low quality indirect evidence comes from an observational study of 459 patients treated with methotrexate (Buchbinder et al, 2008). The SIR for melanoma was 3.0 (95%CI 1.2 to 6.2) suggesting an increased relative risk of melanoma in this group, although the absolute increased risk is likely to be of the order of one additional melanoma per 1000 patient-years of treatment.

Non steroidal anti-inflammatory drugs (NSAIDs)

No evidence was found about the use of NSAIDs in patients with melanoma.

Low quality indirect evidence comes from a meta-analysis of 10 case-control and observational studies, including 6999 patients with melanoma and 490332 controls (Hu et al, 2014). There was no increased risk of melanoma in patients treated with aspirin (RR=0.96, 95%CI 0.89 to 1.03) or with non-aspirin NSAIDs (RR=1.05, 95%CI 0.96 to 1.14).

Very low quality evidence from one case control study (Siiskonen, 2013) including 11318 patients with melanoma and 6786 controls suggest that propionic acid derivative NSAIDs are associated with an increased risk of melanoma (OR=1.33, 95%CI 1.14 to 1.54).

Quinolones

No evidence was found about the use of quinolones in patients with melanoma. Very low quality indirect evidence comes from one case control study (Siiskonen, 2013) including 11318 patients with melanoma and 6786 controls which observed an increased risk of melanoma in people treated with quinolones (OR=1.33, 95%CI 1.01 to 1.76).

GRADE Table8.3 : hormone replacement therapy

Quality assessment							No of patients		Effect		Quality
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Exogenous hormones	No exogenous hormones	Relative (95% CI)	Absolute	
Melanoma											
20	observational studies ¹	no serious risk of bias	no serious inconsistency	serious indirectness	no serious imprecision	none	2548 cases 30922 controls and 7642 patients from cohort studies		OR 1.16 (0.93 to 1.44)	1 more per 1000 (from 0 fewer to 2 more)	VERY LOW
								0.51% ²			
Melanoma (in RCTs of HRT)											
1	855randomized trials	no serious risk of bias	no serious inconsistency	serious indirectness	no serious imprecision ³	none	46/13816 (0.33%)	49/13531 (0.36%)	HR 0.92 (0.61 to 1.37)	0 fewer per 1000 (from 1 fewer to 1 more)	MODERATE
Overall mortality (in melanoma patients) (follow-up median 10.6 years)											
1	observational studies	no serious risk of bias	no serious inconsistency	no serious indirectness	no serious imprecision	none	1/83 (1.2%)	4/123 (3.3%)	HR 0.173 (0.048 to 0.621)	27 fewer per 1000 (from 12 fewer to 31 fewer)	LOW

¹ case-control² Control risk from large UK cohort study included in Gandini et al (2011) (Hannafor, 2007).³ Although the confidence interval for the relative effect is large the difference in the absolute event rate is very small – so the study was not downgraded for imprecision.

GRADE Table 8.4: oral contraceptive use

Quality assessment							No of patients		Effect		Quality
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Oral contraceptives	Control	Relative (95% CI)	Absolute	
Melanoma											
20	observational studies ¹	no serious risk of bias	no serious inconsistency	serious ²	no serious imprecision	none	4171 cases 13644 controls and 283532 women from cohort studies		OR 1.04 (0.92 to 1.18)	0 more per 1000 (from 0 fewer to 1 more)	VERY LOW
								0.51% ³			

¹ case-control and other study designs together² Most of the included women did not have melanoma.³ Rate reported in Hannaford (2007) UK cohort study**GRADE Table 8.5: immunosuppressive therapy in kidney or heart transplant patients**

Quality assessment							No of patients		Effect		Quality
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Immunosuppression	Control	Relative (95% CI)	Absolute	
Melanoma (follow-up 7.3 years)											
2	observational studies	no serious risk of bias	no serious inconsistency	Serious ³	no serious imprecision	none	13/23288 (0.06%) ¹	0.0179% ²	SIR ranged from 1.7 to 3.4	-	LOW
1	Systematic Review ⁴	No serious risk of bias	No serious inconsistency	No serious imprecision	serious						LOW


¹ Rate per person-years (the total number of patients was 3686).² Based on the reported expected rates of melanoma from the included studies (0.00007 to 0.00023 per person-year)³ The included patients did not all have melanoma

⁴This was a systematic review of a number of poor quality retrospective observational studies

GRADE Table 8.6: beta blockers for hypertension

Quality assessment							No of patients		Effect		Quality
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Beta-blockers	No beta-blockers	Relative (95% CI)	Absolute	
Melanoma recurrence or mortality (follow-up median 4.2)											
1	observational studies	Serious ¹	no serious inconsistency	no serious indirectness	serious	none	2/79 (2.5%)	53/662 (8%)	HR 0.03 (0.01 to 0.17)	78 fewer per 1000 (from 66 fewer to 79 fewer)	⚠️⚠️⚠️ VERY LOW
Overall mortality											
3	observational studies	no serious risk of bias	no serious inconsistency	no serious indirectness	no serious imprecision	none	194/557 (34.8%)	1113/4084 (27.3%)	HR 0.80 (0.67 to 0.94)	48 fewer per 1000 (from 14 fewer to 81 fewer)	⚠️⚠️⚠️ LOW

¹ Significant difference in the baseline characteristics of the two groups**GRADE Table 8.7: metformin for type 2 diabetes**

Quality assessment							No of patients		Effect		Quality
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Metformin	Control	Relative (95% CI)	Absolute	
Melanoma (follow-up 4-6 years)											
2	858randomized trials	no serious risk of bias	no serious inconsistency	Serious ²	serious ¹	none	2/2576 (0.78%)	6/4000 (0.15%)	OR 0.87 (0.36 to 2.66)	0 fewer per 1000 (from 1 fewer to 2 more)	 LOW

¹ Low event rate

² This study was not done in melanoma patients

GRADE Table 8.8: methotrexate for rheumatoid arthritis

Quality assessment							No of patients		Effect		Quality
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Methotrexate	Control	Relative (95% CI)	Absolute	
Melanoma (follow-up median 9.3 years)											
1	observational studies	no serious risk of bias	no serious inconsistency	serious indirectness ³	serious ¹	none	7/4145 (0.17%) ²	(0.06%)	SIR 3.0 (1.2 to 6.2)	1 more per 1000 patient-years (0 more to 3 more)	VERY LOW

¹ Low number of events

² There were 4145 person years of follow-up in 459 patients

³ This study was not done in melanoma patients

GRADE Table 8.9: levadopa for Parkinson's disease

Quality assessment							No of patients		Effect		Quality
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Levadopa	Control	Relative (95% CI)	Absolute	
Melanoma											
1	observational studies	no serious risk of bias	no serious inconsistency	serious indirectness ¹	no serious imprecision	none	76/1786 (4.3%)	16/320 (5%)	OR 0.84 (0.48 to 1.47)	8 fewer per 1000 (from 25 fewer to 22 more)	VERY LOW

¹ This study was not done in melanoma patients

GRADE Table 8.10: NSAIDs

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	NSAIDs	Control	Relative (95% CI)	Absolute		
Melanoma (in studies of aspirin)												
8	observational studies ¹	no serious risk of bias	no serious inconsistency	serious ²	no serious imprecision	none	- ³		RR 0.96 (0.89 to 1.03)	-	⊕⊕⊕⊕	VERY LOW
Melanoma (in non-aspirin NSAIDs)												
5	observational studies ¹	no serious risk of bias	no serious inconsistency	serious ²	no serious imprecision	none	- ³		RR 1.05 (0.96 to 1.14)	-	⊕⊕⊕⊕	VERY LOW
Melanoma (in propionic acid derivative (phototoxic) NSAIDs)												
1	observational studies	no serious risk of bias	no serious inconsistency	serious ²	no serious imprecision	none	1318 cases 6786 controls		OR 1.33 (1.14 to 1.54)	-	⊕⊕⊕⊕	VERY LOW

¹ case-control and other study designs together² Most participants in the included studies did not have melanoma.³ Numbers of patients not reported for subgroup analyses

GRADE Table 8.11: quinolones

Quality assessment							No of patients		Effect		Quality
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Quinolones	Control	Relative (95% CI)	Absolute	
Melanoma											
1	observational studies ¹	no serious risk of bias	no serious inconsistency	serious ²	no serious imprecision	none	1318 cases 6786 controls		OR 1.33 (1.01 to 1.76)	-	VERY LOW
								-			

¹ case-control² Not all patients had melanoma in this study

References

Included Studies

- Bastiaannet, E., Homan-van der Heide JJ, Ploeg, R. J., Hoekstra, H. J. No increase of melanoma after kidney transplantation in the northern part of The Netherlands. *Melanoma Research* 17[6], 349-353. 2007.
- Bertoni, John M., Arlette, John Philip, Fernandez, Hubert H., Fitzer-Attas, Cheryl, Frei, Karen, Hassan, Mohamed N., Isaacson, Stuart H., Lew, Mark F., Molho, Eric, Ondo, William G., Phillips, Tania J., Singer, Carlos, Sutton, James P., Wolf, John E Jr, and North American Parkinson's and Melanoma Survey Investigators. Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. *Archives of Neurology* 67[3], 347-352. 2010.
- Buchbinder, R., Barber, M., Heuzenroeder, L., Wluka, A. E., Giles, G., Hall, S., Harkness, A., Lewis, D., Littlejohn, G., Miller, M. H., Ryan, P. F., Jolley, D. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. *Arthritis & Rheumatism* 59[6], 794-799. 15-6-2008.
- Dahlke, E., Murray, C. A., Kitchen, J., and Chan, A. W. Systematic review of melanoma incidence and prognosis in solid organ transplant recipients. *Transplantation Research* 3, 10. 2014.
- De Giorgi, V., Gandini, S., Grazzini, M., Benemei, S., Marchionni, N., & Geppetti, P. (2013). Effect of beta-Blockers and Other Antihypertensive Drugs On the Risk of Melanoma Recurrence and Death. *Mayo Clinic Proceedings*, 88, 1196-1203.
- Franciosi, M., Lucisano, G., Lapice, E., Strippoli, G. F., Pellegrini, F., Nicolucci, A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. *PloS ONE [Electronic Resource]* 8[8], e71583. 2013.
- Gandini, S., Iodice, S., Koomen, E., Di, Pietro A., Sera, F., Caini, S., Gandini, Sara, Iodice, Simona, Koomen, Els, Di Pietro, Alessandra, Sera, Francesco, and Caini, Saverio. Hormonal and reproductive factors in relation to melanoma in women: current review and meta-analysis. [Review]. *European Journal of Cancer* 47[17], 2607-2617. 2011.
- Hu, H., Xie, Y., Yang, G., Jian, C., and Deng, Y. Nonsteroidal anti-inflammatory drug use and the risk of melanoma: a meta-analysis. *European Journal of Cancer Prevention* 23[1], 62-68. 2014.
- Jensen, P., Hansen, S., Moller, B., Leivestad, T., Pfeffer, P., Geiran, O., Fauchald, P., and Simonsen, S. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. *Journal of the American Academy of Dermatology* 40[2 Pt 1], 177-186. 1999.
- Lemeshow, S., Sorensen, H. T., Phillips, G., Yang, E. V., Antonsen, S., Riis, A. H., Lesinski, G. B., Jackson, R., Glaser, R.. beta-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. *Cancer Epidemiology, Biomarkers & Prevention* 20[10], 2273-2279. 2011.
- Livingstone, E., Hollestein, L. M., van Herk-Sukel, M. P., Poll-Franse, L., Nijsten, T., Schadendorf, D., de, Vries E., Livingstone, E., Hollestein, L. M., van Herk-Sukel, M. P. P., Poll-Franse, L., Nijsten, T.,

Schadendorf, D., and de Vries, E. beta-Blocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study. *European Journal of Cancer* 49[18], 3863-3871. 2013.

MacKie, R. M., Bray, C. A., MacKie, R. M., and Bray, C. A. Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma. *British Journal of Cancer* 90[4], 770-772. 23-2-2004.

Tang, J. Y., Spaunhurst, K. M., Chlebowski, R. T., Wactawski, Wende J., Keiser, E., Thomas, F., Anderson, M. L., Zeitouni, N. C., Larson, J. C., and Stefanick, M. L. Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials. *Journal of the National Cancer Institute* 103[19], 1469-1475. 2011.

Olsen, J. H., Tangerud, K., Wermuth, L., Frederiksen, K., Friis, S., Olsen, Jorgen H., Tangerud, Karina, Wermuth, Lene, Frederiksen, Kirsten, and Friis, Soren. Treatment with levodopa and risk for malignant melanoma. *Movement Disorders* 22[9], 1252-1257. 15-7-2007

Siiskonen, S. J., Koomen, E. R., Visser, L. E., Herings, R. M., Guchelaar, H. J., Stricker, B. H., and Nijsten, T. E. Exposure to phototoxic NSAIDs and quinolones is associated with an increased risk of melanoma. *European Journal of Clinical Pharmacology* 69[7], 1437-1444. 2013.

Excluded Studies

Adam, S. A., Sheaves, J. K., Wright, N. H., Mosser, G., Harris, R. W., Vessey, M. P., Adam, S. A., Sheaves, J. K., Wright, N. H., Mosser, G., Harris, R. W., and Vessey, M. P. A case-control study of the possible association between oral contraceptives and malignant melanoma. *British Journal of Cancer* 44[1], 45-50. 1981.

Reason: included in Gandini 2011 systematic review

Amato, M. P., Pracucci, G., Ponziani, G., Siracusa, G., Fratiglioni, L., Amaducci, L. Long-term safety of azathioprine therapy in multiple sclerosis. *Neurology* 43[4], 831-833. 1993.

Reason: not relevant to PICO – looks at all cancer risk

Asgari, M. M., Maruti, S. S., White, E., Asgari, Maryam M., Maruti, Sonia S., and White, Emily. A large cohort study of nonsteroidal anti-inflammatory drug use and melanoma incidence. *Journal of the National Cancer Institute* 100[13], 967-971. 2-7-2008.

Reason: included in Hu 2014 systematic review)

Bain, C., Hennekens, C. H., Speizer, F. E., Rosner, B., Willett, W., Belanger, C., Bain, C., Hennekens, C. H., Speizer, F. E., Rosner, B., Willett, W., and Belanger, C. Oral contraceptive use and malignant melanoma. *Journal of the National Cancer Institute* 68[4], 537-539. 1982.

Reason: included in Gandini 2011 systematic review

Bajaj, A., Driver, J. A., Schernhammer, E. S., Bajaj, A., Driver, J. A., & Schernhammer, E. S. (2010). Parkinson's disease and cancer risk: a systematic review and meta-analysis. *Cancer Causes & Control*, 21, 697-707.

Reason: Systematic review – primary outcome was cancer – excluding melanoma and other skin cancers

Barrett, W. L., First, M. R., Aron, B. S., and Penn, I. Clinical course of malignancies in renal transplant recipients. *Cancer* 72[7], 2186-2189. 1-10-1993.

Reason: Non comparative – describes clinical course only

Baurain, J.-F. Outcomes of ipilimumab treatment-related adverse events in patients with metastatic melanoma (MM) who received systemic corticosteroids in a phase III trial. *Journal of Clinical Oncology Conference*[var.pagings]. 2012.

Reason: abstract – not relevant to PICO

Beral, V., Evans, S., Shaw, H., Milton, G., Beral, V., Evans, S., Shaw, H., and Milton, G. Oral contraceptive use and malignant melanoma in Australia. *British Journal of Cancer* 50[5], 681-685. 1984.

Reason: study included in Gandini systematic review

Biglia, N., Gadducci, A., Ponzzone, R., Roagna, R., Sismondi, P., Biglia, Nicoletta, Gadducci, Angelo, Ponzzone, Riccardo, Roagna, Riccardo, and Sismondi, Piero. Hormone replacement therapy in cancer survivors. [Review] [134 refs]. *Maturitas* 48[4], 333-346. 20-8-2004.

Reason: outdated review – see Gandini 201

Birch-Johansen, F., Jensen, A., Olesen, A. B., Christensen, J., Tjonneland, A., Kjaer, S. K., Birch-Johansen, Fatima, Jensen, Allan, Olesen, Anne Braae, Christensen, Jane, Tjonneland, Anne, and Kjaer, Susanne K. Does hormone replacement therapy and use of oral contraceptives increase the risk of non-melanoma skin cancer? *Cancer Causes & Control* 23[2], 379-388. 2012.

Reason: non-melanoma skin cancer

Borne, E., Desmedt, E., Duhamel, A., Mirabel, X., Dziwniel, V., Maire, C., Florin, V., Martinot, V., Penel, N., Vercambre-Darras, S., Mortier, L.. Oral metronomic cyclophosphamide in elderly with metastatic melanoma. *Investigational New Drugs* 28[5], 684-689. 2010.

Reason: not relevant to PICO

Caldarola, G., Battista, C., Pellicano, R., Caldarola, Giacomo, Battista, Claudia, and Pellicano, Riccardo. Melanoma onset after estrogen, thyroid, and growth hormone replacement therapy. *Clinical Therapeutics* 32[1], 57-59. 2010.

Reason: Case report

Chakravarty, E. F. and Farmer, E. R. Risk of skin cancer in the drug treatment of rheumatoid arthritis. *Expert Opinion on Drug Safety* 7[5], 539-546. 2008.

Reason: Expert review

Chakravarty, E. F., Michaud, K., Wolfe, F., Chakravarty, Eliza F., Michaud, Kaleb, and Wolfe, Frederick. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. *Journal of Rheumatology* 32[11], 2130-2135. 2005.

Reason: Non melanoma skin cancer

Clark, D. A. Do anti-TNF-alpha drugs increase cancer risk in rheumatoid arthritis patients? *Inflammopharmacology* 21[2], 125-127. 2013.

Reason: expert review – non melanoma skin cancer

- 1 Cuchural, G. J., Jr., Levey, A. S., Pauker, S. G., Cuchural, G. J. J., Levey, A. S., and Pauker, S. G. Kidney
2 failure or cancer. Should immunosuppression be continued in a transplant patient with malignant
3 melanoma? *Medical Decision Making* 4[1], 82-107. 1984.
4 Reason: Decision model – no primary data
- 5 Curiel-Lewandrowski, C., Nijsten, T., Gomez, M. L., Hollestein, L. M., Atkins, M. B., Stern, R. S., Curiel-
6 Lewandrowski, Clara, Nijsten, Tamar, Gomez, Maria L., Hollestein, Loes M., Atkins, Michael B., and
7 Stern, Robert S. Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of
8 cutaneous melanoma: results of a United States case-control study. *Journal of Investigative*
9 *Dermatology* 131[7], 1460-1468. 2011.
10 Reason: included in Hu 2014 systematic review
- 11 Curiel-Lewandrowski, C., Swetter, S. M., Einspahr, J. G., Hsu, C. H., Nagle, R., Sagerman, P., Tangrea,
12 J., Parnes, H., Alberts, D. S., Chow, H. H. Randomized, double-blind, placebo-controlled trial of
13 sulindac in individuals at risk for melanoma: evaluation of potential chemopreventive activity.
14 *Cancer* 118[23], 5848-5856. 1-12-2012.
15 Reason: chemoprevention
- 16 De Giorgi, V. The effect of beta-blocker treatment in patients with cutaneous melanoma. *Journal of*
17 *Clinical Oncology Conference*[var.pagings]. 2011.
18 Reason: abstract only – see De Giorgi 2013
- 19 De Giorgi, V., Grazzini, M., Gandini, S., Benemei, S., Lotti, T., Marchionni, N., and Geppetti, P.
20 Treatment With beta-Blockers and Reduced Disease Progression in Patients With Thick Melanoma.
21 *Archives of Internal Medicine* 171[8], 779-781. 2011.
22 Reason: Patients included in De Giorgi 2013
- 23 Dommasch, E. D. A. The safety of tumor necrosis factor antagonists in psoriasis: A systematic review
24 and meta-analysis of randomized controlled trials. *Journal of Investigative Dermatology*
25 *Conference*[var.pagings], April. 2010.
26 Reason: abstract only
- 27 Eigentler, T. K. C. Palliative therapy of disseminated malignant melanoma: A systematic review of 41
28 randomised clinical trials. *Lancet Oncology* 4[12], 748-759. 2003.
29 Reason: not relevant to PICO
- 30 Ellerbroek, W. C. and Ellerbroek, W. C. Oral contraceptives and malignant melanoma. *JAMA* 206[3],
31 649-650. 14-10-1968.
32 Reason: letter – case report
- 33 Faraj, B. A., Camp, V. M., Murray, D. R., Kutner, M., Hearn, J., Nixon, D., Plasma L-dopa in the
34 diagnosis of malignant melanoma. *Clinical Chemistry* 32[1 Pt 1], 159-161. 1986.
- 35 Feskanich, D., Hunter, D. J., Willett, W. C., Spiegelman, D., Stampfer, M. J., Speizer, F. E., Colditz, G.
36 A., Feskanich, D., Hunter, D. J., Willett, W. C., Spiegelman, D., Stampfer, M. J., Speizer, F. E., and
37 Colditz, G. A. Oral contraceptive use and risk of melanoma in premenopausal women. *British Journal*
38 *of Cancer* 81[5], 918-923. 1999.
39 Reason: included in Gandini 2011 systematic review

- 1 Fiala, K. H., Whetteckey, J., Manyam, B. V., Fiala, K. H., Whetteckey, J., & Manyam, B. V. (2003).
- 2 Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence?. [Review] [35
- 3 refs]. *Parkinsonism & Related Disorders*, 9, 321-327.
- 4 Reason: collection of case reports)
- 5 Field S. beta-blockers and survival from melanoma. *Pigment Cell and Melanoma Research*
- 6 *Conference*[var.pagings], 1070. 2011.
- 7 Reason:abstract only
- 8 Frankenthaler, A., Sullivan, R. J., Wang, W., Renzi, S., Seery, V., Lee, M. Y., and Atkins, M. B. Impact of
- 9 concomitant immunosuppression on the presentation and prognosis of patients with melanoma.
- 10 *Melanoma Research* 20[6], 496-500. 2010.
- 11
- 12 Gallagher, R. P., Elwood, J. M., Hill, G. B., Coldman, A. J., Threlfall, W. J., Spinelli, J. J., Gallagher, R. P.,
- 13 Elwood, J. M., Hill, G. B., Coldman, A. J., Threlfall, W. J., and Spinelli, J. J. Reproductive factors, oral
- 14 contraceptives and risk of malignant melanoma: Western Canada Melanoma Study. *British Journal of*
- 15 *Cancer* 52[6], 901-907. 1985.
- 16 Reason: study included in Gandini systematic review
- 17 Gurney, H., Coates, A., Kefford, R., Gurney, H., Coates, A., and Kefford, R. The use of L-dopa and
- 18 carbidopa in metastatic malignant melanoma. *Journal of Investigative Dermatology* 96[1], 85-87.
- 19 1991.
- 20 Reason: not relevant to PICO
- 21 Hannaford, P. C., Villard-Mackintosh, L., Vessey, M. P., Kay, C. R., Hannaford, P. C., Villard-
- 22 Mackintosh, L., Vessey, M. P., and Kay, C. R. Oral contraceptives and malignant melanoma. *British*
- 23 *Journal of Cancer* 63[3], 430-433. 1991.
- 24 Reason: Vessey 2006 study included in Gandini systematic review
- 25 Hartmann, B. W., Huber, J. C., Hartmann, B. W., and Huber, J. C. The mythology of hormone
- 26 replacement therapy. [Review] [98 refs]. *British Journal of Obstetrics & Gynaecology* 104[2], 163-
- 27 168. 1997.
- 28 Reason: expert review
- 29 Hartmann, D. W. R. Unanticipated side effects from treatment with high-dose mechlorethamine in
- 30 patients with malignant melanoma. *Cancer Treatment Reports* 65[3-4], 327-328. 1981.
- 31 Reason: not relevant to PICO
- 32 Helmrich, S. P., Rosenberg, L., Kaufman, D. W., Miller, D. R., Schottenfeld, D., Stolley, P. D., Shapiro,
- 33 S., Helmrich, S. P., Rosenberg, L., Kaufman, D. W., Miller, D. R., Schottenfeld, D., Stolley, P. D., and
- 34 Shapiro, S. Lack of an elevated risk of malignant melanoma in relation to oral contraceptive use.
- 35 *Journal of the National Cancer Institute* 72[3], 617-620. 1984.
- 36 Reason: study included in Gandini systematic review
- 37 Holly, E. A. and Holly, E. A. Cutaneous melanoma and oral contraceptives: a review of case-control
- 38 and cohort studies. *Recent Results in Cancer Research* 102, 108-117. 1986.
- 39 Reason: outdated review superceeded by Gandini systematic review

- 1 Holly, E. A., Cress, R. D., Ahn, D. K., Holly, E. A., Cress, R. D., and Ahn, D. K. Cutaneous melanoma in
2 women. Reproductive factors and oral contraceptive use. American Journal of Epidemiology 141[10],
3 943-950. 15-5-1995.
4 Reason: included in Gandini 2011 systematic review
- 5 Holly, E. A., Weiss, N. S., Liff, J. M., Holly, E. A., Weiss, N. S., and Liff, J. M. Cutaneous melanoma in
6 relation to exogenous hormones and reproductive factors. Journal of the National Cancer Institute
7 70[5], 827-831. 1983.
8 Reason: study included in Gandini systematic review
- 9 Holman, C. D., Armstrong, B. K., Heenan, P. J., Holman, C. D., Armstrong, B. K., and Heenan, P. J.
10 Cutaneous malignant melanoma in women: exogenous sex hormones and reproductive factors.
11 British Journal of Cancer 50[5], 673-680. 1984.
12 Reason: study included in Gandini 2011 systematic review
- 13 Jeter, J. M., Bonner, J. D., Johnson, T. M., Gruber, S. B., Jeter, Joanne M., Bonner, Joseph D., Johnson,
14 Timothy M., and Gruber, Stephen B. Nonsteroidal anti-inflammatory drugs and risk of melanoma.
15 Journal of Skin Cancer 2011, 598571. 2011.
16 Reason: included in Hu 2014 systematic review
- 17 Jeter, J. M., Han, J., Martinez, M. E., Alberts, D. S., Qureshi, A. A., Feskanich, D., Jeter, J. M., Han, J.,
18 Martinez, M. E., Alberts, D. S., Qureshi, A. A., and Feskanich, D. Non-steroidal anti-inflammatory
19 drugs, acetaminophen, and risk of skin cancer in the Nurses' Health Study. Cancer Causes & Control
20 23[9], 1451-1461. 2012.
21 Reason: included in Hu 2014 systematic review
- 22 Johannesdottir, S. A., Chang, E. T., Mehnert, F., Schmidt, M., Olesen, A. B., Sorensen, H. T.,
23 Johannesdottir, Sigrun Alba, Chang, Ellen T., Mehnert, Frank, Schmidt, Morten, Olesen, Anne Braae,
24 and Sorensen, Henrik Toft. Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a
25 population-based case-control study. Cancer 118[19], 4768-4776. 1-10-2012.
26 Reason: included in Hu 2014 systematic review
- 27 Johnson, D. M. H. Rheumatoid arthritis complicating adjuvant interferon-alpha therapy for malignant
28 melanoma [3]. Journal of Rheumatology 26[4], 1009-1010. 1999.
29 Reason: case report
- 30 Joosse, A., Koomen, E. R., Casparie, M. K., Herings, R. M., Guchelaar, H. J., Nijsten, T., Joosse, Arjen,
31 Koomen, Elsje R., Casparie, Mariel K., Herings, Ron M. C., Guchelaar, Henk Jan, and Nijsten, Tamar.
32 Non-steroidal anti-inflammatory drugs and melanoma risk: large Dutch population-based case-
33 control study. Journal of Investigative Dermatology 129[11], 2620-2627. 2009.
34 Reason: included in Hu 2014 systematic review
- 35 Karagas, M. R., Stukel, T. A., Dykes, J., Miglioni, J., Greene, M. A., Carey, M., Armstrong, B., Elwood,
36 J. M., Gallagher, R. P., Green, A., Holly, E. A., Kirkpatrick, C. S., Mack, T., Osterlind, A., Rosso, S., and
37 Swerdlow, A. J. A pooled analysis of 10 case-control studies of melanoma and oral contraceptive use.
38 British Journal of Cancer 86[7], 1085-1092. 8-4-2002.
39 Reason: outdated systematic review superceeded by Gandini systematic review

Koomen, E. R. J. Effect of statins on melanoma of the skin. *Pharmaceutisch Weekblad* 142[42], 133-137. 2007.

Reason: foreign language

Koomen, E. R., Joosse, A., Herings, R. M., Casparie, M. K., Bergman, W., Nijsten, T., Guchelaar, H. J., Koomen, E. R., Joosse, A., Herings, R. M. C., Casparie, M. K., Bergman, W., Nijsten, T., and Guchelaar, H. J. Is statin use associated with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin? *European Journal of Cancer* 43[17], 2580-2589. 2007.

Koomen, E. R., Joosse, A., Herings, R. M., Casparie, M. K., Guchelaar, H. J., Nijsten, T., Koomen, Elsje R., Joosse, Arjen, Herings, Ron M. C., Casparie, Mariel K., Guchelaar, Henk Jan, and Nijsten, Tamar. Does use of estrogens decrease the Breslow thickness of melanoma of the skin? Oral contraceptives and hormonal replacement therapy. *Melanoma Research* 19[5], 327-332. 2009.

Reason: Study included in Gandini 2011 systematic review

Koomen, E. R., Joosse, A., Herings, R. M., Casparie, M. K., Guchelaar, H. J., Nijsten, T., Koomen, E. R., Joosse, A., Herings, R. M. C., Casparie, M. K., Guchelaar, H. J., and Nijsten, T. Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case-control study. *Annals of Oncology* 20[2], 358-364. 2009.

Reason: Study included in Gandini 2011 systematic review

Le, M. G., Cabanes, P. A., Desvignes, V., Chanteau, M. F., Mlika, N., Avril, M. F., Le, M. G., Cabanes, P. A., Desvignes, V., Chanteau, M. F., Mlika, N., and Avril, M. F. Oral contraceptive use and risk of cutaneous malignant melanoma in a case-control study of French women. [Review] [21 refs]. *Cancer Causes & Control* 3[3], 199-205. 1992.

Reason: Study included in Gandini 2011 systematic review

Lens, M. B., Reiman, T., and Husain, A. F. Use of tamoxifen in the treatment of malignant melanoma – Systematic review and metaanalysis of randomized controlled trials. *Cancer* 98[7], 1355-1361. 2003.

Reason: not relevant to PICO

Lens, M., Bataille, V., Lens, Marko, and Bataille, Veronique. Melanoma in relation to reproductive and hormonal factors in women: current review on controversial issues. [Review] [38 refs]. *Cancer Causes & Control* 19[5], 437-442. 2008.

Reason: expert review

Lerner, A. B., Nordlund, J. J., Kirkwood, J. M., Lerner, A. B., Nordlund, J. J., and Kirkwood, J. M. Effects of oral contraceptives and pregnancy on melanomas. *New England Journal of Medicine* 301[1], 47. 5-7-1979.

Reason: letter

Letellier, S., Garnier, J. P., Spy, J., Stoitchkov, K., Le, Bricon T., Baccard, M., Revol, M., Kerneis, Y., Bousquet, B., Letellier, S., Garnier, J. P., Spy, J., Stoitchkov, K., Le Bricon, T., Baccard, M., Revol, M., Kerneis, Y., and Bousquet, B. Development of metastases in malignant melanoma is associated with an increase in the plasma L-dopa/L-tyrosine ratio. *Melanoma Research* 9[4], 389-394. 1999.

Reason: not relevant to PICO

- 1 Li, S., Liu, Y., Zeng, Z., Peng, Q., Li, R., Xie, L., Qin, X., and Zhao, J. Association between non-steroidal
2 anti-inflammatory drug use and melanoma risk: a meta-analysis of 13 studies. *Cancer Causes and*
3 *Control* 24[8], 1505-1516. 2013.
4 Reason: chemoprevention
- 5 Liu, R., Gao, X., Lu, Y., Chen, H., Liu, Rui, Gao, Xiang, Lu, Yi, and Chen, Honglei. Meta-analysis of the
6 relationship between Parkinson disease and melanoma. [Review]. *Neurology* 76[23], 2002-2009. 7-6-
7 2011.
8 Reason: Study does not does not explicitly address the relationship between therapy and melanoma
- 9 Lukacs, L. Serum L-DOPA oxidase activity in patients with malignant cutaneous melanoma. *Orvosi*
10 *Hetilap* 125[41], 2483-2486. 1984.
11 Reason: foreign language
- 12 McCourt, C., Coleman, H. G., Murray, L. J., Cantwell, M. M., Dolan, O., Powe, D. G., and Cardwell, C.
13 R. Beta-blocker usage after malignant melanoma diagnosis and survival: a population-based nested
14 case-control study. *British Journal of Dermatology* 170[4], 930-938. 2014.
- 15 Mackintosh, L. J., Geddes, C. C., Herd, R. M., Mackintosh, L. J., Geddes, C. C., and Herd, R. M. Skin
16 tumours in the West of Scotland renal transplant population. *British Journal of Dermatology* 168[5],
17 1047-1053. 2013.
18 Reason: does not analyze melanoma separately – mostly BCC and SCC
- 19 Nijsten, T., Koomen, E. R., Joesse, A., Herings, R., Casparie, M., and Guchelaar, H. Oestrogens, oral
20 contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma:
21 a population based case control study. *Journal of Investigative Dermatology* 128, S82. 2008.
22 Reason: abstract only
- 23 Osterlind, A., Tucker, M. A., Stone, B. J., Jensen, O. M., Osterlind, A., Tucker, M. A., Stone, B. J., and
24 Jensen, O. M. The Danish case-control study of cutaneous malignant melanoma. III. Hormonal and
25 reproductive factors in women. *International Journal of Cancer* 42[6], 821-824. 15-12-1988.
26 Palmer, J. R., Rosenberg, L., Strom, B. L., Harlap, S., Zaubler, A. G., Warshauer, M. E., Shapiro, S., Oral
27 contraceptive use and risk of cutaneous malignant melanoma. *Cancer Causes & Control* 3[6], 547-
28 554. 1992.
- 29 Pfahlberg, A., Hassan, K., Wille, L., Lausen, B., and Gefeller, O. Systematic review of case-control
30 studies: oral contraceptives show no effect on melanoma risk (Structured abstract). *Public Health*
31 *Reviews* 25[3-4], 309-315. 1997.
32 Reason: outdated systematic review – see Gandini 2011
- 33 Sandyk, R. Accelerated growth of malignant melanoma by levodopa in Parkinson's disease and role
34 of the pineal gland. *International Journal of Neuroscience* 63[1-2], 137-140. 1992.
35 Reason: narrative review
- 36 Sober, A. J., Wick, M. M., Sober, A. J., and Wick, M. M. Levodopa therapy and malignant melanoma.
37 *JAMA* 240[6], 554-555. 11-8-1978.
38 Reason: case report

- 1 Ybot, I., V. Malignancy frequency analysis in a Parkinson's disease patients sample. Movement
2 Disorders Conference[var.pagings], 2010. 2010.
- 3 Reason: abstract only
- 4 Wilson, J. C., Murray, L. J., Hughes, C. M., and Anderson, L. A. Non-Steroidal Anti-Inflammatory Drug
5 and Aspirin Use and the Risk of Malignant Melanoma – A Systematic Review and Meta-Analysis.
6 Pharmacoepidemiology and Drug Safety 21, 419. 2012.
- 7 Reason: abstract only
- 8 Zanetti, R., Franceschi, S., Rosso, S., Bidoli, E., Colonna, S., Zanetti, R., Franceschi, S., Rosso, S., Bidoli,
9 E., and Colonna, S. Cutaneous malignant melanoma in females: the role of hormonal and
10 reproductive factors. International Journal of Epidemiology 19[3], 522-526. 1990.
- 11 Reason: included in Gandini 2011 review

Evidence Tables

Study	Design	Population	Intervention and comparison	Follow up	Outcomes	Comments
Bastiaannet (2007)	Cohort study, Netherlands	1125 kidney transplantation patients	Triple drug immunosuppression therapy (cyclosporin, mycophenolate mofetil and prednisolone).	Total 8165 patient years in 1125 patients	Standardised incidence ratio for melanoma	Not a study of intercurrent drug therapy in patients with melanoma. Retrospective SIR calculated using expected rates on the basis of age and calendar period using Netherlands Cancer Registry data.
Bertoni (2010)	Cohort study, US	2106 patients with idiopathic Parkinson disease.	Patients were screened for melanoma and asked about history of levodopa therapy (N=1786) versus no levodopa therapy (N=320)	N/A	Incidence of melanoma	Not a study of intercurrent drug therapy in patients with melanoma. Allocation to treatment groups likely to be biased. Analysis not adjusted for melanoma risk factors.
Buchbinder (2008)	Cohort study, Australia	458 patients with rheumatoid arthritis	Methotrexate	Average follow up 9.3 years, total 4145 person-years in 458 patients.	Standardised incidence ratio for melanoma	Not a study of intercurrent drug therapy in patients with melanoma.

Study	Design	Population	Intervention and comparison	Follow up	Outcomes	Comments
						SIR calculated using expected rates on the basis of age, gender and calendar period using Victorian Cancer Registry data.
Dahlke et al (2014)	Systematic Review Studies published post 1995 in English or French.	N=17 studies which reported the incidence of melanoma in a population based cohort of solid organ transplant recipients (5 were excluded to avoid double counting) N=1 population based study reporting outcomes of pre-transplant				<i>Incidence of post transplant melanoma</i> From 12 studies, transplant recipients had a pooled estimate of 2.4 times (95% CI 2.0-2.9) the risk of melanoma when compared with the general population ($I^2=46\%$, $p=0.04$). Adjusting for type of organ graft and most recent year of transplant in the cohort reduced the I^2 to 0%. Studies of renal or liver transplant recipients had

Study	Design	Population	Intervention and comparison	Follow up	Outcomes	Comments
		<p>melanoma</p> <p>0 studies of post-transplant melanoma.</p>				<p>an absolute increase in SIR of 0.29 compared with studies of heart or lung transplant recipients (p=0.01)</p> <p>Studies that included patients transplanted after the year 2000 had an increase in SIR of 0.41 compared with older studies (p=0.03).</p> <p><i>Prognosis of post-transplant melanoma</i></p> <p>No studies were identified reporting on outcomes of de novo melanoma arising post-transplantation.</p> <p>One retrospective study (n=638 patients of post</p>

Study	Design	Population	Intervention and comparison	Follow up	Outcomes	Comments
						<p>transplant melanoma) reported that overall survival rates were worse in the transplant population compared with the general population.</p> <p>The study also reported that patients with a Breslow depth of 1.51-3mm and Clark levels III/IV had significantly worse outcomes compared with the expected survival rates in the general population (Brewer et al).</p> <p>A second study reported worse outcomes for late stage (T3/T4) melanoma in transplant recipients compared with the general population. (HR=11.49, 95% CI 3.6-36.8)</p>

Study	Design	Population	Intervention and comparison	Follow up	Outcomes	Comments
						<p><i>Post transplantation prognosis of pre-transplant melanoma</i></p> <p>One study reported that 2/19 patients with a history of pre-transplant melanoma had a recurrence after transplant (Chapman et al).</p> <p>Brewer et al reported no recurrences and 2 melanoma metastases in 59 patients (mean follow-up was 10.5 years)</p> <p>A third study (Matin et al) reported no post transplant deaths after a median of 14 years post-melanoma follow-up and a median of 5 years of post-</p>

Study	Design	Population	Intervention and comparison	Follow up	Outcomes	Comments
						transplant follow-up.
De Giorgi (2013)	Cohort study, Italy	741 patients with melanoma	Beta-blocker use of at least 1 year (N=79) versus no such treatment (N=662)	Median 4.2 years	Overall survival, Disease progression (analyses were adjusted for age, tumour thickness and ulceration)	Baseline differences in patient characteristics (older and more hypertension in the beta-blocker group).
Franciosi (2013)	Systematic review of randomised and observational studies	259043 patients Analysis included 2 RCTs and one observational study.	Metformin therapy	Median 4 and 5 years in the 2 included RCTs that reported melanoma rates.	Incidence of melanoma	Not a study of intercurrent drug therapy in patients with melanoma. Search cut-off April 2012. Methodology appropriate
Gandini (2011)	Systematic review of case control and cohort studies from US, Europe and Australia	Analysis included 5626 patients with melanoma and 344,342 controls. 19 case-control studies: Patients with melanoma	Oral contraceptive (OC) and or hormone replacement therapy (HRT) (ever used) versus never used OC or HRT	Not reported	Incidence of melanoma	Not a study of intercurrent drug therapy in patients with melanoma. Patient characteristics were poorly reported (e.g. mean age of cases only reported in 4/25 studies). 12/25 studies adjusted for

Study	Design	Population	Intervention and comparison	Follow up	Outcomes	Comments
		and controls selected from population or hospital. 6 cohort studies:				pheno-photo types 9/25 studies adjusted for sun exposure Meta-analysis pools case-control and cohort studies (assumes OR=RR?) which may be valid due to low event rate.
Hu (2014)	Systematic review of case-control and cohort studies	10 case-control or cohort studies	6999 patients with melanoma and 490332 controls.	Not reported	Melanoma	Not a study of intercurrent drug therapy in patients with melanoma. Likely to be baseline differences in these studies - but meta-analyses used adjusted effect estimates wherever possible. Meta-analysis pools case-control and cohort studies (assumes OR=RR?) which may be valid due to low event rate.

Study	Design	Population	Intervention and comparison	Follow up	Outcomes	Comments
Jensen (1999)	Cohort study, Norway	2561 heart or kidney transplantation patients	Triple drug immunosuppression therapy (cyclosporin, azathioprine and prednisolone) or dual therapy in those treated pre 1983.	Median 4.8 years (15123 person years in total)	Standardised incidence ratio for melanoma	Not a study of intercurrent drug therapy in patients with melanoma. Retrospective. SIR calculated using expected rates on the basis of age, calendar period and gender using Norway Cancer Registry data.
Lemeshow (2011)	Cohort study, Denmark	4179 melanoma patients	B-blocker use in the 90 day period prior to melanoma diagnosis (N=275) versus no use (N=2916)	Median follow-up 4.9 years	Overall survival (adjusted for age and comorbidity index score)	Patients treated with b-blockers tended to have poorer baseline prognosis – authors attempted to adjust for this.
Livingstone (2013)	Cohort study, Netherlands	709 melanoma patients	B-blocker use (N=203) versus no use (N=506)	Median 3.7 years in beta-blocker group and 2.8 years in control	Overall survival (adjusted for age and sex)	Patients treated with b-blockers tended to have poorer baseline prognosis – authors attempted to adjust for this.
MacKie (2003)	Cohort study, UK	206 women aged between	Any HRT (N=83) versus no HRT	Median 10.6 years	Overall survival, melanoma	Baseline differences between groups – analysis

Study	Design	Population	Intervention and comparison	Follow up	Outcomes	Comments
		40 and 60 following surgery for stage I or II melanoma	(N=123)	(minimum 5 years)	specific survival	adjusted for ulceration, tumour thickness and age.
Siikskonen (2013)	Case-control study, Netherlands	Cases with melanoma (N=1318) versus controls (N=6786)	Phototoxic drug use versus no such use.	3 years. Exposure to phototoxic drug was defined as within the 3 years before diagnosis of melanoma – but excluding the year prior to diagnosis due to the latent period.	Melanoma	Not a study of intercurrent drug therapy in patients with melanoma. Retrospective. 15 drugs included in model Risk factors for melanoma (e.g. lifestyle and family history) were not incorporated into the model
Tang (2011)	RCT	27347 postmenopausal women	HRT versus placebo (2 trials – combined HRT for those with intact uterus only). Combined estrogen plus progestion (N=8506) versus	Mean 5.6 years for combined HRT trial and 7.1 years for the estrogen alone trial	Incidence of melanoma	Not a study of intercurrent drug therapy in patients with melanoma. Appropriate randomisation method Unclear allocation concealment

Study	Design	Population	Intervention and comparison	Follow up	Outcomes	Comments
			placebo (N=8102). Estrogen only (N=5310) versus placebo (N=5429).			Groups comparable at baseline Double blind study Attrition bias unclear Low risk of detection bias

1 Appendix

2 Health Economic Search Strategies

3 For the purposes of the health economics search, a full search was undertaken with no date limit to
 4 ensure full coverage of topics for the economic plan and for dealing with different health economic
 5 analyses. For Medline, Embase and Web of Science, the last two year were searched.

6 Medline search strategy (This search strategy is adapted to each database)

Medline	Embase
1. exp Melanoma/ 2. melanoma\$.tw. 3. (maligna\$2 adj2 lentigo\$1).tw. 4. (hutchinson\$ adj1 (freckle\$ or melano\$)).tw.tw. 5. dubreuilh.tw. 6. LMM.tw. 7. or/1-6	1. Melanoma/ 2. melanoma\$.tw. 3. Amelanotic Melanoma/ 4. Malignant Lentigo/ 5. (maligna\$2 adj2 lentigo\$1).tw. 6. (hutchinson\$ adj1 (freckle\$ or melano\$)).tw.tw. 7. dubreuilh.tw. 8. LMM.tw. 9. or/1-8

7

Database name	No of references found	Finish date of search
<i>Medline</i>	155	26/09/2012
<i>Premedline</i>	3	26/09/2012
<i>Embase</i>	165	09/10/2012
<i>Cochrane: HTA</i>	46	28/09/2012
<i>Cochrane: NHSEED</i>	23	28/09/2012
<i>HEED</i>	71	28/09/2012
Total References retrieved (after de-duplication): 603		

8 Update Search:

Database name	No of references found	Finish date of search
---------------	------------------------	-----------------------

Medline	144	15/10/2014
Premedline	14	15/10/2014
Embase	232	15/10/2014
Cochrane: HTA	0	15/10/2014
Cochrane: NHSEED	0	15/10/2014
HEED		
Total References retrieved (after de-duplication): 316		

1

2 **Excluded Health Economic Studies**

3 Agnese DM, Abdessalam SF, Burak WE Jr, Magro CM, Pozderac RV, Walker MJ "Cost effectiveness of
4 sentinel lymph node biopsy in thin melanomas." Surgery 134:542-548. 2003.

5 Reason: Not a cost utility study

6 Bares, C. B., Trask,P.C. & Schwartz, S.M. "An exercise in cost effectiveness analysis: treating
7 emotional distress in melanoma patients." Journal of Clinical Psychology in Medical Settings
8 9(3):193-200. 2002.

9 Reason: Not a cost utility study

10 Basseres N, Grob JJ, Richard MA, Thirion X, Zarour H, Noe C, Collet-Vilette, AM, Lota I. & Bonerandi
11 JJ "Cost effectiveness of surveillance of stage 1 melanoma: a retrospective appraisal based on a 10-
12 year experience in a dermatology department in France" Dermatology 191:199-203. 1995.

13 Reason: Not a cost utility study

14 Bastiaannet E, Uyl-de Groot CA, Brouwers AH, van der Jagt EJ, Hoekstra OS, Oyen W, Verzijlbergen F,
15 van Ooijen B, Thompson JF, Hoekstra HJ."Cost effectiveness of adding FDG-PET or CT to the
16 diagnostic work-up of melanoma patients stage III." Pigment Cell and Melanoma Research
17 Conference.var.pagings (2010): 941.

18 Reason:Not a cost utility study

19 Bastiaannet E, Uyl-de Groot CA, Brouwers AH, van der Jagt EJ, Hoekstra OS, Oyen W, Verzijlbergen F,
20 van Ooijen B, Thompson JF, Hoekstra HJ "Cost effectiveness of adding FDG-PET or CT to the
21 diagnostic work-up of patients with stage III melanoma" Annals of Surgery 255[4], 771-76. 2012.

22 Reason:Not a cost utility study

23 Bessen T ."Imaging follow-up in melanoma: The potential role of health economic modelling."
24 Pigment Cell and Melanoma Research Conference.var.pagings (2010): 880.

25 Reason:Conference abstract

1 Buck AK, Herrmann K, Stargardt T, Dechow T, Krause BJ, Schreyögg J. "Economic evaluation of PET
2 and PET/CT in oncology: evidence and methodologic approaches. ." Journal of Nuclear Medicine
3 Technology 38.1 (2010): 6-17.

4 Reason: Not relevant to population in PICO

5 Campbell TM. Y & Youker S "Practical application and decision-making in Mohs micrographic surgery
6 and cutaneous oncology." Operative Techniques in Otolaryngology - Head and Neck Surgery 22.1
7 (2011): 101-13.

8 Reason: Not a cost effectiveness study

9 Cashin RP, Lui P, Machado M, Hemels ME, Corey-Lisle PK, Einarson TR. "Advanced cutaneous
10 malignant melanoma: a systematic review of economic and quality-of-life studies. " Value in Health
11 11.2 (2008): 259-71.

12 Reason: Review of economic papers-appraised independently.

13 Chuang T.-Y "Mohs Surgery -The myth and the truth." Dermatologica Sinica 26.1 (2008): 1-9.

14 Reason: Not a cost utility study.

15 Colombo GL, Matteo SD, Mir LM. "Cost effectiveness analysis of electrochemotherapy with the
16 Cliniporator vs other methods for the control and treatment of cutaneous and subcutaneous
17 tumors." Therapeutics and Clinical Risk Management 4.2 (2008): 541-48.

18 Reason: Not a cost utility study.

19 Covarelli P, Badolato M, Tomassini GM, Poponesi V, Listorti C, Castellani E, Boselli C, Noya G.
20 "Sentinel lymph node biopsy under local anaesthesia versus general anaesthesia: reliability and cost
21 effectiveness analysis in 153 patients with malignant melanoma". In Vivo 26(2):315-318. 2012.

22 Reason: Not a cost utility study.

23 Davids V, Kidson SH, & Hanekom GS. "Melanoma patient staging: histopathological versus molecular
24 evaluation of the sentinel node." Melanoma Research 13.3 (2003): 313-24.

25 Reason: Not a cost utility study.

26 DeRose ER, Pleet A, Wang W, Seery VJ, Lee MY, Renzi S, Sullivan RJ, Atkins MB. "Utility of 3-year
27 torso computed tomography and head imaging in asymptomatic patients with high-risk melanoma."
28 Melanoma Research 21.4 (2011): 364-69.

29 Reason: Not a cost effectiveness study

30 Hengge UR, Wallerand A, Stutzki A, Kockel N. "Cost effectiveness of reduced follow-up in malignant
31 melanoma." Journal der Deutschen Dermatologischen Gesellschaft 5.10 (2007): 898-907.

32 Reason: Not a cost utility study.

Hettiaratchy SP, Kang N, O'Toole G, Allan R, Cook MG, Powell BW. "Sentinel lymph node biopsy in malignant melanoma: a series of 100 consecutive patients." *British Journal of Plastic Surgery* 53.7 (2000): 559-62.

Reason: Not a cost utility study

Hoekstra HJ. "Cost effectiveness of melanoma follow-up." *Pigment Cell and Melanoma Research Conference*. var. pagings (2010): 880.

Reason: Conference abstract

Johnson TM, Bradford CR, Gruber SB, Sondak VK, Schwartz JL. "Staging Workup, Sentinel Node Biopsy, and Follow-up Tests for Melanoma: Update of Current Concepts." *Archives of Dermatology* 140.1 (2004): 107-13.

Reason: Not a cost effectiveness study

Johnston K, Levy AR, Lorigan P, Maio M, Lebbe C, Middleton M, Testori A, Bédane C, Konto C, Dueymes A, Sbarigia U, van Baardewijk M. "Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: Results from a retrospective, longitudinal survey (MELODY study)." *European Journal of Cancer* 48.14 (2012): 2175-82.

Reason: Cost of illness study

Kansal AR, Shaul AJ, Stern S, Busam K, Doucet CA, Chalfin DB "Cost effectiveness of a FISH assay for the diagnosis of melanoma in the USA." *Expert Rev Pharmacoecon Outcomes Res.* (2013) 13(3):371-80.

Reason: Patient group not relevant to PICO

Li LX, Scolyer RA, Ka VS, McKinnon JG, Shaw HM, McCarthy SW, Thompson JF. "Pathologic review of negative sentinel lymph nodes in melanoma patients with regional recurrence: a clinicopathologic study of 1152 patients undergoing sentinel lymph node biopsy." *American Journal of Surgical Pathology* 27.9 (2003): 1197-202.

Reason: Not a cost effectiveness study

Losina E, Walensky RP, Geller A, Beddingfield FC 3rd, Wolf LL, Gilchrest BA, Freedberg KA. 'Visual screening for malignant melanoma: a cost effectiveness analysis'. *Archives of Dermatology* . 143.1 (2007) 21-8

Reason: Not relevant to scope of guideline

Morton R & Howard K "Economic considerations in melanoma care." *Pigment Cell and Melanoma Research Conference*. var. pagings (2010): 879-80.

- 1 Reason:Conference Abstract
- 2 Munn, S. "Is teledermoscopy a safe and cost-effective model for triage of pigmented lesions and
3 suspected melanoma in the U.K.?" British Journal of Dermatology Conference.var.pagings (2011):
4 July.
- 5 Reason:Conference abstract
- 6 Picchio M, Mansueto M, Crivellaro C, Guerra L, Marcelli S, Arosio M, Sironi S, Gianolli L, Grimaldi A,
7 Messa C. "PET/CT and contrast enhanced CT in single vs. two separate sessions: A cost analysis
8 study." Quarterly Journal of Nuclear Medicine and Molecular Imaging 56.3 (2012): 309-16.
- 9 Reason:Not a cost effectiveness study
- 10 Stoffels I, Dissemond J, Körber A, Hillen U, Poeppel T, Schadendorf D, Klode J. "Reliability and cost
11 effectiveness of sentinel lymph node excision under local anaesthesia versus general anaesthesia for
12 malignant melanoma: A retrospective analysis in 300 patients with malignant melanoma AJCC Stages
13 I and II." Journal of the European Academy of Dermatology and Venereology 25(3):306-310. 2011.
- 14 Reason:Not a cost utility study
- 15 Stoffels I, Dissemond J, Schulz A, Hillen U, Schadendorf D, Klode J."Reliability and cost effectiveness of
16 complete lymph node dissection under tumescent local anaesthesia vs. general anaesthesia: a
17 retrospective analysis in patients with malignant melanoma AJCC stage III." Journal of the European
18 Academy of Dermatology & Venereology 26.2 (2012): 200-06.
- 19 Reason:Not a cost utility study
- 20 Thomas, J. M." Prognostic false-positivity and cost effectiveness in sentinel node biopsy in
21 melanoma." Annals of Surgical Oncology 16(10):2961. 2009.
- 22 Reason:Letter to the editor
- 23
- 24 Tiern Tierneyv EP & Hanke CW."Cost effectiveness of Mohs micrographic surgery: review of the
25 literature." Journal of Drugs in Dermatology: JDD 8.10 (2009): 914-22.
- 26 Reason:Review identified no relevant cost utility studies.
- 27 van Akkooi AC, Voit CA, Verhoef C, Eggermont AM."Potential cost effectiveness of US-guided FNAC
28 in melanoma patients as a primary procedure and in follow-up." Ann Surg.Oncol 17.2 (2010): 660-62.
- 29 Reason:Letter to the editor
- 30 van der Velde-Zimmermann D, Schipper ME, de Weger RA, Hennipman A, Borel Rinkes IH "Sentinel
31 node biopsies in melanoma patients: a protocol for accurate, efficient, and cost-effective analysis by
32 preselection for immunohistochemistry on the basis of Tyr-PCR." Annals of Surgical Oncology 7.1
33 (2000): 51-54.
- 34 Reason:Not a cost utility study

1 von Schulthess GK, Steinert HC, Dummer R, Weder W. "Cost effectiveness of whole-body PET
2 imaging in non-small cell lung cancer and malignant melanoma." Academic Radiology 5 Suppl 2
3 (1998): S300-S302.

4 Reason:Not a cost utility study

5 Wilson EC, Emery JD, Kinmonth AL, Prevost AT, Morris HC, Humphrys E, Hall PN, Burrows N,
6 Bradshaw L, Walls J, Norris P, Johnson M, Walter FM. 'The cost effectiveness of a novel SIAscopic
7 diagnostic aid for the management of pigmented skin lesions in primary care: a decision-analytic
8 model' Value in Health. 16.2 (2013) 356-66

9 Reason:Primary care setting outside the scope of the guideline

10